,id,ticker,title,category,content,date,provider,url,article_id
119845,341360,VRTX,Better Buy  Vertex Pharmaceuticals vs  Galapagos,news,"Vertex Pharmaceuticals  NASDAQ VRTX  turned in a very good performance in 2019  with its shares jumping 32     slightly outpacing the S P 500 index s 30 4  return  But Galapagos NV  NASDAQ GLPG  had a great year  The stock skyrocketed by nearly 126  
However  for investors trying to decide which of them to buy now  those returns of the past don t matter much  What does matter are the respective strengths of Vertex s and Galapagos  products and pipelines  Here s how the two biotechs stack up against each other 

The case for Vertex
Juggernaut  That s probably the best word to use for Vertex in the cystic fibrosis  CF  arena  The biotech s drugs remain unchallenged in addressing the underlying genetic cause of CF  Further  thanks to new reimbursement deals in several important international markets over the last few months  sales in the CF franchise should pick up momentum 
Even better  Vertex won FDA approval several months earlier than anticipated for its newest CF treatment  Trikafta  The triple drug combo should expand the number of patients who can be treated by Vertex s therapies by more than 50  if it wins regulatory approval in Europe    which seems quite likely 
Meanwhile  Vertex is looking to expand beyond the cystic fibrosis niche  It s partnering with CRISPR Therapeutics to use gene editing in treating the rare genetic blood disorders beta thalassemia and sickle cell disease  Vertex and CRISPR are also working together to develop a gene editing approach for treating the 10  of patients with CF whom its other drugs won t help 
Vertex management thinks that an approach similar to the one that has brought it success in the CF arena will work with other rare diseases  The company s pipeline includes programs targeting genetic disorders such as alpha 1 antitrypsin deficiency  AATD  and APOL1 mediated kidney diseases 
Rare diseases aren t the only area of interest for Vertex  though  Its most advanced pipeline program is VX 150  a pain drug  Vertex s 2019 acquisition of Semma Therapeutics also put the company front and center in an especially ambitious area    attempting to develop a cure for type 1 diabetes 
In the meantime  Vertex s CF drugs continue to generate boatloads of revenue  Vertex should report 2019 sales of close to  3 7 billion  It ended the third quarter with a cash stockpile of  4 billion  
The case for Galapagos
Galapagos doesn t have any approved products yet  The important word in that sentence  though  is the last one  In December  Galapagos and partner Gilead Sciences  NASDAQ GILD  filed for FDA approval of filgotinib as a treatment for rheumatoid arthritis  RA  and used a priority voucher  which will speed up the process 
Assuming filgotinib earns FDA approval  the drug should be a commercial success  Some analysts project peak annual sales in the ballpark of  3 billion for the RA indication  Filgotinib is also being evaluated in several other indications  including atopic dermatitis  Crohn s disease  and psoriatic arthritis  Regulatory approvals in these other areas could boost its potential peak sales to around  6 billion 
Galapagos won t reap all of the rewards from filgotinib  however  The company licensed rights to the drug to Gilead in 2015  and will receive royalties starting at 20  of sales in the U S  and in many key markets  However  Galapagos will split sales 50 50 with Gilead in several major European markets 
The relationship with Gilead is one of the biggest feathers in Galapagos  cap  Last year  the two companies expanded their collaboration agreement with a 10 year deal valued at more than  5 billion  Gilead owns a little over 25  of Galapagos  but can t boost its stake above 29 9  during the period covered by the agreement 
At one point  it looked like Galapagos might be on the road to compete against Vertex in the CF market  However  in 2018 AbbVie acquired Galapagos  entire CF program  Galapagos is eligible to receive royalties if those CF drugs make it to market 
Although Galapagos isn t profitable at this point  it doesn t have to worry about raising capital to fund its operations  Thanks to its deal with Gilead  Galapagos ended the third quarter with cash and cash equivalents of more than  6 billion 
Better buy
Both of these biotech stocks have promising growth prospects  I think that Galapagos might be the bigger winner again in 2020 if filgotinib wins FDA approval  However  my view is that Vertex is the better long term pick 
I expect Vertex to keep racking up higher sales with its CF drugs  I m also cautiously optimistic about the company s chances of success in expanding into at least one new indication  The stock price already reflects a lot of the company s earnings growth potential  but I think shares could move significantly higher over the next few years ",2020-01-25,The Motley Fool,https://invst.ly/pmri9,2067734
119846,341361,VRTX,Singapore Helps Global Cryptocurrency Firms to Expand Their Local Operations,news," Bloomberg     Singapore is introducing new payments legislation that offers global cryptocurrency firms a chance to expand their operations in the country by applying for operating licenses for the first time 
The Payment Services Act  which comes into force Tuesday  is the first comprehensive regulation for companies handling activities ranging from digital payments to trading of tokens such as Bitcoin and Ether  As well bringing crypto firms into the regulatory fold  the law will hand the Monetary Authority of Singapore formal supervisory powers for cyber security risks and controls on money laundering and terrorism financing 
The measure narrows the gap with Japan  currently a major Asian center for cryptocurrency trading after 22 exchanges received licenses there since 2017  Increased investor interest in digital tokens has encouraged several regulators around the world to bring the venues under their scrutiny  especially for money laundering and other illicit activities 
The key advantage of Singapore s new legislation is providing regulatory clarity on new types of payments activities such as e wallets and cryptocurrency exchanges  according to Nizam Ismail  the founder and chief executive officer of Ethikom Consultancy  which helps potential applicants with licensing and compliance issues 
Read how Singapore is seeking a level playing field in digital services
Tokyo based crypto exchange operator Liquid Group Inc  and London based Luno  which already operate in Singapore  are among the firms planning to apply for the licenses   We welcome the Act with open arms   said Liquid s CEO Mike Kayamori  The firm will apply via its local Quoine Pte subsidiary 
The legislation  provides regulatory certainty to industry players but  more importantly  it provides consumers with a clear sense of the players they can trust   said Luno s Singapore general manager Sherry Goh  Luno obtained an operating license in Malaysia last year 
Twenty of the top 50 crypto exchanges are based in the Asia Pacific region and accounted for about 40  of Bitcoin transactions in the first half of last year  according to Chainalysis data 
Binance Holdings Ltd   operator of one of the world s largest crypto exchanges  has an office in Singapore and is backed by Vertex  NASDAQ VRTX  Venture Holdings Ltd   the venture capital arm of Singapore based Temasek Holdings Pte  Kathy Zhu  a Binance spokeswoman  declined to comment on whether the firm will seek a Singapore license ",2020-01-27,Bloomberg,https://www.investing.com/news/cryptocurrency-news/singaporehelps-global-cryptocurrency-firms-to-expand-their-local-operations-2068917,2068917
119847,341362,VRTX,Vertex Earnings  Revenue Beat in Q4,news,"Investing com   Vertex  NASDAQ VRTX  reported on Thursday fourth quarter earnings  that beat analysts  forecasts and revenue that topped expectations 
Vertex announced earnings per share of  1 7 on revenue of  1 26B  Analysts polled by Investing com anticipated EPS of  1 19 on revenue of  1 01B  That with comparison to EPS of  1 3 on revenue of  869 44M in the same period a year before  Vertex had reported EPS of  1 23 on revenue of  949 83M in the previous quarter  Analysts are expecting EPS of  1 45 and revenue of  1 09B in the upcoming quarter 
Vertex shares are up 5 28  from the beginning of the year and are trading at  240 00   still down 2 93  from its 52 week high of  237 47 set on January 22  They are outperforming the Nasdaq which is up 2 87  year to date 
Vertex shares gained 4 12  in after hours trade following the report 
Vertex follows other major Healthcare sector earnings this monthVertex s report follows an earnings beat by J J  on January 22  who reported EPS of  1 88 on revenue of  20 75B   compared to forecasts EPS of  1 87 on revenue of  20 8B 
Novartis ADR had beat expectations on Wednesday with fourth quarter EPS of  1 32 on revenue of  12 4B  compared to forecast for EPS of  1 31 on revenue of  12 33B 
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2020-01-30,Investing.com,https://www.investing.com/news/stock-market-news/vertex-earnings-revenue-beat-in-q4-2072245,2072245
119848,341363,VRTX,Vertex Pharmaceuticals Reports Q4 Financial Earnings  Beats Estimates,news,"Vertex Pharmaceuticals  NASDAQ VRTX  announced its fourth quarter financial results on Thursday afternoon  which were above analyst expectations  For the three months ending on Dec  31  Vertex reported  1 4 billion in product revenues  which was substantially above the  868 million reported in Q4 2018  In comparison  analysts were expecting only  1 0 billion in Q4 2019 revenues 
In terms of specific drug sales  Trikafta was Vertex s best selling product this quarter  accounting for  420 million in revenue  Approved in October 2019 as a treatment for cystic fibrosis  Trikafta was seen as the next potential blockbuster drug for Vertex  The drug costs approximately  311 000 for a year s worth of treatment 

Other key drug sales include the biotech company s other cystic fibrosis treatments  Symdeko Symkevi  which brought in  332 million in revenue  is up 12 9  from last year  while Orkambi generated  270 million  a 14 3  decrease from the same period in 2018  The last cystic fibrosis drug  Kalydeco  also saw revenues fall by 8 9  over the past 12 months  generating just  236 million 
Further details
Trikafta is Vertex s newest cystic fibrosis treatment  and while sales in the company s other drugs are expected to fall a bit  the increase in Trikafta sales is predicted to make up for it 
Net income came in at  583 2 million  while the company s earnings per share  EPS  was reported at  2 23  a significant improvement from the  1 21 EPS expected by analysts  Vertex expects revenues for 2020 to come in somewhere between  5 1 billion to  5 3 billion  a sizable increase from 2019 s  4 16 billion revenue figure ",2020-01-30,The Motley Fool,https://invst.ly/pp5m-,2072447
119849,341364,VRTX,Vertex Pharmaceuticals Inc  VRTX  Q4 2019 Earnings Call Transcript,news,"Vertex Pharmaceuticals Inc  NASDAQ VRTX Q4 2019 Earnings CallJan 30  2020  4 30 p m  ETContents 

Prepared Remarks
Questions and Answers
Call Participants

Prepared Remarks 
Michael Partridge    Senior Vice President Investor RelationsGood evening  Welcome to the Vertex Full Year and Fourth Quarter 2019 Financial Results Conference Call  This is Michael Partridge  Senior Vice President of Investor Relations for Vertex  Making prepared remarks on the call tonight  we have Dr  Jeff Leiden  Chairman and CEO  Dr  Reshma Kewalramani  Chief Medical Officer  Stuart Arbuckle  Chief Commercial Officer  and Charlie Wagner  Chief Financial Officer  We recommend that you access the webcast slides on our website as you listen to this call  This conference call is being recorded  and a replay will be available on our website We will make forward looking statements on this call that are subject to the risks and uncertainties discussed in detail in today s press release and our filings with the Securities and Exchange Commission  These statements  including without limitation those regarding Vertex s marketed CF medicines  our pipeline and Vertex s future financial performance  are based on management s current assumptions  Actual outcomes and events could differ materially I will now turn the call over to Dr  Jeff Leiden Jeffrey Leiden    Chairman  President   Chief Executive OfficerThanks  Michael  Good evening  everyone  We saw many investors and analysts at the JP Morgan conference two weeks ago  So I ll spend just a few moments highlighting our 2019 achievements and what we believe sets Vertex apart for the future  2019 was a truly remarkable year for Vertex  All parts of our business met or exceeded the goals we set at the start of the year  And as a result  we are very well positioned to bring our CF medicines to many more people and to advance our broad pipeline in additional diseases in 2020 In cystic fibrosis  the US approval of TRIKAFTA for patients 12 and older in October  five months ahead of our PDUFA date  was the most significant milestone to date in our efforts to bring new CF medicines to all people with this disease  TRIKAFTA is a remarkable medicine that holds the potential to treat up to 90  of all people with CF  As you ll hear from Stuart  the US launch of TRIKAFTA in patients ages 12 and older is off to a very strong start  This clear interest in TRIKAFTA across all groups of eligible patients and the early feedback from both patients and doctors is highly positive  Outside the US in 2019  we reached a number of key reimbursement agreements for our CF medicines that will allow many thousands of new patients to begin treatment with our CFTR modulators in countries  including England  France  Spain  Australia and many others throughout 2020 We are also making excellent progress advancing and broadening our pipeline beyond CF  As we enter 2020  we are now in the clinic with multiple new medicines in five diseases outside of CF  We continue to implement our strategy of advancing a portfolio of medicines into clinical development for each of the disease areas  Key programs include alpha 1 antitrypsin deficiency  our AAT program where we have multiple small molecule correctors in the clinic aimed at addressing the underlying cause of disease in both the liver and the lung  These include VX 814  which has recently entered Phase 2 clinical development Beta thalassemia and sickle cell disease where we announced clinical data for two patients treated with CTX001  a one time CRISPR Cas9 ex vivo gene editing therapy  which suggests that we may be able to functionally cure these diseases  FSGS where our first small molecule aimed at halting the progression of the disease will move into Phase 2 development in 2020  And type 1 diabetes  where we are developing an autologous islet transplantation therapy with cells alone  and a second  with a combination of cells and a device to correct islet cell function and potentially transform the treatment of this disease  Importantly  these pipeline programs now span multiple modalities  including small molecules where Vertex has excelled in the past  but also new approaches such as cell and genetic therapies  For these new modalities  we ve acquired or partnered with leading companies who have the best teams and unique expertise to manufacture and deliver transformational therapies for diseases that fit our strategy In the business development  we completed more transactions in 2019 than in the four prior years  including our acquisitions of Semma with a leading cell therapy approach for type 1 diabetes and Exonics  the leader in gene editing for DMD and DM1 In summary  the 2019 was the combination of almost a decade of focused execution against our strategy of discovering and developing transformative medicines for serious diseases in specialty areas by focusing on validated targets and predictive biomarkers that will improve the probability of clinical success  Our strategy is playing out exactly as we had planned and will position us for continued short term and long term growth  The Company has never been stronger or better positioned for future success in CF and beyond Let me now turn the call over to Reshma who will talk in more detail about the year ahead Reshma Kewalramani    Executive Vice President  Global Medicines Development and Medical Affairs    Chief Medical OfficerThanks  Jeff  Our 2019 progress has positioned us for continued growth in 2020 and for many years to come  We are focused on bringing our CF medicines to more people  advancing our pipeline and building financial strength to support continued investment in internal and external innovation  In 2020  we expect to gain approval for the triple combination in Europe in patients 12 years and older and to submit TRIKAFTA for approval in the US for children ages six to 11  Beyond CF  we are advancing multiple molecules in our pipeline through late preclinical and early clinical development and are now entering a period of multiple proof of concept data readouts and clinical advances with potentially transformative medicines With our AAT program  we recently initiated a Phase 2 proof of concept study of the small molecule corrector  VX 814 in patients with two copies of the Z mutation and expect data from the study in 2020  In APOL1 mediated FSGS  we completed a Phase 1 study of VX 147 in late 2019 and expect to initiate an open label Phase 2 proof of concept study in 2020 to evaluate the reduction in protein levels in the urine with VX 147 In pain  having established proof of concept data from NaV 1 8 inhibition with VX 150 in multiple Phase 2 studies  our focus is now to find the optimal molecule or molecules to advance into mid and late stage studies  We are continuing to advance a portfolio of medicines into clinical development and will be advancing an additional molecule into Phase 1 development in the first half of 2020  We have discontinued Phase 1 development of VX 961 because it did not display optimal PK and tolerability profile Beyond our small molecule programs  we ve made significant progress in building and progressing a portfolio of cell and genetic therapies  in line with our research strategy primarily through our business development activities  We are highly encouraged by our recent clinical data for our CRISPR Cas9 ex vivo gene editing treatment CTX001 for beta thalassemia and sickle cell disease  Both studies continue to enroll  and we expect to provide additional data for this program in 2020 I d also like to highlight our cell therapy approach for type 1 diabetes  This program comes to us from our acquisition of Semma Therapeutics in October of 2019  The team of scientists at Semma have cracked the biology on both the production and scale up of fully mature islet cells and has developed a novel implantable device to protect these cells from the immune system  while preserving cell health and function  We have set an ambitious goal to progress this program into clinical development in late 2020 or early 2021 In summary  we ve made outstanding progress in CF and multiple other diseases in 2019  And I look forward to updating you on our progress over the coming months and years I ll now turn the call over to Stuart Stuart A  Arbuckle    Executive Vice President   Chief Commercial OfficerThanks  Reshma  I m pleased to review with you this evening our strong commercial performance for 2019  Our full year 2019 CF revenues were  4 billion  up from  3 billion in 2018  which represents year over year growth of 32   This growth in total revenues was driven primarily by the full year impact of the SYMDEKO launch in the US and Germany  label expansions for our CF medicines globally and the early approval and launch of TRIKAFTA in the US  The launch of TRIKAFTA is off to a very strong start Our fourth quarter total CF product revenues were approximately  1 25 billion  including TRIKAFTA revenues of  420 million  making TRIKAFTA already our top selling medicine  I would note that our fourth quarter revenues include  as expected  launch related stocking of approximately  100 million  Approximately 18 000 patients are eligible for TRIKAFTA in the US  which represents the largest patient population eligible for one of our CF medicines at the time of approval and launch  For 6 000 of these people  this is the first time they have had a medicine to treat the underlying cause of their CF  We are seeing strong interest from all groups of eligible patients  including new initiations  as well as patients transitioning from our other CFTR modulators Our commercial supply  market access  patient support  marketing and field teams were ready for an early approval  And since October  these teams have been doing a phenomenal job with CF centers and commercial and government payers  The centers and their multi disciplinary teams have done a remarkable job responding to the high patient demand  And while still early in the launch  we are on track to obtain broad reimbursement for TRIKAFTA in the US  similar to what we have seen for our other CF medicines  Together  these factors have combined to produce the strong start to the launch Outside the US  we reached multiple reimbursement agreements in 2019 in key countries  which will enable many thousands of patients to initiate treatment with certain Vertex medicines for the first time  While TRIKAFTA will be the main driver of Vertex s revenue growth in 2020  we also expect an increase in international revenues based on more patients initiating treatment with our medicines outside the US In summary  I m pleased that we are bringing our medicines to many more patients around the globe And with that  I will now turn the call over to Charlie Charles F  Wagner    Executive Vice President   Chief Financial OfficerThanks  Stuart  I will provide additional remarks this evening regarding our 2019 financial results  and I will also discuss our 2020 financial guidance  All of the results and guidance  I will discuss  are non GAAP  As Stuart mentioned  we had fourth quarter total CF product revenues of approximately  1 25 billion  a 45  increase compared to 2018  Our fourth quarter 2019 combined R D and SG A expenses were  496 million  including the operating expenses of Exonics and Semma  compared to  400 million in the fourth quarter of 2018  The significant growth in revenues and disciplined spending in the fourth quarter resulted in operating income of  593 million  a 70  increase compared to the fourth quarter of 2018  Net income for the fourth quarter of 2019 was  444 million  compared to  337 million for the fourth quarter of 2018 Our full year financial results reflect a similar story of strong revenue growth and disciplined spending  resulting in exceptional operating income growth  Our total CF revenues for 2019 were  4 billion  a 32  increase over full year 2018  Our 2019 combined R D and SG A expenses were  1 69 billion  compared to  1 53 billion for 2018  Our full year operating income was  1 79 billion for 2019  compared to  1 11 billion for 2018  a year over year increase of more than 60  As our profitability and cash flow increase as a result of treating more CF patients globally  we have deliberately reinvested in both internal and external innovation to create future medicines  In 2019  we invested approximately  1 6 billion in external innovation through new acquisitions and collaborations  Even with the significant BD activity  we ended the year with approximately  3 8 billion in cash and marketable securities  compared to  3 2 billion at the end of 2018  As we look ahead to 2020 and beyond  we expect continued increases in cash flow to provide more flexibility for additional investments to fuel our long term growth Now on to 2020 guidance  Today  we re providing 2020 financial guidance for total CF product revenues as well as for combined non GAAP R D and SG A expenses and our anticipated effective tax rate  The strong uptake of TRIKAFTA and the recent completion of reimbursement agreements outside the US have positioned Vertex for continued strong revenue growth in 2020  Our 2020 guidance for total CF product revenues is  5 1 billion to  5 3 billion  which at the midpoint  reflects approximately 30  growth over 2019  I would note a few dynamics that are reflected in our 2020 guidance  As part of the strong launch of TRIKAFTA that Stuart mentioned  we saw an expected launch related inventory build of approximately  100 million in the fourth quarter that we do not expect to repeat in 2020  Also as we move through 2020 as with all of our CFTR modulators  persistence and compliance dynamics will affect TRIKAFTA revenues and therefore  our experience with our other CF medicines is factored into our guidance  Lastly  we expect gross to net adjustments of 13  to 14  for 2020 Focusing in on Q1 2020  we expect our revenues to be modestly higher than Q4 2019 revenues  This reflects the impact of the fourth quarter inventory build  as well as gross to net adjustments in the first quarter of each year that are generally higher relative to the previous quarter  We expect 2020 combined R D and SG A expenses of  1 95 billion to  2 00 billion  The increase compared to 2019 is primarily driven by the launch of TRIKAFTA globally and the expansion of our R D pipeline into additional diseases  Our R D expense growth includes increased investment to advance our programs and cell and genetic therapies  including type 1 diabetes and DMD Now to tax guidance where we expect our full year non GAAP tax rate to be 21  to 22   The tax rate may fluctuate quarter to quarter with the highest rate occurring in the fourth quarter  The vast majority of our tax provision will be non cash expense until we fully use our net operating losses  As Jeff noted  Vertex has a unique long term growth potential that is based on continued revenue growth in CF and an expanding pipeline  And with continued spending discipline  we expect operating margins  earnings and cash flow to continue to increase Now back to Jeff for a few concluding comments Jeffrey Leiden    Chairman  President   Chief Executive OfficerThanks  Charlie  As this is my last quarterly call as CEO  I hope you indulge me for a couple of minutes for some final comments  First  it has been a tremendous pleasure and honor to lead Vertex for the past eight years  I always say the drug discovery and development is the ultimate team sport  None of our successes would have happened without several incredible teams  First  I want to thank the entire Vertex team  including our senior leadership team  most of whom have been with me for the entire journey  I ve never seen a stronger team in my 35 years in the industry  and I m so proud and grateful for all of their work The commitment of our outstanding senior leaders and employees to execute the Vertex strategy of serial innovation to deliver transformational medicines to patients and to grow the business is the driving force for our recent achievements  and it s also what will differentiate us and position us for long term success for the future Second  I want to thank our Board of Directors and our investors for their constant support encouragement and advice  Even when I first became CEO and we were still losing several hundred million dollars a year  we re trying to develop the first transformative CF medicines And finally  and most importantly  I want to thank the entire CF community  patients  families and caregivers for their courage  their persistent encouragement and their enthusiastic participation in this amazing journey toward a cure for all patients with this devastating disease  I look forward to continuing to work with all of you as Executive Chairman to bring more transformative medicines to patients with serious diseases who are waiting I will now open the line to questions Questions and Answers OperatorThank you   Operator Instructions  Our first question comes from Phil Nadeau with Cowen   Co  Your line is now open Phil Nadeau    Cowen   Co     AnalystGood evening  Thanks for taking my question  Jeff  let me be the first to congratulate you and all that    you and the Vertex team have achieved in your eight years of the CEO tenure  It s really been quite something to watch  Then  my question is just in terms of the numbers  First  Stuart  you mentioned really three buckets of TRIKAFTA patients  those transitioning from ORKAMBI and SYMDEKO  new patients being added to therapy  who had no option prior and the new initiations maybe among the holdouts to dropouts in other populations  Could you give us some sense of the dynamics in those three markets in    of the  300 million in end user demand  Where do they come from And then second  just on the inventory  it seems like  100 million of inventory is really just two to three weeks of inventory given the current run rate  So to be clear on your comments  it s not that you expected inventory to come out of the channel during Q1  It s just that there is no subsequent inventory build given that you re already had a kind of average run rate for inventory in the channel  Thanks Jeffrey Leiden    Chairman  President   Chief Executive OfficerYeah  Great  Phil  I ll take the question on the TRIKAFTA uptake  And then  Charlie can talk to the inventory  So  as you know  we had a very strong launch  There are a number of eligible patient populations  As you might tell from the strong launch  we have had a high level of interest from all patient groups  and we ve seen uptake in all of those patient groups and we expect that to continue into 2020  And so to handle the inventory question  I ll throw that over to Charlie Charles F  Wagner    Executive Vice President   Chief Financial OfficerYeah  Phil  to your question  the    first of all  the inventory build in the fourth quarter was expected  and I d say the magnitude of the build is probably even a little bit less than what you mentioned  But    therefore  I think it s fair to say that  that is a    we commented that  that s a build that won t repeat nor do we expect it to get drawn down significantly  Inventory bounces around a couple of day    a day or two on any given quarter  But that s about the right level Phil Nadeau    Cowen   Co     AnalystThat s very helpful  Thanks for my questions and congrats on the performance OperatorThank you  Our next question comes from Michael Yee with Jefferies  Your line is now open Michael Yee    Jefferies    AnalystHi  thanks for the question  And again  congrats on a great result  And obviously Jeff  you are moving and leaving them with a great position  I guess  I just wanted to ask  Stu  you made some comments just now on where the buckets for  but maybe you could just characterize how you think about the swapping dynamic and was there parts of that number of swapping and how do you think  what percent of swapping could happen throughout 2020  just so we can think about that And then maybe a question for Reshma  I mean I know that there ll be a lot of focus on AAT next  I know you ve given a broad guidance on 2020  Can you just talk about the speed of that study  It s a short study  What you re doing there and how fast we can get that data  It just seems like a very broad timeline for 2020 data  Thank you so much Jeffrey Leiden    Chairman  President   Chief Executive OfficerYeah  Mike  on the uptake of TRIKAFTA  As I said  we ve seen interest across all of the patient groups and that includes those who are currently being treated with one of our existing CFTR modulators  Over time  where we have overlapping labels given the superiority of the TRIKAFTA profile  we expect the vast majority of patients who are eligible for TRIKAFTA are going to switch to TRIKAFTA  Exactly how long that process will take  it is hard to tell obviously  we re early in the launch  but in terms of the destination  the vast majority of those patients are going to transition to TRIKAFTA Reshma Kewalramani    Executive Vice President  Global Medicines Development and Medical Affairs    Chief Medical OfficerHi  Mike  With regard to the alpha 1 antitrypsin deficiency program  I think the one you re referring to is VX 814  That s the one that s furthest ahead  It s the one we started Phase 2 proof of concept dose ranging toward the very tail end of 2019  So actually  it s really very early days  We re just getting going with that study  I m expecting that we will have results from the program in 2020  but it s just way too early to give you more color around that Michael Yee    Jefferies    AnalystOkay  thank you OperatorThank you  Our next question comes from Salveen Richter with Goldman Sachs  Your line is now open Salveen Richter    Goldman Sachs    AnalystThanks for taking my question  And Jeff  congrats on all that you ve achieved at Vertex  So firstly  could you just comment on how the 2019 TRIKAFTA launch hold form the cadence of uptake during 2020  And then secondly  as we looked at the pipeline  any new thoughts around the requirements for the regulatory pathway for alpha 1 antitrypsin here regarding the need for liver biopsy or not  And then secondly with Type 1 diabetes  what does a proof of concept study look like here Stuart A  Arbuckle    Executive Vice President   Chief Commercial OfficerYes  Salveen  it s Stuart  I ll take the question on the 2019 and impact on 2020  So obviously  given the results we ve announced today  off to a very  very strong start  Having said that  there are many patients  We continue to need to get onto TRIKAFTA  So we are expecting continued growth through 2020 in terms of adding patients and that s built into our guidance of  5 1 billion to  5 3 billion  As Charlie said  one other factor to take into account as you think about the cadence or the shape of those revenues is the impact of persistence and compliance and how that will impact revenues  It does have an impact although as we ve seen with our other CFTR modulators  Our expectation is that the levels of persistence and compliance will be high with TRIKAFTA  particularly given the strong clinical profile  And then I think on the AAT and type 1  I think Reshma will take those Reshma Kewalramani    Executive Vice President  Global Medicines Development and Medical Affairs    Chief Medical OfficerSure  So  let me tackle the diabetes question first  And I ll take AAT second  So with regard to the diabetes program  that s the cell therapy program that we acquired through the Semma acquisition  So  I mean the proof of concept I imagine to be something you can think about more akin to sickle cell and our beta thal program versus a small molecule program  And what I mean by that is we are going to be able to go into the clinic right into patients  It s not going to have a healthy volunteer step  And whether we go with the cell program alone or the cell with the device  I think the kind of endpoints you could expect are fairly straightforward ones  glucose levels  hemoglobin A1c  Clearly  hypoglycemic episodes on the safety side will be something that we re watching  But I think that kind of gives you a good sense for what we re going to be watching for The other thing to mention is  I think that you can again    similar to beta thal and sickle cell  I anticipate that the proof of concept studies are going to be a reasonable size and a very reasonable duration  With regard to the AAT program  we have not had further regulatory interactions  And so  as I ve commented on before  I was impressed with the October 2019 FDA conference  what the agency indicated was that they would work with each sponsor depending on their approach for what the regulatory enabling endpoint would be  and I anticipate that the key points that we would be looking for from this program that s ongoing is functional serum AAT levels  And as we think forward beyond that  we just need to get through the regulatory interactions  I will remind you that the augmentation companies receive their approval based on AAT levels  That s just the data point to look at  And the last thing I ll say is our approach is obviously very different than those out there and that the small molecule corrector approach holds the opportunity to treat both the liver and lung manifestations  And so  obviously  we re going to be talking through what those liver manifestations and what those endpoints would look like as well Salveen Richter    Goldman Sachs    AnalystGreat  thank you OperatorThank you  Our next question comes from Paul Matteis with Stifel  Your line is now open Paul Matteis    Stifel Nicolaus    AnalystGreat  thank you so much for taking the questions  Just one quick question on guidance  Even with considering inventories when we just take your comments on 1Q  it looks like you re already pretty close to annualizing at the full year number you outlined  And so  we just wanted to get a better understanding of the dynamics that go into your guidance  Are you just being conservative or is there a reason that uptake is slow And then  just second quickly on the cell therapy program in diabetes  I was just curious how do you think about a realistic clinical goal for that program  and do you feel like the bar for true commercial success is insulin independence or are there other ways we should think about a potential benefit  Thanks so much Charles F  Wagner    Executive Vice President   Chief Financial OfficerHey  Paul  this is Charlie  I ll take the first question on guidance  And I would not characterize the guidance is conservative  I think it s appropriate given what we know about the TRIKAFTA launch so far  as well as the reimbursement agreements that we signed in the fourth quarter  Again  just to touch back on the inventory topic  it s tempting to look at the Q4 run rate and want to extrapolate from that  but if you take the  1 25 billion back out of  100 million for the inventory build  you re at  1 15 billion into the guidance  obviously implies significant growth over that  And then again as we touched on    in the remarks  the impact of persistence and compliance is meaningful and will come into the revenues over the course of 2020  So once you factor those things in  we think that the guidance is absolutely appropriate And candidly  when you think about the  5 2 billion number at the midpoint  so  1 2 billion increase year over year  a 30  growth rate  it sets us up for another very strong year Reshma Kewalramani    Executive Vice President  Global Medicines Development and Medical Affairs    Chief Medical OfficerPaul  I ll take the question on the cell therapies program and type 1 diabetes  So if you think about the current approach to type 1 diabetes and whether you think about insulin just injection or you think about closed loop systems or you think about really anything that s available there  what you realize in these over 1 million people who have this disease  neither is the glucose control particularly good  whether you look at glucose or hemoglobin A1c  nor is it particularly safe on the other side  that s to speak to the hypoglycemic episodes Then if you look at cadaveric transplants  that actually shows that people who cadaveric transplants  islet cell transplants  They do very well in terms of glucose control and don t have the deficiencies with hypoglycemia  Now  the problem there of course is that just aren t enough islets    there are not enough cadavers for transplant and then there is the issue of immunosuppression  So the real beauty in this approach and why we re so very excited about this is Doug Melton and the Semma Group have come up with a way to not only produce  but to scale these islet cells and that holds the potential for really excellent glucose control like the cadaveric transplant without the hypoglycemic episodes  So that s what the real goal here is Paul Matteis    Stifel Nicolaus    AnalystGreat  thanks for the color  Appreciate it OperatorThank you  Our next question comes from Alethia Young with Cantor Fitzgerald  Your line is now open Alethia Young    Cantor Fitzgerald    AnalystHey  guys  Thanks for taking my question  Congrats on the quarter  And Jeff  certainly you will be missed in the CEO seat  incredible run  I think we call that CEO might drop  So my two questions are  I guess  when you re thinking about in the field  what have been kind of the biggest surprises  I know you guys talked about bottlenecks and maybe potentially just so much demand  have you seen that to be the case or has been a little better  And then my second question is  it might be a little early  but do you think of compliance and persistence are trending more like a KALYDECO or kind of what are the puts and takes that you think about that as a dynamic in 2020  Thanks Jeffrey Leiden    Chairman  President   Chief Executive OfficerYeah  Alethia  thanks very much for the question  You re right  Prior to the launch  there was a couple of potential bottlenecks as you ve described them that we were concerned about  One was concerns that CF centers  it raised with us about the capacity constraints  They felt they might have given 18 000 patients were going to be eligible for full TRIKAFTA  I have to say they have done a spectacular job in responding to the high level of patient demand  And while they have certainly been some bottlenecks at some centers  in general the multi disciplinary teams have jumped  just an amazing job working to get patients initiated on the medicine  The other potential bottleneck as always with a new product launch is whether we are going to get support from payers  And again  our teams have done a great job working with both government and commercial payers  And clearly  we wouldn t have been able to deliver the results we have in the fourth quarter without very significant access  So both of those bottlenecks have actually    we ve been pleasantly surprised with how well those have turned out in Q4  and I expect that to continue in 2020 In terms of compliance and persistence  really  it s just too early to say in the real world exactly what that is going to look like  We do expect it to be high  We do expect it to be in the range of our other CFTR modulators  which is very high for both of those aspects and certainly given the profile  we d expect it to be similar with TRIKAFTA it has been for all of the medicines  but really too early to tell exactly what it s going to be like for this medicine in the real world Alethia Young    Cantor Fitzgerald    AnalystGreat  thanks OperatorThank you  Our next question comes from Whitney Ijem with Guggenheim  Your line is now open Whitney Ijem    Guggenheim Securities    AnalystHey  guys  Thanks very much for the question  I wanted to follow up on type 1 diabetes  so it sounded like it wasn t clear whether or not you d be moving forward into the clinic with the naked cells or the encapsulation  and I m wondering if you can give us any more color on what the exact encapsulation technology or devices at this point Reshma Kewalramani    Executive Vice President  Global Medicines Development and Medical Affairs    Chief Medical OfficerSure  Thanks so much for the question  It s really one of my favorite late preclinical development progress to talk about for a few reasons  But with regard to your specific question  you re right  we have two shots on goal here  so to speak  One  development pathway involved the cells alone  And for example  that is attractive in a couple of different potential areas  One of them would be patients who are renal transplant recipients as an example  who are on immunosuppressive therapy anyway and they have their renal transplant because of type 1 diabetes  the naked cell approach or the cell alone approach there could be a nice pathway The encapsulation is a device  The Semma Group has not only done amazing work with regard to the development and the maturation of cells and the industrial scale up  but they ve done a really nice job with the device  The device has to be particular  And others have tried this in the past and it s a tough problem to solve  The device is different and I think is really has the opportunity to succeed here for a few different reasons  It has to do with the geometry  It has to do with the material  It needs to allow glucose and insulin to free flow  but to keep the cells in their state  And it also has to do with ensuring that the device in the cells get sufficient oxygenation and that there is in fibrosis  And the data that we have seen to date including in large animals tells us that that s so Whitney Ijem    Guggenheim Securities    AnalystGot it  And just a quick follow up  So we will be moving the encapsulation program forward into the clinic first and you sort of abandoned the naked cell approach or is it still the nearest  which will go first  Thanks Reshma Kewalramani    Executive Vice President  Global Medicines Development and Medical Affairs    Chief Medical OfficerYeah  You can think of it in terms of having two shots on goal  And it s just a matter of which one goes first  But you can think of it as two programs OperatorThank you Michael Partridge    Senior Vice President Investor RelationsOperator  next question please OperatorOur next question comes from Robyn Karnauskas with SunTrust Robinson Humphrey  Your line is now open Robyn Karnauskas    SunTrust Robinson Humphrey    AnalystHi  thank you for taking my question and thanks Jeff for all the hard work you put in  It s been great  So two questions  one for Charlie  First  you have cash that s accumulating  It looks like the studies that you re about to do may not be as expensive  they re very tight and they re maybe small  at least for the next few years  So how are you thinking about thus maximizing cash without running the risk of having loyalty balance sheet  And then Reshma  for pain  you just continued one program  What are you looking for versus the original VX 150  Thanks Charles F  Wagner    Executive Vice President   Chief Financial OfficerSure  Robyn  Thanks for the question  As you point out  the business model is running very well right now and we are generating cash  which gives us flexibility  We continue to feel that the best use of our cash is to reinvest in the business  both in terms of internal innovation and also external innovation  Again  you saw us have a very active year in 2019 with  1 6 billion on a number of deals that got us access to some great enabling technology and some programs that are a perfect fit with our research strategy  So going forward  we will continue to be active in business development to the extent that we have additional cash flow in 2020  That s where the priority will be  I m not going to say that we re committing to a certain number of deals or a certain volume of cash flow  Everything needs to be governed by the research strategy  and the corporate strategy will stay disciplined  but you continue    you will continue to see us be active in 2020 Reshma Kewalramani    Executive Vice President  Global Medicines Development and Medical Affairs    Chief Medical OfficerRobyn  this is Reshma  I ll take the question about pain  So Robyn  I would think about pain just like CF and frankly all of our program  The approach here in Vertex speak is first crack the biology  then pour on the chemistry  And where we are with the pain program is we ve cracked the biology  And I feel confident saying that because of the VX 150 results that we saw in three Phase 2 studies  right in acute pain and neuropathic pain and in osteoporosis  So what we re really doing now is part 2  which is pour on the chemistry  And this is about finding  let me call is the ideal molecule  particularly in this disease state  Safety and efficacy of course  table stakes  But what we re really looking for is a molecule with the perfect PK  something that can be dosed once or twice a day  given that we re talking about pain condition in this instance  We need to ensure that this medicine can be taken with food or without food  If you re talking about acute pain  immediately post surgery being able to take it with our food is going to be really important  We re also thinking about DDIs and COGS  And so  really I guess  I would describe it to you as we re at the stage of pouring on the chemistry and this is our search for the ideal molecule for this pain condition  or I should actually describe as conditions  we think about it as three distinct groups in there Robyn Karnauskas    SunTrust Robinson Humphrey    AnalystAll right  Thank you OperatorThank you  Our next question comes from Cory Kasimov with JPMorgan  Your line is now open Cory W  Kasimov    J P  Morgan    AnalystHey  good afternoon guys  Thanks for taking the question  Congrats on a great quarter  Only you pre announced this a couple of weeks ago  you could have made that Investor Conference a little more exciting this year  I guess  first question I have for you is regarding AAT  As clinical work ramps  are you seeing any broader based efforts to help with the diagnosis rate and what kind of education can you do there to facilitate the process while in development Reshma Kewalramani    Executive Vice President  Global Medicines Development and Medical Affairs    Chief Medical OfficerYeah  Cory  let s take this in two parts  If you would mind  this is Reshma  I ll make a few comments and then I m going to turn it over to Stuart to tell us a little bit more about the market opportunity and such  Cory  as we start our clinical trials and really start to engage with the community  which we ve already started to do  what you realize and what you re alluding to is absolutely true  Unlike CF  this is a disease where there isn t newborn screening and there isn t 100  diagnosis  And while there is a 510 cleared CE marked assay for antigenic level  the diagnosis is not done that frequently  We are working with the community  We are engaged with the Alpha 1 Foundation  And I do see that group providing a real good amount of education  and I see an opportunity to do even more  Let me ask Stuart to comment from his vantage point Stuart A  Arbuckle    Executive Vice President   Chief Commercial OfficerYeah  Cory  So in terms of what we know about the market today  this estimated to be about 100 000 people with the ZZ genotype in the US and the EU  Almost definitely  that s an underestimate  but let s just take that as a starting point  only a fraction of those patients are currently diagnosed to your point  and only a fraction of those that are diagnosed are actually actively treated with the current standard of care  which is the IV augmentation therapy  So if we are able to bring to the market a product  which treats the underlying cause of the disease  which has impact on both the lung and the liver and is an oral small molecule  we think there is multiple opportunities here  One is clearly potentially to replace some of the IV augmentation therapies  Another opportunity would be to increase the treatment rate in those patients who are already diagnosed  But we also do think there is a significant opportunity to increase the diagnosis rate The diagnosis is not difficult to do  It s a simple blood test  It s currently included within treatment guidelines that  that should be done for patients diagnosed with COPD  But I think as so often the case where you don t have a solution  people don t go looking for the problem  And so  we do anticipate that could be an increase in those diagnosis rates  if we are able to bring a better solution to the market Cory W  Kasimov    J P  Morgan    AnalystGreat  thanks guys  Appreciate taking the questions OperatorThank you  Our next question comes from Matthew Harrison with Morgan Stanley  Your line is now open Kostas Biliouris    Morgan Stanley    AnalystHello  this is Kostas on for Matthew  Congratulations on the quarter  Two questions from me  The first one is  can you give us some sense for how to think about the dynamics of European revenues in 2020 please Jeffrey Leiden    Chairman  President   Chief Executive OfficerYes  I ll take that  We were able to finalize reimbursement agreements in a number of major European countries toward the back end of 2019  And as we anticipated  we did not see much of a contribution of those reimbursement agreements in 2019 because even having secured those agreements  you have to work through the administrative process before patients can be initiated  We are expecting our European revenues to grow in 2020 as more patients are able to access our CFTR modulators and that s incorporated in the  5 1 billion to  5 3 billion guidance that Charlie talked to earlier on the call Kostas Biliouris    Morgan Stanley    AnalystThank you  And my second question is on APOL1 mediated kidney disease program  You have mentioned that you are planning to use the protein urea as a clinical market  I was wondering whether you need more key efficacy endpoints or these would suffice Reshma Kewalramani    Executive Vice President  Global Medicines Development and Medical Affairs    Chief Medical OfficerSure  Thanks  Kostas  This is Reshma  I ll take that one  So  for those who may not be as familiar with this one  this is the VX 147 program and this is going into patients    into the clinic in Phase 2 now actually  This is for APOL1 mediated FSGS  So  Kostas  as you may know  the renal community along with regulatory agencies have for the past many years thought and discussed what the appropriate regulatory enabling endpoint might be for a homogeneous pro generic kidney disease  that s a mouthful  but basically what I m saying is that there is a lot of support and what the idea here would be is to measure protein in the urine  That s a fairly simple thing to do  And when you have a disease that s a homogeneous protein leaking disease that most people believe and this has been discussed extensively in the community that protein in the urine is the right measure for one to evaluate  So that s what we re going to be evaluating in this Phase 2 study  and that s the study that is now getting under way Kostas Biliouris    Morgan Stanley    AnalystThank you very much  and congratulations again OperatorThank you  Our next question comes from Liisa Bayko with JMP Securities  Your line is now open Liisa Bayko    JMP Securities    AnalystHi  Wanted to also wish congratulations to the team and during the transition  Wanted to ask about the European roll out  Can you just get into a little more specifics on sort of timing of the different countries  And what you think on ramping could look like given that this is serve a new therapy that s available on some countries  meaning they haven t had access to CFTR modulators in the past  Thanks Jeffrey Leiden    Chairman  President   Chief Executive OfficerYeah  I think there s really two aspects to that question  Liisa  One is the timing in different countries of the uptake of our current medicines  which are approved in Europe  And clearly  we expect that as I had mentioned earlier to begin now that we have reimbursement agreements in some of the major countries  UK  Spain  France  etc  for existing CFTR modulators  In terms of how that might play out for the triple combination  clearly  we have that submission in with the regulatory authorities  Our expectation is for an approval in Q4 of this year and as you know  the regulatory approval is really the trigger to the beginning of reimbursement discussions  And so within our guidance for 2020  there is minimal triple combination regimen revenues included within that guidance OperatorOkay Michael Partridge    Senior Vice President Investor RelationsOperator  we have time for one more question OperatorThank you  Our final question comes from Brian Abrahams with RBC Capital Markets  Your line is now open Brian Abrahams    RBC Capital Markets    AnalystHi there  thanks for taking my questions and congratulations on the quarter and congratulations  Jeff  to on all your accomplishments  What s been your feedback on real world experience with TRIKAFTA efficacy and safety  To what degree  that s been aligning with the clinical trial experiences  anything unexpected or different there  And then secondarily  can you remind us of your plan to collect longer term outcomes data with TRIKAFTA things like exacerbations  the timeline for updating that and how important you think that will be for full market penetration in the US as well as European access  Thanks Jeffrey Leiden    Chairman  President   Chief Executive OfficerSo in terms of the real world experience  I say    I would say  has been very similar to what we saw in the Phase 3 program  Brian  The feedback we ve had from physicians and patients has been almost universally positive  And when I say positive  their experience of the level of efficacy and the impact it s having on their lives is really inspiring  Obviously  safety is something  which needs to play out over time  But certainly  we haven t seen anything in the real world that has surprised us that has been different from what we saw in the Phase 3 programs  And as you know  those studies demonstrated a very  very strong benefit risk profile  In terms of outcomes data and what data we re going to be collecting  I ll hand that over to Reshma Reshma Kewalramani    Executive Vice President  Global Medicines Development and Medical Affairs    Chief Medical OfficerSure  So  Brian  you know that we    in the Phase 3 program for the FMS patients  that was the program with about 400 patients that went out to 24 weeks  We already reported on pulmonary exacerbations and it was a really large reduction of 63   We are continuing to collect data  So patients in both the FS study and the FMS study rolled over into an open label extension  that goes out through 96 weeks  And in addition to that  we have additional studies that we re doing  collecting data from various registries  not only here in the US  but as we ve done with our other CFTR modulators around the globe as well  So we have more data to look forward to not only from the clinical trials program  the open label extension  but also registry data that we re collecting and will be collecting around the globe Brian Abrahams    RBC Capital Markets    AnalystThanks very much Michael Partridge    Senior Vice President Investor RelationsOkay  On behalf of everyone here  thanks everybody for listening to tonight s call  Thanks also for all the kind words  We know that there are other earnings call tonight  So we ll let you get to them  And at the same time  the IR team is in the office and happy to talk to you if you have additional questions Operator Operator Closing Remarks Duration  49 minutesCall participants Michael Partridge    Senior Vice President Investor RelationsJeffrey Leiden    Chairman  President   Chief Executive OfficerReshma Kewalramani    Executive Vice President  Global Medicines Development and Medical Affairs    Chief Medical OfficerStuart A  Arbuckle    Executive Vice President   Chief Commercial OfficerCharles F  Wagner    Executive Vice President   Chief Financial OfficerPhil Nadeau    Cowen   Co     AnalystMichael Yee    Jefferies    AnalystSalveen Richter    Goldman Sachs    AnalystPaul Matteis    Stifel Nicolaus    AnalystAlethia Young    Cantor Fitzgerald    AnalystWhitney Ijem    Guggenheim Securities    AnalystRobyn Karnauskas    SunTrust Robinson Humphrey    AnalystCory W  Kasimov    J P  Morgan    AnalystKostas Biliouris    Morgan Stanley    AnalystLiisa Bayko    JMP Securities    AnalystBrian Abrahams    RBC Capital Markets    Analyst
More VRTX analysis
All earnings call transcripts",2020-01-30,The Motley Fool,https://invst.ly/pp6ro,2072524
119850,341365,VRTX,Vertex Pharmaceuticals  VRTX  Stock Moves  0 11   What You Should Know,opinion,"Vertex Pharmaceuticals  NASDAQ VRTX  closed the most recent trading day at  223 79  moving  0 11  from the previous trading session  This change was narrower than the S P 500 s 0 28  loss on the day  Meanwhile  the Dow lost 0 42   and the Nasdaq  a tech heavy index  lost 0 03  
Prior to today s trading  shares of the drugmaker had gained 2 12  over the past month  This has outpaced the Medical sector s gain of 1 32  and lagged the S P 500 s gain of 3 31  in that time 
Wall Street will be looking for positivity from VRTX as it approaches its next earnings report date  On that day  VRTX is projected to report earnings of  1 20 per share  which would represent a year over year decline of 7 69   Meanwhile  our latest consensus estimate is calling for revenue of  996 44 million  up 14 52  from the prior year quarter 
It is also important to note the recent changes to analyst estimates for VRTX  These revisions help to show the ever changing nature of near term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  Over the past month  the Zacks Consensus EPS estimate remained stagnant  VRTX is currently sporting a Zacks Rank of  3  Hold  
Digging into valuation  VRTX currently has a Forward P E ratio of 33 53  This valuation marks a premium compared to its industry s average Forward P E of 25 55 
We can also see that VRTX currently has a PEG ratio of 1 14  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  Medical   Biomedical and Genetics stocks are  on average  holding a PEG ratio of 1 67 based on yesterday s closing prices 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This group has a Zacks Industry Rank of 49  putting it in the top 20  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2020-01-07,Zacks Investment Research,https://www.investing.com/analysis/vertex-pharmaceuticals-vrtx-stock-moves-011-what-you-should-know-200497086,200497086
119851,341366,VRTX,Vertex Pharmaceuticals  VRTX  Expected To Beat Earnings Estimates  Should You Buy ,opinion,"Vertex Pharmaceuticals  NASDAQ VRTX  is expected to deliver a year over year decline in earnings on higher revenues when it reports results for the quarter ended December 2019  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The earnings report  which is expected to be released on January 30  2020  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This drugmaker is expected to post quarterly earnings of  1 20 per share in its upcoming report  which represents a year over year change of  7 7  
Revenues are expected to be  996 44 million  up 14 5  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Vertex 
For Vertex  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  14 07  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination indicates that Vertex will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Vertex would post earnings of  1 14 per share when it actually produced earnings of  1 23  delivering a surprise of  7 89  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Vertex appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2020-01-23,Zacks Investment Research,https://www.investing.com/analysis/vertex-pharmaceuticals-vrtx-expected-to-beat-earnings-estimates-should-you-buy-200501097,200501097
119852,341367,VRTX,Is Vertex Pharmaceuticals Stock Still a Strong Buy ,news,"Vertex Pharmaceuticals  NASDAQ VRTX   a top shelf rare disease drugmaker  posted stellar fourth quarter results after the closing bell Thursday  The company absolutely crushed Wall Street s consensus bottom  and top line estimates for the three month period  thanks to the outstanding performance of its new cystic fibrosis  CF  medication Trikafta  along with other key CF drugs like Symdeko Symkevi  
Is Vertex s stock a strong buy on the heels of this outstanding Q4 report  That s a tricky question to answer  At present  Vertex sports one of the richest valuations in the entire healthcare sector  which would seem to indicate that this quarterly beat was already baked into the biotech s share price  A deeper look under the hood  however  reveals that this highly prized rare disease company is still a great buy for long term investors  Here s why 

Vertex s deep value
Vertex has earned its premium valuation  As things stand now  Vertex is the undisputed king of the CF drug landscape  What s more  there are no serious competitive threats to Vertex s dominance in CF  The company  in fact  won t even face a major generic threat in CF until the latter half of the next decade  And by then  there s a good chance that Vertex will have changed the game yet again  with the advent of an entirely new class of CF treatments 
The big deal is that CF is forecast to grow into a  10 billion per year drug market by 2026  So while Vertex s ginormous price to sales ratio of 16 36 may seem unreasonable at first glance  the truth is that the biotech s stock is probably only trading at something like six or seven times 2026 revenue    and that may be a gross overestimate  The biotech  after all  is currently pursuing a diverse range of additional high value indications  
What else does Vertex offer  Right now  the biotech has promising clinical and pre clinical assets in development for alpha 1 antitrypsin deficiency  APOL1 mediated kidney diseases  diabetes  Duchenne muscular dystrophy  DMD   pain  and severe hemoglobinopathies  Vertex almost certainly won t come to dominate all of these high value indications  but it should at least end up deriving a significant portion of its future revenue from sources outside the realm of CF 
The company s gene editing collaboration with Crispr Therapeutics  for instance  could easily produce a few billion in annual revenue through the development of functional cures for the rare blood disorders sickle cell disease and beta thalassemia  Its cutting edge work on deadly muscle wasting disorders like DMD could turn out to be a game changer from a value creation standpoint as well     
Another key area to keep an eye on is Vertex s rapidly growing war chest  At the end of the fourth quarter  the company reported having cash  cash equivalents  and marketable securities of  3 8 billion  With its free cash flows set to take a huge jump this year with Trikafta s commercial launch under way  the biotech may end the year with close to  5 billion in the bank  That s a healthy amount of cash for potential business development activities  Simply put  Vertex might emerge as a major force on the merger and acquisition scene in the not so distant future   
Time to buy 
On the surface level  Vertex comes off as just another overpriced biotech stock due for a major correction  But that perfunctory assessment doesn t account for the biotech s rock solid competitive moat in CF  first class clinical pipeline  and proven track record of bringing innovative new treatments to market in a timely manner  Moreover  this biotech stock is arguably dirt cheap once you factor in its long term commercial opportunity in CF    and that s not even considering its massive potential in other disease areas such as diabetes  pain  etc  In short  Vertex s stock is worth the price of admission ",2020-01-31,The Motley Fool,https://invst.ly/ppgqg,2073011
119853,341368,VRTX,Can CF Drugs Drive Growth For Vertex  VRTX  In Q4 Earnings ,opinion,We expect Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   to beat on earnings when it reports fourth quarter 2019 and full year results on Jan 30  2020  after the market closes Vertex boasts an excellent earnings surprise history  surpassing expectations in each of the trailing four quarters  the average being 17 59   In the last reported quarter  the company delivered a positive surprise of 7 89  Shares of Vertex have rallied 22  in the past year versus the  5 1  decrease Let s see  how things are shaping up for the quarter to be reported Factors at PlayVertex s cystic fibrosis  CF  drug portfolio has been performing well  Sales growth in the last reported quarter was driven by a rapid uptake of the company s newest CF medicine Symdeko  a trend that most likely continued in the fourth quarter  The drug  a combination of tezacaftor and ivacaftor  has seen solid demand since its launch in 2018 as more patients are resorting to treatment with the same In June 2019  the FDA approved Symdeko to treat children  aged from six to 11 years  affected by CF with certain mutations in the CFTR gene  This label expansion reflected on incremental sales in the last reported quarter  a trend that most likely continued in the fourth quarter as well Meanwhile  Vertex s other two CF medicines Kalydeco  ivacaftor  and Orkambi are expected to have contributed to the company s top line in the to be reported quarter In the quarter to be reported  Vertex gained a reimbursement approval in England for Orkambi and Symkevi and in France for Orkambi  The reimbursement nods are expected to have driven Vertex s revenues from ex U S  markets in the soon to be reported quarter Key DevelopmentsIn October 2019  the FDA approved Vertex s triple combination regimen Trikafta  elexacaftor tezacaftor ivacaftor and ivacaftor  for the treatment of CF in patients aged 12 years and older  who have at least one copy of the F508del mutation in their CFTR gene  The approval of Trikafta  which can treat about 90  of total CF patients  came five months before the scheduled PDUFA date in March 2020 A regulatory application in the EU seeking approval of elexacaftor tezacaftor ivacaftor combination regimen was validated by the European Medicines Agency  EMA  on Oct 31  2019 We expect management to provide a thorough update on this recent nod and discuss the launch activities for Trikafta during the upcoming investors  call Meanwhile  in November 2019  Vertex and partner CRISPR Therapeutics   NASDAQ CRSP   announced positive preliminary safety and efficacy data from the ongoing phase I II studies evaluating their CRISPR Cas9 gene editing therapy  CTX001  for two severe blood disorders  namely sickle cell disease  SCD  and adult transfusion dependent b thalassemia  TDT  Vertex believes that the interim data from the above mentioned study demonstrated meaningful benefits from CTX001 for patients following a one time intervention  Investors will be keen to get the latest details on the same during fourth quarter earnings call Last month  the European Commission granted marketing authorization to Kalydeco for its expanded use in infants aged from six to less than 12 months with at least one of specified nine mutations in the CFTR gene  Though this label expansion nod is unlikely to have driven Kalydeco sales in the fourth quarter  we expect the same to have contributed to the company s top line in future quarters Earnings WhispersOur proven model predicts an earnings beat for Vertex this season because it has the right combination of the two key ingredients  a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for a likely positive surprise Earnings ESP  Vertex has an Earnings ESP of  14 07   representing the difference between the Most Accurate Estimate of  1 37 and the Zacks Consensus Estimate of  1 20  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Vertex currently has a Zacks Rank  3 Vertex Pharmaceuticals Incorporated Price and EPS Surprise   Other Stocks to ConsiderHere are some other large drug biotech stocks that have the perfect mix of elements to also beat on earnings this time around Regeneron Pharmaceuticals   NASDAQ REGN   has an Earnings ESP of  3 50  and a Zacks Rank of 3  The company is scheduled to release earnings results on Feb 6  You can see  Alexion Pharmaceuticals  Inc    NASDAQ ALXN   has an Earnings ESP of  5 97  and a Zacks Rank  2  The company is scheduled to release earnings results on Jan 30 5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2020-01-27,Zacks Investment Research,https://www.investing.com/analysis/can-cf-drugs-drive-growth-for-vertex-vrtx-in-q4-earnings-200502191,200502191
119854,341369,VRTX,Why Vertex  VRTX  Might Surprise This Earnings Season,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Vertex is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for VRTX in this report In fact  the Most Accurate Estimate for the current quarter is currently at  1 33 per share for VRTX  compared to a broader Zacks Consensus Estimate of  1 21 per share  This suggests that analysts have very recently bumped up their estimates for VRTX  giving the stock a Zacks Earnings ESP of  9 60  heading into earnings season Vertex Pharmaceuticals Incorporated Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that VRTX has a Zacks Rank  3 and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here Clearly  recent earnings estimate revisions suggest that good things are ahead for Vertex  and that a beat might be in the cards for the upcoming report Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2020-01-28,Zacks Investment Research,https://www.investing.com/analysis/why-vertex-vrtx-might-surprise-this-earnings-season-200502581,200502581
119855,341370,VRTX,Where Will Vertex Pharmaceuticals Be in 10 Years ,news,"It s easy to grasp how Vertex Pharmaceuticals  NASDAQ VRTX  got to where it is today  A decade ago  the biotech s market cap hovered around  8 billion  Vertex s lead pipeline candidate was hepatitis C virus  HCV  drug telaprevir  which went on to win FDA approval in 2011  The drug was marketed under the brand name Incivek    but only briefly  Vertex quit selling the HCV drug in 2014 because Gilead Sciences  HCV franchise was dominating the market 
However  Vertex had another program in development targeting cystic fibrosis  CF   Its first CF drug  Kalydeco  won FDA approval in 2012  The rest is history  Vertex went on to gain FDA approvals for three other CF drugs  It s now highly profitable with annual revenue approaching  4 billion  And its stock has skyrocketed more than 500  over the last 10 years 
Trying to predict where Vertex will be 10 years from now isn t as easy  But there are some clues from the present that point to the prospects for another highly successful decade for the biotech 

A reigning juggernaut
The safest prediction of all for Vertex is that it will remain a juggernaut in CF in 2030  Vertex won FDA approval for its most powerful CF drug yet    Trikafta    in October 2019  European approval for the drug is likely on the way this year 
Vertex expects that Trikafta will expand the addressable patient population for its CF therapies by more than 50   The company also has three other CF drugs in its pipeline  including two programs that  like Trikafta  are triple drug combos 
Currently  there are no other approved drugs that treat the underlying cause of CF  AbbVie is evaluating a triple drug CF combo that it picked up from Galapagos in a phase 1 clinical study  but it s way behind Vertex  Even if AbbVie s drug proves to be successful  it would at best be several years before the drug could win approval  By that time  Vertex will already have further entrenched itself in the CF market 
Although the patents for Kalydeco  Orkambi  and Symdeko will expire near the end of the decade  Vertex s patents for Trikafta won t expire until 2037  The company could face generic rivals for its older CF drugs  but there s no reason to expect that Vertex s CF franchise won t still be racking up huge sales 
Most likely additions
Vertex doesn t plan on being a one indication company 10 years from now  though  The biotech has been busy expanding its pipeline and advancing the most promising programs 
The most likely addition to Vertex s lineup in 2030 will be a pain medication  Vertex has already completed phase 2 clinical studies for experimental pain drug VX 150  Chief Medical Officer and soon to be CEO Reshma Kewalramani said in Vertex s Q3 conference call in October that the company is  advancing multiple selective NaV1 8 inhibitors through late stage research and early clinical development  
I think that Vertex and its partner CRISPR Therapeutics also have a good chance of launching a few years from now a gene editing therapy that effectively cures rare blood disorders beta thalassemia and sickle cell disease  The two companies are currently evaluating gene editing therapy CTX001 in phase 1 2 studies targeting both indications and have reported encouraging preliminary results 
Another indication that could be a big winner for Vertex by the end of this decade is alpha 1 antitrypsin deficiency  AATD   Like CF  AATD is a rare genetic disease caused by misfolding proteins  Vertex has two experimental AATD drugs in early stage testing  My hunch is that the company s CF expertise combined with the similarity between AATD and CF could boost the odds of success for this program  
Vertex also has an early stage program targeting APOL 1 mediated kidney diseases  The biotech hopes to advance a drug to phase 2 testing this year  If all goes well  this could be yet another new arena for Vertex to dominate by the end of the decade  
A potential game changer
Then there s the huge potential game changer  Vertex acquired privately held Semma Therapeutics for  950 million last year  Semma is developing a drug that could cure type 1 diabetes 
Semma s approach is to turn pluripotent stem cells into islets that produce insulin in the needed amounts to keep blood sugar levels in check  This program is in its very early innings right now  So far  Semma has conducted promising lab tests but hasn t initiated any clinical studies in humans 
Curing type 1 diabetes presents an enormous opportunity for Vertex  Over 1 5 million people have type 1 diabetes in the U S  alone  Vertex has had its eye on several companies in recent years that have made progress in addressing issues related to islet transplantation to treat type 1 diabetes  The big biotech thinks that Semma has a solution and is confident enough about its prospects to write a really big check to acquire the small drugmaker 
The future looks bright
Will Vertex really have successful drugs on the market that target five or more rare genetic diseases in addition to more common indications like pain and type 1 diabetes 10 years from now  There s no way to know for sure  Many promising early stage programs fail along the way 
However  there are some things we can be certain about with Vertex  It claims a commanding lead in CF  It has the expertise needed to develop therapies targeting other rare genetic diseases  It has plenty of money to continue investing in research and development and acquisitions  And it has multiple shots on goal  Not all of them have to pan out for Vertex to win 
My view is that Vertex is the best biotech stock on the market right now  I think that it s future looks really bright ",2020-02-02,The Motley Fool,https://invst.ly/pp-lz,2073854
119856,341371,VRTX,Big Drug Biotech Stock Earnings On Jan 30  BIIB  ALXN   More,opinion,"The fourth quarter reporting cycle for the  sector has just started  The sector comprises pharma biotech and medical device companies Drug and biotech stocks  quarterly results are likely to reflect the positive impact of new drug approvals and label expansions of already marketed drugs  However  rising generic competition for legacy drugs may have offset growth of newer drugs Per the  report  as of Jan 23  5 7  of the companies in the Medical sector  constituting nearly 23 7  of the sector s market capitalization  reported earnings  While two third of the reported beat earnings estimates  one third of them beat sales estimates  Earnings are up 4 4  year over year on 3 9  higher revenues Overall  fourth quarter earnings and sales growth for this sector is expected to be 3 6  and 5 4   respectively Pharma giant J J   NYSE JNJ   reported its  for the fourth quarter last week  The company beat estimates for earnings but missed the same for sales  Pharma segment sales were above market expectation despite currency headwinds and the impact of biosimilar and generic competition  Another big player in the pharma segment  Pfizer   NYSE PFE    dismal fourth quarter results earlier this week as it missed estimates on both counts Let s analyze five big pharma biotech companies that are set to report fourth quarter 2019 results on Jan 30 What Our Model SuggestsPer our proven model  the combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat   You can uncover the best stocks to buy or sell before they re reported with our  Multiple sclerosis drugmaker  Biogen Inc    NASDAQ BIIB   is scheduled to report before market open The company s performance has been impressive so far  with earnings beating estimates in each of the trailing four quarters  It has a four quarter positive surprise of 9 3   on average  In the last reported quarter  the company s earnings beat estimates by 10 88  For the quarter to be reported  Biogen has an Earnings ESP of  1 89  and a Zacks Rank  3  You can see  The Zacks Consensus Estimate for earnings stands at  7 95 per share Sales of Biogen s multiple sclerosis drugs are likely to have remained flat year over year in the fourth quarter  However  royalties from sales of Roche s newly launched MS drug  Ocrevus is likely to have contributed significantly to the top line  Patient growth in the United States and volume increase in Europe and Japan for Tecfidera are likely to have been offset by ongoing price decreases in certain European countries  Higher demand for Spinraza and the biosimilars portfolio are likely to have driven revenues   Read more   Biogen Inc  Price and EPS Surprise
 

   Alexion Pharmaceuticals  Inc     NASDAQ ALXN    which has an impressive track record so far  is also scheduled to report results before market open The company beat earnings estimates in each of the trailing four quarters with the average being 12 5   In the last reported quarter  the company s earnings beat estimates by 12 05   For the quarter to be reported  Alexion has an Earnings ESP of  5 97  and a Zacks Rank  2  The Zacks Consensus Estimate for earnings stands at  2 58 per share Alexion s key drugs  Soliris and Ultomiris  are likely to have driven the top line in the fourth quarter   Read more    Alexion Pharmaceuticals  Inc  Price and EPS Surprise
    Vertex Pharmaceuticals   NASDAQ VRTX   is scheduled to report results after market close In the last reported quarter  the company beat earnings expectations by 7 89   It has a four quarter positive surprise of 17 59  on average For the quarter to be reported  Vertex has an Earnings ESP of  9 6  and a Zacks Rank  3  The Zacks Consensus Estimate for earnings stands at  1 21 per share Vertex s cystic fibrosis   CF   drug portfolio has been performing well  The company s newest CF drug  Symdeko  is likely to have continued its rapid uptake in the fourth quarter  Meanwhile  Vertex s older two CF medicines Kalydeco  ivacaftor  and Orkambi are expected to have contributed to the company s top line in the to be reported quarter   Read more   Vertex Pharmaceuticals Incorporated Price and EPS Surprise
    Eli Lilly and Company   NYSE LLY    which has a mixed track record so far  will release results before market open  The company delivered a positive earnings surprise of 3 5  in the last reported quarter  Moreover  it beat on earnings in three of the last four quarters  the average beat being 1 2  For the quarter to be reported  Lilly has an Earnings ESP of  0 33  and a Zacks Rank  2  The Zacks Consensus Estimate for earnings stands at  1 52 per share Strong demand for Trulicity  Taltz  Jardiance  Basaglar  Olumiant and Verzenio as well as new migraine drug  Emgality is likely to have continued in the fourth quarter  Higher sales of these drugs are likely to have offset decline in sales of established products  However  rising pricing pressure in the United States  price cuts in some international market and currency headwinds are expected to have negatively impacted the top line in the fourth quarter of 2019   Read more   Eli Lilly and Company Price and EPS Surprise
    Amgen Inc    NASDAQ AMGN   is scheduled to release results after market close  In the last reported quarter  the company beat earnings expectations by 4 27   It has a four quarter positive surprise of 5 82  on average For the quarter to be reported  Amgen has an Earnings ESP of  1 47  and a Zacks Rank  3  The Zacks Consensus Estimate for earnings stands at  3 47 per share Higher sales of newer products like Prolia  Xgeva  Kyprolis and Blincyto are expected to have made up for softer sales of Amgen s mature drugs in the fourth quarter  Biosimilars may have continued to be an important contributor to top line growth driven by the launches of Kanjinti and Mvasi in the United States  However  higher demand for Repatha may have been offset by lower prices  Performance of Aimovig remains to be seen   Read more   Amgen Inc  Price and EPS Surprise
    Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2020-01-28,Zacks Investment Research,https://www.investing.com/analysis/big-drugbiotech-stock-earnings-on-jan-30-biib-alxn--more-200502665,200502665
119857,341372,VRTX,Biotech Stock Roundup  EPZM Drug Gets FDA Nod  XLRN   HEPA Surge On Study Data,opinion,"This week  quite a few biotech companies came out with pipeline and regulatory updates  Epizyme   NASDAQ EPZM   got a significant boost with the FDA approval of its lead drug  Both Acceleron Pharma Inc    NASDAQ XLRN   and Hepion Pharmaceuticals  Inc    NASDAQ HEPA   surged on positive pipeline updates  Incyte   NASDAQ INCY   too came out with positive results from a late stage study on ruxolitinib cream  while Gilead Sciences   NASDAQ GILD   and Regeneron   NASDAQ REGN   provided regulatory updates on their candidates Recap of the Week s Most Important Stories Epziyme Wins FDA Nod for Tazverik  The FDA accelerated approval to Epizyme s lead drug Tazverik  tazemetostat  for the treatment of adults and pediatric patients aged 16 years or older with metastatic or locally advanced epithelioid sarcoma  ES  not eligible for complete resection  Tazverik is a methyltransferase inhibitor  The approval was based on the overall response rate and the duration of response in a phase II study  An approval was in the cards as the Oncologic Drugs Advisory Committee  ODAC  of the FDA had voted  11 0  in favor of the benefit risk profile of the drug for the above mentioned indication in December The continued approval of Tazverik for this indication is contingent upon verification and description of clinical benefit in a confirmatory trial  Epziyme s ongoing  global  randomized  controlled confirmatory trial assessing the combination of Tazverik and doxorubicin compared with doxorubicin plus placebo as a front line treatment for ES is underway  The approval will significantly boost Epizyme s portfolio  which did not have any approved drug in its kitty till now Acceleron Soars on Success of PAH Drug  Acceleron Pharma Inc   after it announced that the mid stage study on pipeline candidate  sotatercept  in patients with pulmonary arterial hypertension  PAH  was successful The phase II study  PULSAR  is a randomized  double blind  placebo controlled trial designed to evaluate the efficacy and safety of sotatercept in PAH patients  In the study  106 patients were randomized to receive placebo  0 3 mg kg of sotatercept  or 0 7 mg kg of sotatercept subcutaneously  every 21 days  in combination with stable background PAH specific therapies over a 24 week treatment period The study results showed that the candidate demonstrated a statistically significant reduction in pulmonary vascular resistance PVR  the trial s primary endpoint  at week 24 versus placebo  PVR  as measured by right heart catheterization  is the resistance that the heart must overcome to pump blood through the pulmonary circulatory system  The study also achieved statistically significant improvements in the key secondary endpoint of six minute walk distance  6MWD  and other secondary endpoints  including amino terminal brain natriuretic propeptide  NT proBNP  and World Health Organization  WHO  functional class Incyte Announces Positive Data From Atopic Dermatitis Study  Incyte announced positive top line results from a late stage study evaluating the safety and efficacy of ruxolitinib cream in adolescent and adult patients with atopic dermatitis  AD   The randomized  vehicle controlled  pivotal phase III TRuE AD2 study met its primary endpoint as a larger number patients treated with ruxolitinib cream 0 75  and 1 5  achieved Investigator s Global Assessment Treatment Success  IGA TS    defined as an IGA score of 0  clear  or 1  almost clear  with at least a two point improvement from baseline at Week 8   than those treated with vehicle control  non medicated cream   The long term safety portion of the study will continue as planned  Additionally  the overall efficacy and safety profile of ruxolitinib cream is consistent with previous data Gilead s Marketing Application for CAR T Cell Therapy Validated  Gilead Sciences announced that its Marketing Authorization Application  MAA  for the experimental chimeric antigen receptor  CAR  T cell therapy  KTE X19  for the treatment of adult patients with relapsed or refractory mantle cell lymphoma  MCL  has been fully validated  It is now under evaluation with the European Medicines Agency  EMA   The MAA is supported by positive data from the single arm  open label  phase II ZUMA 2 study  KTE X19 has been granted Breakthrough Therapy Designation  BTD  by the FDA and Priority Medicines  PRIME  by the EMA  A Biologics License Application  BLA  for the same was also submitted to the FDA in December 2019 Gilead currently carries a Zacks Rank 3  Hold   You can see  Regeneron  Sanofi s sBLA for Dupixent Accepted  Regeneron Pharmaceuticals  Inc  and partner Sanofi   NASDAQ SNY   announced that the FDA has accepted for Priority Review the supplemental Biologics License Application  sBLA  for Dupixent  dupilumab   Both companies are seeking the approval of the drug as an add on maintenance treatment for children aged 6 11 years with moderate to severe atopic dermatitis  whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable  The FDA has set a target action date of May 26  2020  The drug is already approved in the United States to treat patients aged 12 years or older with moderate to severe atopic dermatitis Hepion Surges on Positive Study Data  Shares of Hepion Pharmaceuticals  Inc  surged after it announced positive data from an expanded study with human precision cut liver slices  PCLS   Hepion s drug candidate  CRV431  prevented experimentally induced liver fibrosis to a larger extent than four other leading non alcoholic steatohepatitis  NASH  drug candidates   obeticholic acid  elafibranor  resmetirom and Aramchol   in this specialized experimental model using human liver tissue  Hepion is evaluating CRV431 for NASH  fibrosis and other liver diseases  A phase I  single ascending dose study previously showed CRV431 to be safe and well tolerated in humans  The candidate is currently being administered to humans in a 28 day multiple ascending dose study Performance    Medical   Biomedical and Genetics Industry 5YR   Return
 The Nasdaq Biotechnology index lost 2 65  in the last five trading sessions  Among the biotech giants  Regeneron lost 5 40  in the period  Over the past six months  shares of Vertex  NASDAQ VRTX  have gained 39 55    See the last biotech stock roundup here    What s Next in Biotech Stay tuned for earnings updates from leading biotech giants Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2020-01-28,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-epzm-drug-gets-fda-nod-xlrn--hepa-surge-on-study-data-200502712,200502712
119858,341373,VRTX,Vertex  VRTX  Q4 Earnings Beat On Solid CF Product Sales,opinion,"Vertex Pharmaceuticals Inc    NASDAQ VRTX   reported fourth quarter 2019 earnings per share of  1 70  beating the Zacks Consensus Estimate of  1 21  Moreover  the bottom line surged 31  year over year  Strong cystic fibrosis  CF  product revenues led to higher earnings in the reported quarter 
Vertex s revenues were  1 4 billion in the fourth quarter  also surpassing the Zacks Consensus Estimate of  1 billion  Total revenues included  155 8 million of sales from Orkambi distributed through the early access program in France during the fourth quarter  Excluding this impact  the company s sales surged 45  year over year to  1 26 billion  driven by the early launch of Trikafta triple combination regimen in the United States and the global uptake of Symdeko Symkevi 
Full Year Results
For 2019  Vertex generated revenues of  4 2 billion  reflecting 37  growth year over year 
For the same period  the company reported earnings of  5 33 per share  up 31  year over year 
Quarter in Detail
Vertex s fourth quarter sales comprised only CF product revenues of  1 4 billion  The company markets four CF medicines  namely Kalydeco  ivacaftor   Orkambi  lumacaftor ivacaftor   Symdeko  a combination of tezacaftor and ivacaftor  and Trikafta  elexacaftor tezacaftor ivacaftor and ivacaftor   The company did not record any collaborative and royalty revenues during the reported quarter 
Newly launched Trikafta generated sales of  420 million in the period under review 
A regulatory application in the EU seeking approval of elexacaftor tezacaftor ivacaftor combination regimen was validated by the European Medicines Agency  EMA  on Oct 31  2019  The company expects to gain approval of this triple combination in Europe this year 
Symdeko  Symkevi registered sales of  322 million in the fourth quarter  reflecting a rise of 12 9  year over year 
Meanwhile  Kalydeco  Vertex s first CF medicine  recorded sales of  236 million in the quarter under consideration  reflecting an 8 8  decrease year over year 
Vertex s second CF medicine Orkambi generated sales of  270 million in the reported quarter  accounting for a 14 3  decline year over year 
Notably  a strong adoption of Trikafta might have resulted in sales erosion of the existing combinations  On fourth quarter earnings call  management stated that it expects Trikafta to be the main revenue driver for Vertex in 2020 
Adjusted research and development  R D  expenses rose 22 5  to  337 million in the fourth quarter 
Adjusted selling  general and administrative  SG A  expenses increased 27 2  to  159 million in the reported quarter 
2020 Revenue Guidance
Vertex s current year outlook for sales from CF products was better than management expectations 
The company expects total revenues for CF products in the range of  5 1  5 3 billion  significantly above the Zacks Consensus Estimate of  4 86 billion 
Shares of Vertex were up 5 9   in after hours trading following a favorable outlook for 2020  In fact  the stock has rallied 20 2  in the past year against the  decrease of 5 9  

 
During fourth quarter conference call  management stated that a strong uptake of Trikafta and the recent reimbursement approvals in key countries like England and France for Vertex s CF drugs led to the bullish view for 2020 
Moreover  combined adjusted research and development  R D  plus selling  general and administrative  SG A  expenses for 2020 are anticipated in the band of  1 95  2 billion 
Other Pipeline Updates
Vertex s non CF pipeline  though in early stage  looks interesting with treatments being developed for beta thalassemia  sickle cell disease  alpha 1 antitrypsin deficiency  AAT   APOL1 mediated kidney diseases and pain 
In November 2019  Vertex and partner CRISPR Therapeutics   NASDAQ CRSP   announced positive preliminary safety and efficacy data from the ongoing phase I II studies evaluating their CRISPR Cas9 gene editing therapy  CTX001  for two severe blood disorders  namely sickle cell disease  SCD  and adult transfusion dependent b thalassemia  TDT  
Vertex is enrolling patients in the ongoing phase II proof of concept study on its first oral small molecule corrector VX 814 for the treatment of alpha 1 antitrypsin  AAT  deficiency  The company plans to announce data from the same in 2020  It also has a second AAT corrector  VX 864  currently in phase I development to address AAT deficiency 
In the fourth quarter  Vertex completed the phase I study on its investigational candidate VX 147 in healthy volunteers for the treatment of APOL1 mediated focal segmental glomerulosclerosis  FSGS  and other serious kidney diseases  The company intends to initiate a phase II proof of concept study on the same in 2020 
Vertex Pharmaceuticals Incorporated Price  Consensus and EPS Surprise
    
Zacks Rank   Stocks to Consider
Vertex currently has a Zacks Rank  3  Hold   Better ranked stocks in the biotech sector include Alexion Pharmaceuticals  Inc    NASDAQ ALXN   and Denali Therapeutics Inc    NASDAQ DNLI    While Alexion carries a Zacks Rank  2  Buy   Denali sports a Zacks Rank  1  Strong Buy   You can see  
Alexion s earnings estimates have been revised 1 8  upward for 2020 over the past 60 days 
Denali s loss per share estimates have narrowed 0 4  for 2020 over the past 60 days  The stock has risen 22 2  in the past year 
Today s Best Stocks from Zacks
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2019  while the S P 500 gained and impressive  53 6   five of our strategies returned  65 8    97 1    118 0    175 7  and even  186 7  This outperformance has not just been a recent phenomenon  From 2000   2019  while the S P averaged  6 0  per year  our top strategies averaged up to  54 7  per year ",2020-01-31,Zacks Investment Research,https://www.investing.com/analysis/vertex-vrtx-q4-earnings-beat-on-solid-cf-product-sales-200503615,200503615
119859,341374,VRTX,NASDAQ Reaches New Closing High As Rebound Continues ,opinion,"SPECIAL ALERT  The February episode of the Zacks Ultimate Strategy Session will be available for viewing no later than Wednesday  February 12  Kevin Matras  Sheraz Mian  Ben Rains  Dan Laboe and Kevin Cook will cover the investment landscape from several angles in this popular event 
	Don t miss your chance to hear 
	  Ben and Dan Agree to Disagree on which FANG stocks will still rule in the 2020s
	  Kevin Matras answers your questions in Zacks Mailbag
	  Sheraz and Kevin Cook choose one portfolio to give feedback for improvement
	  And much more
	Remember  we need your input  Please submit your questions for Zacks Mailbag and Portfolio Makeover by Thursday morning  February 6  Email now to mailbag zacks com 
	Then log on to Zacks com and bookmark this page 
	Two of the major indices have now fully recovered from last Friday s virus induced selloff  as stocks rallied for a second straight day to start February 
	The NASDAQ has always been a few steps ahead of its counterparts during this whole ordeal  It was the only major index that was still positive for 2020 after last week s plunge 
	And now  this tech heavy index is back at an all time closing high with today s jump of 2 1   or more than 194 points  to 9467 97 
	That s a gain of more than 300 points in two days  which leaves it approximately 150 points better than before the coronavirus selloff on Friday 
	It should be noted that Tesla  NASDAQ TSLA  continued blowing the doors off the market on Tuesday with another surge of 13 7   Furthermore  all of the FAANGs jumped by 2  or more in the session  except for a 2 6  slump for Alphabet  NASDAQ GOOGL  after reporting soft revenues yesterday 
	The S P has recovered as well with a surge of 1 5  to 3297 59  The next stop could be retaking 3300  which was lost in the virus selloff 
	And the Dow is almost there  after losing more than 600 points on Friday it has gained around 550 back in the past two days  The index finished higher by 1 44   or nearly 408 points  on Tuesday to 28 807 63 
	As fun as these past couple of days have been  we should keep in mind that the coronavirus is still spreading  However  the market appreciated news that China is considering stimulus efforts to combat the impact of the sickness 
	In earnings news  the Disney  streaming service  which only launched in November  now has 26 5 million subscribers 
	This success helped the entertainment powerhouse beat on both the top and bottom lines in its quarterly report  After initially moving lower  shares are barely positive by about 0 4  afterhours as of this writing Today s Portfolio Highlights  Stocks Under  10  With plenty of tech and medical names in the portfolio  Brian decided to add some diversification with an oil name on Tuesday  He picked up Berry Petroleum  BRY   a Zacks Rank  1  Strong Buy  energy company that s engaged in the acquisition  exploration  development and production of domestic oil and natural gas reserves  The stock is back to recent lows  but the editor thinks that will change if oil is bottoming out  He also really likes the valuation  Read the complete commentary for more on the addition of BRY and don t be surprised if there s another buy before the week is over Surprise Trader  For the past nine consecutive quarters  Silicon Motion  SIMO  has either beaten or met the Zacks Consensus Estimate  And now it has a positive Earnings ESP of 25 45  for the quarter being reported after the bell on Thursday  February 6  SIMO is also part of a space  electronics   semiconductors  that s in the Top 6  of the Zacks Industry Rank  Dave likes what he sees and  therefore  added the stock on Tuesday with a 12 5  allocation  He also sold the stalled Rexnord  RXN  position for a 2 2  return in just under two weeks  Read the full write up for more on today s moves TAZR Trader  YouTube advertising monetization is getting better all the time and will soon silence those who were surprised by the contribution only being  15 billion after Alphabet  GOOGL  finally started revealing the segment s numbers  Therefore  Kevin added GOOGL on Tuesday and would buy even more if it gets back to the 50 day near  1380  The portfolio also got back into NVIDIA  NASDAQ NVDA  and sold the short ETFs ProShares UltraPro Short QQQ ETF  SQQQ  and ProShares UltraPro Short S P 500 ETF  SPXU  with the market soaring  Read the full write up for a lot more on all of these moves Zacks Short List  This week s adjustment replaced half of the portfolio  The stocks that were short covered include   NovoCure Ltd   NVCR   2  
	  Live Nation Entertainment  LYV   1 8  
	  Vertex Pharmaceuticals  NASDAQ VRTX 
	  GDS Holdings  GDS 
	  Etsy  Inc   ETSY 
	The new buys that replaced these names were 
	  Alteryx  AYX 
	  China Lodging Group  HTHT 
	  MGM Resorts Int l  MGM 
	  Newmont  NEM 
	  Wynn Resorts  NASDAQ WYNN 
	Learn more about this emotion free portfolio that takes advantage of falling and volatile markets by reading the Short List Trader Guide Have a Great Evening 
	Jim Giaquinto 
Recommendations from Zacks  Private Portfolios   Believe it or not  this article is not available on the Zacks com website  The commentary is a partial overview of the daily activity from Zacks  private recommendation services  If you would like to follow our Buy and Sell signals in real time  we ve made a special arrangement for readers of this website  Starting today you can see all the recommendations from all of Zacks  portfolios absolutely free for 7 days  Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises  which we ve predicted with an astonishing 80   accuracy    Click here to  test drive  Zacks Ultimate for FREE   ",2020-02-05,Zacks Investment Research,https://www.investing.com/analysis/nasdaq-reaches-new-closing-high-as-rebound-continues-200504642,200504642
119860,341375,VRTX,Buy This Cloud Based Business Services Stock After Earnings On Strong Growth ,opinion,"ServiceNow   NYSE NOW   provides cloud based services and solutions to its over 6 200 enterprise customers  on everything from IT to employee and customer workflows  NOW posted stronger than projected Q4 2019 results on January 29  Analysts have since raised their fiscal 2020 and 2021 earnings estimates for the fast growing  cloud focused business services firm 
ServiceNow s Quick Pitch 
ServiceNow was founded in 2004 and went public in 2012  The Santa Clara  California based firm grabbed the No  3 spot on Fortune s  list of global companies  with the best prospects for long term growth  in both 2019 and 2018  This put NOW ahead of the likes of Salesforce   NYSE CRM    Netflix   NASDAQ NFLX    Vertex Pharmaceuticals   NASDAQ VRTX    and many others 
ServiceNow last summer expanded its partnership with Microsoft   NASDAQ MSFT    The updated relationship with Microsoft will help ServiceNow sell to highly regulated industries and see it house its full SaaS offerings on MSFT s Azure cloud  which competes directly against Amazon   NASDAQ AMZN   
More recently  the cloud centered digital workflows firm was added to the S P 500 index in November  And new CEO Bill McDermott  who took over in mid November   worth of NOW shares  This appeared to be a solid vote of confidence in ServiceNow and a possible sign that the CEO might have thought NOW stock was undervalued   
Investors can see from the nearby chart that NOW stock has been on an impressive run  Not only are shares up a whopping 1 330  since their debut  the stock has soared roughly 290  in the last three years 
Shares of ServiceNow have also climbed over 10  since it reported on January 29 and are now up 45  in the last three months to rest at new highs 
 
 
 
 
Outlook 
In the fourth quarter  NOW s subscription revenue surged 35   Meanwhile  it closed the period with 892 total customers with over  1 million in annual contract value  which marked 32  growth 
Our Zacks estimates call for the company s fiscal 2020 revenues to climb 29  to  4 45 billion  with FY21 expected to jump another 26 2  higher to reach  5 62 billion  These would both mark the continuation of 2019 s 33  top line expansion 
On top of that  ServiceNow s adjusted earnings are projected to soar over 29  in both 2020 and 2021   Looking ahead  we remain focused on driving sustainable top line growth as we look to scale our business to  10 billion in revenue and beyond   CFO Gina Mastantuono said in prepared remarks 
 
 
 
 
Bottom Line
ServiceNow is currently a Zacks Rank  3  Hold  that also holds an  A  grade for Growth in our Style Scores system  Overall  NOW stock appears to be worth considering at the moment  as part of the continued digital transformation of businesses big and small   
Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2020-02-05,Zacks Investment Research,https://www.investing.com/analysis/buy-this-cloudbased-business-services-stock-after-earnings-on-strong-growth-200504608,200504608
119884,341399,VRTX,New Strong Buy Stocks For December 16th,opinion,"Here are 4 stocks added to the Zacks Rank  1  Strong Buy  List for today 
Vertex Pharmaceuticals  NASDAQ VRTX  Incorporated  VRTX   This company that engages in developing and commercializing therapies for treating cystic fibrosis has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4 8  over the last 60 days Vertex Pharmaceuticals Incorporated Price and Consensus
    Gaming and Leisure Properties  Inc   GLPI   This company that is engaged in the business of acquiring  financing  and owning real estate property has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0 8  over the last 60 days Gaming and Leisure Properties  Inc  Price and Consensus
    The Charles Schwab Corporation  NYSE SCHW   SCHW   This company that provides wealth management  securities brokerage  banking  asset management  custody  and financial advisory services has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0 4  over the last 60 days The Charles Schwab Corporation Price and Consensus
    Zynerba Pharmaceuticals  Inc   ZYNE   This clinical stage specialty pharmaceutical company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 18 7  over the last 60 days Zynerba Pharmaceuticals  Inc  Price and Consensus
    You can see 
Today s Best Stocks from Zacks 
Would you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  
This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ",2019-12-16,Zacks Investment Research,https://www.investing.com/analysis/new-strong-buy-stocks-for-december-16th-200492806,200492806
119885,341400,VRTX,Vertex Pharmaceuticals  VRTX  Stock Sinks As Market Gains  What You Should Know,opinion,"Vertex Pharmaceuticals  NASDAQ VRTX  closed at  217 62 in the latest trading session  marking a  0 86  move from the prior day  This change lagged the S P 500 s daily gain of 0 03   Elsewhere  the Dow gained 0 11   while the tech heavy Nasdaq added 0 1  
Prior to today s trading  shares of the drugmaker had gained 4 52  over the past month  This has lagged the Medical sector s gain of 5 4  and outpaced the S P 500 s gain of 1 82  in that time 
Investors will be hoping for strength from VRTX as it approaches its next earnings release  On that day  VRTX is projected to report earnings of  1 18 per share  which would represent a year over year decline of 9 23   Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  996 44 million  up 14 52  from the year ago period 
For the full year  our Zacks Consensus Estimates are projecting earnings of  4 81 per share and revenue of  3 74 billion  which would represent changes of  17 89  and  22 84   respectively  from the prior year 
Investors should also note any recent changes to analyst estimates for VRTX  These recent revisions tend to reflect the evolving nature of short term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  The Zacks Consensus EPS estimate remained stagnant within the past month  VRTX is holding a Zacks Rank of  1  Strong Buy  right now 
Looking at its valuation  VRTX is holding a Forward P E ratio of 45 64  Its industry sports an average Forward P E of 24 59  so we one might conclude that VRTX is trading at a premium comparatively 
Also  we should mention that VRTX has a PEG ratio of 1 56  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  VRTX s industry had an average PEG ratio of 1 76 as of yesterday s close 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This group has a Zacks Industry Rank of 56  putting it in the top 22  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow VRTX in the coming trading sessions  be sure to utilize Zacks com ",2019-12-17,Zacks Investment Research,https://www.investing.com/analysis/vertex-pharmaceuticals-vrtx-stock-sinks-as-market-gains-what-you-should-know-200493275,200493275
119886,341401,VRTX,Is Vertex Pharmaceuticals  VRTX  Stock Outpacing Its Medical Peers This Year ,opinion,"Investors focused on the Medical space have likely heard of Vertex Pharmaceuticals  NASDAQ VRTX   but is the stock performing well in comparison to the rest of its sector peers  By taking a look at the stock s year to date performance in comparison to its Medical peers  we might be able to answer that question 
Vertex Pharmaceuticals is one of 883 companies in the Medical group  The Medical group currently sits at  2 within the Zacks Sector Rank  The Zacks Sector Rank considers 16 different sector groups  The average Zacks Rank of the individual stocks within the groups is measured  and the sectors are listed from best to worst 
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks  This system has a long record of success  and these stocks tend to be on track to beat the market over the next one to three months  VRTX is currently sporting a Zacks Rank of  1  Strong Buy  
Over the past three months  the Zacks Consensus Estimate for VRTX s full year earnings has moved 9 18  higher  This is a sign of improving analyst sentiment and a positive earnings outlook trend 
Based on the latest available data  VRTX has gained about 31 42  so far this year  Meanwhile  stocks in the Medical group have gained about 10 31  on average  This means that Vertex Pharmaceuticals is performing better than its sector in terms of year to date returns 
Looking more specifically  VRTX belongs to the Medical   Biomedical and Genetics industry  which includes 374 individual stocks and currently sits at  58 in the Zacks Industry Rank  Stocks in this group have gained about 8 99  so far this year  so VRTX is performing better this group in terms of year to date returns 
Investors in the Medical sector will want to keep a close eye on VRTX as it attempts to continue its solid performance ",2019-12-19,Zacks Investment Research,https://www.investing.com/analysis/is-vertex-pharmaceuticals-vrtx-stock-outpacing-its-medical-peers-this-year-200494141,200494141
119887,341402,VRTX,The Zacks Analyst Blog Highlights  Medtronic  United Technologies  Union Pacific  Vertex Pharmaceuticals And NextEra Energy,opinion,For Immediate ReleaseChicago  IL   December 31  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Medtronic   NYSE MDT    United Technologies   NYSE UTX    Union Pacific   NYSE UNP    Vertex Pharmaceuticals   NASDAQ VRTX   and NextEra Energy   NYSE NEE   Here are highlights from Monday s Analyst Blog  Top Research Reports for Medtronic  United Technologies and Union PacificThe Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Medtronic  United Technologies and Union Pacific  These research reports have been hand picked from the roughly 70 reports published by our analyst team today You can see Medtronic s shares have outperformed the Zacks Medical Products industry year to date   24 6  vs   16 8    The Zacks analyst believes that in recent times  all major business groups at Medtronic contributed to solid top line growth at CER  which highlighted sustainability across groups and regions  in addition to displaying successful achievement of synergy targets In the second quarter fiscal 2019  within RTG  strong sales within spine and brain therapies more than offset slower growth in pain therapies  Within CVG  despite ongoing challenges  the company registered 1 3  growth at CER  MITG arm demonstrated sturdy growth on strength in across all businesses The 2020 guidance also looks promising  Medtronic has been outperforming the industry it belongs to for the past three months  On the flip side  the declining CRHF revenue raises concern for Medtronic  Escalating costs persistently put pressure on gross margin Shares of United Technologies have gained  12 3  in the past three months against the Zacks Diversified Operations industry s rise of  12 4   The Zacks analyst believes that strength in commercial aftermarket and military businesses  coupled with growth in commercial air traffic and high defense spending in the United States  is likely to boost revenues of the company s aerospace business Also  favorable mix in Otis new equipment orders is likely to be a tailwind for the commercial business  However  the company is experiencing softness in its equipment orders at the Carrier segment due to persistent lower transport refrigeration orders  Also  rising cost of sales has been a major cause of concern Rise in debt levels can increase its financial obligations  Moreover  the company expects forex headwind to hurt its revenues and segmental operating profits by  550 million and  75 million  respectively  in 2019 Union Pacific s shares have gained  5 8  over the past six months against the Zacks Rail Services industry s rise of  1 1   The Zacks analyst impressed with Union Pacific s initiatives to reward its shareholders  Since November 2017  the company raised its quarterly dividend payout five times It is also active on the buyback front  Initiatives to control costs to drive the bottom line are also impressive  The company s operating ratio has been constantly improving mainly owing to its cost cutting initiatives  Operating ratio is anticipated to improve further  Backed by these tailwinds  shares of Union Pacific have outperformed its industry in a year s time However  sluggish overall volumes due to freight related weakness are a major headwind  Notably  the company issued a lackluster forecast for fourth quarter 2019 volumes at a conference in December  Union Pacific s escalated debt levels are concerning too  Also  the massive capex might be a headwind Other noteworthy reports we are featuring today include Vertex Pharmaceuticals and NextEra Energy Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-12-30,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-medtronic-united-technologies-union-pacific-vertex-pharmaceuticals-and-nextera-energy-200495696,200495696
119888,341403,VRTX,Vertex Earnings  Revenue Beat in Q2,news,"Investing com   Vertex  NASDAQ VRTX  reported second quarter earnings  that beat analysts  expectations on Wednesday and revenue that topped forecasts 
The firm reported earnings per share of  1 26 on revenue of  941 3M  NYSE MMM   Analysts polled by Investing com forecast EPS of  1 07 on revenue of  885 64M  That compared to EPS of  0 94 on revenue of  751 22M in the same period a year earlier  The company had reported EPS of  1 14 on revenue of  858 29M in the previous quarter 
Vertex shares lost 1 71  to trade at  163 77 in after hours trade following the report 
Vertex follows other major Healthcare sector earnings this monthOn July 16  J J reported second quarter EPS of  2 58 on revenue of  20 56B  compared to forecasts of EPS of  2 46 on revenue of  20 29B 
Pfizer earnings beat analysts  expectations on Monday  with second quarter EPS of  0 8 on revenue of  13 26B  Investing com analysts expected EPS of  0 75 on revenue of  13 41B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-07-31,Investing.com,https://www.investing.com/news/stock-market-news/vertex-earnings-revenue-beat-in-q2-1941116,1941116
119889,341404,VRTX,Singapore s Vertex adds  290 million venture fund for high growth tech firms,news,"By Anshuman Daga and Aradhana Aravindan
SINGAPORE  Reuters    Singapore based Vertex  NASDAQ VRTX  Venture Holdings  the first main backer of Southeast Asia s ride hailing giant Grab  has added a new  290 million venture capital fund targeting investments in high growth technology firms  a senior company official said 
The Vertex Growth Fund will seek to invest about  10 million to  15 million per company  typically in third and fourth round fundings  versus  3 million to  4 million by affiliate funds in early rounds  said Vertex Venture Holdings CEO Chua Kee Lock 
 Markets like Southeast Asia offer lot more opportunities to invest in growth capital   Chua  who has headed the investment firm for more than a decade  told Reuters in an interview 
Technology startups are sprouting up across Southeast Asia   home to about 640 million people   as companies seek to offer a range of services  including ride hailing apps  online payments and e commerce  with consumers rapidly coming online 
The Vertex Ventures Southeast Asia and India Fund invested in Grab when it was a start up  Seven year old Grab has grown to become the region s biggest ride hailing operation  valued at an estimated  14 billion  sources say 
 When a lot of companies had come to a stage where they were accelerating growth  we had to stop investments   Chua said  adding that this was due to a 10  investment cap in each company set by Vertex s early stage funds 
Vertex Growth is the sixth and latest member of Vertex s global network of funds spread across China  Southeast Asia and India  the United States and Israel 
Vertex has about  3 billion in assets under management across its network of funds and has invested in more than 200 companies  The funds focus on investments in their regions of industry specialization and are run independently 
Chua said the Vertex Growth fund exceeded an initial fund target of  250 million 
It secured commitments from Singapore state investor Temasek Holdings  TEM UL   Taiwanese chip design firm Elan Microelectronics and other institutions  family offices and funds based in Southeast Asia and Taiwan 
Many Southeast Asian funds are sprouting up to tap into fast growing firms  while tech giants  Alibaba   NYSE BABA   Tencent Holdings Ltd and SoftBank Group Corp are also expanding their bets in the region 
Chua said the fund will look at global opportunities  including in areas such as cyber security in Israel and consumer related technology in Southeast Asia and China 
Vertex Growth has invested about 10 percent of its capital in companies in the United States  UK and Southeast Asia ",2019-09-12,Reuters,https://www.investing.com/news/technology-news/singapores-vertex-adds-290-million-venture-fund-for-highgrowth-tech-firms-1976346,1976346
119890,341405,VRTX,Israeli checkout free technology startup Trigo raises  22 million,news,"JERUSALEM  Reuters    Trigo  an Israeli startup whose technology allows customers to automatically check out in grocery stores  said on Monday it raised  22 million in an early stage funding round  bringing funds raised to date to  29 million 
The round was led by growth fund Red Dot Capital with participation of existing investors Vertex  NASDAQ VRTX  Ventures Israel and Hetz Ventures 
The funds will enable the company to expand its technology for even larger store sizes and grow its partnerships with leading U S  and European grocery retailers 
Trigo  it said  is currently installed in stores as large as 5 000 square feet 
Trigo is already partnering with a number of global grocery chains including leading European chains and Israel s largest grocer   Shufersal  which will be deploying Trigo s technology in 280 stores over the next 5 years 
The company s computer vision system uses advanced artificial intelligence to identify and record items taken by shoppers while they are in the store  They can later be billed automatically or pay cash or by card ",2019-09-16,Reuters,https://www.investing.com/news/technology-news/israeli-checkoutfree-technology-startup-trigo-raises-22-million-1978869,1978869
119891,341406,VRTX,Singapore s Jungle Ventures raises  240 million for third Southeast Asia fund,news,"By Aradhana Aravindan and Chibuike Oguh
SINGAPORE NEW YORK  Reuters    Singapore s Jungle Ventures said on Wednesday it has raised  240 million from investors  including Temasek Holdings  for a third fund designed to back Southeast Asian startups  highlighting the growing interest in the region s technology firms 
Jungle Ventures  latest fund comes as a growing number of venture capital firms  including Vertex  NASDAQ VRTX  Ventures and Golden Gate Ventures  have been raising funds focused on the region this year 
Investors are betting on the market potential of Southeast Asia s population of 640 million  which is fast going online  and using smartphones to shop  commute and make payments 
The region s Internet economy is forecast to balloon to  300 billion by 2025 from an estimated  100 billion this year  according to a report by Google  NASDAQ GOOGL   Temasek and consultants Bain   Co 
More than 90  of the capital was from institutional investors  with about 60  coming from outside Asia   mainly the United States and Europe  Jungle Ventures  managing partner Amit Anand told Reuters 
The investors include German development finance institution DEG  the World Bank Group s IFC  Bangkok Bank s  BK BBL  corporate venture capital fund Bualuang Ventures  Dutch development bank FMO and Cisco  NASDAQ CSCO  Investments 
The fund exceeded Jungle Ventures  initial target range of  150 million to  200 million  Anand said  In its previous fund  the company raised  100 million from investors in 2016 and its debut fund had raised  10 million in 2012 
Jungle Ventures  portfolio includes Singaporean hotel booking and management platform RedDoorz  cloud based software provider Deskera  research platform Smartkarma and Thai fashion e commerce start up Pomelo Fashion 
The firm has created an internal rate of return of about 79  with its four exits that included vacations rental platform Travelmob  Anand said  It typically allocates  10 million  20 million per company  making 10 to 15 key investments in each fund ",2019-10-29,Reuters,https://www.investing.com/news/stock-market-news/singapores-jungle-ventures-raises-240-million-for-third-southeast-asia-fund-2007039,2007039
119892,341407,VRTX,Vertex Earnings Beat  Revenue Misses In Q3,news,"Investing com   Vertex  NASDAQ VRTX  reported third quarter earnings  that beat analysts  expectations on Wednesday and revenue that fell short of forecasts 
The firm reported earnings per share of  1 23 on revenue of  949 8M  Analysts polled by Investing com anticipated EPS of  1 16 on revenue of  952 28M  That compared to EPS of  1 09 on revenue of  783 86M in the same period a year earlier  The company had reported EPS of  1 26 on revenue of  941 28M in the previous quarter 
Vertex shares lost 1 04  to trade at  197 31 in after hours trade following the report 
Vertex follows other major Healthcare sector earnings this monthOn October 15  J J reported third quarter EPS of  2 12 on revenue of  20 73B  compared to forecasts of EPS of  2 01 on revenue of  20 08B 
Merck Co earnings beat analysts  expectations on Tuesday  with third quarter EPS of  1 51 on revenue of  12 4B  Investing com analysts expected EPS of  1 24 on revenue of  11 65B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-10-30,Investing.com,https://www.investing.com/news/stock-market-news/vertex-earnings-beat-revenue-misses-in-q3-2008093,2008093
119893,341408,VRTX,Is Vertex Pharmaceuticals Stock a Buy ,news,"Vertex Pharmaceuticals  NASDAQ VRTX  hit paydirt when the company s first medicine to treat the underlying causes of cystic fibrosis  CF     a rare condition that affects several internal organs like the lungs    was approved by the U S  Food and Drug Administration in 2012  Since then  the company has strengthened its monopoly on the CF market by developing several new drugs  and its shares are up by more than 500  as a result 
However  it seems Vertex s assumed continued dominance in the CF market is already being factored into its stock price  The company currently trades at 33 times future earnings  Will Vertex continue to deliver market beating returns  Or are the company s best days in the rearview mirror 

CF will continue to be a major growth driver
Because there are 127 known mutations of the gene that causes CF  only 39 000 patients with this rare genetic condition are eligible to be treated with Vertex s first trio of drugs    Kalydeco  Orkambi  and Symdeko    out of 75 000 patients with CF in the U S   Europe  and Australia  However  the company recently received FDA approval for Trikafta  a triple combination therapy with the potential to treat the vast majority  about 90   of patients with CF since it targets the most common CF mutation  In other words  the company s addressable market increased thanks to this approval  and it could continue to get larger as Trikafta racks up more regulatory approvals in Europe  Sales of Trikafta could reach as much as  4 3 billion by 2024  according to projections by research firm EvaluatePharma  
Note that during the third quarter  Vertex s revenue was  950 million  a 21  year over year increase  The company s revenue should continue growing at a nice clip thanks to Trikafta  
Beyond CF
Sales of Vertex s drugs that treat the underlying causes of CF will eventually lose steam since the addressable market for the drugs is limited  With that in mind  the company is looking for ways to diversify its product offerings  Vertex s pipeline includes potential drugs for such illnesses as sickle cell disease  a rare and potentially life threatening genetic condition that affects red blood cells  The company is developing a candidate treatment for sickle cell disease called CTX001 in collaboration with CRISPR Therapeutics  NASDAQ CRSP   In early 2019  CTX001  which is still in phase 1 2 testing  received a fast track designation from the FDA  which is  designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need   
The company s pipeline also includes VX 150  a potential drug for acute pain caused by small fiber neuropathy  a neurological disorder that often arises as a result of some other underlying medical condition  such as diabetes  and causes severe pain most often to the hands and feet of the patient  VX 150 is currently in phase 2 testing  
Further  in September 2019  Vertex announced its acquisition of the privately held biotechnology company Semma Therapeutics for  950 million in cash  Vertex is after Semma s potential cure for type 1 diabetes  and if the company manages to reach that lofty goal  it will reap the benefits for many years to come  
Should you buy 
There is no guarantee that Vertex s goal to find a cure for type 1 diabetes via its acquisition of Semma Therapeutics will bear fruit  Also  the products the company is currently developing could run into regulatory setbacks  However  Vertex s monopoly on the CF market    not to mention its latest approved trio of drugs    means the company s top line is poised to continue growing rapidly  For that reason  and despite the company s high P E ratio  Vertex is  in my view  a growth stock worth buying ",2020-01-04,The Motley Fool,https://invst.ly/pdix-,2052391
119915,341430,VRTX,Three Stocks From The Zacks  1 Rank Uptrends Screen ,opinion,Don t let this shaky start to December distract you from the fact that stocks are up BIG in 2019  In fact  we just came off of several new highs for each of the major indices So Zacks  1 Rank Uptrends is still a good tool to watch before the Santa Claus Rally begins later this month  The screen looks for Zacks Rank  1s  Strong Buys  with upward price momentum and market beating relative price strength that are trading in the top third of their 52 week range Below are three names that had passed this screen lately  See the current list by Applied Materials  NASDAQ AMAT   AMAT What do werewolves  washer machines and the chip industry all have in common They all run in cycles  of course Applied Materials  AMAT  isn t much interested in the full moon or when to add the fabric softener But this global leader in semiconductor equipment sales can t get enough of the comeback for chips this year  which has brought the Semiconductor Equipment   Wafer Fabrication space into the Top 1  of the Zacks Industry Rank  3rd spot out of more than 250  Sales and earnings for AMAT have trended lower over the past several quarters  but its infamously cyclical space seems to be coming back around  Hopefully  its fiscal fourth quarter from last month is a sign of positive things to come in 2020 Earnings per share of 80 cents beat the Zacks Consensus Estimate by nearly 5 3   Net sales of  3 75 billion also topped our expectations by 1 9  Whether in a good part of the chip cycle or a bad one  AMAT usually finds a way to surpass quarterly earnings expectations by a few percentage points  It has surprised for 17 straight quarters now AMAT attributed its success to  a healthy uptick in demand for semiconductor equipment  combined with strong execution across the company  For all of fiscal 2019  revenue reached  14 6 billion for AMAT while adjusted earnings per share were  3 04  As with the quarterly results  these numbers are down from the previous year However  analysts expect earnings of  3 77 for this year  which ends in October 2020  Analysts have raised the consensus by 14 6  in the past 30 days Earnings are then expected to jump by that same percentage to  4 32 in the fiscal year ending October 2021  That consensus has advanced by 10 5  in the past month Shares of AMAT are up more than 77  in 2019 as the cycle of chips ramp up  The best part is that the company sees significant opportunities in several emerging trends  including AI  big data  cloud infrastructure and the Internet of Things  among others DICK S Sporting Goods  DKS The holidays are a perfect time to get a new set of golf clubs or maybe even a state of the art kayak The only problem is wrapping these things for under the tree   Hint  you ain t Santa Claus or Martha Stewart  so just get a big bow and put it in the corner  With 733 stores in 47 states  there s a good chance that many consumers will be buying such items at DICK S Sporting Goods  DKS  The company is feeling so good about the holidays amid this strong consumer that it raised fiscal 2019 non GAAP earnings to between  3 50 and  3 60  Earlier  it was expecting  3 30 to  3 45 In that fiscal third quarter report from last month  DKS reported earnings per share of 52 cents that beat the Zacks Consensus Estimate by nearly 37   It also improved 33 3  from last year The positive surprise was the company s third straight  though it hasn t actually missed since 2017  In fact  the stock has managed a double digit average surprise of 11 5  over the past four quarters even though one of those periods was only a match Sales of  1 96 billion also beat our expectations at around  1 91 billion and improved 5 6  from last year Same store sales rose 6  thanks to higher average ticket and transactions along with growth at hardlines  apparel and footwear  which are its three major categories It s brick and mortar locations saw positive comps in their own right  but DKS is an omni channel retailer  E commerce sales increased 13   It also accounted for 13  of total net sales  which was 1  more than last year Analysts liked what they saw in the quarter and raised estimates  The Zacks Consensus Estimate for this year  ending January 2020  is now  3 59  which has gained 6 2  in the past 30 days Likewise  the Zacks Consensus Estimate for next fiscal year  ending January 2021  is up to  3 77  marking a gain of 8 3  in 30 days  It also suggests year over year improvement of 5  By the way  shares of DKS are up nearly 50  this year  which trounces the performance of the retail   misc  industry at a little more than 10    Vertex Pharmaceuticals  NASDAQ VRTX   VRTX If you or someone you care about is one of the approximately 30 000 people suffering from Cystic Fibrosis  CF  in this country  then you know all about Vertex Pharmaceuticals  VRTX  If you re a biotech investor  you probably know about the company too In late October  the FDA approved the company s TRIKAFTA treatment  which marked its fourth medicine approved to treat the underlying cause of CF VRTX cited this approval as one of the big reasons why its been having such a strong 2019  as TRIKAFTA could provide treatment for up 90  of all people with CF Shares of VRTX are up approximately 34  in 2019  which trounces the performance of the Medical   Biomedical   Genetics space at only about 7   This area is in the top 23  of the Zacks Industry Rank In its third quarter report from late October  VRTX reported earnings per share of  1 23  which improved 13  from last year and beat the Zacks Consensus Estimate by nearly 8  The stock has topped expectations for 12 straight quarters and amassed an average surprise of more than 17  over the past four   Revenue climbed 21  from last year to  949 2 million While CF makes up most of the business right now  VRTX is also looking at other areas  It is working on medicines to treat pain  alpha 1 antitrypsin deficiency  sickle cell disease  beta thalassemia and APOL1 medicated kidney diseases VRTX reiterated its outlook for total revenues of CF products between  3 7 billion and  3 75 billion  which it raised to that level in October after the approval of TRIKAFTA  The drug is expected to be a big help to 2020 as well Over the past 60 days  the Zacks Consensus Estimate for this year has jumped 5  to  4 81 per share The same period saw expectations for 2020 surging 10 6  to  6 67  which suggests year over year growth of nearly 39  Experts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ,2019-12-06,Zacks Investment Research,https://www.investing.com/analysis/three-stocks-from-the-zacks-1-rank-uptrends-screen-200490745,200490745
119916,341431,VRTX,Gilead  GILD  Announces Positive Long Term Data On Yescarta ,opinion,Gilead Sciences  Inc    NASDAQ GILD   announced long term data from the ZUMA 1 study on CAR T cell therapy Yescarta  axicabtagene ciloleucel  in adult patients with refractory large B cell lymphoma at the 61st American Society of Hematology  ASH  Annual Meeting   Exposition in Orlando The data included updated overall survival data from the phase II study after three years  following a single infusion of Yescarta as well as an analysis from a separate safety management cohort of patients receiving early steroid intervention for cytokine release syndrome  CRS  and neurologic events With a minimum follow up of three years after a single infusion of Yescarta  median follow up of 39 1 months   approximately 47  of patients with refractory large B cell lymphoma in ZUMA 1 phase II cohorts were alive  while the median overall survival  OS  was 25 8 months Yescarta is approved in the United States for the treatment of adult patients with relapsed or refractory large B cell lymphoma after two or more lines of systemic therapy  including diffuse large B cell lymphoma  DLBCL   primary mediastinal large B cell lymphoma  and high grade B cell lymphoma and DLBCL arising from follicular lymphoma Moreover  updated results from a separate ZUMA 1 safety management study  Cohort 4  were presented at the meeting  In this analysis  patients with relapsed or refractory large B cell lymphoma treated with Yescarta received earlier steroid intervention  beginning when patients experienced Grade 1 neurologic events or Grade 1 CRS with no improvement after three days of supportive care  Patients could receive optional bridging chemotherapy prior to Yescarta infusion The results from ZUMA 1 Cohort 4 demonstrated that early steroid intervention has the potential to reduce the rate of severe CRS and neurologic events The news bodes well for Yescarta  the uptake of which has been quite slow due to its exorbitant cost  Moreover  Novartis    NYSE NVS   Kymriah is posing stiff competition in this space Gilead s stock has gained 7 2  in the year so far compared with the  s growth of 6 6   The massive decline in sales of the HCV franchise has propelled the company to focus on its HIV franchise  Yescarta and other newer avenues  The rapid adoption of Biktarvy maintains momentum in the HIV space amid stiff competition from the likes of GlaxoSmithKline   NYSE GSK    Gilead s intent to foray into the inflammation market to diversify the revenue base is encouraging as well Zacks Rank   A Stock to ConsiderGilead currently carries a Zacks Rank  3  Hold   A better ranked stock in the biotech space is Vertex Pharmaceuticals Incorporated   NASDAQ VRTX    which sports a Zacks Rank  1  Strong Buy   You can see  Earnings estimates for 2019 have increased 23 cents for Vertex in the past 60 days The Hottest Tech Mega Trend of AllLast year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-12-08,Zacks Investment Research,https://www.investing.com/analysis/gilead-gild-announces-positive-longterm-data-on-yescarta-200491236,200491236
119917,341432,VRTX,Blueprint s  BPMC  Systemic Mastocytosis Study Data Impresses,opinion,Blueprint Medicines Corporation   NASDAQ BPMC   announced encouraging initial data from the dose finding part 1 of phase II PIONEER study on its lead candidate avapritinib for treating patients with indolent systemic mastocytosis  SM   The candidate was well tolerated at all dose levels tested and no patients discontinued treatment due to serious adverse side effects SM is a rare form of disease wherein mast cells accumulate in internal tissues and organs such as liver  spleen  bone marrow and small intestines Data from the study showed that treatment with once daily avapritinib  25 mg  50 mg or 100 mg  led to rapid and robust reductions in serum tryptase  an enzyme released from mast cells when those are activated The results will be released at the annual meeting of American Society of Hematology held in Orlando  FL Blueprint Medicines plans to initiate patient screening in registration enabling part 2 portion of the PIONEER study for indolent SM in the first half of 2020 Shares of Blueprint Medicines were up 5 3  following the aforementioned news  In fact  the stock has surged 45 6  so far this year  outperforming the  increase of 6 6  Blueprint Medicines is pursuing a broad clinical development program for avapritinib across the advanced  indolent and smoldering forms of SM  The candidate is currently being evaluated in three ongoing  registration enabling studies for SM  namely the EXPLORER  the PATHFINDER and the PIONEER The company plans to submit a new drug application  NDA  for avapritinib in the first quarter of 2020 for the advanced SM indication The NDA will be based on response data from approximately 55 patients and safety data pertaining to roughly 100 patients from the EXPLORER and the PATHFINDER studies Meanwhile  Blueprint Medicines is evaluating avapritinib in several late stage studies for some cancer indications  In August 2019  the FDA accepted the NDA for avapritinib to treat patients with PDGFRA Exon 18 mutant gastrointestinal stromal tumors  GIST   regardless of any prior therapy  and the fourth line GIST The FDA has set an action date of Feb 14  2020 for both indications Additionally  Blueprint Medicines is evaluating the safety and efficacy of avapritinib compared with Bayer s   OTC BAYRY   Stivarga  regorafenib  in the phase III VOYAGER study for treating patients with third  and fourth line GIST  The company plans to file a supplemental NDA for avapritinib to the FDA in the second half of 2020 for addressing the third line GIST We remind investors that Blueprint Medicines has no approved product in its portfolio at the moment  Revenues generated by the company are all related to its partnerships with Roche   OTC RHHBY   and CStone Pharmaceuticals for the development and commercialization of its pipeline candidates  A potential approval of avapritinib will lower the company s heavy dependence on its partners for revenues and thus help boost its growth prospects Zacks Rank   Key PickBlueprint Medicines currently carries a Zacks Rank  3  Hold   A better ranked stock in the biotech sector is Vertex Pharmaceuticals Incorporated   NASDAQ VRTX    which sports a Zacks Rank  1  Strong Buy   You can see  Vertex s earnings estimates have been revised 5  upward for 2019 and 10 6  for 2020 over the past 60 days  The stock has surged 34 7  year to date The Hottest Tech Mega Trend of AllLast year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-12-08,Zacks Investment Research,https://www.investing.com/analysis/blueprints-bpmc-systemic-mastocytosis-study-data-impresses-200491231,200491231
119918,341433,VRTX,5 Defensive Stocks To Buy As Volatility Index Soars ,opinion,Lately  the stock market has been highly volatile due to trade war jitters  Uncertainties regarding the completion of a U S  China phase one trade deal and the fate of the 15  tariff imposition on Chinese products scheduled on Dec 15 has left investors rushing to hedge  In fact  the fear gauge has climbed steeply  implying that investors are turning bearish  Given such conditions it is advisable to invest in defensive stocks VIX Jumps 16   Encouraging Investors to Hedge The CBOE Volatility Index  VIX  is a measure of the level of implied volatility based on the S P 500 option prices  In short  VIX represents the market s expectation of the 30 day forward looking volatility and a low VIX reading indicates investors  bullishness Generally  the S P 500 and VIX move in opposite directions 80  of the time  But both may proceed in the same direction in certain market conditions  In May  both indexes rose simultaneously for the first time for two straight weeks  This event was followed by a 7  slump in the S P 500 the very next month On Nov 26  as the stock market rallied to hit record highs and the fear gauge CBOE Volatility Index  VIX  dropped to a new low  declining 2 8  to close at 11 55  The fear gauge closed at the lowest since Oct 3  2018  But  with rising uncertainties over the protracted U S  China trade war owing to a fresh 15  higher tariff on Chinese products scheduled to be imposed on Dec 15  VIX jumped 16  on Dec 9 The market has been highly volatile with fears of  no deal  before Dec 15 creeping in and investors bearish  Despite this  that major benchmarks are merely 1  lower than their all time highs and VIX remains well below its long term average of 19  The steep jump of 16  highlights clouded investors  sentiment Given the uncertainties looming from the U S  China trade deal  investors are looking for options to hedge  Defensive stocks look like safe options in such uncertain times Why Play Defensive Defensive stocks like utilities  consumer staples and healthcare have stable earnings regardless of market conditions  Amid any market gyration  demand for these products or services is constant  as these cater to basic necessities  However  these stocks do not give high returns when the economy is expanding  compared to technology and other sectors But with the prevailing trade war weighing heavily on manufacturing and in turn on the economy  defensive stocks are generating better than expected results  In fact  defective stocks that include utilities  consumer staples and real estate sectors have been quite beneficial in this turbulent market  In fact  the Real Estate Select Sector SPDR Fund  XLRE   the Utilities Select Sector SPDR Fund  XLU  and the Health Care Select Sector SPDR Fund  XLV  have grown 27 3   21 1  and 17   respectively  on a year to date basis 5 Stocks to Buy NowHence  as fear creeps in from uncertainties related to the trade deal completion and imposition of higher tariffs in mid December  it is prudent to invest in defensive stocks  We have shortlisted five defensive stocks that flaunt a Zacks Rank  1  Strong Buy   You can see  Spark Energy  Inc    NASDAQ SPKE   operates as an independent retail energy services company in the United States  providing electricity and natural gas to residential and commercial customers  The company s expected earnings growth rate for the next quarter is more than 100  against the Zacks  industry s projected earnings decline of 16 4   The Zacks Consensus Estimate for the company s current year earnings has advanced more than 100  over the past 60 days  Spark Energy has outperformed the industry in the past year   22 1  versus  7 5    Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   engages in developing and commercializing therapies for treating cystic fibrosis  The company s expected earnings growth rate for the next quarter is 17 5  against the Zacks  industry s projected earnings decline of 76 5   The Zacks Consensus Estimate for the company s current year earnings has advanced 5  over the past 60 days  Vertex Pharmaceuticals has outperformed the industry in the past year   26 3  versus  3 6    ResMed Inc    NYSE RMD   develops  manufactures  distributes and markets medical devices and cloud based software solutions that diagnose  treat and manage respiratory disorders  The company s expected earnings growth rate for the current year is 12 6  compared with the Zacks  industry s projected earnings growth of 4 6   The Zacks Consensus Estimate for the company s current year earnings has advanced 3 5  over the past 60 days  ResMed has outperformed the industry in the past year   32 3  versus  8 8    Prologis  Inc    NYSE PLD   leases modern logistics facilities to customers principally across two major categories  business to business and retail or online fulfillment  The company s expected earnings growth rate for the current year is 9 2  against the Zacks  industry s projected earnings decline of 1 6   The Zacks Consensus Estimate for the company s current year earnings has advanced 1 2  over the past 60 days  Prologis has outperformed the industry in the past year   38 5  versus  12 9    The Boston Beer Company  Inc    NYSE SAM   produces and sells alcohol beverages primarily in the United States  The company s expected earnings growth rate for the next quarter is 19 2  against the Zacks  industry s projected earnings decline of 89 2   The Zacks Consensus Estimate for the company s current year earnings has advanced 1 9  over the past 60 days  The Boston Beer Company has outperformed the industry in the past year   40 1  versus  11    Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ,2019-12-09,Zacks Investment Research,https://www.investing.com/analysis/5-defensive-stocks-to-buy-as-volatility-index-soars-200491472,200491472
119919,341434,VRTX,Biotech Stock Roundup  ASH Data In Focus  Amgen Gets FDA Nod To Remicade Biosimilar,opinion,"This week  the focus was on data presented at the annual conference of the American Society of Hematology   ASH   from Dec 7 10  Apart from this  the regular pipeline updates were also significant to the biotech sector Recap of the Week s Most Important Stories ASH Roundup  Several companies were at ASH with data on approved and pipeline drugs Kite  a Gilead Sciences  Inc    NASDAQ GILD   company  announced long term data from the ZUMA 1 study on CAR T cell therapy  Yescarta  axicabtagene ciloleucel   in adult patients with refractory large B cell lymphoma at the 61st ASH Annual Meeting   Exposition in Orlando This included updated overall survival  OS  data from the phase II study after three years  following a single infusion of Yescarta as well as an analysis from a separate safety management cohort of patients receiving early steroid intervention for cytokine release syndrome  CRS  and neurologic events   With a minimum follow up of three years after a single infusion of Yescarta  median follow up of 39 1 months   approximately 47  of patients with refractory large B cell lymphoma in ZUMA 1 phase II cohorts were alive  while the median OS was 25 8 months The company also announced primary results from ZUMA 2  a global  multicenter  single arm  open label phase 2 study of KTE X19  which is an investigational CD19 CAR T cell therapy  in adult patients with relapsed or refractory mantle cell lymphoma  MCL   In the study  93  of patients treated with investigational KTE X19 achieved response bluebird bio  Inc    NASDAQ BLUE   and partner Bristol Myers Squibb Company  NYSE BMY   positive top line results from a phase II study on their lead investigational BCMA targeted CAR T cell therapy candidate  idecabtagene vicleucel  ide cel  bb2121   The phase II KarMMa study evaluated the efficacy and safety of the candidate in patients with relapsed and refractory multiple myeloma  The study met its primary endpoint and key secondary endpoint demonstrating deep and durable responses in a heavily pre treated multiple myeloma patient population Shares of Fate Therapeutics  Inc    NASDAQ FATE    significantly after it reported positive data on experimental cancer candidates  The company announced initial clinical data on its candidates   FT516 and FT500  Both are off the shelf  induced pluripotent stem cell  iPSC  derived natural killer  NK  cell product candidates  The initial findings show the absence of morphologic evidence of leukemia  at day 42  along with complete neutrophil recovery in the first patient treated with FT516 monotherapy for AML following the first dosing cycle  The company also announced new in vivo preclinical data for FT596  its off the shelf  multi antigen targeting NK cell product candidate derived from a clonal master engineered iPSC line FT596 as a monotherapy demonstrated comparable anti tumor activity to CAR19 T Cells in vivo in the humanized mouse model of lymphoma Amgen  Inc    NASDAQ AMGN   announced additional results from the primary analysis of the phase III CANDOR study  evaluating Kyprolis  carfilzomib  in combination with dexamethasone and Darzalex  daratumumab   KdD  compared to Kyprolis and dexamethasone alone  Kd  in patients with relapsed or refractory multiple myeloma  Treatment with KdD resulted in a significant progression free survival  PFS  benefit Amgen Gets FDA Nod for Remicade Biosimilar  Amgen announced that the FDA has approved its biosimilar version of Remicade  infliximab   The biosimilar will be marketed by the trade name of Avsola  ABP 710  for all approved indications of Remicade  which includes a range of autoimmune disorders  ABP 710 is an anti TNF monoclonal antibody  However  Amgen did not mention when it plans to launch the same The approval was based  partly  on data from a late stage study  which evaluated ABP 710 versus branded Remicade for the treatment of moderate to severe rheumatoid arthritis  RA   Data from the phase III study showed that ABP 710 was non inferior compared to Remicade based on its primary endpoint  which was 20  improvement in American College of Rheumatology core set measurements  ACR20  at week 22 Pipeline Updates From Regeneron  Regeneron   NASDAQ REGN   announced top line data from a mid stage study on pipeline candidate  pozelimab  REGN3918   for the treatment of rare blood disorder   paroxysmal nocturnal hemoglobinuria  The results showed that pozelimab reduced the abnormal destruction of red blood cells  known as  hemolysis   with patients in the initial cohort achieving normal levels of a blood biomarker of elevated hemolysis called lactate dehydrogenase  LDH   Patients in the trial initially received a 30 mg kg IV loading dose of pozelimab  followed by weekly 800 mg subcutaneous injections  All six patients in the initial treatment cohort treated with pozelimab experienced rapid and sustained reductions in LDH up to week 8 Regeneron also announced initial data for REGN5458  a BCMAxCD3 bispecific antibody  in patients with relapsed or refractory  R R  multiple myeloma   the second most common blood cancer  Results from the first two dose groups  3 mg and 6 mg weekly doses  were presented at the ASH Annual Meeting  Patients had a median of seven lines of prior systemic therapy  and all had failed in the CD38 antibody treatment arm  Responses were observed in four out of seven  57   patients  including three out of four  75   in the 6 mg dose group  In the 6 mg dose group  two patients  50   were also minimal residual disease  MRD  negative  which means no cancer cells were detectable in their bone marrow  Two patients achieved the high bar of MRD negativity  and another patient attained a very good partial response despite entering the trial with difficult to treat plasmacytomas outside of the bone marrow Vertex s Kalydeco Label Expanded in Europe  Vertex Pharmaceuticals   NASDAQ VRTX   announced that the European Commission granted approval to the label extension for Kalydeco  ivacaftor  to include the treatment of infants with cystic fibrosis  CF  aged 6 months to less than 12 months  weighing 5 kg and more who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator  CFTR  gene   G551D  G1244E  G1349D  G178R  G551S  S1251N  S1255P  S549N or S549R  The label update was based on data from the ongoing  phase III  open label safety study  ARRIVAL  of children with CF  who are less than 24 months of age and have a CFTR gating mutation  The study showed a safety profile similar to that observed in previous studies of older children and adults  and improvements in sweat chloride  a secondary endpoint Vertex currently carries a Zacks Rank  2  Buy   You can see  Sage Plunges on Study Failure  Shares of Sage Therapeutics   NASDAQ SAGE   plummeted after it announced that a phase III study on SAGE 217 for the treatment of major depressive disorder  MDD  failed to meet the primary endpoint  The MOUNTAIN study evaluated the efficacy  safety and pharmacokinetics of SAGE 217 in adult patients diagnosed with MDD  The phase III study did not meet its primary endpoint of a statistically significant reduction from baseline compared to placebo in the 17 item Hamilton Rating Scale for Depression  HAM D  total score at Day 15  SAGE 217 30 mg  given once daily as an oral treatment  was associated with a mean reduction of 12 6 in HAM D total score compared to 11 2 for placebo Performance     Medical   Biomedical and Genetics Industry 5YR   Return
 The Nasdaq Biotechnology index inched up 0 81  in the last five trading sessions  Among the biotech giants  Biogen  NASDAQ BIIB  gained 2 24  in the period  Over the past six months  shares of Amgen have gained 35 02    See the last biotech stock roundup here  See the last biotech stock roundup here   What s Next in Biotech Stay tuned for more pipeline updates 5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ",2019-12-10,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-ash-data-in-focus-amgen-gets-fda-nod-to-remicade-biosimilar-200491890,200491890
119920,341435,VRTX,Looking For A Growth Stock  3 Reasons Why Vertex  VRTX  Is A Solid Choice,opinion,"Growth stocks are attractive to many investors  as above average financial growth helps these stocks easily grab the market s attention and produce exceptional returns  However  it isn t easy to find a great growth stock 
By their very nature  these stocks carry above average risk and volatility  Moreover  if a company s growth story is over or nearing its end  betting on it could lead to significant loss 
However  it s pretty easy to find cutting edge growth stocks with the help of the Zacks Growth Style Score  part of the Zacks Style Scores system   which looks beyond the traditional growth attributes to analyze a company s real growth prospects 
Vertex Pharmaceuticals  NASDAQ VRTX  is one such stock that our proprietary system currently recommends  The company not only has a favorable Growth Score  but also carries a top Zacks Rank 
Research shows that stocks carrying the best growth features consistently beat the market  And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank  1  Strong Buy  or 2  Buy   returns are even better 
Here are three of the most important factors that make the stock of this drugmaker a great growth pick right now 
Earnings Growth
Arguably nothing is more important than earnings growth  as surging profit levels is what most investors are after  And for growth investors  double digit earnings growth is definitely preferable  and often an indication of strong prospects  and stock price gains  for the company under consideration 
While the historical EPS growth rate for Vertex is 250 6   investors should actually focus on the projected growth  The company s EPS is expected to grow 17 9  this year  crushing the industry average  which calls for EPS growth of 12 8  
Cash Flow Growth
Cash is the lifeblood of any business  but higher than average cash flow growth is more beneficial and important for growth oriented companies than for mature companies  That s because  high cash accumulation enables these companies to undertake new projects without raising expensive outside funds 
Right now  year over year cash flow growth for Vertex is 204   which is higher than many of its peers  In fact  the rate compares to the industry average of 19 5  
While investors should actually consider the current cash flow growth  it s worth taking a look at the historical rate too for putting the current reading into proper perspective  The company s annualized cash flow growth rate has been 37 2  over the past 3 5 years versus the industry average of 8 7  
Promising Earnings Estimate Revisions
Beyond the metrics outlined above  investors should consider the trend in earnings estimate revisions  A positive trend is a plus here  Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near term stock price movements 
The current year earnings estimates for Vertex have been revising upward  The Zacks Consensus Estimate for the current year has surged 0 2  over the past month 
Bottom Line
While the overall earnings estimate revisions have made Vertex a Zacks Rank  2 stock  it has earned itself a Growth Score of B based on a number of factors  including the ones discussed above 
You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
This combination indicates that Vertex is a potential outperformer and a solid choice for growth investors ",2019-12-11,Zacks Investment Research,https://www.investing.com/analysis/looking-for-a-growth-stock-3-reasons-why-vertex-vrtx-is-a-solid-choice-200491947,200491947
119921,341436,VRTX,The Zacks Analyst Blog Highlights  Spark Energy  Vertex  ResMed  Prologis And Boston Beer,opinion,For Immediate ReleaseChicago  IL  December 11  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Spark Energy  Inc    NASDAQ SPKE    Vertex Pharmaceuticals Inc    NASDAQ VRTX    ResMed Inc    NYSE RMD    Prologis  Inc    NYSE PLD   and The Boston Beer Company  Inc    NYSE SAM   Here are highlights from Tuesday s Analyst Blog 5 Defensive Stocks to Buy as Volatility Index SoarsLately  the stock market has been highly volatile due to trade war jitters  Uncertainties regarding the completion of a U S  China phase one trade deal and the fate of the 15  tariff imposition on Chinese products scheduled on Dec 15 has left investors rushing to hedge  In fact  the fear gauge has climbed steeply  implying that investors are turning bearish  Given such conditions it is advisable to invest in defensive stocks VIX Jumps 16   Encouraging Investors to Hedge The CBOE Volatility Index  VIX  is a measure of the level of implied volatility based on the S P 500 option prices  In short  VIX represents the market s expectation of the 30 day forward looking volatility and a low VIX reading indicates investors  bullishness Generally  the S P 500 and VIX move in opposite directions 80  of the time  But both may proceed in the same direction in certain market conditions  In May  both indexes rose simultaneously for the first time for two straight weeks  This event was followed by a 7  slump in the S P 500 the very next month On Nov 26  as the stock market rallied to hit record highs and the fear gauge CBOE Volatility Index  VIX  dropped to a new low  declining 2 8  to close at 11 55  The fear gauge closed at the lowest since Oct 3  2018  But  with rising uncertainties over the protracted U S  China trade war owing to a fresh 15  higher tariff on Chinese products scheduled to be imposed on Dec 15  VIX jumped 16  on Dec 9 The market has been highly volatile with fears of  no deal  before Dec 15 creeping in and investors bearish  Despite this  that major benchmarks are merely 1  lower than their all time highs and VIX remains well below its long term average of 19  The steep jump of 16  highlights clouded investors  sentiment Given the uncertainties looming from the U S  China trade deal  investors are looking for options to hedge  Defensive stocks look like safe options in such uncertain times Why Play Defensive Defensive stocks like utilities  consumer staples and healthcare have stable earnings regardless of market conditions  Amid any market gyration  demand for these products or services is constant  as these cater to basic necessities  However  these stocks do not give high returns when the economy is expanding  compared to technology and other sectors But with the prevailing trade war weighing heavily on manufacturing and in turn on the economy  defensive stocks are generating better than expected results  In fact  defective stocks that include utilities  consumer staples and real estate sectors have been quite beneficial in this turbulent market  In fact  the Real Estate Select Sector SPDR Fund  XLRE   the Utilities Select Sector SPDR Fund  XLU  and the Health Care Select Sector SPDR Fund  XLV  have grown 27 3   21 1  and 17   respectively  on a year to date basis 5 Stocks to Buy NowHence  as fear creeps in from uncertainties related to the trade deal completion and imposition of higher tariffs in mid December  it is prudent to invest in defensive stocks  We have shortlisted five defensive stocks that flaunt a Zacks Rank  1  Strong Buy   You can see  Spark Energy  Inc  operates as an independent retail energy services company in the United States  providing electricity and natural gas to residential and commercial customers  The company s expected earnings growth rate for the next quarter is more than 100  against the Zacks  industry s projected earnings decline of 16 4   The Zacks Consensus Estimate for the company s current year earnings has advanced more than 100  over the past 60 days  Spark Energy has outperformed the industry in the past year   22 1  versus  7 5   Vertex Pharmaceuticals Inc  engages in developing and commercializing therapies for treating cystic fibrosis  The company s expected earnings growth rate for the next quarter is 17 5  against the Zacks  industry s projected earnings decline of 76 5   The Zacks Consensus Estimate for the company s current year earnings has advanced 5  over the past 60 days  Vertex Pharmaceuticals has outperformed the industry in the past year   26 3  versus  3 6   ResMed Inc  develops  manufactures  distributes and markets medical devices and cloud based software solutions that diagnose  treat and manage respiratory disorders  The company s expected earnings growth rate for the current year is 12 6  compared with the Zacks  industry s projected earnings growth of 4 6   The Zacks Consensus Estimate for the company s current year earnings has advanced 3 5  over the past 60 days  ResMed has outperformed the industry in the past year   32 3  versus  8 8   Prologis  Inc  leases modern logistics facilities to customers principally across two major categories  business to business and retail or online fulfillment  The company s expected earnings growth rate for the current year is 9 2  against the Zacks  industry s projected earnings decline of 1 6   The Zacks Consensus Estimate for the company s current year earnings has advanced 1 2  over the past 60 days  Prologis has outperformed the industry in the past year   38 5  versus  12 9   The Boston Beer Company  Inc  produces and sells alcohol beverages primarily in the United States  The company s expected earnings growth rate for the next quarter is 19 2  against the Zacks  industry s projected earnings decline of 89 2   The Zacks Consensus Estimate for the company s current year earnings has advanced 1 9  over the past 60 days  The Boston Beer Company has outperformed the industry in the past year   40 1  versus  11   Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year Media ContactZacks Investment Research800 767 3771 ext  9339 Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-12-11,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-spark-energy-vertex-resmed-prologis-and-boston-beer-200491756,200491756
119922,341437,VRTX,New Strong Buy Stocks For December 12th,opinion,"Here are 5 stocks added to the Zacks Rank  1  Strong Buy  List today American Superconductor Corporation  AMSC   This provider of wind turbine electronic controls and systems  designs and engineering services to reduce the cost of wind energy  has seen the Zacks Consensus Estimate for its current year earnings increasing 23 1  over the last 60 days American Superconductor Corporation Price and Consensus   Vertex Pharmaceuticals  NASDAQ VRTX  Incorporated  VRTX   This biotechnology company has seen the Zacks Consensus Estimate for its current year earnings increasing 4 8  over the last 60 days 
Vertex Pharmaceuticals Incorporated Price and Consensus   Amalgamated Bank  AMAL   provider of commercial banking and retail banking products and services has seen the Zacks Consensus Estimate for its current year earnings increasing 4 2  over the last 60 days 
Amalgamated Bank Price and Consensus   Genesco Inc   GCO   This specialty retailer of footwear and accessories has seen the Zacks Consensus Estimate for its current year earnings increasing 6  over the last 60 days 
Genesco Inc  Price and Consensus   State Street Corporation  NYSE STT   STT   This provider of financial services has seen the Zacks Consensus Estimate for its current year earnings increasing 1 8  over the last 60 days 
State Street Corporation Price and Consensus   Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-12-11,Zacks Investment Research,https://www.investing.com/analysis/new-strong-buy-stocks-for-december-12th-200492253,200492253
119923,341438,VRTX,Vertex ups stake in CRISPR Therapeutics to 10 4 ,news,CRISPR Therapeutics  CRSP  2 4   discloses that CTX001 collaboration partner Vertex Pharmaceuticals  VRTX  has increased its stake to 10 4    5 4M shares  Now read ,2018-12-31,Seeking Alpha,https://www.investing.com/news/stock-market-news/vertex-ups-stake-in-crispr-therapeutics-to-104-1733789,1733789
119924,341439,VRTX,Vertex Earnings  Revenue beat in Q4,news,"Investing com   Vertex  NASDAQ VRTX  reported fourth quarter earnings  that beat analysts  expectations on Tuesday and revenue that topped forecasts 
The firm reported earnings per share of  1 3 on revenue of  869 4M  Analysts polled by Investing com expected EPS of  1 06 on revenue of  819 12M  That compared to EPS of  0 61 on revenue of  651 6M in the same period a year earlier  The company had reported EPS of  1 09 on revenue of  783 86M in the previous quarter 
Vertex shares gained 1 15  to trade at  189 18 in after hours trade following the report 
Vertex follows other major Healthcare sector earnings this month
 On January 22  J J reported fourth quarter EPS of  1 97 on revenue of  20 39B  compared to forecasts of EPS of  1 95 on revenue of  20 2B 
Pfizer earnings beat analyst s expectations on January 29  with fourth quarter EPS of  0 64 on revenue of  13 98B  Investing com analysts expected EPS of  0 63 on revenue of  13 9B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-02-05,Investing.com,https://www.investing.com/news/stock-market-news/vertex-earnings-revenue-beat-in-q4-1770096,1770096
119925,341440,VRTX,Hitting a Moving Target ,news,Technical analyst Glenn Williams  NYSE WMB  Jr   CMT  joins Real Vision for the first time to walk through his trading process and to highlight a stock that recently popped up on his radar  Vertex Pharmaceuticals  NASDAQ VRTX   He drills down on the technicals  examines some key fundamental drivers and discusses how to make the trade  in this interview with Brian Price  Filmed on February 21  2019 ,2019-02-25,RealVision,https://www.investing.com/news/general-news/hitting-a-moving-target-1789293,1789293
119926,341441,VRTX,Vertex Earnings  Revenue Beat in Q1,news,"Investing com   Vertex  NASDAQ VRTX  reported first quarter earnings  that Beat analysts  expectations on Tuesday and revenue that topped forecasts 
The firm reported earnings per share of  1 14 on revenue of  858 4M  Analysts polled by Investing com anticipated EPS of  1 01 on revenue of  851 63M  That compared to EPS of  0 76 on revenue of  638 88M in the same period a year earlier  The company had reported EPS of  1 3 on revenue of  869 44M in the previous quarter 

Vertex follows other major Healthcare sector earnings this month
 On April 16  J J reported first quarter EPS of  2 1 on revenue of  20 02B  compared to forecasts of EPS of  2 04 on revenue of  19 61B 
Pfizer earnings Beat analysts  expectations on Tuesday  with first quarter EPS of  0 85 on revenue of  13 12B  Investing com analysts expected EPS of  0 75 on revenue of  13B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-04-30,Investing.com,https://www.investing.com/news/stock-market-news/vertex-earnings-revenue-beat-in-q1-1851256,1851256
119951,341466,VRTX,Why Biotech ETFs Surged In Monday s Trading Session,opinion,The gained 2 6  in the trading session on Nov 25  This compares favorably with the NASDAQ Composite Index s rise of 1 3   S P 500 Index s 0 8  and Dow Jones Industrial Average s 0 7  on the same day  Increasing M A deals  growing AI dominance and favorable regulatory tidings continue to drive the biotech market  The sector has also been benefitting from a flurry of positive news  including trial results and deal activities  Let s see what could have possible triggered the upside  read    FDA ApprovalThe FDA approved Global Blood Therapeutics  Inc  s   NASDAQ GBT   drug in adults and children aged 12 years or above on Nov 25  The shares of the company rose   The drug will be marketed under the brand name of   With this development  the  has witnessed the approval of the second drug for treating sickle cell anaemia in recent days  Moreover  it has become the first drug to treat the primary cause of the disease instead of the   On Nov 15  Novartis AG   NYSE NVS   received to bring down the frequency of vaso occlusive crises or pain crises in adult and paediatric patients aged 16 years and older with sickle cell disease New Merger Acquisition DealSwiss drugmaker Novartis AG recently   The Medicines Company  for  9 7 billion  The acquisition will give Novartis access to Medicines Co  s near to market heart drug     Medicines Co  is expected to submit the drug to the FDA for approval by the   The company has high chances of getting a clearance from the authorities as it recently presented positive data confirming the  Release of Positive DataCRISPR Therapeutics   NASDAQ CRSP   and its partner Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   recently from the ongoing phase I II studies  Notably  the studies are evaluating the CRISPR Cas9 gene editing therapy CTX001 for two severe blood disorders   sickle cell disease and   TDT  CRISPR Therapeutics and Vertex were each up 17  and 2 5   respectively  on Nov 19  in response to the news  However   due to an underwritten public offering on the same day during after hours trading  read    Biotech ETFs in FocusIn the current scenario  we believe it is prudent to discuss a few ETFs which have considerably wide exposure to the companies discussed iSharesNasdaq Biotechnology ETF This fund seeks to provide exposure to U S  biotechnology stocks and tracks the NASDAQ Biotechnology Index  It comprises 215 holdings  It has AUM of  7 5 billion and charges a fee of 47 basis points a year  The fund gained 2 5  in yesterday s trading session  read    VanEck Vectors Biotech ETF   LON BBH  The underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production  marketing and sales of drugs based on genetic analysis and diagnostic equipment  It holds about 24 securities in its basket  Its AUM is  364 2 million and expense ratio is 0 35   The fund gained 2 1  in yesterday s trading session SPDR S P Biotech  NYSE XBI  ETF The fund seeks daily investment results  before fees and expenses  which match the S P Biotechnology Select Industry Index  It holds about 115 securities in its basket  Its AUM is  4 02 billion and expense ratio  0 35   The fund gained 4 3  in yesterday s trading session  read    First Trust Amex Biotechnology Index The fund measures the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services  It holds about 31 securities in its basket  Its AUM is around  1 73 billion and expense ratio is 0 57   The fund gained 2 4  in yesterday s trading session Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-11-27,Zacks Investment Research,https://www.investing.com/analysis/why-biotech-etfs-surged-in-mondays-trading-session-200488236,200488236
119952,341467,VRTX,Biotech Tops In November  Best ETFs   Stocks,opinion,The biotech space of the broad healthcare sector outperformed others in November  courtesy of a series of positive news including study results  regulatory backdrop and deal activities  Better than expected corporate earnings added to this strength  read     Among the latest top stories  one is about the FDA s approval of a new drug Oxbryta for treating sickle cell disease in adults and children aged 12 years or above  The novel drug was developed by the biotech firm Global Blood Therapeutics   NASDAQ GBT    CRISPR Therapeutics   NASDAQ CRSP   and Vertex Pharmaceuticals   NASDAQ VRTX   announced encouraging preliminary safety and efficacy data from the first two patients treated with investigational CRISPR Cas9 gene editing therapy CTX001 for severe hemoglobinopathies  Meanwhile  Swiss drugmaker Novartis  agreed to merge with The Medicines Company in a  9 7 billion deal  The acquisition will add inclisiran  a potentially first in class treatment to lower cholesterol  to Novartis  pipeline Further  uncertainty over trade lent a boost to the sector given its non cyclical nature  which in turn  provides a cushion to its portfolio  Moreover  the sector is clearly benefiting from impressive trends including new drug nods  an accelerated pace of innovation  promising drug launches  growing importance of biosimilars  cost cutting efforts  an aging population  expanding insurance coverage  the rising middleclass  insatiable demand for new drugs and an ever increasing spending on healthcare In light of the above  we highlight five biotech ETFs and stocks that led the market in November Virtus LifeSci Biotech Clinical Trials ETF   ASX BBC     Up 20 5 This fund has a novel approach to biotechnology investing with exposure to companies that are in the clinical trial stage  This can easily be done by tracking the LifeSci Biotechnology Clinical Trials Index  BBC has amassed  28 6 million in its asset base and charges 79 bps in fees per year from investors  It trades in a light average daily volume of around 4 000 shares and holds 95 securities in its basket  The product carries a Zacks ETF Rank  3  Hold  with a High risk outlook  read    The Cancer Immunotherapy ETF    Up 18 2 This ETF offers exposure to a basket of companies that develop therapies to treat cancer by harnessing the body s own immune system  Holding 26 stocks in its basket  it has AUM of  38 5 million and trades in average daily volume of 9 000 shares  The product charges 79 bps in annual fees and is Zacks  3 Ranked ETF with High risk outlook Global X Genomics   Biotechnology ETF    Up 17 2 This is a new entrant in the space having accumulated  18 6 million since its inception on Apr 5  It seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science  such as companies involved in gene editing  genomic sequencing  genetic medicine therapy  computational genomics and biotechnology  The product follows the Solactive Genomics Index  charging 68 bps in annual fees  It holds 39 stocks in its basket and trades in average daily volume of 4 000 shares Virtus LifeSci Biotech Products ETF   BS BBP     Up 16 3 The ETF follows the LifeSci Biotechnology Products Index  which measures the performance of biotechnology companies with at least one drug therapy approved by the FDA  Holding 40 stocks  the product has accumulated AUM of  28 6 million and charges 79 bps in fees per year  BBP trades in volume of 3 000 shares a day on average and has a Zacks ETF Rank of 3 with a High risk outlook ARK Genomic Revolution Multi Sector ETF    Up 15 8 This is an actively managed ETF  focusing on companies likely to benefit from the extension and enhancement of the quality of human and other life by incorporating technological and scientific developments plus improvements and advancements in genomics into their business  With AUM of  474 5 million  the fund holds 38 stocks in its basket and has 0 75  in expense ratio  It trades in average daily volume of 120 000 shares  read    Karuna Therapeutics Inc    NASDAQ KRTX     Up 446 8 This clinical stage biopharmaceutical company is primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs  The stock has a Zacks Rank  2  Buy  and a VGM Score of C  It has a market cap of  1 78 billion  You can see  Myovant Sciences Ltd    NYSE MYOV     Up 215 7 This biopharmaceutical company is focused on developing and commercializing therapies for women s health diseases and other endocrine related disorders including advanced prostate cancer  With a market cap of  1 55 billion  it has a Zacks Rank  3 and a VGM Score of F Clovis Oncology Inc    NASDAQ CLVS     Up 291 5 This biopharmaceutical company is focused on developing and commercializing treatments targeting specific subsets of cancer population  It has a Zacks Rank of 2 and a VGM Score of F  The stock has a market cap of  680 3 million Constellation Pharmaceuticals Inc    NASDAQ CNST     Up 209 3 This bio pharmaceutical company discovers and develops molecule therapeutics for the treatment of cancer  inflammatory and immunologic disorders  The stock has a Zacks Rank  3 and a VGM Score of D  It has a market cap of  1 43 billion  read    Proteostasis Therapeutics Inc    NASDAQ PTI     Up 189 3 This biopharmaceutical company focuses on the discovery and development of novel therapeutics to treat diseases caused by an imbalance in the proteostasis network  primarily in the United States  With a market cap of  122 7 million  the stock is Zacks  2 Ranked and has a VGM Score of D Want key ETF info delivered straight to your inbox  Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-11-29,Zacks Investment Research,https://www.investing.com/analysis/biotech-tops-in-november-best-etfs--stocks-200489029,200489029
119953,341468,VRTX,Gene Therapy The Next Best Thing  Here s Why  Revised ,opinion,Gene therapy has been growing by leaps and bounds in recent times  This shows on Global X Genomics   Biotechnology ETF s  GNOM  gain of 16 1  compared with the broader S P 500 Index s rally of 10 3  in the past six months  Notably  genomics primarily comprises gene therapy and gene editing  Mergers and acquisitions  collaborative operations  and a broad and intriguing pipeline of research programs have been driving the gene therapy industry Given such positive developments  we have shortlisted five companies involved in gene therapy that can be valuable additions to your portfolio Recent Activities Spurring GrowthAlthough the gene therapy space is impacted negligibly by geopolitical or economic factors  mergers and acquisitions  collaboration and success of R D programs have a significant bearing on the stocks The broader Biomedical and Genetics industry has been in spotlight since the beginning of this year with a bigwig like Bristol Myers Squibb Company  NYSE BMY  acquiring Celgene Corporation  NASDAQ CELG   Moreover  in the gene therapy space  major mergers like Roche s acquisition of Spark Therapeutics  Inc  is pending due to regulatory snags but is expected to close in 2019 In June  Biogen Inc  NASDAQ BIIB   acquired Nightstar Therapeutics for approximately  800 million in an effort to establish clinical pipeline of gene therapy candidates in ophthalmology  On Dec 2  Tokyo based Astellas Pharma also disclosed plans to acquire Audentes Therapeutics for about  3 billion  or  60 per share Audentes Therapeutics  an early startup in the gene therapy area  which develops single shot carrying the correct copy of a gene to cure patients of genetic diseases  This deal will enable Audentes to operate as an independent subsidiary and access Astellas  scientific and development resources Apart from massive mergers and acquisition that benefit this space  its broad and intriguing project pipeline attracts investors  as successful execution will lead to higher revenues  For example  Applied Genetic Technologies Corporation in September announced positive results from its leading pipeline program  X linked retinitis pigmentosa  XLRP  Almost 8 000 Americans suffer from this rare ophthalmologic disorder and a breakthrough will benefit the company financially as treatment would cost  500 000 per patient  This also provides the company an edge over competitors like Biogen and MeiraGTX Additionally  collaborative activities have been driving the gene therapy  On Dec 3  Seattle Genetics  Inc  and Astellas Pharma announced a deal to collaborate  with Merck   Co   Inc to commence a phase III study  that would allow combination of their antibody drug conjugate Enfortumab Vedotin and PD 1 L1 inhibitor Keytruda  pembrolizumab  to address patients with previously untreated metastatic urothelial cancer Earlier in September  Seattle Genetics and Astellas had released encouraging results for the phase I EV 103 study on Enfortumab Vedotin  Such developments indicate growth in the gene therapy space In fact  major biotech ETFs and indexes have exhibited a strong performance year to date as the SPDR S P Biotech ETF  NYSE XBI  gained 28 6  compared with the S P 500 index s rally of 23 2  so far this year  While the ProShares Ultra Nasdaq Biotechnology  BIB  rose 40 5  surpassing the Nasdaq Composite s growth of 27 8  on a year to date basis In fact  the size of the biotechnology market was valued at  399 4 billion in 2017 and is expected to see a CAGR of 9 9  during the forecast period 2018 2024  according to Global Market Insights 5 Biotech Stocks to Buy NowGene therapy falls under Zacks  industry  which primarily comprises of biotechnology stocks  Looking at the positive development in this space we have shortlisted five stocks that flaunt a Zacks Rank  1  Strong Sell  or 2  Buy  and are poised to grow Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   engages in developing and commercializing therapies for treating cystic fibrosis  The company also engages in funding and financing companies testing and developing gene therapies  Recently in June this year  the company acquired Exonics Therapeutics for  245 million  Exonics is developing gene therapies The company s expected earnings growth rate for the current year is 17 9  compared with the Medical   Biomedical and Genetics industry s projected earnings growth of 6 1   The Zacks Consensus Estimate for the company s current year earnings has advanced 5  over the past 60 days  Vertex Pharmaceuticals  a Zacks Rank  1 company  has outperformed the industry in the past year   24 3  versus  7 4    You can see the complete list of today s Zacks  1 Rank stocks here Pieris Pharmaceuticals  Inc    NASDAQ PIRS   is a clinical stage biopharmaceutical company that discovers and develops anticalin based drugs  Pieris engages in several research and development programs and other gene therapy companies  In mid November  the company was scheduled to phase 1 dose escalation data for PRS 343 in combination with Roche s Tecentriq in HER2 positive solid tumor The company s expected earnings growth rate for the current year is 56   The Zacks Consensus Estimate for the company s current year earnings has risen 14 3  over the past 60 days  Pieris  a Zacks Rank  1 company  has outperformed the industry in the past year   9 6  versus  7 4   MeiraGTx Holdings plc   NASDAQ MGTX   is a clinical stage gene therapy company that focuses on developing treatments for patients living with serious diseases  The company s program pipeline in clinical development includes phase 1 2 clinical stage programs in Achromatopsia  X Linked Retinitis Pigmentosa  RPE65 deficiency  and radiation induced Xerostomia  and Parkinson s program  Notably  Johnson   Johnson  NYSE JNJ  owns a stake in this company The company s expected earnings growth rate for the next year is 8 6  compared with the industry s projected earnings growth of 6 9   The Zacks Consensus Estimate for the company s current year earnings has risen 10 1  over the past 60 days  MeiraGTx  a Zacks Rank  2 company  has outperformed the industry in the past year   47 4  versus  7 4   uniQure N V    NASDAQ QURE   is a gene therapy company that engages in the discovery  development  and commercialization of gene therapies  The company s current pipeline has projects like developing AMT 061  a gene therapy that is in phase III clinical trial for the treatment of hemophilia B  uniQure intends to make  1 billion in annual revenues from hemophilia B treatment The company s expected earnings growth rate for the current year is 27 8   The Zacks Consensus Estimate for the company s current year earnings has risen 7 1  over the past 60 days  uniQure  a Zacks Rank  2 company  has outperformed the industry in the past year   115 8  versus  7 4   Intellia Therapeutics  Inc    NASDAQ NTLA   is a genome editing company that focuses on the development of therapeutics utilizing a biological tool known as the CRISPR Cas9 system  The company has several in vivo and ex vivo programs in pipeline  While in vivo program focuses on liver diseases  including transthyretin amyloidosis  alpha 1 antitrypsin deficiency  and primary hyperoxaluria  ex vivo deals with engineering cell therapies to treat various oncological and autoimmune diseases The company s expected earnings growth rate for the next quarter is 12 2  against the industry s expected earnings decline of 31 7   The Zacks Consensus Estimate for the company s current year earnings has risen 8 7  over the past 60 days  Intellia  a Zacks Rank  2 company  has outperformed the industry in the past year   4  versus  7 4    We are reissuing this article to correct a mistake  The original article  issued on December 04  2019  should no longer be relied upon  ,2019-12-05,Zacks Investment Research,https://www.investing.com/analysis/gene-therapy-the-next-best-thing-heres-why-revised-200490197,200490197
119954,341469,VRTX,Ipsen S A  ADR reports Q3 results,news,Ipsen S A  ADR  OTCPK IPSEY   Q3 Revenue of  555 9M   18 3  Y Y Press ReleaseNow read ,2018-10-25,Seeking Alpha,https://www.investing.com/news/stock-market-news/ipsen-sa-adr-reports-q3-results-1659034,1659034
119955,341470,VRTX,Google Temasek study sees  240 billion Southeast Asia internet economy by 2025,news,"SINGAPORE  Reuters    Southeast Asia s internet economy is expected to exceed  240 billion by 2025  a joint study by Google and Temasek Holdings showed  a fifth more than previously estimated  as more consumers use their smartphones to go online  The study  first published in 2016  encompasses ride hailing  e commerce  online travel and online media  The latest report released on Monday adds new sectors such as online food delivery  as well as subscription music and video on demand  It estimated that the gross merchandise value  GMV  of the region s internet economy has reached  72 billion in 2018  rising 37 percent from the year earlier  The GMV of e commerce in the region will exceed  23 billion in 2018  the report said  and rise more than four times to exceed  100 billion by 2025  helped by increased consumer trust   It credited e commerce companies    Alibaba   NYSE BABA  Group Holding Ltd s Lazada  Sea Ltd s Shopee  and Indonesia s Tokopedia   for helping develop the sector  The report estimated that the GMV of the competitive ride hailing sector  with the addition of online food delivery  has reached  7 7 billion in 2018    Powered by the ambitions of Go Jek and Grab to become Southeast Asia s  everyday apps   we project that ride hailing will reach almost  30 billion by 2025   the Google Temasek study said   Both Alphabet  NASDAQ GOOGL  Inc s Google and Singapore state investor Temasek  TEM UL  have invested in Go Jek  Temasek backed Vertex  NASDAQ VRTX  Ventures is an early investor in Grab   The Indonesian internet economy is forecast to grow to  100 billion by 2025  accounting for  4 of every  10 spent in the region  the report said  It added that 2018 was on track to be a record year for fundraising for the region s internet economy companies  with  9 1 billion raised in the first half of the year  nearly as much as in all of 2017   The research covers Southeast Asia s six largest economies   Indonesia  Malaysia  Philippines  Singapore  Thailand  and Vietnam  The growth is being boosted by the world s most engaged internet users  of whom more than 90 percent connect to the web through their smartphones  it said   
The report said the increasing availability of affordable smartphones and the rollout of faster and more reliable mobile telecommunication services were supporting Southeast Asia s growing internet user base ",2018-11-18,Reuters,https://www.investing.com/news/technology-news/googletemasek-study-sees-240-billion-southeast-asia-internet-economy-by-2025-1692801,1692801
119956,341471,VRTX,U S  benefits manager baulks after Novartis values gene therapy at  4 5 million,news,"By John Miller ZURICH  Reuters    Just weeks after Novartis floated the idea that  4 5 million was fair value for its new gene therapy against a deadly neuromuscular disease  a major benefits manager is pushing back  The Swiss drugmaker s assessment of AVXS 101 s value for treating spinal muscular atrophy  SMA  has put the company front and center in the debate over what  super drugs   for rare diseases afflicting relatively few patients  are really worth  Among the first to react was pharmacy benefits manager Express Scripts  NASDAQ ESRX   which helps U S  employers manage workers  prescription costs  Its chief medical officer  Steve Miller  told Reuters he  loves the science  behind Novartis s therapy  a potential cure for newborns who are diagnosed early  But  4 million or more per patient   You just can t keep pushing these price points up   Miller said   I just don t think we can allow it  It is not sustainable over time   Novartis  which bought U S  based AveXis for  8 7 billion in April to add the SMA therapy to its portfolio  is still mulling its asking price as it awaits U S  Food and Drug Administration approval  likely in early 2019  But the company has begun its campaign to convince insurance groups and governments to cover AVXS 101  contending the one and done infusion will save society money over the long haul  even with a cost near the highest ever for a one time therapy  There s now only one approved drug for SMA  Biogen s two year old Spinraza  and it is listed at  750 000 for the first year and  350 000 thereafter  Spinraza is not a cure and must be taken indefinitely   When we look at 10 year costs  you see somewhere between  2 5 million to  5 million being spent by societies to care for these types of patients   Dave Lennon  AveXis s president  said   Four million dollars is a significant amount of money  but we believe this is a cost effective point   Though newborns may stand to benefit the most from AVXS 101  depending on the durability of its effect  the therapy is also being tested in older SMA patients with more advanced disease in hopes it will improve their symptoms  too  A CHILD S LIFE A diagnosis of SMA  which affects one in 10 000 live births  is devastating  Forty percent of victims have the severest form and historically die within months  Children with less severe SMA can live to adulthood  although with profound physical disabilities  Though cognitively normal  many cannot feed themselves and require 24 hour care  wheelchairs and machines to help them breathe and cough  Janice Kress  a Pennsylvania woman  lost her grandson to the disease at 5 months  Today she volunteers for SMA charity events and knows families who have fought their U S  insurers for access to Biogen s Spinraza  as payers seek to rein in costs using eligibility criteria like age or when symptoms began   A child s life    how can you say no   Kress said  PRICE WATCHDOG As Novartis prepares to launch AVXS 101  it also hopes for tacit endorsement of its pricing strategy from the non profit Institute for Clinical and Economic Review  ICER   which is currently reviewing the cost effectiveness of SMA therapies   The Boston based non profit  established in 2006  carries out cost benefit analyses on drugs that it calls independent of  Big Pharma   insurers and government  Unlike European price regulators  ICER cannot dictate costs  But it has steadily gained influence in the U S  pricing debate  as companies like Express Scripts and CVS Caremark and governments rely on its analyses  ICER has reviewed 11 treatments in 2018   Seven times  it concluded drugs  prices aligned with their benefits  like when it said Roche s  482 000 hemophilia medicine Hemlibra could save the U S  system up to  1 9 million for the hardest to treat patients  Four times  however  ICER concluded drugmakers were asking too much  giving payers ammunition to bargain them down   For instance  the New York Department of Health told Reuters that ICER s finding that a  270 000 per year cystic fibrosis drug from Vertex Pharmaceuticals  NASDAQ VRTX  represented  low long term value  helped underpin the state s demand for a steep discount  JUST ONE FINGER Novartis and Biogen  NASDAQ BIIB   as well as Switzerland s Roche  which also has an SMA drug in development  are all lobbying ICER to broaden what it considers a meaningful benefit  potentially helping their therapies fare well in the group s review  The ability to move one finger might not seem like much  but Biogen told ICER such a measure should be considered  since it might allow somebody with SMA to steer an electric wheelchair and maintain a level of independence   We recently spoke with a young man who is   now losing ability and power in his fingers   said Sangeeta Jethwa  Roche s head of patient partnerships  told Reuters   He wants to be able to go out with his friends and open his own bottle of drink  That for him is fantastically meaningful   For its SMA review  ICER aims to quantify factors like quality of life  direct medical costs and how patient and caregiver productivity losses may burden society  A head to head comparison of Spinraza s and AVXS 101 s financial impacts over time is also planned before ICER issues its final report in March  ICER spokesman David Whitrap said ICER s review takes eight months so it can  rigorously evaluate all of the available evidence    The stakes are high for Biogen  after Britain s healthcare cost agency  the National Institute for Health and Care Excellence  has concluded Spinraza was too expensive to be cost effective  Though Spinraza  whose nine month 2018 sales hit  1 25 billion  is available in the United States and elsewhere in Europe  Biogen wants to avoid a negative ICER assessment that gives payers more leverage to demand rebates   We are confident in the evidence supporting the value it provides   a Biogen spokeswoman said  SIGNS OF PROGRESS Treatments for rare diseases like SMA are increasingly popular among drugmakers  because they command high prices while insurers are hard pressed to reject claims  especially for sick children  Sales of rare disease therapies will rise 11 percent annually  nearly twice the overall market rate  through 2024  when they ll hit  262 billion  consultancy Evaluate Pharma has forecast  Novartis Chief Executive Vas Narasimhan  with ambitions of treating hundreds of SMA patients annually  highlights 90 kids in AVXS 101 trials over four years  including some who would otherwise have been incapacitated and fed through tubes   With AVXS 101    patients are alive and thriving   Narasimhan said  There were no SMA therapies  however  when Victoria Gusset  an eight year old Swiss girl with a shy smile and love for horses  was diagnosed as a toddler after failing to stand independently  Today  Victoria is in a trial testing how Spinraza may improve muscle control or halt its decline in older children  Every four months  Victoria and her mother  Nicole Gusset  load her electric wheelchair into their van and drive two hours from their home near Bern to a German hospital for a spinal infusion  Victoria looks forward to each trip  though she sometimes suffers from nausea and headaches following treatment   I get to go shopping with mum   she said  After her daughter s diagnosis  Nicole Gusset founded an SMA patient organization and has been lobbying the Swiss government to expand access to Spinraza  Children under 20 have coverage  but most insurers refuse to pay for adults  Gusset said Novartis s  4 million announcement sent shockwaves through Switzerland s SMA community  heightening fears that escalating costs will keep new treatments out of reach for some who might benefit   The best therapies are useless if patients cannot get them   she said   
  1   0 9988 Swiss francs ",2018-11-23,Reuters,https://www.investing.com/news/stock-market-news/us-benefits-manager-baulks-after-novartis-values-gene-therapy-at-45-million-1698225,1698225
119957,341472,VRTX,Positive data from Vertex pressures Proteostasis  down 9 ,news,Proteostasis Therapeutics  PTI  8 7   is down on below average volume in apparent reaction to positive late stage data on Vertex Pharmaceuticals  NASDAQ VRTX   cystic fibrosis  CF  triplet therapy that includes a next generation corrector  PTI is developing its own triplet therapy for CF  Preliminary Phase 1 data should be available this quarter  Previously  Vertex Pharma s triplet therapy for CF successful in two late stage studies  Nov  27  Now read ,2018-11-27,Seeking Alpha,https://www.investing.com/news/stock-market-news/positive-data-from-vertex-pressures-proteostasis-down-9-1702202,1702202
119958,341473,VRTX,TopGainers   Vertex Pharmaceuticals  Delta  L Brands Climb as Markets Rebound,news,"Investing com   Vertex Pharmaceuticals  Delta Air Lines and L Brands jumped Tuesday  helping the broader market rebound from session lows 
Vertex Pharmaceuticals  NASDAQ VRTX  surged 5 5  after the drugmaker said its combo therapy yielded a 10  improvement in lung function in patients suffering from cystic fibrosis  compared to those treated with placebo 
Delta Air Lines  NYSE DAL  rose more than 3  after revealing Monday that it flew a record 2 3 million customers for the Thanksgiving period between Wednesday and Sunday 
Sunday marked the busiest day of the period  as Delta flew about 646 000 people after the holiday  an all time record for the month of November  the company said 
L Brands  NYSE LB  rose more than 4  on expectations that a record setting Cyber Monday would help ease the retailer s woes just a week after it cut its dividend amid falling sales at Victoria s Secret 
Cyber Monday sales this year surged to new highs  with a record  7 9 billion spent online that day  an increase of 19 3  from a year earlier  according to data from Adobe Analytics ",2018-11-27,Investing.com,https://www.investing.com/news/stock-market-news/topgainers--vertex-pharmaceuticals-delta-l-brands-soar-as-markets-rebound-1702218,1702218
119959,341474,VRTX,U S  stocks higher at close of trade  Dow Jones Industrial Average up 0 44 ,news,"Investing com   U S  stocks were higher after the close on Tuesday  as gains in the Telecoms  Healthcare and Consumer Services sectors led shares higher 
At the close in NYSE  the Dow Jones Industrial Average added 0 44   while the S P 500 index gained 0 33   and the NASDAQ Composite index added 0 01  
The best performers of the session on the Dow Jones Industrial Average were  Verizon Communications  Inc  NYSE VZ   which rose 2 50  or 1 48 points to trade at 60 65 at the close  Meanwhile  Walgreens Boots Alliance Inc  NASDAQ WBA  added 2 23  or 1 82 points to end at 83 52 and  Home Depot  Inc  NYSE HD  was up 2 00  or 3 40 points to 173 22 in late trade 
The worst performers of the session were United Technologies Corporation  NYSE UTX   which fell 4 14  or 5 30 points to trade at 122 68 at the close   Nike  Inc  NYSE NKE  declined 0 85  or 0 62 points to end at 72 09 and DowDuPont Inc  NYSE DWDP  was down 0 83  or 0 48 points to 57 18 
The top performers on the S P 500 were Pacific Gas   Electric Co  NYSE PCG  which rose 7 36  to 26 97  Advanced Micro Devices Inc  NASDAQ AMD  which was up 4 83  to settle at 21 05 and Vertex Pharmaceuticals Inc  NASDAQ VRTX  which gained 4 81  to close at 175 45 
The worst performers were Chesapeake Energy Corporation  NYSE CHK  which was down 5 08  to 2 990 in late trade  Aptiv PLC  NYSE APTV  which lost 4 50  to settle at 71 09 and United Technologies Corporation  NYSE UTX  which was down 4 14  to 122 68 at the close 
The top performers on the NASDAQ Composite were Arsanis Inc  NASDAQ ASNS  which rose 255 17  to 4 12  Wins Finance Holdings Inc  NASDAQ WINS  which was up 33 82  to settle at 34 79 and  Aethlon Medical Inc   NASDAQ AEMD  which gained 25 64  to close at 1 470 
The worst performers were Ferroglobe PLC  NASDAQ GSM  which was down 62 26  to 1 80 in late trade  Smaaash Entertainment Inc  NASDAQ SMSH  which lost 40 11  to settle at 3 30 and Intellipharmaceutics International Inc  NASDAQ IPCI  which was down 39 70  to 0 340 at the close 
Falling stocks outnumbered advancing ones on the New York Stock Exchange by 1879 to 1197 and 73 ended unchanged  on the Nasdaq Stock Exchange  1758 fell and 876 advanced  while 93 ended unchanged 
Shares in Verizon Communications Inc  NYSE VZ  rose to 5 year highs  gaining 2 50  or 1 48 to 60 65  Shares in Walgreens Boots Alliance Inc  NASDAQ WBA  rose to 52 week highs  rising 2 23  or 1 82 to 83 52  Shares in Ferroglobe PLC  NASDAQ GSM  fell to all time lows  losing 62 26  or 2 97 to 1 80  Shares in Smaaash Entertainment Inc  NASDAQ SMSH  fell to all time lows  down 40 11  or 2 21 to 3 30  Shares in Intellipharmaceutics International Inc  NASDAQ IPCI  fell to all time lows  down 39 70  or 0 224 to 0 340  
The CBOE Volatility Index  which measures the implied volatility of S P 500 options  was up 0 63  to 19 02 
Gold Futures for February delivery was down 0 64  or 7 90 to  1220 80 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in January rose 0 50  or 0 26 to hit  51 89 a barrel  while the February Brent oil contract rose 0 35  or 0 21 to trade at  60 77 a barrel 
EUR USD was down 0 28  to 1 1296  while USD JPY rose 0 17  to 113 78 
The US Dollar Index Futures was up 0 29  at 97 265 ",2018-11-27,Investing.com,https://www.investing.com/news/stock-market-news/us-stocks-higher-at-close-of-trade-dow-jones-industrial-average-up-044-1702345,1702345
119960,341475,VRTX,Innovus Pharma initiates a clinical study to evaluate the effect of Musclin on muscle health in U S ,news,Innovus Pharmaceuticals  OTCQB INNV  enrolls first       participant in the clinical study to evaluate the effect and tolerance       of Musclin dietary supplement  The study will enroll up to 20 healthy       subjects  The primary objective is to evaluate the tolerance       of individuals to Musclin and to observe       the effect in the measurements of creatinine kinase and       myostatin levels as well as changes in energy and       stamina levels Data from this trial is expected in H1 2019  Now read ,2018-12-10,Seeking Alpha,https://www.investing.com/news/stock-market-news/innovus-pharma-initiates-a-clinical-study-to-evaluate-the-effect-of-musclin-on-muscle-health-in-us-1716516,1716516
119994,341509,VRTX, Company News For Nov 20  2019,opinion,Shares of Advanced Micro Devices  Inc    NASDAQ AMD   rose 3 5  after the company launched a new graphics card for 3 D designers  architects and engineersShares of SAExploration Holdings  Inc    NASDAQ SAEX   soared 80 9  after the company reported a combined  130 million of new projects in Alaska  Canada and the Middle EastShares of Document Security Systems  Inc    NYSE DSS   jumped 13 1  after the company along with Luminescence Sun Chemical Security  announced the launch of new Augmented Reality Brand Authentication for Wyeth NutritionShares of CRISPR Therapeutics AG   NASDAQ CRSP   gained nearly 17  after the company reported that the gene editing therapyit s co developing with Vertex Pharmaceuticals  NASDAQ VRTX  have produced positive results in human trials,2019-11-19,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-nov-20-2019-200486786,200486786
119995,341510,VRTX,Vertex Pharmaceuticals Shares March Higher  Can It Continue ,opinion,As of late  it has definitely been a great time to be an investor Vertex Pharmaceuticals Incorporated   NASDAQ VRTX    The stock has moved higher by 4 1  in the past month  while it is also above its 20 Day SMA too  This combination of strong price performance and favorable technical  could suggest that the stock may be on the right path We certainly think that this might be the case  particularly if you consider VRTX s recent earnings estimate revision activity  From this look  the company s future is quite favorable  as VRTX has earned itself a Zacks Rank  1  Strong Buy   meaning that its recent run may continue for a bit longer  and that this isn t the top for the in focus company  You can see  Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 5  per year These 7 were selected because of their superior potential for immediate breakout ,2019-11-20,Zacks Investment Research,https://www.investing.com/analysis/vertex-pharmaceuticals-shares-march-higher-can-it-continue-200486928,200486928
119996,341511,VRTX,Amgen  AMGN  Completes Otezla Buyout  Raises 2019 Guidance,opinion,Amgen Inc    NASDAQ AMGN   announced that it has completed the previously announced acquisition of Celgene s blockbuster psoriasis drug Otezla  which the latter had to divest in order to complete its merger with Bristol Myers   NYSE BMY   We remind investors that Amgen agreed to acquire the global commercial rights to Otezla in August Amgen had to pay Celgene  NASDAQ CELG   13 4 billion in cash or approximately  11 2 billion net of anticipated future cash tax benefits for Otezla and certain related assets and liabilities  Following this buyout  the company raised its overall guidance for 2019 Amgen now expects total revenues in the range of  23 1  23 3 billion  previously expected within  22 8  23 0 billion  Adjusted EPS is expected in the band of  14 5   14 7 compared with the previous range of  14 20 14 45 Otezla is approved to treat psoriasis  psoriatic arthritis and oral ulcers associated with Beh et s disease  The drug recorded sales of  1 4 billion during the first nine months of 2019 and has been one of the key revenue drivers for Celgene  Otezla performed well in the United States on the back of higher demand and internationally  owing to steady expansion in the key markets Amgen s guidance lift is a pure indication that the Otezla purchase is a smart strategic move by the company as it strengthens its existing inflammation franchise portfolio  which includes a blockbuster drug Enbrel  Notably  Pfizer   NYSE PFE   markets Enbrel outside the United States and Canada However  pricing pressure and stiff competition are hurting sales of Enbrel  As a result  Otzela will strengthen Amgen s portfolio of inflammatory drugs  Amgen expects Otezla to record at least low double digit sales growth  on average  over the next five years  Notably  Otezla enjoys U S  patent exclusivity through at least 2028 Shares of Amgen were up 1  following this news on Thursday  In fact  the stock has rallied 17  so far this year compared with the  rise of 4 7   Please note  Bristol Myers closed the long impending acquisition of Celgene for a whopping  74 billion on Nov 20 after the U S  Federal Trade Commission  FTC   to close the merger late last week Zacks Rank   Key PickAmgen currently carries a Zacks Rank  3  Hold   A better ranked stock in the biotech sector is Vertex Pharmaceuticals Incorporated   NASDAQ VRTX    which sports a Zacks Rank  1  Strong Buy   You can see  Vertex s earnings estimates have been revised 5  upward for 2019 and 10  for 2020 over the past 60 days  The stock has surged 30 1  so far this year The Hottest Tech Mega Trend of AllLast year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-11-21,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-completes-otezla-buyout-raises-2019-guidance-200487738,200487738
119997,341512,VRTX,Genomics ETFs Surge On CRISPR s Gene Editing Progress,opinion,CRISPR Therapeutics   NASDAQ CRSP   and its partner Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   recently from the ongoing phase I II studies  Notably  the studies were evaluating the CRISPR Cas9 gene editing therapy CTX001 for two severe blood disorders    SCD  and adult transfusion dependent b thalassemia  TDT  CRISPR Therapeutics and Vertex were each up 17  and 2 5   respectively  on Nov 19 in response to this news  However   due to an underwritten public offering on the same day during after hours trading Notably   Cas9 is a very efficient and fast technique to edit genomes  It is in early clinical trials for certain disorders like sickle cell disease  cystic fibrosis and   This comes after six years of CRISPR technique s first application on   The interim data is believed to have  for patients following a one time intervention  read    Insight Into the DataThe data was from the first two patients   one from each disease  The patient with SCD was free of vaso occlusive crises or pain crises    at four months following infusion versus 7 annualized events prior to therapy  The patient with TDT was transfusion independent at nine months after infusion versus  prior to therapy Meanwhile  both patients achieved  and fetal hemoglobin on CTX001 infusion  While the TDT patient had total hemoglobin levels of 11 9 g dL and 10 1 g dL fetal hemoglobin  the same came in at 11 3 g dL and 46 6   respectively  for the patient   However  both the patients developed some severe problems    On the brighter side  the complications were found to be unrelated to the  Genomic ETFs in Focusis a technique to alter or modify the DNA of a cell or organism  It uses an enzyme to cut the DNA at a particular sequence and then it is repaired by the cell  making a change to the   As a result  the characteristics  are changed  According to analysts  growing demand for personalized medicine  solid investments and  will soon make genomics the next big thing in the investing space  In fact    the  18 9 billion global genomics market is expected to reach  35 7 billion by 2024  at a CAGR of 13 5   Here we highlight a host of ETFs that investors can keep a tab on ARK Genomic Revolution Multi Sector ETF This is an actively managed ETF focusing on companies likely to benefit from the extension and enhancement of the quality of human and other life by incorporating technological and scientific developments plus improvements and advancements in genomics into their business  The fund holds 38 stocks in its basket  with CRISPR Therapeutics occupying the second position with 10  weight   Th fund charges 0 75  in expense ratio  It has accumulated  442 1 million in its asset base  The fund has gained 3 7  since the news release  read    Invesco Dynamic Biotechnology   Genome ETF This fund follows the Dynamic Biotech   Genome Intellidex Index  The index comprises companies that are majorly engaged in the research  development  manufacturing and marketing plus distribution of various biotechnological products  services and processes and companies that gain significantly from scientific and technological advances in biotechnology and genetic engineering and research  The fund holds 28 stocks in its basket  with Vertex holding the second position with 6 2  exposure  It has managed  226 9 million in its asset base  Expense ratio is at 0 57   The fund has gained 2 2  since the news release Global X Genomics   Biotechnology ETF This is a new entrant in the space  having accumulated  17 4 million since its inception on Apr 5  2019  It seeks to invest in companies that stand to benefit from advancements in the field of genomic science  such as companies involved in gene editing  genomic sequencing  genetic medicine therapy  computational genomics and biotechnology  The product follows the Solactive Genomics Index  charging 68 bps in annual fees  It holds 39 stocks in its basket  with Vertex and CRISPR Therapeutics together having 7 7  weight  The fund has gained 4 3  since the news release  read    iShares Genomics Immunology and Healthcare ETF This is another new entrant  which was launched in June 2019  Tracking the NYSE FactSet Global Genomics and Immuno Biopharma Index  the fund provides exposure to developed and emerging market companies that could gain from long term growth and innovation in genomics  immunology and bioengineering  Holding a basket of 45 securities with 2 2  exposure to CRISPR Therapeutics  The fund has an AUM of  25 million  It charges a fee of 47 basis points  The fund has gained 2 8  since the news release  as of Nov 22  Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-11-25,Zacks Investment Research,https://www.investing.com/analysis/genomics-etfs-surge-on-crisprs-gene-editing-progress-200487913,200487913
120029,341544,VRTX,Geron  GERN  Q3 Earnings Beat Estimates  Stock Gains 4 1 ,opinion,"Geron Corporation   NASDAQ GERN   incurred a loss of 8 cents per share in third quarter 2019  narrower than the Zacks Consensus Estimate of a loss of 14 cents  In the year ago quarter  the company had incurred a loss of 3 cents per share Quarterly revenues came in at  0 13 million  slightly beating the Zacks Consensus Estimate of  0 1 million  Notably  the top line comprised royalty and license fee revenues received under various non imetelstat license agreements  In the year ago quarter  revenues totaled  0 17 million  The top line declined as the number of active license agreements fell due to expiry of patents of Geron s underlying technology Shares of Geron were up almost 4 1  in afterhours trading on Nov 6  following the earnings release  So far this year  the stock has gained 45  compared with the  s 0 9  increase R D expenses were  11 1 million compared with  2 7 million in the year ago quarter  Transition costs  including resuming sponsorship of imetelstat clinical studies from J J   NYSE JNJ    costs related to start up of phase III portion of the IMerge study  evaluating imetelstat in myelodysplastic syndromes  and expansion of development team  resulted in significantly higher R D expenses General and administrative expenses rose 16 3  to  5 million  reflecting legal costs related to patent litigations and recruitment expenses for additional headcounts Geron ended the third quarter with  159 3 million in cash and investments compared with  162 3 million at the end of the second quarter 2019 Guidance MaintainedGeron reiterated its outlook for 2019  The company expects full year operating expenses to lie in the range of  80  85 million  This includes one time cost of  20  25 million related to activities for transition of imetelstat from Janssen to Geron  and purchase of material for the phase III portion of IMerge study Pipeline UpdateFollowing the termination of the agreement with Janssen  a subsidiary of J J  in September 2018  Geron regained global development rights to imetelstat and decided to continue developing imetelstat independently  The transition activities  including ex U S  clinical and regulatory responsibilities  were completed in the third quarter Geron assumed sponsorship of the investigational new drug application for imetelstat in May this year  In October  the company initiated dosing in the phase III study  IMerge  in patients who have not received prior treatment with hypomethylating agents and lenalidomide  The company is anticipating top line data from the study in mid 2022 Another phase II study   IMbark   is evaluating imetelstat in myelofibrosis patients whose disease relapsed afteror is refractory to a treatment with JAK inhibitor  In December  Geron presented updated median overall survival  OS  data from the higher dosage arm  9 4 mg kg  of the study  The candidate achieved median OS of 29 9 months  which suggests a meaningful survival outcome  The company is planning to conduct an end of phase II meeting with the FDA by the end of first quarter 2020  Following the meeting  it will decide upon potential late stage development of the candidate  In September  the FDA granted Fast Track designation to the candidate for treating myelofibrosis Geron Corporation Price  Consensus and EPS Surprise
    Zacks Rank   Stocks to ConsiderGeron currently carries a Zacks Rank  3  Hold  A couple of better ranked stocks from the biotech sector are Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   and Acorda Therapeutics  Inc    NASDAQ ACOR    Both stocks sport a Zacks Rank  1  Strong Buy   You can see  Vertex s earnings estimates have moved up from  4 58 to  4 79 for 2019 and from  6 03 to  6 62 for 2020 in the past 30 days  The company delivered a positive earnings surprise in all the trailing four quarters  with the average beat being 17 59   Share price of the company has increased 19  so far this year Loss estimates for Acorda have narrowed from  2 98 to  2 18 for 2019  and from  3 74 to  1 95 for 2020 in the past 30 days  The company pulled off a positive earnings surprise in all the last four quarters  with the average beat being 68 8  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-11-06,Zacks Investment Research,https://www.investing.com/analysis/geron-gern-q3-earnings-beat-estimates-stock-gains-41-200483438,200483438
120030,341545,VRTX,Puma  PBYI  Q3 Earnings Beat  Nerlynx Sales Weak  Stock Down,opinion,"Puma Biotechnology  Inc    NASDAQ PBYI   incurred a loss of 44 cents per share in the third quarter of 2019  which was narrower than the Zacks Consensus Estimate of a loss of 76 cents The loss per share includes an impact of stock based compensation expense  Excluding such impact  adjusted net loss per share was 12 cents per share versus earnings of 16 cents in the year ago quarter Total revenues consisted of net product revenues from the sales of Nerlynx  Puma Biotech s only marketed drug  and license and royalty revenues  In the third quarter of 2019  total revenues were  56 4 million  comprising  53 5 million of product revenues from Nerlynx   0 1 million of royalty revenues from licensing partners and license revenues of  2 8 million  However  sales missed the Zacks Consensus Estimate of  61 0 million and were also lower than the year ago figure of  62 6 million Nerlynx  neratinib  is indicated for extended adjuvant treatment of HER2 positive early stage breast cancer in patients  previously treated with Roche s   OTC RHHBY   Herceptin based adjuvant therapy Sales of Nerlynx rose a mere 1 7  year over year and declined 0 6  on a sequential basis  A higher number of patients discontinuing treatment with Nerlynx resulted in a sequential decline in Nerlynx s sales in the third quarter  Nerlynx s bottle volumes declined 2  sequentially in the quarter  However  new prescriptions grew 4  sequentially in the quarter Total operating costs in the quarter were  70 8 million  down 4 2  year over year  Research and development expenses  including for stock based compensation expense  were  30 0 million in the quarter  down 17 6  from the year ago period  Selling  general and administrative expenses  including for stock based compensation expense  rose 10 2  year over year to  31 4 million GuidanceFor 2019  Puma expects Nerlynx sales to be in the range of  205 million to  210 million  lower than the prior expectation of  220 million to  240 million  Meanwhile  licensing and royalty revenues from its licensing partners are still expected in the range of  56 million to  60 million in 2019 The sequential decline in Nerlynx s sales and the cut in full year sales guidance resulted in the stock declining almost 18  in after hours trading on Wednesday  The stock has declined 65  this year so far against the  s increase of 0 9    Pipeline   Other UpdateIn the quarter  Puma s licensing partners announced regulatory approvals for Nerlynx in Canada and Argentina  Earlier this week  its licensing partner in Greater China  CANbridge  received marketing approval in Hong Kong  Puma will be entitled to royalties from the sales of Nerlynx in those territories once it is commercialized Several studies on Nerlynx targeting different types of breast cancer patient populations and in earlier line settings are currently underway  In July 2019  Puma Biotech submitted a supplemental new drug application  sNDA  to the FDA for the approval of Nerlynx to treat third line HER2 positive metastatic breast cancer  The sNDA was based on data from the phase III NALA study  which assessed the combination of Nerlynx   Xeloda compared to Xeloda plus Novartis    NYSE NVS   Tykerb  lapatinib  for treating patients with HER2 positive metastatic breast cancer  who have failed two or more prior lines of treatments  In September 2019  the FDA accepted the sNDA for review and set an action date of April 2020 If the company gets an approval to include the NALA study outcome on Nerlynx s label  it will be eligible to treat a broader breast cancer population  which can drive sales higher In September  the FDA granted Orphan Drug Designation to neratinib for the treatment of breast cancer patients with brain metastasis Apart from the HER2 positive breast cancer indication  Nerlynx is being evaluated for several other cancers as well  including NSCLC and other tumor types that over express or have a mutation in HER2 A key analysis on Nerlynx is the phase II SUMMIT basket study in HER2 mutated cancers  In the third quarter  Puma met with the FDA in the third quarter to discuss the development and regulatory strategy for this study  Puma announced on the conference call that based on this FDA meeting  it is modifying the SUMMIT study to expand the HER2 mutation breast cancer cohorts  It said it will hold a pre NDA meeting with the FDA for both the HER2 mutated breast cancer and HER2 mutated cervical cancer indications in approximately 12 to 18 months  This will likely delay data from the SUMMIT study  which might have also resulted in the stock price decline on Wednesday Zacks Rank   Stocks to ConsiderPuma Biotech currently carries a Zacks Rank  3  Hold   A better ranked stock in the biotech sector is Vertex Pharmaceuticals   NASDAQ VRTX    sporting a Zacks Rank  1  Strong Buy   You can see  Puma Biotechnology  Inc  Price  Consensus and EPS Surprise
    
Vertex s earnings per share estimates have moved up by 5  for 2019 and 9 8  for 2020 over the past 30 days  Share price of the company has increased 18 3  this year so far Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-11-06,Zacks Investment Research,https://www.investing.com/analysis/puma-pbyi-q3-earnings-beat-nerlynx-sales-weak-stock-down-200483531,200483531
120031,341546,VRTX,Esperion  ESPR  Reports Wider Than Expected Loss In Q3,opinion,"Esperion Therapeutics  Inc    NASDAQ ESPR   incurred a loss of  2 52 per share in the third quarter of 2019  wider than the Zacks Consensus Estimate of  2 01  The company had incurred loss of  1 86 per share in the year ago period The company generated revenues of  1 01 million  almost in line with the Zacks Consensus Estimate  Revenues were mainly attributable to initial recognition of the upfront payment related to the commercial agreement with Daiichi Sankyo Europe which Esperion signed in January  The agreement grants exclusive rights to Daiichi Sankyo to commercialize Esperion s bempedoic acid and the bempedoic acid  Merck s   NYSE MRK   Zetia combination pill in Europe and Switzerland  following their potential approval Esperion is seeking approval for bempedoic acid pill and bempedoic acid Zetia combination pill as a treatment for elevated LDL C  bad cholesterol  in hypercholesterolemia patients Esperion s shares have declined 18 9  so far this year against the  s 4 2  increase Quarter in DetailsResearch and development  R D  expenses increased 16 2  from the year ago period to  48 3 million  The rise was primarily due to higher cost needed to support cardiovascular outcomes study on bempedoic acid and manufacture its candidates for commercial supply General and administrative  G A  expenses more than doubled year over year to  18 5 million primarily due to costs related to support pre commercialization activities for bempedoic acid monotherapy  and the bempedoic acid Zetia combination regimen  As of Sep 30  2019  Esperion had cash  cash equivalents and investment securities of  244 8 million compared with  302 2 million as of Jun 30  2019 2019 GuidanceEsperion maintained its 2019 guidance for collaboration revenues and operating expenses  The company expects income from collaboration and license agreement to be  150 million  The company expects cash funding of  125 million under its revenue interest purchase agreement with Oberland Capital The company raised its guidance for R D expense to the range of  135  145 million compared with the previous guidance range of  115  120 million  G A expense guidance range was maintained in the range of  60  65 million The company lowered its guidance for net increase in cash to the range of approximately  70 to  80 million from  90 to  100 million  The reduction reflects higher cash burn due to higher patient enrollment than targeted in the CLEAR cardiovascular outcomes study on bempedoic acid and accelerated certain commercial product manufacturing activities in 2019  previously planned for 2020 Pipeline UpdateIn August  Esperion  top line data from the phase II study evaluating a combination of bempedoic acid and Zetia  Data showed that the combination regimen met the study s primary endpoint of LDL C  bad cholesterol  reduction  The combination regimen lowered LDL C levels by 40  compared to placebo over the 12 week treatment period In September  the company completed enrollment in the CLEAR cardiovascular outcomes study  The study is evaluating bempedoic acid for occurrence of major cardiovascular events in statin averse patients with or at high risk of cardiovascular disease Earlier this year  Esperion had submitted regulatory applications seeking approval for bempedoic acid monotherapy and bempedoic acid Zetia combination pill for treating hypercholesterolemia in the United States and Europe  A decision from the FDA is expected in February 2020 and a decision in Europe is expected in the second quarter of 2020 Esperion Therapeutics  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Key PicksEsperion currently carries a Zacks Rank  2  Buy  Some other top ranked from the biotech sector are Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   and Acorda Therapeutics  Inc    NASDAQ ACOR    Both stocks sport a Zacks Rank  1  Strong Buy   You can see  Vertex s earnings per share estimates have moved up from  4 58 to  4 79 for 2019 and from  6 03 to  6 62 for 2020 in the past 30 days  The company delivered a positive earnings surprise in all the trailing four quarters  with the average beat being 17 59   Share price of the company has increased 19  so far this year Loss estimates for Acorda have narrowed from  2 98 to  2 18 for 2019 and from  3 74 to  1 95 for 2020 in the past 30 days  The company pulled off a positive earnings surprise in all the last four quarters  with the average beat being 68 8  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-11-06,Zacks Investment Research,https://www.investing.com/analysis/esperion-espr-reports-widerthanexpected-loss-in-q3-200483508,200483508
120032,341547,VRTX,Which Biotech Mutual Fund To Consider  FBIOX Or FBDIX ,opinion,The biotechnology sector has provided excellent returns so far this year  Mergers and acquisitions  initial public offerings  collaborative operations  and new job vacancies are among some of the factors propelling the space In fact  biotechnology is a good investment to hedge one s portfolio in times of economic uncertainty  This is because products and services offered by the sector are always in demand  irrespective of market conditions Biotech Indexes Have Fared Well So Far in 2019 Major biotech indexes have had a decent run so far this year  Talking about returns  the SPDR S P Biotech ETF  NYSE XBI   iShares Nasdaq Biotechnology ETF  IBB   ProShares Ultra Nasdaq Biotechnology  BIB  and NASDAQ Biotechnology Index  NBI  have surged 12 5   11 1   16 5  and 11 1   respectively  on a year to date basis Therefore  one could consider purchasing mutual funds that invest in the space  However  choosing the right mutual funds for your portfolio can be cumbersome  Let us take a look at two biotechnology funds and discuss which of these is best suited for your portfolio Choosing the Right FundFidelity Select Biotechnology Portfolio  fund seeks capital appreciation  The fund primarily invests its assets in securities of companies that are engaged in the research  development  manufacture and distribution of biotechnological products and services  In addition  these companies gain considerably from scientific and technological advances in biotechnology  FBIOX mostly invests in common stocks This Sector Health product has a history of positive total returns for over 10 years  Specifically  the fund s returns are 11  over the 3 year and 3 7  of the 5 year period  To see how this fund performed compared in its category  and other  1 and 2 Ranked Mutual Funds     The Fidelity Select Biotechnology Portfolio fund  as of the last filing on Sep 30  2019  allocates its assets in the top two major groups   U S  Equity and Non U S  Equity  Further  as of Sep 30  2019  AbbVie Inc  NYSE ABBV   Amgen Inc  NASDAQ AMGN  and Vertex Pharmaceuticals Inc  NASDAQ VRTX  were the top holdings for FBIOX This product with a Zacks Mutual Fund Rank  1  Strong Buy  was incepted in December 1985 and is managed by   FBIOXcarries an expense ratio of 0 72  and requires no minimal initial investment Franklin Biotechnology Discovery Fund Class A  aims for capital growth by investing the majority of its assets in securities of biotechnology companies and discovery research firms  These are companies involved in the areas of genomics  genetic engineering and gene therapy  The players may also operate in health care  pharmaceuticals and agriculture This Sector Health product has a history of positive total returns for over 10 years  Specifically  the fund s returns are 7 6  over the 3 year and 1 3  of the 5 year period  To see how this fund performed compared in its category  and other  1 and 2 Ranked Mutual Funds     The Franklin Biotechnology Discovery Fund Class A  as of the last filing on Sep 30  2019  allocates its assets in the top two major groups   U S  Equity and Non U S  Equity  Further  as of Sep 30  2019  Amgen Inc  Vertex Pharmaceuticals Inc and Gilead Sciences Inc  NASDAQ GILD  were the top holdings for FBDIX This product with a Zacks Mutual Fund Rank  3  Hold  was incepted in September 1997 and is managed by   FBDIXcarries an expense ratio of 1 02  and requires a minimal initial investment of  1000 ConclusionUpon taking a closer look at FBIOX and FBDIX  we find that the former clearly outpaces  First  FBIOX has provided investors with higher returns over the three  and five year periods  Second  FBIOX has a lower expense ratio than FBDIX  which means that its operational expenses are much less than the latter  Finally  FBIOX has no minimum initial investment  which offers flexibility to its investors  Therefore  one should definitely opt for FBIOX as an addition to their mutual fund portfolio Want key mutual fund info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ,2019-11-08,Zacks Investment Research,https://www.investing.com/analysis/which-biotech-mutual-fund-to-consider-fbiox-or-fbdix-200483800,200483800
120033,341548,VRTX,Celgene   Acceleron Get FDA Nod For Rare Blood Disorder Drug,opinion,Celgene Corporation   NASDAQ CELG   and partner Acceleron Pharma Inc    NASDAQ XLRN   announced that the FDA has approved pipeline candidate Reblozyl  luspatercept aamt  for the treatment of anemia in adult patients with beta thalassemia  who require regular red blood cell  RBC  transfusions Per the company  Reblozyl is the first and only FDA approved erythroid maturation agent  representing a new class of therapy for these patients  The approval comes ahead of the target action date of Dec 4 The approval of Reblozyl for beta thalassemia was based on encouraging results from the pivotal  phase III  randomized  double blind  placebo controlled  multicenter BELIEVE study  The study evaluated the safety and efficacy of the drug for the treatment of anemia in adult patients with beta thalassemia  who require regular RBC transfusions  The study achieved a clinically meaningful and statistically significant improvement in the primary endpoint  The approval comes as a significant boost for Celgene  given the dearth of options for patients living with anemia due to beta thalassemia  who are dependent on long term RBC transfusions Meanwhile  the FDA is also evaluating luspatercept aamt for the treatment of anemia in adults with very low  to intermediate risk myelodysplastic syndromes  MDS   who have ring sideroblasts and require RBC transfusions  The agency has set a target action date of April 4  2020  for the same  Celgene s Marketing Authorization Application for the treatment of anemia in adults with beta thalassemia is currently under review in Europe Additionally  a phase II study  BEYOND  in adult patients with non transfusion dependent beta thalassemia  a phase III study  COMMANDS  in ESA na ve  lower risk MDS patients and a phase II study in myelofibrosis patients are ongoing Shares of Celgene have soared 70 9  so far this year compared with the  s growth of 1 6   Shares of Acceleron were up 6 6  on the news of the approval  Celgene has been in news since the beginning of 2019 for its impending merger with Bristol Myers Squibb Company   NYSE BMY    The transaction is expected to close by the end of the year Zacks Rank   Another Key PickCelgene currently carries a Zacks Rank  2  Buy  Another top ranked stock in the biotech space is Vertex Pharmaceuticals Inc    NASDAQ VRTX    which currently carries a Zacks Rank  1  Strong Buy   You can see  Vertex s earnings estimates have increased to  4 81 from  4 59 in the past 30 days 5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-11-10,Zacks Investment Research,https://www.investing.com/analysis/celgene--acceleron-get-fda-nod-for-rare-blood-disorder-drug-200484325,200484325
120034,341549,VRTX,5 Biotech Stocks Set To Beat Q3 Earnings Estimates,opinion,The third quarter earnings performance of drug biotech companies so far has been mostly better than expected Among the specialty pharma companies  J J  NYSE JNJ   Bristol Myers  Merck  Pfizer  NYSE PFE   AstraZeneca  AbbVie  NYSE ABBV  all beat estimates for both earnings and sales  Lilly beat the Zacks Consensus Estimate for third quarter earnings but missed the same for sales  Among the big biotech stocks  Amgen  NASDAQ AMGN   Alexion  NASDAQ ALXN   Biogen  NASDAQ BIIB  and Regeneron beat estimates on both counts  Vertex  NASDAQ VRTX  beat estimates for earnings but missed the same for sales  Gilead s earnings missed expectations while sales managed to marginally surpass the same The  sector comprises pharma biotech and medical device companies  The  report shows that the companies from this sector  which reported until Nov 6  and constituting nearly 91 6  of the sector s market capitalization  delivered 7  earnings growth and 7 8  sales growth year over year  The beat ratio was 82 6  for both earnings and revenues Overall  new drugs and label expansions of blockbuster drugs drove the top line of most of the big shots backed by higher demand  combating generic plus biosimilar competition for older medicines  However  greater pricing pressure in the United States  increased competition  and negative currency impacts were some other top line headwinds that the companies faced  Importantly  the better than expected results coupled with an optimistic outlook for the fourth quarter led most of the companies to raise their financial guidance for the year  buoying investor optimism on the stocks  A couple of companies like Biogen came up with positive pipeline updates Here we have highlighted five small biotech companies  which are expected to deliver positive earnings surprise in their upcoming quarterly earnings announcements By means of the   we have zeroed in on three drug biotech stocks with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  and a positive   These are valuable tools for investors looking for stocks with high potential to outpace estimates in their upcoming announcements  Moreover  stocks with the said combination have 70  chance to deliver a positive surprise  You can uncover the best stocks to buy or sell before they re reported with our  Our PicksSage Therapeutics  Inc    NASDAQ SAGE  This Cambridge  MA based maker of medicines to treat central nervous system disorders has an Earnings ESP of  2 26  and a Zacks Rank of 3  The Zacks Consensus Estimate for the third quarter is pegged at a loss of  3 41 per share  The company is scheduled to release results on Nov 12 Sage Therapeutics has missed estimates in three of the last four quarters while beating the same in one quarter  with the average being  a negative 7 80  Eyenovia  Inc    NASDAQ EYEN  The New York based ophthalmic biotech has an Earnings ESP of  10 51  and a Zacks Rank  2  The company is scheduled to release results on Nov 13  The Zacks Consensus Estimate for the third quarter is pegged at a loss of 40 cents per share  You can see  Eyenovia s earnings performance has been mixed with the company delivering a positive surprise in two of the trailing four quarters while missing in the other two with the average  negative surprise being 8 4  Ascendis Pharma A S   NASDAQ ASND  This Denmark based small biotech has an Earnings ESP of  8 03  and a Zacks Rank  2  The company is scheduled to release results on Nov 18  The Zacks Consensus Estimate for the third quarter is pegged at a loss of  1 37 per share  In the last reported quarter Ascendis delivered a negative earnings surprise of 6 06  AC Immune SA   NASDAQ ACIU  The Swiss biotech has an Earnings ESP of  420  and is  3 Ranked  The company is expected to report results later this month  The Zacks Consensus Estimate for the third quarter is pegged at a loss of 5 cents per share AC Immune s earnings performance has been mixed  Its earnings beat expectations in two of the last four quarters  while missing in the other two with the average negative surprise being 34 68  NGM Biopharmaceuticals  Inc    NASDAQ NGM  This San Francisco  CA based biotech has an Earnings ESP of  3 85  and a Zacks Rank  2  The company is expected to report results later this month  The Zacks Consensus Estimate for the third quarter is pegged at a loss of 26 cents per share In the last reported quarter  NGM Biopharmaceuticals delivered a positive earnings surprise of 58 06  5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-11-11,Zacks Investment Research,https://www.investing.com/analysis/5-biotech-stocks-set-to-beat-q3-earnings-estimates-200484202,200484202
120035,341550,VRTX,Earnings Estimates Rising For Vertex  VRTX   Will It Gain ,opinion,"Vertex Pharmaceuticals  NASDAQ VRTX  appears an attractive pick given a noticeable improvement in the company s earnings outlook  The stock has been a strong performer lately  and the momentum might continue with analysts still raising their earnings estimates for the company 
Analysts  growing optimism on the earnings prospects of this drugmaker is driving estimates higher  which should get reflected in its stock price  After all  empirical research shows a strong correlation between trends in earnings estimate revisions and near term stock price movements  Our stock rating tool    the Zacks Rank    is principally built on this insight 
The five grade Zacks Rank system  which ranges from a Zacks Rank  1  Strong Buy  to a Zacks Rank  5  Strong Sell   has an impressive externally audited track record of outperformance  with Zacks  1 Ranked stocks generating an average annual return of  25  since 2008 
For Vertex  there has been strong agreement among the covering analysts in raising earnings estimates  which has helped push consensus estimates considerably higher for the next quarter and full year 
The chart below shows the evolution of forward 12 month Zacks Consensus EPS estimate 
12 Month EPS

Current Quarter Estimate Revisions
The company is expected to earn  1 18 per share for the current quarter  which represents a year over year change of  9 23  
Over the last 30 days  seven estimates have moved higher for Vertex while two have gone lower  As a result  the Zacks Consensus Estimate has increased 26 3  
Current Year Estimate Revisions
For the full year  the earnings estimate of  4 81 per share represents a change of  17 89  from the year ago number 
The revisions trend for the current year also appears quite promising for Vertex  with 10 estimates moving higher over the past month compared to two negative revisions  The consensus estimate has also received a boost over this time frame  increasing 8 78  
Favorable Zacks Rank
Thanks to promising estimate revisions  Vertex currently carries a Zacks Rank  1  Strong Buy   The Zacks Rank is a tried and tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
Our research shows that stocks with Zacks Rank  1  Strong Buy  and 2  Buy  significantly outperform the S P 500 
Bottom Line
Vertex shares have added 15 4  over the past four weeks  suggesting that investors are betting on its impressive estimate revisions  So  you may consider adding it to your portfolio right away to benefit from its earnings growth prospects ",2019-11-14,Zacks Investment Research,https://www.investing.com/analysis/earnings-estimates-rising-for-vertex-vrtx-will-it-gain-200485711,200485711
120036,341551,VRTX,CRISPR Therapeutics down 20  after hours on IND hold for sickle cell candidate CTX001,news,CRISPR Therapeutics  NASDAQ CRSP  slumps 20  after hours on robust volume in response to its disclosure that the FDA has placed a clinical hold on its IND for sickle cell disease  SCD  gene therapy candidate CTX001  The suspension will be in effect pending the resolution of certain questions related to the application Once approved  a U S  based Phase 1 2 study in adult SCD patients will commence  A Phase 1 2 study in adults with transfusion dependent beta thalassemia should start in H2 in Europe The company is co developing the therapy with collaboration partner Vertex Pharmaceuticals  NASDAQ VRTX  SCD related tickers   NASDAQ GBT  NASDAQ BLUE  NYSE SNY  NASDAQ SGMO  NASDAQ IRWD Previously  CRISPR Therapeutics and Vertex team up to advance and commercialize lead gene editing candidate for blood disorders  Dec  12  2017 Now read ,2018-05-30,Seeking Alpha,https://www.investing.com/news/stock-market-news/crispr-therapeutics-down-20-after-hours-on-ind-hold-for-sickle-cell-candidate-ctx001-1468988,1468988
120061,341576,VRTX,The Zacks Analyst Blog Highlights  Vertex Pharmaceuticals  PulteGroup  Skyworks Solutions  Lennar And Kansas City Southern,opinion,For Immediate ReleaseChicago  IL   October 28  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Vertex Pharmaceuticals Inc    NASDAQ VRTX    PulteGroup Inc    NYSE PHM    Skyworks Solutions Inc    NASDAQ SWKS    Lennar Corp    NYSE LEN   and Kansas City Southern   NYSE KSU   Here are highlights from Friday s Analyst Blog  5 Top Volatility Defying S P 500 Stocks of the Past MonthAfter completing three impressive quarters of 2019  Wall Street started the final quarter with mixed performance  Despite continuation of volatile trading  both S P 500 and the Nasdaq Composite Indexes are in positive territory month to date while the Dow is marginally in the red  Meanwhile  the benchmark S P 500 Index is within a striking distance of another all time high after July S P 500 Index NorthboundOn Oct  24  the S P 500 Index     generally utilized by market participants as the barometer of the broad market movement     closed at 3 010 29  The index is just 0 5  below the all time closing high of 3 025 86 that it reached on Jul 26  2019 as well as to touch its all time intraday high of 3 027 98 recorded on the same day Year to date  the broad market index has rallied 20 1   an impressive performance after a disappointing 2018  when it lost 6 6   Moreover  the index is up 1 1  so far in October while it returned 1 5  in the past one month Three Possible Drivers of S P 500 Index  First  per a Bloomberg report  on Oct 18  Chinese vice premier said   China and the U S  have made substantial progress in many aspects  and laid an important foundation for a phase one trade agreement   On Oct 21  President Donald Trump said efforts to end a U S  trade war with China were going well as the first phase of the trade deal is likely to be signed in the middle of next month  Per several financial experts and market watchers  even a temporary trade truce between the two largest trading nations of the world will be a huge relief for investors Second  on Oct 8  Fed Chairman Jerome Powell gave signals of a possible third rate cut this month  The FOMC is scheduled to meet on Oct 29 30  The central bank already reduced the benchmark lending interest rate by 50 basis points in two equal tranches in July and September  Rate cut happened for the first time in more than 11 years  Notably  as of Oct 24  the CME FedWatch assigned 93 5  probability of a 25 basis point rate cut in October while just 6 5  expects status quo to be maintained Third  third quarter 2019 earnings so far are not as disappointing as expected initially  However  the forecast of overall earnings dip is still looming large  As of Oct 24  169 S P 500 members reported third quarter results  Total earnings for these index members are up 0 2  from the same period last year on 4 2  higher revenues  Notably  80 5  companies surpassed EPS estimates while 62 7  beat revenue estimates   Read More  Our Top PicksAt this stage  it will be prudent to invest in all those S P 500 stocks that surged in the past month and still have upside left  We have narrowed down our search to five such stocks  each carrying either a Zacks Rank  1  Strong Buy  or 2  Buy   You can see  Vertex Pharmaceuticals Inc is focused on the discovery  development and commercialization of small molecule drugs targeting serious diseases  Its main area of focus is cystic fibrosis  CF   The company has an expected earnings growth rate of 42  for the next year  The Zacks Consensus Estimate for the next year has improved by 10  over the last 30 days  The Zacks Rank  1 stock has jumped 14 7  in the past month PulteGroup Inc is engaged in homebuilding and financial services businesses  mainly in the United States  It conducts operations through two primary business segments    Homebuilding and Financial Services  The company has an expected earnings growth rate of 9 4  for the next year  The Zacks Consensus Estimate for the next year has improved by 2 2  over the last 30 days  The Zacks Rank  1 stock has soared 13 4  in the past month Skyworks Solutions Inc designs  manufactures  and markets a broad range of high performance analog and mixed signal semiconductors that enable wireless connectivity  The company has an expected earnings growth rate of 0 4  for the next year  The Zacks Consensus Estimate for the next year has improved by 20 3  over the last 30 days  The Zacks Rank  2 stock has surged 11 6  in the past month Lennar Corp is engaged in homebuilding and financial services in the United States  Its reportable segments consist of Homebuilding  Lennar Financial Services  Rialto and Lennar Multifamily  The company has an expected earnings growth rate of 9  for the next year  The Zacks Consensus Estimate for the next year has improved by 3 6  over the last 30 days  The Zacks Rank  2 stock has climbed 11 5  in the past month Kansas City Southernis a transportation holding company that has railroad investments in the United States  Mexico and Panama  The company has an expected earnings growth rate of 14 6  for the next year  The Zacks Consensus Estimate for the next year has improved by 3  over the last 30 days  The Zacks Rank  2 stock has gained 9 2  in the past month 5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-10-27,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-vertex-pharmaceuticals-pultegroup-skyworks-solutions-lennar-and-kansas-city-southern-200478997,200478997
120062,341577,VRTX,Vertex Energy  VTNR  To Report Q3 Results  Wall Street Expects Earnings Growth,opinion,"Vertex  NASDAQ VRTX  Energy  VTNR  is expected to deliver a year over year increase in earnings on lower revenues when it reports results for the quarter ended September 2019  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The earnings report might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This environmental services company is expected to post quarterly earnings of  0 01 per share in its upcoming report  which represents a year over year change of  107 7  
Revenues are expected to be  48 50 million  down 4 2  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 66 67  higher over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Vertex Energy 
For Vertex Energy  the Most Accurate Estimate is the same as the Zacks Consensus Estimate  suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate  This has resulted in an Earnings ESP of 0  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that Vertex Energy will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Vertex Energy would post a loss of  0 03 per share when it actually produced earnings of  0 04  delivering a surprise of  233 33  
Over the last four quarters  the company has beaten consensus EPS estimates two times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Vertex Energy doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-10-28,Zacks Investment Research,https://www.investing.com/analysis/vertex-energy-vtnr-to-report-q3-results-wall-street-expects-earnings-growth-200479603,200479603
120063,341578,VRTX,Vertex Pharmaceuticals  VRTX  Beats Q3 Earnings Estimates,opinion,"Vertex Pharmaceuticals  NASDAQ VRTX  came out with quarterly earnings of  1 23 per share  beating the Zacks Consensus Estimate of  1 14 per share  This compares to earnings of  1 09 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 7 89   A quarter ago  it was expected that this drugmaker would post earnings of  1 03 per share when it actually produced earnings of  1 26  delivering a surprise of 22 33  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Vertex  which belongs to the Zacks Medical   Biomedical and Genetics industry  posted revenues of  949 83 million for the quarter ended September 2019  missing the Zacks Consensus Estimate by 0 25   This compares to year ago revenues of  784 54 million  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Vertex shares have added about 19 4  since the beginning of the year versus the S P 500 s gain of 21 1  
What s Next for Vertex 
While Vertex has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Vertex was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  1  Strong Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 10 on  999 07 million in revenues for the coming quarter and  4 67 on  3 74 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Biomedical and Genetics is currently in the top 27  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-10-30,Zacks Investment Research,https://www.investing.com/analysis/vertex-pharmaceuticals-vrtx-beats-q3-earnings-estimates-200480400,200480400
120064,341579,VRTX,Celgene  CELG  Q3 Earnings Beat  Otezla  Revlimid Sales Rise,opinion,"Celgene Corporation   NASDAQ CELG   reported adjusted earnings of  2 99 per share in third quarter 2019  which beat the Zacks Consensus Estimate of  2 73 and increased from  2 29 a year ago 
Moreover  total revenues grew 16 1  year over year to  4 5 billion in the reported quarter  beating the Zacks Consensus Estimate of  4 4 billion 
Shares of Celgene have soared 67 2  so far this year against the  s decline of 0 9  

 
Quarter in Detail
Net sales of Revlimid came in at  2 8 billion  reflecting a 13  year over year increase  The drug performed well  both in the United States  up 14   and international markets  up 11    The growth was driven by the adoption of a triplet therapy for myeloma  which increased treatment duration and market share 
Net sales of Abraxane grew 10  year over year to  318 million  driven primarily by higher demand owing to immuno oncology combinations in non small cell lung cancer and triple negative breast cancer  Also  Pomalyst Imnovid sales came in at  664 million  up 29  year over year 
Sales of psoriasis drug  Otezla  were up 27  year over year to  547 million  The drug performed well in the United States  up 28    driven by higher demand  and the international markets  up 21    owing to continued expansion in the key markets 
All other product sales  including Istodax  Idhifa  Thalomid  Vidaza and an authorized generic version of Vidaza in the United States  totaled  219 million in the reported quarter  up from  208 million in the year ago quarter 
Adjusted research and development expenses dropped 2 1  to  928 million  while adjusted selling  general and administrative expenses increased to  700 million from  642 million in the year ago quarter 
Business Update
Celgene has been in news for its impending merger with Bristol Myers Squibb Company   NYSE BMY    In January  Bristol Myers had announced that it will acquire Celgene for approximately  74 billion 
In June  Bristol Myers announced the planned divestiture of Otezla in light of concerns raised by the U S  Federal Trade Commission  Thereafter  in August  Celgene inked an agreement with Amgen   NASDAQ AMGN    whereby the latter would acquire Otezla for  13 4 billion in cash  The transaction is expected to close by the end of 2019  subject to the FTC s acceptance of a consent order and the satisfaction of customary closing conditions
Pipeline Update
The pipeline progress in the third quarter has been impressive  In August  the FDA approved Inrebic for the treatment of adult patients with intermediate 2 or high risk primary or secondary  post polycythemia vera or post essential thrombocythemia  myelofibrosis 
In September  Celgene announced that the phase III QUAZAR AML 001 study evaluating CC 486 as maintenance therapy in patients with newly diagnosed acute myeloid leukemia AML  who achieved first complete response  CR  or CR with incomplete blood count recovery with induction chemotherapy  met the primary endpoint of prolonged overall survival  Celgene plans regulatory submissions beginning in the first half of 2020 
The BLA submission for liso cel in patients with relapsed or refractory large B cell lymphoma after at least two prior therapies is on track for the fourth quarter of 2019 
Our Take
Celgene s third quarter results were strong as it comfortably beat on both sales and earnings  Investors  are focusing on the closure of the acquisition by Bristol Myers 
Zacks Rank   A Key Pick
Celgene currently carries a Zacks Rank  4  Sell  
A better ranked stock in the biotech space is Vertex Pharmaceuticals Inc    NASDAQ VRTX    which currently carries a Zacks Rank  1  Strong Buy   You can see  
Vertex s earnings estimates have increased to  4 67 from  4 58 in the past 30 days 
Free  Zacks  Single Best Stock Set to Double
Today you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all 
This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ",2019-10-31,Zacks Investment Research,https://www.investing.com/analysis/celgene-celg-q3-earnings-beat-otezla-revlimid-sales-rise-200481060,200481060
120065,341580,VRTX,Will Vertex Pharmaceuticals Continue To Surge Higher ,opinion,As of late  it has definitely been a great time to be an investor Vertex Pharmaceuticals Incorporated   NASDAQ VRTX    The stock has moved higher by 2  in the past month  while it is also above its 20 Day SMA too  This combination of strong price performance and favorable technical  could suggest that the stock may be on the right path We certainly think that this might be the case  particularly if you consider VRTX s recent earnings estimate revision activity  From this look  the company s future is quite favorable  as VRTX has earned itself a Zacks Rank  1  Strong Buy   meaning that its recent run may continue for a bit longer  and that this isn t the top for the in focus company  You can see  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2019-10-31,Zacks Investment Research,https://www.investing.com/analysis/will-vertex-pharmaceuticals-continue-to-surge-higher-200480639,200480639
120066,341581,VRTX,Perrigo  PRGO  Beats On Q3 Earnings  Tightens  19 EPS View,opinion,"Perrigo Company plc   NYSE PRGO   reported third quarter 2019 adjusted earnings of  1 04 per share  which beat the Zacks Consensus Estimate of 93 cents  However  the bottom line decreased 4 6  year over year Net sales increased 5 1  year over year to  1 19 billion but slightly missed the Zacks Consensus Estimate of  1 2 billion  The year over year growth was mainly due to addition of products from the recently closed Ranir acquisition and higher demand for existing products  Sales of  52 million from new products were partially offset by a loss of  9 million in sales from discontinued products  Sales rose 10 2  excluding the impact of foreign currency movement Shares of Perrigo were down almost 1 2  in pre market trading on Nov 6  following the earnings release  However  the company s shares have rallied 39 8  so far this year compared with the  s rise of 10 2  Segment DiscussionPerrigo now reports its results under the following segments   Consumer Self Care Americas   CSCA    Consumer Self Care International   CSCI   and Prescription Pharmaceuticals   RX    In the first quarter of 2019  the company had initiated a process to transform itself from a healthcare to a consumer self care company In July 2019  the company completed the acquisition of Ranir Global Holdings LLC  the global leader in private label oral self care market  as part of its transformation into a self care company  Perrigo stated on its third quarter earnings call that the U S  operations of Ranir will be included in the CSCA segment and non U S  operations will be included in the CSCI segment CSCA  Net sales of the segment in the third quarter of 2019 came in at  613 million  up 2 9  year over year  Excluding net sales from exited businesses and the impact of foreign currency movement  net sales at CSCA increased approximately 9 1  to  619 million  The growth in sales was driven by  54 million of net sales from products added with the Ranir acquisition  higher sales of store brand allergy products  products in smoking cessation category and new product sales of  6 million  However  it was partially offset by lower infant formula contract pack  lower net sales from Mexican business and loss of sales from discontinued business Please note that in July  the company had completed the divestment of its Animal Health business for  185 million in cash to pet medication and wellness company  PetIQ   NASDAQ PETQ   CSCI  The segment reported net sales of  348 million  up 4  from the year ago period  On a constant currency basis  the metric increased 10 1   The growth was driven by new product sales of  28 million  especially weight loss product XLS Forte 5  and  23 million of net sales from Ranir  as well as higher sales in cough cold allergy sinus category The CSCI segment has grown organically over the past 12 months  With the launch of new products and Ranir acquisition  CSCI segment is expected to continue its growth trend  However  currency movement may have an unfavorable impact on the top line Rx Segment Net sales of the segment increased 13 6  to  230 million  The upside can be attributed to new product sales of  18 million and higher volumes of existing products  The company lost  6 million in sales from discontinued products 2019 OutlookPerrigo tightened its guidance for adjusted earnings per share to the range of  3 85 to  4 05 compared with the previously expected range of  3 75 to  4 05 Our TakePerrigo reported mixed third quarter results with earnings beating estimates but sales missing the same  However  sales rose across all segments  The company s transformation initiatives seem to support top  and bottom line growth  Moreover  the company s Rx segment returned to growth in 2019 after a weak 2018 These apart  the Irish High Court granted a leave to Perrigo for judicial review of the Irish Revenue tax assessment  The company has already appealed against the tax assessment before the Tax Appeals Commission  The appeal has been stayed till judicial review is over  Perrigo will lose almost  1 9 billion if the commission rules against the company Perrigo Company plc Price  Consensus and EPS Surprise
    Zacks Rank   Stocks to ConsiderPerrigo currently carries a Zacks Rank  4  Sell  A couple of better ranked stocks in the biotech sector are Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   and Acorda Therapeutics  Inc    NASDAQ ACOR    Both stocks sport a Zacks Rank  1  Strong Buy   You can see  Vertex s earnings per share estimates have moved up from  4 58 to  4 79 for 2019 and from  6 03 to  6 62 for 2020 in the past 30 days  The company delivered a positive earnings surprise in all the trailing four quarters  with the average beat being 17 59   Share price of the company has increased 19  so far this year Loss estimates for Acorda have narrowed from  2 98 to  2 18 for 2019 and  3 74 to  1 95 for 2020 in the past 30 days  The company pulled off a positive earnings surprise in all the last four quarters  with the average beat being 68 8  Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 5  per year These 7 were selected because of their superior potential for immediate breakout ",2019-11-05,Zacks Investment Research,https://www.investing.com/analysis/perrigo-prgo-beats-on-q3-earnings-tightens-19-eps-view-200482986,200482986
120067,341582,VRTX,Vertex Pharmaceuticals beats by  0 07  beats on revenue,news,Vertex Pharmaceuticals  NASDAQ VRTX   Q4 EPS of  0 61 beats by  0 07 Revenue of  651 6M   42 1  Y Y  beats by  56 88M Shares  4 3  Press ReleaseNow read ,2018-01-31,Seeking Alpha,https://www.investing.com/news/stock-market-news/vertex-pharmaceuticals-beats-by-007-beats-on-revenue-1178637,1178637
120068,341583,VRTX,Vertex Q4 sales up 37   earnings up 206   shares up 4  after hours,news,Vertex Pharmaceuticals  NASDAQ VRTX  Q4 results   M   Total revenues  621   36 8   Product sales  ORKAMBI  365   31 8    KALYDECO  256   44 6   Net Income  101   206 1    non GAAP net income  158   79 5    EPS  0 39   200 0    non GAAP EPS  0 61   74 3   2018 Guidance  CF sales outlook will be released after the anticipated FDA approval of the tezacaftor ivacaftor combo  The agency s action date is February 28 Up to  500M in share repurchases will be made through the end of 2019 Marketing applications in the U S  and Europe seeking approval for the use of KALYDECO in infants ages 1  2 year old should be filed this quarter Shares are up 4  after hours on increased volume Now read ,2018-01-31,Seeking Alpha,https://www.investing.com/news/stock-market-news/vertex-q4-sales-up-37-earnings-up-206-shares-up-4-after-hours-1178863,1178863
120069,341584,VRTX,After Hours Gainers   Losers  1 31 2018 ,news,Top gainers  OTEX  12 4   QRVO  7 5   NVTA  6 0   ESIO  4 2   VRTX  4 0  Top losers  EGOV  19 0   TSCO  4 3   PYPL  4 1   FB  3 8   GDS  2 1   Now read ,2018-01-31,Seeking Alpha,https://www.investing.com/news/stock-market-news/after-hours-gainers--losers-1312018-1179234,1179234
120070,341585,VRTX,Vertex launches late stage study of triplet CF therapy in patients with most common mutations,news,Vertex Pharmaceuticals  NASDAQ VRTX  initiates a Phase 3 clinical trial assessing a fixed dose combination of VX 659  240 mg   tezacaftor  100 mg  and ivacaftor  150 mg  in cystic fibrosis  CF  patients with two copies of the F508del mutation  the most common genetic form of the disorder The primary endpoint of the 100 subject study is the mean absolute change from baseline to week four of treatment in lung function as measured by percent predicted forced expiratory volume in one second  ppFEV1  50 participants will receive VX 659 tezacaftor ivacaftor and the other 50 will receive placebo tezacaftor ivacaftor  An open label extension study will be offered to all patients after the initial treatment period during which they will receive the VX 659 combination for up to 96 weeks Previously  Vertex picks two new candidates to advance into late stage development of triplet CF therapy  Jan  31 Now read ,2018-03-01,Seeking Alpha,https://www.investing.com/news/stock-market-news/vertex-launches-latestage-study-of-triplet-cf-therapy-in-patients-with-most-common-mutations-1319541,1319541
120089,341604,VRTX,AstraZeneca  AZN  Q3 Earnings Top  Upgrades  19 Sales View,opinion,"AstraZeneca   NYSE AZN   beat the Zacks Consensus Estimate for both earnings and sales in the third quarter of 2019 and also upgraded its previously issued product sales growth guidance for the year Earnings   Sales BeatThird quarter 2019 core earnings of 50 cents per American depositary share beat the Zacks Consensus Estimate of 45 cents  Core earnings per share of 99 cents increased 36  year over year at constant exchange rates   CER    benefiting from higher product sales Total revenues were up 20   22  at CER  to  6 4 billion in the reported quarter driven by higher product sales  Revenues also beat the Zacks Consensus Estimate of  6 14 billion AstraZeneca s shares rose around 3 1  in pre market trading in response to the better than expected results  In fact  the stock has rallied 17 6  this year so far against the  s decrease of 0 3  All growth rates mentioned below are on a year over year basis and at CER Product Sales RiseProduct sales rose 18  at CER in the quarter to  6 13 billion  Higher sales of newer medicines and higher sales in every sales region  offset lower sales of many other legacy medicines and drove product sales growth The Cambridge  U K  based drugmaker s newer medicines recorded sales of  2 71 billion in the third quarter  up 64  at CER as almost every product it has launched in recent years did well  Sales of newer medicines in emerging markets were  539 million  up 90  year over year Collaboration revenues  formerly Externalization revenues  were  274 million compared with  74 million in the year ago period Among AstraZeneca s various therapeutic areas  Oncology was up 48   New Cardiovascular  Renal and Metabolism was up 11  and Respiratory rose 18   However  other medicines declined 7  Newer Products Drive SalesAmong the newer medicines  Lynparza sales rose 96  year over year and 15 5  sequentially to  327 million in the quarter on the back of expanded use in ovarian and breast cancer  Sales of the drug in the United States increased 86   following successful launch in first line ovarian cancer setting in late 2018  AstraZeneca markets Lynparza in partnership with Merck   NYSE MRK   Tagrisso recorded sales of  891 million  up 78  year over year driven by continued underlying demand growth and strong uptake in the first line setting  Sales increased 17  sequentially in the U S  market Imfinzi generated sales of  412 million in the quarter  up 21 9  sequentially mainly driven by strong demand in lung cancer patients  Like previous quarters  the vast majority of Imfinzi s sales came from the United States and the lung cancer indication Calquence  which was launched in the United States in October 2017  generated sales of  44 million in the third quarter compared with  35 million in the previous quarter Brilinta Brilique sales were  416 million in the reported quarter  up 27  year over year driven by continued patient uptake in acute coronary syndrome and high risk post myocardial infarction indications New hyperkalemia drug  Lokelma recorded sales of  4 million in the quarter  predominantly in the United States  where it was launched last quarter  The drug is expected to be launched in other markets soon Farxiga recorded sales of  398 million in the quarter  up 14  mainly driven by growth in emerging markets and Europe New asthma medicine  Fasenra recorded sales of  202 million in the quarter compared with  167 million in the previous quarter  AstraZeneca said Fasenra enjoys leadership position among novel biologic asthma medicines in the United States and European countries like Germany and Japan Bevespi  a LAMA LABA in a pressurized metered dose inhaler  recorded sales of  10 million in the quarter  similar to the previous two quarters  amid slower than anticipated growth in LAMA LABA class Among other medicines  Iressa sales were down 29  to  91 million  Bydureon sales declined 16  to  127 million and Onglyza sales declined 7  to  127 million  Byetta sales declined 18  to  28 million and Movantik Moventig recorded sales of  25 million in the quarter  down 23  Older ProductsCrestor sales declined 2  to  337 million  U S  and Europe sales were weak as multiple generic versions of the drug entered the market Symbicort sales were up 1  in the quarter to  613 million due to stronger sales in emerging markets  U S  sales were hurt by pricing pressure and the impact of managed market rebates  Pulmicort sales rose 31  to  337 million as higher sales in the emerging and U S  markets made up for weaker performance in Europe Nexium recorded sales of  374 million  down 10  due to lower sales in the United States and Europe  Sales of other legacy drugs including Zoladex  Arimdex  Casodex Seloken and Daliresp Daxas grew in the quarter while sales of others like Faslodex  Synagis  Duaklir and Atacand declined Regional PerformanceIn the United States  product sales were up 17  to  2 billion on the back of higher sales of newer products  Sales in European markets grew 4  in the third quarter to  1 14 billion  Revenues from Emerging Markets were up 29  to  2 12 billion  primarily on the back of strong growth in China  up 40  to  1 28 billion  In Established ROW market  comprising Japan  Canada and other markets   sales were up 19  to  845 million Profit DiscussionAstraZeneca s core gross margin decline one percentage point  at CER  to 79 4   Core selling  general and administrative  SG A  expenses rose 9  to  2 21 billion In the quarter  core research and development  R D  expenses rose 9  to  1 32 billion  Core operating profit rose 41  to  1 88 billion in the quarter  Operating margin increased 4 percentage points to 29 3  in the quarter Upgrades 2019 Product Sales OutlookAstraZeneca upgraded its product sales guidance  following strong performance year to date  The company expects product sales to grow by a low to mid teens percentage versus prior expectation of a low double digit percentage AstraZeneca however maintained core EPS guidance for 2019 in the range of  3 50 to  3 70  Currency movements are expected to unfavorably impact product sales and core earnings per share by a low single digit percentage Adjusted tax rate is expected to be in the range of 20  22  AstraZeneca PLC Price  Consensus and EPS Surprise
    Zacks Rank   Stocks to ConsiderAstraZeneca currently carries a Zacks Rank  3  Hold  Some better ranked stocks from the broader Drug sector are Incyte Corporation   NASDAQ INCY   and Vertex Pharmaceuticals Incorporated   NASDAQ VRTX    both sporting a Zacks Rank  1  Strong Buy   You can see  Shares of Incyte have gained 22 8  this year so far  Earnings estimates for 2019 have risen 1 6  while that for 2020 have increased 4 5  over the past 30 days Vertex s earnings estimates have increased a respective 2  and 10  for 2019 and 2020 over the past 30 days  Shares are up 15  so far this year Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-10-23,Zacks Investment Research,https://www.investing.com/analysis/astrazeneca-azn-q3-earnings-top-upgrades-19-sales-view-200477457,200477457
120091,341606,VRTX,Baxter  BAX  Misses Q3 Revenue Estimates  Issues Guidance,opinion,Baxter International Inc    NYSE BAX   reported preliminary third quarter 2019 revenues of  2 85 billion  which missed the Zacks Consensus Estimate of  2 86 billion by 0 5   However  the top line rose 3  year over year on a reported basis and 5  on both constant currency and operational basis However  the company hasn t released any earnings number in its preliminary results Geographical DetailsBaxter reports preliminary operating results through three geographic segments   Americas  North and South America   EMEA  Europe  Middle East and Africa  and APAC  Asia Pacific  In Americas  Baxter recorded revenues of  1 53 billion  up 2 5  on a year over year basis In EMEA  revenues totaled  730 million  up 3 3  from the year ago quarter In APAC  revenues of  587 million increased 4 3  from the prior year quarter Segmental DetailsPer the preliminary results  Baxter s results of its global business units are as follows Renal CareThis segment reported revenues of  918 million in the quarter under review  up 0 9  year over year Medication DeliveryRevenues at the segment grossed  701 million  up 7 5  from the year ago quarter PharmaceuticalsRevenues at the segment amounted to  527 million  up 1 5  from the year ago quarter Clinical NutritionRevenues at the segment were  219 million  up 0 5  from the year ago quarter Advanced SurgeryRevenues at the segment totaled  216 million  up 8  from the year ago quarter Acute TherapiesThis segment reported revenues of  130 million  up 6 6  from the prior year quarter OtherRevenues in the segment grossed  140 million  down 4 1  on a year over year basis Margin AnalysisBaxter registered preliminary adjusted gross profit of  1 30 billion in the third quarter  up 1 8  year over year  As a percentage of revenues  preliminary adjusted gross margin came in at 45 7  in the third quarter  contracting 60 bps on a year over year basis Preliminary operating income surged 44 2  year over year to  555 million in the quarter under review  As a percentage of revenues  preliminary operating margin expanded 370 bps to 17 6  in the third quarter GuidancePer the preliminary results  the following is the fourth quarter 2019 outlook For the fourth quarter of 2019  management at Baxter expects revenues in the range of 3 4  on a reported basis  and approximately 5  on both cc and operational basis The company projects operating margin to range between 15 2  and 15 9  on a reported basis and 18 5 19  on an adjusted basis Summing UpBaxter reported solid preliminary revenues in the third quarter  The stock continues to benefit from its core Renal Care  Medication Delivery  Advanced Surgery  Pharmaceuticals and Acute Therapies units Higher revenues across all global businesses and regions  and continued execution on business transformation initiatives fueled the company s preliminary third quarter results Growth in APAC buoys optimism  The company initiated the U S  and Canadian launches of its next generation PrisMax system for continuous renal replacement therapy  CRRT  and therapeutic plasma exchange  TPE   Further  Baxter is set to acquire Cheetah Medical that will bolster the company s presence in the specialized patient monitoring space  The company also announced new data relating to the utilization of its automated peritoneal dialysis  APD  cyclers and the Sharesource remote patient management platform with a 39  reduction in hospitalizations for home PD patients receiving care at Baxter Renal Care Services clinics in Colombia However  in the quarter under review  the company witnessed gross margin contraction  Cut throat competition in the MedTech markets is indicative of dull prospects It is important to note here that as per the preliminary results released  the company has announced internal investigation of misstatements in previously reported non operating income related to foreign exchange gains and losses  Moreover  the company does not expect to file its quarterly report on Form 10 Q for the period ended September 30  2019 on a timely basis Zacks RankBaxter currently carries a Zacks Rank  3  Hold  Key PicksA few better ranked stocks in the broader medical space are Incyte Corporation   NASDAQ INCY    Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   and Jazz Pharmaceuticals plc   NASDAQ JAZZ   Incyte is scheduled to release third quarter 2019 results on Oct 29  The Zacks Consensus Estimate for the to be reported quarter s adjusted EPS is pegged at 65 cents per share and the same for revenues stands at  538 9 million  The stock sports a Zacks Rank  1  Strong Buy   You can see  Vertex Pharmaceuticals is scheduled to release third quarter 2019 results on Oct 30  The Zacks Consensus Estimate for third quarter adjusted EPS and revenues is  1 13 per share and  947 8 million  respectively  The stock has a Zacks Rank of 1 Jazz Pharmaceuticals is expected to release third quarter 2019 results on Nov 5  The Zacks Consensus Estimate for adjusted EPS for the to be reported quarter is  3 59 per share and the same for revenues is pegged at  522 6 million  The stock carries a Zacks Rank  2  Buy  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-10-23,Zacks Investment Research,https://www.investing.com/analysis/baxter-bax-misses-q3-revenue-estimates-issues-guidance-200477577,200477577
120092,341607,VRTX,5 Drug Biotech Stocks Likely To Surpass On Earnings In Q3	,opinion,The third quarter earnings season for the pharma biotech sector started last week  putting up an impressive performance so far in the reporting cycle  Good news is that most pharma bigwigs like Johnson   Johnson  NYSE JNJ  and Novartis beat on both sales and earnings as well as raised their guidance  combating generic plus biosimilar competition  Swiss pharma giant Roche too delivered a stellar performance on the back of new drugs  a trend that most likely benefited third quarter sales for other major biggies Additionally  on the biotech front  Alexion  NASDAQ ALXN  and Biogen  NASDAQ BIIB  registered strong numbers  surpassing on both counts as their blockbuster drugs continue to drive growth  Moreover  the companies came up with positive pipeline updates While a decline in the legacy drug sales and pipeline setbacks were expected to leave an adverse impact on the margins and annual guidances  most companies lifted their annual outlook  buoying investor optimism on the stocks  New drug approvals and label expansions of blockbuster drugs are expected to have kept the momentum alive in the third quarter for most companies  enabling them to fight headwinds like pricing pressure and stiff rivalry How to Pick Probable Q3 Winners There are multiple drug biotech companies poised to beat on third quarter earnings  However  given the large number of drug biotech entities  the task of selecting stocks with possibilities to surpass on expectations appears quite daunting With the help of the   we have zeroed in on five drug biotech stocks that carry a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  and a positive   This is a valuable tool for investors looking for stocks with the maximum potential to beat estimates  Our research shows that with this combination  chances of positive surprise are as high as 70   You can uncover the best stocks to buy or sell before they re reported with our  5 Stocks Poised to OutperformGlaxoSmithKline plc   NYSE GSK   has an Earnings ESP of  3 03  and a Zacks Rank  2  The Zacks Consensus Estimate for third quarter 2019 earnings stands at  0 83  The company s earnings topped estimates in three of the last four quarters  the average positive surprise being 12 74   It is scheduled to release earnings on Oct 30  You can see  Incyte Corporation   NASDAQ INCY   has an Earnings ESP of  1 15  and a Zacks Rank of 1  The Zacks Consensus Estimate for third quarter 2019 earnings is pegged at  0 65  The company s earnings trumped estimates in two of the last four quarters  the average beat being 25 01   It is scheduled to release earnings on Oct 29 Vertex Pharmaceuticals   NASDAQ VRTX   has an Earnings ESP of  3 07  and is Zacks  1 Ranked  The Zacks Consensus Estimate for third quarter 2019 earnings stands at  1 13  The company s earnings outpaced estimates in all the trailing four quarters  the average being 17 87   The company is scheduled to release earnings on Oct 30 Jazz Pharmaceuticals   NASDAQ JAZZ   has an Earnings ESP of  1 70  and a Zacks Rank of 2  The Zacks Consensus Estimate for third quarter 2019 earnings stands at  3 59  The company s earnings exceeded estimates in all the previous four quarters  the average being 14 81   The company is scheduled to release earnings on Nov 5 Zoetis  Inc    NYSE ZTS   has an Earnings ESP of  2 58  and is Zacks  2 Ranked  The Zacks Consensus Estimate for third quarter 2019 earnings stands at  0 89  The company s earnings outshined estimates in all the last four quarters  the average being 7 89   It is scheduled to release earnings on Nov 7 Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-10-23,Zacks Investment Research,https://www.investing.com/analysis/5-drugbiotech-stocks-likely-to-surpass-on-earnings-in-q3-200477570,200477570
120093,341608,VRTX,The Zacks Analyst Blog Highlights  Biogen  Vertex  Amgen  Alexion And Achillion Pharmaceuticals,opinion,For Immediate ReleaseChicago  IL   October 24  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Biogen   NASDAQ BIIB    Vertex   NASDAQ VRTX    Amgen   NASDAQ AMGN    Alexion   NASDAQ ALXN   and Achillion Pharmaceuticals  Inc    NASDAQ ACHN   Here are highlights from Wednesday s Analyst Blog  Biotech Stock Roundup  Biogen s  BIIB  Big Jump    MoreIt was a busy week for the biotech sector with updates from quite a few bigwigs  Biogen topped third quarter estimates and reported positive data on AD drug  Vertex got FDA approval for a new CF medicine  while Amgen got a positive opinion for Evenity  Further  Alexion is set to buy a clinical stage biopharmaceutical company to broaden its PNH portfolio  Recap of the Week s Most Important Stories Biogen Up on Positive AD Drug Data  Beats on Q3 Earnings  Shares of Biogen surged significantly after it announced new data on aducanumab in patients with early Alzheimer s disease  AD   The company released results from a new analysis of a larger dataset of the discontinued ENGAGE and EMERGE phase III studies on aducanumab in patients with early AD  This analysis was conducted in consultation with the FDA  Biogen and Japanese partner Eisai had discontinued ENGAGE and EMERGE studies  following a futility analysis  Nevertheless  the new data showed that aducanumab reduced clinical decline of Alzheimer s disease in such patients as measured by the pre specified primary and secondary endpoints  Based on this data  the company plans to submit a biologics license application seeking approval of the drug to the FDA in early 2020 Concurrently  the company also  better than expected results for the third quarter of 2019  driven by higher sales of key multiple sclerosis drugs and continued global launch of spinal muscular atrophy drug  Spinraza Amgen Gets Positive CHMP Opinion for Evenity   Amgen and partner UCB announced that the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency has given a positive opinion for Evenity  romosozumab  following a re examination procedure  The committee recommended Marketing Authorization for the drug for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture and with no history of myocardial infarction or stroke  The recommendation will now be reviewed by the European Commission and a decision is expected by year end  The committee had earlier given a negative opinion on the same  We note that Evenity is already approved in the United States for the treatment of osteoporosis in postmenopausal women at     high risk for fracture Additionally  Amgen announced that the FDA has approved its Supplemental Biologics License Application for Nplate  romiplostim  to include new data in its U S  prescribing information showing sustained platelet responses in adults with immune thrombocytopenia Alexion to Buy Achillion for  930M  Alexion announced that it has entered a definitive agreement to acquire a clinical stage biopharmaceutical company  Achillion Pharmaceuticals  Inc   for  930 million  Achillion primarily focuses on the development of oral small molecule Factor D inhibitors to treat people with complement alternative pathway mediated rare diseases  such as paroxysmal nocturnal hemoglobinuria  PNH  and C3 glomerulopathy  C3G   The acquisition will add two clinical stage candidates to Alexion s pipeline   lead candidate  danicopan  ACH 4471   in phase II and ACH 5228 in phase I  Achillion s shareholders will get  6 30 per share as an initial consideration  Alexion will also be acquiring Achillion s cash balance  The transaction is expected to close in the first half of 2020  Alexion is looking to strengthen its PNH franchise with this acquisition Additionally  the company that the FDA approved a label expansion of its long acting C5 complement inhibitor  Ultomiris  ravulizumab cwvz   The drug has been approved for the treatment of atypical hemolytic uremic syndrome to inhibit complement mediated thrombotic microangiopathy in adult and pediatric  one month or older  patients  Ultomiris is already approved for the treatment of adults with PNH in the United States Vertex Gets FDA Approval for Trikafta  Vertex Pharmaceuticals announced that the FDA has approved Trikafta  elexacaftor tezacaftor ivacaftor and ivacaftor  for the treatment of cystic fibrosis  CF  in patients aged 12 years or above  who have at least one F508del mutation  As a result of this approval  approximately 6 000 patients with one minimal function mutation and one F508del mutation have access to a drug that can treat the underlying cause of their disease  Moreover  approximately 12 000 people with one or two F508del mutations  who are currently eligible for one of Vertex s three other FDA approved CF medicines  are now eligible for Trikafta  Additional studies are ongoing for this combination Vertex currently carries a Zacks Rank  1  Strong Buy   You can see Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-10-23,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-biogen-vertex-amgen-alexion-and-achillion-pharmaceuticals-200477769,200477769
120094,341609,VRTX,Factors Setting The Tone For Celgene  CELG  Q3 Earnings,opinion,"Celgene Corporation   NASDAQ CELG   is scheduled to report third quarter 2019 results on Oct 31  The company s earnings surpassed the Zacks Consensus Estimate in the trailing four quarters  with average positive surprise of 4 21   In the last reported quarter  it delivered a positive earnings surprise of 9 16  Let s see how things are shaping up ahead of this announcement Celgene Corporation Price  Consensus and EPS Surprise
    
Factors at PlayCelgene s key product  Revlimid  was a major growth driver in the second quarter  backed by the adoption of the triplet therapy for myeloma leading to market share gains  a trend that most likely continued in the third quarter  Revlimid  an oral  immunomodulatory drug  is currently approved for several indications  including the newly diagnosed multiple myeloma   MM    myelodysplastic syndromes and mantle cell lymphoma   In May  the European Commission approved the drug in combination with Velcade and dexamethasone  RVd  for the treatment of adult patients with previously untreated MM  who are not eligible for transplant  Also  the FDA approved the drug in combination with a rituximab product for the treatment of adult patients with previously treated follicular lymphoma or marginal zone lymphoma  Sales might have got further boost as this was the first full quarter to benefit from the label expansion of the drug into these indications Psoriasis drug  Otezla  has driven growth for Celgene in the first half of the year on higher demand and is likely to have contributed significantly to the company s top line in the third quarter In addition to Revlimid and Otezla  Pomalyst and Abraxane might have boosted the top line Apart from the regular top and bottom line numbers  investors will focus on pipeline updates from the company  In August  the FDA approved Inrebic  fedratinib  for the treatment of adult patients with intermediate 2 or high risk primary or secondary  post polycythemia vera or post essential thrombocythemia  myelofibrosis Business UpdateCelgene has been in news for its impending merger with Bristol Myers Squibb Company   NYSE BMY    In January  Bristol Myers had announced that it will acquire Celgene for approximately  74 billion  In April  the stockholders of Celgene voted in favor of the proposed merger Share Price PerformanceCelgene s stock has surged 63 4  in the year so far against a 2 8  decline for the   Earnings WhisperOur proven model does not conclusively predict an earnings beat for Celgene this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  Unfortunately  that is not the case here  as you will see below  You can uncover the best stocks to buy or sell before they re reported with our  Earnings ESP  Earnings ESP for Celgene is  3 06  as the Zacks Consensus Estimate is  2 73 and the Most Accurate Estimate is  2 81 Zacks Rank  The company currently carries a Zacks Rank  4  Sell  Stocks to ConsiderHere are some stocks you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Incyte Corporation   NASDAQ INCY   has an Earnings ESP of  1 15  and a Zacks Rank of 1  It is scheduled to release earnings on Oct 29  You can see  Vertex Pharmaceuticals   NASDAQ VRTX   has an Earnings ESP of  3 07  and a Zacks Rank of 1  The company is scheduled to release earnings on Oct 30 Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-10-24,Zacks Investment Research,https://www.investing.com/analysis/factors-setting-the-tone-for-celgene-celg-q3-earnings-200477388,200477388
120097,341612,VRTX,Top Ranked Momentum Stocks To Buy For October 25th,opinion,"Here are four stocks with buy rank and strong momentum characteristics for investors to consider today  October 25th 
Costamare Inc   CMRE   This containership and liner owning and chartering company has a Zacks Rank  1  Strong Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7 1  over the last 60 days Costamare Inc  Price and Consensus   Costamare s shares gained 13 1  over the last one month above the S P 500 s increase 0 9   The company possesses a  of A Costamare Inc  Price   DHT Holdings  Inc   DHT   This owner and operator crude oil tankers has a Zacks Rank  1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing more than 100  over the last 60 days DHT Holdings  Inc  Price and Consensus   DHT Holdings  shares gained 22 6  over the last one month  The company possesses a Momentum Score of A DHT Holdings  Inc  Price   First American Financial Corporation  FAF   This financial services company has a Zacks Rank  1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing nearly 2 8  over the last 60 days First American Financial Corporation Price and Consensus   First American Financial s shares gained 4 4  over the last one month  The company possesses a Momentum Score of A First American Financial Corporation Price   Vertex Pharmaceuticals  NASDAQ VRTX  Incorporated  VRTX   This developer of therapies for treating cystic fibrosis has a Zacks Rank  1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing nearly 2  over the last 60 days Vertex Pharmaceuticals Incorporated Price and Consensus   Vertex Pharmaceuticals  shares gained 13 4  over the last one month  The company possesses a Momentum Score of A Vertex Pharmaceuticals Incorporated Price   See the 
Learn more about the  
5 Stocks Set to Double
Each was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth 
Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ",2019-10-24,Zacks Investment Research,https://www.investing.com/analysis/top-ranked-momentum-stocks-to-buy-for-october-25th-200478617,200478617
120098,341613,VRTX,Can CF Drugs Drive Growth For Vertex  VRTX  In Q3 Earnings ,opinion,Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   is scheduled to report third quarter 2019 results on Oct 30  after the market closes Vertex boasts an excellent earnings surprise history  surpassing expectations in each of the trailing four quarters  the average being 17 87   In the last reported quarter  the company delivered a positive surprise of 22 33  Shares of Vertex have rallied 17 3  so far this year versus the  2 5  decrease Let s see  how things are shaping up for the quarter to be reported Factors at PlayVertex s cystic fibrosis  CF  drug portfolio has been performing well  Sales growth in the last reported quarter was driven by a rapid uptake of the company s newest CF medicine Symdeko  a trend that most likely continued in the third quarter  The drug  a combination of tezacaftor and ivacaftor  has seen solid demand since its launch last year as more patients are resorting to treatment with the same In June this year  the FDA approved Symdeko to treat children  aged from six to 11 years  affected by CF with certain mutations in the CFTR gene  This label expansion might reflect on incremental sales in the to be reported results Moreover  Vertex s other two CF medicines Kalydeco  ivacaftor  and Orkambi are expected to have contributed to the company s top line in the to be reported quarter Though Kalydeco and Orkambi sales were initially hit by a switch in the respective patient base to Symdeko  management had stated on second quarter conference call that owing to new reimbursement agreements in the ex U S  markets and latest regulatory approvals for children  new patients are starting treatment with Kalydeco and Orkambi  It remains to be seen whether this positive trend has continued in the third quarter or not Investors will be keen to get an update during third quarter earnings  call on Vertex s investigational gene editing treatment CTX001  which is being evaluated in early to mid stage studiesfor the two devastating diseases  namely sickle cell disease and thalassemia  Notably  Vertex has a partnership with CRISPR Therapeutics   NASDAQ CRSP   to develop CTX001 Key DevelopmentsEarlier this month  Vertex announced that the FDA has approved its triple combination regimen Trikafta  elexacaftor tezacaftor ivacaftor and ivacaftor  for the treatment of CF in patients aged 12 years and older  who have at least one copy of the F508del mutation in their CFTR gene  The approval of Trikafta  which can treat about 90  of total CF patients  came five months before the PDUFA date in March 2020 We expect management to provide an update on this recent nod and discuss the launch activities for Trikafta during the upcoming investors  call Meanwhile  in September 2019  Vertex inked an all cash deal to acquire the privately held biotech Semma Therapeutics for  950 million  This acquisition will add pre clinical cell based treatment candidates for type I diabetes to Vertex s pipeline  The deal is expected to close in the fourth quarter of 2019 Earnings WhispersOur proven model does not conclusively predict an earnings beat for Vertex this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  But this is not the case here  You can uncover the best stocks to buy or sell before they re reported with our Earnings ESP  Vertex has an Earnings ESP of  0 48  Zacks Rank  Vertex sports a Zacks Rank of 1  which increases the predictive power of ESP  However  its negative ESP leaves surprise prediction inconclusive Vertex Pharmaceuticals Incorporated Price and EPS Surprise   Stocks That Warrant a LookHere are a few healthcare stocks worth considering as our model shows that these have the right mix of elements to beat estimates this time around Incyte Corporation   NASDAQ INCY   has an Earnings ESP of  1 15  and is Zacks  1 Ranked  The company is scheduled to release results on Oct 29  You can see  Amgen  Inc    NASDAQ AMGN   has an Earnings ESP of  0 50  and a Zacks Rank  3  The company is scheduled to release results on Oct 29 5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-10-25,Zacks Investment Research,https://www.investing.com/analysis/can-cf-drugs-drive-growth-for-vertex-vrtx-in-q3-earnings-200478574,200478574
120099,341614,VRTX,MabVax initiates early stage study of MVT 1075 in CA19 9 positive cancers  inks  550K capital raise to support development,news,Enrollment is underway at Memorial Sloan Kettering Cancer Center in a Phase 1 clinical trial assessing MabVax Therapeutics   OTCQB MBVX  HuMab 5B1 targeting radiotherapy candidate MVT 1075 in patients with locally advanced metastatic adenocarcinoma of the pancreas or other CA19 9 positive malignancies such as colon and lung cancers Interim data should be available by year end Concurrently  the company has inked an agreement for the direct sale of 769 231 shares of common stock at  0 65 per share  Net proceeds of   470K will help fund the development of MVT 1075 Now read ,2017-10-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/mabvax-initiates-earlystage-study-of-mvt1075-in-ca199positive-cancers-inks-550k-capital-raise-to-support-development-539956,539956
120100,341615,VRTX,RBC bullish on accelerated approval of Vertex s triple combo CF therapy  price target raised to  181,news,RBC Capital Markets has raised its price target on Vertex Pharmaceuticals  VRTX  0 4   to  181  18  upside  from  175 citing the prospects of accelerated approval for its triplet CF therapy which will expand the treatable population to 90   Its base case assumed approval in 2020 Source  BloombergPreviously  Vertex shares still have headroom   WSJ  July 19 Now read ,2017-10-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/rbc-bullish-on-accelerated-approval-of-vertexs-triple-combo-cf-therapy-price-target-raised-to-181-543617,543617
120101,341616,VRTX,Celgene selloff weighs on biotechs  IBB down 1 ,news,Celgene s  CELG  10   mongersen stoked selloff has engulfed its fellow biotechs Selected tickers   IBB  1 1   XBI  0 1   FBT  0 5   BBH  1 2   BIB  2 3   BIIB  2 2   AMGN  1 1   VRTX  1   GILD  1  Previously  Celgene hits bump in road with IBD candidate GED 0301  two studies terminated  shares poised for down move after hours  Oct  19 Now read ,2017-10-20,Seeking Alpha,https://www.investing.com/news/stock-market-news/celgene-selloff-weighs-on-biotechs-ibb-down-1-545094,545094
120102,341617,VRTX,5 Top Volatility Defying S P 500 Stocks Of Past Month,opinion,After completing three impressive quarters of 2019  Wall Street started the final quarter with mixed performance  Despite continuation of volatile trading  both S P 500 and the Nasdaq Composite Indexes are in positive territory month to date while the Dow is marginally in the red  Meanwhile  the benchmark S P 500 Index is within a striking distance of another all time high after July S P 500 Index NorthboundOn Oct  24  the S P 500 Index     generally utilized by market participants as the barometer of the broad market movement     closed at 3 010 29  The index is just 0 5  below the all time closing high of 3 025 86 that it reached on Jul 26  2019 as well as to touch its all time intraday high of 3 027 98 recorded on the same day Year to date  the broad market index has rallied 20 1   an impressive performance after a disappointing 2018  when it lost 6 6   Moreover  the index is up 1 1  so far in October while it returned 1 5  in the past one month Three Possible Drivers of S P 500 Index  First  per a Bloomberg report  on Oct 18  Chinese vice premier said   China and the U S  have made substantial progress in many aspects  and laid an important foundation for a phase one trade agreement   On Oct 21  President Donald Trump said efforts to end a U S  trade war with China were going well as the first phase of the trade deal is likely to be signed in the middle of next month  Per several financial experts and market watchers  even a temporary trade truce between the two largest trading nations of the world will be a huge relief for investors Second  on Oct 8  Fed Chairman Jerome Powell gave signals of a possible third rate cut this month  The FOMC is scheduled to meet on Oct 29 30  The central bank already reduced the benchmark lending interest rate by 50 basis points in two equal tranches in July and September  Rate cut happened for the first time in more than 11 years  Notably  as of Oct 24  the CME FedWatch assigned 93 5  probability of a 25 basis point rate cut in October while just 6 5  expects status quo to be maintained Third  third quarter 2019 earnings so far are not as disappointing as expected initially  However  the forecast of overall earnings dip is still looming large  As of Oct 24  169 S P 500 members reported third quarter results  Total earnings for these index members are up 0 2  from the same period last year on 4 2  higher revenues  Notably  80 5  companies surpassed EPS estimates while 62 7  beat revenue estimates   Read More  Our Top PicksAt this stage  it will be prudent to invest in all those S P 500 stocks that surged in the past month and still have upside left  We have narrowed down our search to five such stocks  each carrying either a Zacks Rank  1  Strong Buy  or 2  Buy   You can see  Vertex Pharmaceuticals Inc    NASDAQ VRTX   is focused on the discovery  development and commercialization of small molecule drugs targeting serious diseases  Its main area of focus is cystic fibrosis  CF   The company has an expected earnings growth rate of 42  for the next year  The Zacks Consensus Estimate for the next year has improved by 10  over the last 30 days  The Zacks Rank  1 stock has jumped 14 7  in the past month PulteGroup Inc    NYSE PHM   is engaged in homebuilding and financial services businesses  mainly in the United States  It conducts operations through two primary business segments    Homebuilding and Financial Services  The company has an expected earnings growth rate of 9 4  for the next year  The Zacks Consensus Estimate for the next year has improved by 2 2  over the last 30 days  The Zacks Rank  1 stock has soared 13 4  in the past month Skyworks Solutions Inc    NASDAQ SWKS   designs  manufactures  and markets a broad range of high performance analog and mixed signal semiconductors that enable wireless connectivity  The company has an expected earnings growth rate of 0 4  for the next year  The Zacks Consensus Estimate for the next year has improved by 20 3  over the last 30 days  The Zacks Rank  2 stock has surged 11 6  in the past month Lennar Corp    NYSE LEN   is engaged in homebuilding and financial services in the United States  Its reportable segments consist of Homebuilding  Lennar Financial Services  Rialto and Lennar Multifamily  The company has an expected earnings growth rate of 9  for the next year  The Zacks Consensus Estimate for the next year has improved by 3 6  over the last 30 days  The Zacks Rank  2 stock has climbed 11 5  in the past month Kansas City Southern   NYSE KSU   is a transportation holding company that has railroad investments in the United States  Mexico and Panama  The company has an expected earnings growth rate of 14 6  for the next year  The Zacks Consensus Estimate for the next year has improved by 3  over the last 30 days  The Zacks Rank  2 stock has gained 9 2  in the past month 5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-10-25,Zacks Investment Research,https://www.investing.com/analysis/5-top-volatilitydefying-sp-500-stocks-of-past-month-200478243,200478243
120103,341618,VRTX,Biotechs under pressure after Celgene revenue miss and guidance revision,news,In what many investors will perceive as an overreaction  Celgene  CELG  19 4   is getting roughed up in early trading after it release Q3 results that showed flat product sales  The company also modestly revised its 2017 revenue guidance to the lower end of the previously announced range but raised its EPS outlook Biotechs are down in sympathy   IBB  2 4   XBI  1 5   BIB  4 9   BIIB  1 1   AMGN  1 8   VRTX  2 1   GILD  1 2  Previously  Celgene Q3 top line up 10   product sales flat  earnings up 478   shares down 4  premarket on revenue miss  Oct  26 Now read ,2017-10-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/biotechs-under-pressure-after-celgene-revenue-miss-and-guidance-revision-548453,548453
120104,341619,VRTX,Proteostasis advances cystic fibrosis pipeline  shares ahead 59  premarket,news,Thinly traded nano cap Proteostasis Therapeutics  NYSE PTI  is up 59  premarket on light volume in response to its announcement of positive results across its three cystic fibrosis  CF  pipeline programs A Phase 2 study assessing 50 mg of lead candidate PTI 428 once daily for 28 days in CF patients on a background of Vertex Pharmaceuticals   NASDAQ VRTX  ORKAMBI  lumacaftor ivacaftor  showed average absolute improvements in lung function  ppFEV1  of 5 2  from baseline compared to placebo  p 0 05  and average relative improvements of 9 2   p 0 05   The treatment effect was achieved by day 14 and maintained through day 28 PTI 428  a CFTR amplifier  was safe and well tolerated with no clinically meaningful interaction with lumacaftor ivacaftor  There were two discontinuations  both mild grade thrombocytopenia  one on ORKAMBI alone and one on PTI 428  Both resolved spontaneously Initial data from a 14 day study of 100 mg of PTI 801 once daily in four CF patients on background ORKAMBI showed a similar pharmacokinetic profile to healthy volunteers  There were no clinically meaningful drug drug interactions with lumacaftor or ivacaftor  Average absolute improvements in lung function  ppFEV1  were  4  from baseline while average relative improvements were  7  after two weeks of dosing  Enrollment of 20 patients should be completed next quarter  PTI 801 is a CFTR corrector A study of PTI 808  a CFTR potentiator  in 48 healthy volunteers showed favorable safety and pharmacokinetic profiles Co administration of PTI 428  PTI 808 and PTI 801 in 20 healthy volunteers has been completed  The safety profile was favorable and supports potential once daily dosing Now read ,2017-12-12,Seeking Alpha,https://www.investing.com/news/stock-market-news/proteostasis-advances-cystic-fibrosis-pipeline-shares-ahead-59-premarket-981405,981405
120105,341620,VRTX,Premarket analyst action   healthcare,news,Charles River Laboratories  NYSE CRL  initiated with Buy rating and  120  14  upside  price target by Argus Research Catalent  NYSE CTLT  initiated with Outperform rating and  46  15  upside  price target by RBC Capital Markets MEDNAX  NYSE MD  initiated with Overweight rating and  58  12  upside  price target by Piper Jaffray Envision Healthcare  NYSE EVHC  initiated with Neutral rating and  35  5  upside  price target by Piper Jaffray Intercept Pharmaceuticals  NASDAQ ICPT  and Vertex Pharmaceuticals  NASDAQ VRTX  initiated with Strong Buy ratings by  Deutsche Bank   DE DBKGn  Audentes Therapeutics  NASDAQ BOLD  resumed with Overweight rating and  36  31  upside  price target by Piper Jaffray DENTSPLY SIRONA  NASDAQ XRAY  upgraded to Overweight by JPMorgan  NYSE JPM  Bluebird bio  NASDAQ BLUE  downgraded to Hold with a  200  5  upside  price target by Maxim Group Accelerate Diagnostics  NASDAQ AXDX  downgraded to Neutral by BTIG Research  Genomic Health   NASDAQ GHDX  downgraded to Underweight with a  25  17  downside risk  by JPMorgan citing soft U S  invasive breast cancer market and slower than expected reimbursement rate Accuray  NASDAQ ARAY  downgraded to Underweight by JPMorgan citing lack of consistency in quarterly earnings  competitive pressures and execution issues   8 price target removed  Shares down 6  premarket on light volume Now read ,2017-12-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-986843,986843
120128,341643,VRTX,UBS bucks the Vertex upgrade bandwagon  downgrades to Neutral with  174 price target,news,UBS shuns the scrum of giddy sell side shops who upgraded Vertex Pharmaceuticals  VRTX  22 3   after it reported positive results on its triplet therapy for cystic fibrosis  CF  Analyst Carter Gould raised his price target on the stock to  174  7  upside  from  135  but downgraded it to Neutral saying CF is nearing full valuation  He adds that the company s CF franchise could hit  8B in sales by the end of 2020  translating into  160 share  HIs  174 target includes the pipeline  platform and cash EPS estimates for 2017 and 2018 are  1 75 and  3 61  respectively Now read ,2017-07-19,Seeking Alpha,"https://www.investing.com/news/stock-market-news/ubs-bucks-the-vertex-upgrade-bandwagon,-downgrades-to-neutral-with-$174-price-target-507373",507373
120129,341644,VRTX,S P  Nasdaq at records as Vertex rallies  IBM slips,news,"NEW YORK  Reuters    The Nasdaq Composite and the S P 500 hit record highs on Wednesday  powered by technology stocks and a more than 20 percent jump in Vertex Pharmaceuticals  NASDAQ VRTX   while gains on the Dow were capped by a sharp drop in  IBM   NYSE IBM  shares 
The Dow Jones Industrial Average  DJI  rose 66 02 points  or 0 31 percent  to 21 640 75  the S P 500  SPX  gained 13 22 points  or 0 54 percent  to 2 473 83 and the Nasdaq Composite  IXIC  added 40 74 points  or 0 64 percent  to 6 385 04 

The S P 500 tech sector  SPLRCT  set a record closing high  breaking the previous one which held since March 2000 ",2017-07-19,Reuters,"https://www.investing.com/news/stock-market-news/tech-stocks-lift-nasdaq-futures;-dow,-s-amp;p-flat-507210",507210
120130,341645,VRTX,Vertex Pharma raises Kalydeco sales guidance after FDA OKs expanded use,news,The FDA approves the use of Vertex Pharmaceuticals   NASDAQ VRTX  KALYDECO  ivacaftor  for use in more than 600 people at least two years old with cystic fibrosis who have one of five residual function mutations that result in a splicing defect in CFTR gene  The FDA OK d the use of KALYDECO in CF patients with 23 other function mutations in May KALYDECO is now approved to treat CF patients at least two years old who have one of 38 ivacaftor responsive CFTR mutations The company raises its 2017 sales guidance for KALYDECO to  770M   800M and its sales outlook for all CF products to  1 87B   2 1B  including  1 1B   1 3B for ORKAMBI VRTX is up 1  premarket  but only on 60 shares Now read ,2017-08-01,Seeking Alpha,https://www.investing.com/news/stock-market-news/vertex-pharma-raises-kalydeco-sales-guidance-after-fda-oks-expanded-use-512863,512863
120133,341648,VRTX,Biotechs lead the charge  IBB up 2 7 ,news,Biotechs continue to show strength  leading the market again  Gilead s recent  11 9B takeout of Kite Pharma appears to be a major spark igniting buying  The iShares Nasdaq Biotechnology ETF is up over 9  since last Monday Selected tickers   IBB  2 7   XBI  3 1   FBT  2 5   BBH  2 3   GILD  2 1   AMGN  1 9   BIIB  3 3   VRTX  2   CELG  3 2   JUNO  6 1   NTLA  10 1   EDIT  1 5  Now read ,2017-08-31,Seeking Alpha,https://www.investing.com/news/stock-market-news/biotechs-lead-the-charge-ibb-up-27-524426,524426
120134,341649,VRTX,CRISPR Therapeutics Enters New License Agreement  Shares Up,opinion,"CRISPR Therapeutics AG   NASDAQ CRSP   and privately held KSQ Therapeutics entered into a license agreement to gain mutual access to intellectual property  IP  related to editing certain novel gene targets developed individually by them  The financial details have not been disclosed by the companies The deal will give CRISPR Therapeutics rights to access KSQ Therapeutics  intellectual property related to editing of certain novel gene targets in KSQ Therapeutics  allogeneic oncology cell therapy programs  The company is likely to use KSQ Therapeutics  IP to strengthen its CAR T development platform  CRISPR Therapeutics is currently developing two CAR T therapy candidates  CTX110 and CTX120  for treating CD19  malignancies and multiple myeloma  respectively KSQ Therapeutics is a clinical stage biotech formed in 2015  which is using CRISPR technology to increase the chances of successful drug discovery  This agreement will allow the private biotech to access CRISPR Therapeutics  IP related to editing of novel gene targets identified by KSQ Therapeutics as part of its eTILcell programs Shares of CRISPR Therapeutics were up almost 3 5  on Oct 15  following the announcement  The company s shares have increased 32 9  so far this year against the  s decrease of 6 4  CRISPR Therapeutics has been focusing on diversifying its pipeline into additional indications   We note that the company expanded its collaboration agreement in June with its major partner  Vertex Pharmaceuticals   NASDAQ VRTX   to include new disease areas  With the expansion of the agreement  CRISPR Therapeutics will gain rights to any therapies developed using its technology for Duchenne muscular dystrophy  Myotonic dystrophy type 1  cystic fibrosis  sickle cell disease and beta thalassemia Apart from the Vertex collaboration  CRSIPR also has a joint venture with Bayer  DE BAYGN  AG   OTC BAYRY   for developing new therapies using its gene editing technology to cure blood disorders  blindness and congenital heart disease Other than CRISPR Therapeutics  Intellia Therapeutics and Editas Medicine  Inc   NASDAQ EDIT   plan to carry out clinical studies using CRISPR Cas9 to cure diseases CRISPR Therapeutics AG Price
    Zacks RankCRISPR Therapeutics currently carries a Zacks Rank  3  Hold   You can see  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ",2019-10-15,Zacks Investment Research,https://www.investing.com/analysis/crispr-therapeutics-enters-new-license-agreement-shares-up-200474139,200474139
120136,341651,VRTX,Top Research Reports For Southern  Applied Materials   Vertex,opinion,"Wednesday  October 16  2019
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Southern Company  NYSE SO   SO   Applied Materials  NASDAQ AMAT   AMAT  and Vertex Pharmaceuticals  NASDAQ VRTX   VRTX   These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
You can see 
Southern s shares have outperformed the Zacks Electric Power industry year to date  38 2  vs  18 3    The Zacks analyst believes that leveraging the demographics of its operating territories  as in healthy population and job growth  the firm has gradually increased its customer base 
With good rate base growth and constructive regulation  Southern Company is expected to generate steady earnings and dividend growth in the coming years  However  elevated leverage of the firm  along with continued timing and cost overrun issues over its Vogtle project  are the major overhangs 
While the electric utility holding company s debt to capital ratio of 56  restricts financial flexibility  its  25 billion Vogtle nuclear plant has already exceeded budget and is years behind schedule  As such  Southern Company warrants a cautious stance from its investors 
 You can  
Shares of Applied Materials have gained 20 6  in the past six months compared with the Zacks Semiconductor Equipment   Wafer Fabrication industry s rise of 27 6   The Zacks analyst thinks that Applied Materials is benefiting from rising need for specialty nodes in IoT  communications  automotive  power and image sensor applications  This is leading to increased customer spending in foundry and logic 
Further  the company is witnessing solid momentum across the United States and Taiwan which is a major positive  Additionally  strengthening momentum in conductor etch is aiding Applied Materials in gaining traction in DRAM and NAND  The company remains optimistic about the price elasticity of NAND  which is expected to bolster NAND customer spending in the near term 
However  market uncertainties remain headwinds  Softness in semiconductor and display markets on account of a slowdown in memory and display customers  spending is a major concern 
 You can  
Vertex s shares have lost 0 6  over the past three months compared with the Zacks Biomedical and Genetics industry s decline of 4 7   The Zacks analyst believes that Vertex s third cystic fibrosis  CF  medicine  Symdeko  in a very short time  has become the main driver of its CF revenues 
Vertex rapidly advanced its triple combination CF regimen through late stage development and regulatory filings  The regimen is crucial for long term growth as it has the potential to treat up to 90  of CF patients  Meanwhile  Vertex s non CF pipeline  though early stage  looks interesting with several pipeline readouts expected in 2020 21 
However  competitive pressure is rising in the CF market with many other companies developing triple combo CF drugs  Also  Vertex s dependence on just the CF franchise for growth is a concern  Shares have outperformed the industry this year so far  Estimates have gone up slightly ahead of Q3 earnings  Vertex has a positive record of earnings surprises in the recent quarters 
 You can  
Other noteworthy reports we are featuring today include BHP Group  BHP   NVIDIA  NVDA  and Edwards Lifesciences  EW  
Free  Zacks  Single Best Stock Set to Double
Today you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all 
This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain 

Mark VickerySenior Editor
Note  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read
Southern  SO  Buoyed by Customer Growth  Vogtle Costs Hurt


Applied Materials  AMAT  Rides on Logic Spending  Risk Remain


Vertex s  VRTX  Triple Combo Cystic Fibrosis Pill Advances


Featured Reports
NVIDIA  NVDA  Gets a Boost From Gaming Business Recovery
Per the Zacks analyst  NVIDIA is benefiting from the rising traction of GeForce laptops and RTX GPUs in the gaming market 

Edwards  EW  Rides on Solid THV Sales and Global Prospects
The Zacks analyst is bullish about Edwards  strong THV sales in the domestic and global markets 

V F  Corp  VFC  to Gain from Solid Direct to Consumer Sales
Per the Zacks analyst  V F  Corp is gaining from its direct to consumer business that grew 14  in first quarter fiscal 2020 

Solid Pension Risk Transfer Business Aids Prudential  LON PRU 
Per the Zacks analyst  Prudential is set to grow on solid pension risk transfer business  momentum in U S  Financial Wellness and international operations 

Organic Growth   Extensive Global Presence Aid Eaton  NYSE ETN 
Per the Zacks analyst Eaton s steady improvement in end market condition has resulted in organic growth 

Hewlett Packard  HPE  Benefits From Spurt in Aruba Services
Per the Zacks analyst  a strong uptick in Aruba Services is driving Hewlett Packard s Intelligent Edge segment 

Strategic Initiatives Aid Centene  NYSE CNC   High Costs Hurt
Per the Zacks analyst  a number of acquisitions such as that of Fidelis Care and MHM Services poise the company well for growth  

New Upgrades
Chipotle s  CMG  Sales Building Efforts to Drive Growth
Per the Zacks analyst  Chipotle s increased focus on food safety and enhancing customer experience  along with various sales building and strategic initiatives bode well 

Core Health Care Products Unit Aids Fresenius Medical  FMS 
Fresenius Medical has been gaining consistently from its core Health Care Products segment  The Zacks Analyst is also optimistic about a strong view for 2019 and 2020 

Agnico Eagle  AEM  to Gain from Actions to Boost Production
The Zacks analyst is impressed by Agnico Eagle s efforts to boost its production profile and also believes that it will gain from good progress at its major growth projects 

New Downgrades
Higher Unit Costs   Low Metal Prices to Hurt BHP Group  BHP 
The Zacks Analyst is concerned lower metal prices due to the prolonged trade war and higher unit costs due to natural field decline at petroleum and lower copper grades will impact BHP s results 

Wynn Resorts  NASDAQ WYNN  Grapples With High Debt Burden 
Per the Zacks analyst  high debt burden makes it difficult for Wynn Resorts to finance its upcoming projects 

Plunging Natural Gas Prices to Weigh on Cabot  COG 
The Zacks analyst is concerned that the weak natural gas prices will restrict Cabot s cash flow generation considering the company s 100  gas weighted production 
undefined undefined",2019-10-16,Zacks Investment Research,https://www.investing.com/analysis/top-research-reports-for-southern-applied-materials--vertex-200474215,200474215
120137,341652,VRTX,The Zacks Analyst Blog Highlights  Southern Company  Applied Materials  Vertex Pharmaceuticals  NVIDIA And Edwards Lifesciences,opinion,For Immediate ReleaseChicago  IL   October 17  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Southern Company   NYSE SO    Applied Materials   NASDAQ AMAT    Vertex Pharmaceuticals   NASDAQ VRTX    NVIDIA   NASDAQ NVDA   and Edwards Lifesciences  NYSE EW  Here are highlights from Wednesday s Analyst Blog  Top Research Reports for Southern Co   Applied Materials and VertexThe Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Southern Company  Applied Materials and Vertex Pharmaceuticals  These research reports have been hand picked from the roughly 70 reports published by our analyst team today You can see all of today s research reports here    Southern s shares have outperformed the Zacks Electric Power industry year to date  38 2  vs  18 3    The Zacks analyst believes that leveraging the demographics of its operating territories  as in healthy population and job growth  the firm has gradually increased its customer base With good rate base growth and constructive regulation  Southern Company is expected to generate steady earnings and dividend growth in the coming years  However  elevated leverage of the firm  along with continued timing and cost overrun issues over its Vogtle project  are the major overhangs While the electric utility holding company s debt to capital ratio of 56  restricts financial flexibility  its  25 billion Vogtle nuclear plant has already exceeded budget and is years behind schedule  As such  Southern Company warrants a cautious stance from its investors Shares of Applied Materials have gained 20 6  in the past six months compared with the Zacks Semiconductor Equipment   Wafer Fabrication industry s rise of 27 6   The Zacks analyst thinks that Applied Materials is benefiting from rising need for specialty nodes in IoT  communications  automotive  power and image sensor applications  This is leading to increased customer spending in foundry and logic Further  the company is witnessing solid momentum across the United States and Taiwan which is a major positive  Additionally  strengthening momentum in conductor etch is aiding Applied Materials in gaining traction in DRAM and NAND  The company remains optimistic about the price elasticity of NAND  which is expected to bolster NAND customer spending in the near term However  market uncertainties remain headwinds  Softness in semiconductor and display markets on account of a slowdown in memory and display customers  spending is a major concern Vertex s shares have lost 0 6  over the past three months compared with the Zacks Biomedical and Genetics industry s decline of 4 7   The Zacks analyst believes that Vertex s third cystic fibrosis  CF  medicine  Symdeko  in a very short time  has become the main driver of its CF revenues Vertex rapidly advanced its triple combination CF regimen through late stage development and regulatory filings  The regimen is crucial for long term growth as it has the potential to treat up to 90  of CF patients  Meanwhile  Vertex s non CF pipeline  though early stage  looks interesting with several pipeline readouts expected in 2020 21 However  competitive pressure is rising in the CF market with many other companies developing triple combo CF drugs  Also  Vertex s dependence on just the CF franchise for growth is a concern  Shares have outperformed the industry this year so far  Estimates have gone up slightly ahead of Q3 earnings  Vertex has a positive record of earnings surprises in the recent quarters Other noteworthy reports we are featuring today include NVIDIA and Edwards Lifesciences Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain Download Free Report Now   Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-10-16,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-southern-company-applied-materials-vertex-pharmaceuticals-nvidia-and-edwards-lifesciences-200474748,200474748
120138,341653,VRTX,Will New Alliances Aid Quest Diagnostics  DGX  Q3 Earnings ,opinion,"Quest Diagnostics Incorporated   NYSE DGX   is scheduled to report third quarter 2019 earnings on Oct 22  before the opening bell 
The Zacks Consensus Estimate for third quarter earnings of  1 72 implies a 2 38  rise from the year ago reported figure In the last reported quarter  the company s earnings exceeded the Zacks Consensus Estimate by 2 37   the average trailing four quarter positive surprise being 1 33  Let s take a look at how things are shaping up prior to this announcement Factors Likely to Influence Third Quarter ResultsQuest Diagnostics seems well aligned with its two pronged agenda to accelerate growth and drive operational excellence  Per the company  its frequently growing partnerships with other health care leaders and prudent buyouts are creating promising opportunities for the top and the bottom line while at the same time  the patient experience is improved and the overall cost of care  reduced As an evidence  the company satisfied all the five elements of its growth acceleration strategy through the last few quarters  Therefore  we strongly expect this momentum to most likely reflect on the upcoming quarterly results Quest Diagnostics Incorporated Price and EPS Surprise   Going by the first element of its growth strategy  to further strengthen the top line by 2  via strategically accretive acquisitions  so far in 2019  the company completed the purchase of a clinical laboratory services business of Boyce and Bynum  a provider of diagnostic and clinical laboratory services in the Midwest  We expect to see this transaction leave a positive impact on the to be reported results Considering the second element of Quest Diagnostics  key growth plans  which is to expand relationships with hospital health systems  it is executing this strategy quite successfully  The company s top line number is expected to reflect the impact of its recent partnerships with Catholic Health Services  CHS   an integrated health care delivery system  and hc1  a bioinformatics player in precision testing  in the impending quarterly release With respect to the third element of offering its diagnostic innovation a wider access  the company has been witnessing growth in prescription drug monitoring  QuantiFERON  tuberculosis test  T SPOT  Cardio IQ and mutual testing  Per the company  the recently inked consolidation deals are predicted to upgrade its capabilities in advanced diagnostics  especially in the areas of Women s Health and Infectious Disease  These new developments are expected to have contributed to the company s third quarter top line About the fourth element of the company s growth strategy  which is to provide ample choices to consumers  the company s relationship with Walmart  NYSE WMT  has already started adding value to this end with higher patient traffic  Moreover  the company s alliance with Safeway currently has more than 200 patient service centers across its retail store locations  This positive aspect is likely to reflect on the third quarter earnings performance of Quest Diagnostics The fifth element of Quest Diagnostics  growth policies indicates its support to population health within analytics and extended care services  In this regard  the company recently launched Quest Clinical Trial Connect  a patient recruitment service Apart from these five elements  in terms of Quest Diagnostics  efforts to ramp up its operating efficiency  it endeavors to scale up productivity  This  in turn  enabled the company to effectively manage headcount growth We expect these key active catalysts to replicate the company s success story in its impending quarterly results  Also  a better than expected performance is likely to perk up the same primary metrics in the third quarter alike the preceding ones We strongly believe that all these recent developments might have significantly favored the company s top line in the third quarter On the flip side  Quest Diagnostics is suffering a significant PAMA driven reimbursement pressure that remains a major headwind to structural changes in the marketplace  In the first half of 2019  Medicare rates were down by 10  from the prior year  This is expected to affect the company s business through the second half as well  In fact  this should get reflected in third quarter results only The Zacks Consensus Estimate for third quarter earnings of  1 72 implies a 2 38  rise from the year ago reported figure What Our Model SuggestsThe proven Zacks does not conclusively predict an earnings beat for Quest Diagnostics this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of beating estimates  But that s not the case here  You can uncover the best stocks to buy or sell before they re reported with our  Quest Diagnostics has a Zacks Rank  4  Sell  and an Earnings ESP of  0 51  Stocks Worth a LookHere are a few medical stocks worth considering from the same space with the right mix of elements to surpass expectations this time around Akcea Therapeutics  Inc    NASDAQ AKCA   has an Earnings ESP of  18 18  and a Zacks Rank  2  You can see  Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   has an Earnings ESP of  1 97  and a Zacks Rank of 1 DENTSPLY SIRONA Inc    NASDAQ XRAY   has an Earnings ESP of  5 50  and a Zacks Rank  3 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 50  per year  So be sure to give these hand picked 7 your immediate attention ",2019-10-17,Zacks Investment Research,https://www.investing.com/analysis/will-new-alliances-aid-quest-diagnostics-dgx-q3-earnings-200474809,200474809
120139,341654,VRTX,What s In Store For Edwards Lifesciences   EW  Q3 Earnings ,opinion,"Edwards Lifesciences Corporation   NYSE EW   is slated to report third quarter 2019 results on Oct 23  after market close  The company delivered positive earnings surprises in the trailing four quarters  the average beat being 4 3  Let s see how things are shaping up prior to this announcement Which Way Are Estimates Treading For the third quarter  the Zacks Consensus Estimate for earnings per share stands at  1 22  suggesting a year over year rise of 14 02   The same for revenues is pinned at  1 04 billion  indicating year over year growth of 14 4  Key CatalystsCritical CareThe third quarter results are expected to reflect strength in core the Critical Care product group  The segment has been showing solid growth in all product categories over the past few quarters In fact  the Zacks Consensus Estimate for the segment s third quarter revenues is pegged at  179 million  calling for year over year growth of 9 14  Management is optimistic about robust customer adoption of the HemoSphere all in one monitoring platform  particularly in the United States and Europe  As the company had stated earlier  demand for the platform is expected to drive the Critical Care group throughout 2019  The full market launch of the platform with the FloTrac System and Acumen Hypotension Predictive Index earlier this year is likely to show on the company s third quarter results Edwards Lifesciences Corporation Price and EPS Surprise   We are also upbeat about the company s recently completed acquisition of CASMED  a non invasive cerebral oximetry monitoring technology company  The integration of this technology into Edwards Lifesciences  leading hemodynamic monitoring platform is expected to strengthen the company s position in the smart monitoring technology market  This in turn has likely contributed to the company s top line during the third quarter For 2019  the company expects underlying sales growth in Critical Care of 8  to 10  on momentum from the recent HemoSphere launch  We assume this segment has started driving growth for the company from the third quarter Surgical Structural HeartWithin the Surgical Structural Heart Group  the company is gaining on solid aortic unit volume and continued adoption of its latest premium aortic valves  Strong rollout and steady adoption of the INSPIRIS RESILIA aortic valve across the globe are expected to have strongly contributed to the third quarter top line Edwards Lifesciences expects 2019 underlying sales growth within this segment at the range of 1  to 3   We assume this segment has started driving growth for the company from the third quarter The Zacks Consensus Estimate for the segment s third quarter revenues is pegged at  195 million  suggesting a year over year growth of 5 4  Other Factors at PlayWithin the Transcatheter Aortic Valve Replacement  TAVR  arm  the recent market launches of the SAPIEN 3 Ultra in Europe are expected to have contributed to third quarter revenues  Mid teens growth in the total number of TAVR procedures outside the United States is likely to have driven growth as well The latest European regulatory approval and continued rollout of PASCAL transcatheter valve repair system  a crucial addition to the Transcather Mitral and Tricuspid Therapies portfolio  is likely to reflect in third quarter results The company s international sales for the third quarter are expected to show growth on continued adoption of TAVR procedures in Japan  driven by SAPIEN 3 The Zacks Consensus Estimate for third quarter international net sales is pinned at  437 million  suggesting a rise of 12 6  year over year What Our Model SuggestsOur proven model predicts an earnings beat for Edwards Lifesciences this time around  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the chances of an earnings beat  You can uncover the best stocks to buy or sell before they re reported with our  Edwards Lifesciences has a Zacks Rank  3 and an Earnings ESP of  0 35   You can see  Other Stocks Worth a LookHere are a few other medical stocks worth considering from the same space with the right mix of elements to surpass expectations this earnings season Akcea Therapeutics   NASDAQ AKCA   has an Earnings ESP of  18 18  and a Zacks Rank of 2 Vertex Pharmaceuticals   NASDAQ VRTX   has an Earnings ESP of  1 97  and a Zacks Rank  1 
DENTSPLY SIRONA   NASDAQ XRAY   has an Earnings ESP of  5 50  and a Zacks Rank of 3 7 Best Stocks for the Next 30 Days Just released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 50  per year  So be sure to give these hand picked 7 your immediate attention ",2019-10-17,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-edwards-lifesciences-ew-q3-earnings-200474422,200474422
120140,341655,VRTX,What s In Store For IDEXX Laboratories   IDXX  Q3 Earnings ,opinion,"IDEXX Laboratories  Inc    NASDAQ IDXX   is slated to report third quarter 2019 results on Oct 31  before market open  In the last reported quarter  the company delivered a positive earnings surprise of 4 38   IDEXX s earnings beat the Zacks Consensus Estimate in the last four quarters  the average positive surprise being 8 23  Let s take a look at how things are shaping up prior to this announcement Key CatalystsIDEXX s strong earnings trajectory is expected to have continued through the third quarter  courtesy of a global surge in Companion Animal Group  CAG  Diagnostics revenues Of late  the company has been registering solid organic revenues in this segment on gains from consumable and reference lab as well as the growing acceptance of Rapid Assays  and Veterinary Software  Services and Diagnostic Imaging Systems In the United States  IDEXX has been generating strong CAG Diagnostic recurring revenues  led by steady growth in reference lab  consumables and rapid assay sales  Growth in the Veterinary Software portfolio can be attributed to strength in the global catalyst install base of Cornerstone  Neo and Animana systems  These trends are expected to have continued in the to be reported quarter IDEXX Laboratories  Inc  Price and EPS Surprise
    International reference laboratory services are likely to have seen a robust third quarter  courtesy of the company s efforts to advance commercial measures while maintaining momentum in international markets  catalyst install bases The Zacks Consensus Estimate of  527 million for CAG Diagnostics revenues suggests a 10 3  improvement from the year ago quarter s reported figure The company expects organic growth of 11 12  for 2019 CAG Diagnostic recurring revenues  We assume that this segment has started contributing to the company s top line from the third quarter Other FactorsAdditionally  the Water Business  of late  is gaining traction from encouraging test results in the United States and the global go direct initiatives  The business witnessed 10  organic growth in the last reported quarter  driven by mid single digit growth in the United States  and considerable growth in Asia and Latin America  This trend most likely continued in the third quarter The consensus mark for Water business revenues stands at  35 6 million for the to be reported quarter  implying a 7 6  increase from the year earlier reported number Strong organic revenue growth in the Livestock  Poultry and Dairy  LPD  segment is likely to show on the company s third quarter results  led by gains in herd health screening  poultry and pregnancy products sales On the flip side  increased pressure on China LPD revenues in the last reported quarter  due to the African swine fever outbreak and Brexit  is likely to have adversely impacted the company s top line during the to be reported quarter The Zacks Consensus Estimate for third quarter 2019 revenues is pegged at  597 4 million  indicating a 9 5  rise from the prior year quarter s reported figure Earnings WhispersOur proven model does not conclusively predict an earnings beat for IDEXX this time around  The combination of a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  But this is not the case here as you will see below Earnings ESP   IDEXX has an Earnings ESP of 0 00   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  The stock carries a Zacks Rank  3 Stocks Worth a LookHere are a few medical stocks worth considering from the same space with the right combination to surpass expectations this earnings season Alexion Pharmaceuticals  Inc   NASDAQ ALXN   has an Earnings ESP of  1 22  and a Zacks Rank  3  You can see  Vertex Pharmaceuticals   NASDAQ VRTX   has an Earnings ESP of  2 24  and a Zacks Rank  1 DENTSPLY SIRONA   NASDAQ XRAY   has an Earnings ESP of  5 05  and a Zacks Rank of 3 7 Best Stocks for the Next 30 Days Just released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 50  per year  So be sure to give these hand picked 7 your immediate attention ",2019-10-21,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-idexx-laboratories-idxx-q3-earnings-200476212,200476212
120165,341680,VRTX,Biotechs break through recent downtrend  IBB up 1 ,news,Beaten up biotechs are finally showing strength  The iShares Nasdaq Biotech ETF  IBB  1 1   has rebounded 3 5  over the past three sessions since bottoming at 283 70 on Tuesday  breaking out of the downtrend that started in early May Selected tickers   REGN  3 1   CELG  1 1   GILD  0 8   AMGN  1 5   BIIB  0 9   VRTX  1 6   ILMN  0 5   ALXN  0 9  Now read ,2017-06-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/biotechs-break-through-recent-downtrend;-ibb-up-1-491292,491292
120166,341681,VRTX,Eaton Vance fund managers see major upside for healthcare stocks  Barron s,news," Reuters    The portfolio managers of the  1 2 billion Eaton Vance Worldwide Health Sciences fund are expecting big gains from a trio of healthcare stocks 
Jason Kritzer and Samantha Pandolfi  co managers of the fund  highlighted Vertex Pharmaceuticals  O VRTX   Zoetis  N ZTS  and  Shire   L SHP  for future outperformance in an article in Barron s 
Kritzer said he expects to see Vertex increase its revenue by at least 20 percent in 2017 and 30 percent in 2018  with per share profit potentially doubling this year and again next year  He sees the stock price rising to  between  152 and  155  
Vertex closed at  130 99 on Friday 
Pandolfi says she sees 15 percent upside for drugmaker Zoetis and 40 percent upside for Dublin based drugmaker Shire She said Shire s stock price has been held back by investor concerns the company is losing ground to other manufacturers of hemophilia drugs  which Shire relies on for a large portion of its annual revenue 
 If the hemophilia fears persist  it could take two to three years to deliver those returns   she said   If the fears abate  it will happen sooner  
The pair said that the pharmaceutical and biotechnology industries have been proactive in the face of uncertainty surrounding the possible repeal of the Affordable Care Act  noting also that  The leaked draft executive order on drug pricing reads favorably for industries  With repeal and replace  of the Affordable Care Act   depending on how things shake out  hospitals are the big losers long term  due to cuts in Medicaid  ",2017-07-16,Reuters,https://www.investing.com/news/stock-market-news/eaton-vance-fund-managers-see-major-upside-for-healthcare-stocks:-barron's-506116,506116
120167,341682,VRTX,Stifel bullish on Vertex ahead of triple combo CF data  sees 19  upside,news,Anticipating positive data from Vertex Pharmaceuticals   VRTX  0 2   Phase 2 clinical trial assessing a triple combo approach to cystic fibrosis  Stifel Nicolaus raises its price target to  154 from  130 Stifel says physician uptake will be strong in the large het min CF population even if the combination of tezacaftor  ivacaftor  KALYDECO  and VX 152 performs on par with Orkambi  lumacaftor ivacaftor  since there is no approved therapy for this group of patients The study completion date is October Source  Briefing com Now read ,2017-07-18,Seeking Alpha,"https://www.investing.com/news/stock-market-news/stifel-bullish-on-vertex-ahead-of-triple-combo-cf-data,-sees-19-upside-506844",506844
120168,341683,VRTX,Vertex Pharma s gain is Galapagos  pain  down 6  premarket,news,Galapagos NV  NASDAQ GLPG  is under modest pressure premarket  down 6  on increased volume on the heels of promising results from Vertex Pharmaceuticals   NASDAQ VRTX  triple combination regimen in cystic fibrosis  CF  Galapagos is also betting big in CF with triple combo regimens  GLPG3067  2222  2737 and  3067  2222   3221  in early stage development Previously  Vertex Pharma s triple combo regimens show positive effect in treatment resistant CF patients  shares ahead 24  after hours  July 18 Now read ,2017-07-19,Seeking Alpha,"https://www.investing.com/news/stock-market-news/vertex-pharma's-gain-is-galapagos'-pain,-down-6-premarket-507290",507290
120169,341684,VRTX,Premarket Gainers as of 9 05 am,news,AEZS  46  on FDA accepting Aeterna s resubmitted marketing application for Macrilen VRTX  26  on sell side updates on the announcement of positive results from studies assessing its triple combo regimens for the treatment of certain cystic fibrosis patients MYSZ  22  SNI  14  on potential merger talks with Discovery Communications  NASDAQ DISCA  XGTI  13  DISCA  7  on potential merger talks with Scripps Network Interactive  NYSE SNI  NVAX  6  Now read ,2017-07-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-gainers-as-of-9:05-am-507278,507278
120170,341685,VRTX,Vertex Pharma shares hit life high as cystic fibrosis data wows,news," Reuters    Shares of Vertex Pharmaceuticals Inc  O VRTX  soared to touch a record high on Wednesday  a day after the drugmaker revealed data on its triple combinations of cystic fibrosis  CF  treatments that wowed both analysts and investors 
Vertex s shares climbed 26 percent to  165 97  adding nearly  8 billion to its market valuation  They had earlier touched a life high of  167 00 
Analysts said the data exceeded expectations  raised the bar for competitors and positioned the treatments to help up to 90 percent of patients with the life shortening lung disease 
Vertex already sells two therapies that can treat up to 40 percent of CF patients  Kalydeco and Orkambi brought in sales of  481 million in the first quarter 
 Not only does this data set up well to reach a large majority of the CF patient population  it greatly increases the competitive hurdle while also enhancing the scarcity value of the company   J P  Morgan analyst Cory Kasimov said in a note 
The data on Tuesday showed three different triple combinations of CF treatments significantly improving patient lung function in clinical trials   nL1N1K91UW 
CF is a rare  life shortening genetic disease affecting about 75 000 people in North America  Europe and Australia that causes progressive lung damage and loss of lung function 
 The triple combo results came in an order of magnitude better than we  or really anyone  expected   Baird analyst Brian Skorney noted 
At least three brokerages raised their ratings on Vertex s stock   Barclays   LON BARC  to  overweight   Janney to  buy  and Raymond James to  outperform  
Analysts are bullish on the stock with 21 out of 25 covering Vertex rating it  buy  or higher and the rest  hold  
Eight brokerages increased their price target on Vertex  The drugmaker s median price target is  180  up from  129 50 in June 
Shares of  Galapagos  NV  AS GLPG   which is developing a rival CF treatment with  AbbVie Inc   N ABBV   slipped about 4 5 percent 
 Galapagos AbbVie s planned path to the triple combo is not impossible  but faces a much higher hurdle as compared with Vertex s triple combo strategy   William Blair analyst Katherine Xu said in a note 
Including Wednesday s gain  Vertex shares have more than doubled this year ",2017-07-19,Reuters,https://www.investing.com/news/stock-market-news/vertex-pharma-shares-hit-life-high-as-cystic-fibrosis-data-wows-507307,507307
120171,341686,VRTX,Healthcare   Top 5 Gainers   Losers as of 11 00 am,news,Gainers  AEZS  84   VRTX  22   AVEO  13   AGRX  9   CFRX  7  Losers  CYCC  40   EKSO  18   LAKE  9   CAPR  8   SBBP  7  Now read ,2017-07-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/healthcare---top-5-gainers---losers-as-of-11:00-am-507359,507359
120176,341691,VRTX,Vertex Gains Reimbursement For Orkambi   Symkevi In Scotland,opinion,Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   announced that it has received a reimbursement approval in Scotland for its cystic fibrosis  CF  medicines Orkambi and Symkevi  Following this  approximately 400 eligible CF patients in Scotland will now get access to both these drugs for their immediate treatment Vertex s CF medicines are reimbursed in 17 countries across the world  However  the company has faced some challenges with respect to commercialization of Orkambi in the ex U S  markets due to re imbursement hurdles Though Vertex has reached reimbursement agreements for Orkambi in several European countries including Germany  Ireland  Netherlands  Sweden  Italy  Denmark and now Scotland  its negotiations continue with several other countries on the Continent that represent significant potential markets including the United Kingdom and France  The company has generated limited revenues from Orkambi in these countries due to the ongoing pricing discussions on Orkambi s reimbursement rate Shares of Vertex have increased 4 1  so far this year against the decrease of 1 3  We would like to remind investors that Vertex s three CF medicines  namely Kalydeco  Orkambi and Symdeko  known as Symkevi in Europe  are collectively approved for treating a good number of CF patients in North America  Europe and Australia  Total CF product revenues in the first half of 2019 were around  1 8 billion  reflecting a rise of 28 6  year over year Vertex s newest CF medicine Symdeko has become the main driver of CF revenues within a short span  Approval of Kalydeco and Orkambi for new patient populations is also driving sales growth Symdeko  Symkevi generated sales of  682 million in the first half of 2019  reflecting a massive surge of more than 200  year over year  Symdeko s uptake is being driven by new patient starts as well as shifts from Orkambi and Kalydeco Meanwhile  last month  the FDA accepted and granted a priority review to Vertex s new drug application  NDA  for its triple combination regimen comprising VX 445  elexacaftor   tezacaftor and ivacaftor to treat CF patients aged 12 years and above  The regulatory body has set an action date of Mar 19  2020 If approved  the triple combination regimen will help Vertex address a significantly larger CF patient population  almost 90  of patients with CF  in the future Even though Vertex enjoys a strong position in the CF market  it is likely to face a tough competition from several companies like AbbVie   NYSE ABBV    Eloxx Pharmaceuticals  ProQR Therapeutics   NASDAQ PRQR   and Proteostasis Therapeutics  which are also developing medicines to treat CF Zacks Rank   Another Key PickVertex currently has a Zacks Rank  2  Buy   Another top ranked stock in the healthcare sector is Amgen Inc    NASDAQ AMGN    which sports a Zacks Rank  1  Strong Buy   You can see  Amgen s earnings estimates have been revised 2 9  upward for 2019 and 4 3  for 2020 over the past 60 days  The stock has inched up 0 4  year to date Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-09-12,Zacks Investment Research,https://www.investing.com/analysis/vertex-gains-reimbursement-for-orkambi--symkevi-in-scotland-200464523,200464523
120177,341692,VRTX,Top Stock Reports For Celgene  Sinopec   HSBC,opinion,"Monday  September 16  2019
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Celgene  CELG   Sinopec  SNP  and HSBC Holdings  LON HSBA   HSBC   These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
You can see 
Celgene s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past three months  1 2  vs   4 3    The Zacks analyst thinks that Celgene s lead drug  Revlimid  continues to drive revenues on label expansions and market share gains 
Robust performance of psoriasis drug  Otezla  is also boosting Celgene s performance  Investors are focusing on the company s merger with large cap pharma Bristol Myers for a whopping  74 billion 
Per the terms  Celgene shareholders will receive  50 plus one share of Bristol Myers and one tradeable Contingent Value Right  which will entitle the holder to receive a cash payment of  9 00 upon the receipt of FDA approval for three candidates   ozanimod  liso cel and bb2121  The merger was initially opposed but was eventually given a green signal 
 You can  
Shares of Sinopec have lost 26 4  in the past six months  underperforming the Zacks Integrated Oil industry s fall of 18 3   The Zacks analyst believes that the company has made major progress in identifying attractive and economically viable oil and natural gas reserves 
A huge scale of prospective reserves was discovered in a number of prolific natural gas basins like Sichuan and Ordos  The discoveries will help Sinopec capitalize on mounting clean energy demand as China is transitioning from coal to natural gas for electricity generations  However  China s bleak economic outlook will continue to hurt the firm s refining business 
In fact  soft refining margin primarily led the company to report dismal second quarter 2019 earnings  Moreover  the firm s cash flow declined 54  year over year in the first half of 2019  reflecting weak operations  
 You can  
HSBC s shares have lost 4 8  year to date  underperforming the Zacks Foreign Banks industry s rise of 2 9  over the same period 
The Zacks analyst believes that the company s initiatives to improve market share in the U K  and China are likely to lead to an increase in expenses and hurt bottom line growth  These efforts will support financials over the long term  Also  initiatives to strengthen digital capabilities globally  improve operating efficiency and open 50 new retail banking branches in the United States will go a long way in supporting profits 
Its steady capital deployments are impressive  reflecting a strong balance sheet position  and will enhance shareholder value  Nevertheless  disappointing economic growth in Europe and weak loan demand are likely to hurt revenue growth to some extent  Additionally  uncertainty related to the implication of Brexit on its financials remains a major near term concern 
 You can   
Other noteworthy reports we are featuring today include BHP Group  BHP   Vertex Pharmaceuticals  NASDAQ VRTX   VRTX  and Prudential Financial  NYSE PRU   PRU  
7 Best Stocks for the Next 30 Days
Just released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  
Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention 

Mark VickerySenior Editor
Note  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read
Solid Revlimid Boost Celgene  CELG   Dependence A Concern


Sinopec  SNP  Banks on Sichuan Gas Discovery  Refining Weak


Digital Capabilities to Aid HSBC  HSBC  Amid Revenue Concern


Featured Reports
Focus on Renewables Aids AES Corp   AES   Regulations Hurt
Per the Zacks analyst  AES Corp  s focus on renewables should boost growth led by rapid expansion of renewable overseas footprint  However  stringent environmental regulations are a major headwind 

Fleet Modernization Efforts Aid SkyWest  SKYW   Costs Ail
The Zacks analyst is impressed by SkyWest s fleet modernization initiatives  which are helping the company streamline its operations 

Tiffany s  TIF  Omnichannel Bodes Well  Soft Margins a Woe
Per the Zacks analyst  Tiffany s omni channel platform  innovative brands and store expansion plans bode well 

Solid Pension Risk Transfer Business Aids Prudential  LON PRU 
Per the Zacks analyst  Prudential is set to grow on solid pension risk transfer business  momentum in U S  Financial Wellness and international operations 

Solid Performance by Food Safety Segment Aids Neog  NEOG  
Robust performance by the AccuPoint advanced test system  a core food safety product line  contributes to Neogen s revenue growth 

Gibraltar  ROCK  to Gain From Solid Backlog  Weak Volume Ail
Per the Zacks analyst  higher backlog and Four Pillar Value Creation strategy bode well for Gibraltar 

Healthcare Initiatives Boost FUJIFILM s  FUJIY  Prospects
Per the Zacks analyst  FUJIFILM is benefiting from robust performance of its Healthcare driven by acquisitions and investments in CDMO and regenerative medicine businesses 

New Upgrades
Vertex s  VRTX  Cystic Fibrosis Sales Strong  Pipeline Solid
New regulatory approvals line extensions are driving Vertex s Cystic Fibrosis  CF  drugs  sales  Its pipeline comprising a triple combo CF pill and other non CF drugs is strong  per the Zacks analyst 

Franco Nevada  FNV  Bets on Cobre Panama   Energy Revenues
Per the Zacks analyst  Franco Nevada is well poised to gain from the Cobre Panama project  solid energy revenues and healthy portfolio of streaming and royalty agreements 

Cimpress N V  CMPR  Gains From Solid Product Line  Buyouts
The Zacks analyst believes that robust mass customization businesses  supported by improved product offerings  and accretive acquisitions like BuildASign will continue to lend momentum to Cimpress 

New Downgrades
Higher Unit Costs   Low Metal Prices to Hurt BHP Group  BHP 
The Zacks Analyst is concerned lower metal prices due to the ongoing trade war and higher unit costs due to natural field decline at petroleum and lower copper grades will impact BHP s results 

Delek  DK  Hurt by Declining Permian Discount
The Zacks analyst believes that the declining discounts on Permian oil  to which 70  of Delek s refining capacity is exposed  might continue to hamper the company s bottom line 

Cheniere  LNG  Wrecked by Huge Debt Burden  Low Cash Flow
A massive debt burden of nearly  30 billion coupled with low internally generated cash flow  has made the Zacks analyst turn bearish on Cheniere Energy 
undefined undefined",2019-09-16,Zacks Investment Research,https://www.investing.com/analysis/top-stock-reports-for-celgene-sinopec--hsbc-200465111,200465111
120178,341693,VRTX,The Zacks Analyst Blog Highlights  Celgene  Sinopec  HSBC  Vertex Pharmaceuticals And Prudential Financial,opinion,For Immediate ReleaseChicago  IL   September 17  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Celgene   NASDAQ CELG    Sinopec   NYSE SNP    HSBC Holdings   NYSE HSBC    Vertex Pharmaceuticals   NASDAQ VRTX   and Prudential Financial   NYSE PRU   Here are highlights from Monday s Analyst Blog  Top Stock Reports for Celgene  Sinopec and HSBCThe Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Celgene  Sinopec and HSBC Holdings  These research reports have been hand picked from the roughly 70 reports published by our analyst team today You can see Celgene s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past three months  1 2  vs   4 3    The Zacks analyst thinks that Celgene s lead drug  Revlimid  continues to drive revenues on label expansions and market share gains Robust performance of psoriasis drug  Otezla  is also boosting Celgene s performance  Investors are focusing on the company s merger with large cap pharma Bristol Myers for a whopping  74 billion Per the terms  Celgene shareholders will receive  50 plus one share of Bristol Myers and one tradeable Contingent Value Right  which will entitle the holder to receive a cash payment of  9 00 upon the receipt of FDA approval for three candidates   ozanimod  liso cel and bb2121  The merger was initially opposed but was eventually given a green signal Shares of Sinopec have lost 26 4  in the past six months  underperforming the Zacks Integrated Oil industry s fall of 18 3   The Zacks analyst believes that the company has made major progress in identifying attractive and economically viable oil and natural gas reserves A huge scale of prospective reserves was discovered in a number of prolific natural gas basins like Sichuan and Ordos  The discoveries will help Sinopec capitalize on mounting clean energy demand as China is transitioning from coal to natural gas for electricity generations  However  China s bleak economic outlook will continue to hurt the firm s refining business In fact  soft refining margin primarily led the company to report dismal second quarter 2019 earnings  Moreover  the firm s cash flow declined 54  year over year in the first half of 2019  reflecting weak operations  HSBC s shares have lost 4 8  year to date  underperforming the Zacks Foreign Banks industry s rise of 2 9  over the same period The Zacks analyst believes that the company s initiatives to improve market share in the U K  and China are likely to lead to an increase in expenses and hurt bottom line growth  These efforts will support financials over the long term  Also  initiatives to strengthen digital capabilities globally  improve operating efficiency and open 50 new retail banking branches in the United States will go a long way in supporting profits Its steady capital deployments are impressive  reflecting a strong balance sheet position  and will enhance shareholder value  Nevertheless  disappointing economic growth in Europe and weak loan demand are likely to hurt revenue growth to some extent  Additionally  uncertainty related to the implication of Brexit on its financials remains a major near term concern Other noteworthy reports we are featuring today include Vertex Pharmaceuticals and Prudential Financial 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-09-16,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-celgene-sinopec-hsbc-vertex-pharmaceuticals-and-prudential-financial-200465383,200465383
120179,341694,VRTX,3 Big Biotech Stocks Worth Adding To Your Portfolio Now,opinion,It has been a roller coaster ride for the biotech sector so far this year  While 2019 started with a bang announcing the mega merger between Bristol Myers   NYSE BMY   and Celgene   NASDAQ CELG   that significantly perked up prices of quite a few stocks  these gains were partially offset over the course of time  primarily due to the overall weakness in the global market Nevertheless  the NASDAQ Biotechnology Index has seen 7 4  growth year to date Relatively  the biotech sector persisted to be riskier than the more stable  industry or the overall medical sector as investors are mostly banking on the companies  product pipelines with a very few having approved drugs in the portfolios  An unfavorable outcome of a key study on a promising candidate can spell doomsday for the respective biotech player The sector has been in spotlight since the onset of the year as a slowdown in mature products due to increasing competition and rise of biosimilars have forced most pharma biotech behemoths to target lucrative buyouts in this space to bolster their pipelines   Evidently  the focus is back on the mergers   acquisitions activity  The recent spree of consolidations is expected to continue with both big biotech and small biotech stocks  which have a dominant position in the lesser competitive arena of rare diseases and NASH and are well equipped with path breaking technology  respectively  A slew of licensing and buyout deals is struck with most companies eyeing smaller entities with impressive pipelines  Meanwhile  new drug approvals and label expansions of blockbuster drugs boosted investor sentiment and this upside should drive growth As fears of a global recession loom large on the overall economy  the inherent risk of the sector gets intensified  In such a scenario  choosing a biotech stock for investment can be tricky  Particularly  smaller biotechs are more hazardous as their product pipelines are several years away from commercialization  In contrast  investing in biotech biggies provides a cushion against volatility in the sector  Moreover  the  industry is placed within the top 36  of the 256 Zacks ranked industries Here we zero in on the three big biotech companies  which have outperformed the sector so far in 2019 and still hold enough room for an upside  backed by a broad and a strong product portfolio Alexion Pharmaceuticals  Inc    NASDAQ ALXN   is a biopharmaceutical company  focused on developing and commercializing life transforming drugs for the treatment of patients with ultra rare disorders  Alexion s blockbuster drug Soliris   approved for paroxysmal nocturnal hemoglobinuria  PNH  and atypical hemolytic uremic syndrome  aHUS    continues to perform well  The drug s label expansion for the generalized myasthenia gravis indication boosted sales significantly  The company received a significant boost with the FDA approval of its long acting C5 complement inhibitor Ultomiris for the treatment of adult patients with PNH  The approval has strengthened Alexion s PNH franchise and reduced the company s dependence on Soliris for growth  Alexion is working on the label expansion of Ultomiris and taking steps to further diversify its pipeline  which should reap returns in the long run Shares of the company have gained 8 5  in the year so far against the industry s decline of 1 7  Alexion currently carries a Zacks Rank  2  Buy   You can see  Vertex Pharmaceuticals Incorporated s   NASDAQ VRTX   key area of focus is cystic fibrosis  CF  and the company has a market leading portfolio for the same  The company s chief marketed products are Symdeko Symkevi  tezacaftor in combination with ivacaftor   Orkambi  lumacaftor in combination with ivacaftor  and Kalydeco  ivacaftor   Consistent positive regulatory nods increased the eligible patient population for these drugs  The CF market represents a huge commercial potential and Vertex has been striving hard to further cement its pipeline  Notably  the company s CF pipeline is already quite strong and approval of new treatments will further leverage its dominant position in the market  Meanwhile  the company is also developing treatments for sickle cell disease  thalassemia and pain management Vertex presently carries a Zacks Rank of 2  Shares of the company have gained 6 3  in the year so far  Amgen   NASDAQ AMGN   is one of the top biotechnology companies in the world with a strong presence in the oncology hematology  cardiovascular disease  neuroscience  inflammation  bone health and nephrology markets  While its legacy products reached the end of respective life cycles  growth products  such as Prolia  Xgeva  Vectibix  Nplate plus Kyprolis and Blincyto are performing well  gaining consistent approvals for label expansions  Moreover  Amgen has a solid biosimilars  pipeline  which is expected to drive growth  The company has already launched two biosimilars in the EU  namely Amjevita  biosimilar of AbbVie s Humira  and Kanjinti  biosimilar of Roche s Herceptin  Amgen currently sports a Zacks Rank  1  Shares of the company have inched up 0 5  in the year so far Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ,2019-09-20,Zacks Investment Research,https://www.investing.com/analysis/3-big-biotech-stocks-worth-adding-to-your-portfolio-now-200466519,200466519
120180,341695,VRTX,Vertex Enters Into Collaboration With Privately Held Ribometrix,opinion,Vertex Pharmaceuticals   NASDAQ VRTX   announced that it has entered into a strategic collaboration with privately held biotech  Ribometrix  Inc   for an upfront payment of  20 million to develop RNA targeted treatments for serious diseases  The upfront payment also includes equity investment by Vertex in Ribometrix Ribometrix is focused in discovering small molecule drugs  which modulate RNA function by targeting three dimensional  3D  RNA structures to treat diseases Per the terms of the collaboration  Ribometrix is also eligible to receive milestone payments related to research  development  regulatory and commercialization of more than  700 million  Vertex will also pay royalties on future net global sales for products developed under the collaboration The collaboration will give Vertex access to Ribometrix s proprietary discovery platform to discover and develop up to three therapeutic programs  Initially  Ribometrix and Vertex will undertake two discovery programs  Vertex also has the option to add a third program under this collaboration  Vertex can opt to gain exclusive global license for the development and commercialization of novel therapeutic molecules arising from this collaboration So far this year  Vertex a leader in the CF market  has entered into  few other collaborations and made acquisitions to boost and diversify its pipeline into non CF diseases  Vertex collaborated with another privately held Kymera Therapeutics in May to develop small molecule protein degraders targeting several serious diseases  The company also  its collaboration agreement with CRISPR Therapeutics   NASDAQ CRSP   in June to include gene editing therapies targeting new disease areas   Duchenne muscular dystrophy   DMD   and Myotonic dystrophy type 1  DM1    using CRISPR s technology In July  Vertex  privately held Exonics Therapeutics  focused on developing gene editing therapies for Duchenne muscular dystrophy and other severe genetic neuromuscular diseases  Vertex acquired all outstanding shares of Exonics and paid an upfront payment of  245 million  The company is likely to transform Exonics into its subsidiary  In September  Vertex inked an all cash deal to acquire   a privately held biotech  for  950 million  This acquisition will add pre clinical cell based treatment candidates for type I diabetes to Vertex s pipeline  which is expected to be completed in the fourth quarter Meanwhile  Vertex s non CF pipeline  though in early stage  looks interesting with treatments being developed for beta thalassemia  sickle cell disease  alpha 1 antitrypsin deficiency  APOL1 mediated kidney diseases and pain Meanwhile  the company s first  CF regimen   next generation CFTR corrector VX 445  elexacaftor  plus tezacaftor and Kalydeco   is under review in the United States  The regulatory submission  seeking approval for the combination regimen  was granted priority review by the FDA with a decision from the regulatory body expected on Mar 19  2020 Please note that many other companies like AbbVie   NYSE ABBV   and Proteostasis Therapeutics  Inc    NASDAQ PTI   are also developing triple CFTR combinations for CF 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ,2019-10-01,Zacks Investment Research,https://www.investing.com/analysis/vertex-enters-into-collaboration-with-privatelyheld-ribometrix-200469923,200469923
120181,341696,VRTX,Can Vertex  VRTX  Keep The Earnings Surprise Streak Alive ,opinion,"Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report  Vertex Pharmaceuticals  NASDAQ VRTX   which belongs to the Zacks Medical   Biomedical and Genetics industry  could be a great candidate to consider 
When looking at the last two reports  this drugmaker has recorded a strong streak of surpassing earnings estimates  The company has topped estimates by 19 33   on average  in the last two quarters 
For the last reported quarter  Vertex came out with earnings of  1 26 per share versus the Zacks Consensus Estimate of  1 03 per share  representing a surprise of 22 33   For the previous quarter  the company was expected to post earnings of  0 98 per share and it actually produced earnings of  1 14 per share  delivering a surprise of 16 33  
Price and EPS Surprise

With this earnings history in mind  recent estimates have been moving higher for Vertex  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the company is positive  which is a great sign of an earnings beat  especially when you combine this metric with its nice Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Vertex has an Earnings ESP of  1 97  at the moment  suggesting that analysts have grown bullish on its near term earnings potential  When you combine this positive Earnings ESP with the stock s Zacks Rank  1  Strong Buy   it shows that another beat is possibly around the corner 
With the Earnings ESP metric  it s important to note that a negative value reduces its predictive power  however  a negative Earnings ESP does not indicate an earnings miss 
Many companies end up beating the consensus EPS estimate  though this is not the only reason why their shares gain  Additionally  some stocks may remain stable even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-10-13,Zacks Investment Research,https://www.investing.com/analysis/can-vertex-vrtx-keep-the-earnings-surprise-streak-alive-200473199,200473199
120182,341697,VRTX,Can Balanced Segmental Growth Aid Abbott  ABT  Q3 Earnings ,opinion,Abbott Laboratories   NYSE ABT   is slated to report third quarter 2019 results on Oct 16  before the market opens  In the last reported quarter  the company came up with a positive surprise of 2 5   Abbott delivered positive surprises in three of the trailing four quarters  the average beat being 1 78  Let s see  how things are shaping up for this announcement Factors at PlayOver the last few quarters  Abbott has been riding high on a healthy growth curve within its Diabetes Care business  The company has been hogging the limelight for developments in its flagship  sensor based continuous glucose monitoring  CGM  system   FreeStyle Libre System  This upside is likely to reflect on the upcoming quarterly resultsNotably  in the last reported quarter  Diabetes Care sales surged at a stupendous rate  up 35 3  year over year organically   led by FreeStyle Libre  Libre is once again expected to have performed exceptionally well  registering strong worldwide sales in the to be reported quarter According to Abbott  FreeStyle Libre has achieved global leadership in CGM systems for both Type 1 and Type 2 users  In order to meet higher demand for Libre  Abbott is currently adding a significant amount of new manufacturing capacity  which is gradually coming online  starting from the third quarter of 2019 onward  This might reflect on the company s third quarter performance throughout Meanwhile  in September  the company announced its newly formed alliance with Sanofi  PA SASY  to integrate glucose sensing and insulin delivery technologies  The two companies are developing tools that combine Abbott s FreeStyle Libre technology with Sanofi s insulin dosing information for future smart pens  insulin titration apps and cloud software  This new development is expected to have contributed to the company s third quarter top line The Zacks Consensus Estimate of  640 million for third quarter Diabetes Care revenues indicates a rise of 25  from the year ago reported figure Alike the prior reported quarter  Abbott in the impending quarterly release is anticipated to gain from a solid performance by the Established Pharmaceuticals Division  EPD  business  which has been recording operational sales growth over the last few quarters  Per Abbott  its EPD business is growing at a faster pace than the market rate across the key emerging markets that represent the most attractive long term growth pertaining to its branded generics portfolio  These include India  Brazil  Russia and China among others Abbott Laboratories Price and EPS Surprise   Management expects EPD to deliver a mid to high single digit uptick in the to be reported results Currently  the Zacks Consensus Estimate of  1 22 billion for EPD revenues suggests a 5  decline from the year earlier reported number We are optimistic about the consistently sturdy Diagnostics business  courtesy of robust contributions from all sub segments  namely Core Laboratories Diagnostics  Molecular Diagnostics and Point of Care Moreover  we are impressed by the accelerated global rollout of the company s Alinity suite of instrument  Currently in Europe  the company is converting its existing customers to Alinity and is progressing strongly with its systems for immunoassay and clinical chemistry testing  which is helping drive double digit growth in international Core Laboratory business   In the United states  this business is growing rapidly on achievement of regulatory approvals for broad menu of core laboratory tests  In this regard  in July  the company clinched an FDA approval of Alinity S for blood and plasma screening  This in turn might have also strongly contributed to the company s third quarter top line performance Per Abbott  it is well positioned for sustainable growth in years to come  based on the company s rollout of the full suite of Alinity systems across additional geographies including the United States Within Diagnostics  the company forecasts the legacy diagnostics businesses  comprising Core Laboratory  Molecular and Point of Care  to grow in high single digits and in Rapid Diagnostics  it forecasts low to mid single digit growth The Zacks Consensus Estimate of  1 92 billion for Diagnostic revenues implies a 5 3  improvement from the figure registered in the comparable quarter last year We also encouragingly note that Nutrition is Abbott s most speedily growing business owing to aging population  increasing rate of chronic diseases and the rise of the middle class in the emerging markets  Furthermore  Abbott s pediatric nutrition business continues to thrive in the United States  For the third quarter  the company projects mid single digit sales growth The Zacks Consensus Estimate of  1 89 billion for Nutritional revenues indicates a 2 9  rise from the number recorded in the prior year quarter What the Model SuggestsThe proven Zacks model clearly shows that a company with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has significant chances of beating estimates if it also has a positive Earnings ESP  You can uncover the best stocks to buy or sell before they re reported with our Earnings ESP Filter Abbott has a Zacks Rank  3  which increases the predictive power of ESP  However  its Earnings ESP of 0 00  in the combination makes surprise prediction difficult for the stock this reporting cycle  The Zacks Consensus Estimate for third quarter bottom line of 84 cents suggests a 12  climb from the year earlier reported figure Stocks Worth a LookHere are a few medical stocks worth considering from the same space with the right mix of elements to surpass expectations this time around Akcea Therapeutics  Inc    NASDAQ AKCA   has an Earnings ESP of  18 18  and a Zacks Rank of 2  You can see  Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   has an Earnings ESP of  1 97  and a Zacks Rank  1 DENTSPLY SIRONA Inc    NASDAQ XRAY   has an Earnings ESP of  5 50  and a Zacks Rank of 3 Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-10-13,Zacks Investment Research,https://www.investing.com/analysis/can-balanced-segmental-growth-aid-abbott-abt-q3-earnings-200473230,200473230
120183,341698,VRTX,Can Structural Heart Strength Aid Abbott  ABT  Q3 Earnings ,opinion,Abbott s   NYSE ABT   Structural Heart business has been gaining a strong traction of late on the back of innovations We expect this strength to get reflected in third quarter 2019 results  which are scheduled for release on Oct 16 before the market opens to know how the company s overall Q3 performance is expected to be Structural Heart in FocusAbbott s Structural Heart business consistently maintained an impressive top line performance in recent times  The company has been grabbing attention for developments in its flagship  market leading device to treat mitral regurgitation   MitraClip  This upside is likely to reflect on the upcoming quarterly release In the last reported quarter  this business witnessed a surge of more than 30  in global sales that also soared above 50  in the United States  With MitraClip s new expanded indication  we expect this trend to have continued in the third quarter as well  To be precise  in July 2019  Abbott achieved an FDA approval for the fourth generation MitraClip device with enhanced features and new clip sizes Abbott Laboratories Price and EPS Surprise   Further  in September  the company announced gaining a CE Mark for two new structural heart devices in Europe  These are the Masters HP 15mm rotatable mechanical heart valve and the Amplatzer Piccolo Occluder  both appropriate for treating pediatric heart patients  This pioneering approach to paediatric heart treatment has undoubtedly broadened Abbott s structural heart portfolio  We expect the company s top line to reflect this gain in the to be reported results Additionally  Abbott s structural heart product line has a robust pipeline of technologies and development including Tendyne and Cephea to replace faulty mitral heart valves  Further  there is TriClip  a first of its kind device for the repair of a leaky tricuspid heart valve  and Amplatzer Amulet  the company s left atrial appendage device to reduce the risk of stroke in patients with atrial fibrillation  We expect these to have once again registered a strong top line contribution in the third quarter The Zacks Consensus Estimate of  379 million for Structural Heart revenues also indicates a rise of 24 3  from the year ago reported figure Zacks Rank   Stocks to ConsiderAbbott carries a Zacks Rank  3  Hold   Some better ranked stocks from the same space are as follows Akcea Therapeutics  Inc    NASDAQ AKCA   has an  of  18 18  and a Zacks Rank  2  Buy   You can see  Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   has an Earnings ESP of  1 97  and a Zacks Rank  1  Strong Buy   You can uncover the best stocks to buy or sell before they re reported with our Earnings ESP Filter DENTSPLY SIRONA Inc    NASDAQ XRAY   has an Earnings ESP of  5 50  and a Zacks Rank of 3 Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-10-14,Zacks Investment Research,https://www.investing.com/analysis/can-structural-heart-strength-aid-abbott-abt-q3-earnings-200473572,200473572
120203,341718,VRTX,Oil drop stymies Dow s march to 20 000  health stocks boost Nasdaq,news,"By Sinead Carew  Reuters    Declines in energy and financial stocks weighed on the S P 500 on Monday and helped stall the Dow s pursuit of the 20 000 milestone ahead of earnings season and expected U S  policy changes under the Donald Trump presidency  The Nasdaq notched a record high close  extending its bullish run with help from healthcare stocks   The S P s energy sector  SPNY  dropped 1 5 percent as oil prices slid on concerns that rising Iraqi exports and U S  output could dampen the impact of a deal among major producers to limit output  Elsewhere  investors were taking a breather ahead of fourth quarter earnings and the Jan  20 presidential inauguration   The S P 500 benchmark has risen more than 6 percent since the Nov  8 election of Donald Trump  who has pledged tax cuts  lighter regulation and fiscal stimulus  but investors are now waiting to see if he can deliver on those promises   People are waiting for more information  We re waiting for political news  we re waiting for earnings  There s a lot of uncertainty out there  As the month goes on I expect we ll see some movement   said Peter Jankovskis  co chief investment officer at OakBrook Investments LLC in Lisle  Illinois  The financial sector  SPSY  fell 0 8 percent on Monday  It had risen almost 18 percent since the election  led by banking stocks   Big banks will provide the first peek into how U S  companies fared in the fourth quarter later this week  S P 500 companies overall are expected to post a 5 8 percent increase in profit in the quarter  according to Thomson Reuters I B E S   There is some hope we ll see some movement upward  Investors want to see some of those reports come out first   said Jankovskis  Two thirds of the 30 Dow Jones Industrial Average components fell  keeping the psychologically significant 20 000 mark at bay  Goldman Sachs   N GS  0 8 percent fall was its biggest drag followed by International Business Machine s  N IBM  0 9 percent drop and Exxon Mobil s  N XOM  1 7 percent decline  The Dow had come tantalizingly close to the milestone on Friday  hitting a peak of 19 999 63  as the S P 500 and the Nasdaq also touched records after a late pop in tech stocks   Our view about the Dow  hitting  20 000 is not a matter of if  but a matter of when   said Matt Jones  U S  head of equity strategy at J P  Morgan Private Bank in New York  The Dow Jones Industrial Average  DJI  was down 76 42 points  or 0 38 percent  to 19 887 38  the S P 500  SPX  had lost 8 08 points  or 0 354856 percent  to 2 268 9 and the Nasdaq Composite  IXIC  had added 10 76 points  or 0 19 percent  to 5 531 82  Eight of the 11 major S P 500 sectors were lower  The S P s health sector  SPXHC  was the biggest gainer with Merck   Co   N MRK  the leading boost and Vertex Pharmaceuticals  O VRTX  the biggest percentage gainer with a 4 4 pct jump after it issued guidance  Nasdaq s biggest drivers in the healthcare sector were  Ariad Pharmaceuticals   O ARIA   which closed up 72 9 percent on a  5 20 billion buyout deal with Japan s Takeda 4502 T Incyte  O INCY  with a 9 4 percent jump after it announced advancements in its cancer drug program with Merck   Declining issues outnumbered advancing ones on the NYSE by a 1 77 to 1 ratio  on Nasdaq  a 1 45 to 1 ratio favored decliners  The S P 500 posted 6 new 52 week highs and no new lows  the Nasdaq Composite recorded 55 new highs and 16 new lows  
About 6 4 billion shares changed hands on U S  exchanges on Monday compared with the 6 6 billion average for the last 20 sessions ",2017-01-09,Reuters,"https://www.investing.com/news/stock-market-news/u.s.-stock-futures-dip-with-oil-prices;-all-eyes-on-dow-20,000-451910",451910
120204,341719,VRTX,U S  stocks indecisive after Brexit kick off and ahead of Fed speakers,news,"Investing com   Wall Street showed mixed trading on Wednesday as market players digested the official start of the negotiations between the U K  and the European Union  EU  for Britain to exit the bloc  known as Brexit  and investors waited for more hints from policymakers on the future path of the Federal Reserve s monetary policy 
At 11 25AM ET  15 25GMT   the Dow Jones lost 46 points  or 0 22   the S P 500 inched up 1 point  or 0 05   while the Nasdaq Composite traded up 12 points  or 0 21  
British Prime Minister Theresa May confirmed on Wednesday that Article 50 of the Lisbon Treaty has been triggered  formally beginning the two year process of the U K  s withdrawal from the EU 
Failure to strike a new trade deal before the deadline would force the adoption of World Trade Organization  WTO  arrangements  bringing with it a host of new negotiations and complications that would theoretically leave both parties worse off 
In positive economic data stateside  pending home sales surged 5 5  in February  more than double the forecast  to hit a 10 month high 
Also in the U S   market players continued to keep an eye on developments for Fed policy tightening 
Though Fed chair Janet Yellen steered away from commentaries on monetary policy or the economic outlook a day earlier  other policymakers were giving their point of view on the economic outlook  the number of rate hikes this year and their considerations for when the central bank will return to balance sheet normalization 
After the market close on Tuesday  Fed governor Jerome Powell indicated that the uncertainty surrounding U S  President Donald Trump s fiscal policy and its eventual impact on the economy was making it difficult to assess the outlook  while Kansas City Fed president Esther George admitted she was not yet factoring any possible Trump policy changes 
Chicago Fed president Charles Evans reiterated Wednesday that he thought there would be one to two more hikes this year 
 For the first time in quite a while  I see more notable upside risks to growth   he said 
Boston Fed chief Eric Rosengren and San Francisco Fed president John Williams were still scheduled for appearances later on Wednesday 
Fed fund futures priced in about a 45  chance for a rate hike to come in June  according to Investing com s Fed Rate Monitor Tool  While odds for a move in July narrowly passed the 50  threshold  they rose to around 70  for the September meeting 
In company news  Vertex Pharmaceuticals  NASDAQ VRTX  soared 23   leading advancers on the S P 500  after the biotech firm said its cystic fibrosis treatment met endpoints in two late stage clinical studies 
Leading decliners  F5 Networks  NASDAQ FFIV  sank nearly 4  as  Deutsche Bank   DE DBKGn  cut the firm to sell from hold based on its outlook due to stiff competition 
In other big moves  Exar Corporation  NYSE EXAR  jumped more than 20  as the circuit maker received a buyout offer of about  700 million from  MaxLinear Inc   NYSE MXL  
Shares in RH  NYSE RH  also climbed more than 13  as the luxury furniture retailer beat on quarterly revenue and provide a first quarter sales forecast that topped analyst expectations 
Meanwhile  oil prices jumped more than 1  with the barrel of West Texas popping back above  49 as U S  crude inventories rose by just 867 000 barrels  below forecasts for a build of 1 357 million 
U S  crude futures gained 1 76  to  49 22 by 11 26AM ET  15 26GMT   while Brent oil traded up 1 73  to  51 78 ",2017-03-29,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-stocks-indecisive-after-brexit-kick-off-and-ahead-of-fed-speakers-469678,469678
120205,341720,VRTX,U S  stocks mixed at close of trade  Dow Jones Industrial Average down 0 20 ,news,"Investing com   U S  stocks were mixed after the close on Wednesday  as gains in the Oil   Gas  Consumer Services and Technology sectors led shares higher while losses in the Utilities  Financials and Telecoms sectors led shares lower 
At the close in NYSE  the Dow Jones Industrial Average fell 0 20   while the S P 500 index climbed 0 11   and the NASDAQ Composite index climbed 0 38  
The best performers of the session on the Dow Jones Industrial Average were  Chevron  Corporation  NYSE CVX   which rose 0 84  or 0 90 points to trade at 108 07 at the close  Meanwhile  Wal Mart Stores Inc  NYSE WMT  added 0 60  or 0 42 points to end at 70 74 and  Pfizer  Inc  NYSE PFE  was up 0 50  or 0 17 points to 34 33 in late trade 
The worst performers of the session were UnitedHealth Group Incorporated  NYSE UNH   which fell 1 16  or 1 91 points to trade at 163 44 at the close  The Travelers Companies Inc  NYSE TRV  declined 1 04  or 1 27 points to end at 120 53 and Cisco Systems Inc  NASDAQ CSCO  was down 0 82  or 0 28 points to 33 74 
The top performers on the S P 500 were Vertex Pharmaceuticals Inc  NASDAQ VRTX  which rose 20 45  to 108 01  Chesapeake Energy Corporation  NYSE CHK  which was up 7 79  to settle at 5 810 and  Nordstrom Inc   NYSE JWN  which gained 5 37  to close at 45 92 
The worst performers were  F5 Networks Inc   NASDAQ FFIV  which was down 3 42  to 142 10 in late trade   Mylan Inc   NASDAQ MYL  which lost 3 28  to settle at 40 35 and  Arconic Inc   NYSE ARNC  which was down 3 12  to 26 20 at the close 
The top performers on the NASDAQ Composite were Tonix Pharmaceuticals Holding Corp  NASDAQ TNXP  which rose 34 54  to 5 570  Performant Financial Corporation  NASDAQ PFMT  which was up 31 69  to settle at 2 410 and Cerulean Pharma Inc  NASDAQ CERU  which gained 25 50  to close at 0 910 
The worst performers were  Alliqua Inc   NASDAQ ALQA  which was down 30 98  to 0 431 in late trade  Catalyst Biosciences Inc  NASDAQ CBIO  which lost 29 98  to settle at 10 510 and  Atossa Genetics Inc   NASDAQ ATOS  which was down 27 52  to 0 7900 at the close 
Rising stocks outnumbered declining ones on the New York Stock Exchange by 2089 to 1120 and 54 ended unchanged  on the Nasdaq Stock Exchange  1524 rose and 972 declined  while 115 ended unchanged 
Shares in Vertex Pharmaceuticals Inc  NASDAQ VRTX  rose to 52 week highs  up 20 45  or 18 34 to 108 01  Shares in Alliqua Inc  NASDAQ ALQA  fell to all time lows  down 30 98  or 0 194 to 0 431  Shares in Atossa Genetics Inc  NASDAQ ATOS  fell to 52 week lows  down 27 52  or 0 3000 to 0 7900  
The CBOE Volatility Index  which measures the implied volatility of S P 500 options  was down 0 95  to 11 42 
Gold Futures for April delivery was down 0 26  or 3 25 to  1252 35 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in May rose 2 21  or 1 07 to hit  49 44 a barrel  while the June Brent oil contract rose 1 98  or 1 02 to trade at  52 44 a barrel 
EUR USD was down 0 43  to 1 0768  while USD JPY fell 0 11  to 111 04 
The US Dollar Index Futures was up 0 24  at 99 77 ",2017-03-29,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-stocks-mixed-at-close-of-trade;-dow-jones-industrial-average-down-0.20-469752,469752
120206,341721,VRTX,Energy  consumer shares lift S P 500 to slight gain,news,"By Lewis Krauskopf  Reuters    The benchmark S P 500 eked out a gain on Wednesday as strength in the energy and consumer sectors offset declines in financial shares and investors began looking ahead to first quarter earnings season  The Dow Jones Industrial Average ended slightly lower  falling for the ninth session out of the past 10  while the Nasdaq rose for a fourth straight day  Investors have been assessing what the Republicans  failure to pass a healthcare bill means for tax reform and the rest of President Donald Trump s agenda  hopes for which have helped drive stocks to record highs  They are looking to first quarter earnings to support lofty valuations for stocks  with the S P 500 trading at nearly 18 times earnings estimates for the next 12 months against its long term average of 15 times   First quarter earnings for S P 500 companies are expected to rise 10 1 percent  according to Thomson Reuters I B E S   The policy risk has increased     but economic data still remains solid and therefore earnings should be good   said Walter Todd  chief investment officer of Greenwood Capital in Greenwood  South Carolina   Absent some revelation on the policy front  I think that s the next catalyst for the market  is when we start seeing companies report   The Dow Jones Industrial Average  DJI  fell 42 18 points  or 0 2 percent  to 20 659 32  the S P 500  SPX  gained 2 56 points  or 0 11 percent  to 2 361 13 and the Nasdaq Composite  IXIC  added 22 41 points  or 0 38 percent  to 5 897 55  The energy sector  SPNY  gained 1 2 percent  leading all sectors  supported by stronger oil prices  CLc1   The consumer discretionary sector  SPLRCD  rose 0 6 percent as retailers such as Nordstrom  N JWN  and Kohl s  N KSS  surged  Amazon com  O AMZN  rose 2 1 percent and hit an all time high  giving the biggest boost to the S P 500 and Nasdaq   Financial shares  SPSY  fell back 0 5 percent a day after leading a rally  Investors also digested comments from Federal Reserve officials  Chicago Fed President Charles Evans said he favors further interest rate hikes this year  while Boston Fed President Eric Rosengren said the Fed should raise rates three more times in 2017   The market seems to be unfazed by the fact that the Fed is looking to be somewhat aggressive in raising rates   said Paul Nolte  portfolio manager at Kingsview Asset Management in Chicago  The stock rally fueled by optimism President Donald Trump will boost the economy may be near its peak  according to a Reuters poll of strategists  who forecast U S  shares will gain less than 3 percent between now and year end  In corporate news  Vertex Pharmaceuticals  O VRTX  soared 20 5 percent after the company s cystic fibrosis treatment succeeded in a late stage study  The stock boosted the S P and helped drive the Nasdaq Biotechnology index  NBI  up 0 9 percent  About 5 8 billion shares changed hands in U S  exchanges  well below the 6 9 billion daily average over the last 20 sessions and among the lightest volume days in 2017  Advancing issues outnumbered declining ones on the NYSE by a 1 88 to 1 ratio  on Nasdaq  a 1 59 to 1 ratio favored advancers  
The S P 500 posted 14 new 52 week highs and 1 new lows  the Nasdaq Composite recorded 86 new highs and 24 new lows ",2017-03-29,Reuters,https://www.investing.com/news/stock-market-news/u.s.-stocks-futures-flat-as-investors-await-fed-speakers-469605,469605
120207,341722,VRTX,Nasdaq and S P close higher while Dow dips ,news,"Investing com   U S  stocks closed mostly higher on Wednesday  led by energy  after crude prices closed above  49 for the first time in nearly three weeks  while better than expected economic data lifted sentiment 
Investors piled into U S  stocks  after better than expected housing data supported the narrative of a strengthening U S  economy 
The U S  National Association of Realtors said its pending home sales increased by 5 5  last month  which was far above economists  forecast of a 2 4  increase 
Energy stocks led the move higher  driven by a strong rebound in crude prices  after the latest Energy Information Administration  EIA  report showed a smaller than expected rise in U S  crude stockpiles 
On the New York Mercantile Exchange crude futures for April delivery added  1 14 to settle at  49 51 a barrel 
Elsewhere  a flurry of hawkish comments from several Federal Reserve officials had a muted impact on market moves 
San Francisco Federal Reserve President John Williams said Wednesday that his central bank colleagues should not  rule out more than three  rate  increases total for this year   as the U S economy is close to achieving the Federal Reserve s dual mandate 
Meanwhile  Fed member Charles Evans said Wednesday  he has confidence that two total rate increases in 2017 seems  very safe  while Federal Reserve Bank of Boston President Eric Rosengren opted for a more bullish outlook  after he said the U S  central bank should be prepared to raise interest rates a total of four times in 2017 to prevent the U S  economy from overheating 
Investors also mulled over the effect of Brexit  after Article 50  the legal process by which Britain will leave the European Union  EU  was triggered on Wednesday 
In corporate earnings news  shares of Lululemon sank in after hours trade  as the yoga apparel retailer revealed quarterly performance and forward guidance that missed analysts  expectations 
The Dow Jones Industrial Average closed 0 20  lower at 20 659  The S P 500 gained 0 11  and the Nasdaq Composite closed 0 38  higher at 5897 55
The top S P 500 gainers included Vertex Pharmaceuticals Inc  NASDAQ VRTX  up 20 5   and Chesapeake Energy Corporation  NYSE CHK  up 7 8   while  Nordstrom Inc   NYSE JWN  added 5 4  
 F5 Networks Inc   NASDAQ FFIV  down 3 4    Mylan Inc   NASDAQ MYL  down 3 3  and  Arconic Inc   NYSE ARNC  slumped 3 1   were among the worst S P 500 performers of the session ",2017-03-29,Investing.com,https://www.investing.com/news/stock-market-news/nasdaq-and-s-p-close-higher-while-dow-dips-469756,469756
120208,341723,VRTX,Wall St closes higher  Nasdaq notches second straight daily win,news,"Investing com   U S  stocks closed higher on Tuesday  after the release of upbeat U S trade data ahead of a key meeting between U S  President Donald Trump and Chinese President Xi Jinping 
The latest batch of U S  economic trade data  added to the narrative of a stronger U S  economy  as the U S  trade deficit narrowed by more than expected in February 
The Commerce Department said Tuesday  the trade deficit shrank by 9 6  to  43 6 billion  while January s trade deficit was revised down to  48 2 billion from  48 5 billion 
Economists had forecast the trade gap contracting to  44 8 billion in February 
Meanwhile  investors looked ahead to the meeting on Thursday between U S  President Donald Trump and Chinese President Xi Jinping 
President Trump last week  raised expectations that the meeting could be unproductive  when he tweeted the meeting will be  very difficult   given the many economic and security issues that divide the U S  and China 



Meanwhile  Richmond Federal Reserve President Jeffrey Lacker announced his immediate resignation Tuesday  admitting that he discussed sensitive information with an analyst regarding the Federal Reserve s plans for economic stimulus 
In corporate news  Nvidia slumped to a three week low  after investment firm Pacific Crest lowered its rating on Nvidia to  underweight   from Sector Weight  amid worries of saturation in the desktop PC market 
The Dow Jones Industrial Average closed 0 19  higher at 20 689  The S P 500 gained 0 06  and the Nasdaq Composite closed 0 07  higher at 5 898 61 
The top S P 500 gainers  Staples Inc   NASDAQ SPLS  up 9 8   and Chesapeake Energy Corporation  NYSE CHK  up 6 8   while Vertex Pharmaceuticals Inc  NASDAQ VRTX  added 4 5  
 Acuity Brands Inc   NYSE AYI  down 14 8   NVIDIA Corporation  NASDAQ NVDA  down 7  and  Nordstrom Inc   NYSE JWN  down 5 5   were among the worst S P 500 performers of the session ",2017-04-04,Investing.com,https://www.investing.com/news/stock-market-news/wall-st-closes-higher:-nasdaq-notches-second-straight-daily-win-471382,471382
120209,341724,VRTX,Concert shareholders back CF asset sale to Vertex,news,Concert Pharmaceuticals  CNCE  0 4   stockholders have approved the sale of CF candidate CTP 656 to Vertex Pharmaceuticals  NASDAQ VRTX  for  160M in cash plus up to  90M in milestones  The transaction should close by the end of October Previously  Vertex buys Concert s CF candidate CTP 656 for up to  250M  March 6 Now read ,2017-05-24,Seeking Alpha,https://www.investing.com/news/stock-market-news/concert-shareholders-back-cf-asset-sale-to-vertex-488089,488089
120216,341731,VRTX,Top Research Reports  Amazon  Caterpillar  Vertex   More,opinion,"Wednesday  August 14  2019The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features updated research reports on 12 major stocks  including Amazon  AMZN   Caterpillar  CAT  and Vertex  VRTX   These research reports have been hand picked from roughly 70 reports published by our analyst team today You can see Amazon s shares have outperformed the broader market year to date  the stock is up  21 5  vs  the  15 4  increase for the S P 500 as a whole   Amazon reported mixed second quarter results  While earnings missed estimates  revenues outpaced the same  However  the company exhibited year over year growth on both counts  The Zacks analyst thinks Amazon benefited from its solid Prime momentum owing to robust grocery services and strong content portfolio  Also  Prime Free One Day service helped Amazon in gaining traction across customers  Strengthening AWS services and its growing adoption rate made strong contributions  Additionally  improving Alexa skills and features remained a major positive  However  rising transportation costs related to its free one day shipping service remained an overhang  Transportation costs are expected to increase further  Also  Amazon expects foreign exchange headwinds to continue impacting its top line  You can   Shares of Caterpillar have outperformed the Zacks Construction and Mining industry   9 8  vs   11 8   in the past year  Caterpillar reported global retail sales growth of 4  for the three month period ended July 2019  the lowest so far this year  Further  the metric was at a level last seen in 2017  The global machine sales growth rate has been on a downward spiral over the past few months  which is a concern  per the Zacks analyst  The company anticipates earnings per share at the lower end of its guidance of  12 06  13 06 for 2019 and expects modest sales growth for the year  In the Construction Industries segment  North America will aid growth while China will be a headwind  Improving commodity prices will support capital expenditure in the mining sector  which should drive performance of the Resource Industries segment  Investments in expanded offerings and services  and digital initiatives like e commerce will also fuel growth  Its cost reduction efforts should help sustain margins despite material cost inflation  You can   Vertex s shares have outperformed the Zacks Biomedical and Genetics industry year to date   11  vs   0 9    Vertex beat estimates for both earnings and sales in the second quarter  The Zacks analyst thinks approval of its cystic fibrosis   CF   drugs  Kalydeco and Orkambi  for new patient populations  is driving sales growth  Its third CF medicine  Symdeko  has become the main driver of CF revenues in a very short time  Vertex rapidly advanced its triple combination CF regimens through late stage development regulatory filings  The regimens are crucial for long term growth as these have the potential to treat up to 90  of CF patients  Meanwhile  Vertex s non CF pipeline  though early stage  looks interesting with several pipeline readouts expected in 2020 21  However  competition is rising in the CF market with many companies developing triple combo CF drugs  Also  Vertex s overdependence on the CF franchise for growth is a concern  You can   Other noteworthy reports we featured today include Kraft Heinz  NASDAQ KHC   Diamondback Energy  FANG  and Evergy  EVRG  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look    Note  Our Director of Research Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read
Prime Momentum   Growing AWS Adoption Benefit Amazon  AMZN 


Caterpillar  CAT  Bets on Improving Demand Amid High Costs


Vertex s  VRTX  Cystic Fibrosis Sales Strong  Pipeline Solid


Featured Reports
Energen Buy Boosts Diamondback  FANG  Amid Gas Pricing Woes
The Zacks analyst believes Diamondback s twin buys of Energen and Ajax Resources should bolster its Permian hold  However  the region s extremely low natural gas price is a concern 

Investments  Renewable Energy Focus Aid Evergy  EVRG 
Per the Zacks analyst  Evergy s  6 billion investment in the 2019 2023 period to strengthen its operations and plans to produce more electricity from renewable sources will boost its performance 

Cost Cuts Aid Old Dominion  ODFL  Amid Freight Weakness
The Zacks analyst is impressed with Old Dominion s efforts to check costs  

Continental  CLR  Banks on Oil Rich Bakken Play  Debts High
While premium drilling positions in Bakken play will boost Continental s oil production  the company s levered balance sheet is a concern  per the Zacks analyst  

International Strength Drives Wayfair  W   Expenses Worrying
The Zacks analyst believes that Wayfair s strong retail business along with its efforts to expand in international markets are positives  

New Upgrades
Higher Las Vegas Demand Boosts Wynn Resorts  NASDAQ WYNN  
The Zacks analyst believes Wynn Resorts is likely to gain from increasing visitation pattern in Las Vegas  Revenues from Las Vegas operations rose 5 1  in second quarter 2019 

Product Launches   Digitalization Aid CNH Industrial  CNHI 
Per the Zacks analyst  CNH Industrial is launching several products across segments to remain at par with advancements  It is also working towards digitalization  electrification and automation 

New Downgrades
Travel Ban to Cuba   High Costs Hurt Norwegian Cruise  NCLH 
The Zacks analyst thinks that Norwegian Cruise is bearing the brunt of high fuel and net cruise costs  Meanwhile  policy change on travel to Cuba is likely to have a negative impact on profits 

High Input Costs Weigh on Kraft Heinz s  KHC  Bottom Line
Kraft Heinz witnessed high fixed and supply chain costs  including packaging and logistics  in the first half fiscal of 2019  Per the Zacks analyst  rising input costs are a threat to its bottom line 
undefined undefined",2019-08-13,Zacks Investment Research,https://www.investing.com/analysis/top-research-reports-amazon-caterpillar-vertex--more-200455179,200455179
120217,341732,VRTX,Surging Earnings Estimates Signal Upside For Vertex  VRTX  Stock,opinion,"Vertex Pharmaceuticals  NASDAQ VRTX  could be a solid addition to your portfolio given a notable revision in the company s earnings estimates  While the stock has been gaining lately  the trend might continue since its earnings outlook is still improving 
The rising trend in estimate revisions  which is a result of growing analyst optimism on the earnings prospects of this drugmaker  should get reflected in its stock price  After all  empirical research shows a strong correlation between trends in earnings estimate revisions and near term stock price movements  Our stock rating tool    the Zacks Rank    is principally built on this insight 
The five grade Zacks Rank system  which ranges from a Zacks Rank  1  Strong Buy  to a Zacks Rank  5  Strong Sell   has an impressive externally audited track record of outperformance  with Zacks  1 Ranked stocks generating an average annual return of  25  since 2008 
For Vertex  there has been strong agreement among the covering analysts in raising earnings estimates  which has helped push consensus estimates considerably higher for the next quarter and full year 
The chart below shows the evolution of forward 12 month Zacks Consensus EPS estimate 
12 Month EPS

Current Quarter Estimate Revisions
For the current quarter  the company is expected to earn  1 12 per share  which is a change of  2 75  from the year ago reported number 
Over the last 30 days  the Zacks Consensus Estimate for Vertex has increased 14 1  because six estimates have moved higher while three have gone lower 
Current Year Estimate Revisions
For the full year  the company is expected to earn  4 58 per share  representing a year over year change of  12 25  
The revisions trend for the current year also appears quite promising for Vertex  with eight estimates moving higher over the past month compared to three negative revisions  The consensus estimate has also received a boost over this time frame  increasing 11 25  
Favorable Zacks Rank
Thanks to promising estimate revisions  Vertex currently carries a Zacks Rank  2  Buy   The Zacks Rank is a tried and tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
Our research shows that stocks with Zacks Rank  1  Strong Buy  and 2  Buy  significantly outperform the S P 500 
Bottom Line
While strong estimate revisions for Vertex have attracted decent investments and pushed the stock 7 5  higher over the past four weeks  further upside may still be left in the stock  So  you may consider adding it to your portfolio right away ",2019-08-19,Zacks Investment Research,https://www.investing.com/analysis/surging-earnings-estimates-signal-upside-for-vertex-vrtx-stock-200456740,200456740
120218,341733,VRTX,Has Vertex Pharmaceuticals  VRTX  Outpaced Other Medical Stocks This Year ,opinion,"For those looking to find strong Medical stocks  it is prudent to search for companies in the group that are outperforming their peers  Has Vertex Pharmaceuticals  NASDAQ VRTX  been one of those stocks this year  Let s take a closer look at the stock s year to date performance to find out 
Vertex Pharmaceuticals is a member of our Medical group  which includes 866 different companies and currently sits at  4 in the Zacks Sector Rank  The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors 
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months  The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks  VRTX is currently sporting a Zacks Rank of  2  Buy  
Over the past 90 days  the Zacks Consensus Estimate for VRTX s full year earnings has moved 11 39  higher  This means that analyst sentiment is stronger and the stock s earnings outlook is improving 
Our latest available data shows that VRTX has returned about 8 73  since the start of the calendar year  In comparison  Medical companies have returned an average of 0 83   As we can see  Vertex Pharmaceuticals is performing better than its sector in the calendar year 
Breaking things down more  VRTX is a member of the Medical   Biomedical and Genetics industry  which includes 367 individual companies and currently sits at  95 in the Zacks Industry Rank  This group has lost an average of 2 96  so far this year  so VRTX is performing better in this area 
VRTX will likely be looking to continue its solid performance  so investors interested in Medical stocks should continue to pay close attention to the company ",2019-08-25,Zacks Investment Research,https://www.investing.com/analysis/has-vertex-pharmaceuticals-vrtx-outpaced-other-medical-stocks-this-year-200458550,200458550
120219,341734,VRTX,Moving Average Crossover Alert  Vertex Pharmaceuticals,opinion,Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   is looking like an interesting pick from a technical perspective  as the company is seeing favorable trends on the moving average crossover front  Recently  the 50 Day Moving Average for VRTX broke out above the 200 Day Simple Moving Average  suggesting a short term bullish trend This has already started to take place  as the stock has moved higher by 8 7  in the past four weeks  Plus  the company currently has a Zacks Rank  2  Buy  suggesting that now could definitely be the time for this breakout candidate More bullishness may especially be the case when investors consider what has been happening for VRTX on the earnings estimate revision front lately  Three estimates have gone lower in the past two months  compared to 8 higher  while the consensus estimate has also moved higher too So given this move in estimates  and the positive technical factors  investors may want to watch this breakout candidate closely for more gains in the near future  You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-08-27,Zacks Investment Research,https://www.investing.com/analysis/moving-average-crossover-alert-vertex-pharmaceuticals-200459477,200459477
120220,341735,VRTX,Vertex Pharmaceuticals  VRTX  Gains But Lags Market  What You Should Know,opinion,"Vertex Pharmaceuticals  NASDAQ VRTX  closed the most recent trading day at  178 98  moving  0 36  from the previous trading session  This change lagged the S P 500 s 1 27  gain on the day  Meanwhile  the Dow gained 1 25   and the Nasdaq  a tech heavy index  added 1 48  
Heading into today  shares of the drugmaker had gained 7 03  over the past month  outpacing the Medical sector s loss of 2 58  and the S P 500 s loss of 4 37  in that time 
Investors will be hoping for strength from VRTX as it approaches its next earnings release  The company is expected to report EPS of  1 12  up 2 75  from the prior year quarter  Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  945 82 million  up 20 56  from the year ago period 
For the full year  our Zacks Consensus Estimates are projecting earnings of  4 58 per share and revenue of  3 71 billion  which would represent changes of  12 25  and  21 69   respectively  from the prior year 
Investors might also notice recent changes to analyst estimates for VRTX  Recent revisions tend to reflect the latest near term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Our research shows that these estimate changes are directly correlated with near term stock prices  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  Within the past 30 days  our consensus EPS projection has moved 11 07  higher  VRTX is holding a Zacks Rank of  2  Buy  right now 
Digging into valuation  VRTX currently has a Forward P E ratio of 38 93  This represents a premium compared to its industry s average Forward P E of 27 08 
Investors should also note that VRTX has a PEG ratio of 1 73 right now  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  The Medical   Biomedical and Genetics was holding an average PEG ratio of 1 92 at yesterday s closing price 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This group has a Zacks Industry Rank of 82  putting it in the top 33  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2019-08-29,Zacks Investment Research,https://www.investing.com/analysis/vertex-pharmaceuticals-vrtx-gains-but-lags-market-what-you-should-know-200460103,200460103
120242,341757,VRTX,Gilead has multiple prospects if it decides to pull trigger on acquisition,news,Barron s Ben Levisohn reports that Gilead Sciences  GILD  1 3   has a range of attractive candidates should it decide to spend some its  32B cash hoard on an acquisition  a virtual certainty after the recent momelotinib disappointment Considering the company s stated interest in oncology  obvious choices are Incyte  INCY  1 1   and TESARO  TSRO  3   Venturing out into the rare disease space  Alexion Pharmaceuticals  ALXN  1 6    Vertex Pharmaceuticals  VRTX  1 6   and BioMarin Pharmaceutical  BMRN  1 1   are attractive fare None of these companies are a surprise to biotech followers  All have been noted as buyout targets for some time now ,2016-11-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/gilead-has-multiple-prospects-if-it-decides-to-pull-trigger-on-acquisition-442319,442319
120249,341764,VRTX,Biotech Stock Roundup  BIIB Q2 Earnings Top   CELG s Otezla Label Expanded ,opinion,"It was a busy week for the biotech sector with Biogen   NASDAQ BIIB   kick starting the second quarter earnings season  Meanwhile  pipeline updates from quite a few companies were also a key area of focus in the sector  Celgene   NASDAQ CELG   obtained FDA approval for the label expansion of Otezla  while Vertex   NASDAQ VRTX   submitted its NDA for a triple combination to treat cystic fibrosis Recap of the Week s Top Stories Biogen Fires on All Cylinders in Q2  Biogen  second quarter 2019 results  wherein it easily beat earnings and sales expectations  Revenue growth was principally driven by higher sales of key multiple sclerosis  MS  drug  Tecfidera  globally and spinal muscular atrophy  SMA  drug  Spinraza  in the United States  Backed by a strong second quarter  the company raised its annual guidance for revenues and earnings per share  and lowered the same for costs and tax expenses Vertex Submits NDA for Triple Combination Regime  Vertex Pharmaceuticals Incorporated submitted a New Drug Application  NDA  to the FDA for its triple combination regimen   VX 445  elexacaftor   tezacaftor and ivacaftor   for cystic fibrosis   The NDA includes a request for Priority Review  which will shorten the FDA s review period to eight months from the date of submission versus the standard review timeline of 12 months from submission  The NDA was supported by previously disclosed positive results of two global phase III studies   a 24 week phase III study in patients with one F508del mutation and one minimal function mutation  and a 4 week phase III study in patients with two F508del mutations Vertex currently carries a Zacks Rank  1  Strong Buy   You can see  Celgene Gets FDA Nod for Label Expansion of Otezla  Updates Collaboration With Jounce  Celgene announced that the FDA has approved Otezla for the treatment of adult patients with oral ulcers associated with Beh et s Disease  The approval was based on positive results from the RELIEF study  wherein Otezla reduced the number and pain of oral ulcers in the 12 week placebo controlled phase III study  Notably  the drug is already approved for two additional indications in the United States  for the treatment of patients with moderate to severe plaque psoriasis  who are candidates for phototherapy or systemic therapy  and adult patients with active psoriatic arthritis  Hence  the drug is now approved for three indications in the United States  The drug is also under review in Japan  regulatory decision is expected in the second half of 2019  and Europe for this indication Meanwhile  Celgene also updated its collaboration with Jounce Therapeutics   NASDAQ JNCE    following which shares of the latter surged  The original collaboration was announced in July 2016  Under the terms of a new agreement  Celgene has licensed worldwide rights to JTX 8064  a highly selective  potential first in class antibody that targets the LILRB2 receptor on macrophages  to Jounce  Jounce will retain full worldwide rights to its pipeline beyond JTX 8064  including vopratelimab  JTX 4014 and all discovery programs  Both companies have also entered a mutual agreement to terminate their original collaboration agreement Gilead Licenses Research Programs From Novartis  Provides Other Updates  Gilead Sciences   NASDAQ GILD   licensed three preclinical antiviral programs from Novartis  including investigational agents for the treatment of human rhinovirus  influenza and herpes viruses  Per the terms  the company will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets  In exchange  Novartis will receive an upfront payment and an additional  291 million as milestone payments Gilead also announced data from two phase III trials   one demonstrating the effectiveness of switching to Biktarvy  bictegravir 50mg emtricitabine 200mg tenofovir alafenamide 25mg tablets  B F TAF  from other regimens in women  and another evaluating the potential for the single tablet regimen to be an effective treatment option in virologically suppressed patients with known resistance to nucleo s tide or non nucleo s tide reverse transcriptase inhibitors  At week 96  99 5  of women  who received Biktarvy throughout the study duration  and 98 5  of women  who switched to Biktarvy at week 48  maintained virologic suppression with no development of treatment emergent resistance FDA Cancels Meeting for Intra Cellular s Schizophrenia Treatment  Intra Cellular Therapies  Inc    NASDAQ ITCI   announced that the FDA has cancelled the Psychopharmacologic Drugs Advisory Committee meeting scheduled for Jul 31  2019  to discuss its NDA for lumateperone for the treatment of schizophrenia  The company recently provided additional information to the FDA in response to information requests related to non clinical studies  The FDA cancelled the meeting to get sufficient time to review this and any forthcoming information  as it continues the NDA review  Consequently  the Prescription Drug User Fee Act  PDUFA  target action date of Sep 27  2019  for the same might be extended PerformanceMedical   Biomedical and Genetics Industry 5YR   Return
 The NASDAQ Biotechnology index lost 0 20  in the last five trading sessions  Among the major biotech giants  Regeneron lost 3 65  in the period  Over the past six months  shares of Celgene have gained 2 89   whereas the Biogen stock has declined 26 55    See the last biotech stock roundup here    What s Next in Biotech Stay tuned for earnings updates and other pipeline news The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-07-23,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-biib-q2-earnings-top--celgs-otezla-label-expanded-200444126,200444126
120250,341765,VRTX,Vertex Pharmaceuticals  VRTX  Tops Q2 Earnings And Revenue Estimates,opinion,"Vertex Pharmaceuticals  NASDAQ VRTX  came out with quarterly earnings of  1 26 per share  beating the Zacks Consensus Estimate of  1 03 per share  This compares to earnings of  0 94 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 22 33   A quarter ago  it was expected that this drugmaker would post earnings of  0 98 per share when it actually produced earnings of  1 14  delivering a surprise of 16 33  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Vertex  which belongs to the Zacks Medical   Biomedical and Genetics industry  posted revenues of  941 29 million for the quarter ended June 2019  surpassing the Zacks Consensus Estimate by 6 52   This compares to year ago revenues of  752 16 million  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Vertex shares have added about 2 3  since the beginning of the year versus the S P 500 s gain of 20 2  
What s Next for Vertex 
While Vertex has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Vertex was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  1  Strong Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 03 on  898 60 million in revenues for the coming quarter and  4 21 on  3 55 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Biomedical and Genetics is currently in the top 24  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-07-31,Zacks Investment Research,https://www.investing.com/analysis/vertex-pharmaceuticals-vrtx-tops-q2-earnings-and-revenue-estimates-200448483,200448483
120251,341766,VRTX,Vertex  VRTX  Beats On Q2 Earnings  Ups CF Product Sales View,opinion,Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   delivered second quarter 2019 earnings per share of  1 26  beating the Zacks Consensus Estimate of  1 03  Moreover  the figure came ahead of the year ago earnings of 94 cents  Strong cystic fibrosis  CF  product revenues led to higher profits in the reported quarter Vertex s revenues logged  941 2 million in the second quarter  also surpassing the Zacks Consensus Estimate of  884 million  The company s sales increased 25  year over year  driven by the rapid uptake of its newest CF medicine  Symdeko  in the United States and Germany  Symdeko is marketed under the trade name Symkevi in the EU Shares of Vertex were up almost 1  in after hours trading following the earnings announcement on Wednesday  In fact  so far this year  the stock has inched up 0 6  compared with the  rise of 0 1  Last week  Vertex appointed Dr  Reshma Kewalramani as its new president and CEO  replacing the former chairman  president and CEO Dr  Jeffrey Leiden  who will now take responsibility as the board s executive chairman effective Apr 1  2020 Quarter in DetailVertex s second quarter top line comprised CF product revenues of  940 3 million plus collaborative and royalty revenues of  0 91 million  The company markets three CF medicines  namely Kalydeco  ivacaftor   Orkambi  lumacaftor ivacaftor  and Symdeko  a combination of tezacaftor and ivacaftor  Total CF product revenues rose 25 4  year over year  mainly driven by the speedy adoption and strong demand for its newest CF medicine Symdeko in the United States  The drug was approved both in the United States and Europe last year Symdeko generated sales of  362 million in the reported quarter  reflecting an increase of 94 6  year over year  The drug has seen strong demand since its launch as more patients are resorting to treatment with the same  Symdeko is off to a flying start in the ex U S  markets  especially with its recent launch in Germany In June  the FDA approved Symdeko to treat children with CF aged from six to 11 years with certain mutations in the CFTR gene  This label expansion should boost the drug s sales in the future quarters  Vertex plans to submit a marketing application in Europe in the second half of 2019 for the given patient population Meanwhile  Kalydeco   Vertex s first CF medicine   generated sales of  262 million in the reported quarter  reflecting an increase of 3 6  year over year Vertex s second CF medicine  Orkambi  generated sales of  316 million in the reported quarter  reflecting an increase of 1 6  year over year On second quarter conference call  management stated that owing to new reimbursement agreements in countries outside the United States and new regulatory approvals for children  Vertex continues to see new patients starting treatment with Kalydeco and Orkambi Notably  Kalydeco and Orkambi were initially hit by a switch in their patient base to Symdeko Costs RiseAdjusted research and development  R D  expenses decreased 3 4  to  271 2 million in the second quarter Adjusted selling  general and administrative  SG A  expenses escalated 14 5  to  122 7 million in the reported quarter 2019 Revenue GuidanceVertex raised its 2019 outlook for sales from CF products and the combined operating costs The company now expects total revenues for CF products in the range of  3 60 3 70 billion  which was previously expected in the band of  3 45  3 55 billion However  combined adjusted research and development  R D  plus selling  general and administrative  SG A  expenses in 2019 are anticipated in the band of  1 65  1 70 billion  which is unchanged from the previous view Pipeline   Regulatory UpdatesLast month  Vertex submitted a new drug application  NDA  to the FDA for its triple combination regimen comprising VX 445  elexacaftor   tezacaftor and ivacaftor to treat CF patients aged 12 years and older  If approved  the triple combination regimen will help Vertex address a significantly larger CF patient population   almost 90  of patients with CF   in the future  A similar regulatory filling in Europe is expected in the fourth quarter of 2019 Vertex chose the VX 445 triple combination regimen over the VX 659   tezacaftor   ivacaftor triple regimen for regulatory submission  based on a detailed analysis of multiple factors  which showed that the VX 445 triple regimen will be beneficial to a larger patient population compared to the VX 665 combo Another phase III study is currently enrolling patients to evaluate the triple combination of VX 445  tezacaftor and ivacaftor in children aged from six to 11 years Vertex s non CF pipeline  though in early stage  looks interesting with treatments being developed for beta thalassemia  sickle cell disease  alpha 1 antitrypsin deficiency  AAT   APOL1 mediated kidney diseases and pain Notably  Vertex has a partnership with CRISPR Therapeutics   NASDAQ CRSP   to evaluate an investigational gene editing treatment  CTX001  for the two devastating diseases   sickle cell disease and thalassemia  Phase I II studies on CTX001 in adult patients with transfusion dependent b thalassemia and sickle cell disease are currently ongoing In June  Vertex announced the expansion of its collaboration with CRISPR Therapeutics and the acquisition of the privately held Exonics Therapeutics to boost its gene editing capabilities to develop novel therapies for Duchenne muscular dystrophy  DMD  and Myotonic dystrophy type 1  DM1  Vertex is advancing VX 814 into a phase II dose ranging study for the treatment of AAT deficiency for patients with two Z mutations  Vertex plans to have clinical data from this study in 2020  The company also has a second AAT corrector  VX 864  in phase I development On the conference call  Vertex announced that it initiated a phase I study on VX 961  a NaV1 8 inhibitor  to address various pain indications  Recently  Vertex also began a phase 1 study on VX 147 for the treatment of APOL1 mediated focal segmental glomerulosclerosis  FSGS  and other serious kidney diseases Vertex Pharmaceuticals Incorporated Price  Consensus and EPS Surprise   Zacks Rank   Stocks to ConsiderVertex currently sports a Zacks Rank  1  Strong Buy   Other top ranked stocks from the healthcare sector include Acorda Therapeutics  Inc    NASDAQ ACOR   and Repligen Corporation   NASDAQ RGEN    both carrying a Zacks Rank of 1  You can see  Acorda s loss per share estimates have been narrowed 2 2  for 2019 and 1 3  for 2020 over the past 60 days Repligen s earnings estimates have been revised 4 3  upward for 2019 and 3 6  for 2020 over the past 60 days  The stock has surged 79  year to date Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-08-01,Zacks Investment Research,https://www.investing.com/analysis/vertex-vrtx-beats-on-q2-earnings-ups-cf-product-sales-view-200449331,200449331
120252,341767,VRTX,Puma  PBYI  Q2 Earnings Miss  Nerlynx Sales Rise  Stock Up,opinion,"Puma Biotechnology  Inc    NASDAQ PBYI   incurred a loss of 97 cents per share in the second quarter of 2019  wider than the Zacks Consensus Estimate of a loss of 90 cents The loss per share includes an impact of stock based compensation expense  Excluding such impact  adjusted net loss per share was 57 cents per share versus 59 cents in the year ago quarter Total revenues consist of net product revenues from the sales of Nerlynx  Puma Biotech s only marketed drug  and royalty revenues  In the second quarter of 2019  total revenues were  53 9 million  comprising  53 8 million of product revenues from Nerlynx and  0 1 million of royalty revenues from two licensing partners  Moreover  sales beat the Zacks Consensus Estimate of  53 0 million and were also higher than the year ago figure of  50 8 million Nerlynx is indicated for extended adjuvant treatment of HER2 positive early stage breast cancer in patients  previously treated with Roche s   OTC RHHBY   Herceptin based adjuvant therapy  It was approved in the EU last September Sales of Nerlynx were up 18  on a sequential basis  We remind investors that a higher number of patients discontinuing treatment with Nerlynx due to its side effects had resulted in a sequential decline in Nerlynx s sales in the first quarter  Sales improved sequentially in the second quarter due to higher bottle volumes  Nerlynx s bottle volumes rose 7 6  sequentially in the quarter Puma has established a specialty distribution network in the past two years by striking partnerships with physician networks to allow in office dispensing  Growth in in office dispensing setting coupled with aggressive sales efforts led to better volumes in the second quarter  The improvement in Nerlynx s sales and volumes drove the stock almost 23  higher in after hours trading on Thursday  However  the stock has declined 54 7  this year so far  underperforming the  s decrease of 2 5  Total operating costs in the quarter were  79 7 million  down 13 6  year over year  Research and development expenses  including for stock based compensation expense  were  36 9 million in the quarter  down 14 8  from the year ago period  Selling  general and administrative expenses  including for stock based compensation expense  decreased 16 5  year over year to  33 5 million Pipeline   Other UpdateSeveral studies on Nerlynx targeting different types of breast cancer patient populations and in earlier line settings are currently underway  In July 2019  the company submitted a supplemental new drug application  sNDA  to the FDA for the approval of Nerlynx in combination with Roche s Xeloda  capecitabine  to treat third line HER2 positive metastatic breast cancer  The sNDA was based on data from the phase III NALA study   If the company gets an approval to include the NALA study outcome on Nerlynx s label  it will be eligible to treat a broader breast cancer population  which can drive sales higher Apart from the HER2 positive breast cancer indication  the company believes that neratinib holds potential for the treatment of several other cancers as well  including non small cell lung cancer and other tumor types that over express or have a mutation in HER2 A key analysis on Nerlynx is the phase II SUMMIT basket study in HER2 mutated cancers  Puma plans to meet with the FDA in the third quarter to discuss the development and regulatory strategy for this study In April  Puma entered into a licensing agreement with Pierre Fabre per which the latter will develop and commercialize Nerlynx within Europe and parts of Africa  Pierre Fabre is expected to launch Nerlynx in Germany  the United Kingdom and Austria in the fourth quarter of this year In July  Puma s licensing partner in Canada  Knight Therapeutics gained marketing approval for Nerlynx from Health CanadaGuidanceIn 2019  Puma expects Nerlynx U S  sales to be in the range of  220 million to  240 million  Meanwhile  licensing and royalty revenues from its licensing partners are expected in the range of  56 million to  60 million in 2019Zacks Rank   Stocks to ConsiderPuma Biotech currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the biotech sector include Vertex Pharmaceuticals   NASDAQ VRTX   and Amgen   NASDAQ AMGN    both carrying a Zacks Rank  2  Buy   You can see  Puma Biotechnology  Inc  Price  Consensus and EPS Surprise
    
Vertex s earnings per share estimates have moved up from  4 22 to  4 58 for 2019 and from  5 76 to  6 03 for 2020 over the past 30 days  The company delivered a positive earnings surprise in all the trailing four quarters with the average being 17 87   Share price of the company has increased 10 4  this year so far Amgen s earnings estimates have risen from  13 92 to  14 23 for 2019 and from  14 76 to  14 87 for 2020 over the past 30 days Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-08-08,Zacks Investment Research,https://www.investing.com/analysis/puma-pbyi-q2-earnings-miss-nerlynx-sales-rise-stock-up-200453700,200453700
120265,341780,VRTX,U S  stocks mixed  as Draghi vows not to cut interest rates any further,news,"Investing com    U S  stocks were mixed on a volatile  choppy day of trading as European Central Bank president Mario Draghi spooked global markets by vowing not to reduce rates any further after its Governing Council approved a wide range of stimulus measures on Thursday 
Earlier  the ECB unveiled a comprehensive set of easing initiatives on Thursday aimed at boosting economic growth throughout the euro zone and staving off deflation  The Governing Council used nearly all of the tools at its disposal to stimulate the economy by lowering three key rates at the meeting and extending the scope of its comprehensive Quantitative Easing program  Draghi s comments  however  triggered a sharp reversal on global equity and foreign exchange markets  as investors worried that Thursday s decisive moves could be the ECB s last attempts to rescue a flagging euro zone economy 
The Dow Jones Industrial Average fell by 5 23 or 0 03  to 16 995 13  while the S P 500 Composite index gained 0 31 or 0 02  to 1 989 57  Previously  both the Dow and the S P 500 closed higher in six of seven trading sessions dating back to last week  The Dow swung by as much as 300 points on Thursday  The NASDAQ Composite index  meanwhile  dipped by 12 22 or 0 26  to 1 989 57  as pharmaceutical and media stocks lagged 
On the S P 500  six of 10 sectors closed in the red  as stocks in the Technology and Industrials sectors lagged  Stocks in the Basic Materials and Telecommunications industries led  each gaining more than 0 3  on the session 
The top performer on the Dow was Merck   Company Inc  NYSE MRK   which gained 0 56 or 1 07 to 52 92 after the pharmaceutical giant announced plans to discontinue to a 20 year joint venture to sell vaccines with Sanofi  PA SASY  in the euro zone  The worst performer was EI du Pont de Nemours and Company  NYSE DD   which fell 1 29 or 2 03  to 62 16  Shares in DuPont  NYSE DD  are down approximately 16  since the multinational conglomerate announced a  130 billion merger with  Dow Chemical  Company  NYSE DOW  in mid December 
The biggest gainer on the NASDAQ was  Dollar Tree Inc   NASDAQ DLTR   which added 3 01 or 3 92  to 79 74 after chief rival DG saw its sales surge by 7  over the last quarter  The worst performer was Vertex Pharmaceuticals Inc  NASDAQ VRTX   which fell 2 34 or 2 76  to 82 29  Vertex Pharmaceuticals  NASDAQ VRTX  has come under heavy pressure in recent weeks amid allegations of price gouging with its Cystic Fibrosis drug 
Dollar General was the top performer on the S P 500 after surging 7 82 or 10 40  to 83 03  During the quarter  the company s revenues soared as customer demand rose for candy  tobacco products and perishables  The worst performer was Whole Foods Market Inc  NASDAQ WFM   which fell 1 00 or 2 95  to 32 92 
On the New York Stock Exchange  declining issues outnumbered advancing ones by a 1 844 to 1 241 margin ",2016-03-10,Investing.com,"https://www.investing.com/news/stock-market-news/u.s.-stocks-mixed,-as-draghi-vows-not-to-cut-interest-rates-any-further-389281",389281
120266,341781,VRTX,Wall Street rally fizzles out as oil  materials fall,news,"By Laila Kearney  Reuters    Wall Street closed lower on Wednesday as oil and materials share prices dropped while investors remained cautious a day after deadly bombing attacks in Belgium   The benchmark S P 500 index fell back into negative territory for the year after closing positive on Friday for the first time in 2016  U S  stocks  fading five week rally was further diminished by comments over the past two days by Federal Reserve officials  who expressed views that suggested an appetite for more U S  interest rate hikes than investors had anticipated  The possibility of more than the two expected rate hikes through December has sent the dollar higher  DXY   pushing down commodity prices  TRJCRB    That s basically what s leaning on the market today   said Peter Cardillo  Chief Market Economist at First Standard Financial in New York   It s all about commodities   Gold  and metals  prices fell as the dollar strengthened  U S  oil prices  CLc1   LCOc1  also were also damaged after data showing a rise in U S  stockpiles last week rekindled worries about a global glut  Eight of the 10 major S P sectors were lower  led by a 2 1 percent fall in the energy sector  SPNY    Chevron   N CVX  and ConocoPhillips  N COP  were among the biggest decliners  Utilities  SPLRCU  rose 0 7 percent and was the best performing sector  The Dow Jones industrial average  DJI  closed down 79 98 points  or 0 45 percent  to 17 502 59  the S P 500  SPX  lost 13 09 points  or 0 64 percent  to 2 036 71 and the Nasdaq Composite  IXIC  fell 52 80 points  or 1 1 percent  to 4 768 86  Adding to the downturn  investors were deterred by the shortened trading week ahead of the Good Friday holiday and uncertainty tied to Tuesday s bombings in Brussels  Cardillo said  Earnings weakness has been another concern for investors  with first quarter S P 500 earnings forecast to fall 6 9 percent from a year ago  according to Thomson Reuters data    Nike   N NKE  shares were down 3 8 percent at  62 44 after the world s largest footwear maker reported quarterly revenue below estimates  Gilead Sciences  O GILD  was down 3 9 percent at  90 08 while Merck  N MRK  was up 0 09 percent  A federal jury upheld the validity of two Merck patents in a high profile dispute over Gilead s blockbuster cure for hepatitis C  Gilead was the biggest drag on the S P 500 and the Nasdaq  Vertex Pharmaceuticals  O VRTX  fell 7 6 percent to  80 15 after Goldman Sachs  NYSE GS  cuts its price target on the stock  Yum Brands  N YUM  was up 2 percent at  80 55 after the Wall Street Journal reported that the fast food chain s owner was in talks with KKR  N KKR  about a possible sale of a 19 9 percent stake in its China business  Volume was lighter than in recent sessions  About 6 8 billion shares changed hands on U S  exchanges  compared with the 8 1 billion daily average for the past 20 trading days  Declining issues outnumbered advancing ones on the NYSE by 2 257 to 771  for a 2 93 to 1 ratio on the downside  on the Nasdaq  2 221 issues fell and 579 advanced for a 3 84 to 1 ratio favoring decliners  
The S P 500 posted 17 new 52 week highs and no new lows  the Nasdaq recorded 21 new highs and 40 new lows ",2016-03-23,Reuters,https://www.investing.com/news/stock-market-news/decline-in-energy-stocks-weighs-on-wall-street-391508,391508
120273,341788,VRTX,Is Vertex Pharmaceuticals  VRTX  Outperforming Other Medical Stocks This Year ,opinion,"The Medical group has plenty of great stocks  but investors should always be looking for companies that are outperforming their peers  Vertex Pharmaceuticals  NASDAQ VRTX  is a stock that can certainly grab the attention of many investors  but do its recent returns compare favorably to the sector as a whole  One simple way to answer this question is to take a look at the year to date performance of VRTX and the rest of the Medical group s stocks 
Vertex Pharmaceuticals is one of 870 individual stocks in the Medical sector  Collectively  these companies sit at  2 in the Zacks Sector Rank  The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors 
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks  This system has a long record of success  and these stocks tend to be on track to beat the market over the next one to three months  VRTX is currently sporting a Zacks Rank of  1  Strong Buy  
Over the past three months  the Zacks Consensus Estimate for VRTX s full year earnings has moved 3 24  higher  This means that analyst sentiment is stronger and the stock s earnings outlook is improving 
Our latest available data shows that VRTX has returned about 6 90  since the start of the calendar year  In comparison  Medical companies have returned an average of 4 58   As we can see  Vertex Pharmaceuticals is performing better than its sector in the calendar year 
Looking more specifically  VRTX belongs to the Medical   Biomedical and Genetics industry  a group that includes 368 individual stocks and currently sits at  64 in the Zacks Industry Rank  On average  stocks in this group have gained 0 98  this year  meaning that VRTX is performing better in terms of year to date returns 
Investors with an interest in Medical stocks should continue to track VRTX  The stock will be looking to continue its solid performance ",2019-07-17,Zacks Investment Research,https://www.investing.com/analysis/is-vertex-pharmaceuticals-vrtx-outperforming-other-medical-stocks-this-year-200441267,200441267
120278,341793,VRTX,U S  stocks mixed as Nike boosts Dow  biotech s weigh on NASDAQ  S P 500,news,"Investing com    U S  stocks were mixed on Friday ending a bearish week  as investors digested hawkish comments from Janet Yellen suggesting that it is likely the Federal Reserve will raise short term interest rates before the end of the year 
Speaking at the University of Massachusetts Amherst on Thursday evening  the Fed chair said conditions in the economy will likely be appropriate for the U S  central bank to raise the target range on its benchmark Federal Funds Rate at some point in 2015  Downplaying widespread concerns related to the deceleration of inflation  Yellen noted that the Fed believes inflation can move to its targeted goal of 2  once transitory factors from falling energy prices and a stronger dollar evaporate 
The Dow Jones Industrial Average still closed higher for the session  after receiving a much needed boost from  Nike  Inc  NYSE NKE   One day after crushing analysts  expectations for its first quarter earnings  the global apparel giant surged nearly 9  on Friday to reach a fresh all time high at 125 94  The NASDAQ Composite index and the S P 500 Composite index  however  both closed lower amid a weak performance among biotech stocks  The Dow gained 113 35 or 0 7  to close at 16 314 67  while the NASDAQ fell 47 98 or 1 01  to end the week at 4 686 50  The NASDAQ Biotechnology exchange traded fund slumped nearly 5  on the day  suffering one of its worst one day declines since April  2014 
The S P 500  meanwhile  lost 0 90 or 0 05  to 1 931 34  even as six of 10 sectors closed in the green  Stocks in the Health Care  Consumer Services and Basic Materials sectors lagged  while stocks in the Financials  Utilities and Consumer Goods industries led  Health Care stocks plunged nearly 3  on the session 
Nike ended Friday as the top performer on the Dow after soaring 10 21 or 8 89  to 125 00  On Thursday  the Beaverton  Oregon apparel company posted earnings of  8 4 billion and adjusted earnings per share of 1 34 for the first quarter of fiscal year 2016  significantly above analysts  forecasts of  8 22 billion and 1 19 respectively  In terms of revenues  Nike sales increased in North America by more than 8  on a currency neutral basis and 30  in China  Nike shares are now up more than 40  year to date  The worst performer was UnitedHealth Group Incorporated  NYSE UNH   which fell 4 72 or 3 90  to 116 37 
The biggest gainer on the NASDAQ was Cisco Systems Inc  NASDAQ CSCO   which rose 0 62 or 2 42  to 26 03  Earlier this week  Inspur  a Chinese cloud computing company said it inked a deal with the Silicon Valley based networking device company to sell networking technologies in China  The worst performer was Vertex Pharmaceuticals Inc  NASDAQ VRTX   which plunged 7 83 and 7 05  to 103 28 
Nike was also the top performer on the S P 500  just ahead of Genworth Financial Inc  NYSE GNW  which gained 0 20 or 4 21  to 4 95  Shares in Genworth Financial  NYSE GNW  are still down by nearly 65  on the year  A host of prominent pharmaceutical stocks  including  Vertex Pharmaceutical  Regeneron Pharmaceuticals Inc  NASDAQ REGN   Alexion Pharmaceuticals Inc  NASDAQ ALXN  and Perrigo all closed Friday s session among the biggest losers on the S P 500 
On the New York Stock Exchange  declining issues outnumbered advancing ones by a 1 625 to 1 479 margin ",2015-09-25,Investing.com,"https://www.investing.com/news/commodities-news/u.s.-stocks-mixed-as-nike-boosts-dow,-biotech's-weigh-on-nasdaq,-s-p-500-363345",363345
120283,341798,VRTX,Biotech Stock Roundup  Label Expansion For CELG s Drugs  Setback For IMGN,opinion,"It was a busy week for the biotech sector  While leading biotech Celgene Corporation   NASDAQ CELG   obtained EC approval for label expansion of its drugs  ImmunoGen   NASDAQ IMGN   crashed on the outcome of a meeting with the FDA  However  Adverum   NASDAQ ADVM   gained on the news of removal of clinical hold on its study Recap of the Week s Top Stories Label Expansion of Celgene s Revlimid  Imnovid Approved in Europe  Celgene  that the European Commission  EC  has approved the label expansion of IMiD medications  leading oncology drug Revlimid  lenalidomide  and Imnovid  The EC approved Revlimid in combination with Velcade and dexamethasone  RVd  for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant  The approval for RVd was supported by data from SWOG S0777  a phase III trial evaluating the triplet combination  RVd  in adult patients with previously untreated multiple myeloma The commission also approved Imnovid in combination with Velcade and dexamethasone  PVd  for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide  The approval of PVd was supported by data from OPTIMISMM study  which evaluated the regimen in patients who were previously treated with Revlimid An approval was in the cards as the CHMP had recommended approval of the same last month  The new triplet regimens should improve outcomes for both newly diagnosed patients as well as those who have relapsed or become refractory to first line therapy Celgene currently carries a Zacks Rank  2  Buy   You can see  FDA Recommends New Study for ImmunoGen Lead Drug  Shares of ImmunoGen  after the FDA recommended a new study on lead candidate   mirvetuximab soravtansine  The agency has advised the company to conduct a phase III study to evaluate the safety and efficacy of mirvetuximab soravtansine in patients with high folate receptor alpha  FR   positive  platinum resistant ovarian cancer  ImmunoGen requested the meeting to discuss the results of the phase III FORWARD I trial and a potential path for registration of mirvetuximab as monotherapy The agency concluded that the data  assessing the secondary endpoints from the study  could not be used to support an application for accelerated approval and the company needs to conduct an additional trial  An additional study will involve extra costs  The company had approximately  270 million on the balance sheet at the end of the first quarter FDA Lifts Hold on Adverum Study  The FDA lifted the clinical  on the second cohort of phase I trial on lead candidate  ADVM 022  The hold was lifted as the independent data monitoring committee  DMC  unanimously voted to proceed with dose escalation per protocol  following their review of the safety data from the first cohort  No patient in the first cohort has experienced a serious adverse event  SAE   with the first patient completing the 24 week  6 month  assessment The phase I study  OPTIC  is evaluating the candidate for age related macular degeneration  wet AMD   As a result  the study can now evaluate a higher dose of 2 x 10 12 vg eye  which is three times the dose of 6 x 10 11 vg eye evaluated in the first cohort  However  Adverum will begin dosing in the second cohort with a lower dose of 2 x 10 11 vg eye  which is three times lesser than the dosage in the first cohort based on the robust preliminary anatomical response observed to date   The dosing of patients in the second cohort will start next month Vertex Enters Into a Collaboration With Kymera  Vertex Pharmaceuticals   NASDAQ VRTX   entered into a four year strategic agreement with Kymera Therapeutics to advance small molecule protein degraders against multiple targets  The collaboration will leverage Kymera s expertise in targeted protein degradation and its proprietary Pegasus drug discovery platform to accelerate the development of first in class drugs for serious diseases Kymera will conduct research activities in multiple targets under the collaboration while Vertex has the option to exclusively license molecules against the designated target  Kymera is also eligible to receive more than  1 billion in potential payments based upon the successful achievement of specified research  development  regulatory  and commercial milestones for up to six programs optioned as part of the collaboration  Moreover  Vertex will pay tiered royalties on future net sales on any products that result from this collaboration Biogen Urges Shareholders to Reject Tender Offer  Biogen   NASDAQ BIIB   announced that it has received a notice of an unsolicited mini tender offer by TRC Capital Corporation to purchase up to 500 000 shares of Biogen s common stock at a price of  216 25 per share in cash  However  the company does not endorse TRC Capital s unsolicited mini tender offer and had urged shareholders not to accept the offer PerformanceMedical   Biomedical and Genetics Industry 5YR   Return
  
The NASDAQ Biotechnology index has gained 1 4  in the past five trading sessions  Among the major biotech giants  Celgene gained 2 2  in the period  Over the past six months  shares of Celgene have surged 42 5  whereas Biogen stock has lost 26 2    See the last biotech stock roundup here    What s Next in Biotech Stay tuned for pipeline development news Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-05-21,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-label-expansion-for-celgs-drugs-setback-for-imgn-200423985,200423985
120287,341802,VRTX,Why Is Vertex  VRTX  Down 3 5  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Vertex Pharmaceuticals  NASDAQ VRTX   Shares have lost about 3 5  in that time frame  outperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Vertex due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Vertex Q1 Earnings and Revenues Surpass EstimatesVertex s first quarter 2019 earnings per share of  1 14 beat the Zacks Consensus Estimate of 98 cents  Moreover  earnings rose 50  year over year as higher product sales were partially offset by higher costs and taxes Revenues were  858 4 million in the first quarter and surpassing the Zacks Consensus Estimate of  851 0 million  The company s sales surged 34  year over year  driven by the rapid uptake of its newest CF medicine  Symdeko  in the United States CF Franchise Sales StrongVertex s first quarter revenues consisted of sales from its CF products such as Kalydeco  Orkambi and Symdeko and collaborative and royalty revenues of  1 2 million Total CF product revenues were  857 0 million in the quarter  up 34 4  year over year  mainly driven by the rapid uptake of Symdeko in the United States and the recent launch of Symkevi in Germany However  CF product revenues declined sequentially in the first quarter hurt by a channel inventory build that occurred at the end of 2018 and higher gross to net adjustments this quarter Symdeko generated sales of  320 3 million in the reported quarter  reflecting an increase of 8 8  sequentially as new patients initiated treatment  Symdeko revenues included  32 million of Symkevi revenues from ex U S  markets primarily from Germany  On the call  the company said that Symkevi launch is off to a strong start in Germany The company said that Symdeko demand came from all eligible groups of patients including treatment na ve F508del homozygous patients  those who have discontinued Orkambi treatment and also patients switching from Orkambi or Kalydeco to Symdeko In 2019  the company expects additional patients to initiate treatment with Symdeko in the United States and EU  including younger patients in the United States  which should boost revenues from the drug Kalydeco sales declined 2 4  to  244 million year over year due to patient switching to Symdeko Orkambi sales decreased 17 2  year over year to  293 million due to a switch in patient base to Symdeko from Orkambi as patients discontinued Orkambi to start treatment with Symdeko  which partially offset the increase in eligible patient population due to label expansion approvals Costs RiseAdjusted operating income rose 81  to  377 million in the quarter driven by higher revenues and disciplined spending Adjusted research and development  R D  expenses increased 5 1  to  273 2 million in the first quarter due to expansion of Vertex s pipeline in CF and other new disease areas Adjusted selling  general and administrative  SG A  expenses escalated 14 8  to  114 3 million in the reported quarter due to investments made in supporting CF patients  treatment  globally 2019 Revenue GuidanceVertex maintained its 2019 outlook for CF product sales and combined operating costs The company expects total full year revenues for CF products to be in the range of  3 45  3 55 billion  indicating year over year growth of approximately 15   The full year impact of Symdeko s launch  ex US reimbursement agreements and label expansions of the CF drugs are expected to drive CF product revenue growth in 2019 Combined adjusted research and development  R D  plus selling  general and administrative  SG A  expenses in 2019 are anticipated in the range of  1 65  1 70 billion  Adjusted tax rate is still expected to be between 21  and 22  The increase in operating expense was due to estimated costs related to the development and the potential launch of triple combinations regimen and expansion of early stage non CF pipeline 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates  The consensus estimate has shifted 7 35  due to these changes 
VGM Scores
At this time  Vertex has a nice Growth Score of B  a grade with the same score on the momentum front  However  the stock was allocated a grade of D on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending upward for the stock  and the magnitude of these revisions looks promising  It comes with little surprise Vertex has a Zacks Rank  2  Buy   We expect an above average return from the stock in the next few months ",2019-05-29,Zacks Investment Research,https://www.investing.com/analysis/why-is-vertex-vrtx-down-35-since-last-earnings-report-200426534,200426534
120288,341803,VRTX,Vertex Selects Triple Combo Regimen For Regulatory Submission,opinion,"Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   announced that it has selected the triple combination regimen of next generation CFTR corrector VX 445  elexacaftor   tezacaftor and Kalydeco  ivacaftor  for regulatory submissions globally  The company is developing the combination regimen for treating cystic fibrosis  CF  patients  aged 12 and older  with one F508del mutation and one minimal function mutation or with two F508del mutations The company is planning to file a new drug application in the third quarter of 2019  followed by a marketing authorization application in Europe in the fourth quarter of this year Investors cheered the news as shares of Vertex gained 2 2  on May 30  Vertex s shares have increased 3 7  this year so far against the  s decrease of 0 2  Notably  Vertex was developing two triple combination regimens   either VX 445 or VX 659 in combination with tezacaftor and Kalydeco   simultaneously for a similar patient population with CF  Two 4 week and two 24 week phase III studies were evaluating the combination regimens separately Both regimens achieved unprecedented and statistically significant results in phase III studies in eligible patient population and had similar and positive benefit risk profiles  However  Vertex chose the VX 445 triple combination regimen for regulatory submission based on detailed analysis of multiple factors  which showed that the regimen will be beneficial for larger patient population compared to the VX 665 combo Two phase III studies evaluating its VX 445 combo met the primary endpoint of significant improvement in lung function in patients suffering from CF  The improvement in lung function was measured as mean absolute improvements in percent predicted forced expiratory volume in one second or ppFEV1  Cystic fibrosis is a rare genetic disease that causes chronic lung infections and progressive lung damage In the 24 week study evaluating patients with one F508del mutation and one minimal function mutation  data showed that the triple combination regimen led to a mean absolute improvement in ppFEV1 of 13 8 percentage points from baseline through week four of treatment compared to placebo  The improvement was maintained over 24 weeks of treatment The 4 week study yielded a mean absolute improvement in ppFEV1 of 10 0 percentage points from baseline at week four when VX 445 was added in patients already receiving tezacaftor and ivacaftor compared to placebo plus tezacaftor and ivacaftor Please note that many other companies like AbbVie   NYSE ABBV   and Proteostasis Therapeutics  Inc    NASDAQ PTI   are also developing triple CFTR combinations for CF  Proteostasis Therapeutics is expected to report top line data from its triple combo CF medicine in 2019 Apart from its strong CF pipeline  Vertex is also developing other treatments targeting several indications and is focusing on gene therapies as well  Vertex has a partnership with CRISPR Therapeutics   NASDAQ CRSP   to evaluate an investigational gene editing treatment  CTX001  for the two devastating diseases   sickle cell disease and thalassemia Vertex Pharmaceuticals Incorporated Price
    Zacks RankVertex currently carries a Zacks Rank  2  Buy   You can see  This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-05-31,Zacks Investment Research,https://www.investing.com/analysis/vertex-selects-triple-combo-regimen-for-regulatory-submission-200426994,200426994
120292,341807,VRTX,5 Biotech Stocks To Buy Right Now,opinion,"Many of the companies in the biotech sector have had a rough past few weeks with many stocks hitting their lowest levels since January  That being said  here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years  All the stocks in this list are a Zacks Rank  2  Buy  or better 
Vertex Pharmaceuticals Inc    NASDAQ VRTX  
Zacks Rank  2  Buy 
Vertex Pharmaceuticals is a Boston based biotech firm that specializes in the development and production of Cystic Fibrosis treatments  Vertex was recently upgraded to a Zacks Rank  2  Buy  on the back of earnings estimate revisions for the current fiscal year trending in the right direction  On top of 3 4  projected growth this year  the Zacks Consensus Estimate calls for VRTX s fiscal 2020 earnings to climb 37  above our 2019 estimate  This bottom line growth is projected to be fueled by estimated revenue growth of 16 7  this year and a further 22  expansion in 2020  Vertex currently earns a Style Score of  B  for Growth 
Gilead Sciences Inc    NASDAQ GILD  
Zacks Rank  2  Buy 
California based Gilead Sciences is a drug company primarily focused on developing antiviral drugs  Gilead had 11 upwards earnings estimate revisions over the past 60 days  compared to just 1 downward revision for fiscal 2019  This shows analysts are more optimistic about the company s current year earnings  Gilead also boasts a Zacks Style Score of  A  for Value due to multiple factors including its low P E of 9 23 compared to its industry s average of 23 89  The combination of good value and expected earnings growth could make Gilead a great addition to a portfolio 
Repligen Corp    NASDAQ RGEN  
Zacks Rank  1  Strong Buy 
Repligen is a biotech company based out of Massachusetts that develops and produces materials used to manufacture biological drugs  Repligen is the first of two Zacks Rank  1  Strong Buy  companies on this list  The Zacks Consensus Estimates for Repligen s earnings growth are 28 8  and 19  for fiscal year 2019 and 2020  respectively  These earnings growth rates are accompanied by expected revenue growth of 30  and 16 9  for fiscal year 2019 and 2020  respectively  This expected growth helped earn Repligen a Zacks Style Score of  A  for Growth 
Illumina Inc    NASDAQ ILMN  
Zacks Rank  2  Buy 
Illumina is a San Diego based biotech company that has created products to help genome sequencing and reduce its cost  Illumina  like many of the companies on this list is expected to have good growth over the next couple of fiscal years  Over the past 60 days  Illumina had 11 upwards earnings revisions for fiscal year 2019 and 8 upwards earnings revisions for fiscal year 2020 while also having 0 downwards revisions for those same estimates  Zacks Consensus Estimates have Illumina s revenue growth around 12 8  along with earnings growth of 16 7  for the current fiscal year  The company s revenue is expected to increase slightly more the following fiscal year  Overall  the signs for Illumina point to solid future growth  which could help its stock price grow in the coming months 
Bio Techne Corp    NASDAQ TECH  
Zacks Rank  1  Strong Buy 
Minneapolis based Bio Techne is a holding company for biotech and clinical diagnostic brands  Bio Techne was recently upgraded to a Zacks Rank  1  Strong Buy    Analysts seem optimistic about the company as it has received multiple upward earnings estimate revisions for the current fiscal year recently  Additionally  Zacks Consensus Estimates call for earnings growth to surge 14  in fiscal year 2020  on the back of 10  revenue growth that same year  Bio Techne s expected growth helps to make it a good option to add to a portfolio 
Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-06-04,Zacks Investment Research,https://www.investing.com/analysis/5-biotech-stocks-to-buy-right-now-200428364,200428364
120294,341809,VRTX,The Zacks Analyst Blog Highlights  Vertex Pharmaceuticals  Gilead Sciences  Repligen  Illumina And Bio Techne,opinion,"For Immediate Release
Chicago  IL   June 5  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Vertex Pharmaceuticals Inc    NASDAQ VRTX    Gilead Sciences Inc    NASDAQ GILD    Repligen Corp    NASDAQ RGEN    Illumina Inc    NASDAQ ILMN   and Bio Techne Corp    NASDAQ TECH   
Here are highlights from Tuesday s Analyst Blog  
5 Biotech Stocks to Buy Right Now
Many of the companies in the biotech sector have had a rough past few weeks with many stocks hitting their lowest levels since January  That being said  here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years  All the stocks in this list are a Zacks Rank  2  Buy  or better 
Vertex Pharmaceuticals Inc  
Zacks Rank  2  Buy 
Vertex Pharmaceuticals is a Boston based biotech firm that specializes in the development and production of Cystic Fibrosis treatments  Vertex was recently upgraded to a Zacks Rank  2  Buy  on the back of earnings estimate revisions for the current fiscal year trending in the right direction  On top of 3 4  projected growth this year  the Zacks Consensus Estimate calls for VRTX s fiscal 2020 earnings to climb 37  above our 2019 estimate  This bottom line growth is projected to be fueled by estimated revenue growth of 16 7  this year and a further 22  expansion in 2020  Vertex currently earns a Style Score of  B  for Growth 
Gilead Sciences Inc  
Zacks Rank  2  Buy 
California based Gilead Sciences is a drug company primarily focused on developing antiviral drugs  Gilead had 11 upwards earnings estimate revisions over the past 60 days  compared to just 1 downward revision for fiscal 2019  This shows analysts are more optimistic about the company s current year earnings  Gilead also boasts a Zacks Style Score of  A  for Value due to multiple factors including its low P E of 9 23 compared to its industry s average of 23 89  The combination of good value and expected earnings growth could make Gilead a great addition to a portfolio 
Repligen Corp  
Zacks Rank  1  Strong Buy 
Repligen is a biotech company based out of Massachusetts that develops and produces materials used to manufacture biological drugs  Repligen is the first of two Zacks Rank  1  Strong Buy  companies on this list  The Zacks Consensus Estimates for Repligen s earnings growth are 28 8  and 19  for fiscal year 2019 and 2020  respectively  These earnings growth rates are accompanied by expected revenue growth of 30  and 16 9  for fiscal year 2019 and 2020  respectively  This expected growth helped earn Repligen a Zacks Style Score of  A  for Growth 
Illumina Inc  
Zacks Rank  2  Buy 
Illumina is a San Diego based biotech company that has created products to help genome sequencing and reduce its cost  Illumina  like many of the companies on this list is expected to have good growth over the next couple of fiscal years  Over the past 60 days  Illumina had 11 upwards earnings revisions for fiscal year 2019 and 8 upwards earnings revisions for fiscal year 2020 while also having 0 downwards revisions for those same estimates  Zacks Consensus Estimates have Illumina s revenue growth around 12 8  along with earnings growth of 16 7  for the current fiscal year  The company s revenue is expected to increase slightly more the following fiscal year  Overall  the signs for Illumina point to solid future growth  which could help its stock price grow in the coming months 
Bio Techne Corp  
Zacks Rank 1  Strong Buy 
Minneapolis based Bio Techne is a holding company for biotech and clinical diagnostic brands  Bio Techne was recently upgraded to a Zacks Rank  1  Strong Buy    Analysts seem optimistic about the company as it has received multiple upward earnings estimate revisions for the current fiscal year recently  Additionally  Zacks Consensus Estimates call for earnings growth to surge 14  in fiscal year 2020  on the back of 10  revenue growth that same year  Bio Techne s expected growth helps to make it a good option to add to a portfolio 
Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  
This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year 

Media Contact
Zacks Investment Research
800 767 3771 ext  9339
 
 
Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ",2019-06-04,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-vertex-pharmaceuticals-gilead-sciences-repligen-illumina-and-biotechne-200428623,200428623
120297,341812,VRTX,CRISPR Therapeutics Up On Collaboration Expansion By Vertex,opinion,"Shares of CRISPR Therapeutics AG   NASDAQ CRSP   rallied 15 1  on Jun 7 as Vertex Pharmaceuticals   NASDAQ VRTX   announced expansion of their collaboration agreement to include new disease areas With the expansion of the collaboration  Vertex will get exclusive worldwide rights to CRISPR Therapeutics  existing and future intellectual property including foundational CRISPR Cas9 technology  Vertex is planning to discover and develop gene editing therapies targeting Duchenne muscular dystrophy   DMD   and Myotonic dystrophy type 1  DM1  using CRISPR s technology We remind investors that Vertex and CRISPR signed a research collaboration back to October 2015  Per this agreement  Vertex and CRISPR are developing gene editing therapies for cystic fibrosis and sickle cell disease indications  In December last year  the companies selected gene therapy  CTX001  to move into clinical development for sickle cell disease and beta thalassemia Per the terms of updated collaboration agreement  CRISPR is eligible to receive up to  1 billion  including  175 million in upfront payment and potential research  development  regulatory  and commercial milestone payments for DMD and DM1 programs  The payments terms are likely to boost CRISPR s cash funds significantly With no marketed product  CRISPR is solely dependent on milestone payments for revenues  The expanded collaboration with Vertex will boost the potential for revenue income in the future quarters  The increase in income will also fund CRISPR plannned initiation of early stage immuno oncology studies to evaluate its CAR T cell therapy candidates  CTX110 and CTX120  for treating CD19  malignancies and multiple myeloma  respectively Moreover  CRISPR will bear no cost related to development and commercialization of candidates in DMD and DM1 programs except for a specified guide RNA research related to DM1 program  All research  development  manufacturing  and commercialization activities and related costs will be borne by Vertex  while both the companies will share cost for the specified guide RNA research The updated collaboration is likely to be finalized by the third quarter of 2019 Apart from the Vertex collaboration  CRSIPR also has a joint venture with Bayer  DE BAYGN  AG   OTC BAYRY   for developing new therapies using its gene editing technology to cure blood disorders  blindness and congenital heart disease CRISPR s share have increased 4 7  so far this year compared with the  s increase of 1 8  Other than CRISPR Therapeutics  Intellia Therapeutics and Editas Medicine  Inc   NASDAQ EDIT   plan to carry out clinical studies using CRISPR Cas9 to cure diseases CRISPR Therapeutics AG Price
    Zacks RankCRISPR Therapeutics currently carries a Zacks Rank  3  Hold   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-06-09,Zacks Investment Research,https://www.investing.com/analysis/crispr-therapeutics-up-on-collaboration-expansion-by-vertex-200430219,200430219
120298,341813,VRTX,Biotech Stock Roundup  Celgene Submits MS Drug To FDA  INSY   CBAY Crash,opinion,The biotech sector was back in focus this week with quite a few regulatory updates  While Celgene s   NASDAQ CELG   multiple sclerosis  MS  drug was submitted for approval  Vertex expanded its collaboration with CRISPR  Meanwhile  shares of both Insys   NASDAQ INSY   and CymaBay Therapeutics   NASDAQ CBAY   plunged on disappointing news Recap of the Week s Top Stories Celgene s MS Drug Accepted for Review in US EU  Celgene  that the FDA has accepted for review the new drug application  NDA  for ozanimod for the treatment of people with relapsing forms of multiple sclerosis  RMS  in the United States  The European Medicines Agency  EMA  also accepted for review the Marketing Authorization Application for ozanimod for the treatment of adults with relapsing remitting multiple sclerosis  in the European Union  The FDA has set an action date of Mar 25  2020  A regulatory decision from the EMA is expected in the first half of 2020  The FDA and EMA applications are based primarily on ozanimod data from the SUNBEAM and RADIANCE Part B phase III studies  In February 2018  the company received a Refusal to File letter from the FDA regarding its NDA for ozanimod for the treatment of people with RMS  Upon its preliminary review  the FDA determined that the nonclinical and clinical pharmacology sections in the NDA were insufficient to permit a complete review  The company then submitted a NDA again in March 2019 to the FDA based on data from the SUNBEAM and RADIANCE studies Celgene currently carries a Zacks Rank  2  Buy   You can see Insys Crashes on Bankruptcy News  Insys Therapeutics  51 4  after it filed for bankruptcy protection under Chapter 11 of the U S  Bankruptcy Code in the U S  Bankruptcy Court in the District of Delaware  The protection will enable the company to facilitate the sale of substantially all its assets and address its legacy legal liabilities  Insys has been embroiled in various litigations in recent times amid allegations of fueling the ongoing opioid endemic in the United States  The company has also been accused of bribing doctors to prescribe its lead drug  Subsys  to patients  This month  Insys signed a settlement with the United States  formalizing its previously announced settlement relating to certain civil statutory claims  As part of this agreement  the company agreed to pay  195 million Biogen Acquires Nightstar  Biogen   NASDAQ BIIB   announced that it has acquired clinical stage gene therapy company Nightstar Therapeutics for  800 million  The acquisition will add NST s lead asset  NSR REP1  to the company s pipeline  The candidate is being evaluated for the treatment of choroideremia  CHM   a rare  degenerative  X linked inherited retinal disorder  which leads to blindness and has no approved treatments  NSR RPGR is NST s second clinical program for the treatment of X linked retinitis pigmentosa  XLRP   which is also a rare inherited retinal disease  primarily affecting males with no approved treatments  Biogen now has added two mid  to late stage clinical assets  as well as preclinical programs  in ophthalmology Vertex Expands Collaboration With CRISPR  Vertex Pharmaceuticals   NASDAQ VRTX   announced that it is  its collaboration with CRISPR Therapeutics   NASDAQ CRSP   for an exclusive licensing agreement to discover and develop gene editing therapies targeting Duchenne muscular dystrophy   DMD   and Myotonic dystrophy type 1  DM1  Per the expanded collaboration terms  Vertex will pay CRISPR  1 billion  including  175 million in upfront payment and potential research  development  regulatory  and commercial milestone payments for the DMD and DM1 programs  Vertex will get exclusive worldwide rights to CRISPR Therapeutics  existing and future intellectual property including foundational CRISPR Cas9 technology Moreover  Vertex will be responsible for all research  development  manufacturing  and commercialization activities and related costs  However  research costs for a specified guide RNA research related to DM1 program will be shared by both the companies  Vertex and CRISPR had signed a four year research collaboration back to October 2015  Per this agreement  Vertex and CRISPR are developing gene editing therapies for cystic fibrosis and sickle cell disease  In December last year  the companies selected gene therapy  CTX001  to move into clinical development for sickle cell disease and beta thalassemia Concurrently  Vertex announced it will acquire privately held Exonics Therapeutics  which is focused on developing gene editing therapies for DMD and other severe genetic neuromuscular diseases  With the acquisition of Exonics  Vertex will gain intellectual property  technology  and scientific expertise in transformative gene editing therapies  Vertex will pay  245 million upfront to Exonics for acquiring all its outstanding shares and form a wholly owned subsidiary  Shareholders of Exonics are eligible to receive approximately  1 billion including upfront and potential milestone payments related to the DMD and DM1 programs Both the transactions are expected to close in the third quarter of 2019 CymaBay Crashes on Disappointing NASH Data  Shares of CymaBay plunged 45 5  after the company reported disappointing data from a mid stage study on lead candidate  seladelpar for the treatment of nonalcoholic steatohepatitis  NASH   12 week top line results from the ongoing 52 week phase IIb dose ranging  paired liver biopsy study of seladelpar showed that treatment with the candidate resulted in minimal reductions in liver fat that were not significant when compared to placebo  While the reductions in markers of liver injury were robust and clinically meaningful  investors were clearly disappointed with the dismal results  given the potential of the NASH space PerformanceMedical   Biomedical and Genetics Industry 5YR   Return The NASDAQ Biotechnology index lost 0 53  in the last four trading sessions  Among the major biotech giants   Alexion lost 0 34  in the period  Over the past six months  shares of Celgene have surged 38 1  whereas Biogen stock has lost 28 3    See the last biotech stock roundup here   What s Next in Biotech Stay tuned for more pipeline and regulatory updates The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-06-11,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-celgene-submits-ms-drug-to-fda-insy--cbay-crash-200431000,200431000
120300,341815,VRTX,Wall Street closes up slightly ahead of jobs report,news,"By Sinead Carew NEW YORK  Reuters    U S  stocks closed modestly higher in light trading on Thursday as investors held back on big bets ahead of Friday s jobs report  which is expected to be a big factor in influencing the timing of a Federal Reserve interest rate hike  Focus on the report was heightened as many investors see it as one of the most import economic indicators due to be released ahead of the Fed s meeting in mid March    People are anticipating some fireworks tomorrow  That s the best way to describe the waiting today   said Paul Schatz  president and chief investment officer at Heritage Capital in Woodbridge  Connecticut   The S P and the Dow had hit records and the Nasdaq surpassed 5 000 at the start of the week after a strong February performance for U S  stocks  giving additional reason for investors to take a breather on Thursday  European news was some help to U S  markets but higher than expected U S  jobless claims took  a little bit of the wind out of the sails   said Paul Brigandi  managing director of portfolio management at Direxion Funds in New York  Initial jobless claims rose to 320 000 in the latest week  above the 295 000 estimate  The disappointing numbers came after a weaker than expected private payrolls report on Wednesday and ahead of Friday s monthly employment report  A separate report showed new orders for U S  factory goods unexpectedly fell in January for a sixth month  a sign of weakness in the manufacturing sector   The Dow Jones industrial average  DJI  rose 38 82 points  or 0 21 percent  to 18 135 72  the S P 500  SPX  gained 2 51 points  or 0 12 percent  to 2 101 04 and the Nasdaq Composite  IXIC  added 15 67 points  or 0 32 percent  to 4 982 81  Earlier in the day  the European Central Bank raised growth and inflation targets and announced it would start its government bond buying program of 60 billion euros a month on March 9  AbbVie  N ABBV  said it would buy  Pharmacyclics   O PCYC  for about  21 billion  giving it access to what is expected to be one of the world s top selling cancer drugs  Pharmacyclics shares jumped 10 3 percent to  254 22 while AbbVie fell 5 7 percent to  56 86  The news also helped lift other healthcare stocks such as Vertex Pharmaceuticals  O VRTX   which closed up 5 8 percent at  126 96  Regeneron Pharmaceuticals  O REGN  added 3 8 percent to  428 95 and Biogen Idec  O BIIB  rose 2 8 percent to  425 60  About 5 7 billion shares changed hands on U S  exchanges  below the 6 5 billion average for the last five sessions  according to BATS Global Markets   Advancing issues outnumbered declining ones on the NYSE by 1 660 to 1 371  for a 1 21 to 1 ratio  on the Nasdaq  1 560 issues rose and 1 154 fell  for a 1 35 to 1 ratio favoring advancers  
The S P 500 posted 21 new 52 week highs and 2 new lows  the Nasdaq Composite recorded 97 new highs and 42 new lows ",2015-03-05,Reuters,https://www.investing.com/news/stock-market-news/futures-climb-after-two-day-fall;-initial-claims-on-tap-331002,331002
120301,341816,VRTX,Glaxo Inks Genome Research Deal With University Of California,opinion,GlaxoSmithKline plc   NYSE GSK   announced that it has entered into a five year collaboration agreement with the University of California to establish a state of the art laboratory for discovering medicines  using the popular CRISPR technologies The laboratory  to be called the Laboratory for Genomics Research  LGR   has been built for funding scientists to research on how genetic mutations cause disease and develop new medicines for the same with the help of CRISPR tech tools Per the deal  Glaxo will provide  67 million for funding the LGR over the stipulated five year period including facilities for 24 full time university employees plus up to 14 full time Glaxo employees  The LGR will be based in San Francisco and focus on developing novel therapies in the field of immunology  oncology and neuroscience  Moreover  Glaxo s artificial intelligence and machine learning team will assist in building the necessary computational pipelines to analyze all the data Shares of Glaxo have gained 5  so far this year  outperforming the increase of 3 1  Genomic editing using CRISPR technology to repair a defective genetic material that causes diseases is probably one of the most promising and exciting healthcare innovations seen in decades  CRISPR is an acronym for  Clustered Regularly Interspaced Short Palindromic Repeats  Other than Glaxo  many companies are trying to foray into this lucrative market as it holds an immense commercial potential  Companies like Intellia Therapeutics   NASDAQ NTLA    Editas Medicine   NASDAQ EDIT    Vertex Pharmaceuticals   NASDAQ VRTX   and several others are carrying out clinical studies using CRISPR technologies to develop novel therapies and new medicines for curing diseases Zacks RankGlaxo currently carries a Zacks Rank  3  Hold   You can see  Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-06-13,Zacks Investment Research,https://www.investing.com/analysis/glaxo-inks-genome-research-deal-with-university-of-california-200431623,200431623
120302,341817,VRTX,U S  stocks move broadly higher  as dollar continues to weaken,news,"Investing com    Stocks on the U S  equities markets soared on Friday  as the dollar continued to move lower following relatively dovish comments by Federal Reserve chair Janet Yellen earlier in the week 
The Dow Jones Industrial Average closed more than 165 points higher  marking its fifth triple digit gain in a maddening volatile month of March 
The NASDAQ Composite index gained nearly 0 75  to move above the 5 000 level  finishing its best week since October  At one point late in the trading day  the NASDAQ moved less than 15 points away from reaching its record high of 5 048 62 from March  2000  The NASDAQ closed at 5 026 42  up 0 68  or 34 04 

Led by strong gains in the Financial  Oil   Gas and Consumer Goods sectors  the S P 500 edged higher by 18 79 or 0 90  to 2 108 06  All 10 sectors on the S P 500 closed in the green on Friday 

Stocks on the Dow increased 0 94  or 168 36 on Friday to close the week at 18 127 39  Nike  one of the world s largest sneaker and athletic apparel companies  gained more than 4  to reach a record high at 103 79  It came one day after Nike announced strong fourth quarter forecasts in after hour trading on the basis of an 11  increase in global future orders  Nike  which ended the session as the top performer on the Dow  gained 4 15 points to close at 102 47 

The worst performer of the day was UnitedHealth Group  NYSE UNH   which fell 1 20  or 1 46 to close at 119 31 

The biggest gainer of the day on the NASDAQ was Biogen Idec  NASDAQ BIIB   Inc  which rose more than 9 5  to 475 00  after receiving positive test results for its Alzheimer s drug Aducanumab  Presenting at a biotech conference in Nice  France  Biogen indicated that the drug was responsible for creating reductions in amyloid plaque levels in the brains of patients with the neurodegenerative disease  The worst performer of the day was Vertex Pharmaceuticals  NASDAQ VRTX   which dropped 2 78 or 2 07  to 131 47 

Biogen was also the top performer on the S P 500  ahead of Phoenix based copper mining company Freeport McMoRan which gained 1 15 or 6 66  to close at 18 41  At one point on Friday  copper futures rose by more than 3  a pound  The worst performer was Airgas  NYSE ARG   Inc  which fell 5 71 or 5 05  to 107 30 

Tiffany   Company  a worldwide luxury jeweler and specialty retailer  fell 3 44 or 3 98  to 82 95 amid disappointing quarterly results  Macerich  a California based real estate investment trust  which is embroiled in a potential hostile takeover by fellow mall owner Simon Property Group  NYSE SPG   dropped 4 22 or 4 51  to 82 93 ",2015-03-20,Investing.com,"https://www.investing.com/news/stock-market-news/u.s.-stocks-move-broadly-higher,-as-dollar-continues-to-weaken-333472",333472
120303,341818,VRTX,Shares in Vertex Pharma surge after FDA backs its cystic fibrosis drug,news,"Investing com    Shares in Vertex Pharmaceuticals Inc  NASDAQ VRTX  surged more than 7  in after hours trading after an FDA advisory committee voted 12 to 1 on Tuesday to recommend preliminary approval of its Cystic Fibrosis drug Orkambi 
If approved  Orkambi will be the first and only drug on the market to treat patients above the age of 12  who have two copies of the F508del mutation in the CFTR gene  Cystic fibrosis is caused by missing or defective proteins in a cell that result from mutations in the CFTR gene  Nationwide  there are roughly 8 500 people in the U S  over the age of 12 with two copies of the mutation 
Orkambi combines two other Vertex drugs  Ivacaftor  which is also known as Kalydeco and Lumacaftor  a CFTR corrector  Lumacaftor is designed to correct the defect in the protein  while Ivacaftor can enhance its functioning potential  according to a Vertex statement 
 Today s positive recommendation brings the cystic fibrosis community one step closer to potential approval of the first medicine to treat the underlying cause of this disease for many more people   Dr  Jeffrey Chodakewitz  Executive Vice President and Chief Medical Officer at Vertex said in a statement   We look forward to continuing to work with the FDA and other regulatory agencies throughout the world to make Orkambi available to eligible patients as soon as possible  
The FDA is expected to make a final decision on approval of Orkambi by early July 
Shares in Vertex Pharmaceuticals soared 9 41 points or 7 58  to 133 49 in after hours trading ",2015-05-12,Investing.com,https://www.investing.com/news/stock-market-news/shares-in-vertex-pharma-surge-after-fda-backs-its-cystic-fibrosis-drug-341523,341523
120304,341819,VRTX,How DNA sequencing is transforming the hunt for new drugs,news,"By Julie Steenhuysen CHICAGO  Reuters    Drug manufacturers have begun amassing enormous troves of human DNA in hopes of significantly shortening the time it takes to identify new drug candidates  a move some say is transforming the development of medicines  The efforts will help researchers identify rare genetic mutations by scanning large databases of volunteers who agree to have their DNA sequenced and to provide access to detailed medical records   It is made possible by the dramatically lower cost of genetic sequencing   it took government funded scientists  3 billion and 13 years to sequence the first human genome by 2003  As of last year  the cost was closer to  1 500 per genome  down from  20 000 five years ago  Regeneron Pharmaceuticals Inc  which signed a deal with Pennsylvania s Geisinger Health System in January 2014 to sequence partial genomes of some 250 000 volunteers  is already claiming discoveries based on the new approach  Company executives told Reuters they have used data from the first 35 000 volunteers to confirm the promise of 250 genes on a list of targets for drugs aimed at common medical conditions  including high levels of cholesterol and triglycerides  Regeneron says it has also identified  several dozen  new gene targets  including a novel gene that plays a role in obesity   Pfizer Inc  Roche Holding  SIX ROG  AG and Biogen  NASDAQ BIIB  Inc are working on similar projects that use DNA and patient health data to find new drug targets or predict the effects of drugs   Their investments have been inspired by early successes in cancer with drugs such as Pfizer s lung cancer treatment Xalkori  which was approved in 2011 and targets mutations in tumors driving the disease  More recently  Vertex Pharmaceuticals  NASDAQ VRTX  has changed the treatment of cystic fibrosis with Kalydeco  which targets the disease s underlying genetic cause   All of a sudden  it all opened up   as companies recognize the potential for drugs targeting genetic glitches  Dr  Eric Topol  a genomics expert at the Scripps Translational Science Institute   It s starting to really become a new preferred model for drug development   In the past  discovering such genes was a painstaking process  often involving years of research into isolated populations  In 1991  for example  researchers discovered a rare mutation in a gene called Angptl3 that caused very low levels of artery clogging cholesterol and triglycerides among families in the remote Italian village of Campodimele  It took nearly two more decades and several groups of scientists to fully understand the potential cardiovascular benefits linked to mutations in that gene   Since last autumn  the Regeneron Genetics Center has sequenced the DNA of more than 35 000 Geisinger patients and is on track to sequence 100 000 by year end  Already  the company has identified 100 people carrying similar cholesterol affecting mutations to those first observed in Campodimele and elsewhere   You no longer have to find that one rare family in Italy  because it s just in the database   said Dr  George Yancopoulos  chief scientific officer of Regeneron       PRECISION MEDICINE    Identifying target genes is just a first step  though  and does not guarantee that a drug can be developed on a genetic lead  or that it will ultimately be safe and effective enough to be used  Experts also differ on approach  Regeneron is sequencing exomes  the protein making genes that comprise 1 to 2 percent of the genome  a search that costs roughly  700 per person  Others favor looking at the whole genome  which costs the  1 500 per person  Craig Venter  one of the first scientists to sequence the human genome  believes the whole genome approach will be more meaningful over time   I d rather have a gold mine with a deep vein of gold and modern industrial equipment to mine it rather than sitting there with a pan in a stream looking for gold   he said   Both will find gold  It s a question of how much you find   Even so  the early returns from new  genomic  medicines have attracted attention from the White House  In January  President Barack Obama said he would seek  130 million from Congress to gather genetic data from 1 million volunteers as part of a  precision medicine  initiative  Regeneron is lobbying for the Geisinger database to become a cornerstone of that effort  and proposes creating a consortium of drugmakers to fund it  In return  Yancopoulos said  the company hopes to recoup some of its investment  Dr  Francis Collins  director of the National Institutes of Health  which is in charge of the precision medicine project  identified Regeneron among a short list of potential contributors to the 1 million strong DNA study  Others on the list include Kaiser Permanente  Mayo Clinic  and the Marshfield Clinic in Wisconsin  A decision is expected by early fall  For drug companies  the lure of a big payoff is strong  Regeneron and its partner Sanofi  PARIS SASY  are expected to soon win regulatory approval for a cholesterol lowering drug that works by blocking the PCSK9 gene  Amgen  NASDAQ AMGN  and Pfizer have developed similar treatments  Individuals born with non functioning versions of PCSK9 have very low cholesterol  The new drugs mimic that effect and are considered a poster child for treatments that take advantage of glitches in the genome that prove beneficial to the rare individuals who carry them  Wall Street analysts project Regeneron Sanofi s PCSK9 drug will generate revenues of  4 4 billion by 2019       MINING THE DATA  Amgen bolstered its search for gene targets by buying Decode Genetics in late 2012 for  415 million  giving it a database of complete genetic sequences of 2 636 Icelanders  The community shares a relatively homogenous genetic profile due to its geographic isolation  allowing researchers to identify gene variations more easily  In March  Amgen reported the discovery of a new mutation that increases the risk of Alzheimer s and confirmed the role of two mutations involved in diabetes and atrial fibrillation  This past January  Roche s Genentech unit tapped Venter s Human Longevity Inc for a large sequencing project   Genetic testing company 23andMe announced deals this year with Genentech and Pfizer  Genentech will have access to 3 000 individuals in 23andMe s community of Parkinson s patients  and Pfizer will expand an existing collaboration with the company to study the genetics of lupus  That same month  Biogen formed a  30 million research alliance to support the formation of a sequencing center at Columbia University   All of the companies are feeling like   Oh my gosh  We have to do something substantial in genomics   yesterday    said Dr  David Goldstein  director of Columbia s Institute for Genomic Medicine  At the heart of Regeneron s model is finding rare mutations that disable normal gene function  So far  it has identified people with at least one such  loss of function  gene that correlates with nearly all 250 genes on the company s list of drug targets   That includes essentially every gene previously linked to triglyceride regulation and several novel candidates  Yancopoulos said  They have done the same for cholesterol and coronary artery disease  Regeneron has also partnered with academic centers studying families with extreme genetic disorders  collaborations that already have led to the discovery of a couple of dozen new candidate genes  said Dr  Aris Baras  who runs Regeneron s genetics center  In one case  they are using the Geisinger database to study a rare gene they believe causes severe obesity in young children  The team has found milder mutations in the overall population that may cause an average 10 pound weight gain in adults  That would validate the role that such genes play in regulating body weight and suggests that   if you had a drug it could have a profound effect   Yancopoulos said  
 This is why everybody is excited about it   he said ",2015-05-13,Reuters,https://www.investing.com/news/general-news/how-dna-sequencing-is-transforming-the-hunt-for-new-drugs-341613,341613
120317,341832,VRTX,Biotechs lift Wall Street  Dow back in black for 2014,news,"By Akane Otani  NEW YORK  Reuters    U S  stocks ended higher on Wednesday  with the Dow Jones industrial average returning to positive territory for the year  as surging biotech shares helped investors shrug off disappointing retail sales data   Retail stocks capped the market s gains after Commerce Department data showed that U S  retail sales unexpectedly stalled in July  marking the weakest report since January  Macy s Inc  N M  reported quarterly earnings that missed analysts  estimates and slashed its full year same store sales forecast  driving the stock down 5 5 percent to  56 47   The selloff in Macy s stock  a bellwether for department stores  gave investors a reason to unload some shares of Kohl s Corp  N KSS   down 1 5 percent at  55 11  Nordstrom Inc  N JWN   down 0 9 percent at  68 12  and Wal Mart Stores Inc  N WMT   down 0 3 percent at  74 03  All are expected to report results on Thursday   Although the weak retail sales pointed to some loss of momentum in the economy  the July reading could give the Federal Reserve more support to move slowly on raising interest rates  a situation that favors investors in equities    Investors seem to be looking past the retail numbers and seeing the silver lining  which is that the Fed could be less hawkish and keep interest rates down for longer   said Lawrence Glazer  managing partner at Mayflower Advisors in Boston    Domestically  despite some questionable earnings reports  areas like biotech  transports and Amazon all gave a boost to markets today    All 10 S P primary sector indexes gained  even as some heavyweights  stocks plunged on missed earnings and downgraded revenue forecasts   Biotech shares surged  with the Nasdaq Biotech Index  NBI  climbing 2 1 percent in sync with a rally in the stocks of InterMune Inc  B ITMN  and Jazz Pharmaceuticals PLC  O JAZZ    The Dow Jones Transportation Average  DJT  gained 0 7 percent   Investors have been sensitive in recent weeks to signs of flaring tensions abroad  but were not affected on Wednesday  The declaration by the White House that the United States would not send combat ground troops to Iraq  has given the market some upward momentum   said Kim Forrest  senior equity research analyst at Fort Pitt Capital Group in Pittsburgh   The Dow Jones industrial average  DJI  rose 91 26 points  or 0 55 percent  to close at 16 651 80  The S P 500  SPX  gained 12 97 points  or 0 67 percent  to finish at 1 946 72  The Nasdaq Composite  IXIC  added 44 88 points  or 1 02 percent  to end at 4 434 13   Wednesday s advance lifted the Dow back into the black for 2014 after last week s sharp selloff had wiped out the year s gains   For the year  the Dow is now up 0 45 percent   After the bell  Cisco Systems Inc  O CSCO  reported a smaller than expected drop in quarterly revenue after the bell and its stock lost 2 9 percent in extended hours trading  The network equipment maker had expected a revenue decline between 1 percent and 3 percent  but reported a drop of only 0 5 percent instead   An S P index of healthcare stocks  jumped 1 2 percent during the regular session and led the S P 500 higher  Vertex Pharmaceuticals  O VRTX  shares  the biggest gainer in the S P 500 healthcare sector  shot up 3 9 percent to  88 75   Amazon shares  O AMZN  gained 2 2 percent to  326 28  Earlier in the day  the company unveiled a  10 credit card reader and mobile app that will let it grab a bigger share of the mobile payments and bricks and mortar retail markets   The stocks of both King Digital Entertainment plc  N KING  and SeaWorld Entertainment Inc  N SEAS  marked their biggest one day declines ever following quarterly results that missed analysts  forecasts   Shares of King  maker of the social media and mobile game  Candy Crush Saga   plummeted 23 1 percent to close at  13 99  SeaWorld shares sank 32 9 percent to end at  18 90 after the company slashed its full year revenue forecast because of a huge controversy over its amusement park shows featuring killer whales   
About 4 7 billion shares traded on all U S  platforms  according to BATS exchange data  compared with the five day average of 5 7 billion     Editing by Nick Zieminski and Jan Paschal ",2014-08-13,Reuters,"https://www.investing.com/news/stock-market-news/stock-futures-rise-as-tensions-in-ukraine,-iraq-seem-to-wane-303093",303093
120320,341835,VRTX,Wall St  rallies  S P back above 14 day moving average,news,"By Ryan Vlastelica  NEW YORK  Reuters    U S  stocks jumped in a broad advance on Wednesday  with the S P 500 snapping a three day losing streak and climbing back above a key technical level in a move that pointed to improving near term momentum   The day s gains were spread across industries  with nine of the ten primary S P 500 sectors up on the day  though healthcare  and biotechnology stocks  NBI  led the gains  Housing stocks also rose following bullish data on the sector   The S P posted its biggest one day advance in more than a month and closed above its 14 day moving average  which it had ended under for the previous two sessions  The day s advance continues a long running trend of investors buying on dips   At its session low on Wednesday  the benchmark index neared its 50 day moving average before rebounding  If that level continues to serve as support  it could provide a floor against deeper equity losses  The S P hasn t had a correction  defined as a 10 percent decline from a peak  since 2012    We re having a nice bounce on the housing data  which hasn t been very good in a while  and people are buying the recent dip   said Tim Ghriskey  chief investment officer of Solaris Group in Bedford Hills  New York   This is a market that continues to attract capital from other asset classes  because where else can investors go for yield    New home sales jumped sharply in August  easing concerns over the sector stemming from Monday s weak report on existing home sales  The PHLX Housing index  HGX  rose 0 6 percent   Equities were also supported after a top Federal Reserve official said at a conference that the Fed should be  exceptionally patient  in removing monetary policy accommodation   The Dow Jones industrial average  DJI  rose 155 6 points  or 0 91 percent  to 17 211 47  the S P 500  SPX  gained 15 65 points  or 0 79 percent  to 1 998 42 and the Nasdaq Composite  IXIC  added 46 53 points  or 1 03 percent  to 4 555 22   In company news  Bed Bath   Beyond  O BBBY  jumped 7 3 percent to  67 28 as the biggest S P 500 gainer a day after reporting earnings and revenue that beat expectations   The Nasdaq biotech index  NBI  rose 2 8 percent in its biggest one day advance since July 18  Among specific names  Vertex Pharma  O VRTX  climbed 6 7 percent to  111 91 while Alexion Pharma  O ALXN  added 6 4 percent to  168 79 and Biogen  O BIIB  rose 4 3 percent to  346 41   Biotech stocks had fallen in Monday s and Tuesday s sessions  pressured as investors took profits in the high flying group  which many traders view as overvalued   After the market closed  Jabil Circuit  N JBL  shares rose 5 8 percent to  22 06 in extended trading after the company reported its results   About 56 percent of stocks traded on the New York Stock Exchange ended higher while 64 percent of Nasdaq listed names closed in positive territory   
About 5 63 billion shares traded on all U S  platforms  according to BATS exchange data  compared with the month to date average of 6 01 billion     Editing by Meredith Mazzilli ",2014-09-24,Reuters,"https://www.investing.com/news/stock-market-news/futures-move-higher-after-third-day-skid,-housing-data-due-310591",310591
120321,341836,VRTX,AbbVie board ditches planned  55 billion Shire acquisition,news,"By Ben Hirschler  LONDON  Reuters    U S  drugmaker AbbVie  N ABBV  has pulled the plug on its plan to buy Dublin based Shire  L SHP   recommending shareholders vote against the proposed  55 billion takeover following new U S  tax rules   Shire stands to be paid a break up fee of about  1 64 billion  assuming AbbVie s shareholders follow the advice and reject the transaction   The reversal    which had been anticipated after Chicago based AbbVie said it was reconsidering the deal    hands a major scalp to the U S  Treasury  which has been fighting to make tax avoiding acquisitions more difficult   That has hit the value of other potential takeover targets in Europe and cast a shadow over transactions that have yet to be completed   But AbbVie s retreat could spark fresh deal making by Shire  which has a strong track record of acquisitions to fuel its fast growing business and may now look around to buy other companies  with its firepower boosted by the break up fee   The U S  government s tax proposals are designed to make it harder for American firms to shift their tax bases out of the country and into lower cost jurisdictions in Europe    The agreed upon valuation is no longer supported as a result of the changes to the tax rules and we did not believe it was in the best interests of our stockholders to proceed   AbbVie s chief executive Richard Gonzalez said in a statement   AbbVie s move for Shire  a leader in drugs to treat attention deficit disorder and rare diseases  was announced in July amid a spate of deals in the pharmaceutical sector   Gonzalez said at the time that the acquisition  involving the creation of a new U S  listed holding company with a tax domicile in Britain  was not just about tax   But the firm said on Thursday that the changes in the U S  tax regime  eliminated certain of the financial benefits of the transaction  most notably the ability to access current and future global cash flows in a tax efficient manner as originally contemplated in the transaction  This fundamentally changed the implied value of Shire to AbbVie in a significant manner    Shire said it was considering the current situation and would make a further announcement in due course   News on Wednesday that AbbVie was cooling to the transaction hammered shares in Shire  sending them down 22 percent to where they were before the deal talks emerged in June  and the shares were down a further 12 percent at 3 525 pence by 1145 GMT   AbbVie s charge of heart has been a bombshell for some of the world s top hedge funds  which have lost out heavily on the Shire stock they were holding   SHAREHOLDER MEETING  AbbVie said the withdrawal of its recommendation alone would not cause a lapse in the offer for Shire and it must convene a shareholder meeting before Dec  14 to vote on the deal   A spate of so called tax inversion merger deals  particularly in healthcare  prompted the U S  move to change tax regulations  including placing a ban on loans that allow U S  firms to access foreign cash without paying U S  tax   AbbVie said the breadth and scope of the changes  introduced an unacceptable level of uncertainty to the transaction    The company also took a swipe at the  unilateral  nature of the U S  government s move and complained about  the unexpected nature of the exercise of administrative authority to impact longstanding tax principles    AbbVie s second thoughts on the deal have surprised Shire investors  coming just weeks after Gonzalez  in the wake of the Treasury proposals  told employees of both companies he was  more energized than ever  about the transaction   Aside from the tax benefits  buying Shire offered AbbVie a way to reduce reliance on arthritis treatment Humira  the world s top selling medicine  whose  13 billion in annual sales accounts for more than 60 percent of company revenue   The episode has fueled doubts about whether Pfizer  N PFE  will ever make another run at AstraZeneca  L AZN   after abandoning a  118 billion bid in May  AstraZeneca shares fell 2 5 percent on Thursday  after losing ground on Wednesday   Shares in Britain s Smith   Nephew  L SN  and Switzerland s Actelion  VX ATLN   also tipped as inversion targets  both fell a further 3 percent   Tax experts say inversions are still possible but the U S  action has cut their appeal  suggesting they will only make sense if there is a compelling strategic fit between two firms   Two other U S  drugmakers  Salix Pharmaceuticals  O SLXP  and Auxilium Pharmaceuticals  O AUXL   have already called off smaller inversion deals this month   SHIRE S OWN DEAL MAKING  Analysts are now looking ahead to Shire s strategy as an independent company once again and its own potential for making acquisitions    or else becoming a target for another company   Before the AbbVie agreement  Shire Chief Executive Flemming Ornskov had made clear he was interested in buying assets and Jefferies analysts said a standalone Shire could now be poised to aggressively target acquisitions   
Shire itself might also be a target for other pharmaceutical companies less driven by tax considerations  Allergan  N AGN   for example  which is fighting a bid from Valeant Pharmaceuticals International  O VRTX   has approached Shire in the past     Additional reporting by Abhiram Nandakumar and Aurindom Mukherjee in Bangalore  Editing by Greg Mahlich  Pravin Char and Clara Ferreira Marques ",2014-10-16,Reuters,https://www.investing.com/news/stock-market-news/abbvie-board-turns-against-$55-billion-shire-acquisition-313184,313184
120324,341839,VRTX,Will Vertex  VRTX  Beat Estimates Again In Its Next Earnings Report ,opinion,"Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report  Vertex Pharmaceuticals  NASDAQ VRTX   which belongs to the Zacks Medical   Biomedical and Genetics industry  could be a great candidate to consider 
This drugmaker has an established record of topping earnings estimates  especially when looking at the previous two reports  The company boasts an average surprise for the past two quarters of 16 40  
For the last reported quarter  Vertex came out with earnings of  1 30 per share versus the Zacks Consensus Estimate of  1 05 per share  representing a surprise of 23 81   For the previous quarter  the company was expected to post earnings of  1 per share and it actually produced earnings of  1 09 per share  delivering a surprise of 9  
Price and EPS Surprise

With this earnings history in mind  recent estimates have been moving higher for Vertex  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the company is positive  which is a great sign of an earnings beat  especially when you combine this metric with its nice Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Vertex has an Earnings ESP of  3 48  at the moment  suggesting that analysts have grown bullish on its near term earnings potential  When you combine this positive Earnings ESP with the stock s Zacks Rank  3  Hold   it shows that another beat is possibly around the corner  The company s next earnings report is expected to be released on April 30  2019 
Investors should note  however  that a negative Earnings ESP reading is not indicative of an earnings miss  but a negative value does reduce the predictive power of this metric 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-04-28,Zacks Investment Research,https://www.investing.com/analysis/will-vertex-vrtx-beat-estimates-again-in-its-next-earnings-report-200412494,200412494
120327,341842,VRTX,The Zacks Analyst Blog Highlights  Biogen  Celgene  Incyte  Alexion And Vertex,opinion,For Immediate ReleaseChicago  IL   May 2  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Biogen   NASDAQ BIIB    Celgene   NASDAQ CELG    Incyte   NASDAQ INCY    Alexion   NASDAQ ALXN   and Vertex   NASDAQ VRTX   Here are highlights from Wednesday s Analyst Blog  Biotech Stock Roundup  BIIB  CELG  INCY   MoreThe past week was busy for the biotech sector with earnings updates by most biotech bigwigs along with regulatory and other pipeline updates as well as collaborations  Most companies have delivered better than estimated top and the bottom line numbers  Label expansion of existing drugs and other pipeline updates grabbed headlines Recap of the Week s Top Stories Alexion  Celgene  Biogen Fire on All Cylinders  The going has been good so far for the biotech sector in first quarter earnings season  Most bigwigs surpassed on both earnings and sales  For instance  Biogen emerged with flying colors  fueled mainly by a strong performance of its newest drug  Spinraza  Other biotechs like Celgene and Incyte too beat on both counts  Also  Alexion s earnings and sales topped the Zacks Consensus Estimate in the first quarter and therefore  the company upped its guidance  Additionally  Vertex s earnings and sales exceeded expectations  Alexion currently carries a Zacks Rank  2  Buy   You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here Vertex Gets FDA Nod for Label Expansion of Kalydeco  Vertex Pharmaceuticals announced the FDA approval of cystic fibrosis  CF  drug Kalydeco s label expansion  The drug has been approved for use in children suffering cystic fibrosis aged from six to less than 12 months with at least one mutation in their cystic fibrosis transmembrane conductance regulator  CFTR  gene that is responsive to Kalydeco based on the clinical and or in vitro assay data  Kalydeco is already approved in the United States  Canada and EU for the treatment of CF in patients aged 12 months and above  The regulatory agency s approval was based on data from a 24 week phase III open label safety cohort  ARRIVAL  of 11 children with CF  aged from six to less than 12 months Alexion s Ultomiris Receives Positive CHMP Opinion  Alexion announced that the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  has rendered a positive opinion  recommending marketing authorization for the long acting C5 complement inhibitor  Ultomiris  ravulizumab   The committee has recommended the drug s approval for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria  PNH  with haemolysis involving clinical symptoms  indicative of a high disease activity  The drug has also been recommended for adult patients  who are clinically stable after being treated with Soliris for at least the past six months The European Commission will review the CHMP recommendation and a final decision is expected in two months  The FDA approved Ultomiris for adult patients with PNH last December Celgene  Acceleron Pharma Submit Luspatercept Application in Europe  Celgene announced that it has submitted a Marketing Authorization Application  MAA  to the European Medicines Agency  EMA  for luspatercept  The company along with partner Acceleron Pharma is seeking an approval of the drug for treating adult patients with very low to intermediate risk myelodysplastic syndromes  MDS  associated anemia  who have ring sideroblasts  require red blood cell  RBC  transfusions and have received or are not eligible for erythropoiesis stimulating agents  The same is also sought for the treatment of adult subjects with beta thalassemia associated anemia  requiring RBC transfusions Concurrently  both companies announced that European Medicines Agency s  EMA  CHMP has adopted a positive opinion for the marketing authorization of Libtayo  cemiplimab   The CHMP recommended its conditional approval for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma  CSCC   who are not candidates for curative surgery or curative radiation Incyte Opts Out of Baricitinib Development Program  Incyte announced that it will no longer co fund the development of baricitinib in order to reallocate capital for other promising internal projects  However  the company will continue to receive royalties on global net sales of Olumiant  pursuant to the terms of its agreement with Lilly  Lilly plans to share data from BREEZE AD1 and BREEZE AD2  the two phase III studies of baricitinib on patients with moderate to severe atopic dermatitis later this year  and also expects to provide top line results from the other ongoing phase III programs for this indication later in 2019 Join us on Facebook  NASDAQ FB   Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media Contact                                               Zacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-05-01,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-biogen-celgene-incyte-alexion-and-vertex-200415736,200415736
120328,341843,VRTX,Trade Anxieties Return With A Vengeance,opinion,"The May episode of the Zacks Ultimate Strategy Session is now available for viewing  Tune in to this  must see  event when Kevin Matras  David Bartosiak  Brian Bolan and Sheraz Mian discuss the investment landscape from several angles 

Don t miss your chance to hear 

  Sheraz and Brian Agree to Disagree on whether  Sell in May and Go Away  makes sense this year
	  Kevin answers questions about trading differently with the market at all time highs  and rules to use for cutting losses in Zacks Mailbag
	  Sheraz and David choose one portfolio to give feedback for improvement
	  And much more

Simply log on to Zacks com and view the May episode here  And please let us know what you think of this format  Email all feedback to mailbag zacks com 
	The renewed trade anxieties finally sunk their teeth into the market on Tuesday  sending each of the major indices lower by more than 1 5  
	Stocks again finished the session well off its lows  But unlike yesterday  the bounce never came close to getting us back to breakeven 
	Nevertheless  the Dow soared approximately 175 points in the final moments  Not bad at all  Unfortunately  it plunged about 650 points at its worst  so the index still declined by a hefty 1 8   or around 473 points  to 25 965 09 
	The NASDAQ was the worst performer with a drop of nearly 2  to 7963 76  while the S P slipped 1 65  to 2884 05  Many investors are concerned that a trade war will stunt global growth  However  the broad based selling suggests that some folks were just taking profits after a string of good news for the market  including strong data for GDP and employment along with a better than feared earnings season 
	There was a nagging suspicion that the modest pullback yesterday wasn t enough  The market had priced in a trade deal long ago  and then suddenly those encouraging meetings were in danger of completely falling apart  The less than 0 5  declines for the indices on Monday didn t seem to reflect the surprise and frustration of this trade whiplash 
	In a couple Tweets this weekend  President Trump threatened to raise tariffs to 25  from 10  on  250 billion worth of Chinese goods  while also placing new tariffs on  325 billion worth of additional goods  According to U S  officials  this tougher stance was taken after China attempted to walk back some of the concessions made during the negotiations 
	But all is not lost  The two sides are scheduled to meet for more talks in Washington later this week  Perhaps this recent kerfuffle will prove to be nothing  The market still hopes that something gets done  but its confidence has been shaken  Today s Portfolio Highlights Healthcare Innovators  One of the most dangerous things about cancer is how hard it can be to detect the disease  But companies like Arcus Biosciences  RCUS  specialize in finding and fighting cancer  even if the body is tricked into hiding its presence  Kevin likes this emerging stage biotech because analysts are giving good reviews to AB928  its lead candidate  and because of its new collaboration with Strata Oncology  But most of all  the editor likes its CEO Terry Rosen Ph D   who sold his previous company to Bristol Myers Squibb  NYSE BMY  in early 2015 for  1 25 billion  Kevin calls this a  betting on the jockey  move and warns that it is highly speculative  Read the complete commentary for a lot more on RCUS Counterstrike  Jeremy has always been skeptical that we would get a real trade deal  Earlier this month  he added the double leveraged ProShares Ultra VIX Short Term Futures ETF  UVXY  just in case the S P took a sharp step backward  It certainly paid off on Tuesday  The fund soared nearly 25   which easily made it the best performer among all ZU names today    
	Zacks Short List  The portfolio swapped two names this week  It short covered Baidu  BIDU  and Vertex Pharma  NASDAQ VRTX   These names were replaced through the additions of Neurocrine Biosciences  NBIX  and Live Nation Entertainment  LYV   Learn more about this emotion free portfolio that takes advantage of falling and volatile markets by reading the Short List Trader Guide 

All the Best 
	Jim Giaquinto 
Recommendations from Zacks  Private Portfolios   Believe it or not  this article is not available on the Zacks com website  The commentary is a partial overview of the daily activity from Zacks  private recommendation services  If you would like to follow our Buy and Sell signals in real time  we ve made a special arrangement for readers of this website  Starting today you can see all the recommendations from all of Zacks  portfolios absolutely free for 7 days  Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises  which we ve predicted with an astonishing 80   accuracy    Click here to  test drive  Zacks Ultimate for FREE   ",2019-05-07,Zacks Investment Research,https://www.investing.com/analysis/trade-anxieties-return-with-a-vengeance-200418571,200418571
120329,341844,VRTX,CELG Vs  VRTX  Which Stock Should Value Investors Buy Now ,opinion,"Investors looking for stocks in the Medical   Biomedical and Genetics sector might want to consider either Celgene  CELG  or Vertex Pharmaceuticals  NASDAQ VRTX   But which of these two companies is the best option for those looking for undervalued stocks  Let s take a closer look 
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system  The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions  while our Style Scores work to identify stocks with specific traits 
Celgene and Vertex Pharmaceuticals are both sporting a Zacks Rank of   2  Buy  right now  Investors should feel comfortable knowing that both of these stocks have an improving earnings outlook since the Zacks Rank favors companies that have witnessed positive analyst estimate revisions  But this is only part of the picture for value investors 
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels 
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics  These include the long favored P E ratio  P S ratio  earnings yield  cash flow per share  and a variety of other fundamentals that help us determine a company s fair value 
CELG currently has a forward P E ratio of 8 89  while VRTX has a forward P E of 40 90  We also note that CELG has a PEG ratio of 0 40  This figure is similar to the commonly used P E ratio  with the PEG ratio also factoring in a company s expected earnings growth rate  VRTX currently has a PEG ratio of 1 82 
Another notable valuation metric for CELG is its P B ratio of 8 25  Investors use the P B ratio to look at a stock s market value versus its book value  which is defined as total assets minus total liabilities  By comparison  VRTX has a P B of 9 23 
These are just a few of the metrics contributing to CELG s Value grade of B and VRTX s Value grade of D 
Both CELG and VRTX are impressive stocks with solid earnings outlooks  but based on these valuation figures  we feel that CELG is the superior value option right now ",2019-05-07,Zacks Investment Research,https://www.investing.com/analysis/celg-vs-vrtx-which-stock-should-value-investors-buy-now-200418765,200418765
120332,341847,VRTX,Vertex Energy  VTNR  Reports Q1 Loss  Lags Revenue Estimates,opinion,"Vertex  NASDAQ VRTX  Energy  VTNR  came out with a quarterly loss of  0 02 per share versus the Zacks Consensus Estimate of a loss of  0 06  This compares to loss of  0 07 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 66 67   A quarter ago  it was expected that this environmental services company would post a loss of  0 02 per share when it actually produced a loss of  0 03  delivering a surprise of  50  
Over the last four quarters  the company has surpassed consensus EPS estimates two times 
Vertex Energy  which belongs to the Zacks Pollution Control industry  posted revenues of  39 32 million for the quarter ended March 2019  missing the Zacks Consensus Estimate by 11 24   This compares to year ago revenues of  41 37 million  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Vertex Energy shares have added about 60 8  since the beginning of the year versus the S P 500 s gain of 15 1  
What s Next for Vertex Energy 
While Vertex Energy has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Vertex Energy was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is   0 02 on  49 80 million in revenues for the coming quarter and   0 10 on  190 million in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Pollution Control is currently in the top 5  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-05-08,Zacks Investment Research,https://www.investing.com/analysis/vertex-energy-vtnr-reports-q1-loss-lags-revenue-estimates-200418827,200418827
120339,341854,VRTX,CELG Vs  VRTX  Which Stock Is The Better Value Option ,opinion,"Investors looking for stocks in the Medical   Biomedical and Genetics sector might want to consider either Celgene  CELG  or Vertex Pharmaceuticals  NASDAQ VRTX   But which of these two stocks is more attractive to value investors  We ll need to take a closer look to find out 
There are plenty of strategies for discovering value stocks  but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns  The Zacks Rank favors stocks with strong earnings estimate revision trends  and our Style Scores highlight companies with specific traits 
Celgene has a Zacks Rank of  1  Strong Buy   while Vertex Pharmaceuticals has a Zacks Rank of  5  Strong Sell  right now  Investors should feel comfortable knowing that CELG likely has seen a stronger improvement to its earnings outlook than VRTX has recently  But this is only part of the picture for value investors 
Value investors analyze a variety of traditional  tried and true metrics to help find companies that they believe are undervalued at their current share price levels 
Our Value category grades stocks based on a number of key metrics  including the tried and true P E ratio  the P S ratio  earnings yield  and cash flow per share  as well as a variety of other fundamentals that value investors frequently use 
CELG currently has a forward P E ratio of 7 98  while VRTX has a forward P E of 45 07  We also note that CELG has a PEG ratio of 0 36  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  VRTX currently has a PEG ratio of 1 73 
Another notable valuation metric for CELG is its P B ratio of 9 74  Investors use the P B ratio to look at a stock s market value versus its book value  which is defined as total assets minus total liabilities  By comparison  VRTX has a P B of 10 52 
Based on these metrics and many more  CELG holds a Value grade of B  while VRTX has a Value grade of F 
CELG is currently sporting an improving earnings outlook  which makes it stick out in our Zacks Rank model  And  based on the above valuation metrics  we feel that CELG is likely the superior value option right now ",2019-03-12,Zacks Investment Research,https://www.investing.com/analysis/celg-vs-vrtx-which-stock-is-the-better-value-option-200397247,200397247
120341,341856,VRTX,Biotech Stock Roundup  REGN Gets FDA Nod For Dupixent   Other Pipeline News ,opinion,"The past week was busy for the biotech sector with several pipeline updates as the reporting cycle ended  Regeneron Pharmaceuticals  Inc    NASDAQ REGN   won the FDA approval for the label expansion of its leading asthma drug Dupixent while Celgene   NASDAQ CELG   made a notable progress with its MS  multiple sclerosis  candidate Meanwhile  AMAG Pharmaceuticals   NASDAQ AMAG   suffered a setback with Makena Recap of the Week s Top Stories Regeneron Sanofi Get FDA Nod for Label Expansion   Regeneron and partner Sanofi   NASDAQ SNY     dupilumab   Dupixent  a targeted biologic therapy that inhibits signaling of interleukin 4  IL 4  and interleukin 13  IL 13   is now approved for the treatment of adolescent patients  aged 12 17 years with moderate to severe atopic dermatitis  whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable  The approval was based on positive results from the phase III study  which showed that treatment with Dupixent significantly improved skin lesions  reduced itching and helped clear the skin of patients   Hence  Dupixent is now approved for treating both adults and adolescents suffering atopic dermatitis  The regulatory body also accepted the priority review of the supplemental Biologics License Application  sBLA  for Dupixent as an add on maintenance treatment for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps  CRSwNP   A decision on the same is expected on Jun 26  Dupixent is already approved in combination with other asthma medicines for the maintenance treatment of moderate to severe asthma Celgene Submits Ozanimod s MAA for Review in Europe  Celgene announced that it has filed a Marketing Authorization Application to the European Medicines Agency  EMA  for its    The company is seeking an approval for ozanimod  an oral  sphingosine 1 phosphate  S1P  receptor modulator  for the treatment of adults with relapsing remitting multiple sclerosis  RRMS    The application was based on results from the SUNBEAM and RADIANCE part B phase III  multicenter  randomized  double blind  double dummy  active controlled studies  Celgene intends to submit a New Drug Application  NDA  to the FDA for the relapsing forms of MS  RMS  by the end of this month Celgene also announced updates on Abraxane  The FDA gave a nod to the immuno oncology drug Tecentriq in combination with Abraxane for treating adult patients with unresectable locally advanced or metastatic triple negative breast cancer  TNBC   whose tumors express PD L1  determined by an FDA approved test  According to the company  this is the second FDA approval of a PD 1 PD L1 antibody combined with Abraxane  However  the phase III Apact study  evaluating Abraxane in combination with gemcitabine following surgical resection  adjuvant treatment  in patients with pancreatic cancer did not achieve the primary endpoint of improvement in disease free survival as confirmed by independent radiological review in comparison to gemcitabine alone  
Celgene currently sports a Zacks Rank  1  Strong Buy   You can see  AMAG Slumps on Study Failure  Shares of AMAG Pharmaceuticals    NASDAQ AMAG     Progestin s Role in Optimizing Neonatal Gestation   a study evaluating Makena in patients with a history of a prior spontaneous singleton preterm delivery  The PROLONG study did not show a statistically significant difference between the treatment and placebo arms for the co primary endpoints  About 11  of women  who were administered Makena  delivered their babies 35 weeks into their pregnancy or earlier  which wasn t substantially better than the 11 5  placebo participants  Further  the percentage patient population  which met the criteria for the pre specified neonatal morbidity and mortality composite index  experienced an even smaller disparity compared with placebo patients   The PROLONG study was conducted as part of an approval commitment under the FDA s  Subpart H  accelerated approval process Vertex  Combo Study for CF Succeeds  Vertex Pharmaceuticals   NASDAQ VRTX   announced that  in lung function in patients suffering from cystic fibrosis  CF   While one study is evaluating the triple combination regimen in patients with one F508del mutation and one minimal function mutation  the other study is evaluating patients with two F508del mutations In the study evaluating patients with one F508del mutation and one minimal function mutation  the interim data showed that the triple combination regimen led to a mean absolute improvement in ppFEV1 of 13 8 percentage points from baseline through week four of treatment as compared to placebo  The second study yielded a mean absolute improvement in ppFEV1 of 10 0 percentage points from baseline at week four when VX 445 was added in patients already receiving tezacaftor and ivacaftor compared with placebo plus tezacaftor and ivacaftor  Vertex believes that safety and efficacy profile observed in the study supports a potential NDA submission Zafgen Tanks on Discontinuation of Candidate   Shares of Zafgen   NASDAQ ZFGN   plummeted following the company s decision to suspend plans to file an investigational new drug  IND  application for ZGN 1258  The candidate was being evaluated for rare metabolic disorders including Prader Willi syndrome  PWS   This decision was based on a recent  unexpected finding in muscle tissue from four  and six month long term rodent toxicology studies  Nonclinical data showed degeneration and other anomalies in rat muscle tissue to different degrees in both vehicle and dose arms of the studies PerformanceMedical   Biomedical and Genetics Industry 5YR   Return
 The NASDAQ Biotechnology index inched up 0 8  in the past five trading sessions  Among the major biotech biggies  Regeneron gained 2 6  of value  Over the past six months  shares of Alexion have rallied 14 8  while the Gilead  NASDAQ GILD  stock has declined 10 2    See the last biotech stock roundup here    What s Next in Biotech Stay tuned for regular pipeline updates Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  
This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-03-12,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-regn-gets-fda-nod-for-dupixent--other-pipeline-news-200397396,200397396
120345,341860,VRTX,Proteostasis Plunges On Weak Data From Cystic Fibrosis Study,opinion,"Shares of Proteostasis Therapeutics  Inc    NASDAQ PTI   plunged 67 8  on Mar 25  after it announced data from a dose selecting phase I study evaluating its triple combination candidate in patients with cystic fibrosis   CF   Data showed that statistically significant improvement in percent predicted FEV1  ppFEV1   a measurement of lung function  at day 14 was achieved in the study cohort with the higher dose of the company s cystic fibrosis transmembrane conductance regulator   CFTR   corrector  However  the improvement was much lower than that achieved by triple combinations of Vertex Pharmaceuticals   NASDAQ VRTX   in late stage clinical studies in CF Data from clinical studies have shown that two triplet combinations of Vertex achieved improvement in ppFEV1 from baseline in the range of 13 14  in CF patients Shares of Proteostasis have decreased 59 6  so far this year against the  s 8 1  growth The phase I study evaluated two separate triplet combination of a CFTR corrector  PTI 801   a CFTR potentiator  PTI 808  and a CFTR amplifier  PTI 428  in two cohorts in patients  Patients were administered 30 mg of PTI 428 in combination with either 200 mg of PTI 801 and 300 mg of PTI 808 or 600 mg of PTI 801 and 150 mg of PTI 808 Data from the study showed that patients receiving 600mg of PTI 801 achieved an improvement of 5  in ppFEV1 at day 14 compared to baseline  which is considered statistically significant  However  data suggests that the improvement in ppFEV1 can increase with the rise in duration of treatment for both the arms Proteostasis is planning to advance the combination in phase II development with the optimal dose as there was no plateau in ppFEV1 improvement at day 14  The company believes that longer duration studies are likely to increase ppFEV1 improvement from baseline  The company is anticipating phase III development to start in mid 2020 Meanwhile  data from two add on studies evaluating PTI 801 or PTI 428 in patients receiving Symdeko showed improvement in average sweat chloride levels  Patient population also include Orkambi intolerant patients  Although improvement in ppFEV1 was not of statistical significance  it showed potential of PTI 801 as CF treatment  These data suggest opportunity for Proteostasis products in patients non responsive to Vertex s products Data readouts expected in 2019 end or early 2020 are anticipated to provide clarity on the progress of Proteostasis  triplet combination However  stiff competition prevails in the CF market with Vertex s strong hold and several other companies developing their CF pipeline including Eloxx Pharmaceuticals   NASDAQ ELOX    Corbus Pharmaceuticals and Catabasis Pharmaceuticals   NASDAQ CATB   Proteostasis Therapeutics  Inc  Price
    Zacks RankProteostasis currently carries a Zacks Rank  3  Hold   You can see  Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-03-26,Zacks Investment Research,https://www.investing.com/analysis/proteostasis-plunges-on-weak-data-from-cystic-fibrosis-study-200401181,200401181
120348,341863,VRTX,4 Small Biotech Stocks Likely To Witness More Upside In 2019 ,opinion,"The biotech space is off to a good start in 2019  The  industry  comprising mainly small and mid cap companies  has outperformed the broader  sector  whereas the  industry  comprising some of the largest drugmakers of the world  has lagged the sector so far in 2019 
The Zacks Biomedical and Genetics industry has increased 9 6  so far in 2019 compared with the broader Zacks Medical sector s rise of 7 5  With increasing risk of recession in the United States amid tariff wars with several global trade partners  the biotech sector is expected to do well  Investors park their money in recession proof industries like drug biotech and consumer goods to avoid the risk of a downfall We note that the majority of the companies in the biotech sector have no marketed products  which results in operating losses  With no earnings and sales  growth of these companies is primarily driven by progress in their pipeline candidates in clinical stage  Several positive study data readouts and progress of candidates to advanced stage have pulled the sector higher in 2019 so far  Moreover  a rise in merger   acquisition  M A  activity this year has fueled speculations of smaller companies being potential acquisition targets These speculations have boosted the stock price of these smaller players  The biggest deal of the year was  of  74 billion to buy Celgene  NASDAQ CELG   Several other large cap pharma as well as bigger biotech companies are entering collaboration deals with smaller ones to boost their pipeline The larger companies in the biotech sector  which hold the majority of the industry s market capitalization  have a strong portfolio of drugs  commercial as well as a solid pipeline of innovative candidates  These big biotechs have a strong balance sheet and a steady stream of revenues  Among the bigwigs  Celgene  Vertex   NASDAQ VRTX    Biogen   NASDAQ BIIB   and Amgen   NASDAQ AMGN   beat earnings estimates in the last quarter of 2018 With rising M A activity and risk of recession  the biotech sector is poised to pick up and adding stocks from this sector will likely boost portfolio returns Importantly  the Zacks Biomedical and Genetics industry features among the top 32  of the 256 Zacks ranked industries Stocks to BuyHere we have zeroed in on four companies from the biotech drug sector which have performed well so far in 2019 and still hold upside  All these stocks have seen their share price and earnings estimates rise this year These stocks carry a Zacks Rank  1  Strong Buy  or 2  Buy  and have a  of A or B  You can see  Our research shows that stocks with a VGM Score of A or B when combined with a Zacks Rank  1 or 2 offer the best upside potential ANI Pharmaceuticals  Inc     NASDAQ ANIP   ANI Pharmaceuticals sports a Zacks Rank  1  The company has a VGM Score of A  The Zacks Consensus Estimate for earnings has moved 1 2  and 0 6  north for 2019 and 2020  respectively  in the past 60 days  Shares of the company have rallied 50 5  so far this year ANI Pharmaceuticals  Inc  Price
    Kamada Ltd     NASDAQ KMDA   Kamada sports a Zacks Rank  1  The company has a VGM Score of A  The Zacks Consensus Estimate for earnings has moved up 34 3  and 5  for 2019 and 2020  respectively  in the past 60 days  Shares of the company have rallied 15 8  year to date Kamada Ltd  Price
    Genomic Health  Inc     NASDAQ GHDX   Genomic Health carries a Zacks Rank  2  The company has a VGM Score of B  The Zacks Consensus Estimate for earnings has moved up 21 1  and 6 4  for 2019 and 2020  respectively  in the past 60 days  Shares of the company have risen 7 3  so far in 2019 Genomic Health  Inc  Price
    NewLink Genetics Corporation    NASDAQ NLNK   NewLink Genetics carries a Zacks Rank  2  The company has a VGM Score of B  The Zacks Consensus Estimate for loss has narrowed 10 9  and 19 2  for 2019 and 2020  respectively  in the past 60 days  Shares of the company have rallied 25 7  in 2019 NewLink Genetics Corporation Price
    However  a few companies faced developmental or regulatory setbacks  These setbacks wiped out majority of the valuation of smaller companies dependent on a single candidate   Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-03-28,Zacks Investment Research,https://www.investing.com/analysis/4-small-biotech-stocks-likely-to-witness-more-upside-in-2019-200402305,200402305
120349,341864,VRTX,The Zacks Analyst Blog Highlights  ANI  Kamada  Genomic Health And NewLink,opinion,For Immediate ReleaseChicago  IL  April 1  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  ANI Pharmaceuticals  Inc    NASDAQ ANIP    Kamada Ltd    NASDAQ KMDA    Genomic Health  Inc    NASDAQ GHDX   and NewLink Genetics Corp    NASDAQ NLNK   Here are highlights from Friday s Analyst Blog  4 Small Biotechs Likely to Witness More Upside in 2019The biotech space is off to a good start in 2019  The  industry  comprising mainly small and mid cap companies  has outperformed the broader  sector  whereas the  industry  comprising some of the largest drugmakers of the world  has lagged the sector so far in 2019 The Zacks Biomedical and Genetics industry has increased 9 6  so far in 2019 compared with the broader Zacks Medical sector s rise of 7 5  With increasing risk of recession in the United States amid tariff wars with several global trade partners  the biotech sector is expected to do well  Investors park their money in recession proof industries like drug biotech and consumer goods to avoid the risk of a downfall We note that the majority of the companies in the biotech sector have no marketed products  which results in operating losses  With no earnings and sales  growth of these companies is primarily driven by progress in their pipeline candidates in clinical stage  Several positive study data readouts and progress of candidates to advanced stage have pulled the sector higher in 2019 so far  Moreover  a rise in merger   acquisition  M A  activity this year has fueled speculations of smaller companies being potential acquisition targets These speculations have boosted the stock price of these smaller players  The biggest deal of the year was  of  74 billion to buy Celgene  NASDAQ CELG   Several other large cap pharma as well as bigger biotech companies are entering collaboration deals with smaller ones to boost their pipeline The larger companies in the biotech sector  which hold the majority of the industry s market capitalization  have a strong portfolio of drugs  commercial as well as a solid pipeline of innovative candidates  These big biotechs have a strong balance sheet and a steady stream of revenues  Among the bigwigs  Celgene  Vertex  NASDAQ VRTX   Biogen  NASDAQ BIIB  and Amgen  NASDAQ AMGN  beat earnings estimates in the last quarter of 2018 With rising M A activity and risk of recession  the biotech sector is poised to pick up and adding stocks from this sector will likely boost portfolio returns Importantly  the Zacks Biomedical and Genetics industry features among the top 32  of the 256 Zacks ranked industries Stocks to BuyHere we have zeroed in on four companies from the biotech drug sector which have performed well so far in 2019 and still hold upside  All these stocks have seen their share price and earnings estimates rise this year These stocks carry a Zacks Rank  1  Strong Buy  or 2  Buy  and have a  of A or B  You can see  Our research shows that stocks with a VGM Score of A or B when combined with a Zacks Rank  1 or 2 offer the best upside potential ANI Pharmaceuticals  Inc  ANI Pharmaceuticals sports a Zacks Rank  1  The company has a VGM Score of A  The Zacks Consensus Estimate for earnings has moved 1 2  and 0 6  north for 2019 and 2020  respectively  in the past 60 days  Shares of the company have rallied 50 5  so far this year Kamada Ltd Kamada sports a Zacks Rank  1  The company has a VGM Score of A  The Zacks Consensus Estimate for earnings has moved up 34 3  and 5  for 2019 and 2020  respectively  in the past 60 days  Shares of the company have rallied 15 8  year to date Genomic Health  Inc Genomic Health carries a Zacks Rank  2  The company has a VGM Score of B  The Zacks Consensus Estimate for earnings has moved up 21 1  and 6 4  for 2019 and 2020  respectively  in the past 60 days  Shares of the company have risen 7 3  so far in 2019 NewLink Genetics Corp NewLink Genetics carries a Zacks Rank  2  The company has a VGM Score of B  The Zacks Consensus Estimate for loss has narrowed 10 9  and 19 2  for 2019 and 2020  respectively  in the past 60 days  Shares of the company have rallied 25 7  in 2019 However  a few companies faced developmental or regulatory setbacks  These setbacks wiped out majority of the valuation of smaller companies dependent on a single candidate   Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year Media ContactZacks Investment Research800 767 3771 ext  9339   Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-03-31,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-ani-kamada-genomic-health-and-newlink-200402694,200402694
120354,341869,VRTX,Vertex Pharmaceuticals  VRTX  Earnings Expected To Grow  What To Know Ahead Of Next Week s Release,opinion,"Vertex Pharmaceuticals  NASDAQ VRTX  is expected to deliver a year over year increase in earnings on higher revenues when it reports results for the quarter ended March 2019  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The earnings report  which is expected to be released on April 30  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This drugmaker is expected to post quarterly earnings of  0 99 per share in its upcoming report  which represents a year over year change of  29  
Revenues are expected to be  846 45 million  up 32 1  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 1 97  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Vertex 
For Vertex  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  4 62  
On the other hand  the stock currently carries a Zacks Rank of  4 
So  this combination makes it difficult to conclusively predict that Vertex will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Vertex would post earnings of  1 05 per share when it actually produced earnings of  1 30  delivering a surprise of  23 81  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Vertex doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-04-22,Zacks Investment Research,https://www.investing.com/analysis/vertex-pharmaceuticals-vrtx-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release-200409418,200409418
120376,341891,VRTX,5 Drug Biotech Stocks Set To Beat Estimates In Q4 Earnings,opinion,The fourth quarter earnings season has crossed the half way mark  Per the latest  report  total earnings for the medical sector are up 11 3  from the same period last year on 8 4  higher revenues so far The current year got off to a flying start for the   industry  Bristol Myers Squibb Company   NYSE BMY    one of the largest pharma giants  announced that it will acquire the leading biotech company Celgene  NASDAQ CELG  for a whopping  74 billion in what could be one of the largest buyout deals inked of late  Following suit  another large cap pharma company Eli Lilly   NYSE LLY   is all set to purchase Loxo Oncology for  8 billion to broaden its oncology portfolio  Meanwhile  Japan based Takeda Pharmaceutical completed its takeover of the Irish company Shire plc The landscape in the drug biotech sector is rapidly changing  A slowdown in mature products due to intense competition and the rise of biosimilars has forced most pharma bigwigs to eye lucrative integrations to bolster their pipelines  Small tuck in consolidations are quite frequent too  While amalgamation of complementary product portfolios and overlapping arms are a key reason for mega deals  smaller biotechs are generally bought owing to innovative platforms Meanwhile  the Trump government s focus on high drug prices might propel companies to slash prices of key drugs  Incidentally  issues like government scrutiny of high prices  pricing and competitive pressure  sluggish sales of some of the most high profile older drugs and major pipeline setbacks will persistently weigh on the industry  However  most companies seem to have combated the pressure  courtesy of new drug approvals Among the companies that have already reported  Celgene and Alexion reported better than expected results for the fourth quarter of 2018  Vertex  NASDAQ VRTX  and Biogen  NASDAQ BIIB  too beat on earnings and sales   However  results were mixed for Gilead Sciences  NASDAQ GILD   Inc  as the company missed on earnings but beat on sales How to Pick Potential Q4 Winners While maximum big shots from the drug biotech sector have already announced results  there are a few companies  poised to surpass on the fourth quarter s key metrics  However  given the huge count of drug biotech firms  the process of selecting stocks with beat prospects could appear cumbersome By means of the   we have zeroed in on five drug  biotech stocks with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  and a positive   These are valuable tools for investors hunting stocks with potential to outpace on earnings  Moreover  stocks with a top Zacks Rank and a positive ESP have 70  chance to deliver a positive surprise in the ongoing reporting cycle  While you can see   you can uncover the best stocks to buy or sell before they re reported with our  Bet on These 5 Stocks for Robust ReturnsAcadia Pharmaceuticals Inc    NASDAQ ACAD   has an Earnings ESP of  3 39  and a Zacks Rank  3  The Zacks Consensus Estimate for fourth quarter 2018 is pegged at a loss of 55 cents  The company has average trailing four quarter positive surprise of 6 77   It is scheduled to release financial figures on Feb 28 Recro Pharma  Inc    NASDAQ REPH   has an Earnings ESP of  3 03  and a Zacks Rank  2  The Zacks Consensus Estimate for fourth quarter 2018 stands at a loss of 74 cents  The company has average earnings surprise of 23 4  in the last four reported quarters  It is scheduled to report earnings numbers on Feb 19 Pacira Pharmaceuticals  Inc    NASDAQ PCRX   has an Earnings ESP of  32 24  and a Zacks Rank of 3  The Zacks Consensus Estimate for fourth quarter 2018 is pegged at 25 cents  The company came up with average beat of 164 8  in the previous four reported quarters Puma Biotechnology  Inc   NASDAQ PBYI   has an Earnings ESP of  0 54  and is a  3 Ranked stock  The Zacks Consensus Estimate for fourth quarter 2018 is pegged at a loss of 92 cents  The company has average trailing four quarter positive surprise of 67 31   It is scheduled to report results on Feb 28 Epizyme  Inc    NASDAQ EPZM   has an Earnings ESP of  7 93  and is a Zacks  3 Ranked player  The Zacks Consensus Estimate for fourth quarter 2018 is pegged at a loss of 49 cents  The company pulled off average positive surprise of 11 97  in the preceding four reported quarters Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2019-02-14,Zacks Investment Research,https://www.investing.com/analysis/5-drugbiotech-stocks-set-to-beat-estimates-in-q4-earnings-200388354,200388354
120377,341892,VRTX,Should You Invest In The Invesco Dynamic Biotechnology   Genome ETF  PBE  ,opinion,"If you re interested in broad exposure to the Healthcare   Biotech segment of the equity market  look no further than the Invesco Dynamic Biotechnology   Genome ETF  PBE   a passively managed exchange traded fund launched on 06 23 2005 
Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost  transparency  flexibility and tax efficiency  They are excellent vehicles for long term investors 
Sector ETFs are also funds of convenience  offering many ways to gain low risk and diversified exposure to a broad group of companies in particular sectors  Healthcare   Biotech is one of the 16 broad Zacks sectors within the Zacks Industry classification  It is currently ranked 3  placing it in top 19  
Index Details
The fund is sponsored by Invesco  It has amassed assets over  282 53 M  making it one of the average sized ETFs attempting to match the performance of the Healthcare   Biotech segment of the equity market  PBE seeks to match the performance of the Dynamic Biotechnology   Genome Intellidex Index before fees and expenses 
This is comprised of stocks of 30 U S  biotechnology and genome companies  These are companies that are principally engaged in the research  development  manufacture and marketing and distribution of various biotechnological products  services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research 
Costs
Since cheaper funds tend to produce better results than more expensive funds  assuming all other factors remain equal  it is important for investors to pay attention to an ETF s expense ratio 
Annual operating expenses for this ETF are 0 59   making it one of the more expensive products in the space 
Sector Exposure and Top Holdings
Even though ETFs offer diversified exposure which minimizes single stock risk  it is still important to look into a fund s holdings before investing  Luckily  most ETFs are very transparent products that disclose their holdings on a daily basis 
This ETF has heaviest allocation in the Healthcare sector  about 100  of the portfolio 
Looking at individual holdings  Regeneron Pharmaceuticals Inc  NASDAQ REGN  accounts for about 5 81  of total assets  followed by Qiagen Nv  QGEN  and Vertex Pharmaceuticals Inc  NASDAQ VRTX  
The top 10 holdings account for about 48 80  of total assets under management 
Performance and Risk
So far this year  PBE has added about 11 15   and is up roughly 0 87  in the last one year  as of 02 20 2019   During this past 52 week period  the fund has traded between  43 44 and  60 27 
The ETF has a beta of 1 56 and standard deviation of 25 38  for the trailing three year period  making it a high risk choice in the space  With about 30 holdings  it has more concentrated exposure than peers 
Alternatives
Invesco Dynamic Biotechnology   Genome ETF holds a Zacks ETF Rank of 2  Buy   which is based on expected asset class return  expense ratio  and momentum  among other factors  Because of this  PBE is an excellent option for investors seeking exposure to the Health Care ETFs segment of the market  There are other additional ETFs in the space that investors could consider as well 
SPDR S P Biotech ETF  NYSE XBI  tracks S P Biotechnology Select Industry Index and the iShares Nasdaq Biotechnology ETF  IBB  tracks Nasdaq Biotechnology Index  SPDR S P Biotech ETF has  4 06 B in assets  iShares Nasdaq Biotechnology ETF has  8 25 B  XBI has an expense ratio of 0 35  and IBB charges 0 47  
Bottom Line
To learn more about this product and other ETFs  screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe  please visit Zacks ETF Center ",2019-02-19,Zacks Investment Research,https://www.investing.com/analysis/should-you-invest-in-the-invesco-dynamic-biotechnology--genome-etf-pbe-200390091,200390091
120378,341893,VRTX,The Zacks Analyst Blog Highlights  Nike  3M  Vertex  PepsiCo And Verisk,opinion,For Immediate ReleaseChicago  IL  February 22  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Nike   NYSE NKE    3M   NYSE MMM    Vertex   NASDAQ VRTX    PepsiCo   NASDAQ PEP   and Verisk   NASDAQ VRSK   Here are highlights from Thursday s Analyst Blog Top Stock Reports for Nike  3M and VertexThe Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Nike  3M and Vertex  These research reports have been hand picked from the roughly 70 reports published by our analyst team today You can see Buy ranked Nike s shares have gained  26 5  in the past year  outperforming the Zacks Shoes and Retail Apparel industry  which gained  19 9  over the same period  driven by a strong earnings trend stemming from the solid execution of Consumer Direct Offense  Nike has delivered positive earnings surprise for over three years now  with second quarter fiscal 2019 marking 26th straight quarter of earnings beat Moreover  sales topped estimates for the seventh straight quarter  The Zacks analyst thinks strong progress on Consumer Direct Offense through innovation and focus on direct to customer are the key drivers  Growth at international and Nike Direct businesses alongside momentum in North America also aided fiscal second quarter results Continued strength in Nike Digital is driving the top line  However  higher SG A expenses due to increased demand creation expense and operating overheads are likely to remain a drag  Further  the unfavorable currency environment due to the global trade and geopolitical dynamics is likely to weigh on the company s sales  You can   Shares of 3M have lost  5  in the past three months  underperforming the Zacks Diversified Operations industry  which has gained  8 7  over the same period  The Zacks analyst thinks 3M stands to gain from efforts to innovate products  solid demand and portfolio restructuring moves  Its acquisition of the technology business of M Modal is likely to strengthen the Health Information Systems business in the months ahead In the fourth quarter of 2018  the company s earnings and revenues surpassed estimates  However  on a year over year basis  net sales declined 0 6  due to the impact of divestiture and forex woes For 2019  the company lowered its earnings projection and net sales growth guidance  Foreign currency translation is predicted to adversely influence sales by 1   In addition  inflation in prices of major inputs and rising competitive pressures pose threats to near term profitability  Shares also look comparatively overvalued  You can   Vertex s shares have outperformed the Zacks Biomedical and Genetics industry in the past year   19 2  vs   15 9    Vertex beat estimates for both earnings and sales in the fourth quarter  The Zacks analyst likes Vertex s dominance in the CF market  A significant increase in the eligible patient population for its CF drugs is driving sales growth Vertex s third CF medicine  Symdeko  in a very short time  became the primary driver of the significant growth in CF revenues in 2018  Vertex s CF pipeline is also accelerating rapidly  Studies on Vertex s triple combination CF regimens are moving fast  The CF triple pill regimes are crucial for long term growth as these have the potential to treat up to 90  of CF patients Meanwhile  Vertex s non CF pipeline  though early stage  looks interesting  However  competitive pressure is rising in the CF market with many other companies developing triple combo CF drugs  Also  Vertex s dependence on just the CF franchise for growth is a concern  You can   Other noteworthy reports we are featuring today include PepsiCo and Verisk Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year Media ContactZacks Investment Research800 767 3771 ext  9339 Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-02-21,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-nike-3m-vertex-pepsico-and-verisk-200391426,200391426
120379,341894,VRTX,CRISPR Therapeutics Up As Dosing Starts In Thalassemia Study,opinion,CRISPR Therapeutics   NASDAQ CRSP   and its partner Vertex Pharmaceuticals   NASDAQ VRTX   announced the dosing of the first patient in a phase I II study evaluating the CRISPR Cas9 gene editing therapy  CTX001  in patients with beta thalassemia  a form of anemia  This is the first in human use of CTX001 in any clinical study The companies also enrolled first patients in another phase I II study evaluating CTX001 in patients with severe sickle cell disease   SCD    a severe hereditary form of anemia  Dosing in the study is expected to start in mid 2019 Shares of CRISPR Therapeutics surged more than 25  following the announcement of the progress made by the company in studies on CTX001  However  the stock has declined 14 3  in the past year We remind investors that last month  the FDA assigned Fast Track designation CTX001 for the treatment of SCD  With this designation  the drug is expected to be granted a priority review once the company files a new drug application In December 2018  Vertex and CRISPR Therapeutics selected CTX001 to move into clinical development as a gene edited treatment for sickle cell disease and beta  thalassemia  CTX001 has been developed using CRISPR Therapeutics  proprietary CRISPR Cas9 technology  The companies had entered into a strategic research collaboration in 2015 to co develop and co commercialize CTX001  Per the agreement  they will equally share all R D costs and profits worldwide  Vertex has rights to license up to six new gene editing treatments  including CTX001   developed using the CRISPR Cas9 technology from CRISPR that will emerge from the joint research deal Other than CRISPR Therapeutics  Intellia Therapeutics   NASDAQ NTLA   and Editas Medicine  Inc   NASDAQ EDIT   plan to carry out clinical studies using CRISPR Cas9 to cure diseases CRISPR Therapeutics also announced its fourth quarter results in a separate press release   The company reported revenues of  0 1 million  which came from collaborations  compared to  32 3 million in year ago period  Reported loss was 92 cents per share in the fourth quarter  The company achieved breakeven results in the year ago quarter The company remains on track to initiate an immuno oncology study in the first half of 2019 on its CAR T cell therapy candidate  CTX110  for treating CD19  malignancies  The company is the sole owner of the candidate  Since September  the company has inked or modified several collaboration agreements with other pharma companies for pre clinical development of its new CRISPR Cas9 gene editing candidates Zacks RankCRISPR Therapeutics currently carries a Zacks Rank  3  Hold   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-02-25,Zacks Investment Research,https://www.investing.com/analysis/crispr-therapeutics-up-as-dosing-starts-in-thalassemia-study-200392599,200392599
120385,341900,VRTX,Vertex s VX 445 Triple Combo Cystic Fibrosis Trials Succeed,opinion,Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   announced that two phase III studies evaluating its next generation CFTR corrector  VX 445 in combination with tezacaftor and Kalydeco  ivacaftor  met the primary endpoint of significant improvement in lung function in patients suffering from cystic fibrosis   CF   The improvement in lung function was measured as mean absolute improvements in percent predicted forced expiratory volume in one second  or ppFEV1  Cystic fibrosis is a rare genetic disease that causes chronic lung infections and progressive lung damage While one study is evaluating the triple combination regimen in patients with one F508del mutation and one minimal function mutation  the other study is evaluating patients with two F508del mutations In the study evaluating patients with one F508del mutation and one minimal function mutation  the interim data showed that the triple combination regimen led to a mean absolute improvement in ppFEV1 of 13 8 percentage points from baseline through week four of treatment compared to placebo The second study yielded a mean absolute improvement in ppFEV1 of 10 0 percentage points from baseline at week four when VX 445 was added in patients already receiving tezacaftor and ivacaftor compared to placebo plus tezacaftor and ivacaftor  Vertex believes that safety and efficacy profile observed in the study supports a potential NDA submission Other than VX 445  Vertex is also evaluating another next generation CFTR corrector  VX 659 in phase III studies as part of a triple combination with tezacaftor and ivacaftor  Vertex is also evaluating this combination in two separate studies for F508del Min and F508del homozygous patients  In November  the VX 659 phase III studies also met the primary endpoint showing a significant improvement in lung function  The safety and efficacy profile shown in VX 659 studies also supported a NDA submission Given the similarity of the four week data between the studies of the two regimens  Vertex has decided to wait for the final 24 week data for both regimens  expected to be available in the second quarter of 2019  Accordingly  it will file a regulatory application in the United States for the better of the two regimens in both F508del Min and F508del homozygous patient populations in the third quarter of 2019  A regulatory application in the EU is expected to be filed in the fourth quarter  The regulatory filing timeline has been slightly delayed from prior timeline of no later than mid 2019 to select the drugs for filing after including the 24 week data in global submissions Despite the positive data from the of VX 445 studies  Vertex s shares were down almost 4  on Wednesday as the company delayed the timeline for the regulatory filing  Vertex s stock has increased 9 3  this year so far compared with the  increase of 14 5    If the triple combo regimes are successful  Vertex can address a significantly larger CF patient population   almost 90  of patients with CF   in the future  This can expand its reach in the CF market  At present  approximately half of all CF patients are eligible to be treated with a marketed Vertex CF medicine   Kalydeco  Orkambi or Symdeko Meanwhile  many other companies like AbbVie   NYSE ABBV   and Proteostasis Therapeutics  Inc    NASDAQ PTI   are also developing triple CFTR combinations for CF  Proteostasis Therapeutics is expected to report top line data from its triple combo CF medicine in 2019 In 2017  Vertex bought Concert Pharmaceuticals  Inc  s   NASDAQ CNCE   CF pipeline candidate  VX 561  previously CTP 656  and expanded its ongoing triple combination studies to add cohorts to develop VX 561 as a potential once daily triple combination regimen with its other pipeline drugs  VX 561   VX 659  tezacaftor and VX 561   VX 445  tezacaftor  to treat the underlying cause of CF Positive phase II data were announced in 2018  Phase III studies of the once daily triple combination regimen are expected to be initiated after data from a dose ranging phaseII study of VX 561  as a monotherapy in gating mutations  are available Vertex has a Zacks Rank  5  Strong Sell  You can see  Is Your Investment Advisor Fumbling Your Financial Future  See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-03-06,Zacks Investment Research,https://www.investing.com/analysis/vertexs-vx445-triple-combo-cystic-fibrosis-trials-succeed-200395396,200395396
120389,341904,VRTX,Why Is Vertex  VRTX  Down 0 7  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Vertex Pharmaceuticals  NASDAQ VRTX   Shares have lost about 0 7  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Vertex due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Vertex Q4 Earnings Beat on Solid CF Products SalesVertex reported fourth quarter 2018 earnings per share of  1 30  which beat the Zacks Consensus Estimate of  1 05  Moreover  the figure came ahead of the year ago earnings of 61 cents driven by higher revenues Vertex s revenues logged  870 1 million in the fourth quarter  surpassing the Zacks Consensus Estimate of  822 million  The company s sales surged 33 5  year over year  driven by strong CF product sales CF Franchise Sales StrongVertex s fourth quarter revenues consisted of sales from its CF products such as Kalydeco  Orkambi and Symdeko and collaborative and royalty revenues of  1 9 million Total CF product revenues were  868 2 million in the quarter  up 39 8  year over year  mainly driven by the rapid uptake of Symdeko in the United States Kalydeco sales rose 1 2  to  259 million due to increase in number of eligible patient population driven by continued label expansions Orkambi sales declined 13 7  year over year to  315 million due to a switch in patient base to Symdeko from Orkambi as patients are discontinuing Orkambi to start treatment with Symdeko Symdeko generated sales of  294 in the reported quarter  reflecting an increase of 15 3  sequentially as new patients initiated treatment  The company said that Symdeko demand came from all eligible groups of patients including the treatment na ve F508del homozygous patients  those who have discontinued Orkambi treatment and also patients switching from Orkambi or Kalydeco to Symdeko Costs RiseAdjusted research and development  R D  expenses increased 10 4  to  275 million in the fourth quarter  primarily due to the advancement of the company s portfolio of triple combination regimens for CF Adjusted selling  general and administrative  SG A  expenses escalated 17 9  to  125 million in the reported quarter due to investments made in supporting CF patients  treatment  globally 2018 ResultsAdjusted earnings per share rose 109  to  4 08 per share in 2018  Total revenues rose 22 5  to  3 05 billion in 2018 Full year 2018 CF product revenues of  3 04 billion rose 40  2019 Revenue GuidanceVertex provided 2019 outlook for CF products and combined operating costs The company expects total full year revenues for CF products to be in the range of  3 45  3 55 billion  indicating year over year growth of approximately 15   The full year impact of Symdeko s launch  ex US reimbursement agreements and label expansions of the CF drugs are expected to drive CF product revenue growth in 2019 However  a channel inventory build of approximately  10 million that occurred at the end of 2018 is expected to hurt first quarter revenues  First quarter CF product revenues could therefore be sequentially lower than the fourth quarter of 2018 as potential growth from new patients is expected to be offset by channel inventory dynamics Combined adjusted research and development  R D  plus selling  general and administrative  SG A  expenses in 2019 are anticipated in the range of  1 65  1 70 billion The increase in operating expense was due to estimated costs related to the development and the potential launch of triple combinations regimen and expansion of early stage non CF pipeline 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates 
VGM Scores
At this time  Vertex has a strong Growth Score of A  a grade with the same score on the momentum front  However  the stock was allocated a grade of F on the value side  putting it in the lowest quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision indicates a downward shift  It s no surprise Vertex has a Zacks Rank  5  Strong Sell   We expect a below average return from the stock in the next few months ",2019-03-06,Zacks Investment Research,https://www.investing.com/analysis/why-is-vertex-vrtx-down-07-since-last-earnings-report-200395472,200395472
120414,341929,VRTX,Will Gilead  GILD  Q4 Earnings Disappoint On Weak HCV Sales ,opinion,"Biotech major Gilead Sciences Inc    NASDAQ GILD   is scheduled to report fourth quarter and full year results on Feb 4  after the market closes 
Gilead has a decent track record  with the company s earnings beating estimates in three of the last four quarters  In the last reported quarter  the company s earnings beat expectations by 10 8   Overall  the company delivered average positive earnings surprise of 6 99  
Gilead s stock has declined 8 8  in the last six months  against the  s decline of 14 1  

 
Factors in Play
Along with third quarter results  Gilead updated its annual guidance  Gilead expects net product sales of  20 8  21 3 billion in 2018 compared with the earlier estimate of  20  21 billion  Adjusted R D and adjusted SG A expenses are projected to be  3 4  3 6 billion and  3 4  3 6 billion  respectively  Adjusted product gross margin is expected to be 85 87  
While Gilead s third quarter results beat estimates  the year over year decline was disappointing as the magnitude of decline in hepatitis C virus  HCV  sales continues to deepen 
The franchise suffered a significant plunge in sales due to new competition and fewer patient starts  HCV revenues are projected to decline further and will constitute a smaller portion of the top line  Gilead s HCV drug  Harvoni has been approved in China 
Nevertheless  the HIV franchise is expected to maintain momentum  Strong HIV performance and other antiviral product sales are being driven by continued uptake of tenofovir alafenamide   TAF   based products   Genvoya  Descovy and Odefsey  We expect the trend to continue in the third quarter  Genvoya has been listed as a preferred regimen in several HIV treatment guidelines  
Truvada  for use in the pre exposure prophylaxis setting  continued the momentum with an estimated 193 000 patients using the drug by the end of the third quarter  The China National Drug Administration has approved Genvoya for the treatment of HIV 1 infection  The Zacks Consensus Estimate for sales of Genvoya is  1 2 billion 
HIV is one of the primary areas of focus for Gilead and the company is working to bringnew HIV treatments to market to further boost sales of the franchise  The company received a major boost when the FDA approved its once daily single tablet regimen   STR    Biktarvy  bictegravir 50mg emtricitabine 200mg tenofovir alafenamide 25mg  BIC FTC TAF  for HIV 1 infection  
The approval in Europe has boosted sales further  Gilead currently expects Biktarvy to overtake Genvoya as the most successful launch in HIV history  In March  Biktarvy was added as one of the recommended initial regimens to the U S  DHHS guidelines for the use of antiretroviral agents in adults and adolescents living with HIV 
In December 2018  the board of directors appointed Daniel O Day as the company s chairman and CEO 
Apart from the regular top and bottom line numbers  we expect investors to focus on pipeline updates  Gilead intends to foray into the non alcoholic steatohepatitis  NASH  and inflammation market with late stage candidates  selonsertib and filgotinib  respectively  Both the candidates are being evaluated in late stage studies and a tentative approval will diversify Gilead s portfolio  
Earlier this month  Gilead announced that it entered into a licensing and collaboration agreement with South Korea based Yuhan Corporation to co develop novel therapeutic candidates for the treatment of patients suffering from advanced fibrosis due to NASH  In December 2018  Gilead entered into a deal with Agenus   NASDAQ AGEN   to develop and commercialize up to five immuno oncology  I O  therapies 
Earnings Whispers
Our proven model does not conclusively show that Gilead will beat on earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  Unfortunately  that is not the case here  as you will see below 
Earnings ESP  Earnings ESP for Gilead is  4 72    The Zacks Consensus Estimate is pegged at  1 74  while the Most Accurate Estimate is pegged at  1 65  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Gilead currently carries a Zacks Rank  4  Sell   which when combined with a negative ESP indicates very low chances of an earnings beat  As it is  we caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Gilead Sciences  Inc  Price  Consensus and EPS Surprise
 

   Stocks to Consider
Here are some health care stocks you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter 
ACADIA Pharmaceuticals Inc    NASDAQ ACAD   has an Earnings ESP of  3 89  and a Zacks Rank  3  You can see  
Vertex Pharmaceuticals   NASDAQ VRTX   is scheduled to release its results on Feb 5  The company has an Earnings ESP of  4 52  and a Zacks Rank  3 
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-02-01,Zacks Investment Research,https://www.investing.com/analysis/will-gilead-gild-q4-earnings-disappoint-on-weak-hcv-sales-200382343,200382343
120415,341930,VRTX,Vertex Pharmaceuticals  VRTX  Q4 Earnings And Revenues Top Estimates,opinion,"Vertex Pharmaceuticals  NASDAQ VRTX  came out with quarterly earnings of  1 30 per share  beating the Zacks Consensus Estimate of  1 05 per share  This compares to earnings of  0 61 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 23 81   A quarter ago  it was expected that this drugmaker would post earnings of  1 per share when it actually produced earnings of  1 09  delivering a surprise of 9  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Vertex  which belongs to the Zacks Medical   Biomedical and Genetics industry  posted revenues of  870 11 million for the quarter ended December 2018  surpassing the Zacks Consensus Estimate by 6 27   This compares to year ago revenues of  651 63 million  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Vertex shares have added about 13 4  since the beginning of the year versus the S P 500 s gain of 8 7  
What s Next for Vertex 
While Vertex has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Vertex was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 on  841 61 million in revenues for the coming quarter and  4 18 on  3 57 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Biomedical and Genetics is currently in the top 28  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-02-05,Zacks Investment Research,https://www.investing.com/analysis/vertex-pharmaceuticals-vrtx-q4-earnings-and-revenues-top-estimates-200384017,200384017
120416,341931,VRTX,Vertex  VRTX  Q4 Earnings Beat On Solid CF Products Sales,opinion,Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   reported fourth quarter 2018 earnings per share of  1 30 which beat the Zacks Consensus Estimate of  1 05  Moreover  the figure came ahead of the year ago earnings of 61 cents  Strong cystic fibrosis  CF  product revenues led to higher profits in the reported quarter Vertex s revenues logged  870 1 million in the fourth quarter  also surpassing the Zacks Consensus Estimate of  822 million  The company s sales surged 33 5  year over year  driven by the rapid uptake of its newest CF medicine  Symdeko  in the United States and the impact of the label expansion of Kalydeco Shares of Vertex were up almost 3  in after hours trading following its earnings announcement on Tuesday  In fact  the stock has rallied 17 5  in the past year against the  decrease of 17 1  CF Drugs Sales Remain StrongVertex s fourth quarter revenues grossed  868 2 million in sales of its CF products such as Kalydeco  ivacaftor   Orkambi  lumacaftor ivacaftor  and Symdeko  a combination of tezacaftor and ivacaftor  plus collaborative and royalty revenues of  1 9 million Total CF product revenues rose 39 8  year over year  mainly driven by the rapid uptake and strong demand of its newest CF medicine  Symdeko  in the United States  The drug was approved both in the United States and Europe last February and November  respectively  Symdeko is marketed under the trade name of Symkevi in the EU Symdeko generated sales of  294 in the reported quarter  reflecting an increase of 15 3  sequentially  The drug has seen solid demand since its launch as more patients are resorting to treatment with the same  The company expects to witness a rise in Symdeko revenues in future quarters Kalydeco sales inched up 1 2  to  259 million year over year  driven by continued label expansions wherein the drug s eligible patient population has grown  The drug was approved by the FDA and the European Commission  EC  for use in children aged 12 months to two years with at least one of specified nine mutations in the CFTR gene last August and November  respectively Orkambi sales declined 13 7  year over year to  315 million due to a switch in patient base to Symdeko from Orkambi as patients are discontinuing Orkambi to start treatment with Symdeko  Last month  the EC granted an approval to a regulatory application seeking Orkambi s label expansion for its use in 2 5 year old children suffering CF  who have two copies of the F508del mutation  Orkambi was approved by the FDA for the same patient population last August Costs RiseAdjusted research and development  R D  expenses increased 10 4  to  275 million in the fourth quarter  primarily due to the advancement of the company s portfolio of triple combination regimens for CF Adjusted selling  general and administrative  SG A  expenses escalated 17 9  to  125 million in the reported quarter due to investments made in supporting CF patients  treatment  globally 2019 Revenue GuidanceVertex provided 2019 outlook for CF products and combined operating costs The company expects total full year revenues for CF products to be in the range of  3 45  3 55 billion Combined adjusted research and development  R D  plus selling  general and administrative  SG A  expenses in 2019 are anticipated in the range of  1 65  1 70 billion The increase in operating expense is due to estimated costs related to development and the potential launch of triple combinations regimen for treating CF Pipeline   Regulatory UpdatesVertex is evaluating two next generation CFTR correctors  VX 659 and VX 445  in phase III evaluations as part of a triple combo regime with tezacaftor and ivacaftor  During the reported quarter  two phase III studies evaluating VX 659 in combination with tezacaftor and Kalydeco met the primary endpoint of improvement in lung function amid patients afflicted with CF Meanwhile  enrollment in the VX 445 phase III studies is now complete with the top line data predicted to be presented during the first quarter of 2019  A regulatory submission in the United States for one of the two regimes is planned for mid 2019 If the triple combo therapies are successful  Vertex can then address a significantly larger CF patient population   almost 90  of patients with CF   in the future Vertex has collaborated with CRISPR Therapeutics   NASDAQ CRSP   to evaluate an investigational gene editing treatment  CTX001  for two devastating diseases  namely sickle cell disease and thalassemia  Last month  the FDA granted a Fast Track designation to CTX001 for the treatment of sickle cell disease  a severe hereditary form of anaemia  Also  a phase I II program on CTX001 for treating sickle cell disease and beta thalassemia is currently underway Last December  Vertex announced positive results from a phase II study  evaluating its NaV1 8 inhibitor   VX 150   on patients afflicted with pain caused by small fiber neuropathy  Also  the FDA granted a Breakthrough Therapy status to VX 150 for treating moderate to severe acute pain  Data from this phase IIb dose ranging study is expected in the first half of 2019 Vertex Pharmaceuticals Incorporated Price  Consensus and EPS Surprise   Zacks Rank   Stocks to ConsiderVertex currently carries a Zacks Rank  3  Hold   Two better ranked stocks in the biotech sector are Celgene Corporation   NASDAQ CELG   and Ligand Pharmaceuticals Incorporated   NASDAQ LGND    both sporting a Zacks Rank  1  Strong Buy  You can see  Celgene s earnings estimates have been revised 3 4  upward for 2019 over the past 60 days Ligand s earnings estimates have moved 2 9  north for 2019 over the past 60 days Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2019-02-05,Zacks Investment Research,https://www.investing.com/analysis/vertex-vrtx-q4-earnings-beat-on-solid-cf-products-sales-200384382,200384382
120438,341953,VRTX,CELG Or VRTX  Which Is The Better Value Stock Right Now ,opinion,"Investors interested in stocks from the Medical   Biomedical and Genetics sector have probably already heard of Celgene  CELG  and Vertex Pharmaceuticals  NASDAQ VRTX   But which of these two companies is the best option for those looking for undervalued stocks  Let s take a closer look 
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system  The Zacks Rank favors stocks with strong earnings estimate revision trends  and our Style Scores highlight companies with specific traits 
Right now  Celgene is sporting a Zacks Rank of  1  Strong Buy   while Vertex Pharmaceuticals has a Zacks Rank of  3  Hold   This system places an emphasis on companies that have seen positive earnings estimate revisions  so investors should feel comfortable knowing that CELG is likely seeing its earnings outlook improve to a greater extent  But this is just one piece of the puzzle for value investors 
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels 
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics  These include the long favored P E ratio  P S ratio  earnings yield  cash flow per share  and a variety of other fundamentals that help us determine a company s fair value 
CELG currently has a forward P E ratio of 8 29  while VRTX has a forward P E of 46 42  We also note that CELG has a PEG ratio of 0 41  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  VRTX currently has a PEG ratio of 1 18 
Another notable valuation metric for CELG is its P B ratio of 12 37  The P B ratio is used to compare a stock s market value with its book value  which is defined as total assets minus total liabilities  For comparison  VRTX has a P B of 16 89 
These metrics  and several others  help CELG earn a Value grade of A  while VRTX has been given a Value grade of D 
CELG stands above VRTX thanks to its solid earnings outlook  and based on these valuation figures  we also feel that CELG is the superior value option right now ",2019-01-22,Zacks Investment Research,https://www.investing.com/analysis/celg-or-vrtx-which-is-the-better-value-stock-right-now-200378329,200378329
120439,341954,VRTX,Vertex Pharmaceuticals  VRTX  Reports Next Week  Wall Street Expects Earnings Growth,opinion,"Wall Street expects a year over year increase in earnings on higher revenues when Vertex Pharmaceuticals  NASDAQ VRTX  reports results for the quarter ended December 2018  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on January 30  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This drugmaker is expected to post quarterly earnings of  1 05 per share in its upcoming report  which represents a year over year change of  72 1  
Revenues are expected to be  822 45 million  up 26 2  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is subject to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Vertex 
For Vertex  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  4 52  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination indicates that Vertex will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Vertex would post earnings of  1 per share when it actually produced earnings of  1 09  delivering a surprise of  9  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Vertex appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-01-22,Zacks Investment Research,https://www.investing.com/analysis/vertex-pharmaceuticals-vrtx-reports-next-week-wall-street-expects-earnings-growth-200378401,200378401
120440,341955,VRTX,What s Behind The Biotech ETF Rally To Start 2019  ,opinion,"This year  biotech stocks have seen their  since 2012  A solid merger and acquisition momentum has been instrumental in this rally  The announcement of the mega merger deal between Bristol Myers   NYSE BMY   and Celgene  NASDAQ CELG   at the beginning of 2019 has set the space on fire  Bristol Myers has offered  74 billion to take over Celgene 
Also  Eli Lilly and Company   NYSE LLY   has announced that it will acquire Loxo Oncology for  8 billion to expand its oncology portfolio to precision medicines or targeted therapies  The winning momentum started from December 2018  when Glaxo   NYSE GSK   offered to acquire TESARO for almost  5 1 billion  With this deal  Glaxo will gain access to TESARO s PARP inhibitor  Zejula  which is approved for ovarian cancer 

More Deals Ahead 
Heightened speculation about increasing consolidation in the cancer space is doing rounds  Analysts have predicted a sizable increase in merger and acquisition activity in both  
Needless to say  all these acquisitions have acted as a cornerstone in the industry   for treating cancer are from smaller biotechs  This makes them lucrative acquisition targets  As a result  smaller biotech companies like Clovis Oncology   NASDAQ CLVS    Epizyme  and Blueprint Medicines   LON BPM   have been on a tear this year 
Eli Lilly s chief executive officer affirmed its desire to ink more deals in the areas of   Investors should note that biotech giants are cash rich and can pay rich premium if they eye any specific company  per Bloomberg  Gilead Sciences   NASDAQ GILD    Biogen   NASDAQ BIIB    AbbVie   NYSE ABBV   and AstraZeneca   NYSE AZN   can act as potential acquirers down the line 
Success Story Beyond Cancer
While researches and approvals have been solid in the oncology space  the other areas have also held strong   so far this year include that of Gilead Sciences  HIV regimen  Biktarvy  Vertex  NASDAQ VRTX  Pharmaceuticals  Symdeko  tezacaftor ivacaftor and ivacaftor  for the treatment of cystic fibrosis  CF   Regeneron Pharmaceuticals  Libtayo and BioMarin s Palynziq for the treatment of phenylketonuria  Sage Therapeutics  SAGE  reported positive late stage data  
Upbeat Zacks Rank 
The   currently comes from the top ranked Zacks industry  top 21    The index is up 11 54  this year compared with 6 54  gains in the iShares Core S P 500 ETF  
Any Roadblock Ahead  
While momentum is pretty strong and is likely to stay the same ahead  the ongoing U S  government shutdown could play foul  There are products in the pipeline  at the U S  Food and Drug Administration and the shutdown is not helping  as quoted on Bloombergquint  However  even if there is a short term lull  the momentum should pick up once the impasse clears 
ETFs in Focus 
Against this backdrop  investors may want to have a look at some of the wining biotech ETFs of this year 
Principal Healthcare Innovators Index ETF    Up 14 20 
Virtus LifeSci Biotech Products ETF   BS BBP     Up 14 0 
VanEck Vectors Biotech ETF   LON BBH     Up 13 4 
First Trust Amex Biotechnology Index   LON FBT     Up 13 4 
iShares Nasdaq Biotechnology ETF    Up 12 7 
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2019-01-24,Zacks Investment Research,https://www.investing.com/analysis/whats-behind-the-biotech-etf-rally-to-start-2019-200379167,200379167
120441,341956,VRTX,Merck KGaA Gives Vertex Rights To Two Gene Editing Compounds,opinion,German drug company Merck KGaA  announced that it has given Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   exclusive rights to two DNA dependent protein kinase  DNA PK  inhibitors for use in gene editing application for six specific genetic disease indications In addition to milestones and royalties on future net sales  Merck KGaA will receive an undisclosed upfront payment  The company retains the rights to both compounds in all other disease areas  including oncology  Moreover  the company holds back the rights to develop both these compounds in house  or out license them to future partners in the gene editing field outside of the six specified disease areas  Vertex has the option to add indications to the license grant Both the molecules   M9831 and an additional pre clinical compound   were acquired by Merck KGaA in 2017 in a licensing agreement from Vertex and are part of the former s DNA Damage Response  DDR  inhibitors pipeline portfolio  Merck KGaA aims to be a leader in developing DDR molecules  The company sees the potential benefit of DNA PK in genetic diseases through the enhancement of its CRISPR Cas9 mediated gene editing Share price pf Merck KGaA has decreased 8 2  in the past year compared with the  s decline of 25 1  We remind investors that last month  Merck KGaA announced a strategic alliance in the CRISPR Cas9 rodent model market with France based biotechnology company genOway  Through an exclusive worldwide license of Merck s foundational CRISPR integration patents  genOway will develop new models and solutions  allowing non profit and for profit scientists to use CRISPR Cas9 technology We remind investors that last month  Merck KGaA also inked a deal with Intrexon Corporation   NASDAQ XON   for the development of Chimeric Antigen Receptor T cell  CAR T  therapies  Per the agreement  Merck KGaA will assign its exclusive CAR T development rights to Intrexon  Merck KGaA will receive shares of Intrexon common stock  valued at  150 million  in exchange for assigning Intrexon its CAR T rights  The agreement enables Merck KGaA to maintain an investment in the rapidly advancing oncology field of CAR T while focusing on its R D efforts  Merck KGaA Price    Zacks Rank and Stocks to ConsiderMerck KGaA currently does not carry any Zacks Rank A better ranked stock is Eli Lilly and Company   NYSE LLY   carrying a Zacks Rank  2  Buy   You can see  Lilly s earnings per share estimates have moved up from  5 47 to  5 58 for 2018 and from  5 78 to  5 87 for 2019 in the past 90 days  The company delivered a positive earnings surprise in all the trailing four quarters  the average being 10 03  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-01-24,Zacks Investment Research,https://www.investing.com/analysis/merck-kgaa-gives-vertex-rights-to-two-geneediting-compounds-200379574,200379574
120442,341957,VRTX,Is A Beat In The Cards For Celgene  CELG  In Q4 Earnings ,opinion,"Celgene Corporation   NASDAQ CELG   is likely to beat expectations when it reports fourth quarter results on Jan 31  before the opening bell  In the last reported quarter  the company delivered a positive earnings surprise of 2 23  Celgene s track record has been excellent  with the company beating earnings estimates in all of the trailing four quarters  Overall  the company has delivered average positive surprise of 2 54  Let s see how things are shaping up ahead of this announcement Why a Likely Positive Surprise Our proven model indicates that Celgene is likely to beat earnings estimates this quarter because it has the right combination of two key ingredients   a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  Earnings ESP  Earnings ESP  which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate  is pegged at  2 31   This is because the Most Accurate Estimate stands at  2 37  while the Zacks Consensus Estimate is  2 32  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Celgene currently carries a Zacks Rank  1  Strong Buy   The combination of a favorable rank and a positive ESP makes us confident of an earnings beat We caution against Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Factors at PlayEarlier this month  Celgene announced preliminary results for 2018 and issued its financial guidance for 2019 The preliminary results show that Celgene has achieved guidance for 2018 that it had provided on Oct 25  2018  revenues of  15 2 billion and earnings per share of  8 75   8 80  Revlimid sales are projected to be  9 7 billion and Abraxane sales are expected to be around  1 billion  Pomalyst s revenues are expected to be  2 0 billion  whereas Otezla sales are projected at  1 6 billion  up from  1 5 billion projected earlier Celgene s key product  Revlimid should continue to act as the main growth driver in the second quarter  Revlimid  an oral immunomodulatory drug  is currently approved for several indications  including newly diagnosed multiple myeloma   MM    myelodysplastic syndromes   MDS   and mantle cell lymphoma   MCL    Market share gains in key markets and longer treatment duration are contributing to the drug s growth  Continued uptake in front line non stem cell eligible and post stem cell transplant maintenance segments have propelled sales Data from the phase III ROBUST trial  evaluating Revlimid in combination with Rituxan  cyclophosphamide  doxorubicin hydrochloride  vincristine sulfate and prednisone  R CHOP  in patients with first line ABC subtype diffuse large B cell lymphoma  DLBCL   is expected in 2019 Apart from Revlimid  Pomalyst  Otezla and Abraxane are also expected to contribute to the top line  Otezla sales in the third quarter were driven by increased demand  with continued benefit from expanded market access and higher channel inventory levels  We expect the momentum to continue in the fourth quarter  Encouragingly  Celgene is also working on label expansion of drugs like Pomalyst Imnovid  Abraxane and Otezla  among others  Pomalyst in combination with bortezomib and dexamethasone  PVd  is being evaluated for the treatment of relapsed refractory multiple myeloma   RRMM   and an approval for the same is expected in Europe and Japan The sNDA for plaque psoriasis drug Otezla has been accepted for Behcet s disease  with a Prescription Drug User Fee Act  PDUFA  action date of Jul 21  2019  The company is expected to submit an sNDA to the FDA for Otezla for a label update to include moderate to severe scalp psoriasis  in the second quarter of 2019 A decision from the FDA is expected by Mar 12  2019 on the supplemental Biologics License Application  sBLA  filed by Roche for Tecentriq in combination with Celgene s Abraxane for the initial treatment of patients with PD L1 positive  metastatic triple negative breast cancer We also expect the company to throw more light on its promising candidates  Celgene and partner Acceleron Pharma   NASDAQ XLRN   are evaluating luspatercept in two phase III studies   BELIEVE and MEDALIST  Both the companies intend to submit regulatory applications for the drug in the United States and Europe in 2019 Celgene has been in news since the beginning of 2019  due to the recent announcement of a merger agreement made by large cap pharma company  Bristol Myers Squibb Company   NYSE BMY    Share price of Celgene increased on the news  The acquisition is expected to close in the third quarter of 2019  We expect management to throw more light on the same 
Share Price Performance
Celgene s stock lost 1 9  in the last six months compared with the  s 11 3  decline 

 Another Stock That Warrants a LookHere is a health care stock you may want to consider as our model shows that this too has the right combination of elements to post an earnings beat this quarter Vertex Pharmaceuticals   NASDAQ VRTX   is scheduled to release its results on Feb 5  The company has an Earnings ESP of  4 52  and a Zacks Rank  3 You can see  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-01-28,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-the-cards-for-celgene-celg-in-q4-earnings-200380760,200380760
120443,341958,VRTX,Vertex s Kalydeco Wins Health Canada Nod To Treat CF In Kids,opinion,Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   announced that Health Canada has granted marketing authorization to its cystic fibrosis  CF  drug  Kalydeco  ivacaftor   for expanded use in children aged 12 months to two years with at least one of specified nine mutations in the CFTR gene Following this nod  Kalydeco becomes the first and the only approved medicine in Canada to treat the underlying cause of CF among such young patient population The approval was based on data from an ongoing phase III study  ARRIVAL  which evaluated children with one of the specified mutations in the CF transmembrane conductance regulator  CFTR  gene  The study demonstrated improvements in sweat chloride  a key secondary efficacy endpoint Kalydeco was approved by the FDA and the European Commission for same patient populations last August and November  respectively Shares of Vertex have gained 12 5  in the past year against the decline of 23 8   Kalydeco is a key revenue driver for Vertex  During the first nine months of 2018  the drug generated sales of  748 million  reflecting a 27 1  year over year increase  driven by continued label expansions and higher patient population Notably  CF is Vertex s main area of focus  Apart from Kalydeco  its other two approved CF products are Orkambi and Symdeko  the constant revenue catalysts  Total CF product revenues were  2 2 billion in the first nine months of 2018  indicating a 46 7  surge year over year Evidently  Vertex s CF pipeline is also quite strong  The company is investigating two next generation CFTR correctors  VX 659 and VX 445  in phase III studies as part of a triple combination with tezacaftor and ivacaftor Studies on Vertex s triple combination CF regimens are advancing fast  The CF triple pill regimes are crucial for long term growth as these have potential to treat at least 90  of CF patient population Zacks Rank   Stocks to ConsiderVertex currently carries a Zacks Rank  3  Hold   Better ranked stocks in the healthcare sector include BioDelivery Sciences International  Inc    NASDAQ BDSI    Merus N V    NASDAQ MRUS   and ProQR Therapeutics N V    NASDAQ PRQR    all sporting a Zacks Rank  1  Strong Buy   You can see  BioDelivery Sciences  loss per share estimates have been narrowed 20  for 2019 in the last 60 days  The stock has soared 79 6  in the past year Merus  loss per share estimates have been narrowed 12 7  for 2019 in the last 60 days ProQR Therapeutics  loss per share estimates have been narrowed 5 9  for 2019 over the past 60 days  The stock has skyrocketed 366 6  in a year Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-01-28,Zacks Investment Research,https://www.investing.com/analysis/vertexs-kalydeco-wins-health-canada-nod-to-treat-cf-in-kids-200380666,200380666
120450,341965,VRTX,Vertex Pharmaceuticals  VRTX  Earnings Expected To Grow  Should You Buy ,opinion,"Vertex Pharmaceuticals  NASDAQ VRTX  is expected to deliver a year over year increase in earnings on higher revenues when it reports results for the quarter ended December 2018  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on February 5  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This drugmaker is expected to post quarterly earnings of  1 05 per share in its upcoming report  which represents a year over year change of  72 1  
Revenues are expected to be  818 77 million  up 25 7  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is subject to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Vertex 
For Vertex  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  4 52  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination indicates that Vertex will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Vertex would post earnings of  1 per share when it actually produced earnings of  1 09  delivering a surprise of  9  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Vertex appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-01-28,Zacks Investment Research,https://www.investing.com/analysis/vertex-pharmaceuticals-vrtx-earnings-expected-to-grow-should-you-buy-200380557,200380557
120474,341989,VRTX,7  Strong Buy  Stocks To Snap Up This December,opinion,"Top Wall Street firm Oppenheimer is out with a list of its Top 32 best equity ideas for December  Each of the firm s analysts was asked to contribute one stock idea that they think could outperform over the next 12 months  This is based on both fundamentals and current market conditions 
From this list of 32 stock picks  we used TipRanks to select 7 stocks with a Strong Buy consensus from the Street  With the market so volatile right now this consensus rating provides reassurance that the Street as a whole has a bullish outlook on these stocks  At the same time  we take a deeper look into why the firm s analysts  many of whom have a very high ranking on TipRanks  believe that these stocks represent the most compelling investment opportunities 
Are you ready  Let s dive in now 
Salesforce com Inc  NYSE CRM 
Salesforce calls itself the world s No  1 customer relationship management platform  Right now  the stock is buzzing following the release of strong earnings results that beat expectations 
Business remained very solid in the third quarter  with total revenue of  3 39 billion up 26 percent year over year  And while guidance for the fourth quarter came in mixed  Salesforce gave very encouraging guidance for both 2019 and 2020 
 We consider CRM one of the healthiest long term growth stories in our SaaS applications software universe  claims five star Oppenheimer analyst Brian Schwartz  His bullish  180 price target sees shares surging 28  from current levels 
He predicts ongoing upward revisions beyond the current consensus as  CRM is a proven market share taker that possesses disruptive products and a powerful corporate culture  and is led by a visionary CEO  
And we can see here that the Street clearly shares Schwartz s upbeat take on this software stock 

XPO
XPO Logistics Inc  NYSE XPO  is a top ten global logistics company  Its services span everything from shipping to freight brokerage to trucks and tractors 
The stock is also the top pick of Oppenheimer s Scott Schneeberger  With a buy rating and a  114 price target  he is predicting juicy upside potential of 50   This is down to XPO s solid organic revenue growth and strong operational execution 
 An industry leader spanning key transportation and logistics categories  XPO possesses a compelling adjusted EBITDA free cash flow growth story  the analyst explains 
He anticipates continued top line growth with gradual margin expansion over 2018E 2020E  writing  we expect the tail end of the period to again be augmented by sizable  accretive acquisition contribution  
Overall  this  Strong Buy  stock boasts 7 top analyst buy ratings in the last three months  This is vs 1 hold rating  The average analyst price target stands at  114 
EVH
Evolent Health Inc  NYSE EVH  sells software and consulting services to help healthcare providers  like hospital systems  offer care at lower costs  This is particularly important given the ongoing shift to value based payments systems  From a Street perspective  this is a first class stock with a lot of potential 
In the last three months alone  we are looking at 9 top analyst buy ratings  And with an average price target of  33  analysts see prices spiking 27  in the coming months 
 We continue to be encouraged by the momentum in the transition toward risk based reimbursement and by EVH s position to gain from it  says five star Oppenheimer analyst Mohan Naidu  He reiterated his buy rating with a  31 price target on November 7  Plus the recent acquisition New Century Health adds nicely to numbers and moves estimates higher for Q4 
He says   While there is competition  we believe EVH is differentiated in its proven ability  technology offerings  service and credibility in helping organizations make the switch successfully  

VRTX
Global biotech stock Vertex  NASDAQ VRTX  Pharma is a prime investing pick right now with a growing portfolio of cystic fibrosis  CF  drugs  This is a genetic disorder that causes severe damage to the lungs  digestive system and other organs in the body 
Oppenheimer s Hartaj Singh has been bullish on the stock since June 2017   Vertex  VRTX  reported two positive phase 3 efficacy readouts for VX 659  the first of its two triplet therapies development  The data continues to impress  with 4  week efficacy being incrementally better than phase 2 results published in the NEJM recently  We stay bullish  he wrote on November 27 
 We believe the company is positioned to deliver strong sales and earnings growth over the next five years  with the potential for even greater growth if product launches outperform and OPEX reaches steady state  Singh says 
Net net   This could be just the beginning of the upside story   His price target currently stands at  200 
LOGM
Enjoy the freedom to work remotely with LogMeIn Inc  NASDAQ LOGM   The company describes itself as the world s most reliable remote desktop tool  As well as remote services  the company also provides IT management and customer engagement solutions 
According to Top 100 Oppenheimer analyst Shaul Eyal  LOGM is a bargain buy right now 
 LOGM is becoming a compelling value play representing one of the sector s cheaper companies  says Eyal   With two differentiated acquisitions  GoTo and Jive  now aligned with LOGM s longer term strategy  we view the discount to the group as unwarranted  
In total this  Strong Buy  stock has received 4 top analyst buy ratings in the last three months  This is versus 1 hold rating  Meanwhile the  107 average price target suggests shares can soar 20  from current levels 
HD
Home Depot  NYSE HD  is the U S  s largest home improvement retailer with over 2 200 retail stores  The company has just reported much better than expected Q3 results alongside updated FY18  Jan  2019  guidance  In Q3  domestic comps rose an impressive 5 4  and EPS increased 36  to  2 51  easily topping Street s  2 27 
 For some time now  we have highlighted home improvement as a bright spot within the retail sector and HD as the clear best run operator within the space  cheers top ranked Oppenheimer analyst Brian Nagel 
He believes HD can surprise investors with solid and persistent comp and EPS upside  Nagel has a Buy rating on the stock with a  200 price target  13  upside potential  

WCN
True this may not be the most appealing company in the world  As the name suggests  Waste Connections Inc  NYSE WCN  deals with solid waste collection  disposal and recycling  It provides waste treatment  landfills  intermodal facilities and recovery landfills 
However  from an investing perspective the stock is certainly worth a closer look  Top Oppenheimer analyst Noah Kaye reveals why he picked WCN as his No  1 stock here   We believe industry dynamics will continue to support strong cash flows in WCN s core business and return of cash to shareholders  
Not only that but in comparison to its waste management peers  WCN is a growth play with upside potential  Kaye expects management s history of strong execution on post merger integration with Progressive Waste Solutions  BIN  to continue  Note that the stock boasts 100  Street support  with five buy ratings over the last three months ",2018-12-16,TipRanks Ltd,https://www.investing.com/analysis/7-strong-buy-stocks-to-snap-up-this-december-200368462,200368462
120475,341990,VRTX,Vertex s  VRTX  3rd Study On Pain Drug Meets Primary Endpoint,opinion,Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   announced positive results from a phase II study evaluating its NaV1 8 inhibitor VX 150 in patients suffering from pain caused by small fiber neuropathy  The study met its primary endpoint  and showed that treatment with VX 150 led to statistically significant and clinically meaningful pain reduction in the above mentioned patients  VX 150 was well tolerated in this study Other than pain caused by small fiber neuropathy  VX 150 was evaluated in phase II studies for the treatment of acute pain following bunionectomy surgery and pain from osteoarthritis of the knee The company now has positive phase II data for VX 150 in all of the three pain conditions  which demonstrate the potential role of NaV1 8 inhibitor in the future treatment of a variety of pain conditions Vertex also announced today that the FDA has granted Breakthrough Therapy designation to VX 150 for the treatment of moderate to severe acute pain The company also recently initiated a phase IIb dose ranging study  evaluating VX 150 in patients with acute pain following bunionectomy surgery  The study is designed to evaluate multiple oral doses of VX 150 to potentially support pivotal development  The company also expects to advance additional NaV1 8 inhibitors into clinical development beginning 2019 Shares of Vertex have increased 9 1   against the  s decline of 21 4  year to date While Vertex s main focus is on the development and strengthening of its cystic fibrosis  CF  franchise  the company is also working on other serious diseases like pain  and hemoglobinopathies like sickle cell disease and thalassemia  Apart from the key non CF pipeline candidate VX 150  Vertex is also co developing a gene editing treatment  CTX001 in partnership with CRISPR Therapeutics   NASDAQ CRSP   in two devastating diseases   sickle cell disease and thalassemia   Vertex Pharmaceuticals Incorporated Price    Zacks Rank and Stocks to ConsiderVertex currently carries a Zacks Rank  3  Hold  Some better ranked stocks worth considering are Alexion Pharmaceuticals Inc    NASDAQ ALXN   and Gilead Sciences Inc    NASDAQ GILD    Both the companies sport a Zacks Rank  1  Strong Buy   You can see  Alexion s earnings per share estimates have increased from  7 23 to  7 61 for 2018 and from 8 59 to  8 77 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters  with average of 16 77  Gilead s earnings per share estimates have increased from  6 65 to  6 93 for 2018 and  6 64 to  6 83 for 2019 over the past 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with average of 6 99  Wall Street s Next Amazon  NASDAQ AMZN  Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-12-18,Zacks Investment Research,https://www.investing.com/analysis/vertexs-vrtx-3rd-study-on-pain-drug-meets-primary-endpoint-200369575,200369575
120476,341991,VRTX,Biotech Stock Roundup  Pipeline Updates From VRTX   AMGN  ADRO Teams Up With LLY,opinion,"It was a busy week for the biotech sector with regular pipeline and regulatory updates  The key events include Aduro s collaboration with Eli Lily and FDA approval for Amgen s   NASDAQ AMGN   label expansion of ITP drug Recap of the Week s Top Stories Aduro Biotech Collaborates with Lilly  Aduro Biotech  Inc    NASDAQ ADRO   announced a research collaboration and exclusive license agreement with pharma giant Eli Lilly  NYSE LLY    The companies have entered into a license agreement for Aduro s cGAS STING Pathway Inhibitor program for the research and development of novel immunotherapies for autoimmune and other inflammatory diseases  Per the agreement  Lilly will gain access to novel molecules from Aduro that are designed to inhibit the cGAS STING pathway  Both the companies will advance these molecules  as well as others from Lilly  into clinical development  In exchange  Aduro will receive an upfront payment of  12 million and also be eligible for development and commercial milestones up to approximately  620 million per product and royalty payments in the single to low double digits should Lilly successfully commercialize a therapy from the collaboration  Moreover  Aduro will obtain research funding during the research term  The company has the option to co fund the clinical development of each product in exchange for an increase in royalty payments  Lilly will be responsible for all costs of global commercialization Aduro carries a Zacks Rank  2  Buy   You can see  Vertex Announces Positive Data on Pipeline Candidate  Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   announced that the mid stage study on investigational NaV1 8 inhibitor VX 150 in patients with pain caused by small fiber neuropathy was successful  Data showed that treatment with VX 150 demonstrated statistically significant and clinically meaningful pain reduction  as measured by the within group change from baseline in the weekly average of daily pain intensity on the 11 point numeric rating scale  NRS  at week 6  The study met its primary endpoint  The candidate provided significant relief from pain in patients with small fiber neuropathy and was generally well tolerated  Additionally  a phase IIb dose ranging study of VX 150 following bunionectomy surgery is currently ongoing to support potential pivotal development  Moreover  Vertex is advancing multiple pain molecules through late stage preclinical development  The first of these candidates is expected to enter the clinic in 2019 Previously  the company announced that Health Canada has granted Market Authorization for cystic fibrosis  CF  drug  Orkambi  to include use in children ages 2 through 5 years who have two copies of the F508del CFTR mutation Evofem Gains on Positive Data on Birth Control Gel  Shares of Evofem Biosciences  Inc    NASDAQ EVFM   surged after the company announced that its late stage trial AMPOWER on lead candidate Amphora for the prevention of pregnancy was successful  Amphora is a non hormonal  on demand  woman controlled prescription birth control vaginal gel  The phase III study assessed the efficacy  safety and subject satisfaction with Amphora in approximately 1 400 healthy women aged 18 35 years at 112 centers  The primary endpoint of the study was the pregnancy rate over seven cycles of use  one cycle equals to 21 35 days  as assessed by the Kaplan Meier statistical method  The data from the study showed a cumulative pregnancy rate of 14 0  over seven cycles of use  which corresponds to an efficacy rate of 86   Consequently  the study met its primary endpoint  The efficacy went up to 98 7  with the cumulative pregnancy rate of 1 3  over seven cycles of use when Amphora was used as directed  The company plans to submit the New Drug Application to the FDA for Amphora in the second quarter of 2019 and analyse the data further  Assuming approval  the company will commercialize this first in class MVP R for birth control in January 2020 Incyte Collaborates With Innovent Biologics   Incyte   NASDAQ INCY   announced that it has entered into a strategic collaboration agreement with China based Innovent Biologics  Inc   Both the companies have entered into an agreement  through their respective subsidiaries  for the development of three clinical stage product candidates   pemigatinib  FGFR1 2 3 inhibitor   itacitinib  JAK1 inhibitor  and parsaclisib  PI3K  inhibitor   Per the terms  Innovent will pay Incyte  40 million in cash up front  Additionally  Incyte is eligible to receive an additional  20 million in consideration in connection with the first investigational new drug  IND  application by Innovent in China  expected in 2019   In exchange  Innovent will receive the rights to develop and commercialize the three assets  pemigatinib  itacitinib and parsaclisib  in hematology and oncology in Mainland China  Hong Kong  Macau and Taiwan  Moreover  Incyte will be eligible to receive up to  129 million in potential development and regulatory milestones  and up to  202 5 million in milestone achievements  Further  Incyte is eligible to receive tiered royalties from the high teens to the low twenties on future sales of products resulting from the collaboration  Moreover  Incyte retains an option to assist in the promotion of the three product candidates in China Amgen Gets Thrombocytopenia Drug Approval   Amgen announced that the FDA has approved the supplemental Biologics License Application  sBLA  for immune thrombocytopenia  ITP  drug Nplate  The drug is approved for the treatment of pediatric patients who are one year of age and older with immune thrombocytopenia  ITP  for at least six months and have had an insufficient response to corticosteroids  immunoglobulins or splenectomy  The drug is already approved for the treatment of adults   The company also submitted a Biologics License Application  BLA  to the FDA for ABP 710  a biosimilar version of Remicade The company also announced a strategic collaboration with Molecular Partners AG  MOLN   Both the companies entered into a license agreement for the clinical development and commercialization of MP0310  FAP x 4 1BB   Per the terms  Amgen obtained exclusive global development and commercial rights for MP0310  MP0310 will be evaluated in combination with Amgen s oncology pipeline products  including its investigational BiTE molecules  Molecular Partners retains certain rights to develop and commercialize its proprietary DARPin pipeline products in combination with MP0310  The latter will also receive an upfront payment of  50 million and is eligible to receive up to  497 million in development  regulatory and commercial milestone payments  and double digit  tiered royalties up to the high teens PerformanceMedical   Biomedical and Genetics Industry 5YR   Return
 The NASDAQ Biotechnology index lost 5 69  in the last five trading sessions  Among the major biotech stocks  Alexion lost 7 7   Over the past six months  shares of Regeneron have rallied 16 92   while Celgene  NASDAQ CELG  has dropped 14 28    See the last biotech stock roundup here    What s Next in Biotech Stay tuned for more regulatory and pipeline updates Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-12-18,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-pipeline-updates-from-vrtx--amgn-adro-teams-up-with-lly-200369572,200369572
120477,341992,VRTX,The Zacks Analyst Blog Highlights  Amgen  Aduro  Vertex  Evofem And Incyte,opinion,For Immediate ReleaseChicago  IL  December 20  2018   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Amgen   NASDAQ AMGN    Aduro Biotech  Inc    NASDAQ ADRO    Vertex Pharmaceuticals Incorporated   NASDAQ VRTX    Evofem Biosciences  Inc    NASDAQ EVFM   and Incyte   NASDAQ INCY   Here are highlights from Wednesday s Analyst Blog  Biotech Stock Roundup  VRTX  AMGN   MoreIt was a busy week for the biotech sector with regular pipeline and regulatory updates  The key events include Aduro s collaboration with Eli Lily and FDA approval for Amgen s label expansion of ITP drug Recap of the Week s Top Stories Aduro Biotech Collaborates with Lilly  Aduro Biotech  Inc  announced a research collaboration and exclusive license agreement with pharma giant Eli Lilly  NYSE LLY   The companies have entered into a license agreement for Aduro s cGAS STING Pathway Inhibitor program for the research and development of novel immunotherapies for autoimmune and other inflammatory diseases  Per the agreement  Lilly will gain access to novel molecules from Aduro that are designed to inhibit the cGAS STING pathway  Both the companies will advance these molecules  as well as others from Lilly  into clinical development  In exchange  Aduro will receive an upfront payment of  12 million and also be eligible for development and commercial milestones up to approximately  620 million per product and royalty payments in the single to low double digits should Lilly successfully commercialize a therapy from the collaboration  Moreover  Aduro will obtain research funding during the research term  The company has the option to co fund the clinical development of each product in exchange for an increase in royalty payments  Lilly will be responsible for all costs of global commercialization Aduro carries a Zacks Rank  2  Buy   You can see  Vertex Announces Positive Data on Pipeline Candidate  Vertex Pharmaceuticals Incorporated announced that the mid stage study on investigational NaV1 8 inhibitor VX 150 in patients with pain caused by small fiber neuropathy was successful  Data showed that treatment with VX 150 demonstrated statistically significant and clinically meaningful pain reduction  as measured by the within group change from baseline in the weekly average of daily pain intensity on the 11 point numeric rating scale  NRS  at week 6  The study met its primary endpoint  The candidate provided significant relief from pain in patients with small fiber neuropathy and was generally well tolerated  Additionally  a phase IIb dose ranging study of VX 150 following bunionectomy surgery is currently ongoing to support potential pivotal development  Moreover  Vertex is advancing multiple pain molecules through late stage preclinical development  The first of these candidates is expected to enter the clinic in 2019 Previously  the company announced that Health Canada has granted Market Authorization for cystic fibrosis  CF  drug  Orkambi  to include use in children ages 2 through 5 years who have two copies of the F508del CFTR mutation Evofem Gains on Positive Data on Birth Control Gel  Shares of Evofem Biosciences  Inc  surged after the company announced that its late stage trial AMPOWER on lead candidate Amphora for the prevention of pregnancy was successful  Amphora is a non hormonal  on demand  woman controlled prescription birth control vaginal gel  The phase III study assessed the efficacy  safety and subject satisfaction with Amphora in approximately 1 400 healthy women aged 18 35 years at 112 centers  The primary endpoint of the study was the pregnancy rate over seven cycles of use  one cycle equals to 21 35 days  as assessed by the Kaplan Meier statistical method  The data from the study showed a cumulative pregnancy rate of 14 0  over seven cycles of use  which corresponds to an efficacy rate of 86   Consequently  the study met its primary endpoint  The efficacy went up to 98 7  with the cumulative pregnancy rate of 1 3  over seven cycles of use when Amphora was used as directed  The company plans to submit the New Drug Application to the FDA for Amphora in the second quarter of 2019 and analyse the data further  Assuming approval  the company will commercialize this first in class MVP R for birth control in January 2020 Incyte Collaborates with Innovent Biologics   Incyte announced that it has entered into a strategic collaboration agreement with China based Innovent Biologics  Inc   Both the companies have entered into an agreement  through their respective subsidiaries  for the development of three clinical stage product candidates   pemigatinib  FGFR1 2 3 inhibitor   itacitinib  JAK1 inhibitor  and parsaclisib  PI3K  inhibitor   Per the terms  Innovent will pay Incyte  40 million in cash up front  Additionally  Incyte is eligible to receive an additional  20 million in consideration in connection with the first investigational new drug  IND  application by Innovent in China  expected in 2019   In exchange  Innovent will receive the rights to develop and commercialize the three assets  pemigatinib  itacitinib and parsaclisib  in hematology and oncology in Mainland China  Hong Kong  Macau and Taiwan  Moreover  Incyte will be eligible to receive up to  129 million in potential development and regulatory milestones  and up to  202 5 million in milestone achievements  Further  Incyte is eligible to receive tiered royalties from the high teens to the low twenties on future sales of products resulting from the collaboration  Moreover  Incyte retains an option to assist in the promotion of the three product candidates in China Amgen Gets Thrombocytopenia Drug Approval   Amgen announced that the FDA has approved the supplemental Biologics License Application  sBLA  for immune thrombocytopenia  ITP  drug Nplate  The drug is approved for the treatment of pediatric patients who are one year of age and older with immune thrombocytopenia  ITP  for at least six months and have had an insufficient response to corticosteroids  immunoglobulins or splenectomy  The drug is already approved for the treatment of adults   The company also submitted a Biologics License Application  BLA  to the FDA for ABP 710  a biosimilar version of Remicade The company also announced a strategic collaboration with Molecular Partners AG  MOLN   Both the companies entered into a license agreement for the clinical development and commercialization of MP0310  FAP x 4 1BB   Per the terms  Amgen obtained exclusive global development and commercial rights for MP0310  MP0310 will be evaluated in combination with Amgen s oncology pipeline products  including its investigational BiTE molecules  Molecular Partners retains certain rights to develop and commercialize its proprietary DARPin pipeline products in combination with MP0310  The latter will also receive an upfront payment of  50 million and is eligible to receive up to  497 million in development  regulatory and commercial milestone payments  and double digit  tiered royalties up to the high teens Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2018-12-19,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-amgen-aduro-vertex-evofem-and-incyte-200370085,200370085
120478,341993,VRTX,Vertex Joins Forces With Arbor To Build Gene Editing Therapies,opinion,Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   announced that it has entered into a strategic research collaboration deal with privately held  Massachusetts based Arbor Biotechnologies to discover novel proteins that the former may use in developing gene editing therapies to treat five serious diseases including cystic fibrosis  CF  Following this deal  Vertex is looking to leverage Arbor s protein biodiscovery platform based on machine learning  genome sequencing  gene synthesis and high throughput screening Per the agreement  Arbor is eligible to receive an undisclosed upfront cash payment from Vertex along with research funding  potential milestones payments and royalties on net sales  While Arbor will look after the discovery activities  Vertex will provide funding for the same Additionally  Vertex will make an investment in Arbor s convertible notes and subsequently  take an observer seat on the latter s board Shares of Vertex have increased 5 1  in the past year against the  decline of 24 2  Notably  CF is Vertex s main area of focus  Its three approved CF products are Kalydeco  Orkambi and Symdeko  the company s consistent revenue drivers  Total CF product revenues were  2 2 billion in the first nine months of 2018  reflecting a 46 7  surge year over year Evidently  Vertex s CF pipeline is quite strong  The company is evaluating two next generation CFTR correctors  VX 659 and VX 445  in phase III studies as part of a triple combination with tezacaftor and ivacaftor Studies on Vertex s triple combination CF regimens are advancing fast  The CF triple pill regimes are crucial for long term growth as these have potential to treat up to 90  of CF patient population Zacks Rank   Stocks to ConsiderVertex currently carries a Zacks Rank  4  Sell  Better ranked stocks in the healthcare sector include Genomic Health  Inc    NASDAQ GHDX    Vanda Pharmaceuticals Inc    NASDAQ VNDA   and Inovio Pharmaceuticals  Inc    NASDAQ INO    all sporting a Zacks Rank  1  Strong Buy   You can see  Genomic Health s earnings estimates have been revised 61 8  upward for 2019 over the past 60 days  The stock has soared 75 5  in the past year Vanda s earnings estimates have moved 9 1  north for 2019 over the past 60 days  The stock has surged 70 5  in a year Inovio s loss per share estimates has been narrowed 2 8  for 2019 in the last 60 days The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-01-03,Zacks Investment Research,https://www.investing.com/analysis/vertex-joins-forces-with-arbor-to-build-geneediting-therapies-200372889,200372889
120479,341994,VRTX,Vertex  CRISPR s Sickle Disease Drug Gets FDA s Fast Track Tag,opinion,Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   and partner CRISPR Therapeutics AG   NASDAQ CRSP   announced that the FDA has assigned Fast Track designation to their gene editing candidate  CTX001  for the treatment of sickle cell disease  SCD   a severe hereditary form of anaemia The fast track status from the FDA is designed to provide certain benefits for new drugs that treat serious or life threatening conditions and demonstrate potential to address the unmet medical needs  With this designation  the drug is expected to be granted a priority review once it files a new drug application  NDA  Shares of Vertex and CRISPR Therapeutics were each up 5 5  and 8  on Friday in response to the news  In fact  in the past year  the CRISPR Therapeutics stock has rallied 16 1  while Vertex has increased 10 1  versus the decline of 18 9    We remind investors that last May  the FDA had placed a clinical hold on the companies  investigational new drug  IND  application for CTX001  Both companies had filed the IND application in April to start a phase I II study on CTX001 for SCD in the United States  The clinical hold was lifted in October  Vertex and CRISPR Therapeutics are presently enrolling in the phase I II SCD study on CTX001 in the United States  Also  a phase I II study of CTX001 for adult transfusion dependent b thalassemia is currently enrolling patients in Europe In December  as part of a strategic research collaboration formed in 2015  Vertex and CRISPR Therapeutics selected CTX001 to move into clinical development as a gene edited treatment for sickle cell disease and   thalassemia  which is developed using CRISPR Therapeutics  proprietary CRISPR Cas9 technology  Back then  the companies had opted toco develop and co commercialize CTX001 and equally share all R D costs and profits worldwide  Vertex has rights to license up to six new gene editing treatments  including CTX001   developed using the CRISPR Cas9 technology that emerged from the joint research deal Genomic editing technology using CRISPR technology to repair defective genetic material that causes diseases is probably one of the most promising and exciting healthcare innovations seen in decades  Though there are several methods to use CRISPR for targeting genetic defects that cause specific diseases  the most promising is the use of an enzyme called Cas9 to deliver CRISPR for the affected cells Other than CRISPR Therapeutics  Intellia Therapeutics   NASDAQ NTLA   and Editas Medicine  Inc   NASDAQ EDIT   plan to carry out clinical studies using CRISPR Cas9 to cure diseases While CRISPR Therapeutics currently carries a Zacks Rank  2  Buy   Vertex has a Zacks Rank  4  Sell  You can see  3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2019-01-06,Zacks Investment Research,https://www.investing.com/analysis/vertex-crisprs-sickle-disease-drug-gets-fdas-fast-track-tag-200373369,200373369
120480,341995,VRTX,Moderna  MRNA  Announces Pipeline Progress  Shares Rise,opinion,"Moderna  Inc    NASDAQ MRNA   announced positive updates on its pipeline of immuno oncology and rare disease candidates at the Annual J P  Morgan Healthcare Conference in San Francisco  The company s pipeline consists of only messenger RNA  mRNA  therapeutics candidates in early stages of development Following the update  shares of Moderna were up 4 2  on Jan 8  However  its shares have declined 8 9  since its initial public offering   IPO   compared with the  s decline of 1 4  in that period The company has 21 mRNA investigational candidates with 11 candidates in clinical development stage The company completed raised around  600 million in its IPO and started trading publicly since Dec 7  2018 Immuno oncology Pipeline UpdateThe company s key immuno oncology candidates include OX40L  mRNA 2416  and a triplet   OX40L   IL23   IL36   mRNA 2752    which are directly injected into tumors to drive anti cancer T cell responses Based on data from a phase I study  which evaluated mRNA 2416 in advanced ovarian carcinoma  the company has submitted an investigational new drug   IND   application with the FDA to initiate a phase II study  The phase I study is also evaluating the candidate in patients with advanced relapsed refractory solid tumor malignancies and lymphomas The triple combination candidate  mRNA 2752  is being evaluated  as a single agent or in combination with AstraZeneca s   NYSE AZN   Imfinzi  durvalumab  or tremelimumab  in a phase I study in patients with advanced or metastatic solid tumor malignancies or lymphoma Cancer VaccinesModerna has two vaccine candidates in clinical development   personalized cancer vaccine  mRNA 4157  and KRAS vaccine  mRNA 5671   A dose escalation phase I study is currently evaluating mRNA 4157 for antigen specific T cell responses  while Moderna and its partner Merck   NYSE MRK   are planning to initiate a phase II study to investigate a combination of mRNA 4157 and Keytruda Moderna had submitted an IND for the KRAS vaccine candidate but has transferred the rights to Merck  Merck will lead the dose escalation and dose expansion Phase I study  which will evaluate the safety and tolerability of mRNA 5671 both as a monotherapy and in combination with Keytruda in epithelial cancers Rare Disease Pipeline UpdateTwo candidates   mRNA 3704 and mRNA 3927   are in pre clinical stage of development  However  Moderna has submitted IND for mRNA 3704 to initiate a phase I study on patients with methylmalonic academia  an inherited disorder in which the body is unable to process certain proteins and fats  lipids  properly  mRNA 3927 is being studied for propionic acidemia  another rare metabolic disorder  Both the candidates enjoy Orphan Drug status and have been granted Rare Pediatric Disease designation With several candidates in its pipeline  the company s operating expense is high  Although the company has a strong balance sheet  no marketed drug and early stage of pipeline development is likely to put pressure on it  However  collaboration with other pharma companies including AstraZeneca  Merck  Vertex Pharmaceuticals   NASDAQ VRTX   and Alexion Pharma will generate revenues MODERNA INC Price
    Zacks RankModerna currently carries a Zacks Rank  3  Hold   You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2019-01-08,Zacks Investment Research,https://www.investing.com/analysis/moderna-mrna-announces-pipeline-progress-shares-rise-200374018,200374018
120481,341996,VRTX,Why Vertex  VRTX  Is Poised To Beat Earnings Estimates Again,opinion,"If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report  you should consider Vertex Pharmaceuticals  NASDAQ VRTX   This company  which is in the Zacks Medical   Biomedical and Genetics industry  shows potential for another earnings beat 
This drugmaker has seen a nice streak of beating earnings estimates  especially when looking at the previous two reports  The average surprise for the last two quarters was 19 78  
For the last reported quarter  Vertex came out with earnings of  1 09 per share versus the Zacks Consensus Estimate of  1 per share  representing a surprise of 9   For the previous quarter  the company was expected to post earnings of  0 72 per share and it actually produced earnings of  0 94 per share  delivering a surprise of 30 56  
Price and EPS Surprise

For Vertex  estimates have been trending higher  thanks in part to this earnings surprise history  And when you look at the stock s positive Zacks Earnings ESP  Expected Surprise Prediction   it s a great indicator of a future earnings beat  especially when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Vertex currently has an Earnings ESP of  1 19   which suggests that analysts have recently become bullish on the company s earnings prospects  This positive Earnings ESP when combined with the stock s Zacks Rank  4  Sell  indicates that another beat is possibly around the corner  We expect the company s next earnings report to be released on January 30  2019 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  though this is not the only reason why their shares gain  Additionally  some stocks may remain stable even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-01-20,Zacks Investment Research,https://www.investing.com/analysis/why-vertex-vrtx-is-poised-to-beat-earnings-estimates-again-200377695,200377695
120485,342000,VRTX,Vertex s Orkambi Wins EU Nod To Treat Cystic Fibrosis In Kids,opinion,Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   announced that the European Commission  EC  has granted an approval to a regulatory application seeking Orkambi s label expansion for its use in children aged two to five years with cystic fibrosis  CF   who have two copies of the F508del mutation The EU approval was based on data from a phase III open label safety study evaluating 60 patients  who showed good tolerance for a 24 week regimen under the influence of Orkambi and the safety profile was similar to that of patients aged six years or older Following this nod  Orkambi becomes the first and only approved medicine in Europe to treat CF in kids aged from two to five years  Approximately 1 500 children in Europe within the mentioned age group suffer this most common form of CF disease  thus making Orkambi eligible to treat an expanded patient population Orkambi is already approved in the United States and Europe for treating CF in patients aged six or above who have two copies of the F508del mutation  The drug was given a nod in the United States for the two to five year age group last August Shares of Vertex were up 2 19  on Monday following this news  In fact  the stock has rallied 20 2  in the past year against the  decline of 21 4  However  Orkambi sales have been waning of late due to patients  switch to Vertex s third and the newest CF medicine   Symdeko   from Orkambi  which targets the same patient population  In the first nine months of 2018  Orkambi generated sales of  947 million  down 0 8  year over year Notably  CF is Vertex s main area of focus  Apart from Orkambi  its other two approved CF products are Kalydeco and Symdeko  which are constant revenue drivers  Total CF product revenues were  2 2 billion in the first nine months of 2018  reflecting a 46 7  surge year over year Evidently  Vertex s CF pipeline is also quite strong  The company is evaluating two next generation CFTR correctors  VX 659 and VX 445  in phase III studies as part of a triple combination with tezacaftor and ivacaftor Studies on Vertex s triple combination CF regimens are advancing fast  The CF triple pill regimes are crucial for long term growth as these have potential to treat up to 90  of CF patient population Zacks Rank   Stocks to ConsiderVertex currently carries a Zacks Rank  4  Sell  Better ranked stocks in the healthcare sector include Genmab A S   Acorda Therapeutics  Inc    NASDAQ ACOR   and Aduro Biotech  Inc    NASDAQ ADRO    all sporting a Zacks Rank  1  Strong Buy   You can see  Genmab s earnings estimates have moved 4  north for 2019 over the past 60 days Acorda s loss per share estimates have been narrowed 1 3  for 2019 in the last 60 days Aduro s loss per share estimates have been narrowed 4 5  for 2019 over the past 60 days Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-01-21,Zacks Investment Research,https://www.investing.com/analysis/vertexs-orkambi-wins-eu-nod-to-treat-cystic-fibrosis-in-kids-200377941,200377941
120517,342032,VRTX,Spectrum  SPPI  Earnings And Sales Beat Estimates In Q3,opinion,"Spectrum Pharmaceuticals  Inc    NASDAQ SPPI   incurred an adjusted loss of 17 cents per share in the third quarter of 2018  narrower than the Zacks Consensus Estimate of a loss of 21 cents but wider than the year ago quarter loss of 11 cents per share Quarterly revenues came in at  25 3 million  down 21 4  from the year ago quarter  The top line  however  beat the Zacks Consensus Estimate of  24 6 million Spectrum Pharma s shares have declined 32 3  so far this year compared with the  s decrease of 2 7  Quarter in DetailTotal product sales came in at  24 6 million  down 23 8  year over year  Sales were generated by six marketed products   Fusilev   0 6 million   Folotyn   11 3 million   Zevalin   1 5 million   Marqibo   1 1 million   Beleodaq   3 2 million  and Evomela   6 9 million   Evomela is facing pricing pressure due to generic entry License fees and service revenues were  0 7 million compared with  5 2 million in the prior year quarter Adjusted research   development expenses were  20 2 million  up 53  from the year ago quarter  Adjusted selling  general and administrative spending was up 3 4  to  16 6 million 2018 GuidanceThe company tightened its revenue guidance range for 2018 to  100  110 million from the previous guidance of  95  115 million  The company expects to have enough liquid funds to continue its operations into 2020 Pipeline UpdateSpectrum Pharma is evaluating one of its key pipeline candidates  poziotinib  in several mid stage studies for the treatment of lung cancer and breast cancer  In September  the company presented updated interim data from a phase II study evaluating poziotinib in heavily pre treated non small cell lung cancer   NSCLC   patients with an exon 20 mutation in EGFR or HER2 The candidate achieved confirmed overall response rate   ORR   of 43   disease control rate   DCR   of 90  and median progression free survival   PFS   of 5 5 months in patients with EGFR mutation  The confirmed ORR was 42   DCR was 83  and median PFS was 5 1 months in patients with HER2 mutation The company successfully completed two phase III studies on its another pipeline candidate  Rolontis  which showed that the candidate was non inferior to Amgen Inc  s   NASDAQ AMGN   Neulasta in improving duration of severe neutropenia in patients with breast cancer Spectrum Pharma is planning to submit a Biologics License Application   BLA   by the year end  following a positive pre BLA meeting with the FDA In October  the FDA approved Khapzory  levoleucovorin  for three indications  The drug is approved as a rescue after high dose methotrexate therapy in patients with osteosarcoma to reduce toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination and for treating metastatic colorectal cancer in combination with fluorouracil Spectrum Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Stocks to ConsiderSpectrum Pharma currently carries a Zacks Rank  3  Hold  Some better ranked stocks in the biotech sector are Vertex Pharmaceuticals   NASDAQ VRTX   and CRISPR Therapeutics   NASDAQ CRSP    Both the stocks carry a Zacks Rank  2  Buy   You can see  Vertex s earnings per share estimates have moved up from  3 75 to  3 83 for 2018 in the past 30 days  The company delivered a positive surprise in all the trailing four quarters with an average beat of 18 94   Share price of the company has increased 20 3  in a year CRISPR Therapeutics  loss per share estimates narrowed from  2 95 to  2 92 for 2018 in the last 60 days  The company delivered a positive earnings surprise in two of the trailing four quarters  with an average beat of 9 18   The company s shares have rallied 60 6  year to date The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-08,Zacks Investment Research,https://www.investing.com/analysis/spectrum-sppi-earnings-and-sales-beat-estimates-in-q3-200357487,200357487
120518,342033,VRTX,Celldex  CLDX  Q3 Earnings Beat Estimates  Revenues Miss,opinion,"Celldex Therapeutics  Inc    NASDAQ CLDX   incurred adjusted third quarter 2018 loss  excluding gain on fair value re measurement of contingent consideration  of 8 cents per share  narrower than the Zacks Consensus Estimate of a loss of 11 cents and the year ago loss of 14 cents  However  including the fair value re measurement item  the reported loss was 4 cents Total revenues in the quarter declined 76 9  year over year to  0 9 million  It also missed the Zacks Consensus Estimate of  2 million  The year over year decline was due to decrease in contract revenues from the International AIDS Vaccine Initiative Shares of the company rallied 12 8  on Nov 8  presumably on promising pipeline progress  However  the stock s performance has been disappointing so far this year  It has declined 86 6  compared with the  s 14  decrease Quarterly DetailsResearch and development expenses were down 45 7  year over year to  11 9 million during the quarter mainly due to lower personnel costs and decline in clinical study and contract manufacturing related expenses  General and administrative expenses were  3 7 million  down 30 2  year over year mainly attributable to lower personnel and marketing expense As of Sep 30  2018  Celldex had cash  cash equivalents and marketable securities of  105 6 million compared with  114 million as of Jun 30  2018  The biotech company s weakened cash position was due to higher operating expense including costs related to discontinuation of glembatumumab vedotin development  partially offset by net proceeds raised from sales of its common stock under a contract with Cantor 2018 OutlookCelldex expects that its cash position as of the end of September plus anticipated net proceeds from future sales of its common stock under the agreement with Cantor will be adequate to fund working capital requirements as well as planned operations through 2020 Pipeline FocusFollowing the discontinuation of development of its earlier lead candidate glembatumumab vedotin in April  Celldex is focused on development of CDX 1140 and CDX 3379  Although the candidates are in early to mid stage studies  the company is progressing well with the studies In the earnings release  the company announced that currently enrollment remains on track in a phase I study evaluating CDX 1140 in solid tumors and a phase II study evaluating CDX 3379 in combination with Eli Lilly s   NYSE LLY   Erbitux for the treatment of advanced head and neck squamous cell cancer  Interim data from CDX 1140 study  which showed desired safety profile  has been accepted for presentation at the Society for Immunotherapy of Cancer Annual Meeting later this month Moreover  in August  two separate cohorts were initiated in the CD 1140 study to evaluate CDX 1140 monotherapy with a dose of 0 36 mg kg and a combination of CDX 1140 and CDX 301 Other pipeline candidate like varlilumab and CDX 301 will be evaluated externally through investigator sponsored studies and internally in combination studies  There are also several preclinical candidates in its pipeline  including CDX 0159 The company is evaluating varlilumab in a phase I II study in combination with Bristol Myers    NYSE BMY   Opdivo in five indications namely colorectal cancer  ovarian cancer  head and neck squamous cell carcinoma  renal cell carcinoma and glioblastoma  Data from the glioblastoma arm has been accepted for presentation this month at the Society for Neuro oncology Annual Meeting The acceptance of data for presentation at the scientific body suggests encouraging study activity and has raised investors  enthusiasm about the progress of the company s pipeline Celldex Therapeutics  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Stock to ConsiderCelldex currently carries a Zacks Rank  3  Hold  Vertex Pharmaceuticals   NASDAQ VRTX   is a better ranked stock in the pharma sector  carrying a Zacks Rank  2  Buy   You can see  Vertex s earnings per share estimates have moved up from  3 75 to  3 83 for 2018 in the past 30 days  The company delivered a positive surprise in all the trailing four quarters with the average beat being 18 94   Share price of the company has increased 20 3  in a year s time The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-08,Zacks Investment Research,https://www.investing.com/analysis/celldex-cldx-q3-earnings-beat-estimates-revenues-miss-200357567,200357567
120519,342034,VRTX,Vertex  VRTX  Gets Positive CHMP Opinion For Orkambi In Kids,opinion,"Vertex Pharmaceuticals Inc    NASDAQ VRTX   announced that the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  adopted a positive opinion recommending approval for expanded use of Orkambi  The opinion is given for Orkambi  lumacaftor ivacaftor  to treat children with cystic fibrosis  CF  aged two to five years who have two copies of the F508del mutation 
Approximately 1 500 people in Europe in this age group suffer from this most common form of CF disease  thus making Orkambi eligible to treat expanded patient populations 
Orkambi is already approved in the U S  and Europe for the treatment of CF in patients aged six or older who have two copies of the F508del mutation  It was approved in the United States for the two to five years age group in August 
The CHMP opinion was based on data from a phase III open label safety study in 60 patients that showed treatment with Orkambi to be generally well tolerated for 24 weeks  with a safety profile similar to that in patients aged 6 years or older 
The stock has gained 10 2  so far this year  against the 18  decline registered by the  

 
Sales of Orkambi were down 16 1  year over year in the third quarter of 2018 to  282 million due to a switch in patient base to Vertex s third and newest CF medicine  Symdeko from Orkambi  which targets the same population  Orkambi revenues are expected to be hurt by this switch during the third quarter of 2018 
Other than Orkambi and Symdeko  Vertex also has Kalydeco  ivacaftor  in its CF product portfolio  We remind investors that  Symdeko is a combination of tezacaftor and ivacaftor  which was launched in the United States in February 2018 for treating CF patients  The drug has shown strong uptake so far 
 The company is developing many new combination regimens with CFTR modulators  The CF correctors could bring in multi billion dollar sales for Vertex Vertex is evaluating two next generation CFTR correctors  VX 659 and VX 445  in phase III studies as part of a triple combination with tezacaftor and ivacaftor  Vertex is evaluating both the combinations in two separate studies for F508del Min and F508del homozygous patients 
Both AbbVie   NYSE ABBV   and Galapagos NV s   NASDAQ GLPG   were jointly developing CF product candidates  which included a triple regimen combination  However  last month  AbbVie announced that it is taking full commercial and development responsibility of all clinical pre clinical programs in cystic fibrosis products  which were originally discovered and developed in partnership with Galapagos 
AbbVie will now continue the development of the triple combination therapy for CF  Corbus Pharmaceuticals Holdings  Inc    NASDAQ CRBP   is developing a CF candidate  lenabasum  in a mid stage study Vertex Pharmaceuticals Inc  Price

   Zacks Rank
Vertex is a Zacks Rank  3  Hold  stock  You can see  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-19,Zacks Investment Research,https://www.investing.com/analysis/vertex-vrtx-gets-positive-chmp-opinion-for-orkambi-in-kids-200360738,200360738
120520,342035,VRTX,Should You Invest In The Invesco Dynamic Biotechnology   Genome ETF  PBE  ,opinion,"If you re interested in broad exposure to the Healthcare   Biotech segment of the equity market  look no further than the Invesco Dynamic Biotechnology   Genome ETF  PBE   a passively managed exchange traded fund launched on 06 23 2005 
An increasingly popular option among retail and institutional investors  passively managed ETFs offer low costs  transparency  flexibility  and tax efficiency  they are also excellent vehicles for long term investors 
Investor friendly  sector ETFs provide many options to gain low risk and diversified exposure to a broad group of companies in particular sectors  Healthcare   Biotech is one of the 16 broad Zacks sectors within the Zacks Industry classification  It is currently ranked 2  placing it in top 13  
Index Details
The fund is sponsored by Invesco  It has amassed assets over  275 95 M  making it one of the average sized ETFs attempting to match the performance of the Healthcare   Biotech segment of the equity market  PBE seeks to match the performance of the Dynamic Biotechnology   Genome Intellidex Index before fees and expenses 
This is comprised of stocks of 30 U S  biotechnology and genome companies  These are companies that are principally engaged in the research  development  manufacture and marketing and distribution of various biotechnological products  services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research 
Costs
Since cheaper funds tend to produce better results than more expensive funds  assuming all other factors remain equal  it is important for investors to pay attention to an ETF s expense ratio 
Annual operating expenses for this ETF are 0 59   making it one of the more expensive products in the space 
Sector Exposure and Top Holdings
Even though ETFs offer diversified exposure that minimizes single stock risk  investors should also look at the actual holdings inside the fund  Luckily  most ETFs are very transparent products that disclose their holdings on a daily basis 
This ETF has heaviest allocation in the Healthcare sector  about 100  of the portfolio 
Looking at individual holdings  Amgen Inc  NASDAQ AMGN  accounts for about 5 71  of total assets  followed by Vertex Pharmaceuticals Inc  NASDAQ VRTX  and Biogen Inc  NASDAQ BIIB  
The top 10 holdings account for about 49 06  of total assets under management 
Performance and Risk
The ETF has gained about 5 43  so far this year and it s up approximately 11 01  in the last one year  as of 11 21 2018   In that past 52 week period  it has traded between  44 73 and  60 27 
The ETF has a beta of 1 46 and standard deviation of 26 23  for the trailing three year period  making it a high risk choice in the space  With about 30 holdings  it has more concentrated exposure than peers 
Alternatives
Invesco Dynamic Biotechnology   Genome ETF holds a Zacks ETF Rank of 2  Buy   which is based on expected asset class return  expense ratio  and momentum  among other factors  Because of this  PBE is an excellent option for investors seeking exposure to the Health Care ETFs segment of the market  There are other additional ETFs in the space that investors could consider as well 
SPDR S P Biotech ETF  NYSE XBI  tracks S P Biotechnology Select Industry Index and the iShares Nasdaq Biotechnology ETF  IBB  tracks Nasdaq Biotechnology Index  SPDR S P Biotech ETF has  4 25 B in assets  iShares Nasdaq Biotechnology ETF has  7 96 B  XBI has an expense ratio of 0 35  and IBB charges 0 47  
Bottom Line
To learn more about this product and other ETFs  screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe  please visit Zacks ETF Center ",2018-11-20,Zacks Investment Research,https://www.investing.com/analysis/should-you-invest-in-the-invesco-dynamic-biotechnology--genome-etf-pbe-200361440,200361440
120521,342036,VRTX,4 Biotech Stocks Investors Can Add To Their Portfolio In 2019,opinion,It has been a disappointing year for the biotech industry  The NASDAQ Biotechnology Index    has lost 5  so far in 2018  While the year started on a choppy note  things were steady in the middle of the year  However  the industry lost momentum in the last two months The performance of biotech bigwigs has been affected by slowdown in growth of key drugs  Competitive pressure also affected sales  Nevertheless  new drug approvals boosted investor sentiment  Key approvals so far this year include that of Gilead Sciences    NASDAQ GILD   HIV regimen  Biktarvy  Vertex  NASDAQ VRTX  Pharmaceuticals  Symdeko  tezacaftor ivacaftor and ivacaftor  for the treatment of cystic fibrosis  CF   Amgen s Aimoviq for the treatment of migraine  Regeneron Pharmaceuticals  Libtayo and BioMarin s Palynziq for the treatment of phenylketonuria  among others  The approval of these drugs should boost their respective companies  top line as a few of them are struggling with decline in sales of legacy drugs Meanwhile  mergers and acquisitions  M A  picked up pace in the sector as a slowdown in mature products forced companies to eye lucrative acquisitions to bolster their pipeline  Additionally  the increase in M A activity was propelled by the implementation of the new tax law  which has slashed corporate tax rate from 35  to 21  In addition  in licensing deals are on the rise with the bigwigs collaborating with smaller and mid sized players that boast promising mid to late stage pipeline candidates or interesting technology   Celgene  NASDAQ CELG  acquired Juno Therapeutics to gain traction in the promising CAR T space  In February 2018  the company acquired Impact Biomedicines and added a late stage candidate  fedratinib  a highly selective JAK2 kinase inhibitor  to its pipeline  Alexion acquired Sweden based Wilson Therapeutics and added a late stage candidate  WTX101  to its pipeline  which is currently in phase III for the treatment of Wilson disease  a rare genetic disorder What Lies Ahead The  carries a Zacks Industry Rank of  66  which places it in the top 26  of the 256 plus Zacks industries  Although issues like drug pricing and threat of biosimilars loom large on the healthcare sector  we expect the sector to recover  New drug approvals  label expansion of existing high profile drugs  pipeline progress  growing demand for drugs  especially for rare to treat diseases  an aging population and increased health care spending are some of the factors that should positively impact performance Our ChoicesHere we list some biotech stocks backed by a Zacks Rank  1  Strong Buy  or  2  Buy   which have fared better than the industry in 2018 so far and are poised for a good run in 2019 Headquartered in Foster City  CA  Gilead Sciences is a leading company in the biotech industry with a wide and diverse portfolio of drugs for the treatment of human immunodeficiency virus  HIV   liver diseases such as chronic hepatitis C virus  HCV  infection and chronic hepatitis B virus  HBV  infection  cardiovascular  hematology oncology and inflammation respiratory diseases  While the once leading portfolio of blockbuster HCV drugs is facing competitive pressure  Gilead s HIV franchise maintains momentum  driven by the continued uptake of Genvoya and Odefsey  and the rapid adoption of Biktarvy  The FDA approval of Biktarvy has further widened the company s portfolio  Biktarvy has also been approved in Europe  The launch of Yescarta is progressing well in the United States and the approval in Europe should boost sales  Meanwhile  Gilead intends to foray into the nonalcoholic steatohepatitis  NASH  and inflammation markets with late stage candidates  selonsertib and filgotinib  respectively  A tentative approval will diversify Gilead s portfolio  The company has also made strategic collaborations to boost its pipeline Gilead Sciences currently carries a Zacks Rank  1   You can see  Its shares have declined 2 7  in the year so far  outperforming the industry s 18 4  decline   Estimates for 2019 have increased 20 cents in the past 60 days  Based in New Haven  CT  Alexion Pharmaceuticals   NASDAQ ALXN   focuses on the development and commercialization of life transforming drugs  for the treatment of patients with ultra rare disorders  Alexion s key growth driver  Soliris  is approved for the treatment of two severe and ultra rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system   paroxysmal nocturnal hemoglobinuria  PNH  and atypical hemolytic uremic syndrome  aHUS   Soliris continues to perform well  FDA approval for the generalized myasthenia gravis indication has boosted sales significantly  leading to an increase in annual guidance  Strensiq and Kanuma are doing well and are expected to boost revenues  Meanwhile  Alexion has been quite active on the acquisition front as the company is looking to diversify its portfolio and reduce dependence on Soliris  Alexion recently acquired Wilson Therapeutics Syntimmune Alexion currently carries a Zacks Rank  1  Its shares have lost 3 4  so far in 2018  Estimates for 2019 have increased 3 cents in the past 60 days  Tarrytown  NY based Regeneron Pharmaceuticals  Inc    NASDAQ REGN   is a biopharmaceutical company focused on the discovery  development and commercialization of treatments targeting serious medical conditions  The company s portfolio boasts of marketed drugs like Eylea  for several eye diseases   Dupixent  moderate to severe atopic dermatitis   Praluent  heterozygous familial hypercholesterolemia  among others  The company s key growth driver  Eylea continues to drive sales and label expansion into additional indications has further boosted growth  The uptake of Dupixent has been strong too and the company is working to expand Dupixent s label further in several other indications  This should diversify the company s revenue base and reduce dependence on Eylea  In September 2018  the FDA approved its immuno oncology therapy  Libtayo for the treatment of patients with metastatic or locally advanced CSCC who are not candidates for curative surgery or curative radiation  Approval of new drugs should further boost the top line Regeneron currently carries a Zacks Rank  2  Its shares have lost 0 8  in the year so far  Estimates for 2019 have increased 43 cents in the past 60 days  Based in Cambridge  MA  Biogen Inc    NASDAQ BIIB   is one of the world s leading biotechnology companies focusing on developing innovative therapies for treating serious neurological and neurodegenerative diseases  including its core growth areas of multiple sclerosis  MS  and neuroimmunology  Alzheimer s disease  AD  and dementia  movement disorders and neuromuscular disorders  including spinal muscular atrophy  SMA  and amyotrophic lateral sclerosis  ALS  Biogen has a strong position in the MS market with a wide range of products including Avonex  Tysabri  Tecfidera and Plegridy   The company is also looking to diversify beyond MS to other areas like Alzheimer s  Parkinson s and stroke among others  Spinraza  nusinersen  also consolidated its position in the neurological disease market with the drug being the first and only treatment to be approved in the United States for SMA  The company also has a robust pipeline and approval of new drugs will boost growth Biogen currently carries a Zacks Rank  2  Shares have lost 0 6  so far in 2018  Estimates for 2019 are up  50 cents in the past 60 days   Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-12-10,Zacks Investment Research,https://www.investing.com/analysis/4-biotech-stocks-investors-can-add-to-their-portfolio-in-2019-200366963,200366963
120522,342037,VRTX,The Zacks Analyst Blog Highlights  Gilead Sciences  Alexion Pharmaceuticals  Regeneron Pharmaceutical And Biogen,opinion,For Immediate ReleaseChicago  IL   December 12  2018   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Gilead Sciences   NASDAQ GILD    Alexion Pharmaceuticals   NASDAQ ALXN    Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and Biogen Inc    NASDAQ BIIB   Here are highlights from Tuesday s Analyst Blog  4 Biotech Stocks Investors Can Add to Their Portfolios for 2019It has been a disappointing year for the biotech industry  The NASDAQ Biotechnology Index  has lost 5  so far in 2018  While the year started on a choppy note  things were steady in the middle of the year  However  the industry lost momentum in the last two months The performance of biotech bigwigs has been affected by slowdown in growth of key drugs  Competitive pressure also affected sales  Nevertheless  new drug approvals boosted investor sentiment  Key approvals so far this year include that of Gilead Sciences  HIV regimen  Biktarvy  Vertex  NASDAQ VRTX  Pharmaceuticals  Symdeko  tezacaftor ivacaftor and ivacaftor  for the treatment of cystic fibrosis  CF   Amgen s Aimoviq for the treatment of migraine  Regeneron Pharmaceuticals  Libtayo and BioMarin s Palynziq for the treatment of phenylketonuria  among others  The approval of these drugs should boost their respective companies  top line as a few of them are struggling with decline in sales of legacy drugs Meanwhile  mergers and acquisitions  M A  picked up pace in the sector as a slowdown in mature products forced companies to eye lucrative acquisitions to bolster their pipeline  Additionally  the increase in M A activity was propelled by the implementation of the new tax law  which has slashed corporate tax rate from 35  to 21  In addition  in licensing deals are on the rise with the bigwigs collaborating with smaller and mid sized players that boast promising mid to late stage pipeline candidates or interesting technology   Celgene  NASDAQ CELG  acquired Juno Therapeutics to gain traction in the promising CAR T space  In February 2018  the company acquired Impact Biomedicines and added a late stage candidate  fedratinib  a highly selective JAK2 kinase inhibitor  to its pipeline  Alexion acquired Sweden based Wilson Therapeutics and added a late stage candidate  WTX101  to its pipeline  which is currently in phase III for the treatment of Wilson disease  a rare genetic disorder What Lies Ahead The  carries a Zacks Industry Rank of  66  which places it in the top 26  of the 256 plus Zacks industries  Although issues like drug pricing and threat of biosimilars loom large on the healthcare sector  we expect the sector to recover  New drug approvals  label expansion of existing high profile drugs  pipeline progress  growing demand for drugs  especially for rare to treat diseases  an aging population and increased health care spending are some of the factors that should positively impact performance Our ChoicesHere we list some biotech stocks backed by a Zacks Rank  1  Strong Buy  or  2  Buy   which have fared better than the industry in 2018 so far and are poised for a good run in 2019 Headquartered in Foster City  CA  Gilead Sciences is a leading company in the biotech industry with a wide and diverse portfolio of drugs for the treatment of human immunodeficiency virus  HIV   liver diseases such as chronic hepatitis C virus  HCV  infection and chronic hepatitis B virus  HBV  infection  cardiovascular  hematology oncology and inflammation respiratory diseases  While the once leading portfolio of blockbuster HCV drugs is facing competitive pressure  Gilead s HIV franchise maintains momentum  driven by the continued uptake of Genvoya and Odefsey  and the rapid adoption of Biktarvy  The FDA approval of Biktarvy has further widened the company s portfolio  Biktarvy has also been approved in Europe  The launch of Yescarta is progressing well in the United States and the approval in Europe should boost sales  Meanwhile  Gilead intends to foray into the nonalcoholic steatohepatitis  NASH  and inflammation markets with late stage candidates  selonsertib and filgotinib  respectively  A tentative approval will diversify Gilead s portfolio  The company has also made strategic collaborations to boost its pipeline Gilead Sciences currently carries a Zacks Rank  1   You can see  Its shares have declined 2 7  in the year so far  outperforming the industry s 18 4  decline   Estimates for 2019 have increased 20 cents in the past 60 days Based in New Haven  CT  Alexion Pharmaceuticals focuses on the development and commercialization of life transforming drugs  for the treatment of patients with ultra rare disorders  Alexion s key growth driver  Soliris  is approved for the treatment of two severe and ultra rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system   paroxysmal nocturnal hemoglobinuria  PNH  and atypical hemolytic uremic syndrome  aHUS   Soliris continues to perform well  FDA approval for the generalized myasthenia gravis indication has boosted sales significantly  leading to an increase in annual guidance  Strensiq and Kanuma are doing well and are expected to boost revenues  Meanwhile  Alexion has been quite active on the acquisition front as the company is looking to diversify its portfolio and reduce dependence on Soliris  Alexion recently acquired Wilson Therapeutics Syntimmune Alexion currently carries a Zacks Rank  1  Its shares have lost 3 4  so far in 2018  Estimates for 2019 have increased 3 cents in the past 60 days Tarrytown  NY based Regeneron Pharmaceuticals  Inc  is a biopharmaceutical company focused on the discovery  development and commercialization of treatments targeting serious medical conditions  The company s portfolio boasts of marketed drugs like Eylea  for several eye diseases   Dupixent  moderate to severe atopic dermatitis   Praluent  heterozygous familial hypercholesterolemia  among others  The company s key growth driver  Eylea continues to drive sales and label expansion into additional indications has further boosted growth  The uptake of Dupixent has been strong too and the company is working to expand Dupixent s label further in several other indications  This should diversify the company s revenue base and reduce dependence on Eylea  In September 2018  the FDA approved its immuno oncology therapy  Libtayo for the treatment of patients with metastatic or locally advanced CSCC who are not candidates for curative surgery or curative radiation  Approval of new drugs should further boost the top line Regeneron currently carries a Zacks Rank  2  Its shares have lost 0 8  in the year so far  Estimates for 2019 have increased 43 cents in the past 60 days Based in Cambridge  MA  Biogen Inc  is one of the world s leading biotechnology companies focusing on developing innovative therapies for treating serious neurological and neurodegenerative diseases  including its core growth areas of multiple sclerosis  MS  and neuroimmunology  Alzheimer s disease  AD  and dementia  movement disorders and neuromuscular disorders  including spinal muscular atrophy  SMA  and amyotrophic lateral sclerosis  ALS  Biogen has a strong position in the MS market with a wide range of products including Avonex  Tysabri  Tecfidera and Plegridy   The company is also looking to diversify beyond MS to other areas like Alzheimer s  Parkinson s and stroke among others  Spinraza  nusinersen  also consolidated its position in the neurological disease market with the drug being the first and only treatment to be approved in the United States for SMA  The company also has a robust pipeline and approval of new drugs will boost growth Biogen currently carries a Zacks Rank  2  Shares have lost 0 6  so far in 2018  Estimates for 2019 are up  50 cents in the past 60 days  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ,2018-12-12,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-gilead-sciences-alexion-pharmaceuticals-regeneron-pharmaceutical-and-biogen-200367276,200367276
120523,342038,VRTX,5 Drug Biotech Stocks With Promise To Sustain Bull Run In 2019,opinion,The performance of the drug biotech space has been mixed so far this year  The Zacks  industry  comprising some of the world s biggest drugmakers  has gained 8 3  against the S P 500 Composite s decrease of 0 9  However  the riskier Zacks  industry  which includes large as well as small biotech companies  has underperformed the S P 500 Composite  The biotech sector has declined 17 8   wider than the S P 500 Composite s fall of 0 9   probably due to some pipeline setbacks faced by the industry Large Cap Pharma and Biomed Genetics Versus S P 500Notably  the s Medical Biomedical and Genetics industry includes large and small biotech companies  The larger ones  namely Amgen   NASDAQ AMGN    Vertex   NASDAQ VRTX    Regeneron  Biogen have done relatively well this year  Most of them have handily outperformed the Medical Biomedical and Genetics industry  The chart below shows the scenario  We believe that strong quarterly results along with increases in full year sales and earnings guidance  new product sales ramp up with rising demand  successful innovation and product line extensions  strong clinical study results and frequent FDA approvals have helped these big drug biotech giants consistently do well this year despite broader macro issues and the industry s internal challenges  Moreover  the sector is likely to perform well even if the global economy slows down next year  This is because it is a defensive growth space  almost insulated from broader macroeconomic factors  Importantly  merger and acquisition activity are gaining momentum with the tax reform in place  Notably  the big drug biotech companies face their share of headwinds like government scrutiny of high drug prices  pricing and competitive pressure  generic competition for blockbuster treatments  slowdown in sales of some of the most high profile older drugs and major pipeline setbacks  Meanwhile  the drug pricing issue will remain a headline risk for this sector Nonetheless  we believe  pipeline success  cost cutting  share buybacks  product launches  increased M A and collaboration activity and appropriate utilization of cash should keep these stocksafloat in 2019 Here we have highlighted five stocks that did well in 2018  outperforming the S P 500 Composite indexand are expected to continue with the positive trend next year  All these stocks carry a Zacks Rank  2  Buy  and have seen their share price and earnings estimates rise this year  You can see  A chart showing the year to date share price movement of all five stocks compared with the S P 500 Composite is given below Eli Lilly   Company   NYSE LLY  Shares of Lilly have surged 36  this year so far  Lilly s earnings estimates have inched up 1  for 2019 over the past 90 days Lilly s new products like Trulicity  Taltz  Basaglar  Cyramza  Jardiance  Lartruvo and Verzenioare driving sales growth  a trend expected to continue in 2019   The company is also on a strong footing in terms of its pipeline with several positive late stage data readouts this year along with various regulatory approvals  A key regulatory success for Lilly was the FDA approval of Emgality galcanezumab  a calcitonin gene related peptide  CGRP  antibody for migraine prevention  which could emerge as a significant contributor to sales growth in 2019 and thereafter Several key regulatory and pipeline events are expected in 2019  Any positive outcome will push up the share price further Merck   Co   Inc    NYSE MRK  Merck s earnings estimates have moved 1 9  north for 2019 over the past 90 days  The stock has soared 40 3  year to date Strong performance and positive regulatory updates related to its PD 1 inhibitor  Keytruda  aided the company s strong performance this year  Within a very short span  Keytruda has become Merck s largest product  It is already approved for use in 12 indications across eight different tumor types in the United States  In fact  the Keytruda development program is also progressing rapidly  Several regulatory decisions for new indications in the United States and Europe are due in 2019  which  if approved  can further boost sales Key recent nods for Merck include Steglatro and its fixed dose combinations for type II diabetes  two new HIV drugs   Pifeltro and Delstrigo   containing doravirine and Prevymis  letermovir  for cytomegalovirus  CVM  infection  Merck also gained several label expansion approvals for Keytruda and another cancer drug  Lynparza  which it markets in partnership with AstraZeneca  AZN  All these new drugs and line extension approvals can drive the company s pharmaceuticals sales in 2019 Merck s animal health and vaccine products are also performing strongly and remain core growth drivers for the company Johnson   Johnson   NYSE JNJ  Shares of J J s have risen 5 8  so far this year  Its earnings estimates for 2019 have moved 0 5  up in the past 90 days J J s Pharma segment is performing better than the market in 2018 so far despite the impact of biosimilars on sales of its blockbuster rheumatoid arthritis medicine  Remicade  Also  the Medical Devices and Consumer units are seeing improving organic growth trends J J has also raised its full year organic sales growth outlook thrice this year  Though quite a few key products in J J s portfolio like Remicade and Concerta are facing generic competition  we believe that new products in all segments  successful label expansion of cancer drugs like Imbruvica and Darzalex and contribution from recent acquisitions will continue to drive top line improvement in 2019  J J enjoys a robust multi year pipeline of new drugs and line extensions  Share buybacks and restructuring initiatives should provide bottom line support Biogen Inc    NASDAQ BIIB  Shares of Biogen have increased 0 5  year to date  Its earnings estimates have been revised 1 6  upward for 2019 over the past 90 days Though Biogen has a strong position in the multiple sclerosis  MS  market  its efforts to diversify beyond MS to other areas like Alzheimer s  Parkinson s and stroke etc  is encouraging  Spinraza  approved for spinal muscular atrophy  SMA  in 2016  has performed beyond expectations so far  witnessing a strong patient uptake in the United States and internationally  We expect Spinraza sales to remain solid in 2019  Meanwhile  Biogen has a sturdy portfolio of biosimilar drugs  which will continue to aid its top line  Biogen is optimistic that its biosimilars business has the opportunity to potentially double over the next couple of years We are encouraged by Biogen s efforts to regularly in license assets to build its pipeline with several having transformative potential  Multiple data readouts are anticipated next year Roche Holding  SIX ROG  AG   OTC RHHBY  Shares of Roche have climbed 1  this year so far  Its earnings estimates have been raised 2 6  for 2019 over the past 90 days Roche has a strong presence in the oncology market  In particular  the company dominates the breast cancer space with steep demand for its HER2 franchise drugs  The HER2 franchise includes drugs like Herceptin  Perjeta and Kadcyla  Apart from its strong breast cancer franchise  Roche s oncology portfolio boasts drugs like Avastin and Tarceva for indications like lung cancer  Imuno oncology is another key focus area for Roche with the company currently having multiple candidates under development  Its immuno oncology drug  Tecentriq  has been a consistent performer as several label expansion studies on the drug are underway Roche is actively seeking acquisitions to strengthen its portfolio further  The company also has a robust pipeline and approval of new drugs will lead to growth In addition to the stocks discussed above  would you like to know about our 10 top tickers to buy and hold for the entirety of 2019 These 10 are painstakingly handpicked from over 4 000 companies covered by the Zacks Rank  They are our primary picks poised to outperform in the year ahead ,2018-12-13,Zacks Investment Research,https://www.investing.com/analysis/5-drugbiotech-stocks-with-promise-to-sustain-bull-run-in-2019-200368163,200368163
120543,342058,VRTX,Vertex CRISPR s Sickle Disease Candidate Put On Hold By FDA,opinion,Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   and partner CRISPR Therapeutics AG   NASDAQ CRSP   announced that the FDA has placed a clinical hold on the companies  investigational new drug  IND  application for CTX001  The companies had filed the IND application last month to start a phase I II study on CTX00 in sickle cell disease in the United States As part of the review of the IND  the FDA will put forward certain questions to the companies  Vertex and CRISPR Therapeutics plan to work rapidly with the FDA to resolve the issue so that the clinical hold is lifted and the study initiated In December  as part of a strategic research collaboration formed in 2015  Vertex and CRISPR Therapeutics selected CTX001 to move into clinical development as a gene edited treatment for sickle cell disease and   thalassemia developed using CRISPR Therapeutics  proprietary CRISPR Cas9 technology  Back then  the companies had opted toco develop and co commercialize CTX001 and equally share all R D costs and profits worldwide  Vertex has rights to license up to six new gene editing treatments  including CTX001  developed using the CRISPR Cas9 technology that emerge from the joint research deal An application has also been submitted to begin a phase I II study in   thalassemia in 2018 in Europe  The plan to begin this study   in the second half of this year   is intact and unaffected by the hold on the sickle cell disease study Shares of CRISPR Therapeutics were down more than 14  in after hours trading on Wednesday in response to the negative pipeline update while Vertex s stock did not show any movement  In fact  so far this year CRISPR Therapeutics  shares have gained 213 4  while that of Vertex are up 4 5  compared to the  decline of 9 9  Genomic editing technology using CRISPR technology to repair defective genetic material that causes diseases is probably one of the most promising and exciting healthcare innovations in decades  Though there are several methods to use CRISPR to target genetic defects that cause specific diseases  the most promising is the use of an enzyme called Cas9 to deliver CRISPR to affected cells Other than CRISPR Therapeutics  Intellia Therapeutics   NASDAQ NTLA   and Editas Medicine  Inc   NASDAQ EDIT   also plan to carry out clinical studies using CRISPR Cas9 to address diseases Shares of both Intellia Therapeutics and Editas Medicine were down more than 3  in after hours on Wednesday While CRISPR Therapeutics currently has a Zacks Rank  1  Strong Buy   Vertex has a Zacks Rank  3  Hold   You can see  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-05-30,Zacks Investment Research,https://www.investing.com/analysis/vertexcrisprs-sickle-disease-candidate-put-on-hold-by-fda-200320977,200320977
120544,342059,VRTX,Biotech Stock Roundup  Celgene  Amgen  Vertex Impress In Q3  DRNA Soars On LLY Deal,opinion,"Earnings took center stage for the biotech sector this week  with quite a few bigwigs like Gilead Sciences   NASDAQ GILD    Amgen   NASDAQ AMGN    Vertex Pharmaceuticals   NASDAQ VRTX   and Celgene   NASDAQ CELG   coming up with third quarter results   Apart from these  regular pipeline updates and data read outs were also in the news Recap of the Week s Top Stories Celgene  Vertex  Amgen Shine in Q3  The going has been good for the biotech bigwigs in the third quarter   and upped its guidance on a jump in psoriasis drug Otezla sales  Lead drug  Revlimid too maintained momentum for the company  Alexion Pharmaceuticals   NASDAQ ALXN    but missed on revenues  The company upped its annual guidance though  in Q3 on strong cystic fibrosis  CF  product revenues  Amgen also surpassed earnings and sales estimates in Q3  Meanwhile    but the year over year decline was disappointing as the magnitude of decline in hepatitis C virus  HCV  sales continues to deepen 
Alexion currently carries a Zacks Rank  1  Strong Buy   You can see  Regeneron s Eylea Succeeds Diabetic Retinopathy Trial  Regeneron Pharmaceuticals  Inc    NASDAQ REGN   announced that the phase III trial  PANORAMA  evaluating lead drug Eylea injection in patients suffering from moderately severe and severe non proliferative diabetic retinopathy  NPDR  met its one year  52 week  primary endpoint and key secondary endpoints  The data showed that every eight week and every 16 week dosing groups met primary and key secondary endpoints at one year   We note that the supplemental application for Eylea for the treatment of diabetic retinopathy  based on previously announced 24 week results is currently under FDA review with an action date of May 13  2019   Concurrently  Regeneron announced that the FDA issued a complete response letter  CRL  regarding the Chemistry  Manufacturing and Controls  CMC  Prior Approval Supplement  PAS  for the Eylea pre filled syringe  The FDA has requested additional information regarding manufacturing and supply processes and the completion of a usability study evaluating a single injection of the Eylea pre filled syringe in approximately 30 patients  Regeneron plans to resubmit the PAS in early 2019 after collecting necessary information Dicerna Soars on Collaboration Deal With Lilly  Shares of Dicerna Pharmaceuticals   NASDAQ DRNA   surged after the company announced a global licensing and research collaboration with pharma giant Eli Lilly  NYSE LLY   Both companies have collaborated for the discovery  development and commercialization of potential new medicines in the areas of cardio metabolic disease  neurodegeneration and pain  Both companies will use Dicerna s proprietary GalXCRNA interference  RNAi  technology platform to advance new drug targets toward clinical development and commercialization   Per the terms  Dicerna will obtain an upfront payment of  100 million and an equity investment of  100 million   The company is also eligible to receive up to approximately  350 million per target in development and commercialization milestones along with royalties  Dicerna also collaborated with Alexion to discover and develop RNAi therapies for complement mediated diseases Ultragenyx s Late Stage Candidate Fails  Ultragenyx Pharmaceutical Inc    NASDAQ RARE   announced that a late stage study on pipeline candidate  UX007  failed to meet its goals  The phase III study in patients with glucose transporter type 1 deficiency syndrome  Glut1 DS  experiencing disabling paroxysmal movement disorders did not achieve its primary endpoint  The candidate did not demonstrate a statistically significant reduction in the frequency of paroxysmal movement events with UX007 treatment compared to placebo  and did not demonstrate a meaningful difference between treatment groups  The study failed to meet its key secondary endpoints  Consequently  Ultragenyx plans to discontinue the Glut1 DS development program  The company also stated that it will work with its investigators and patients on a reasonable transition plan for patients with Glut1 DS  who are still on UX007 PerformanceMedical   Biomedical and Genetics Industry 5YR   Return
 The NASDAQ Biotechnology index lost 5  over the last five trading sessions  Among the major biotech stocks  Regeneron lost 10 77  in the last five trading sessions  Over the past six months  shares of Biogen  NASDAQ BIIB  have rallied 11 9  while Celgene has lost 16 9    See the last biotech stock roundup here   What s Next in Biotech Stay tuned for more earnings results as a few companies are scheduled to report later in the week 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ",2018-10-31,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-celgene-amgen-vertex-impress-in-q3-drna-soars-on-lly-deal-200352600,200352600
120545,342060,VRTX,The Zacks Analyst Blog Highlights  Gilead Sciences  Amgen  Vertex Pharmaceuticals  Celgene And Regeneron Pharmaceuticals,opinion,For Immediate ReleaseChicago  IL   November 1  2018   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Gilead Sciences   NASDAQ GILD    Amgen   NASDAQ AMGN    Vertex Pharmaceuticals   NASDAQ VRTX    Celgene   NASDAQ CELG   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN   Today  Zacks is promoting its   Buy   stock recommendations    Here are highlights from Wednesday s Analyst Blog Biotech Stock Roundup  Celgene  Amgen  Vertex Impress in Q3Earnings took center stage for the biotech sector this week  with quite a few bigwigs like Gilead Sciences  Amgen  Vertex Pharmaceuticals and Celgene coming up with third quarter results  Apart from these  regular pipeline updates and data read outs were also in the news Recap of the Week s Top Stories Celgene  Vertex  Amgen Shine in Q3  The going has been good for the biotech bigwigs in the third quarter  Celgene topped both revenue and earnings estimates in Q3 and upped its guidance on a jump in psoriasis drug Otezla sales  Lead drug  Revlimid too maintained momentum for the company Vertex Pharmaceuticals topped both earnings and sales estimates in Q3 on strong cystic fibrosis  CF  product revenues  Amgen also surpassed earnings and sales estimates in Q3  Meanwhile  Gilead Sciences  Inc  s third quarter earnings beat estimates  but the year over year decline was disappointing as the magnitude of decline in hepatitis C virus  HCV  sales continues to deepen Alexion currently carries a Zacks Rank  1  Strong Buy   You can see the complete list of today s Zacks  1 Rank stocks here Regeneron s Eylea Succeeds Diabetic Retinopathy Trial  Regeneron Pharmaceuticals  Inc  announced that the phase III trial  PANORAMA  evaluating lead drug Eylea injection in patients suffering from moderately severe and severe non proliferative diabetic retinopathy  NPDR  met its one year  52 week  primary endpoint and key secondary endpoints  The data showed that every eight week and every 16 week dosing groups met primary and key secondary endpoints at one year   We note that the supplemental application for Eylea for the treatment of diabetic retinopathy  based on previously announced 24 week results is currently under FDA review with an action date of May 13  2019  Concurrently  Regeneron announced that the FDA issued a complete response letter  CRL  regarding the Chemistry  Manufacturing and Controls  CMC  Prior Approval Supplement  PAS  for the Eylea pre filled syringe  The FDA has requested additional information regarding manufacturing and supply processes and the completion of a usability study evaluating a single injection of the Eylea pre filled syringe in approximately 30 patients  Regeneron plans to resubmit the PAS in early 2019 after collecting necessary information About Zacks Equity ResearchZacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  Follow us on Twitter  Join us on Facebook  NASDAQ FB   Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2018-11-01,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-gilead-sciences-amgen-vertex-pharmaceuticals-celgene-and-regeneron-pharmaceuticals-200352933,200352933
120547,342062,VRTX,Geron s  GERN  Q3 Earnings Beat  Revenues Miss  Shares Down,opinion,"Geron Corporation   NASDAQ GERN   reported a loss of 3 cents per share for the third quarter of 2018  narrower than the Zacks Consensus Estimates of a loss of 5 cents and the year ago quarter loss of 4 cents Quarterly revenues increased 1 2  from the year ago quarter to  0 17 million  which missed the Zacks Consensus Estimate of  0 22 million  Revenues comprised royalty and license fee revenues received under various non imetelstat license agreements Shares were down 1 6  in pre market trading on Nov 2  So far this year  Geron s shares have risen 2 8  against the  s decline of 16 2  Research and development  R D  expenses increased 2 7  to  2 7 million  The rise was due to variation in costs for the proportionate share of clinical development of imetelstat under collaboration with Janssen  General and administrative  G A  expenses fell 10 6  to  4 3 million The company ended the quarter with  184 8 million in cash and investments compared with  181 4 million at the end of the second quarter Pipeline UpdateIn September  Geron announced that Johnson   Johnson   NYSE JNJ   had decided to discontinue the collaboration agreement to co develop Geron s sole pipeline candidate  imetelstat  With the termination of the agreement  Geron regained global development rights to imetelstat and decided to continue developing the candidate independently Imetelstat is being evaluated in two clinical studies  Phase II IMbark and phase II III IMerge are evaluating the candidate in myelofibrosis and myelodysplastic syndromes   MDS    respectively Geron remains confident about the potential of imetelstat in MDS indication based on supportive data from initial and expansion arms of phase II portion of IMerge study  The company expects to initiate the phase III portion of the IMerge study by mid 2019 Earlier this month  the company announced the acceptance of two oral presentations at the American Society of Hematology   ASH   meeting to be held in December  This has boosted investors  confidence in imetestat development which was evident from the 20  rally in share price on Nov 1 Our TakeWith the termination of the agreement  Geron lost a strong and experienced partner as well as its major source of funds  Moreover  the cash resources  as of third quarter end  will be sufficient to initiate the phase III study in MDS but it is not enough to support the continuation of the study  Meanwhile  operating expenses are likely to increase as J J shared half of the imetelstat development costs in the past 
We expect that the company may face serious difficulties if it is unable to find new avenues for funds like new partnerships or share sale Geron Corporation Price  Consensus and EPS Surprise
    Zacks Rank   Stocks to ConsiderGeron currently carries a Zacks Rank  3  Hold  A couple of better ranked stocks in the biotech sector are CRISPR Therapeutics   NASDAQ CRSP   and Vertex Pharmaceuticals Inc    NASDAQ VRTX    While CRISPR Therapeutics sports a Zacks Rank  1  Strong Buy   Vertex carries a Zacks Rank  2  Buy   You can see  CRISPR Therapeutics  estimates have narrowed from loss of  2 95 to  2 92 for 2018 over the past 60 days  The company delivered a positive earnings surprise in two of the trailing four quarters  delivering average beat of 19 50   Share price of the company has increased 51 6  year to date Vertex s earnings per share estimates have moved up from  3 73 to  3 83 for 2018 over the past 30 days  The company delivered a positive earnings surprise in all the trailing four quarters  delivering average beat of 18 94   The company s shares have rallied 17  year to date Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-01,Zacks Investment Research,https://www.investing.com/analysis/gerons-gern-q3-earnings-beat-revenues-miss-shares-down-200353984,200353984
120549,342064,VRTX,VIVUS  VVUS  Q3 Loss Narrower Than Expected  Revenues Up Y Y,opinion,"VIVUS Inc    NASDAQ VVUS   reported a loss of 87 cents per share for the third quarter of 2018  wider than a loss of 57 cents in the year ago period but narrower than the Zacks Consensus Estimate of  1 10  Quarterly revenues increased 19 1  from the year ago period to  18 1 million mainly due to contribution of sales from recently acquired drug  Pancreaze So far this year  VIVUS shares have decreased 32 1  compared with the  s decline of 16 2  Quarter in DetailProduct revenues during the quarter rose 66 3  to  16 5 million The company s weight management drug Qsymia generated net product sales of  9 7 million  down 1 8  from the year ago period due to decrease in shipments of the drug Pancreaze brought in sales of  6 7 million in its first full quarter of sales  VIVUS acquired the exocrine pancreatic insufficiency drug in June this year from Janssen  a subsidiary of Johnson   Johnson   NYSE JNJ   However  supply revenues from Stendra Spedra were significantly down to  0 47 million in this quarter compared with  2 1 million in the year ago period  Royalty revenues from sales of Pancreaze in Canada and Spedra in Europe were  1 1 million  up 73 5  Selling  general and administrative  SG A  expense was  8 5 million  a 0 8  increase year over year  The increase was due to higher marketing and promotional activities for Qsymia  which was mostly offset by cost control initiatives Research and development expense increased 133  to  2 1 million in the reported quarter due to increased development efforts for VI 0106 for the treatment of pulmonary arterial hypertension Our TakePerformance of VIVUS  obesity drug  Qsymia  was poor this quarter with its sales declining year over year as well as sequentially in the third quarter  The drug s sales continued to be impacted by seasonality  However  the company remains focused on efforts to promote Qsymia  and cost cutting initiatives  The acquisition of Pancreaze boosted product revenues significantly  Moreover  retirement of its convertible debt during the quarter will reduce interest payments VIVUS stated that it anticipates higher operating expenses going forward due to post marketing requirements  integration and commercialization efforts for Pancreaze Although the acquisition of more cash flow positive drugs like Pancreaze is likely to boost sales  it will also increase operating expenses VIVUS  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Stocks to ConsiderVIVUS currently carries a Zacks Rank  3  Hold  A couple of better ranked stocks in the biotech sector are CRISPR Therapeutics   NASDAQ CRSP   and Vertex Pharmaceuticals Inc    NASDAQ VRTX    While CRISPR Therapeutics sports a Zacks Rank  1  Strong Buy   Vertex carries a Zacks Rank  2  Buy   You can see  CRISPR Therapeutics  estimates have narrowed from loss of  2 95 to  2 92 for 2018 over the past 60 days  The company delivered a positive earnings surprise in two of the trailing four quarters  delivering average beat of 19 50   Share price of the company has increased 39 6  year to date Vertex s earnings per share estimates have moved up from  3 73 to  3 83 for 2018 over the past 30 days  The company delivered a positive earnings surprise in all the trailing four quarters  delivering average beat of 18 94   The company s shares have rallied 17  year to date Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-01,Zacks Investment Research,https://www.investing.com/analysis/vivus-vvus-q3-loss-narrower-than-expected-revenues-up-yy-200354123,200354123
120553,342068,VRTX,Perrigo  PRGO  Beats On Q3 Earnings  Cuts View  Shares Down,opinion,"Perrigo Company plc   NYSE PRGO   reported third quarter 2018 adjusted earnings of  1 09 per share  which beat the Zacks Consensus Estimate of  1 05  Earnings fell 21 9  year over year Net sales in the reported quarter decreased 8  year over year to  1 13 billion  missing the Zacks Consensus Estimate of  1 17 billion  The decline was mainly due to lower sales volume in prescription segment  Sales of  35 million from new products were partially offset by loss of  9 million in sales of discontinued products Perrigo s shares were down 10  in pre market trading on Thursday possibly due to lowered earnings and revenue guidance for 2018  The company s shares have declined 13 8  against the  s increase of 2 7  Segment DiscussionThe company reports under three segments  Consumer Health Care Americas   CHCA    Consumer Healthcare International   CHCI   and Prescription Pharmaceuticals   RX   CHCA   CHCA net sales in the third quarter of 2018 came in at  596 million  down 0 4  year over year  This downside can be attributed to lower net sales in the animal health business and gastrointestinal categories  However  strong performance of smoking cessation  infant nutrition and dermatological categories partially offset the decline in CHCA net sales  While new product sales of  13 million contributed to the top line  the company lost sales of  1 million from discontinued products  Excluding animal health category  sales increased 3  organically CHCI CHCI segment reported net sales of  358 million  down 2 1  from the year ago period  However  sales increased 0 6  on a constant currency basis  Excluding the exited Russian and unprofitable distribution businesses in 2017 and unfavorable foreign currency movements of  10 million  net revenues increased 1   The growth was driven by higher sales of anti parasite and personal care categories  partially offset by lower sales in lifestyle category and non branded U K  businesses While new product sales of  19 million contributed to the top line  the company lost sales of  5 million from discontinued products RX   This segment s net sales declined 28 5  to  179 million on a reported basis as well as on a constant currency basis  The decline in sales was due to lower sales volume amid challenges in generics market and customer services  Lost sales due to discontinued products were  4 million 2018 Earnings OutlookPerrigo lowered its full year revenue guidance and now expects it to be approximately  4 72 billion in 2018 compared with the previous expectation of  4 8  4 9 billion  This includes the impact of reduced RX segment sales outlook and unfavorable foreign currency movement expectation of  65 millionThe company also reduced its adjusted earnings guidance to the band of  4 45 to  4 65 per share from the previously announced  4 75 to  4 95 per share due to pricing pressure in Rx segment and reduced margin expectations in the CHCA segment  partially offset by CHCI s improved expectations Our TakePerrigo s revenues and margin have been under pressure in 2018 mainly due to the challenges faced by its Rx segment  However  the company will divest this segment to better capitalize on its differentiated generic pharmaceutical products and focus on expanding its leading consumer businessMeanwhile  the company is also focusing on switching of prescription drugs to over the counter   OTC   brands and expanding store brand solution to drive growth in Consumer Healthcare Americas segment  During the quarter  the company gained FDA approval for a stored brand OTC equivalent of Johnson   Johnson s   NYSE JNJ   multi symptom relief drug  Imodium  and also entered into an agreement with Merck   NYSE MRK   to gain exclusive rights to the OTC version of the latter s allergy drug  Nasonex nasal spray However  Perrigo is likely to face revenue decline and contraction of margins in 2018  Any improvement in margins are likely to happen after Rx divestment which is likely to happen next year  Also  OTC growth strategy is a complex process and will take time to yield results Perrigo Company plc Price  Consensus and EPS Surprise
    Zacks Rank   Stock to ConsiderPerrigo currently carries a Zacks Rank  3  Hold  Vertex Pharmaceuticals   NASDAQ VRTX   is a better ranked stock in the biotech sector  carrying a Zacks Rank  2  Buy   You can see  Vertex s earnings per share estimates have moved up from  3 75 to  3 83 for 2018 in the past 30 days  The company delivered a positive surprise in all the trailing four quarters with the average beat being 18 94   Share price of the company has increased 22 7  in a year s time Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-07,Zacks Investment Research,https://www.investing.com/analysis/perrigo-prgo-beats-on-q3-earnings-cuts-view-shares-down-200357024,200357024
120574,342089,VRTX,Is A Beat In Store For Vertex  VRTX  This Earnings Season ,opinion,"We expect Vertex Pharmaceuticals  Inc    NASDAQ VRTX   to beat expectations when it reports first quarter 2018 results on Apr 26  after market close Vertex s shares have increased 5 9  so far this year while the  has recorded a decrease of 9  Vertex s track record has been impressive so far  The company delivered positive earnings surprises in each of the last four quarters  The average positive earnings surprise for the last four quarters is 25 31   In the last reported quarter  Vertex came up with a positive surprise of 5 17  Let s see how things are shaping up for this quarter Factors at PlayVertex s cystic fibrosis   CF   drugs   Kalydeco   Orkambi   performed consistently in 2017  with sales rising almost 30   We expect this positive trend to continue in the soon to be reported quarter However  the company announced on its last quarter earnings call that first quarter revenues will be unfavorably impacted by higher gross to net revenue adjustments and buildup of channel inventory in the fourth quarter of 2017 In January 2018  Vertex announced that an extension of the marketing application for Orkambi was approved in Europe  With the approval  Orkambi s marketing label in EU will now include use in children with CF aged between six and 11 years and have two copies of the F508del mutation  expanding patient population by about 3 400  The expanded patient population is expected to boost sales of the drug  The Zacks Consensus Estimate for Orkambi s sales in the first quarter is  368 million In 2017  Kalydeco received approval for two line extensions including in patients 2 years and older with certain residual mutations in CFTR gene  The drug generated significant sales last year due to rapid uptake in expanded patient population and we expect the trend to continue  The Zacks Consensus Estimate for first quarter Kalydeco sales is pegged at  228 millionIn a boost to Vertex s CF franchise  the FDA approved Vertex s third CF drug  Symdeko  which is a combination of tezacaftor and ivacaftor  in February 2018  The drug is under review in Europe  However  we expect the new drug to contribute minimally to first quarter sales  We expect the company to provide update on Symdeko s commercialization plan and its initial uptake The company remains focused on development of its triple combination regimens  During the quarter  Vertex advanced VX 659 and VX 445 for phase III development  Also  two phase III studies were initiated  evaluating VX 659 in combination with tezacaftor and Kalydeco  ivacaftor  in CF patients Investor focus on the call will be on these triple combination CF regimens  which are crucial for long term growth of Vertex  The company is also likely to provide full year revenue guidance including Symdeko sales on the call However  operating expenses are likely to be on the higher side due to initiation of two pivotal studies and launch of Symdeko Why a Likely Positive Surprise Our proven model indicates that Vertex is likely to beat earnings estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen Zacks ESP  Earnings ESP  which represents the difference between the Most Accurate estimate  62 cents  and the Zacks Consensus Estimate  57 cents   stands at  8 28   This is a leading indicator of a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Vertex has a Zacks Rank  3  The combination of a positive Earnings ESP and a favorable Zacks Rank makes us reasonably confident of an earnings beat Conversely  we caution against the Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Vertex Pharmaceuticals Incorporated Price and EPS Surprise
    Other Stocks to ConsiderHere are some biotech stocks that you may also want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Celgene Corporation   NASDAQ CELG   is scheduled to release its results on May 4  The company has an Earnings ESP of  0 63  and a Zacks Rank  3  You can see  Amgen Inc    NASDAQ AMGN   is scheduled to release its results on Apr 26  The company has an Earnings ESP of  3 34  and a Zacks Rank  3 Gilead Sciences  Inc    NASDAQ GILD   is scheduled to release its results on May 1  The company has an Earnings ESP of  0 32  and a Zacks Rank  2 Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-04-23,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-store-for-vertex-vrtx-this-earnings-season-200308281,200308281
120575,342090,VRTX,Vertex  VRTX  Q1 Earnings Beat On Strong CF Products Sales,opinion,"Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   reported first quarter 2018 earnings per share of 76 cents  which beat the Zacks Consensus Estimate of 58 cents and came ahead of the year ago earnings of 41 cents  Strong product revenues led to higher profits in the quarter Vertex reported revenues of  640 8 million in the first quarter  beating the Zacks Consensus Estimate of  617 56 million  However  sales were down 10 3  year over year due to significantly lower collaborative revenues The company had received an upfront payment of  230 million from Germany based Merck  NYSE MRK  KGaA in the year ago period for out licensing of four oncology programs CF Drugs Sales Remain StrongVertex s first quarter revenues consisted of sales from cystic fibrosis   CF   products   Kalydeco  Orkambi and Symdeko  collaborative   1 7 million  and royalty revenues   1 4 million   CF product revenues were  637 7 million in the first quarter  up 33  year over year due to continuous expansion of patient population Kalydeco sales surged 34 4  to  250 million while Orkambi  lumacaftor ivacaftor  delivered sales of  354 million  up 20  year over year The growth was supported by continued approvals in expanded population and uptake globally During the quarter  Vertex received approval for its third CF drug  Symdeko  in the United States  The drug has contributed  34 million to the top line Costs RiseAdjusted research and development  R D  expenses increased 14 7  to  260 million in the first quarter due to higher costs related to phase III development of triple combination CF regimens  Adjusted selling  general and administrative  SG A  expenses increased 15 4  to  99 6 million mainly driven by worldwide investments to support the treatment of CF patients 2018 Revenue GuidanceVertex provided guidance for 2018 revenues  primarily driven by CF drugs sales  The company expects revenues to be in the range of  2 65 to  2 8 billion Guidance for combined adjusted research and development  R D  and selling  general and administrative  SG A  expenses in 2018 was maintained in the range of  1 50 to  1 55 billion Pipeline   Regulatory UpdatesVertex remained focused on developing its triple combination regimens for treatment of CF  The company has advanced two next generation CFTR correctors   VX 659 and VX 445   to phase III stage In February 2018  the FDA approved Symdeko for the treatment of CF patients aged 12 and older who have two copies of the F508del mutation or who have at least one mutation that is responsive to Symdeko  The drug is under review in the EU for a similar indication An ongoing phase III study is evaluating Symdeko in children aged 6 through 11 years with similar mutations A label expansion of Kalydeco to include patients aged 2 to 12 years is under review in the United States as well as Europe  A decision from the FDA is expected in August  Meanwhile  Vertex is also evaluating the drug in a phase II study for the treatment of infants below 12 months Similarly  Vertex is also seeking approval of Orkambi in patients aged two to five years  Regulatory applications are under review in the United States and Europe with a decision expected in August in the United States  A phase III study will be initiated in the second half of 2018 to evaluate the drug in patients aged between 12 months and less than 24 months Moreover  in January 2018  the European Commission approved a line extension for Orkambi to include use in children with CF aged between six and 11 years and who have two copies of the F508del mutation Apart from CF  Vertex is also developing treatments for sickle cell disease  thalassemia  influenza and pain management  During the first quarter  Vertex announced positive data from a Phase II proof of concept study evaluating its pain candidate  VX 150  for acute pain following bunionectomy surgery  Two other phase II studies are evaluating the candidate in neuropathic pain and pain from osteoarthritis of the knee  A phase III study on pimodivir in combination with standard of care treatment in patients with influenza is being conducted in collaboration with Janssen Pharmaceuticals  a subsidiary of Johnson   Johnson   NYSE JNJ   Our TakeVertex s first quarter results reflect strong performance of its CF products  which helped it to beat estimates on both counts Shares rose almost 2  in after hours trading in response to the strong quarterly results  After a robust increase in share price last year  Vertex s share price has increased 5 9  so far this year against a decrease of 10 1  for the  Vertex s CF pipeline is quite strong with a broad portfolio of next generation CF correctors  The approval of Symdeko further strengthens the franchise  Its triple combination CF regimens are considered crucial for long term growth  If the triple combo regimes are successful  Vertex can address a significantly larger CF patient population   almost 90  of the patients   in the future  However  competition is increasing as several major companies are expressing interest in CF Vertex Pharmaceuticals Incorporated Price  Consensus and EPS Surprise
    Zacks Rank and Key PicksVertex carries a Zacks Rank  2  Buy  A couple of better top ranked stocks from the biotech sector are Ligand Pharmaceuticals   NASDAQ LGND   and Protagonist Therapeutics   NASDAQ PTGX    Both the companies sport a Zacks Rank  1  Strong Buy   You can see  Ligand s earnings per share estimates moved up from  4 15 to  4 43 for 2018 over the last 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with an average beat of 24 88   The company s shares have rallied 13  year to date Protagonist Therapeutics  loss estimates narrowed from  1 68 to 66 cents for 2018 and from  2 43 to  1 26 for 2019  over the last 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with an average beat of 24 95  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-04-26,Zacks Investment Research,https://www.investing.com/analysis/vertex-vrtx-q1-earnings-beat-on-strong-cf-products-sales-200310265,200310265
120576,342091,VRTX,Biotech Stock Roundup  ALXN  VRTX Post Solid Results  GILD Disappoints In Q1,opinion,"The Biotech space remained a key area of investors focus as several bigwigs announced quarterly results  While Alexion   NASDAQ ALXN   reported solid results  Gilead   NASDAQ GILD   reported dismal numbers  Among other developments over the week  Regeneron   NASDAQ REGN   and Sanofi  PA SASY  announced plans to lower the price of Praluent  while Amgen   NASDAQ AMGN   received a positive opinion for Prolia Recap of Important Stories Q1 Progress Report  Companies like Alexion  Gilead and Vertex   NASDAQ VRTX    among others reported first quarter results over the last five trading sessions  While Alexion and Vertex delivered solid results for the quarter  Gilead s both earnings and sales missed estimates on wider than expected decline in HCV franchise Following the Q1 results  Alexion raised guidance and also reported positive data on its long acting C5 complement inhibitor   ALXN1210 which showed that patients with PNH can be effectively and safely switched from treatment with Soliris every two weeks to treatment with ALXN1210 every eight weeks A tentative approval will bode well for Alexion  read more    Vertex s first quarter results were driven by the stellar performance of CF products  read more    
Gilead is a Zacks Rank  2  Buy  stock  You can see  Amgen Gets Positive Opinion For Prolia   Amgen announced that the Committee for Medicinal Products for Human Use   CHMP   of the European Medicines Agency   EMA   has adopted a positive opinion for the marketing authorization of Prolia for the treatment of bone loss associated with long term systemic glucocorticoid therapy in adult patients at increased risk of fracture The CHMP opinion will now be reviewed by the European Commission  Meanwhile  the company s supplemental Biologics License Application for Prolia for this expanded indication is also under review in the United States with a Prescription Drug User Fee Act action date of May 28  2018 We note that the drug is already approved in the United States for the treatment of postmenopausal women with osteoporosis at high risk for fracture In addition  the CHMP has adopted a positive opinion recommending a label variation for Kyprolis  carfilzomib  to include the final overall survival data from the phase III trial  ASPIRE which demonstrated that the addition of Kyprolis to lenalidomide and dexamethasone  KRd  reduced the risk of death by 21  versus lenalidomide and dexamethasone alone  Rd  and extended OS by 7 9 months in patients with relapsed or refractory multiple myeloma Regeneron and partner Sanofi to Cut Praluent Price  Regeneron and partner Sanofi announced that both companies will lower the net price of PCSK9 inhibitor Praluent  alirocumab  injection for more affordable patient access from Express Scripts Consequently  Praluent will become the exclusive PCSK9 inhibitor therapy on the Express Scripts national formulary   The agreement  effective Jul 1  provides Praluent at lower net price and enables streamlined patient access based on physician attestation   Meanwhile  the FDA has accepted for priority review the companies  Biologics License Application for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma   CSCC   or patients with locally advanced CSCC who are not candidates for surgery  The candidate was granted Breakthrough Therapy designation status by the FDA in September 2017  The target action date is Oct 28  2018 Biogen Negotiates Agreement With Neurimmune  Biogen   NASDAQ BIIB   and Neurimmune announced that the former has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of its Alzheimer s disease candidate  aducanumab The candidate is currently in phase III  As a result  Biogen will make a one time  50 million payment to Neurimmune in exchange for a 5  reduction in the original royalty rates on potential commercial sales of aducanumab  Both companies had earlier announced a 15  reduction in royalty rates  The reduced royalty rates on potential commercial sales of aducanumab will be in the high single digits to low teens  Biogen licensed the worldwide rights to aducanumab from Neurimmune in 2007 PerformanceMedical   Biomedical and Genetics Industry 5YR   Return
  
The NASDAQ Biotechnology Index gained 0 83  over the last five trading sessions  Among major biotech stocks  Alexion gained 11 86   Over the last six months  Regeneron lost 24 13   while Vertex gained 6 91   see the last biotech stock roundup here    
  What s Next in Biotech Stay tuned for more earnings along with regulatory updates Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-05-01,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-alxn-vrtx-post-solid-results-gild-disappoints-in-q1-200311734,200311734
120579,342094,VRTX,4 Stocks To Watch This Week  ANF  IOVA  LGCY  XNCR,opinion,"Abercrombie   Fitch  NYSE ANF   since the inverse head and shoulders formed  and it broke out  we put a swing on it  It worked out great  It has gone from the 15 15 1 2 range  all the way up into the high 20 s  reaching to 29 20  so almost doubling  Recently  it s been consolidating  holding the 50 day moving average and trend line  On Wednesday  it popped 1 28  or 5   to 27 15  on 3 5 million shares  What I m looking for is a test and takeout of the 29 range  If it gets through that  I m looking at 32  and 39 potentially down the road  This is a great looking chart 
Iovance Biotherapeutics Inc  NASDAQ IOVA  broke out on Wednesday  jumping 1 20  or 7 87   to 16 45  on 1 4 million shares  I liked the way it looked and put a swing on it  That s the best volume in about eight weeks  It may have crossed resistance price wise and the moving average  It has already broken through near the declining topsline as much as a couple weeks ago  but hasn t really made an advance of this caliber  Wednesday s pop came with good volume and broke through price and moving average resistance  Look for a quick test of 17 17 1 4  and then maybe a run to 18 18 1 4  before getting up near 20 
Legacy Reserves LP  NASDAQ LGCY   one of the better swing trades this year  popped out  pulled back and flagged for two weeks  and then exploded  literally going up every day for the last eight days  On Wednesday  it was up another 96 cents  or 11   to 9 65  which is the highest price we ve seen going back three years  on 1 4 million shares  At this point  I will have to step back and ask where the next target should be on this one  and I will say it s at 16 1 2  My current targets are 11 and 14  If this run continues  with the earnings they had  this will be a blowout 
Xencor Inc  NASDAQ XNCR   one of our old swings  had a big  engulfing reversal day on Wednesday  first getting down to 31  and closing up 1 01  or 3   to 34 12  on 157 306 shares traded  I really like the look of that move  The  is rising  What you want to watch is 34 63  If it gets through that  my targets are in the 38  and 42 3 range 
Stocks on the long side included Abercrombie   Fitch Co   ANF   Atara Biotherapeutics Inc  NASDAQ ATRA   Blink Charging Co   BLNK   Codexis  Inc   CDXS   Daqo New Energy Corp ADR  NYSE DQ   Eleven Biotherapeutics  Inc   EBIO   Endocyte  Inc   ECYT   Enphase Energy Inc  NASDAQ ENPH   Amicus Therapeutics  Inc   FOLD   GTx  Inc   GTXI   Turtle Beach Corporation  HEAR   Iovance Biotherapeutics  Inc   IOVA   Intrepid Potash  Inc   IPI   Legacy Reserves LP  LGCY   Macy s  Inc   NYSE M   Pandora Media  Inc   P   Rocket Pharmaceuticals  Inc   RCKT   Square  Inc   NYSE SQ   STAAR Surgical Company  STAA   Travelzoo  TZOO   Under Armour Inc A  NYSE UAA   Vertex Pharmaceuticals Incorporated  NASDAQ VRTX   21Vianet Group  Inc   VNET   and Xencor  Inc   XNCR  
Watch video  ",2018-05-17,Harry Boxer,https://www.investing.com/analysis/anf-iovalgcy-xncr-200316819,200316819
120580,342095,VRTX,Is Genome Editing The Next Biotech Breakthrough ,opinion,"One of the most promising and exciting healthcare innovations in decades is genomic editing technology using CRISPR technology to repair defective genetic material that causes disease   CRISPR is an acronym for  Clustered Regularly Interspaced Short Palindromic Repeats    CRISPR research is an offshoot of the Human Genome Project which mapped all the genes in the human body in 2003  Armed with the knowledge of how genetic material is supposed to be structured  researchers then endeavored to devise ways to  fix  it when it is incorrect 
A breakthrough came from the field of bacteria research  Certain bacteria have developed an immune response in which they retain a piece of DNA of an invading virus as a reminder  and then if that DNA is encountered again  the bacteria use CRISPR to alter it  rendering the virus innocuous 
Thousands of scientists are currently researching ways to use this same mechanism to alter human DNA but  cutting out  defective portions of the sequence and replacing them with the correct code   As many as 6 000 diseases are caused by genetic factors  including Alzheimer s  hemophilia  sickle cell disease  ALS and many cancers   The ability to identify and fix faulty genes could make many of these diseases effectively curable 
Research has delivered several methods to use CRISPR to target the genetic defects that cause specific diseases  but the most promising at this point uses an enzyme called Cas9 to deliver CRISPR to affected cells   Three companies currently have plans to do studies this year on human subjects using CRISPR Cas9 to address disease 
 has been one of the best performing stocks in the U S  in 2018  up nearly 200  YTD  Though already on the radar of traders and analysts  the stock got additional boosts from a 60 Minutes piece on the technology in April and favorable response to the company s presentation at a Merrill Lynch Healthcare Conference last week 
CRSP is about to begin trials of CRISPR Cas9 in the treatment of two related genetic blood disorders in humans  B thalassemia and Sickle Cells Disease   The  approach  internally named CTX001  has had a Clinical Trial Application  CTA  granted for B thalassemia study in Europe and has an Investigational New Drug  IND  application pending for study on Sickle Cell Disease in the U S 
Though CRSP s potential therapies are still in the developmental stages and the company has yet to turn a profit  promising results in animal trials and joint ventures with Vertex Pharmaceuticals  NASDAQ VRTX   and Casebia Therapeutics have analysts turning more bullish on the potential of these technologies to one day turn into potential blockbuster drugs   CRSP is a Zacks Rank  1  Strong Buy  
Also focused on genetic therapies using the CRISPR Cas9 system   recently announced that its first cell therapy target will be acute myeloid leukemia and other potential hematological malignancies as well as solid tumors 
Intellia has a diversified strategy toward selecting disease targets using various types of genetic edits and using both in vivo and ex vivo delivery  insulating the company from the possibility of disappointing results in specific categories Intellia has partnered with  for in vivo delivery  specifically for liver disease and Novartis    for ex vivo delivery to treat various cancers 
Three analyst upward revisions in the past 30 days for both quarterly and 2018 earnings suggest increasing optimism about the future of NTLA s CRISPR therapies and the shares are up 34  in 2018  versus a return of  10  for the genetic therapies industry as a whole   NTLA is a Zacks Rank  3  Hold  
Cambridge  MA based  is a discovery phase company applying CRISPR Csa9 genetic therapies to the treatment of Leber Congenital Amaurosis   a degenerative and debilitating eye disease   
Results from non human primate trials were encouraging  with test subject tolerating the injected treatment and with immunity to bacterial infections not impacting the pharmacological activities of the drug    Immuno response destroying the active properties of the drugs is sometimes a concern with CRISPR Cas9 therapies  
Editas also has drugs in the pipeline to treat cancer  muscular dystrophy and cystic fibrosis 
The company is bolstered by a strong balance sheet with  329 million in cash and equivalents and has thus far retained commercial rights to all but one of it s pipeline programs  EDIT is a Zacks Rank  2  Buy  
Obviously  investing in development stage companies carries significant risk and should only be a small part of a diversified strategy  but for real home run potential  Genetic Editing is an extremely promising sector Wall Street s Next Amazon  NASDAQ AMZN  Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-05-24,Zacks Investment Research,https://www.investing.com/analysis/is-genome-editing-the-next-biotech-breakthrough-200319224,200319224
120581,342096,VRTX,Vertex Pharmaceuticals  VRTX  Down 1 2  Since Earnings Report  Can It Rebound ,opinion,"It has been about a month since the last earnings report for Vertex Pharmaceuticals Incorporated   NASDAQ VRTX    Shares have lost about 1 2  in that time frame 
Will the recent negative trend continue leading up to its next earnings release  or is VRTX due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts Vertex Q1 Earnings Beat on Strong CF Products SalesVertex reported first quarter 2018 earnings per share of 76 cents  which beat the Zacks Consensus Estimate of 58 cents and came ahead of the year ago earnings of 41 cents  Strong product revenues led to higher profits in the quarter Vertex reported revenues of  640 8 million in the first quarter  beating the Zacks Consensus Estimate of  617 6 million  However  sales were down 10 3  year over year due to significantly lower collaborative revenues The company had received an upfront payment of  230 million from Merck  NYSE MRK  KGaA in the year ago period for out licensing four oncology programs  which was missing in the first quarter of 2018 CF Franchise Sales StrongVertex s first quarter revenues consisted of sales from cystic fibrosis   CF   products  Kalydeco and Orkambi  collaborative   1 7 million  and royalty revenues   1 4 million   CF product revenues were  637 7 million in the first quarter  up 33  year over year  Continued label expansion of Kalydeco and Orkambi and launch of Symdeko pulled up CF sales in the quarter Kalydeco sales surged 34 4  to  250 million  following approvals to treat an expanded population Orkambi  lumacaftor ivacaftor  delivered sales of  354 million  up 20  year over year due to higher sales in the United States as well as international markets Symdeko contributed  34 million to the top line in the quarter which reflects the initial seven weeks of sales  On the call  the company said that Symdeko launch is off to a strong start in the United States while approval in the EU is expected in the second half  Costs RiseAdjusted research and development  R D  expenses increased 14 7  to  260 million in the first quarter due to higher costs related to phase III development of triple combination CF regimens  Adjusted selling  general and administrative  SG A  expenses increased 15 4  to  99 6 million mainly driven by worldwide investments to support its drugs  Kalydeco and Orkambi and costs incurred to prepare for the launch of Symdeko 2018 GuidanceVertex provided guidance for 2018 CF revenues in the range of  2 65 to  2 8 billion  The midpoint of this range represents approximately 26  growth over 2017 Combined adjusted research and development  R D  and selling  general and administrative  SG A  expense guidance for 2018 was maintained in the range of  1 50 to  1 55 billion The increase in operating expense reflects anticipated costs related to pivotal studies for the two triple combinations regimens and investment to support the launch of Symdeko The company is optimistic that operating margins and earnings will expand in 2018 as increase in revenues will exceed increase in costs 
How Have Estimates Been Moving Since Then 
It turns out  fresh estimates have trended upward during the past month  There have been seven revisions higher for the current quarter compared to two lower Vertex Pharmaceuticals Incorporated Price and Consensus    VGM Scores
At this time  VRTX has a strong Growth Score of A  though it is lagging a lot on the momentum front with a C  The stock was allocated a grade of D on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Our style scores indicate that the stock is more suitable for growth investors than momentum investors 
Outlook
Estimates have been broadly trending upward for the stock and the magnitude of these revisions looks promising  Notably  VRTX has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-05-28,Zacks Investment Research,https://www.investing.com/analysis/vertex-pharmaceuticals-vrtx-down-12-since-earnings-report-can-it-rebound-200319749,200319749
120605,342120,VRTX,Vertex s Third Cystic Fibrosis Treatment Gets FDA Approval,opinion,Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   announced that the FDA has granted approval to its cystic fibrosis  CF  corrector  tezacaftor  VX 661   in combination with ivacaftor  Kalydeco  under the brand name  Symdekotm  The combo therapy is approved to treat the underlying cause of CF in patients aged 12 years and above with certain mutations in the CF transmembrane conductance regulator gene This approval marks the company s third treatment for the underlying cause of CF  The company said that it is ready to launch the product in the U S  market this week  With this nod from the regulatory agency  Vertex can address a significantly larger CF patient population in the United States Notably  the combination regime is also under review in the EU with a decision expected in the second half of 2018 Vertex s share price has soared 73 2  in a year s time  comparing favorably with the  s decrease of 2 5   The aforementioned approval was supported by positive data from two phase III studies on tezacaftor ivacaftor combination  EVOLVE and EXPAND  Both trials met primary endpoints and demonstrated statistically significant improvements in lung function in two different CF patient population  The combination treatment was found to be well tolerated in both cases The company presently markets two CF drugs  Kalydeco and Orkambi  and also boasts a strong CF pipeline  Its broad portfolio of next generation CF correctors could bring in multi billion dollar sales for the company  if approved Notably  Vertex is evaluating some next generation CFTR correctors  VX 152  VX 440  VX 659 and VX 445  as part of a triple combination with tezacaftor and ivacaftor Data from VX 152 and VX 440 phase II and VX 659 phase I triple combination programs presented in July 2017 showed that all three combos led to a marked improvement in lung function  The company is also developing the fourth next generation corrector  VX 445  in a phase II study with data expected in early 2018 Meanwhile  the company is looking to buy CF candidates  which can be put together with tezacaftor and ivacaftor to create triple combinations  Last July  Vertex bought Concert Pharmaceuticals  Inc  s   NASDAQ CNCE   CF pipeline candidate  VX 561  CTP 656   The company is developing the candidate as a promising once daily triple combination compiled with other pipeline drugs to treat the underlying cause of CF We remind investors that the CF market represents huge commercial potential  It is a rare  life threatening disease estimated to affect about 75 000 people in North America  Europe and Australia  The CF combination regimens  if approved  can further strengthen the market position  translating into higher revenues Vertex Pharmaceuticals Incorporated Price    Zacks Rank   Key PicksVertex carries a Zacks Rank  3  Hold   Two better ranked stocks in the health care sector are XOMA Corporation   NASDAQ XOMA   and Exelixis  Inc    NASDAQ EXEL    While XOMA sports a Zacks Rank  1  Strong Buy   Exelixis carries a Zacks Rank  2  Buy   You can see  XOMA s loss per share estimates have narrowed from 99 cents to 42 cents for 2018 over the last 60 days  The company came up with an average beat of 47 92   The stock has skyrocketed 430  in the last 12 months Exelixis  earnings per share estimates have been revised upward from 72 cents to 77 cents for 2018 over the last 60 days  The company pulled off a positive surprise in all the trailing four quarters with an average beat of 572 92   Share price of the company has rallied 36 4  in a year s time The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-02-12,Zacks Investment Research,https://www.investing.com/analysis/vertexs-third-cystic-fibrosis-treatment-gets-fda-approval-200290084,200290084
120607,342122,VRTX,Biotech Stock Round Up  Celgene Suffers Setback  Gilead Teams Up With Sangamo,opinion,"Key highlights of the week include FDA s refusal to file letter for Celgene Corp  s   NASDAQ CELG   ozanimod  Gilead Sciences  Inc  s   NASDAQ GILD   collaboration with Sangamo Therapeutics  Inc  for using the latter s technology and positive CHMP opinion for Amgen Inc  s   NASDAQ AMGN   Xgeva  Incyte Corp    NASDAQ INCY   beat on revenues on strong Jakafi sales in fourth quarter 2017 
Recap of the Week s Most Important Stories
FDA Refuses Ozanimod NDA  Following the announcement of the receipt of a Refusal to File letter from the FDA regarding its New Drug Application   NDA   for multiple sclerosis candidate ozanimod  shares of Celgene are down in pre market trading  The candidate is being developed for the treatment of patients with relapsing forms of multiple sclerosis 
However  the FDA determined that the nonclinical and clinical pharmacology sections in the NDA were inadequate to allow a complete review  Hence  Celgene will request a Type A meeting with the FDA to ascertain the additional information needed for resubmission of the NDA 
The news comes as a great disappointment for investors as Celgene is taking desperate attempts to bolster its portfolio and reduce overdependence on lead drug  Revlimid  The company recently obtained antitrust clearance for its impending Juno acquisition  Celgene is a Zacks Rank  3  Hold  stock  You can see  
Gilead Collaborates with Sangamo  Gilead s Kite has entered into a collaboration agreement with Sangamo Therapeutics  Inc  Per the agreement  Kite will use Sangamo s ZFN technology to modify genes to develop next generation cell therapies for autologous and allogeneic use in oncology  In lieu  Sangamo will receive an upfront payment of  150 million and up to  3 01 billion in potential milestone payments 
Sangamo is also entitled to receive tiered royalties on sales of the potential future products resulting from the collaboration  On the other hand  Kite will be responsible for all development  manufacturing and commercialization of products under the collaboration  Sangamo shares skyrocketed to a high of  25 40 on the news of the collaboration as investors had lots to cheer for given Gilead s expertise in the biotech field 
CHMP Positive on Amgen s Xgeva Label Expansion  The Committee for Medicinal Products for Human Use   CHMP   of the European Medicines Agency has given a positive opinion to expand the current indication for Amgen s Xgeva to include skeletal related events in patients with multiple myeloma  Given the positive results of the phase III study   482  the candidate should get approval for the aforementioned indication 
The study results showed Xgeva successfully met the primary endpoint  demonstrating non inferiority to zoledronic acid in delaying the time to first on study skeletal related event in patients with multiple myeloma  The FDA already approved the company s Supplemental Biologics License Application for XGEVA to expand the currently approved indication for the prevention of skeletal related events in patients with bone metastases from solid tumors to include patients with multiple myeloma in January 2018 
Vertex Initiates Phase III Triple Combination Study for CF  Vertex Pharmaceuticals Inc    NASDAQ VRTX    a leader in cystic fibrosis   CF   market  announced the initiation of a phase III study  VX 659  tezacaftor and Kalydeco as an investigational triple combination regimen for patients suffering from CF who have one F508del mutation and one minimal function mutation  The study is being conducted to support the submission of a NDA in the United States using data from the four week primary efficacy endpoint together with safety data through 12 weeks of treatment 
Earlier in the month  the FDA approved Symdeko for the treatment of the underlying cause of CF in patients aged 12 or older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene or who have at least one mutation that is responsive to tezacaftor ivacaftor 
PerformanceMedical   Biomedical and Genetics Industry 5YR   Return
 


The NASDAQ Biotechnology Index gained 0 79  over the last five trading sessions  Among major biotech stocks  Vertex gained 3 04   Over the last six months  Regeneron lost 33 02  while Amgen gained 9 72   see the last biotech stock roundup here    
What s Next in the Biotech World 
Stay tuned for more regulatory and pipeline updates as we approach the last leg of this earnings season 
Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-02-28,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-round-up-celgene-suffers-setback-gilead-teams-up-with-sangamo-200295159,200295159
120608,342123,VRTX,Why Sarepta  SRPT  Jumped And We Sold,opinion,"Monday morning s news from Sarepta Therapeutics  SRPT  pushed shares to a 16 year high above  78 
The biotech company will file a new drug application  NDA  with the Food and Drug Administration by the end of the year seeking accelerated approval for its second drug  golodirsen  to treat Duchenne muscular dystrophy  DMD  
What is Duchenne Muscular Dystrophy DMD is a rare  inherited  muscle wasting disease that primarily attacks young boys whose genome doesn t properly produce the muscle protein dystrophin  Affected patients die in their mid 20s 
DMD affects 1 in every 3 500 newborn boys and very rarely it also affects girls  approximately 1 in 50 million girls   More boys have Duchenne because the gene that causes it   the dystrophin gene   is located on the X chromosome Sarepta already has commercial success with one DMD drug  EXONDYS 51  This produced 2017 revenues of  155 million  which are expected to nearly double this year for a drug whose average annual treatment cost starts at  300 000  but can be double that for larger boys because it is based on body weight 
Skipping the Genetic ErrorTo give you a better idea how rare and small this treatment population and market are  consider that EXONDYS 51 only treats 13  of the DMD population with that defect  And there are only about 5 000 DMD patients in the US Golodirsen is designed to treat patients whose DMD is caused by an error in the DNA sequence known as exon 53  The drug  administered via monthly infusions  works by  skipping  over that mutation and producing dystrophin  And only about 8 percent of the 5 000 DMD patients carry the exon 53 defect Cambridge  MA based Sarepta said the decision to seek a rapid approval of golodirsen was made after receiving a report last week that summarized a meeting with FDA officials held in February  This could result in accelerated approval in 2019  two years ahead of expectations But Adam Feuerstein  writing for STAT com  the watchdog journal of the life sciences and medicine  spoke with the CEO of Sarepta last night and sheds some interesting light on the situation  Below are some of his key notes in a column this morning   The  FDA  meeting  sought by Sarepta to seek regulatory guidance on golodirsen  could have been treacherous  In attendance on the FDA side were clinical reviewers who vehemently disagreed with the agency s top level decision in late 2016 to approve Exondys 51  Sarepta s first drug to treat DMD Among those once angry FDA officials  Ellis Unger  director of the Office of Drug Evaluation  who had called Exondys 51 an  elegant placebo  that should never have been approved But there was no residual hostility or hard feelings  including from Unger  during the February meeting  just a willingness to re establish a collaborative relationship with the company  said Sarepta CEO Doug Ingram  What we encountered were FDA people who were professional  productive  and helpful  They gave us straightforward  unequivocal guidance   said Ingram  who spoke with STAT on Sunday night   In exchange  I gave them my personal commitment that Sarepta will let golodirsen live or die by the data  We d be fully transparent  and we d be thoughtful about how we communicated with the agency and the public  
This is good news when so much of biotech investing land can be fraught with hazards where the incentives sometimes favor investor wealth over science and medical efficacy and safety 
But Feuerstein further explains the FDA gauntlet that lies ahead for golodirsen  First  the NDA won t be submitted until a long term safety study in animals in completed in Q4 
Second  Sarepta will still need to correlate research proving golodirsen generates dystrophin with real clinical outcomes like improved walking ability for patients Again  you can read the excellent Adam Feuerstein article in the link above Why We Sold SRPT From the Healthcare Innovators PortfolioLast week I wrote about several stocks making new highs in my Zacks Healthcare Innovators portfolio     bluebird bio  BLUE   Editas Medicine  EDIT   Edwards Lifesciences  NYSE EW   Vertex Pharmaceuticals  NASDAQ VRTX   Align Technology  ALGN   Intellia Therapeutics  NTLA  and Sarepta So why am I selling SRPT today if I just said last week that it wasn t  done yet  As with all public companies involved in complicated medical science  it s a full time job keeping up with the R D  Biotech is arguably the hardest investing field of all  even if you are a trained life sciences professional Since I don t have a degree in molecular biology  I have my homework cut out for me analyzing and keeping up with all the news  data  and FDA rulings And so after today s good news  I decided that we could take profits of 115  out of our Sarepta position and know that we captured the biggest chunk of risk reward available in the past year Here s what I told subscribers this morning   The gains have come quickly here as the company makes advances in clinical trials and  more importantly  with the FDA  But with the recent gains  we have quickly reached the point where lots of good news  and potential good news  is priced in to shares And that means the potential has risen for disappointments or delays to have an outsized affect on shares The bottom line for me is that the short to medium term risks outweigh the long term rewards for a stock that has so quickly realized its potential  Let s bag our  stock that doubled  and get ready for the next one CookerDisclosure  I own shares of ALGN  BLUE  EDIT  NTLA  EW  and VRTX for the  portfolio Kevin Cook is a Senior Stock Strategist for Zacks Investment Research where he runs the Healthcare Innovators service ",2018-03-12,Zacks Investment Research,https://www.investing.com/analysis/why-sarepta-srpt-jumped-and-we-sold-200297454,200297454
120613,342128,VRTX,Pharma M A Active This Week  4 Potential Buyout Targets,opinion,The current year began on widespread optimism  predicting a significant increase in drug biotech mergers and acquisitions  M A  activity  mainly buoyed by the new tax law enacted in December 2017 and purchasing newer technologies  The tax reform has lowered the tax rate and provided a low tax window to bring back huge cash stashed overseas  These will certainly improve the cash position of the companies and fuel M A activities amid struggling organic growth With a quarter of the year already gone by  we have seen quite a few billion dollar buyout deals being inked  For instance  Celgene Corporation  NASDAQ CELG  acquired  to add a CAR T therapy to its pipeline for approximately  9 billion  Moreover  the company is in process to complete the  of Impact Biomedicines for an upfront amount of  1 1 billion  Also  Sanofi  PA SASY  in a bid to strengthen its blood disorder pipeline purchased  for  11 6 billion and even offered to buy Belgian Biotech Company   for  4 8 billion Additionally  Pfizer  NYSE PFE  is aggressively on the lookout for a buyer for its Consumer Healthcare unit after British firms Glaxo and Reckitt Benckiser Group withdrew from discussions  However  Glaxo announced its acquisition of Novartis    NYSE NVS   stake in their healthcare joint venture for  13 billion  Meanwhile late last month  Takeda also  to integrate Dublin based Shire into its portfolio to boost its core therapeutic areas Moreover  this week bore news of a couple of more M A deals  A brief description of the two deals is as follows Novartis to Buy AveXisNovartis inked a deal to acquire the U S  based clinical stage gene therapy company  AveXis  Inc   NASDAQ AVXS    to boost its presence in gene therapy and neuroscience space AveXis  lead gene therapy candidate  AVXS 101  is being developed to treat spinal muscular atrophy   SMA    a neurodegenerative disease  accounting for the highest genetic cause of death in infants  The only approved treatment for SMA is the Biogen s Spinraza Per the agreement  Novartis will close the acquisition in an all cash deal of  8 7 billion  The company proposed a cash tender offer of  218 per share for AveXis  common stock  The deal is expected to culminate in the second half of 2018   Read more   Alexion Wilson DealAlexion Pharmaceuticals  Inc    NASDAQ ALXN   announced that it will consolidate Sweden based Wilson Therapeutics in its portfolio to add a late stage candidate to its pipeline for the treatment of Wilson disease  a rare genetic disorder  The acquisition is line with the company s strategy to diversify its portfolio and lower its dependence on its blockbuster drug  Soliris Alexion has offered 232 Swedish Krona in cash for each outstanding share of Wilson Therapeutics  which translates into a total transaction value of  855 million  The buyout is expected to get wrapped up this quarter   Read more   In this article  we suggest three drug biotech companies as logical acquisition targets this year  The parameters counting for buying a drug biotech stock are the current sales performance of its drugs products  prospects of future sales growth and the quality of the company s pipeline  Takeovers of small cap drug biotech companies are very difficult to forecast and are quite frequent in the said space  Hence  these have been excluded from the discussion Agios Pharmaceuticals  Inc    NASDAQ AGIO  Agios Pharmaceuticals  share price is witnessed to rally this week on speculations that the company might be bought by other big players in the pharma and biotech industry The company received an FDA approval for Idhifa  enasidenib  in August 2017 for treatment of acute myeloid leukemia   AML   with IDH2 mutation  lending a huge boost to its immense commercial potential in the target market  Agios  ivosidenib is under review in the United States as a therapy for relapsed refractory AML with IDH1 mutation  The candidate is also being developed for addressing advanced hematologic malignancies Agios  pipeline also includes a mid stage genetic diseases candidate  A consistent progress with its investigational candidates makes the company one of the most lucrative takeover options for other large players in the drug biotech space at the moment   Read more   Agios carries a Zacks Rank  3  Hold  You can see  BioMarin Pharmaceutical Inc    NASDAQ BMRN  Companies with product pipeline portfolios comprising rare disease drugs are in great demand as there is less competition in the concerned space and the expensive treatments can garner huge profits  BioMarin is one such drug developer with a market cap of around  15 billion BioMarin s key orphan disease drugs  Vimizim and Kuvan  are doing well  backed by strong underlying patient demand trends  Also  another orphan drug Brineura s earlier than expected approval this year for the treatment of children with CLN2 disease is likely to be a huge boost to BioMarin  A potential approval for pegvaliase is expected next month BioMarin has already been a target of takeover speculation  Companies like Gilead  Amgen  NASDAQ AMGN  and Roche might be interested in buying BioMarin BioMarin carries a Zacks Rank  3 Vertex Pharmaceuticals  Inc    NASDAQ VRTX  For Vertex  a consistent expansion in patient population raised revenues quarter to quarter throughout 2017  Moreover  the approval to its third cystic fibrosis   CF   drug  Symdeko  tezacaftor ivacaftor combination   will further drive the company s sales  The company is hopeful that a positive trend of CF sales will continue in 2018 as it gains additional reimbursement approvals for Orkambi in the ex U S  marketsMeanwhile  the company is focused on triple combination therapies for treating CF  which will further expand its patient population  The market cap of Vertex is more than  40 billion Vertex carries a Zacks Rank  3 Incyte Corporation  NASDAQ INCY  Incyte s strong oncology portfolio makes it an attractive pick for companies  namely Gilead  Amgen and Bristol Myers  Incyte s market cap is also around  15 billion The primary reason why Incyte is ready for buyout is because of the encouraging performance of its two marketed products such as  Jakafi and Iclusig  Jakafi is seeing a strong sales performance  driven by solid patient demand in the approved indications The company is also working on its further label expansion  Meanwhile  Incyte s pipeline boasts candidates like immune therapy epacadostat  which is being studied in combination with other drugs for the cure of cancer and rheumatoid arthritis Incyte carries a Zacks Rank  3 Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-04-12,Zacks Investment Research,https://www.investing.com/analysis/pharma-ma-active-this-week-4-potential-buyout-targets-200305339,200305339
120630,342145,VRTX,Amgen Gets FDA Nod To Add ENDEAVOR Data On Kyprolis Label ,opinion,Amgen  Inc    NASDAQ AMGN   announced that the FDA has approved its regulatory application to include overall survival  OS  data from the head to head ENDEAVOR study on the label of its multiple myeloma drug  Kyprolis  Please note that the FDA s decision comes much earlier than expected  It was initially expected in April Amgen had submitted the supplemental New Drug Application  sNDA  to the FDA in July last year  The regulatory application in the EU seeking approval to include OS data from ENDEAVOR study was also submitted in the same month Data presented from the ENDEAVOR study earlier had demonstrated that a combination of Kyprolis plus dexamethasone led to superior overall survival when compared to Takeda s Velcade plus dexamethasone in second line multiple myeloma setting  The Kyprolis plus dexamethasone arm reduced the risk of death by 21  and increased OS by 7 6 months compared to the combination of Velcade plus dexamethasone While Kyprolis is already approved for this patient population  the overall survival data should help drive usage and boost sales Other ongoing studies for Kyprolisinclude a phase III ARROW study  which is evaluating a weekly dosing regimen of Kyprolis in relapsed and refractory multiple myeloma patients and a phase III ASPIRE study evaluating a triple combination regimen of Kyprolis plus Celgene s   NASDAQ CELG   Revlimid  lenalidomide  and dexamethasone  KRd  in patients with relapsed multiple myeloma compared to Revlimid and dexamethasone  Rd  Amgen has also formed collaboration with J J   NYSE JNJ   to study the combination of Kyprolis and J J s Darzalex in multiple clinical studies for the treatment of multiple myeloma Kyprolis generated sales of  207 million in the third quarter of 2017  recording year over year growth of 13  driven by higher demand and robust uptake from outside U S  markets Shares of Amgen were up more than 1  on Wednesday  In the past year  Amgen s shares have returned 22 2   compared with 3 8  increase registered by the  Amgen carries a Zacks Rank  3  Hold  A better ranked biotech stock is Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   with a Zacks Rank  1  Strong Buy   You can see   Vertex s stock has returned 90 2  in the past year while earnings estimates for 2018 have gone up by almost 2 8  in the past 30 days Zacks Top 10 Stocks for 2018In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2018 Last year s 2017 Zacks Top 10 Stocks portfolio produced double digit winners  including FMC Corp  NYSE FMC   and VMware which racked up stellar gains of  67 9  and  61   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ,2018-01-18,Zacks Investment Research,https://www.investing.com/analysis/amgen-gets-fda-nod-to-add-endeavor-data-on-kyprolis-label-200281505,200281505
120637,342152,VRTX,What s In The Cards For Novartis  NVS  This Earnings Season  ,opinion,Novartis AG   NYSE NVS   is scheduled to report fourth quarter 2017 results on Jan 24  2018  The Swiss pharmaceutical company s stock has rallied 3 2  in the last six months compared with the   s 10 4  gain Novartis has an excellent track record  In the last quarter  Novartis delivered a positive earnings surprise of 3 2   The company posted an average positive earnings surprise of 3 25  in the trailing four quarters  Let s see how things are shaping up for this announcement Factors at PlayConcurrent with the third quarter results  Novartis reiterated its annual guidance  Net sales are expected to be in line with the 2016 levels after including the impact of continued genericization of Gleevec Glivec in the United States and Europe Novartis operates under three segments  Innovative Medicines  Pharmaceuticals   Alcon and Sandoz  Generics   Novartis has a strong oncology portfolio of drugs like Afinitor  Exjade  Jakavi  Zykadia  Tasigna  Jadenu  and Kisqali  The recent approval of Kymriah for acute lymphoblastic leukemia is a major boost for Novartis  given the potential in the CAR T therapy space  Sales from this division are expected to grow marginally New products like Cosentyx and Entresto are expected to boost the top line  Cosentyx has been strong and the company has grabbed market shares from rivals like AbbVie  Inc  s   NYSE ABBV   Humira and Amgen  Inc s   NASDAQ AMGN   Enbrel  Cosentyx achieved the blockbuster status in 2016 and recorded over  1 billion of sales  While Entresto is expected to record  500 million revenues  sales of Cosentyx are projected to reach  2 billion in 2017 Additionally  Novartis  generic arm  Sandoz  is making efforts to strengthen its biosimilars portfolio  The company plans to launch five biosimilars of major oncology and immunology biologics across key geographies by 2020  The company is  however  facing significant pricing pressures which might impact the fourth quarter results  The company now expects sales to decline or broadly in line Meanwhile  the loss of exclusivity of some of the key drugs in Novartis  portfolio will continue to hurt the company s top line   The company s blockbuster drug  Diovan  is facing stiff generic competition in the United States  the EU and Japan  Gleevec lost exclusivity in the United States in February 2016 and in the EU in December 2016  thereby leading to generic competition  Exforge is also facing generic competition in the United States and the EU  Further  the oncology drugs are facing new competition in the form of immuno oncology therapies  The negative impact of generic competition is expected to impact sales by  2 5 billion The performance of the ophthalmology division  Alcon business was weak due to competition faced by intraocular lens and a slowdown in demand for equipment purchases  Consequently  Novartis took a few steps to revive the business  The turnaround has been encouraging and management believes creating a standalone company via a capital markets exit could create additional shareholder value  A decision is expected in the first half of 2019  depending on Alcon s performance in the future Earnings WhispersOur proven model does not conclusively show that Novartis will beat on earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  Unfortunately  that is not the case here  as you will see below Zacks ESP  Earnings ESP for Novartis is 0 00    This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at  1 16  You can uncover the best stocks to buy or sell before they re reported with our   Zacks Rank  Novartis currently carries a Zacks Rank  3  Although the rank is favorable  the company s 0 00  ESP makes surprise prediction difficult Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stock to ConsiderHere is one stock in the healthcare sector that you may want to consider  as our model shows that it has the right combination of elements to post earnings beat this quarter Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   has an Earnings ESP of  6 90  and a Zacks Rank  1  The company is scheduled to release fourth quarter results on Jan 31      The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-01-21,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-novartis-nvs-this-earnings-season-200282358,200282358
120638,342153,VRTX,Celgene  CELG  Q4 Preview  Will It Beat On Earnings Again ,opinion,"Celgene Corporation   NASDAQ CELG   is scheduled to report fourth quarter 2017 results on Jan 25  before the opening bell 

Celgene s stock has tumbled 9 3  in the last year compared with the  s gain of 7 4  
Celgene has an excellent track record with the company beating earnings estimates in the last four trailing quarters  Last quarter  the company topped estimates by 1 6   Overall  the company has delivered an average positive surprise of 2 5  
Why a Likely Positive Surprise 
Our proven model shows that Celgene is likely to beat on earnings estimates this quarter  This is because it has the right combination of two key ingredients  a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  
Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  0 94   You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Celgene currently carries a Zacks Rank  3  The combination of Zacks Rank  3 and a positive ESP makes us confident of an earnings beat 
Conversely  Sell rated stocks  Zacks Rank  4 or 5  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions 
Revlimid to Drive Growth
Earlier in the month  Celgene released preliminary results for 2017  The company expects earnings per share  EPS  of around  7 44 in 2017  up 25  year over year  Operating margin is anticipated around 58 1   For the fourth quarter  EPS is anticipated to be around  2 00  a 24  increase year over year  Operating margin is expected to be around 55 3   The Zacks Consensus Estimate for earnings in the fourth quarter is  1 94 and  7 37 for 2017 
Total revenues are expected around  3 5 billion in fourth quarter 2017 and  13 0 billion in 2017  The Zacks Consensus Estimate for revenues is  3 50 billion for the fourth quarter and  13 billion for 2017  Revlimid revenues are expected around  2 2 billion in the fourth quarter and  8 2 billion for 2017 
Revlimid  an oral immunomodulatory drug  is currently approved for several indications including MM  myelodysplastic syndromes and mantle cell lymphoma  The drug performed well in the first nine months of 2017 and combated the challenges of uneven buying patterns and coverage gap  Market share gains in key markets and longer treatment duration are contributing to the drug s growth 
Continued momentum in the core indication  label expansion and global launches should help the product to keep contributing to the top line  The Zacks Consensus estimate for Revlimid currently stands at  2 2 billion for the fourth quarter 
Pomalyst revenues are expected around  442 million and  1 6 billion in 2017  Pomalyst Imnovid is being evaluated in multiple combination studies in relapsed refractory MM  The drug s label was updated in the United States and the Europe to include data from a pooled pharmacokinetics analysis of patients with relapsed and or refractory MM and impaired renal function which should boost sales 
Otezla revenues are expected around  371 million in the fourth quarter and  1 3 billion in 2017  The deep and persistent slowing growth of the psoriatic arthritis and psoriasis markets  especially during the entire third quarter led to weak performance of Otezla in the quarter which should impact sales in the fourth quarter also  Abraxane revenues are around  251 million in the fourth quarter and  992 million in 2017 
Meanwhile  the approval of Idhifa for the treatment of adult patients with relapsed or refractory AML  R R AML  will further boost Celgene s portfolio  The drug was developed in collaboration with Agios Pharmaceuticals   NASDAQ AGIO   
Celgene is on the look out of new deals and acquisitions given the recent setbacks   In January 2018  Celgene announced it will acquire Impact Biomedicines  The company recently announced that it will acquire smaller biotech Juno Therapeutics   NASDAQ JUNO   whose pipeline includes CD19 and CD22 directed CAR T cell product candidates for  9 billion 
During fourth quarter earnings call investors are expected to remain focused on the company s performance and label expansion efforts  along with updates on recent acquisitions 
Stock to Consider
Here is one stock in the healthcare sector that you may want to consider  as our model shows that it has the right combination of elements to beat on earnings this quarter 
Vertex Pharmaceuticals Inc    NASDAQ VRTX   has an Earnings ESP of  6 90  and a Zacks Rank  1  The company is scheduled to release fourth quarter results on Jan 31  You can see      
The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-01-22,Zacks Investment Research,https://www.investing.com/analysis/celgene-celg-q4-preview-will-it-beat-on-earnings-again-200282446,200282446
120639,342154,VRTX,Vertex  VRTX  Stock Up 70  In A Year s Time  Here s Why,opinion,"Vertex Pharmaceuticals  Inc    NASDAQ VRTX   shares are up 70 1  in the past year  comparing favorably with an increase of 9 6  for the  The company presently markets two cystic fibrosis   CF   drugs   Kalydeco and Orkambi   and also boasts a strong CF pipeline Its broad portfolio of next generation CF correctors  which could bring in multi billion dollar sales for the company if approved  has been attracting investor attention For Vertex  2017 was a tremendous year with positive data read outs and regulatory approvals leading to an increase in the eligible patient population for Kalydeco   Orkambi In May 2017  Kalydeco gained FDA approval for use in patients 2 yearsand older who have one of 23 residual function mutations in the CFTR gene  More than 900 people in the United States have one of these mutations  In August 2017  Vertex received FDA approval for use in more than 600 additional people who have mutations responsive to Kalydeco  including one of five  splice  mutations  These line extensions have expanded the eligible patient population to treat with Kalydeco to 6000 and boosted the drug s salesMeanwhile  in January 2018  Kalydeco showed improvement across multiple endpoints  including measures of pancreatic function in a phase III study in children less than two years of age  Based on this data  Vertex plans to file regulatory applications for approval of Kalydeco in children aged 1 to 2 years in the first quarter of 2018 Moreover  Vertex is also focused on increasing patient access for Orkambi by signing reimbursement agreement in several countries  Meanwhile  the European Commission has approved a line extension for Orkambi this month to include use in children with CF aged between six and 11 years and have two copies of the F508del mutation  This line extension is expected to expand the targeted patient population by about 3 400 patients Vertex is evaluating CF corrector tezacaftor  VX 661  in combination with ivacaftor  In March 2017  Vertex announced positive data from two phase III studies on VX 661   EVOLVE and EXPAND  Both studies met their primary endpoints and demonstrated statistically significant improvements in lung function in two different CF patient population  Based on positive outcome from the studies  regulatory application is under review in the United States  with a decision expected next month Moreover  Vertex is also evaluating some next generation CFTR correctors  VX 152  VX 440  VX 659 and VX 445  as part of a triple combination with tezacaftor and ivacaftor Data from VX 152 and VX 440 phase II and VX 659 phase I triple combination studies presented in July 2017 showed that all three combinations led to pronounced improvement in lung function  The company is also developing fourth next generation corrector  VX 445 in a phase II study  with data expected in early 2018 Successful data readout will further boost the stock Meanwhile  the company is also looking to buy CF candidates  which can be combined with tezacaftor and Kalydeco to create triple combinations  In July 2017  Vertex bought Concert Pharmaceuticals  Inc  s   NASDAQ CNCE   CF pipeline candidate  VX 561  CTP 656   Vertex is developing the candidateas a potential once daily triple combination in combination with its other pipeline drugs to treat the underlying cause of CF We remind investors that the CF market represents huge commercial potential  It is a rare  life threatening disease estimated to affect about 75 000 people in North America  Europe and Australia  The CF combination regimens  if approved  can strengthen its position further in this market  which can translate into higher revenues Vertex Pharmaceuticals Incorporated Price
    Zacks Rank   Stocks to ConsiderVertex carries a Zacks Rank  3  Hold   Better ranked stocks in the sector include Exelixis  Inc    NASDAQ EXEL   and Bioverativ Inc   NASDAQ BIVV    both sporting a Zacks Rank  1  Strong Buy   You can see  Exelixis  earnings per share estimates have remained stable at 49 cents for 2017 and increased from 72 cents to 73 cents for 2018 over the last 60 days  The company delivered positive earnings surprises in all four trailing quarters with an average beat of 572 92  Bioverativ s earnings estimates have increased from  3 08 to  3 21 for 2017 and from  3 39 to  4 04 for 2018 over the last 60 days  The company delivered positive earnings surprises in three of the four trailing quarters with an average beat of 17 09  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-01-24,Zacks Investment Research,https://www.investing.com/analysis/vertex-vrtx-stock-up-70-in-a-years-time-heres-why-200283645,200283645
120642,342157,VRTX,Drug Biotech Stocks Q4 Earnings Due On Jan 31  LLY   VRTX,opinion,"The fourth quarter 2017 earnings season is in full swing with financial figures from 133 S P 500 members or 26  of the index already out as of Jan 26  2018 per the latest  Total earnings for these index members jumped 12 3  from the year ago quarter  driven by 8 8  improvement in revenues  The beat ratio was 81 2  for the bottom line and 78 9  for the top line On a positive note  the ongoing earnings phase seems to have begun well for the Drug Biotech sector  Among major large cap players  Johnson   Johnson   NYSE JNJ   kicked off the season with earnings beating estimates while sales slightly missing the same  A few other large pharma companies released their earnings results last week and the picture looks quite encouraging 
The pharma bigwigs having reported last week are Novartis   NYSE NVS   and AbbVie   NYSE ABBV    which surpassed both earnings and sales estimates in the quarter under review  While Novartis raised its sales guidance for 2018  AbbVie increased its previously issued earnings expectations for the year Of the major players in the biotech sector  Biogen   NASDAQ BIIB   announced a mixed performance in the reported period with earnings lagging estimates while sales exceeding the same  However  Celgene Corp    NASDAQ CELG   outpaced both the metrics  expectations during the fourth  stocks remained on a growth trajectory in 2017  courtesy of a slew of FDA approvals  rise in demand for new product sales  successful innovation and product line expansion  strong clinical reports as well as a continued robust performance of legacy products  Moreover  these impressive factors  along with regular acquisitions  are expected to drive the sector s growth in 2018 as well Also  per the Earnings Preview  the broader Medical sector  inclusive of drug  biotech as well as Medical Device companies  is likely to record 4 9  year over year growth in revenues and a 4 2  rise in earnings in the period under discussion Two pharma biotech giants are scheduled to report earnings numbers on Jan 31  Let s see how things are shaping up for the companies in the upcoming releases Eli Lilly and Company   NYSE LLY  Lilly is scheduled to release fourth quarter earnings before the market opens  The company delivered a positive surprise of 1 94  last quarter  Lilly s earnings performance has been modest with earnings missing expectations in three of the last four quarters while beating the same in the remaining one  thus bringing the average beat to 1 68  Our proven model shows that Lilly is likely to beat on earnings this quarter  The combination of Lilly s Zacks Rank  3  which increases the predictive power of ESP as a solid Zacks Rank  and a positive  of  0 47  makes us confident about an earnings beat in the impending report  The Zacks Consensus Estimate for the quarter to be reported is pegged at  1 08 per share You can uncover the best stocks to buy or sell before they re reported with our  
We expect a sturdy uptake of new products like Trulicity  Taltz  Basaglar  Cyramza  Jardiance and Lartruvo  This upside is likely to make up for the decline in sales of established products like Zyprexa  Alimta  Cialis  Strattera and Effient in the fourth quarter   Read More    Vertex Pharmaceuticals  Inc    NASDAQ VRTX  Vertex is slated to release fourth quarter earnings after the market closes  The company s track record has also been impressive so far  It delivered a positive surprise in each of the trailing four quarters with an average beat of 32 67   In third quarter 2017  Vertex came up with a positive surprise of 43 24  However  our proven model does not conclusively show that Vertex is likely to beat on earnings this quarter  Though the company s favorable Zacks Rank  3  Hold  increases the predictive power of ESP  its Earnings ESP of  4 00  leaves surprise prediction inconclusive  The Zacks Consensus Estimate is pegged at 58 cents per share  You can see  Vertex s cystic fibrosis  CF  drugs  Kalydeco   Orkambi  performed consistently in the first three quarters of 2017  We expect this uptrend to be reflected in the results of the soon to be reported quarter   Read More    Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks  has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ",2018-01-30,Zacks Investment Research,https://www.investing.com/analysis/drugbiotech-stocks-q4-earnings-due-on-jan-31-lly--vrtx-200285168,200285168
120645,342160,VRTX,Vertex  VRTX  Q4 Earnings Beat On Strong CF Products Sales,opinion,"Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   reported fourth quarter 2017 earnings per share of 61 cents  which beat the Zacks Consensus Estimate of 58 cents and came ahead of the year ago earnings of 35 cents  Strong product revenues led to higher profits in the quarter and lower operating expense ratio year over year Vertex reported revenues of  651 6 million in the fourth quarter  up almost 42  year over year driven by strong product revenues  Revenues also beat the Zacks Consensus Estimate of  596 13 million Fourth Quarter Sales StrongVertex s fourth quarter revenues consisted of sales from cystic fibrosis   CF   products   Kalydeco and Orkambi  collaborative   29 1 million  and royalty revenues   1 3 million   CF product revenues were  621 2 million in the fourth quarter  up 37  year over year Kalydeco sales surged 44  to  256 million following approvals to treat an expanded population In May 2017  Kalydeco was approved for use in CF patients 2 years and older who have one of 23 residual function mutations in the CFTR gene  In August 2017  Kalydeco was approved in CF patients  2 years and older  who have one of five residual function mutations that result in a splicing defect in the CFTR gene  These line extensions increased the eligible patient population for Kalydeco Orkambi  lumacaftor ivacaftor  delivered sales of  365 million  up 32  year over year  The growth was supported by continued uptake globally  especially in pediatric patients in the United States Costs RiseAdjusted research and development  R D  expenses increased 20 3  to  249 2 million in the fourth quarter due to higher costs related to development of triple combination CF regimens  Adjusted selling  general and administrative  SG A  expenses increased 20  to  105 5 million 2017 ResultsVertex s full year revenues increased 46 2  year over year to  2 49 billion mainly driven by upfront payment of  315 2 million earned from Germany based Merck  NYSE MRK  KGaA  and strong CF portfolio sales  The upfront payment was part of a collaboration agreement per which Vertex out licensed four oncology programs to Merck KGaA  Adjusted earnings for 2017 were up 129  year over year to  1 95 per share Adjusted R D expenses increased 10 8  year over year to  1 33 billion  However  it excluded an upfront payment of  160 million related to acquisition of a CFTR potentiator  VX 561  from Concert Pharmaceuticals  Inc    NASDAQ CNCE    Adjusted SG A expenses increased 9  year over year to  375 3 million  which included costs related to the potential launch of tezacaftor ivacaftor combination in the United States  The increase was also due to increased investment to support the global commercialization of Orkambi and Kalydeco Stock Repurchase ProgramConcurrent with the earnings release  Vertex announced that the board has authorized a share repurchase program to buy back its common stock to the tune of  500 million in 2018 and 2019 2018 GuidanceVertex provided 2018 guidance for combined operating costs Combined adjusted research and development  R D  and selling  general and administrative  SG A  expenses in 2018 are anticipated in the range of  1 50 to  1 55 billion The increase in operating expense reflects anticipated costs related to development and commercialization of triple combinations for treating CF and planned launch of tezacaftor ivacaftor combination Pipeline   Regulatory UpdatesIn December 2017  Vertex announced data from phase III study   ARRIVAL   evaluating Kalydeco in children  age 1 2 years who have one of 10 mutations in the CFTR gene  It showed improvement across multiple endpoints  including measures of pancreatic function  Based on this data  Vertex plans to file regulatory applications for approval of Kalydeco in children aged one to two years in the first quarter of 2018 In January 2018  the European Commission approved a line extension for Orkambi to include use in children with CF aged between six and 11 years and have two copies of the F508del mutation  The approval increases the targeted patient population by about 3 400 patients  The company has plans to file regulatory applications for approval of Orkambi in children aged two to five with CF who have two copies of the F508del mutation in the first quarter of 2018 Vertex is also seeking approval for a combination of tezacaftor and Kalydeco  ivacaftor  in CF patients aged 12 and older who have two copies of the F508del mutation or who have at least one residual function mutation  Regulatory applications are under review in the United States and Europe  A decision is expected in the United States on Feb 28  2018 and in Europe in the second half of 2018 The company is also developing triple combination regimens for treating CF  which are capable of treating almost 90  of patients  Vertex has selected two out of four next generation correctors   VX 659 and VX 445   for advancing into two separate phase III triple combination studies  The candidates will evaluated in combination with tezacaftor and Kalydeco Apart from CF  Vertex is also developing treatments for sickle cell disease  thalassemia  influenza and pain management  During the fourth quarter  the company initiated a phase III study on pimodivir in combination with standard of care treatment in patients with influenza  This study is being conducted in collaboration with Janssen Pharmaceuticals  a subsidiary of Johnson   Johnson   NYSE JNJ   Our TakeVertex s fourth quarter results reflect strong performance of the CF products  The company beat estimates on both counts as sales of its CF drugs rose Shares rose over 6  in after hours trading in response to the strong quarterly results  In the past year  Vertex s share price has increased a massive 100 9   comparing favorably with an increase of 6 8  for the  Vertex s CF pipeline is quite strong with a broad portfolio of next generation CF correctors  Its triple combination CF regimens are considered crucial for long term growth  If the triple combo regimes are successful  Vertex can address a significantly larger CF patient population   almost 90  of the patients   in the future  However  competition is increasing as several major companies are expressing interest in CF Vertex carries a Zacks Rank  3  Hold   You can see  Vertex Pharmaceuticals Incorporated Price  Consensus and EPS Surprise
    Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-01-31,Zacks Investment Research,https://www.investing.com/analysis/vertex-vrtx-q4-earnings-beat-on-strong-cf-products-sales-200286131,200286131
120667,342182,VRTX,Value Biotech ETFs To Buy Now,opinion,"The biotech sector has had a great year  with SPDR S P Biotech  MX XBI  ETF  adding over 39   as of Dec 11  2017   Ebbing tensions over the price gouging issue  hopes of easing regulation  positive clinical trials  FDA approvals of drugs and success in the immune oncology field led to this rally 
One of the top performers in the space Virtus LifeSci Biotech Clinical Trials ETF   HM BBC    is up about 50 8  in the year to date frame  as of Dec 11  2017   However  a steep price rise results in overvaluation concerns  Many may fear high beta sell off in the space next year 
Below we highlight a few factors that could power the rally 
Likely Tax Reform
With the tax reform a few hurdles away from enactment  there is a reason to cheer for biotech stocks  The reforms seek to lower the corporate tax rate from 35  to 20   which can boost drug biotech companies  The change in tax code will also permit companies to bring back huge cash held overseas at a   read    
Upbeat Clinical Trials   FDA Approvals
Successful clinical trials for new drugs are also acting as tailwinds for the space  Notable improvement was noted in cancer drug data  Clovis Oncology   NASDAQ CLVS   said in June that the clinical trial data on its ovarian cancer drug treatment indicated that it may substantially help more patients than expected  The news acted as a catalyst to the entire space  read    
This month  impressive clinical data on  were released  Among breakthrough U S  Food and Drug Administration  FDA  approvals  Vertex Pharmaceuticals    NASDAQ VRTX   new FDA approval for cystic fibrosis drug and the Novartis AG breakthrough gene transfer treatment were notable 
Merger and Acquisitions to Perk Up 
Tax reform and cash repatriation may lead to a rise in biotech merger and acquisitions  In any case  mergers and acquisitions over the last few years have been great for biotech companies to reduce competition for the same kind of offerings and attain synergies  Tax reform should leave companies with more cash to pursue their dream deals  Expectations are rife  Sanofi  PA SASY   Pfizer  NYSE PFE  and Merck  NYSE MRK  will announce M A deals in 2018 
ETFs to Tap 
That said  we would like to note that overvaluation may come in the way of the rally  So  it s better to bet on ETFs that still have low valuation  For that  below we highlight a few biotech ETFs that have considerably a low P E in the sector and can benefit investors with solid gains   here  
SPDR S P Biotech ETF    P E 16 41x
VanEck Vectors Biotech ETF   LON BBH     P E 18 14x
Loncar Cancer Immunotherapy ETF    P E 20 01x
iShares Nasdaq Biotechnology ETF    P E 21 98x
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2017-12-13,Zacks Investment Research,https://www.investing.com/analysis/value-biotech-etfs-to-buy-now-200272993,200272993
120668,342183,VRTX,Galapagos Reports Topline Data From Osteoarthritis Study,opinion,"Galapagos NV   NASDAQ GLPG   announced positive top line data from phase Ib study evaluating its osteoarthritis   OA   candidate  GLPG1972  The candidate reduced the level of ARGS neoepitope  a cartilage breakdown biomarker  by more than half in its highest dosage Shares of the company have risen 43 1  in the past year  outperforming the  s decline of 1 7  in that period The phase Ib study evaluated three doses of GLPG1972 versus placebo over a period of four weeks  GLPG1972 reduced level of ARGS neoepitope by 38 4   44 9    50 4  for low  medium and high dose  respectively  compared to 3 6  for placebo GLPG1972 works by targeting ADAMTS 5  a cartilage degrading enzyme Meanwhile  Galapagos is working on designing the phase II program to further evaluate the candidate in OA  The study is expected to start by the end of this year Apart from GLPG1972  Galapagos is also developing another candidate  filgotinib in Sjogren s syndrome  non infectious uveitis  ankylosing spondylitis  and psoriatic arthritis  The company has a global collaboration with Gilead Sciences  Inc    NASDAQ GILD   for the development and commercialization of filgotinib in inflammatory indications Moreover  Galapagos is developing GLPG2222 in cystic fibrosis   CF   patients who are on long term stable treatment with Vertex Pharmaceuticals Incorporated s   NASDAQ VRTX   CF drug  Kalydeco  In November last year  Galapagos announced positive top line data from a phase II study  demonstrating an improvement of 2 2  in lung function compared to baseline The company has three CF candidate including GLPG2222  which are being developed in partnership with AbbVie Inc    NYSE ABBV   Galapagos NV Price
    Galapagos carries a Zacks Rank  3  Hold   You can see  5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-01-07,Zacks Investment Research,https://www.investing.com/analysis/galapagos-reports-topline-data-from-osteoarthritis-study-200278499,200278499
120669,342184,VRTX,Amgen s  AMGN  Xgeva Gets FDA Approval For Multiple Myeloma ,opinion,"Amgen  Inc    NASDAQ AMGN   announced that the FDA has approved its supplemental Biologics License Application  sBLA  to expand the label of its key drug  Xgeva 
Xgeva is currently approved for the prevention of skeletal related events  SREs  in solid tumors in patients with bone metastases  With the latest FDA approval  the label of Xgeva will be expanded to include patients with multiple myeloma 
The FDA decision comes earlier than the PDUFA date of Feb 2  2018  A similar regulatory application is also under review in the EU 
In the past year  Amgen s shares have returned 13 8  in contrast to 1 7  decrease registered by the  

The FDA approval was based on safety and efficacy from the pivotal phase III  482 study  which enrolled 1 718 patients  The head to head study  which compared Xgeva to Novartis AG s   NYSE NVS   Zometa  zoledronic acid   met the primary endpoint of non inferiority of the drugs in delaying the time to first on study SRE in patients with multiple myeloma 
Bone complications in patients with multiple myeloma can be quite damaging  Until now  bisphosphonates were the only treatment option available for bone protection in multiple myeloma patients  However  bisphosphonates may cause renal toxicity and lead to renal impairment  Xgeva  which is not cleared through the kidneys  offers a better treatment option for such patients 
Xgeva is key revenue driver for Amgen and generated revenues of  1 18 billion in the first nine months of 2017  up 3  year over year  We expect approval for the expanded patient population to help in further boosting sales of the drug 
Amgen carries a Zacks Rank  3  Hold  
Better ranked biotech stocks are Vertex Pharmaceuticals Inc    NASDAQ VRTX   and Exelixis  Inc    NASDAQ EXEL    both with a Zacks Rank  1  Strong Buy   You can see    
Vertex s stock has returned 87 9  in the past year while earnings estimates for 2018 have gone up by almost 3  in the past 30 days 
Earnings estimates for Exelixis have moved north by 1 4  in the past 30 days while the stock price has increased 79 9  in the past year 
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia and other conditions 
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-01-08,Zacks Investment Research,https://www.investing.com/analysis/amgens-amgn-xgeva-gets-fda-approval-for-multiple-myeloma-200278474,200278474
120670,342185,VRTX,Vertex s Cystic Fibrosis Drug Ok d For Pediatric Use In EU,opinion,Vertex Pharmaceuticals  Inc   NASDAQ VRTX   announced that the European Commission has approved an extension of the marketing application for its cystic fibrosis product  Orkambi  With the approval  Orkambi s marketing label in EU will now include use in children with CF aged between six and 11 years and have two copies of the F508del mutation The label expansion approval in EU was based on positive data from asix month phase III efficacy study in this patient population  Data from the study  presented in November 2016  demonstrated that treatment with Orkambi led to a statistically significant improvement in absolute change in lung clearance index   a measure of lung function in early CF disease   compared with placebo through 24 weeks of treatment Approval for this age group would expand the targeted patient population by about 3 400 patients In Ireland  Vertex already has reimbursement agreements for use in these children while in other countries  a country by country reimbursement process will now be initiated by Vertex Please note that in the United States  Orkambi is already marketed for this patient population since September 2016 Year 2017 was a tremendous one for Vertex with positive data read outs and regulatory approvals leading to an increase in eligible patient population for Kalydeco   Orkambi  With a consistent expansion in patient population  Vertex s CF product revenues increased through 2017  With the latest label expansion approval in EU  it looks like the trend will continue in 2018 The company is optimistic that the positive trend in CF sales will continue in 2018 as it gains additional reimbursement approvals for Orkambi in ex U S  markets and gets approval to launch tezacaftor  VX 661  ivacaftor combination medicine The stock has surged 92 1  in the past year  substantially outperforming the 1  increase registered by the  Estimates have also moved northward in the past 30 days Vertex s CF pipeline is also quite strong with a broad portfolio of next generation CF correctors  Vertex also made decent clinical progress across multiple CF studies in 2017 and has meaningful pipeline catalysts  Investor focus is on triple combination CF regimens  which are crucial for long term growth as these have the potential to treat up to 90  of CF patients  Vertex plans to initiatepivotal phase III studies on up to two of the four triple combination regimens in the first half of 2018 Vertex sports a Zacks Rank  1  Strong Buy   Some other biotech stocks worth considering are Exelixis  Inc    NASDAQ EXEL    XOMA Corporation   NASDAQ XOMA   and Paratek Pharmaceuticals  Inc    NASDAQ PRTK    While Exelixis has the same rank as Vertex  XOMA and Paratek carry a Zacks Rank  2  Buy   You can see  Exelixis  earnings estimates have gone up by 1 4  for 2018 over the last 30 days  Share price of the company has soared 64 5  in the past year XOMA s loss estimates have narrowed from 99 cents to 42 cents for 2018 over the last 30 days  Share price of the company has skyrocketed 590 2  in the past year Paratek s loss estimates for 2018 have narrowed by 2 1  in the last 60 days  Shares have risen 19  in the past year Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-01-10,Zacks Investment Research,https://www.investing.com/analysis/vertexs-cystic-fibrosis-drug-okd-for-pediatric-use-in-eu-200279518,200279518
120671,342186,VRTX,Can Biotech Keep Last Year s Momentum Alive In 2018 ,opinion,"The year 2017 has been better than expected for the biotech sector  The NASDAQ Biotechnology index was up 18 7  in 2017  While drug pricing issue  competition and a slowdown in growth of key drugs are expected to remain a hangover in 2018 as well  approval of new drugs and strategic acquisitions by several big wigs in 2017 are likely to boost investors  sentiments  Thus 2018 needless to say  holds promise for generating stellar returns 
The slowdown in mature products compelled bigwigs like Gilead Sciences   NASDAQ GILD   to undertake acquisitions to bolster pipelines  Gilead acquired erstwhile Kite Pharma and added Yescarta to its kitty  The company also inked an agreement to acquire Cell Design Labs  Gilead currently carries a Zacks Rank  3  Hold   You can see Recently  Celgene  Inc    NASDAQ CELG   inked a deal to acquire Impact Biomedicines for an upfront amount of  1 1 billion  The acquisition will add a late stage candidate  fedratinib  a highly selective JAK2 kinase inhibitor  to Celgene s pipeline   The candidate is being developed for the treatment of myelofibrosis and polycythemia vera  Celgene was on the look out of new deals and acquisitions given a lacklustre 2017  having suffered a few pipeline setbacks and weakness in Otezla sales  Celgene currently carries a Zacks Rank Acquisitions and mergers will keep investors focused in the space in 2018   In addition  new drug approvals and label expansion of existing drugs will boost the top line of prominent biotech companies Amgen  Inc    NASDAQ AMGN   looks poised for growth with several blockbuster drugs in its portfolio  Amgen s new drugs   Prolia  Xgeva  Vectibix  Nplate and Sensipar   are performing well  The company recently won the FDA approval for the supplemental Biologics License Application  sBLA  of Xvega to expand the drug s label for the treatment of multiple myeloma  Amgen carries a Zacks Rank  3 Exelixis  Inc    NASDAQ EXEL   is another biotech which looks poised for growth in 2018  The recent FDA approval of the label expansion of lead drug Cabometyx for the treatment previously untreated advanced renal cell carcinoma is expected to drive growth  The drug has performed impressively since approval in 2016  Exelixis currently carries a Zacks Rank  1 Alexion Pharmaceuticals  Inc  s   NASDAQ ALXN   blockbuster drug  Soliris  continues to perform well and the FDA approval of the drug for generalized myasthenia gravis will further boost sales  Among new products  while Strensiq is gaining momentum  the company redefined its strategy for Kanuma   Alexion carries a Zacks Rank  3 Investors should also keep an eye on key upcoming PDUFA dates  Regeneron Pharmaceuticals  Inc    NASDAQ REGN   is looking to expand label for its newly approved drug Dupixent  The drug is already approved for the treatment of adults with moderate to severe atopic dermatitis  The company is also evaluating the drug for treating asthma in adults  LIBERTY ASTHMA QUEST study    sBLA for the same is expected to be filed shortly  Regeneron is working on expanding lead ophthalmology drug Eylea label into additional indications  The FDA has accepted for review the company s sBLA for the label expansion of Eylea Injection  The company is seeking approval a for a 12 week dosing interval of Eylea Injection in patients with wet age related macular degeneration  wet AMD  based on physician s assessment  The action date set by the FDA is Aug 11  2018  Regeneron carries a Zacks Rank  3 Another big biotech  Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   is taking measures to strengthen its already dominant position in the cystic fibrosis market  CF   Vertex has two CF drugs   Kalydeco   Orkambi   in its portfolio with blockbuster potential   The company has developed another CF corrector tezacaftor  VX 661    in combination with ivacaftor   Regulatory applications are under review in the United States  PDUFA Date  Feb 28  2018  and the EU   A potential approval would further bolster demand   Vertex currently carries a Zacks Rank  1 Medical   Biomedical and Genetics Industry 5YR   Return
  Conclusion 
While the threat of biosimilars loom large on key drugs of most companies  we expect investors to remain focussed on this dynamic sector eying new drug approvals and important data read outs 
Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-01-10,Zacks Investment Research,https://www.investing.com/analysis/can-biotech-keep-last-years-momentum-alive-in-2018-200279606,200279606
120672,342187,VRTX,The Zacks Analyst Blog Highlights  Celgene  Amgen  Exelixis  Alexion And Vertex,opinion,For Immediate ReleaseChicago  IL   January 12  2018   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Celgene  Inc    NASDAQ CELG    Amgen  Inc    NASDAQ AMGN    Exelixis  Inc    NASDAQ EXEL    Alexion Pharmaceuticals  Inc  s   NASDAQ ALXN   and Vertex Pharmaceuticals Inc    NASDAQ VRTX   Here are highlights from Thursday s Analyst Blog  Can Biotech Keep Last Year s Momentum Alive The year 2017 has been better than expected for the biotech sector  The NASDAQ Biotechnology index was up 18 7  in 2017  While drug pricing issue  competition and a slowdown in growth of key drugs are expected to remain a hangover in 2018 as well  approval of new drugs and strategic acquisitions by several big wigs in 2017 are likely to boost investors  sentiments  Thus 2018 needless to say  holds promise for generating stellar returns The slowdown in mature products compelled industry majors to undertake acquisitions to bolster pipelines  Gilead acquired erstwhile Kite Pharma and added Yescarta to its kitty  The company also inked an agreement to acquire Cell Design Labs  Gilead currently carries a Zacks Rank  3  Hold   You can see Recently  Celgene  Inc  inked a deal to acquire Impact Biomedicines for an upfront amount of  1 1 billion  The acquisition will add a late stage candidate  fedratinib  a highly selective JAK2 kinase inhibitor  to Celgene s pipeline   The candidate is being developed for the treatment of myelofibrosis and polycythemia vera  Celgene was on the look out of new deals and acquisitions given a lackluster 2017  having suffered a few pipeline setbacks and weakness in Otezla sales  Celgene currently carries a Zacks Rank Acquisitions and mergers will keep investors focused in the space in 2018   In addition  new drug approvals and label expansion of existing drugs will boost the top line of prominent biotech companies Amgen  Inc  looks poised for growth with several blockbuster drugs in its portfolio  Amgen s new drugs   Prolia  Xgeva  Vectibix  Nplate and Sensipar   are performing well  The company recently won the FDA approval for the supplemental Biologics License Application  sBLA  of Xvega to expand the drug s label for the treatment of multiple myeloma  Amgen carries a Zacks Rank  3 Exelixis  Inc  is another biotech which looks poised for growth in 2018  The recent FDA approval of the label expansion of lead drug Cabometyx for the treatment previously untreated advanced renal cell carcinoma is expected to drive growth  The drug has performed impressively since approval in 2016  Exelixis currently carries a Zacks Rank  1 Alexion Pharmaceuticals  Inc  s blockbuster drug  Soliris  continues to perform well and the FDA approval of the drug for generalized myasthenia gravis will further boost sales  Among new products  while Strensiq is gaining momentum  the company redefined its strategy for Kanuma  Alexion carries a Zacks Rank  3 Another big biotech  Vertex Pharmaceuticals Inc  is taking measures to strengthen its already dominant position in the cystic fibrosis market  CF   Vertex has two CF drugs   Kalydeco   Orkambi   in its portfolio with blockbuster potential   The company has developed another CF corrector tezacaftor  VX 661    in combination with ivacaftor   Regulatory applications are under review in the United States  PDUFA Date  Feb 28  2018  and the EU   A potential approval would further bolster demand   Vertex currently carries a Zacks Rank  1 ConclusionWhile the threat of biosimilars loom large on key drugs of most companies  we expect investors to remain focused on this dynamic sector eying new drug approvals and important data read outs Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius Join us on Facebook  NASDAQ FB   Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit f or information about the performance numbers displayed in this press release ,2018-01-11,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-celgene-amgen-exelixis-alexion-and-vertex-200279879,200279879
120677,342192,VRTX,Concert Pharmaceuticals Plunges On Patent Petition Setback,opinion,Shares of Concert Pharmaceuticals  Inc    NASDAQ CNCE   plunged more than 25   following the announcement that the Patent Trial and Appeal Board  PTAB  of the U S  Patent and Trademark Office has refused to grant the company a Post Grant Review petition in a dispute related to Incyte Corporation s  INCY   335 patent However  shares of the company have gained 92 4  in the past year  significantly outperforming the  s gain of 10 4  in that period The patent  335 protects Incyte s JAK inhibitor  ruxolitinib  which is sold under the tradename Jakafi for treating myelofibrosis and polycythemia vera  Concert Pharma s pipeline candidate  CTP 543  is a modified version of ruxolitinib  which is being developed as a treatment for alopecia areata Alopecia areata is an auto immune disease  which result in partial or complete hair losson the scalp and or body However  the company said that it may challenge the validity of the patent in the future in federal court  It will also continue developing CTP 543 In a separate press release  Concert Pharma announced that the FDA has granted Fast Track designation to CTP 543 as a treatment for moderate to severe alopecia areata The FDA grants a fast track designation to expedite a candidate s development and its faster review  which treat serious and unmet medical conditions  With this designation  a candidate is expected to be granted a priority review once it files a new drug application The candidate is currently being evaluated in a phase IIa study Apart from CTP 543  Concert Pharma is also developing AVP 786 for treating agitation associated with Alzheimer s disease  JZP 386 in collaboration with Jazz Pharmaceuticals PLC   NASDAQ JAZZ   in narcolepsy and CTP 730 in collaboration with Celgene Corporation   NASDAQ CELG   in inflammatory disease However  in an asset purchase agreement  the company sold its cystic fibrosis candidate  CTP 656  to Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   in July last year Zacks RankConcert Pharma carries a Zacks Rank  3  Hold   You can see  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-01-15,Zacks Investment Research,https://www.investing.com/analysis/concert-pharmaceuticals-plunges-on-patent-petition-setback-200280420,200280420
120692,342207,VRTX,Drug Biotech Stocks Q3 Earnings On Oct 25  AMGN  GSK  VRTX,opinion,The third quarter reporting cycle is in full swing  Corporate earnings have been reassuring so far this quarter and we expect the momentum to continue going ahead As of Oct 20  2017  87 S P 500 members  accounting for 24 7  of the index s total market capitalization  have reported results  according to  Total earnings of these 87 index members were up 9 4  from the year ago quarter on a 7 3  improvement in revenues  The growth in revenues is impressive  ahead of the previous quarter s growth of 4 4  and significantly higher than the 12 quarter average of 1 1   The beat ratio was 71 3  for earnings and 70 1  for revenues  More than half of the 87 companies have beaten both EPS and revenue estimates Per the report  total earnings of the S P 500 companies in the third quarter are expected to grow 2 6  year over year on 5  higher revenues  Meanwhile  the broader Medical sector  includes drug  biotech as well as Medical Device companies  is expected to record year over year growth of 4 8  in revenues and 2 2  in earnings in Q3 Only two big names in the biotech pharma sector have reported thus far   Johnson   Johnson   NYSE JNJ   and Swiss based Novartis AG   NYSE NVS    J J s Q3 results were better than expected and the company raised its sales and profit outlook for this year as well  Novartis also beat estimates for both revenues and earnings this quarter Let s take a look at three pharma biotech companies that are set to report third quarter results on Oct 25 Amgen Inc     NASDAQ AMGN   Amgen  which is scheduled to release earnings after market closes  had delivered a positive earnings surprise of 5 83  last quarter  Amgen beat expectations in the last four quarters with an average positive surprise of 5 85  For this quarter  Amgen has an  of  0 41  and a Zacks Rank  3  Hold   This does not conclusively show that Amgenis likely to beat estimates this quarter  The Zacks Consensus Estimate is pegged at  3 09 per share  You can uncover the best stocks to buy or sell before they re reported with our  Higher demand for Amgen s new drugs is expected to offset lower sales of its mature brands  The company s key drug  Neulasta  is facing competition from newer cancer therapies  The threat of biosimilars also lurks as several companies are looking to launch generic version of the drug   Read More   GlaxoSmithKline plc    NYSE GSK   London  U K  based Glaxo is scheduled to announceresults before the opening bell tomorrow Glaxo has beaten estimates in three of the last four quarters and met the same in one  resulting in an average positive surprise of 8 34   In the last reported quarter  Glaxo delivered a positive surprise of 2 94  The company has an Earnings ESP of  1 28  and a Zacks Rank  3  which indicates that it is poised to deliver a beat this time around You can see  Glaxo s HIV products are expected to drive sales for the pharmaceutical segment this quarter  Moreover  the newly launched respiratory drugs are expected to offset declining sales of Seretide  Advair and Avodart  Meanwhile  the slowdown in consumer segment due to market conditions and the impact of divestures is expected to continue   Read More   Vertex Pharmaceuticals Incorporated    NASDAQ VRTX   The company  which specially focuses on cystic fibrosis   CF    will report results tomorrow after market closes  In the last quarter  Vertex delivered a positive earnings surprise of 11 43   The company came up with an average positive earnings surprise of 17 91  in the trailing four quarters  The company has an Earnings ESP of  7 24  and a Zacks Rank  3  indicating a likely positive surprise  The Zacks Consensus Estimate is pegged at 37 cents per share The approval for two label expansions of CF drug  Kalydeco  in the United States in May and August has broadened the patient population  which can drive sales of the drug  Moreover  the re imbursement agreements in Ireland and Italy for Orkambi are also a positive   Read More   Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-10-23,Zacks Investment Research,https://www.investing.com/analysis/drugbiotech-stocks-q3-earnings-on-oct-25-amgn-gsk-vrtx-200220623,200220623
120693,342208,VRTX,Why Earnings Season Could Be Great For Vertex Pharmaceuticals  VRTX ,opinion,"Investors are always looking for stocks that are poised to beat at earnings season and Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Vertex Pharmaceuticals is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for VRTX in this report In fact  the Most Accurate Estimate for the current quarter is currently at 39 cents per share for VRTX  compared to a broader Zacks Consensus Estimate of 37 cents per share  This suggests that analysts have very recently bumped up their estimates for VRTX  giving the stock a Zacks Earnings ESP of  7 24  heading into earnings season Vertex Pharmaceuticals Incorporated Price and EPS Surprise
   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that VRTX has a Zacks Rank  3  Hold  and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see  Clearly  recent earnings estimate revisions suggest that good things are ahead for Vertex Pharmaceuticals  and that a beat might be in the cards for the upcoming report Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-10-24,Zacks Investment Research,https://www.investing.com/analysis/why-earnings-season-could-be-great-for-vertex-pharmaceuticals-vrtx-200220646,200220646
120694,342209,VRTX,Vertex Gets CHMP Recommendation For Orkambi Label Expansion,opinion,"Vertex Pharmaceuticals Inc    NASDAQ VRTX   announced that the Committee for Medicinal Products for Human Use   CHMP   has recommended approval of a label expansion for Orkambi in Europe  The company is seeking extension of its marketing authorization for Orkambi to include use in children with cystic fibrosis   CF   who are aged between 6 and 11 years and have two copies of the F508del mutation 
We note that the European Commission generally follows the recommendation of the CHMP but is not bound by it  A decision is typically expected within three months of recommendation 
We remind investors that Orkambi is currently approved in the EU for the treatment of CF in patients aged 12 years and above who have two copies of the F508del mutation in their CF transmembrane conductance regulator   CFTR   gene 
Vertex s stock has outperformed the  so far this year  Shares are up 101 9  compared with the industry s gain of 2 3  in the period 

The company believes that the label expansion will increase the eligible patient population by 3400 in Europe  The drug is already approved in the United States for this indication 
Orkambi generated net sales of  955 5 million in the first nine months of 2017  growing over 35  from the year ago period  The potential label expansion will further boost the drug s sales 
Meanwhile  the company has completed part 2 of a phase III study evaluating Orkambi in CF patients of two to five years of age who have two copies of the F508del mutation in their CFTR gene  Last month the company announced that the study met its primary endpoint of safety  Vertex expects to file applications for expanding Orkambi s label in this patient population to the regulatory authorities in the United States and Europe in the first quarter of 2018 
CF  a rare  life threatening disease  is estimated to affect approximately 75 000 people in the United States  Europe and Australia  Vertex currently has another CF drug  Kalydeco  in its portfolio  The company generated CF product revenues of more than  1 5 billion  including sales of Kalydeco and Orkambi  in the first nine months of 2017 
Moreover  to boost its CF portfolio and curb competition Vertex bought Concert Pharmaceuticals  Inc  s   NASDAQ CNCE   CF candidate  CTP 656  in July 2017 
The CF market has been attracting lot of interest with several companies developing their candidates as potential therapy for patients Vertex Pharmaceuticals Incorporated Price
 

   Zacks Rank   Stocks to Consider
Vertex carries a Zacks Rank  3  Hold  
A couple of better ranked health care stocks include Ophthotech Corporation   NASDAQ OPHT   and Ligand Pharmaceuticals Inc    NASDAQ LGND    While Ophthotech sports a Zacks Rank  1  Strong Buy   Ligand carries a Zacks Rank  2  Buy   You can see  
Ophthotech s earnings per share estimates have moved up from 81 cents to  2 31 for 2017 over the last 30 days  The company delivered a positive earnings surprise in all the trailing four quarters  with an average beat of 14 23  
Ligand s earnings per share estimates have moved up from  3 68 to  3 70 for 2018 over the last 60 days  The company pulled off a positive earnings surprise in two of the trailing four quarters  with an average beat of 8 22   The share price of the company has increased 37 7  year to date 
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2017-11-13,Zacks Investment Research,https://www.investing.com/analysis/vertex-gets-chmp-recommendation-for-orkambi-label-expansion-200264716,200264716
120697,342212,VRTX,Galapagos  CF Candidate Shows Potential In Phase II Study,opinion,"Galapagos NV   NASDAQ GLPG   announced positive top line data from a phase II study   ALBATROSS   evaluating its cystic fibrosis transmembrane conductance   CFTR   corrector candidate  GLPG2222  in cystic fibrosis   CF   patients  It led to improvements in lung function So far this year  Galapagos shares have outperformed the   The stock has gained 41 5  compared with an increase of 1 5  registered by the industry The phase II study evaluated two once daily doses   150 mg and 300 mg   of the candidate in CF patients who have one gating mutation and an F508del mutation and were on long term stable treatment with Vertex Pharmaceuticals Incorporated s   NASDAQ VRTX   CF drug  Kalydeco  Treatment with Kalydeco was continued during the course of the study The study achieved its primary objective of safety and was well tolerated in the patient population  Data also showed an improvement of 2 2  in mean percent predicted FEV1  a measure of lung function  compared to baseline in 300 mg arm of the study Meanwhile  Vertex is also developing a combination therapy  tezacaftor plus Kalydeco  in similar indication Apart from GLPG2222  Galapagos is also developing GLPG2737  a CFTR regulator  in a phase I study and GLPG1837  a CFTR potentiator  in a phase II study in CF patients  All three candidates are being developed in partnership with AbbVie Inc    NYSE ABBV    The company has a diverse pipeline with candidates being developed in several other indications including atopic dermatitis  psoriatic arthritis  uveitis and lupus membranous nephropathy among others Galapagos NV Price
    Zacks Rank   Stock to ConsiderGalapagos carries a Zacks Rank  3  Hold  Sucampo Pharmaceuticals  Inc    NASDAQ SCMP   is a better ranked health care stock  sporting a Zacks Rank  1  Strong Buy   You can see  Sucampo s earnings per share estimates have increased from  1 01 to  1 12 for 2017 and from  1 06 to  1 19 for 2018 over the last 30 days  The company delivered positive earnings surprises in three of the trailing four quarters with an average beat of 15 63  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-11-19,Zacks Investment Research,https://www.investing.com/analysis/galapagos-cf-candidate-shows-potential-in-phase-ii-study-200266707,200266707
120698,342213,VRTX,New Pharma ETF PILL   What Investors Need To Know,opinion,"The pharma sector has been a moderate performer this year with the NYSE ARCA Pharmaceutical Index adding about 10 4  so far this year  as of Nov 24  2017   underperforming the S P 500  up 15 3   and the Nasdaq  26 9   
But this underperformance did not eat into the issuer s enthusiasm  Direxion recently launched a triple leverage pharmaceutical fund  in the name of Daily Pharmaceutical   Medical Bull 3X Shares  
Let s delve a little deeper and find out what caused the issuer to shoot a leveraged fund on this apparently underperforming  at the current level  space 
Inside PILL
The fund looks to track 300  of the performance of the Dynamic Pharmaceutical Intellidex Index  The underlying index comprises common shares of companies that are into research and development  manufacturing and distribution of pharmaceuticals and drugs of all types 
Abbvie Ord Shs  6 13    Bristol Myers Squibb Ord  5 19   and Pfizer  NYSE PFE  Ord  5 17   are the top three holdings of the fund  Pharmaceutical stocks occupy about 66 8  of the portfolio while biotechnology stocks account for the rest  The fund charges 1 13  annually 
How Does It Fit in a Portfolio 
Price gouging has been nagging the space  Though the threat has subsided a lot in the Trump era after a more vocal protest against it by his democratic opponent Hillary Clinton during the campaign days  the sector still faces risks of price controversies  Still  the long term prospects of the space appear bright 
However  as we progress toward the close of 2017  the pharma sector continues to perform well on breakthrough U S  Food and Drug Administration  FDA  approvals  success in the immune oncology field  and mergers and acquisitions  read    
In the third quarter of 2017  biotech stock Vertex Pharmaceuticals   NASDAQ VRTX   received a new FDA approval for cystic fibrosis drug    In early September  FDA approved Novartis AG s breakthrough gene transfer treatment 
Gilead Sciences   NASDAQ GILD   announced the buyout of Kite Pharma KITE for  11 9 billion in late August to foray into the trending CAR T Therapy space   The FDA s approval of Yescarta  axicabtagene ciloleucel   the  is expected to drive Gilead Sciences  read    
Overall  the fund is a good choice for those seeking to bet primarily on large cap stocks in the pharmaceuticals sector  These are large  stable companies that generate solid cash flow and add stability to the portfolio  Healthcare is one of the most defensive sectors in the U S  markets  This sector is expected to continue to benefit from increased M A activities  new drug approvals and innovations 
Competition 
Investors intending to target the space with lesser risk appetite may find the non leverage ETF PowerShares Dynamic Pharmaceuticals Portfolio   WA PJP   more appealing In the leveraged ETF space  the newly launched fund may face stiff competition from Direxion Daily Healthcare Bull 3x Shares   AS CURE   and Direxion Daily S P Biotech Bull 3x Shares  and ProShares UltraPro Nasdaq Biotechnology   see  here  
While CURE gives 300  of the performance of the Healthcare Select Sector Index  LABU tracks 300  of the performance of the S P Biotechnology Select Industry Index and UBIO offers daily investment results that correspond to three times the daily performance of the NASDAQ Biotechnology Index 
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2017-11-28,Zacks Investment Research,https://www.investing.com/analysis/new-pharma-etf-pill--what-investors-need-to-know-200268885,200268885
120700,342215,VRTX,Vertex Kalydeco Study Successful In Children Aged 1 2 Years,opinion,Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   announced that a phase III study evaluating its key cystic fibrosis  CF  drug  Kalydeco in children  age 1 2 years  met its primary safety endpoint Kalydeco  ivacaftor  is presently marketed for the treatment of patients  two years and above  with CF who have one of the 38 mutations in their cystic fibrosis transmembrane conductance regulator  CFTR  gene The ARRIVAL study was conducted in young children less than two years of age who have one of 10 mutations in the CFTR gene  Not only did it reveal that Kalydeco was well tolerated in children as young as one year  the study also showed improvement across multiple endpoints  including measures of pancreatic function  Based on this data  Vertex plans to file regulatory applications for approval of Kalydeco in children aged 1 to 2 years in the first quarter of 2018  The study  however  continues in infants less than one year of age If approved for use in this additional patient population  sales of Kalydeco may improve further  Please note that Kalydeco s sales rose 35  in 2015  11  in 2016 and 12  in the first nine months of 2017 Year to date  Vertex s shares have gained 88 3   outperforming the increase of 0 3  for the  For Vertex  2017 so far has been a tremendous year with positive data read outs and regulatory approvals leading to an increase in eligible patient population for its approved CF medicines   Kalydeco   Orkambi  With a consistent expansion in patient population  Vertex s CF product revenues have increased quarter to quarter throughout 2017 While Vertex raised its guidance for Orkambi once  that for Kalydeco was upped twice this year  The company is optimistic that the positive trend of CF sales will continue in 2018 as it gains additional reimbursement approvals for Orkambi in ex U S  markets and gets approval to launch tezacaftor VX 661   ivacaftor combination medicine Meanwhile  the company has also made decent clinical progress across multiple CF studies this year with meaningful pipeline catalysts lying ahead Vertex carries a Zacks Rank  3  Hold   Better ranked stocks in the biotech genetics sector include Emergent BioSolutions Inc    NYSE EBS    XOMA Corporation   NASDAQ XOMA   and Myriad Genetics  Inc    NASDAQ MYGN    all with a Zacks Rank  1  Strong Buy  You can see Emergent BioSolutions  earnings estimates have moved up by 1 4  for 2018 over the last 30 days  Share price of the company has risen 29 2  year to date Myriad Genetics  shares have risen 98 4  year to date while 2018 earnings estimates have risen by 2 5  over the past 30 days XOMA shares have risen a massive 688 6  year to date while 2018 loss estimates have narrowed by almost 20  over the past 30 days Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-12-07,Zacks Investment Research,https://www.investing.com/analysis/vertex-kalydeco-study-successful-in-children-aged-12-years-200271744,200271744
120701,342216,VRTX,4 Drug Biotech Stocks That Could Be Buyout Targets In 2018,opinion,Last week  we issued an  where we mentioned that mergers and acquisitions  which were quite lean in 2017  may pick up significantly in 2018 if the proposed tax reforms are finally approved The reforms aim to cut the corporate tax rate from 35  to 20   which can boost profits of large drug biotech companies  The change in tax code will also allow companies to bring back huge cash held overseas at a one time tax rate of 10  These changes will definitely leave more cash in the hands of drug biotech companies  Also  with focus on drug pricing taking a backseat and large drug biotech companies struggling with organic growth  there is a lot of chatter about a possible increase in large M As in 2018 Given that it takes several years and millions of dollars to develop new therapeutics from scratch  large pharmaceutical companies sitting on huge piles of cash may prefer to buy innovative small mid cap biotech companies to build out their pipelines In this article  we discuss some mid  and large cap names that may be logical acquisition targets next year for companies like Pfizer   NYSE PFE    Merck   NYSE MRK    Johnson   Johnson   NYSE JNJ   and others  What matters for buying a drug biotech stock is the current sales performance of its drugs products  prospects of future sales growth  and the quality of the pipeline The four companies we discuss have most of these factors going in their favor  Acquisitions of small cap drug biotech companies are very difficult to predict and quite frequent  Hence  these have been excluded from the discussion BioMarin Pharmaceutical Inc    NASDAQ BMRN  Companies whose product pipeline portfolio includes rare disease drugs are in great demand as it is a less competitive space and the expensive treatments can bring in huge profits  BioMarin is one such drug developer  Its market cap is around  14 billion BioMarin s key orphan disease drugs   Vimizim and Kuvan   continue to do well  backed by strong underlying patient demand trends  BioMarin expects sustained growth in both the drugs  Brineura s earlier than expected approval this year for the treatment of children with CLN2 disease  a form of Batten disease  was also a huge boost for BioMarin Its impressive rare disease pipeline is also progressing well with approval for pegvaliase for the treatment of phenylketonuria expected in 2018  On the pipeline  we believe both late stage candidates   vosoritide   for achondroplasia  the most common form of dwarfism  and BMN27   for hemophilia A    have blockbuster potential BioMarin has already been the target of takeover speculation  Companies like Gilead  GILD   Amgen  NASDAQ AMGN  and Roche may be interested in buying BioMarin Vertex Pharmaceuticals  Inc    NASDAQ VRTX  For Vertex  2017 so far has been a tremendous year with positive data read outs and regulatory approvals leading to an increase in eligible patient population for its two approved cystic fibrosis  CF    Kalydeco   Orkambi  CF is Vertex s main area of focus  With a consistent expansion in patient population  Vertex s CF product revenues have increased quarter to quarter throughout 2017 The company is optimistic that the positive trend of CF sales will continue in 2018 as it gains additional reimbursement approvals for Orkambi in ex U S  markets and gets approval to launch tezacaftor VX 661  ivacaftor combination medicine Meanwhile  the company has also made decent clinical progress across multiple CF studies this year and has meaningful pipeline catalysts  The market cap of Vertex is around  36 billion Incyte Corporation   NASDAQ INCY   Incyte s strong oncology portfolio makes it a lucrative target for companies like Gilead  Amgen and Bristol Myers  The market cap of Incyte is more than  20 billion The primary reason why Incyte is ripe for buyout is its two products on the market  Jakafi and Iclusig Jakafi  a JAK inhibitor  is the first and the only product to be approved by the polycythemia vera  PV  and myelofibrosis   MF     two rare blood cancers  Jakafi is seeing strong sales performance driven by strong patient demand for both indications   In order to expand the patient population and increase the commercial potential of the drug  the company is working on expanding its label further  Iclusig is approved for chronic myeloid leukemia and acute lymphoblastic leukemia Meanwhile  Incyte s pipeline boasts candidates like immune therapy epacadostat   being studied in combination with anti PD L1 agents of Merck  Bristol Myers and others   and Olumiant for rheumatoid arthritis   approved in Europe and regulatory application to be filed in the United States in January 2018 Alexion Pharmaceuticals  Inc    NASDAQ ALXN  Like BioMarin  Alexion is also focused on the development and commercialization of life transforming drugs for the treatment of patients with ultra rare disorders  Its key drug is Soliris  approved for two severe and ultra rare disorders   paroxysmal nocturnal hemoglobinuria  PNH  and atypical hemolytic uremic syndrome  aHUS    have been consistently doing well  Meanwhile  Alexion is working on expanding the drug s label to include additional indications  which if approved  can boost further sales growth  It has two other drugs for rare diseases called Strensiq and Kanuma  which are emerging as growth drivers  Alexion also has a robust pipeline of several candidates under development including Soliris follow up candidate  ALXN1210 Roche  Pfizer  or Novartis may be interested in buying Alexion  The market cap of Alexion is more than  25 billion Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-12-10,Zacks Investment Research,https://www.investing.com/analysis/4-drugbiotech-stocks-that-could-be-buyout-targets-in-2018-200272183,200272183
120722,342237,VRTX,Amgen Label Expansion Application For Prolia Accepted By FDA,opinion,Amgen  Inc    NASDAQ AMGN   announced that the FDA has accepted its regulatory application in the United States seeking label expansion for Prolia for the treatment of patients with glucocorticoid induced osteoporosis  GIOP   The FDA is expected to give its decision on May 28 next year Prolia is presently marketed in the United States for the treatment of postmenopausal women with osteoporosis at high risk for fracture as well as to increase bone mass in men with osteoporosis at high risk for fracture The supplemental Biologics License Application  sBLA  was submitted in July this year  The sBLA was based on a phase III study evaluating the safety and efficacy of Prolia compared with risedronate in patients receiving glucocorticoid medications GIOP is the most common form of secondary osteoporosis  This serious condition is presently treated with glucocorticoid treatment  which increases fracture risk within the first three months of beginning treatment  Prolia  if approved for the treatment of GIOP  can cater to an expanded patient population and drive sales higher Prolia is a key revenue generator for Amgen and is witnessing market share gains in both the United States and international markets  In the first half of 2017  the drug generated sales of  930 million  up 17  year over year Amgen s shares have rallied 26 9  this year so far  better than the  s growth of 14 1  so far this year Currently  Amgen holds a Zacks Rank  2  Buy   You can see Key PicksSome other top ranked biotech stocks include Vertex Pharmaceuticals Incorporated   NASDAQ VRTX    PDL BioPharma  Inc    NASDAQ PDLI   and Celgene Corporation   NASDAQ CELG    While Vertex and PDL BioPharma sport a Zacks Rank  1  Strong Buy   Celgene has the same Zacks Rank as Amgen Vertex has witnessed the Zacks Consensus Estimate for current year earnings climb 1 8  for 2017 and 6 8  for 2018 over the past 90 days  The company s shares have increased 111 2  this year so far PDL BioPharma s earnings estimates have gone up by 263  for 2017 and 174  for 2018  Its shares have risen 60 4  this year so far Celgene s earnings estimates for 2017 inched up 0 7  while that for 2018 went up by 1 1  in the past 90 days  The stock has rallied 20 4  so far this year  outperforming the industry Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-10-09,Zacks Investment Research,https://www.investing.com/analysis/amgen-label-expansion-application-for-prolia-accepted-by-fda-200218037,200218037
120723,342238,VRTX,Vertex Pharmaceuticals  USG And J  Jill Highlighted As Zacks Bull And Bear Of The Day ,opinion,For Immediate ReleaseChicago  IL   October 13  2017    Vertex Pharmaceuticals  Nasdaq   NASDAQ VRTX       as the Bull of the Day  USG Corporation  NYSE   NYSE USG       as the Bear of the Day  In addition  Zacks Equity Research provides analysis on J  Jill Inc   NYSE   NYSE JILL      Here is a synopsis of all three stocks   Vertex Pharmaceuticals  Nasdaq      is the leading biotechnology company with a treatment for cystic fibrosis  CF  The company holds a strong position in this market with two commercial products  Orkambi and Kalydeco  Early in August  Vertex had said that it expects its CF franchise to deliver revenues of  1 87 billion to  2 1 billion in 2017 including Orkambi revenues of  1 1 billion to  1 3 billion The CF market represents huge commercial potential  It is a rare  life threatening disease estimated to affect about 75 000 people in North America  Europe and Australia  Vertex enjoys a strong position in this market being the first company to successfully develop a drug  Kalydeco  that treats the underlying cause of CF Vertex is working on expanding its CF portfolio and is currently seeking both FDA and EMA approval for new combination treatments of its so called  correctors   With the FDA granting priority review  a response should be out by Feb 28  2018 What is CF Cystic fibrosis is an inherited disorder that causes severe damage to the lungs  digestive system and other organs in the body  According to the Mayo Clinic   Cystic fibrosis affects the cells that produce mucus  sweat and digestive juices  These secreted fluids are normally thin and slippery  But in people with cystic fibrosis  a defective gene causes the secretions to become sticky and thick  Instead of acting as a lubricant  the secretions plug up tubes  ducts and passageways  especially in the lungs and pancreas Although cystic fibrosis requires daily care  people with the condition are usually able to attend school and work  and often have a better quality of life than people with cystic fibrosis had in previous decades  Improvements in screening and treatments mean people with cystic fibrosis now may live into their mid  to late 30s  on average  and some are living into their 40s and 50s Why Did VRTX Jump 20  in July On the morning of July 19  VRTX shares popped nearly  30 from  130 to  160  My colleague Brian Hamilton wrote about this in his Bull of the Day shortly after   On Tuesday July 18  management announced that three of their four next generation correctors in development to treat cystic fibrosis  CF  patients had positive Phase 1  and Phase 2 data Highlighting the report was the efficacy and safety shown by three different triple combination regimens  The data showed consistency across many regimen and patient populations  and is viewed as a game changer for the disease Given this positive data  it is expected that the company will be granted Breakthrough Therapy Designation  BTD  for their triplet regimens  cutting the 12 month timeline to 6 months  It is estimated that the 24 week Phase three trials will begin in the first half of 2018  and commercial treatments potentially be launched in the late part of 2019 This breakthrough therapy is expected to deliver increased sales and earnings growth over the next 5 years for Vertex if and when it eventually gets full approval  Further  it is estimated that these triplet regimens will penetrate almost 90  of the  9 billion CF market  USG Corporation  NYSE      is the  4 6 billion maker of construction wallboard with its iconic  ubiquitous brand Sheetrock  which just celebrated its 100th birthday earlier this year But the stock has struggled this year on the back of declining earnings estimates and it s back in the cellar of the Zacks Rank And this follows a strong 2016 which saw the company revenues  trough  and bounce back while USG shares more than doubled from  16 to  34 between January 2016 and February 2017 The recovery in sales was not matched by one in earnings though  Below is the Zacks proprietary Price   Consensus chart which plots changes in annual EPS estimates against the stock price   As you can see  annual EPS estimates for both 2017  blue line  and 2018  gold line  have been on the decline all of this year This pessimism about future growth took USG shares back down to  26  but they ve since seen a run back up to near the recent 52 week highs And right now  consensus sales estimates for 2017 have fallen back too  The current top line haul for this year is expected to be just  3 14 billion vs last year s  3 47 billion  for a 9 6  drop So while the economy is strong and real estate seems to be in high gear  this doesn t seem like a good time to be starting or adding to USG positions at 20X earnings Investors should at least wait until the estimates stop going down and start heading back up Additional content Why Did J  Jill Plunge 50  Thursday On Thursday  shares of women s apparel retailer J  Jill Inc   NYSE      are plunging today  down over 50  to  4 86 per share in morning trading on the heels of the company s  to its third quarter fiscal 2017 guidance J  Jill now expects total company comparable sales in the range of  3  to  5   and a moderate decline in gross margin when compared to last year  The retailer also anticipated GAAP diluted EPS of 7 cents to 9 cents and adjusted diluted EPS between 8 cents to 10 cents for Q3  We have experienced a lower than expected sales trend across both our retail and direct channels  and are updating our guidance for the quarter  We have been assessing the change in trend and have identified product and marketing calendar issues that are affecting traffic and conversion  and we are reacting quickly   said President and CEO Paula Bennett  Given our long track record of consistent sales and earnings growth driven by a strong connection with our customers  we are very disappointed with our soft sales trend  I am confident in the actions we are taking to regain momentum and once again delight our customer with the product and service experience she expects from us   she continued The company said that it would provide investors and analysts a revised outlook for its full year fiscal 2017 when its reports third quarter results on December 5  About the Bull and Bear of the DayEvery day  the analysts at Zacks Equity Research select two stocks that are likely to outperform  Bull  or underperform  Bear  the markets over the next 3 6 months About Zacks Equity ResearchZacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term Continuous analyst coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2017-10-12,Zacks Investment Research,https://www.investing.com/analysis/vertex-pharmaceuticals-usg-and-j-jill-highlighted-as-zacks-bull-and-bear-of-the-day-200218714,200218714
120724,342239,VRTX,Will Quest Diagnostics  DGX  Disappoint In Q3 Earnings ,opinion,Quest Diagnostics Inc    NYSE DGX   is scheduled to report third quarter 2017 earnings results before the opening bell on Oct 19 Last quarter  the company surpassed the Zacks Consensus Estimate by 14 cents delivering a positive earnings surprise of 9 9   Also  Quest Diagnostics outperformed the Zacks Consensus Estimate in all trailing four quarters with an average beat of 7 1  Let s take a look at how things are shaping up prior to this announcement Factors at PlayAfter several quarters of sustained drag in the company s revenue per requisition performance last quarter saw a slight rebound  However  it still remains to be seen if this improvement is here to stay or not  The company s two Professional Lab Services  PLS  engagements   WJ Barnabas Health and HealthONE System of HCA Holdings  Inc   HCA    carry lower revenue per requisition due to the nature of work Overall  we believe that a low level of employment and slow growth of commercially insured lives will continuously impact the company s volume  measured by the number of requisitions  environment till the economy turns around for better Quest Diagnostics Incorporated Price and EPS Surprise   This apart  unit price headwinds were less than 100 bps in the previously reported second quarter  While unit price headwinds hovered in moderate ranges  at approximately 1   over the last few years  the company continues to expect the same for the rest of 2017 too Also  over the last two years  Quest Diagnostics has faced several reimbursement issues that affected its revenues  The company is concerned about the CMS  Centers for Medicare   Medicaid Services  proposal related to Protecting Access to Medicare Act  PAMA   We believe  reimbursement pressure will be reflected as an overhang in the company s performance this soon to be reported quarter too Notably  the company has not positively taken the latest Centers for Medicare and Medicaid Services  CMS  publication of proposed 2018 Medicare reimbursement rates for clinical laboratory tests under the Clinical Lab Fee Schedule  CLFS   However  this leaves no impact on its yet to be reported quarter s revenue numbers On a positive note  Quest Diagnostics seems to be determined to repeat its well meaning efforts from second quarter 2017 by stimulating the company s performance via a two point growth strategy to accelerate growth and drive operational excellence We are also optimistic about the company s successful execution of its strategy to grow esoteric testing business and drive profitable growth Additionally  Quest Diagnostics has recently witnessed significant growth through infectious disease testing  prescription drug monitoring and industry leading wellness business  We expect these growth drivers to remain active through the third quarter as well  driving the same metrics as in the preceding quarter We strongly believe all these recent developments to significantly contribute to the company s top line in the third quarter The company currently expects full year 2017 revenues in the range of  7 69  7 74 billion  annualized growth of 2 6 3 4    The current Zacks Consensus Estimate for revenues is pegged at  7 7 billion  just above the lower end of the guided range In addition  the company s 2017 adjusted EPS range remains at  5 62  5 72  The Zacks Consensus Estimate of  5 65 is within this range Earnings WhispersOur proven model does not conclusively show that Quest Diagnostics is likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here as you will see below Zacks ESP  Quest Diagnostics has an Earnings ESP of  2 52   This is because the Most Accurate estimate of  1 33 is pegged lower than the Zacks Consensus Estimate of  1 37  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Quest Diagnostics has a Zacks Rank  4  Sell   which decreases the predictive power of ESP  Combined with a negative ESP  Quest Diagnostics  chances of an earnings beat can not be conclusively predicted We caution against the stocks with Zacks Rank  4 or 5  Strong Sell  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are a few stocks worth considering from the same space as our proven model shows them to comprise the right combination of elements to beat estimates this quarter   The Cooper Companies  Inc    NYSE COO   has an Earnings ESP of  0 62  and a Zacks Rank  2  You can see  Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   has an Earnings ESP of  6 84  and a Zacks Rank  1 Humana Inc    NYSE HUM   has an Earnings ESP of  1 39  and a Zacks Rank of 1 as well 5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-10-15,Zacks Investment Research,https://www.investing.com/analysis/will-quest-diagnostics-dgx-disappoint-in-q3-earnings-200218969,200218969
120725,342240,VRTX,4 Of The Most Efficient Stocks To Buy Now,opinion,Companies with favorable efficiency levels are likely to be on investors  radar irrespective of market conditions  This is because a company with a favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with its price performance Efficiency  which is the ability to transform inputs into outputs  is a potential indicator of a company s financial health Key Ratios to Identify EfficiencySometimes it becomes difficult to measure the efficiency level of a company  This is the reason why one must consider popular efficiency ratios while selecting stocks  These efficiency ratios are Inventory Turnover  The ratio of 12 month cost of goods sold  COGS  to a four quarter average inventory is considered one of the most popular efficiency ratios  It indicates a company s ability to maintain a suitable inventory position  While a high value indicates that the company has a relatively low level of inventory compared to COGS  a low value indicates that the company is facing declining sales  which resulted in excess inventory  Receivables Turnover   This is the ratio of 12 month sales to four quarter average receivables  It shows a company s potential to extend its credit and collect debt in terms of that credit  A high receivables turnover ratio or the  accounts receivable turnover ratio  or  debtor s turnover ratio  is desirable as it shows that the company is capable of collecting its accounts receivables or that it has quality customers Asset Utilization  This ratio indicates a company s capability to convert assets into output and is thus a widely known measure of efficiency level  It is calculated by dividing total sales over the past 12 months by the last four quarter average of total assets  Like the above ratios  high asset utilization may indicate that a company is efficient Operating Margin  This efficiency measure is the ratio of operating income over the past 12 months to sales over the same period  It measures a company s ability to control operating expenses  Hence  a high value of the ratio may indicate that the company manages its operating expenses more efficiently than its peers Screening ParametersIn addition to the above mentioned ratios  we have added a favorable Zacks Rank  2  Buy  to the screen with an objective to make this strategy more profitable  You can see  Inventory Turnover  Receivables Turnover  Asset Utilization and Operating Margin greater than industry average  Values of these ratios higher than industry averages may indicate that the efficiency level of the company is higher than its peers      The use of these few criteria narrowed down the universe of over 7 906 stocks to only 19 Here are four stocks from the 19 that made it through the screen Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   is engaged in discovering  developing  manufacturing and commercializing medicines for serious diseases  This company has an average four quarter positive earnings surprise of 17 9  Lululemon Athletica inc    NASDAQ LULU   is a designer  distributor and retailer of athletic apparel  The company operates through two segments  Company operated stores and Direct to consumer  It has an average four quarter positive earnings surprise of 8 5  Sanderson Farms  Inc    NASDAQ SAFM   is an integrated poultry processing company  produces  processes  markets  and distributes fresh  frozen  and prepared chicken products in the United States  The company has an average four quarter positive earnings surprise of 14  Farmers   Merchants Bancorp Inc   NASDAQ FMAO   operates as a bank holding company for The Farmers   Merchants State Bank that provides commercial banking  retail banking  and other financial services to individuals and small businesses in northwest Ohio and northeast Indiana  The company has an average four quarter positive earnings surprise of 4 9  You can get the rest of the stocks on this list by signing up now for your 2 week free trial to the Research Wizard and start using this screen in your own trading  Further  you can also create your own strategies and test them first before taking the investment plunge The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at  Zacks Restaurant Recommendations  In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector ,2017-10-19,Zacks Investment Research,https://www.investing.com/analysis/4-of-the-most-efficient-stocks-to-buy-now-200220152,200220152
120726,342241,VRTX,Is A Beat In The Cards For Vertex  VRTX  In Q3 Earnings ,opinion,"We expect Vertex Pharmaceuticals  Inc    NASDAQ VRTX   to beat expectations when it reports its third quarter 2017 results on Oct 25  after the market closes Year to date  Vertex s shares have soared 109 9  while the  has recorded an increase of 12 1  Vertex s track record has been impressive so far  The company delivered positive earnings surprises in three of the last four quarters and missed expectations in one  The average positive earnings surprise in the last four quarters is 17 91   In the last reported quarter  Vertex came up with a positive surprise of 11 43  Let s see how things are shaping up for this quarter Factors at PlayVertex s cystic fibrosis   CF   drugs   Kalydeco   Orkambi   did well in the second quarter  We expect this positive trend to continue in the second as well In May 2017  Kalydeco gained FDA approval for use in patients 2 years and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator   CFTR   gene  Over 900 people in the United States have one of these mutations  In August  Kalydeco received approval for CF patients who have one of five residual function mutation  which causes splicing defect in the CFTR gene  Over 600 people in the United States have one of these mutations  Following these approvals for label expansion  Vertex upped its Kalydeco 2017 revenue guidance to  770  800 million  The Zacks Consensus Estimate for Kalydeco for the third quarter is  197 million Orkambi s sales growth will be dependent on reimbursement discussions in Europe in 2017  In June and July this year  Vertex struck re imbursement agreements in Ireland and Italy  respectively  for Orkambi  thereby making the medicine more accessible in the countries  The expanded accessibility is expected to bring in more sales for the drug In the first quarter  the company had also mentioned that if it gains reimbursement in France this year  it would contribute significantly to revenue growth  However  the company is yet to sign the agreement  The consensus estimate for Orkambi for the third quarter is  322 million Vertex is also evaluating some next generation CFTR correctors  VX 152  VX 440  VX 659 and VX 445  as part of a triple combination with tezacaftor and ivacaftor  Investor focus at the call will be on these triple combination CF regimens  which are crucial for long term growth of Vertex However  operating expenses are likely to shoot up as Vertex expands its pipeline What Our Model IndicatesOur proven model shows that Vertex is likely to beat estimates this quarter because it has the right combination of two key ingredients  A stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen Zacks ESP Earnings ESP  which represents the difference between the Most Accurate estimate  earnings of 39 cents  and the Zacks Consensus Estimate  earnings of 37 cents   stands at  7 24   This is a leading indicator of a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank Vertex currently has a Zacks Rank  2  The combination of a positive Earnings ESP and a favorable Zacks Rank makes us reasonably confident of an earnings beat Conversely  we caution against the Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Vertex Pharmaceuticals Incorporated Price and EPS Surprise
    Other Stocks That Warrant a LookHere are some biotech stocks that you may also want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Clovis Oncology  Inc    NASDAQ CLVS   is expected to release its results on Nov 2  The company has an Earnings ESP of  2 01  and a Zacks Rank  2  You can see  Celgene Corp    NASDAQ CELG   is scheduled to release its results on Oct 26  The company has an Earnings ESP of  0 93  and a Zacks Rank  3 Trevena  Inc    NASDAQ TRVN    which is expected to release results on Nov 2  has an Earnings ESP of  25 93  and a Zacks Rank  2 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-19,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-the-cards-for-vertex-vrtx-in-q3-earnings-200220142,200220142
120730,342245,VRTX,Zacks com Highlights  Vertex Pharmaceuticals  Lululemon Athletica  Sanderson Farms And Farmers   Merchants Bancorp,opinion,For Immediate ReleaseChicago  IL   Oct 23  2017   Stocks in this week s article include  Vertex Pharmaceuticals Inc  NASDAQ VRTX    Lululemon Athletica Inc   Sanderson Farms  Inc  and Farmers   Merchants Bancorp Inc Screen of the Week of Zacks Investment Research  4 of the Most Efficient Stocks to Buy NowCompanies with favorable efficiency levels are likely to be on investors  radar irrespective of market conditions  This is because a company with a favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with its price performance Efficiency  which is the ability to transform inputs into outputs  is a potential indicator of a company s financial health Key Ratios to Identify EfficiencySometimes it becomes difficult to measure the efficiency level of a company  This is the reason why one must consider popular efficiency ratios while selecting stocks  These efficiency ratios are Inventory Turnover  The ratio of 12 month cost of goods sold  COGS  to a four quarter average inventory is considered one of the most popular efficiency ratios  It indicates a company s ability to maintain a suitable inventory position  While a high value indicates that the company has a relatively low level of inventory compared to COGS  a low value indicates that the company is facing declining sales  which resulted in excess inventory Receivables Turnover   This is the ratio of 12 month sales to four quarter average receivables  It shows a company s potential to extend its credit and collect debt in terms of that credit  A high receivables turnover ratio or the  accounts receivable turnover ratio  or  debtor s turnover ratio  is desirable as it shows that the company is capable of collecting its accounts receivables or that it has quality customers Asset Utilization  This ratio indicates a company s capability to convert assets into output and is thus a widely known measure of efficiency level  It is calculated by dividing total sales over the past 12 months by the last four quarter average of total assets  Like the above ratios  high asset utilization may indicate that a company is efficient Operating Margin  This efficiency measure is the ratio of operating income over the past 12 months to sales over the same period  It measures a company s ability to control operating expenses  Hence  a high value of the ratio may indicate that the company manages its operating expenses more efficiently than its peers Screening ParametersIn addition to the above mentioned ratios  we have added a favorable Zacks Rank  2  Buy  to the screen with an objective to make this strategy more profitable  You can see  Inventory Turnover  Receivables Turnover  Asset Utilization and Operating Margin greater than industry average Values of these ratios higher than industry averages may indicate that the efficiency level of the company is higher than its peers  The use of these few criteria narrowed down the universe of over 7 906 stocks to only 19 Here are four stocks from the 19 that made it through the screen Vertex Pharmaceuticals Inc is engaged in discovering  developing  manufacturing and commercializing medicines for serious diseases  This company has an average four quarter positive earnings surprise of 17 9  Lululemon Athletica Inc is a designer  distributor and retailer of athletic apparel  The company operates through two segments  Company operated stores and Direct to consumer  It has an average four quarter positive earnings surprise of 8 5  Sanderson Farms  Inc is an integrated poultry processing company  produces  processes  markets  and distributes fresh  frozen  and prepared chicken products in the United States  The company has an average four quarter positive earnings surprise of 14  Farmers   Merchants Bancorp Inc operates as a bank holding company for The Farmers   Merchants State Bank that provides commercial banking  retail banking  and other financial services to individuals and small businesses in northwest Ohio and northeast Indiana  The company has an average four quarter positive earnings surprise of 4 9  You can get the rest of the stocks on this list by signing up now for your 2 week free trial to the Research Wizard and start using this screen in your own trading  Further  you can also create your own strategies and test them first before taking the investment plunge The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  And that s what we re screening for today For the rest of this Screen of the Week article please visit Zacks com at  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material About Screen of the WeekZacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine   But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has more than doubled the market from 1988 through 2016  Its average gain has been a stellar  25  per year  Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Contact  Jim GiaquintoCompany  Zacks comPhone  312 265 9268Email  Visit  Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2017-10-22,Zacks Investment Research,https://www.investing.com/analysis/zackscom-highlights-vertex-pharmaceuticals-lululemon-athletica-sanderson-farms-and-farmers--merchants-bancorp-200220378,200220378
120733,342248,VRTX,Is Gilead  GILD  Poised For A Beat This Earnings Season ,opinion,"A leader in the hepatitis C virus  HCV  space  Gilead Sciences Inc    NASDAQ GILD    is expected to beat expectations when it reports third quarter results on Oct 26  after the market closes Gilead s track record is pretty mixed  with the company beating estimates in two of the last four and missing in one two  Last quarter  the company beat expectations by 17 4   Overall  the company recorded an average positive earnings surprise of 6 4    Gilead s stock has gained 15 9  year to date against the  11 7   A strong performance in the third quarter will boost share price performance further Why a Likely Positive Surprise Our proven model shows that Gilead is likely to beat on earnings estimates this quarter  This is because it has the right combination of two key ingredients  a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  0 23   This is because the Most Accurate estimate is  2 09 while the Zacks Consensus Estimate is pegged a penny lower at  2 08  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Gilead currently carries a Zacks Rank  3  The combination of Zacks Rank  3 and a positive ESP makes us confident of an earnings beat Conversely  Sell rated stocks  Zacks Rank  4 or 5  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions Gilead Sciences  Inc  Price and EPS Surprise
     
Factors at PlayConcurrent with the second quarter earnings call  Gilead updated its annual guidance  Based on a better than expected performance in the first half of 2017 specifically in the United States  the company raised its guidance for 2017   Gilead now expects net product sales in the range of  24 0  25 5 billion  up from  22 5  24 5 billion provided earlier  Non HCV product sales are projected between  15 5 and  16 0 billion  earlier projection   15 million and  15 5 billion   HCV product sales are projected between  8 5 billion and  9 5 billion  earlier projection   7 5 billion and  9 0 billion   Adjusted R D expenses and adjusted SG A expenses are now projected in the range of  3 2  3 4 billion and  3 2  3 4 billion  respectively  Adjusted product gross margin is expected in the range of 86 88   Earnings per share are now projected around 86 93 cents  earlier projection  84 91 cents  Strong HIV performance and other antiviral product sales are being driven by continued uptake of tenofovir alafenamide  TAF  based products   Genvoya  Descovy and Odefsey  We expect the trend to continue in the third quarter as well  Genvoya has already become the most prescribed regimen for both treatment na ve and switch patients since its launch  This should drive the non HCV product sales   The TAF based regimens now represent 51  of total Gilead HIV prescription volume following the launch of Genvoya and Odefsey and Descovy in 2016   Specifically  Genvoya is now the company s bestselling HIV product with a treatment na ve patient share of 41   The Zacks Consensus estimate for Genvoya stands at  923 million  Strong uptake for Truvada for use in the pre exposure prophylaxis setting is also expected to boost sales   However  Gilead will lose exclusivity for Viread in 2017 in some countries outside the United States which might impact sales Meanwhile  the HCV franchise continues to be under competitive and pricing pressure leading to a massive decline in Harvoni and Sovaldi sales  Harvoni and Sovaldi has been facing competition from AbbVie Inc  s   NYSE ABBV   Viekira Pak and Viekira XR among others  Higher discounts and payer mix continue to impact sales adversely  Despite this  the company increased its guidance for HCV franchise   The Zacks Consensus Estimate for lead HCV drug Sovaldi and Harvoni currently stand at  24 6 million and  1 0 million for the third quarter  The HCV portfolio received a major boost when Epclusa gained approval in 2016  The FDA also approved Vosevi tablets as a single tablet regimen  STR  for the re treatment of chronic HCV infection in adults On the other hand  we expect the company to increase its guidance further for the incremental contribution from the recent Kite Pharma acquisition  The FDA recently approved its chimeric antigen receptor T cell  CAR T  therapy  Yescarta  axicabtagene ciloleucel   for the treatment of refractory aggressive non Hodgkin lymphoma  which includes DLBCL  transformed follicular lymphoma and primary mediastinal B cell lymphoma   We expect the management to throw more light on the same during the third quarter s call  Investors are also likely to keep an eye on other pipeline updates Other Stocks Poised to Beat EstimatesHere are some other health care stocks that you may want to consider  as our model shows that they too have the right combination of elements to post an earnings beat this quarter Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   has an Earnings ESP of  7 24  and a Zacks Rank  2  The company is scheduled to release third quarter results on Oct 25  You can see the complete list of today s Zacks  1 Rank stocks here GlaxoSmithKline plc   NYSE GSK   has an Earnings ESP of  1 28  and a Zacks Rank  2  The company is scheduled to release third quarter results on Oct 25 Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research  It s not the one you think ",2017-10-22,Zacks Investment Research,https://www.investing.com/analysis/is-gilead-gild-poised-for-a-beat-this-earnings-season-200220453,200220453
120746,342261,VRTX,Should You Keep Your Portfolio Healthy With Biotech ETFs ,opinion,"The biotech sector is going through the roof right now with SPDR S P Biotech  MX XBI  ETF  adding over 9  in a month  as of Sep 11  2017   Plenty of factors are powering the sector  Among these  breakthrough U S  Food and Drug Administration  FDA  approvals  success in the immune oncology field  and mergers and acquisitions are at the forefront 
Biotech stock Vertex Pharmaceuticals   NASDAQ VRTX   received a new FDA approval for cystic fibrosis drug    In early September  FDA approved  Novartis AG  breakthrough gene transfer treatment  Kymriah  tisagenlecleucel  suspension for the treatment of patients up to 25 years of age with B cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse   as per  
Investors should note that CAR T is a fresh immunocellular therapy and many companies are eyeing it  In fact  Gilead Sciences   NASDAQ GILD   announced the buyout of Kite Pharma   NYSE K   for  11 9 billion in late August  read     Kite Pharma is expected to receive approval for its CAR T therapy axicabtagene ciloleucel  axi cel  shortly  With this acquisition  Gilead will step into the new arena of oncology treatment  known as CAR T  which targets the body s own immune system to fight tumors 
Two months ago  Clovis Oncology   NASDAQ CLVS   shares also skyrocketed following the company s positive cancer drug data  The company then said that clinical trial data on its ovarian cancer drug treatment indicated that it may substantially help more patients than expected  read    
If this was not enough  Teva Pharmaceutical  NYSE TEVA   shares surged over 19  on Sep 11 as it appointed a former Novo Nordisk  CO NOVOb   NVO  as CEO  The new recruitment followed Teva s last full time CEO s seven month term and resignation  
Compelling Valuation 
Biotech stocks were the  among the S P 500 members last year  This has probably made the space cheap and helped it to be back with a bang  Biotech ETF XBI added about 17 7  in the last three months  as of Sep 11  2017  while SPDR S P 500 ETF  NYSE SPY    AX SPY   was up 2 9   The fund XBI has a relative strength index of 66 95  This means that the fund is yet to enter the overbought territory 
Also  fears over price gouging are ebbing substantially in the Trump administration  In a nutshell  the space is riding on research and development and may log more returns ahead 
ETFs to Tap 
Below we highlight a few biotech ETFs that can benefit investors with solid gains   here  
Direxion Daily S P Biotech Bull 3X  
Ultrapro Nasdaq Biotechnology Proshares  
ProShares Ultra Nasdaq Biotechnology  
iShare Nasdaq Biotech ETF  
Bioshares Biotech Clinical Trial   HM BBC   
VanEck Vectors Biotech ETF   LON BBH   
Bioshares Biotech Products   BS BBP    
Loncar Cancer Immunotherapy ETF  
ALPS Medical Breakthroughs ETF   SI SBIO  

Want key ETF info delivered straight to your inbox  
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2017-09-12,Zacks Investment Research,https://www.investing.com/analysis/should-you-keep-your-portfolio-healthy-with-biotech-etfs-200212886,200212886
120747,342262,VRTX,5 Top Performing Stocks Driving S P 500 ETF Higher,opinion,After weeks of shaky trading  the Wall Street continued its second largest bull run  dodging the list of woes including geopolitical tension  Washington turmoil  elevated valuations  the aftermath of hurricanes Harvey   Irma as well as rounds of downbeat economic data In particular  the S P 500 is in the spotlight  with the index breaching the 2 500 milestone for the first time  bringing its year to date gains to nearly 12   According to   this rally overtook the 266  increase in the index during the 1949 56 bull run and added almost  20 trillion to the value of American equities  The journey of 100 points came in less than four months  suggesting strong complacency in the stock market Renewed hopes for Trump s tax reform by the end of the year is the main catalyst in driving the stock market to new highs  Additionally  steady economic fundamentals and strong corporate earnings added to the strength  The upward trend is likely to continue in the months ahead  read    Given the enthusiasm  investors are flocking to its ETF  iShares Core S P 500 ETF   Let s take a closer look at the fundamentals of IVV and its performance IVV in FocusIVV is the top asset creator this year pulling in nearly  24 1 billion in capital  It tracks the S P 500 Index and holds 505 stocks in its basket  with each security holding no more than 3 85  of total assets  This suggests a nice balance across each security and prevents heavy concentration  However  the product is slightly tilted toward information technology sector with 23 1  share while health care  financials  consumer discretionary and industrials account for a double digit exposure each  The ETF is the low cost choice in the space  charging 4 bps in fees per year from investors and trades in solid volume of 3 4 million shares a day on average The fund has gained 13 1  in the year to date time frame and has a Zacks ETF Rank  2  Buy  with a Medium risk outlook  Though most of the stocks in the fund s portfolio have delivered impressive returns  a few were the real stars gaining more than 60   read    Below  we have highlighted the five best performing stocks in the ETF with their respective positions in the fund s basket Best Performing Stocks of IVVVertex Pharmaceuticals   NASDAQ VRTX    The stock has surged 108 5  so far this year and carries a Zacks Rank  3  Hold  with a VGM Style Score of A  The company has seen positive earnings estimate revision of eight cents for this year over the past three months with an expected earnings growth rate of 95 19  compared with the industry average of 5 69   The stock has a solid Zacks Industry Rank in the  and accounts for just 0 2  share in IVV Align Technology Inc    NASDAQ ALGN    This stock makes up for 0 06  allocation in the fund s basket and has delivered incredible returns of 91 9  so far this year  The stock has seen solid earnings estimate revision of 13 cents over the past three months for this year  reflecting year over year earnings growth of 41 16   much higher than the industry average growth of 9 83   Further  Align Technology has a Zacks Rank  3 with a VGM Style Score of C and has a dismal Zacks Industry Rank in the  NRG Energy Inc    NYSE NRG    The stock has gained about 87  in the year to date time frame  Though NRG has seen positive earnings estimate revision of six cents over the past three months for this year  its earnings are expected to decline 53 59  annually compared with the industry s average growth of 6 19   NRG Energy currently has a Zacks Rank  2 with a VGM Style Score of B  The stock has an ugly Zacks Industry Rank in the  and makes up for 0 03  share in IVV  read    Activision Blizzard Inc   NASDAQ ATVI    This stock has surged 80  so far this year and has 0 23  exposure in the fund s basket  Though it has seen solid earnings estimate revision of 10 cents over the past three months for this year  its earnings are expected to decline 3 50  year over year compared with the industry s average growth of 18 26   Activision Blizzard has a Zacks Rank  1  Strong Buy  with a VGM Style Score of D and belongs to solid Zacks Industry Rank in the  Centene Corporation   NYSE CNC    This stock accounts for 0 08  of assets in the fund s basket  It has gained 69 8  in the year to date time frame and has seen solid earnings estimate revision of 16 cents over the past three months for this year  However  its earnings are expected to grow 11 04   well below the industry average of 18 89   Centene Corporation has a Zacks Rank  2 with a VGM Style Score of A  It belongs a robust Zacks Industry Rank in the  Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2017-09-17,Zacks Investment Research,https://www.investing.com/analysis/5-topperforming-stocks-driving-sp-500-etf-higher-200213937,200213937
120748,342263,VRTX,Top Stock Reports For Goldman Sachs  PepsiCo And Johnson   Johnson,opinion,"Wednesday  September 27  2017
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 12 major stocks  including Goldman Sachs Group Inc  NYSE GS   GS   PepsiCo  Inc   PEP  and Johnson   Johnson  NYSE JNJ   JNJ   These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
You can see 
Goldman Sachs  shares have lost  3 9  in the year to date period  compared with the  11 3  gain of the Zacks Investment Bank industry  Yet the company carries an impressive earnings surprise history  It has surpassed the Zacks Consensus Estimate for earnings in three of the trailing four quarters 
Though the company s well diversified business  expected lesser regulations and its focus to capitalize on growth opportunities through strategic moves should continue to bolster overall business  various lawsuits which have yet to be resolved are likely to lead to elevated expenses and litigation provisions in the near term 
 You can   
PepsiCo s shares have gained  4 1  over the last year  outperforming the Zacks Soft Beverages industry  which has increased  3 8  over the same period  PepsiCo has been doing well on the back of significant innovation  continued momentum in Frito Lay business  revenue management strategies  improved productivity and cost saving initiatives  along with better market execution  
Moreover  it has been seeing higher volumes and profits in the North American segments due to an improving economy  better industry pricing dynamics and a consistency in positive innovation 
 You can   
Johnson   Johnson s shares have gained  13 8  in the year to date period  compared with the  11 8  gain of the Zacks Large Cap Pharmaceuticals industry  J J is optimistic that sales growth will accelerate in 2H17  We believe that new drugs like Xarelto  Stelara  Darzalex and Imbruvica remain the key to growth  
Meanwhile  share buybacks and restructuring initiatives should provide bottom line support  J J is also making rapid progress with its pipeline and line extensions  The Actelion buy adds an attractive new therapeutic area   PAH   which should contribute to sales growth 
 You can   
Other noteworthy reports we are featuring today include Vertex Pharmaceuticals Inc  NASDAQ VRTX    VRTX   Cummins Inc  NYSE CMI    CMI  and Fidelity National Information Servcs Inc   FIS  
4 Promising Stock Picks to Keep an Eye On 
With news stories about computer hacking and identity theft becoming increasingly commonplace  the cybersecurity industry looks like a promising investment opportunity  But which stocks should you buy  Zacks just released Cybersecurity  An Investor s Guide to Locking Down Profits to help answer this question 
This new Special Report gives you the information you need to make well informed investment choices in this space  More importantly  it also highlights 4 cybersecurity picks with strong profit potential 

Mark Vickery
Senior Editor
Note  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read









Featured Reports

Per the Zacks analyst  JA Solar s focus on widening its geographical customer base has resulted in incremental global sales  


While Cabot s cost management and attractive Marcellus program bode well  the Zacks analyst would prefer to wait for further natural gas price recovery before recommending investors purchase shares 


The Zacks analyst views favorably changes in its sales mix aimed at reducing long term claims variability  but will hurt from high cost from investments in digitization 


Per the Zacks analyst  Cummins  revenues in India are likely to remain flat in 2017  Also  in Brazil  weak demand is adversely affecting its the truck production 


Per the Zacks analyst  Fidelity is well poised to benefit from investment in mobile banking and innovative products such as PayNet and BuyWay  

New Upgrades

Vertex has two cystic fibrosis  CF  drugs  Kalydeco   Orkambi in its portfolio with blockbuster potential  The Zacks analyst says that Vertex s triple combination CF regimens are crucial for growth


Per the Zacks analyst  revival of gaming revenues in Macau and the opening of Wynn Palace is likely to propel the top line  Continued improvement in the Las Vegas business should further drive growth 

New Downgrades

Per the Zacks analyst  Nucor s Q3 results are expected to be hurt by pricing pressure stemming from higher steel imports as well as unplanned outages  Nucor sees earnings to fall sequentially in Q3 


Per the Zacks analyst  delay in launching Acorda s Parkinson s candidate Inbrija with FDA issuing refusal to file letter and patent issues with its key drug Ampyra may affect the top line in near term",2017-09-27,Zacks Investment Research,https://www.investing.com/analysis/top-stock-reports-for-goldman-sachs-pepsico-and-johnson--johnson-200215761,200215761
120749,342264,VRTX,Mallinckrodt  MNK  Closes InfaCare Pharmaceutical Buyout,opinion,"Mallinckrodt plc   NYSE MNK   announced that it has acquired privately held InfaCare Pharmaceutical Corporation This specialty pharmaceutical company focuses on the development and commercialization of proprietary pharmaceuticals for neonatal and pediatric patients InfaCare s product candidate  stannsoporfin  is expected to become the first and only pharmacologic option for the treatment of neonates for severe hyperbilirubinemia  or severe jaundice if and when approved The company made an upfront payment of  80 million  Mallinckrodt is also required to pay up to  345 million as milestone payments  The acquisition to be dilutive to the bottom line by 15 cents to 20 cents for 2017 and modestly higher in 2018 Per estimates  the total number of term births is estimated at 3 7 million per year and  of those  approximately 750 000 infants are treated for jaundice  Among these  a large number are unresponsive to phototherapy  Hence  there is an unmet need for treatment of these infants  The combined potential patient treatments required annually in the United States for severe jaundice is approximately 70 000 to 125 000 We note that Mallinckrodt is currently focused on reshaping its product portfolio through strategic acquisitions and non core asset divestitures to transform the portfolio and become a high performing specialty pharmaceutical company The acquisition will diversify its pediatric pipeline and strengthen the brands business The company s generic segment continues to face weakness as various product categories are witnessing stiff competition  which is hurting both volumes and prices  The company expects double digit declines in revenues from this segment  In addition  continued expected weakness in this segment will adversely impact gross profit margins also  The company sold its Nuclear Imaging business due to persistent challenging conditions  The company also sold its Intrathecal Therapy business to focus on key areas  While Acthar sales continue to be strong on the back of increased formulary positions and access for appropriate patients in both the commercial and public environments  sales of Therakos is expected to decline Investors interested in the healthcare sector can consider stocks stocks like include Alexion Pharmaceuticals  Inc    NASDAQ ALXN   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and Vertex Pharmaceuticals  Incorporated   NASDAQ VRTX   as valuable picks 
Will You Make a Fortune on the Shift to Electric Cars  
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers 
Some are already reaching 265 miles on a single charge  With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2017-09-28,Zacks Investment Research,https://www.investing.com/analysis/mallinckrodt-mnk-closes-infacare-pharmaceutical-buyout-200216225,200216225
120750,342265,VRTX,3 Top Ranked Big Biotech Stocks To Buy Now,opinion,The biotech industry has witnessed a great turnaround this year after the drug pricing issue crippled its performance last year  After declining 27 1  last year  the industry has risen 15 3  this year so far  outpacing 12 7  gain for the S P 500 in the same time frame The NASDAQ Biotechnology Index is up almost 26  year to date after sliding 19 1  in 2016  The Zacks Industry Rank is  106  to 40  of the 250 plus Zacks industries  for Medical Biomed and Genetics  indicating a bright outlook for the sector going forward The biotech sector has a number of things going in its favor  Strong quarterly results  new product sales ramp up with rising demand  successful innovation and product line expansion  strong clinical study results  more frequent FDA approvals and continued strong performance from legacy products have played a pivotal role in bringing the sector on track this year  Another factor that has contributed to the sector s surge is that President Trump s expected action on drug prices may not be as onerous as previously feared These factors should continue to drive the sector through the rest of this year and probably the next as well despite challenges like rising competition  pipeline setbacks  slowdown in growth of mature products and generic competition for certain key drugs  On the broader macro front  the proposed tax reforms  if approved  will leave more cash in the hands of these companies  The cash can be invested for mergers acquisitions  which have been relatively fewer this year compared with the last With biotech stocks on a tear  here we have picked three of the biggest biotech companies which look well poised for growth and can be added to one s portfolioAmgen  Inc    NASDAQ AMGN  Amgen is one of the leading biotechnology companies in the world with several blockbuster drugs in its portfolio  Amgen s newer drugs   Prolia  Xgeva  Vectibix  Nplate and Sensipar   are all performing well  Amgen is also progressing with its pipeline  including biosimilar drugs  Last month  it received FDA approval for Mvasi  its biosimilar version of Roche s cancer drug  Avastin  Mvasi is the first biosimilar approved in the United States for the treatment of cancer  Other recent positive pipeline regulatory developments at Amgen include EU approval for a pediatric formulation of Mimpara  positive long term data from Kyprolis ENDEAVOR study  and regulatory filings for label expansion of Prolia and Kyprolis  among others Supported by the positive developments  Amgen s shares have outperformed the industry so far this year  Shares have risen 28   comparing favorably with the industry s gain  Amgen carries a Zacks Rank  2  Buy   You can see  Earnings estimates for 2017 have risen 1 2  while that for 2018 have gone up by 1 3  in the past 90 days Celgene Corporation   NASDAQ CELG  Celgene s key growth driver  multiple myeloma drug Revlimid  continues to drive revenues at the company  Meanwhile  Celgene s label expansion efforts for Revlimid bode well for further sales growth of the drug  Other key products   Pomalyst Imnovid  Abraxane and Otezla   are also performing well  A recent positive development at Celgene was the FDA approval for Idhifa for the treatment of adult patients with relapsed or refractory acute myeloid leukemia  AML Celgene also carries a Zacks Rank of 2  Earnings estimates for both 2017 and 2018 have risen by 0 7  in the past 90 days  The stock has gone up by 26 1  this year  outperforming the industry Biogen  Inc    NASDAQ BIIB  Biogen has a strong position in the multiple sclerosis market backed by a wide range of products  Biogen is trying to diversify its pipelineand is looking to strengthen its Alzheimer s disease  AD  and other neurodegenerative disorders pipeline  Newly launched Spinraza for spinal muscular atrophy is also off to a promising start  Spinraza has witnessed faster than expected adoption in the United States and Biogen is ramping up launch efforts  internationally Recent key positive pipeline regulatory developments at Biogen include promising long term dataon Alzheimer disease candidate  aducanumab and EU approval of Imraldi  Biogen s biosimilar version of AbbVie s top selling blockbuster drug  Humira  Biogen has made several new executive appointments to bring its management team back on track after several key executives departed over the past couple of years including CEO George A  Scangos and CFO Paul Clancy Biogen  also a  2 Ranked stock  has seen its 2017 earnings estimates rise 4 7  for 2017 and 2 3  for 2017 over the past 90 days  Shares have risen 11 5  this year Two other biotech companies  though smaller than the above mentioned companies  are worth mentioning Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   has seen its share price shoot up 106 6  this year so far with earnings estimates rising 5  for 2017 and 6 8  for 2018  The stock is riding high on the success of its cystic fibrosis  CF  pipeline  particularly its triple combination CF regimens as these have the potential to treat up to 90  of CF patients Regeneron Pharmaceuticals  Inc    NASDAQ REGN   saw the launch of its key pipeline candidates Dupixent for atopic dermatitis and Kevzara for rheumatoid arthritis in the United States this year  Both the drugs are also approved in the EU  Meanwhile  Regeneron s key growth driver  Eylea  continues to drive revenues on market share gains and the company is expanding the drug s label for additional indications  While Regeneron s shares have risen 25 9  this year  its earnings estimates have gone up by 16 6  for 2017 and 7 3  for 2018 Both Vertex and Regeneron have been sporting a Zacks Rank  1  Strong Buy  for quite some time and may soon join the league of the big biotech stocks Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-10-02,Zacks Investment Research,https://www.investing.com/analysis/3-topranked-big-biotech-stocks-to-buy-now-200216691,200216691
120756,342271,VRTX,Forget Teva  TEVA   Buy These 5 Drug Stocks Instead,opinion,"Israel based generic drug maker  Teva Pharmaceutical Industries Limited   NYSE TEVA    saw its shares decline 9 4  last week with the company suffering a fresh setback in the form of FDA approval of a generic version of the company s top selling branded drug  Copaxone  multiple sclerosis   Mylan NV   NASDAQ MYL   gained FDA approval for its generic version of the 40 mg  thrice weekly  dosage as well as the once daily 20 mg formulation of Copaxone  With Mylan being among the first applicants to challenge the 40 mg patent  the company could enjoy 180 days of exclusivity  Mylan has launched both products  Mylan also gained approval for the 40 mg dose in the EU The FDA approval of generic Copaxone is a major blow for Teva which is currently facing a whole lot of challenges  Teva issued a statement saying that the launch of the 40 mg formulation before the final resolution of pending patent infringement lawsuits with Mylan will be treated as an  at risk  launch   this means Mylan would have to pay significant damages if the court upholds the patents protecting the drug Copaxone brought in total sales of  1 99 billion in the first half of 2017  At the end of the second quarter of 2017  Copaxone 40 mg accounted for more than 85  of total Copaxone prescriptions in the United States The entry of the 40 mg formulation and the entry of a second generic version of the 20 mg formulation  Sandoz and Momenta have been on the market for quite a while with Glatopa  a generic version of the 20 mg dose  is expected to cut Teva s 4Q earnings by at least 25 cents per share  Additional details should be out when the company announces third quarter results on November 2  The entry of generic Copaxone just adds to the existing list of problems being faced by Teva Generic pricing erosion remains a huge issue for generic companies like Teva  The sharp decline in generic drug prices  while a blessing for patients  is proving to be a major challenge for generic drugmakers as well as drug distributors Consolidation in the industry has increased the ability to negotiate lower prices for generic drugs leading to increasing price erosion and decreasing volume  Moreover  the FDA is speeding up the approval of generic drugs which means more competition  increasing price cuts and decreasing volume  Teva said that price erosion was around 6  in the second quarter and is expected to increase to high single digits over the remainder of the year  All these headwinds will persist for the U S  Generics unit into the near future  resulting in lower revenue and profit in this segment in 2018 and potentially 2019 Meanwhile  the company said that it does not expect any earnings contribution from its businesses in Venezuela given the significant devaluation of the Venezuelan currency  Teva also cut its dividend by 75  Teva has many challenges ahead   paying down debt  divesting non core businesses to increase focus on core areas and generate cash  delivering on the pipeline and getting the U S  generics business back on track The company has been working on addressing these issues and recently announced the appointment of a new CEO  Read more     Teva has also made significant progress in the divestment of non core businesses  However  the entry of Copaxone 40 mg is a major setback for the company and it could well be a while before Teva is able to get back on track Teva is a Zacks Rank  4  Sell  stock  The company has seen the Zacks Consensus Estimate for current year earnings being revised 1 9  downward over the last 7 days while the Zacks Consensus Estimate for 2018 has been revised 5 1  downward over the last 7 days  Teva has lost 56  of its value year to date versus the 20 5  decline of its  
While Teva deals with these challenges  here is a look at five drug companies that sport a strong Zacks Rank and look well positioned Celgene Corporation   NASDAQ CELG    Celgene is focused on the discovery  development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases  The company has several blockbuster products in its portfolio including Revlimid  Pomalyst  and Otezla  Celgene has a rich and promising pipeline as well with key data readouts lined up for the next two years Celgene  a Zacks Rank  2  Buy  stock  has gained 20 3  year to date  outperforming the 14 1  rally of the  it belongs to  The company also has a  of A  The VGM Score is a useful tool that allows investors to gain an insight into a stock s strengths and weaknesses Our research shows that stocks with a VGM Score of A or B when combined with a Zacks Rank  1 or  2 offer the best upside potential  You can see  
Pfizer Inc    NYSE PFE    Pfizer is focused on the development and commercialization of a wide range of medicines and vaccines as well consumer health care products  During the first half of the year  the company paid  8 9 billion in dividends and share buybacks to its shareholders including a  5 billion accelerated share repurchase program Pfizer  which expects 2017 revenues to be affected by about  2 5 billion due to loss of exclusivities  LOEs   is working on bringing new products to market to make up for lost sales  The company has 15 potential blockbusters lined up for the next 5 years with about half of these potentially by 2020  Focus also remains on growing new products like Ibrance  Eliquis and Xeljanz  Meanwhile  the impact of LOEs should continue declining in the coming years  about  2 billion in 2018 as well as 2019   1 billion    2 billion in 2020   1 billion in 2021  and  0 5 billion or less from 2022 to 2025  Pfizer  a Zacks Rank  2 stock  carries a VGM Score of B 
Amgen   NASDAQ AMGN    Amgen  one of the most well known names in the biotech industry  has a presence in the oncology hematology  inflammation  nephrology  bone health and cardiovascular disease markets  Key products include Enbrel  Neulasta  Aranesp  Prolia  Xgeva  Epogen  Kyprolis  Repatha  and Blincyto among others  Most of these products are either blockbusters or have blockbuster potential  Amgen has a deep pipeline with the company working on bringing new products to market to combat the impact of potential biosimilar competition for mature products in its franchise  The company has been returning value to shareholders in the form of share buybacks and dividends Amgen is also a Zacks Rank  2 stock with a VGM Score of B  The stock has gained 27 1  year to date  outperforming the 14 1  rally of the  it belongs to 
Vertex Pharmaceuticals   NASDAQ VRTX    Vertex is a key player in the cystic fibrosis  CF  market  The company holds a strong position in this market with two marketed products   Orkambi and Kalydeco  Vertex is working on expanding its CF portfolio and is currently seeking both FDA and EMA approval for a tezacaftor ivacaftor combination  With the FDA granting priority review  a response should be out by Feb 28  2018 Vertex  a Zacks Rank  1 stock  has gained 110 5  year to date  substantially outperforming the 14 1  rally of the  it belongs to 
Ligand Pharmaceuticals Incorporated   NASDAQ LGND    Ligand s business model is based on developing or acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure  The company is focused on the development and licensing of biopharmaceutical assets  Ligand s Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties  The company s partners include big names like Amgen and Novartis among others  Ligand also has licensing deals based on its OmniAb technology Ligand s recent decision to acquire Crystal Bioscience  a leader in avian genetics and the generation of fully human therapeutic antibodies  is expected to boost the company s 2018 revenues by at least  5 million and earnings by at least 9 cents per share Ligand  a Zacks Rank  1 stock  has gained 39 4  year to date  substantially outperforming the 14 1  rally of the  it belongs to 
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana       Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-10-08,Zacks Investment Research,https://www.investing.com/analysis/forget-teva-teva-buy-these-5-drug-stocks-instead-200217780,200217780
120757,342272,VRTX,5 Pharma   Biotech Stocks That Could Be Big Winners In Q3 Earnings,opinion,"Pharma and biotech stocks started 2017 on a strong note with this part of the market remaining in favor as the year progresses  So far this year  the Nasdaq Biotechnology Index and the NYSE ARCA Pharmaceutical Index are up 25 6  and 14 6   respectively With investors being more comfortable with the drug pricing scenario  focus has shifted to the fundamentals of the sector  Although the drug pricing issue will remain a headwind  expectations are that steps taken by the Trump administration to drive down drug prices will not be as draconian as previously expected   Deregulation and increased competition seem to be some of the ways that will be used to control drug prices  The FDA is working to lower healthcare costs by speeding up the development of next generation treatments  especially for rare diseases or targeted cancer therapies and is also working on clearing up a backlog of orphan drug applications 
The FDA has approved far more drugs this year than it did in the whole of 2016  Key approvals this year include Novartis s   NYSE NVS   Kymriah  the first gene therapy in the United States   Lilly s Verzenio  advanced or metastatic breast cancer   Gilead s   NASDAQ GILD   Vosevi  hepatitis C virus   Puma s Nerlynx  to reduce the risk of breast cancer returning   J J s Tremfya  moderate to severe plaque psoriasis   Regeneron Sanofi s Kevzara  rheumatoid arthritis   Roche s multiple sclerosis treatment  Ocrevus  Regeneron and Sanofi s eczema treatment  Dupixent  Tesaro s PARP inhibitor  Zejula  and BioMarin s Brineura  treatment of a specific form of Batten disease  among others  Quite a few of these drugs have blockbuster potential Meanwhile  some other factors that should continue having a positive impact on pharma and biotech stocks are new product sales ramp up  R D success and innovation  strong results  a higher number of FDA approvals and continued strong performance from legacy products According to the Zacks  report  the medical sector  which has been among the better performing sectors over the last several quarters  is expected to record earnings growth of 1  on revenue growth of 4 7  in the third quarter Given this scenario and with medical sector earnings round the corner  it would make sense to look at some pharma and biotech stocks that are expected to report a positive earnings surprise in the quarter Investing in such stocks could prove beneficial for investors as an earnings beat usually leads to significant share price appreciation 5 Drug Stocks to Keep an Eye on This Earnings SeasonWith the help of the   we have zeroed in on five pharma and biotech stocks that sport a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  and have a positive   Earnings ESP is a very valuable tool for investors looking for stocks that are most likely to beat earnings estimates  Moreover  adding a Zacks Rank of  1  2 or 3 has produced a positive surprise 70  of the time  While you can see   you can uncover the best stocks to buy or sell before they re reported with our  Pfizer Inc    NYSE PFE    Pfizer is focused on the development and commercialization of a wide range of medicines and vaccines as well consumer health care products  The company has surpassed earnings expectations in each of the first two quarters of 2017  Key revenue drivers include Ibrance  Eliquis and Xeljanz  Pfizer  which expects 2017 revenues to be affected by about  2 5 billion due to loss of exclusivities  LOEs   is working on bringing new products to market to make up for lost sales  The company has 15 potential blockbusters lined up for the next 5 years with about half of these potentially by 2020  Focus also remains on growing new products like Ibrance  Eliquis and Xeljanz  Meanwhile  the impact of LOEs should continue declining in the coming years  about  2 billion in 2018 as well as 2019   1 billion    2 billion in 2020   1 billion in 2021  and  0 5 billion or less from 2022 to 2025  Pfizer  a Zacks Rank  2 stock  carries a  of B  The VGM Score is a useful tool that allows investors to gain an insight into a stock s strengths and weaknesses Our research shows that stocks with a VGM Score of A or B when combined with a Zacks Rank  1 or  2 offer the best upside potential This company  which will be reporting third quarter results on October 31  has an earnings ESP of  0 84  
Eli Lilly and Company   NYSE LLY    Lilly  which has a strong presence in the pharmaceuticals as well as animal health segments  is slated to report third quarter 2017 results on October 24  This Zacks Rank  3 stock has an earnings ESP of  4 46  for the third quarter  Lilly surpassed earnings expectations in the first two quarters of 2017  Although the company is facing challenges including generic competition  new products should drive results  Lilly has several important pipeline catalysts lined up for the coming quarters as well  Estimated earnings growth for the current year is 17 9  Lilly has gained 18 4  year to date  compared to the 18  rally of the  it belongs to 
Vertex Pharmaceuticals   NASDAQ VRTX    Vertex  a key player in the cystic fibrosis  CF  market  surpassed earnings expectations in three of the last four quarters with an average surprise of 17 9   The company holds a strong position in the CF market with two products  Orkambi and Kalydeco  in its portfolio  Early in August  Vertex had said that it expects its CF franchise to deliver revenues of  1 87 billion    2 1 billion in 2017 including Orkambi revenues of  1 1 billion    1 3 billion 
The company is working on expanding its CF portfolio and is currently seeking both FDA and EMA approval for a tezacaftor ivacaftor combination  With the FDA granting priority review  a response should be out by Feb 28  2018 Vertex  a Zacks Rank  1 stock  has gained 111 1  year to date  substantially outperforming the 13 9  rally of the  it belongs to  The company  which is expected to report third quarter results on October 24  has an Earnings ESP of  2 56  for the quarter 
Biogen Inc    NASDAQ BIIB    Biogen is a key name in the multiple sclerosis   MS   market with several approved products like Tecfidera  Tysabri and Avonex in its portfolio  The company also has a spinal muscular atrophy product  Spinraza  in its portfolio and is working on developing treatments for diseases like Alzheimer s  Parkinson s and amyotrophic lateral sclerosis Biogen s earnings track record is good with the company surpassing earnings expectations in each of the last four quarters with an average surprise of 6 4   The company  which is scheduled to report third quarter results on October 24  has an Earnings ESP of  0 32   Over the last 7 days  the stock has seen the Zacks Consensus Estimate for third quarter and current year earnings being revised 0 5  and 0 2   respectively Biogen  a Zacks Rank  3 stock  has gained 16  year to date  outperforming the 13 9  rally of the  it belongs to 
Merck   NYSE MRK    Merck  a Zacks Rank  3 stock  has consistently surpassed earnings expectations over the last four quarters with an average surprise of 8 1   The company will be reporting Q3 earnings on October 27   earnings ESP for Q3 is  0 28   Although the company does have challenges in the form of generic competition as well as safety issues related to some studies being conducted with Keytruda  new products like Keytruda and the strong performance of the base business should provide support  Merck also has a deep pipeline which bodes well for long term growth 
Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-10-09,Zacks Investment Research,https://www.investing.com/analysis/5-pharma--biotech-stocks-that-could-be-big-winners-in-q3-earnings-200217964,200217964
120772,342287,VRTX,Can Intercept  ICPT  Beat Estimates This Earnings Season ,opinion,"Intercept Pharmaceuticals  Inc    NASDAQ ICPT   is scheduled to report second quarter 2017 results on Jul 31 In the last reported quarter  the company beat expectations by 15 4   Let s see how things are shaping up for this announcement Intercept s share price movement in the year so far reveals that the stock outperformed the   The company s shares have rallied 18 3  during this period compared with the industry s 12 8  gain Surprise HistoryIntercept s track record has been decent so far  with the company surpassing expectations in three of the last four quarters  The company has posted an average positive earnings surprise of 0 06  over this period Why a Likely Positive Surprise Our proven model shows that Intercept is likely to beat estimates this quarter because it has the right combination of two key ingredients  a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is at  9 39   This is because the Most Accurate estimate is pegged at a loss of  3 28 while the Zacks Consensus Estimate is pegged at a loss of  3 62  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Intercept currently carries a Zacks Rank  3  The combination of Zacks Rank  3 and a positive ESP makes us confident of an earnings beat in the upcoming release Conversely  Sell rated stocks   4 or 5  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions Factors at PlayIntercept received a major boost with the FDA s approval  in May 2016  of its lead drug  Ocaliva  in combination with ursodeoxycholic  UDCA   for the treatment of primary biliary cholangitis  PBC  in adults with an inadequate response to UDCA or as monotherapy in adults unable to bear with UDCA  In Dec 2016  the European Commission also granted conditional approval to Ocaliva for the same indication Ocaliva generated sales of  20 6 million in the last quarter The initial uptake of Ocaliva has been encouraging and sales of the drug is expected topick up further in 2017 Meanwhile  Ocaliva is being evaluated for other indications including non alcoholic steatohepatitis  NASH  and primary sclerosing cholangitis  PSC  Intercept expects operating expenses in the range of  380  420 million in 2017 to support the continued commercialization of Ocaliva in PBC in the United States and other markets  sustained clinical development for OCA in PBC and NASH and the continued advancement of INT 767 and other pipeline programs The company initiated a phase III study  REGENERATE  on Ocaliva for the treatment of non cirrhotic NASH in patients with advanced liver fibrosis  The FDA approved a redesign of the REGENERATE trial for the safety and efficacy in treating NASH patients with liver fibrosis  The company now needs to achieve only one co primary endpoint   either fibrosis improvement or NASH resolution as compared to the earlier target of achieving both  The sample size of the trial has also been reduced to approximately 750 patients or about 250 patients per arm  The company plans to complete enrolment for the interim analysis cohort in the REGENERATE trial soon  data readout in 2019  Intercept also initiated a phase II study  CONTROL  Combination OCA aNdsTatins for monitoRing Of Lipids   on OCA  Enrolment in the study was completed in third quarter 2016  with top line data expected shortly  The company also plans to initiate a phase III trial on Ocaliva in NASH patients with cirrhosis in the second half of 2017  The company also expects top line results from the phase II trial  AESOP  in primary sclerosing cholangitis  PSC   We expect investors to remain focused on sales ramp up of Ocaliva and pipeline updates on the call Intercept Pharmaceuticals  Inc  Price and EPS Surprise
    Stocks That Warrant a LookHere are some other health care stocks that you may want to consider  as our model shows that they too have the right combination of elements to post an earnings beat this quarter 
Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   scheduled to release results on Jul 26  has an Earnings ESP of  33 3  and a Zacks Rank  1  You can see  Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  3 32  and a Zacks Rank  3  The company is scheduled to release results on Jul 26 Alexion Pharmaceuticals  Inc    NASDAQ ALXN   has an Earnings ESP of  6 48  and a Zacks Rank  3  The company is scheduled to release results on Jul 27 More Stock News  Tech Opportunity Worth  386 Billion in 2017
From driverless cars to artifical intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential   ",2017-07-24,Zacks Investment Research,https://www.investing.com/analysis/can-intercept-(icpt)-beat-estimates-this-earnings-season-200203268,200203268
120773,342288,VRTX,Drug Stocks Q2 Earnings Releases On Jul 26  GILD  VRTX  GSK,opinion,We are entering the peak period of the second quarter reporting cycle this week  The quarter  undoubtedly  is off to a strong start As of Jul 21  2017  97 S P 500 members  accounting for 28 1  of the index s total market capitalization  reported results  according to    Of these  59 8  beat both revenues and earnings estimates compared with 50 5  in the first quarter Total earnings for these 97 index members were up 8 4  from the year ago quarter on a 5 1  improvement in revenues  The beat ratio was 78 4  for earnings and 72 2  for revenues The earnings momentum is expected to continue through the season  Per the report  total earnings for S P 500 companies in the second quarter are expected to grow 8 6  year over year on 4 7  higher revenues  This follows 13 3  earnings growth in the first quarter on 7  increase in revenues  the highest in almost two years Among the pharma bigwigs  Johnson   Johnson   NYSE JNJ   J J reported mixed second quarter results  beating on earnings but missing on sales  On the other hand  Novartis    NYSE NVS   second quarter results were encouraging as the company topped both earnings and sales estimates  On Jul 25  Lilly   NYSE LLY   and Biogen Inc    NASDAQ BIIB   released their second quarter results  Both the companies beat earnings and revenue estimates  Lilly raised its previously issued 2017 adjusted earnings and sales outlook  Biogen also raised its earnings and sales outlook for 2017 Let s take a look at three pharma giants that are set to report second quarter results on Jul 26  Let s see how things are shaping up for this quarter Gilead Sciences  Inc     NASDAQ GILD   Gilead which is scheduled to release earnings after the closing bell  had delivered a positive earnings surprise of 0 92  last quarter  Gilead s earnings performance has been mixed with earnings missing expectations in one of the last four quarters and beating in the remaining three  resulting in an average positive surprise of 3 52  For this quarter  Gilead has an  of  3 32  and a Zacks Rank  3  Hold   indicating a likely beat this quarter  The Zacks Consensus Estimate is pegged at  2 11 per share  You can uncover the best stocks to buy or sell before they re reported with our  HIV and other antiviral product are expected to boost sales in 2017  However  the HCV franchise continues to be under pricing pressure   Read More     Gilead Sciences  Inc  Price and EPS Surprise    Vertex Pharmaceuticals  Inc    NASDAQ VRTX  Vertex is also scheduled to announce results after the closing bell  Vertex s average positive earnings surprise for the last four quarters is 406 25   In the last reported quarter  Vertex posted a positive surprise of 225  The company has an Earnings ESP of  33 33  and a Zacks Rank  1  Strong Buy  and is thus expected to beat earnings estimates this quarter  You can see  Investor focus at Vertex s second conference call will be on its triple combination cystic fibrosis  CF  regimens  which are crucial for long term growth of Vertex  Data from VX 152 and VX 440 phase II and VX 659 phase I triple combination studies presented last week  have showed that all three combinations led to a pronounced improvement in lung function    Read More   Vertex Pharmaceuticals Incorporated Price and EPS Surprise    GlaxoSmithKline plc   NYSE GSK  The company is expected to report before market hours  GlaxoSmithKline reported in line earnings last quarter  Glaxo s performance has been pretty impressive  with the company reporting positive surprises consistently  The average earnings beat over the last four quarters is 12 28  The company has an Earnings ESP of 0 00  and a Zacks Rank  3 Glaxo s Pharmaceuticals and Vaccines segments are expected to drive sales in the second quarter as well  Meanwhile  the Consumer Healthcare segment has slowed down due to the impact of general sales tax and continued slowdown in the nutrition category in India  challenging economic conditions in some other international markets and the Nigerian beverage business divestment  These factors might impact second quarter results as well    Read More    GlaxoSmithKline PLC Price and EPS Surprise    More Stock News  Tech Opportunity Worth  386 Billion in 2017From driverless cars to artifical intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future   Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential ,2017-07-24,Zacks Investment Research,"https://www.investing.com/analysis/drug-stocks-q2-earnings-releases-on-jul-26:-gild,-vrtx,-gsk-200203344",200203344
120774,342289,VRTX,Top Stock Picks For The Week Of July 24th ,opinion,"Facebook Inc    NASDAQ FB    operates a social networking website worldwide  This Zacks Rank  1  Strong Buy  stock with a Growth score of  A   has ample growth catalysts  Not the least of which are earnings estimates that continue to rise  A strong balance sheet and significant cash flow also make it attractive for investors  
Vertex Pharmaceuticals Inc    NASDAQ VRTX    discovers  develops and markets small molecule drugs that address major unmet medical needs   This company has two cystic fibrosis drugs in its portfolio with blockbuster potential  The company also has a strong history of beating consensus earnings estimates  It s not only a Zacks Rank  1  Strong Buy  but has both Growth and Momentum scores of  A  
More Stock News  Tech Opportunity Worth  386 Billion in 2017 
From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future                                                                                 
Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential ",2017-07-25,Zacks Investment Research,https://www.investing.com/analysis/top-stock-picks-for-the-week-of-july-24th-200203390,200203390
120775,342290,VRTX,Pharma Stocks To Watch For Earnings On Jul 28  ABBV  MRK,opinion,The second quarter reporting cycle is in full swing  The quarter  undoubtedly  is off to a strong start As of Jul 26  2017  171 S P 500 members  accounting for 44 1  of the index s total market capitalization  reported results  according to  Total earnings for these 171 index members were up 8 8  from the year ago quarter on a 3 4  improvement in revenues  The beat ratio was 78 9  for earnings and 70 8  for revenues The earnings momentum is expected to continue through the season  Per the report  total earnings for S P 500 companies in the second quarter are expected to grow 8 7  year over year on 4 7  higher revenues  This follows 13 3  earnings growth in the first quarter on 7  increase in revenues  the highest in almost two years Among the pharma bigwigs  Eli Lilly and Company   NYSE LLY   and Biogen Inc    NASDAQ BIIB   released their second quarter results this week  Both the companies beat earnings and revenue estimates and raised their sales and earnings expectations for the full year  Moreover  Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   and Amgen Inc    NASDAQ AMGN   reported encouraging second quarter results on Jul 26  beating estimates on both counts  However  GlaxoSmithKline plc   NYSE GSK   reported mixed second quarter results the same day  beating on earnings but missing on sales Let s take a look at two large cap pharma companies that are set to report second quarter results on Jul 28 AbbVie Inc    NYSE ABBV  AbbVie  which is scheduled to release earnings before market opens  had delivered a positive earnings surprise of 1 59  last quarter  AbbVie s earnings performance has been mixed with earnings beating expectations in two of the last four quarters and meeting the same in the remaining two  resulting in an average positive surprise of 1 65  For this quarter  AbbVie has an  of  0 71  and a Zacks Rank  3  Hold   This does not conclusively show that AbbVieis likely to beat estimates this quarter  The Zacks Consensus Estimate is pegged at  1 40 per share  You can uncover the best stocks to buy or sell before they re reported with our  AbbVie Inc  Price and EPS Surprise   AbbVie s key drug Humira is performing well and is expected to continue to do well in the second quarter  Imbruvica has been recording strong sales since the past few quarters  We expect the trend to continue  However  the HCV franchise continues to be under pricing pressure   Read More   Merck   Co   Inc    NYSE MRK  Merck is also scheduled to announce results before the opening bell  Merck has beaten estimates in each of the last four quarters  resulting in an average positive surprise of 4 36   In the last reported quarter  Merck delivered a positive surprise of 6 02  Merck   Company  Inc  Price and EPS Surprise   The company has an Earnings ESP of 0 00  and a Zacks Rank  2  Buy  and thus does not look poised to deliver a beat this time around You can see  Merck s new products like Keytruda  cancer   Zepatier  HCV  and Bridion  sugammadex  injection may drive the top line this quarter  However  the company is expected to face headwinds in the form of genericization  increasing competition and the negative impact of currency exchange   Read More   More Stock News  Tech Opportunity Worth  386 Billion in 2017From driverless cars to artifical intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future  Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential ,2017-07-26,Zacks Investment Research,"https://www.investing.com/analysis/pharma-stocks-to-watch-for-earnings-on-jul-28:-abbv,-mrk-200203968",200203968
120776,342291,VRTX,Vertex  VRTX  Q2 Earnings Top On Solid Cystic Fibrosis Sales,opinion,Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   reported second quarter 2017 earnings per share of 10 cents  including the impact of stock based compensation expense   which beat the Zacks Consensus Estimate of 6 cents  Notably  the company had posted a loss of 1 cent in the year ago quarter  Strong product revenues led to higher profits in the quarter Excluding stock based compensation expense  second quarter adjusted earnings were 39 cents per share compared with the year ago figure of 24 cents Vertex reported revenues of  544 1 million in the second quarter  up 26 1  year over year driven by strong product revenues  Revenues also beat the Zacks Consensus Estimate of  487 9 million by 11 5  CF Franchise Sales StrongVertex s second quarter revenues consisted of sales from cystic fibrosis  CF  products   Kalydeco and Orkambi  collaborative   27 3 million  and royalty revenues   2 9 million   CF product revenues were  514 million in the second quarter  up 21  year over year Kalydeco sales rose 5  to  190 million gaining from inventory stocking of  5 million ahead of the Jul 4 holiday In May this year  Kalydeco was approved for use in CF patients 2 years and older who have one of 23 residual function mutations in the CFTR gene  More than 900 people in the U S  have one of these mutations  The expanded indication should boost sales of the drug in future quarters Orkambi  lumacaftor ivacaftor  delivered sales of  324 0 million  up 32  year over year  On a sequential basis  Orkambi sales rose almost 10  in the second quarter  supported by continued uptake globally and further uptake in the pediatric indication for which approval was received in Sep 2016  Meanwhile  an inventory stocking of  10 million ahead of the Jul4 holiday also benefited sales in the second quarter Costs RiseAdjusted  including stock based compensation expenses  research and development expenses increased 10  to  284 3 million in the second quarter due to higher costs related to development of triple combination CF regimens  Adjusted  including stock based compensation expenses  selling  general and administrative  SG A  expenses increased 10 7  to  121 7 million due to increased investment to support the global launch of Orkambi Maintains 2017 GuidanceVertex maintained its 2017 guidance for Orkambi and Kalydeco sales but raised its guidance for combined operating costs Orkambi revenues are expected in the range of  1 1  1 3 billion while Kalydeco revenues are estimated in the range of  740 million    770 million  We remind investors that following the approval for the additional indication in May  Kalydeco 2017 revenue guidance was upped to  740 million    770 million from  710 to  730 million  Total CF product revenues are expected in the range of  1 84 billion to  2 07 billion in 2017 Combined adjusted research and development  R D  and selling  general and administrative  SG A  expenses in 2017 are anticipated in the range of  1 33 to  1 36 billion  higher than  1 25  1 30 billion expected previously Costs are expected to be higher due to accelerated development of the triple combination CF pipeline and investment to develop CTP 656 Focus on Triple Combination CF RegimensVertex is evaluating some next generation CFTR correctors  VX 152  VX 440  VX 659 and VX 445  as part of a triple combination withVX 661  tezacaftor  and ivacaftor Data from VX 152 and VX 440 phase II and VX 659 phase I triple combination studies  conducted on CF patients who have one F508del mutation and one minimal function mutation  F508del Min   were presented last week  The data demonstrated that all three combinations led to pronounced improvement in lung function  In fact  these are the first data to show the potential to treat the underlying cause of CF in patients who have a severe and difficult to treat type of the disease Following discussions with regulatory agencies  Vertex will initiate pivotal phase III studies on one or two of the four triple combination regimens in the first half of 2018 Other CF Pipeline UpdateIn March  positive data from two phase III studies   EVOLVE and EXPAND   evaluating Kalydeco in combination with VX 661  tezacaftor  in CF patients with two copies of the F508del mutation were also announced  Both studies met their primary endpoints and demonstrated statistically significant improvements in lung function  Based on positive outcome from the studies  the company recently submitted regulatory applications in both the U S  and EU  Encouragingly  the combination was also granted Orphan Drug designation by the FDA in June Earlier this week  Vertex announced that it has closed the previously announced agreement to buy Concert Pharmaceuticals  Inc  s   NASDAQ CNCE   CF pipeline candidate  CTP 656  Vertex plans to develop CTP 656 for potential use in future once daily regimens in combination with its other pipeline drugs to treat the underlying cause of CF Our TakeVertex s second quarter results were encouraging  topping estimates on both counts as sales of both its CF drugs rose Shares declined slightly in after hours trading probably in response to the hike in operating costs expectations for the year  However  so far this year  Vertex s share priceis up a massive 121 8   comparing favorably with an increase of 12  for the  Meanwhile  Vertex s CF pipeline is quite strong with a broad portfolio of next generation CF correctors  Its triple combination CF regimens are considered crucial for long term growth  If the triple combo regimes are successful  Vertex can address a significantly larger CF patient population  almost 90  of patients with CF   in the future However  one cannot forget potential competition for Vertex s triple combos  Belgian company  Galapagos NV   NASDAQ GLPG   and AbbVie  Inc    NYSE ABBV   are also developing triple CFTR combination therapy for CF Vertex Pharmaceuticals Incorporated Price  Consensus and EPS Surprise    Vertex sports a Zacks Rank  1  Strong Buy   You can see More Stock News  Tech Opportunity Worth  386 Billion in 2017                 From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity   Most importantly  it reveals 4 stocks with massive profit potential ,2017-07-27,Zacks Investment Research,https://www.investing.com/analysis/vertex-(vrtx)-q2-earnings-top-on-solid-cystic-fibrosis-sales-200203924,200203924
120777,342292,VRTX,Vertex s Cystic Fibrosis Combo Gets Priority Review In U S ,opinion,Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   announced that its regulatory applications for tezacaftor ivacaftor  Kalydeco  combination have been accepted by the FDA and the European Medicines Agency  EMA  for review The regulatory applications have been filed to seek approval of Kalydeco in combination with tezacaftor  VX 661  for the treatment of cystic fibrosis  CF  patients  12 and older  with two copies of the F508del mutation We note that Kalydeco is already approved for the treatment of patients  two years and above  with CF who have one of 33 mutations in their cystic fibrosis transmembrane conductance regulator  CFTR  gene Meanwhile  the application in the U S  has been granted a priority review with the FDA expected to give its decision on Feb 28  2018 Shares of Vertex were up 1 9  on Thursday  In fact  Vertex s share price is up a massive 111 9  so far this year  comparing favorably with an increase of 7 9 for the  Coming back to the latest news  the regulatory applications in the U S  and EU were submitted on the basis of positive outcome from two phase III studies   EVOLVE and EXPAND  Data from the studies was announced in March this year  Both studies met their primary endpoints and demonstrated statistically significant improvements in lung function in patients with CF The combination had also been granted Orphan Drug designation by the FDA Per the company s press release  approximately 75 000 people in North America  Europe and Australia suffer from CF  In fact  more than 29  people of ages 12 years or older have two copies of the F508del mutation  and more than 1 500 people of the age 12 have one mutation  Hence  approval of the drug will provide the company access to a huge base of patients affected by the disease and bring it closer to the goal of serving people with the disease In fact  Vertex s CF pipeline is quite strong with a broad portfolio of next generation CF correctors Vertex is evaluating some next generation CFTR correctors  VX 152  VX 440  VX 659 and VX 445  as part of a triple combination with tezacaftor and ivacaftor Data from VX 152 and VX 440 phase II and VX 659 phase I triple combination studies  conducted on CF patients who have one F508del mutation and one minimal function mutation  F508del Min   were presented in July 2017  The data demonstrated that all three combinations led to pronounced improvement in lung function  In fact  these are the first data to show the potential to treat the underlying cause of CF in patients who have a severe and difficult to treat type of the disease Following discussions with regulatory agencies  Vertex will initiate pivotal phase III studies on one or two of the four triple combination regimens in the first half of 2018 Its triple combination CF regimens are considered crucial for long term growth  If the triple combo regimes are successful  Vertex can address a significantly larger CF patient population  almost 90  of patients with CF   in the future Vertex carries a Zacks Rank  3  Hold  Stocks to ConsiderBetter ranked biotech stocks include Alexion Pharmaceuticals  Inc    NASDAQ ALXN    Ligand Pharmaceuticals Incorporated   NASDAQ LGND   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN    all with a Zacks Rank  1  Strong Buy   You can see  Shares of Alexion are up 12 7  year to date while estimates for both 2017 and 2018 have risen by 5 5  over the past 30 days Shares of Ligand have risen 24 8  so far this year while estimates for 2017 and 2018 have risen by 10 4  and 2 2   respectively  over the past 30 days Regeneron s shares up 32 2  this year so far  Estimates have risen 15 1  for 2017 while that for 2018 have gone up by 5 8  over the past 30 days 4 Surprising Tech Stocks to Keep an Eye OnTech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really takes off ,2017-08-24,Zacks Investment Research,https://www.investing.com/analysis/vertexs-cystic-fibrosis-combo-gets-priority-review-in-us-200209649,200209649
120778,342293,VRTX,Biotech Stock Roundup  CAR T In Focus On Gilead Kite Deal  Incyte Up On Baricitinib Update,opinion,"CAR T stocks were in the news this week with key biotech player  Gilead Sciences   NASDAQ GILD   announcing its intention to acquire Kite Pharma   NASDAQ KITE    one of the most advanced players in the CAR T therapy market  Moreover  the FDA approved Novartis  Kymriah yesterday  making it the first CAR T therapy to gain approval in the U S Recap of the Week s Most Important StoriesGilead Looks to Boost Oncology Pipeline with Kite Deal  Gilead has finally announced an M A deal with the company saying that it will acquire Kite Pharma for  180 per share in cash or approximately  11 9 billion  Gilead has been under a lot of pressure to utilize its huge pile of cash for a major acquisition deal given the dwindling sales of its erstwhile top selling hepatitis C virus   HCV   franchise  The Kite acquisition  slated to close in the fourth quarter  will place Gilead among the top players in the emerging field of cell therapy  Kite s expertise lies in developing engineered cell therapies that express either a chimeric antigen receptor   CAR   or an engineered T cell receptor   TCR    depending on the type of cancer Kite already has a CAR T therapy  axicabtagene ciloleucel  axi cel   under priority FDA review with a response expected by Nov 29  2017  EU approval could come next year  Axi cel is under review for the treatment of refractory aggressive non Hodgkin lymphoma   NHL    which includes diffuse large B cell lymphoma   DLBCL    transformed follicular lymphoma   TFL   and primary mediastinal B cell lymphoma   PMBCL    Other candidates in Kite s pipeline include those targeting hematologic cancers as well as solid tumors  Also read     Axi cel has blockbuster potential though Novartis is currently the first company to gain approval in the U S  for a CAR T treatment with the FDA approving the company s Kymriah Kite s shares were up 28  following the acquisition news while year to date  the stock has gained 296 9   substantially outperforming the 9 7  rally of the  it belongs to With the Kite Gilead deal being announced  other companies involved in CAR T treatment saw their shares shooting up on hopes that more M A deals will be announced in this segment of the market  While Juno shot up 20 1   bluebird bio was up 8 6     Gilead is a Zacks Rank  2  Buy  stock  You can see  Incyte Up on Baricitinib Regulatory Update  Incyte   NASDAQ INCY   and partner Eli Lilly and Company  NYSE LLY  provided an update regarding the resubmission of their regulatory application in the U S  for their experimental rheumatoid arthritis  RA  treatment  baricitinib  The companies  which had previously said that they expect a delay of at least 18 months in the resubmission of the regulatory application for baricitinib  announced that they will be resubmitting the regulatory application by Jan 2018  New safety and efficacy data will be included in the resubmission  Investors reacted positively to the news sending Incyte s shares up 10 6  The Medicines Co  s Vabomere Gets FDA Nod  The Medicines Company   NASDAQ MDCO   got a boost with the accelerated approval of Vabomere for the treatment of adult patients with complicated urinary tract infections  including pyelonephritis  The drug addresses pathogens designated by the U S  Centers for Disease Control   CDC   as urgent and serious antimicrobial resistance threats  and pathogens cited by the World Health Organization   WHO   as a critical need for new antibiotics  Vabomere will enjoy an additional 5 years of exclusivity given its status as a Qualified Infectious Disease Product   QIDP   under the Generating Antibiotics Incentives Now   GAIN   Act  The Medicines Company intends to launch Vabomere in the fourth quarter Priority Review for BioMarin Drug  BioMarin Pharmaceutical s   NASDAQ BMRN   pegvaliase got priority review in the U S  for the reduction of blood phenylalanine  Phe  levels in adult patients with phenylketonuria   PKU   who have uncontrolled blood Phe levels on existing management  This means a response from the agency regarding the approval status of pegvaliase should be out by Feb 28  2018  However  with the FDA asking the company to submit additional Chemistry  Manufacturing  and Controls   CMC   information  BioMarin said that it expects the review period to be extended by an additional three months  Also read    Acorda Down on Inbrija Regulatory Update  Acorda Therapeutics   NASDAQ ACOR   saw its shares fall 24 3  on news that the FDA has issued a Refusal to File   RTF   letter for Inbrija  The agency has raised two questions in the RTF   one regarding the date when the manufacturing site will be ready for inspection and the other regarding the submission of the drug master production record  The FDA has also asked for additional information at resubmission though it has not asked for additional efficacy or safety studies  Acorda intends to meet with the FDA to discuss the RTF Acorda is looking to get Inbrija approved for the treatment of the symptoms of OFF periods in people with Parkinson s disease taking a carbidopa levodopa regimen  The company needs to add new products to its marketed product portfolio considering flagship drug  Ampyra  is likely to face generic competition post Jul 2018  Performance
Medical   Biomedical and Genetics Industry 5YR   ReturnIt was a good week for biotech stocks with the NASDAQ Biotechnology Index gaining 4 9  over the last five trading sessions  Among major biotech stocks  Gilead was up 10 2  while Biogen  NASDAQ BIIB  was up 7 5  on Alzheimer s disease data  Also read     Over the last six months  Vertex   NASDAQ VRTX   was up 72 5  while Amgen  NASDAQ AMGN  slipped 0 3   See the last biotech stock roundup here    
What s Next in the Biotech World Watch out for the usual regulatory and pipeline updates One Simple Trading IdeaSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ",2017-08-31,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-cart-in-focus-on-gileadkite-deal-incyte-up-on-baricitinib-update-200210766,200210766
120799,342314,VRTX,What s In The Offing For Bristol Myers  BMY  In Q2 Earnings ,opinion,Bristol Myers Squibb Company   NYSE BMY   is scheduled to report first quarter 2017 results on Jul 27  before the opening bell  Last quarter  the company beat earnings estimates by 16 7  Bristol Myers Squibb Company Price and EPS Surprise   Bristol Myers  stock has lost 26 4  in the past year  underperforming the   which remained flat in that period Bristol Myers has a decent track record so far  The company s earnings beat estimates in three of the trailing four quarters  with an average positive surprise of 8 39   Will Bristol Myers surpass expectations this time as well Let s see how things are shaping up for this quarter Factors to Impact This QuarterBristol Myers  high profile immuno oncology drug  Opdivo  should continue to drive the company s top line in the to be reported quarter  Opdivo s U S  sales are driven by the melanoma  second line non small cell lung cancer and renal cell carcinoma indications Recent label expansions into the classical Hodgkin lymphoma and head and neck cancer indications should boost the drug s sales   However  the lung cancer market in the U S  became more competitive in 2016 due to the entry of Tecentriq Bristol Myers expects the second line lung cancer business to be under competitive pressure  As a result  sales of the drug in the U S  market is projected be flat in 2017  Although the first quarter saw some stability in the second line lung cancer  the recent FDA approval of Merck s   NYSE MRK   Keytruda for the first line treatment of metastatic nonsquamous NSCLC will further impact sales On the other hand  the virology business is expected to decline significantly in 2017 due to competition from Epclusa  The HIV business continues to face competitive pressure  Recent launches by other companies in the same space are expected to further impact the Sustiva franchise Bristol Myers is also looking to diversify its portfolio with the development of BMS 986036 for NASH On a positive note  Bristol Myers raised its earnings expectations for 2017 concurrent with the first quarter results  The company now projects earnings in the range of  2 85  3 00 per share  old guidance   2 70 to  2 90   Revenues are expected to grow in mid  to single digit range due to strong trends across the business  particularly in key products like Opdivo  Eliquis and Yervoy  Gross margins are projected to decline as the year progresses and are estimated in the 72 73  range   R D expenses are expected to increase in the low double digit range In the second quarter earnings call  investors are expected to focus on the company s performance and label expansion efforts for Opdivo  along with updates on business development activities Earnings WhispersOur proven model does not conclusively show that Bristol Myers is likely to beat earnings estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  Unfortunately  that is not the case here  as elaborated below Zacks ESP  The Earnings ESP for Bristol Myers is 0 0  since both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at 73 cents  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Bristol Myers currently carries a Zacks Rank  3 which increases the predictive power of ESP  However  its 0 0  ESP makes it unlikely for the stock to beat earnings this quarter  As it is  we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks That Warrant a LookHere are some health care stocks that you may want to consider  as our model shows that they have the right combination of elements to post an earnings beat this quarter Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   has an Earnings ESP of  66 7  and carries a Zacks Rank  1  The company is scheduled to release results on Jul 26  You can see  Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  3 32  and carries a Zacks Rank  3  The company is scheduled to release results on Jul 26 Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-07-20,Zacks Investment Research,https://www.investing.com/analysis/what's-in-the-offing-for-bristol-myers-(bmy)-in-q2-earnings-200202713,200202713
120800,342315,VRTX,Is A Beat In The Cards For Vertex  VRTX  In Q2 Earnings ,opinion,"We expect Vertex Pharmaceuticals  Inc    NASDAQ VRTX   to beat expectations when it reports its second quarter 2017 results on Jul 26  after the market closes 
Year to date  Vertex s shares have soared 116 3  while the  has recorded an increase of 11 2  

Vertex s track record has been impressive so far  The company delivered positive earnings surprises in three and missed expectations in one of the last four quarters  The average positive earnings surprise for the last four quarters is 406 25   In the last reported quarter  Vertex posted a positive surprise of 225  Vertex Pharmaceuticals Incorporated Price and EPS Surprise

   Let s see how things are shaping up for this quarter 
Factors at Play
Sales of Vertex s both cystic fibrosis  CF  drugs   Kalydeco   Orkambi   rose in the first quarter  We expect this positive trend to continue in the second as well 
In May 2017  Kalydeco gained an FDA approval for use in patients 2 and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator  CFTR  gene  Over 900 people in the U S  have one of these mutations  Following the approval  Vertex upped its Kalydeco 2017 revenue guidance to  740  770 million  We expect this expanded indication to boost Kalydeco sales in the second quarter 
Orkambi s sales growth will be dependent on reimbursement discussions in Europe in 2017  Last week  Vertex announced that it has struck a re imbursement agreement in Italy for Orkambi  thereby making the medicine more accessible in the country  Though the reimbursement agreement will not be beneficial in the second quarter  it should contribute to sales in the second half of the year  In the first quarter  the company had also mentioned that if it gains reimbursement in France this year  it would contribute significantly to revenue growth this year 
Vertex is also evaluating some next generation CFTR correctors  VX 152  VX 440  VX 659 and VX 445  as part of a triple combination with tezacaftor and ivacaftor 
Data from VX 152 and VX 440 phase II and VX 659 phase I triple combination studies presented earlier this week  have showed that all three combinations led to a pronounced improvement in lung function  Phase II study on VX 659 is expected to be initiated in early Aug 
 Phase II studies on the fourth next generation corrector  VX 445  triple combination with tezacaftor and ivacaftor   are already going on  Data from VX 445 and VX 659 phase II studies are expected in early 2018  Thereafter  upon discussion with regulatory agencies  Vertex will initiate its pivotal studies on one or more of these triple combination regimens in the first half of 2018 
If the triple combo regimes are successful  Vertex can address a significantly larger CF patient population 
Investor focus at the call will be on these triple combination CF regimens  crucial for long term growth of Vertex 
However  operating expenses are likely to shoot up as Vertex expands its pipeline 
What Our Model Indicates
Our proven model shows that Vertex is likely to beat estimates this quarterbecause it has the right combination of two key ingredients  For astock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen 
Zacks ESP    which represents the difference between the Most Accurate estimate  earnings of 10 cents  and the Zacks Consensus Estimate  earnings of 6 cents   stands at  66 7   This is a leading indicator of a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Vertex currently flaunts a Zacks Rank  1  Strong Buy   So its desirable combination makes us reasonably confident of an earnings beat 
Conversely  we caution against the Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Stocks That Warrant a Look
Here are some health care stocks that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter 
Gilead Sciences  Inc    NASDAQ GILD   is scheduled to release its results on Jul 26  The company has an Earnings ESP of  3 23  and a Zacks Rank  3  You can see  
Celgene Corp    NASDAQ CELG   is scheduled to release its results on Jul 27  The company has an Earnings ESP of  0 62  and a Zacks Rank  3 
Proteostasis Therapeutics  Inc    NASDAQ PTI    which is expected to release results on Aug 8  has an Earnings ESP of  6 56  and a Zacks Rank  3 
Will You Make a Fortune on the Shift to Electric Cars  
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2017-07-21,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-the-cards-for-vertex-(vrtx)-in-q2-earnings-200202683,200202683
120802,342317,VRTX,Zacks com Featured Highlights  Vertex Pharmaceuticals  AGCO  Owens Corning  Five9 And Axcelis Technologies,opinion,"For Immediate Release

	Chicago  IL  July 24  2017   Stocks in this week s article include  Vertex Pharmaceuticals  NASDAQ VRTX  Incorporated          AGCO Corporation          Owens Corning   NYSE         Five9 Inc   NASDAQ         and Axcelis Technologies Inc   NASDAQ         

5 Stock Picks with Earnings Beat Potential

	Tapping stocks that come up with solid earnings is a common practice  But instead of picking them post earnings  investing in those that are like to beat market expectations may increase your gains manifolds 

Why Is Positive Earnings Surprise So Important 

	Historically  stocks of companies with solid quarterly earnings  on a nominal basis  fall if they miss or just come in line with market expectations  After all  a 20  earnings rise  though it looks good apparently  doesn t tell you if earnings growth has been exhibiting a decelerating trend  If that is the case  the company s fundamentals are in serious question 

	There is also the factor of seasonal fluctuation  If a company s Q1 is seasonally weak and Q4 is strong  then it is likely to report a sequential earnings decline  In a such case  growth rates are ambiguous while judging the company s true health 

	On the other hand  Wall Street analysts study companies  financials and initiatives to forecast earnings  They in fact club their insights and the company s guidance to derive an earnings estimate  So  outperforming that estimate is almost equivalent to beating the company s own expectation as well as market perception  And if the company manages to surpass earnings by a wide margin  it typically drives the stock higher right after the release 

How to Find Out Those Gems 

	Since it is hard to predict if a company will beat or miss in the upcoming earnings season  investors can check its earnings surprise history  A notable track record generally acts as a tailwind  It revs up chances of beating estimates in the next release too as investors expect the company to use the same old trick to come ahead of expectations  or is smart enough to pull off a beat in the next release 

The Winning Strategy

	In order to shortlist stocks that are likely to come up with an earnings surprise  we chose the following as our primary screening parameters 

Last EPS Surprise greater than or equal to 10    Stocks delivering positive surprise in the last quarter tend to surprise again 

Average EPS Surprise in the last four quarters greater than 20    We lifted the bar for outperformance slight higher by setting the average earnings surprise for the last four quarters at 20  

Average EPS Surprise in the last two quarters greater than 20    This points to a more consistent surprise history and makes the case for another surprise even stronger 

	In addition  we place a few other criteria that push up the chance of a positive surprise 

Zacks Rank less than or equal to 2  Only companies with a Zacks Rank  1  Strong Buy  or 2  Buy  rating can get through 

 greater than zero   A stock needs to have both a positive Earnings ESP and a Zacks Rank of  1  2 or 3 for an earnings beat to happen  as per our proven model 

	In order to zero in on those that have long term growth potential and high trading liquidity we have added the following parameters too 

Next 3 5 Years Estimated EPS Growth  Per Year  greater than 10    Solid expected earnings growth exhibits the stock s long term growth prospects 

Average 20 day Volume greater than 100 000   High trading volume implies that the stocks have adequate liquidity 

	A handful of criteria has narrowed down the universe from over 7 700 stocks to around seven 

	Here are five out of seven stocks that passed the screen 

Vertex Pharmaceuticals Incorporated          The company is a developer and marketer of small molecule drugs  The stock belongs to a Zacks Industry Rank in the top 46   It has a Zacks Rank  2 

AGCO Corporation          The company is engaged in the manufacturer and distribution of farm equipment  machinery and replacement parts in the United States and Canada  The stock belongs to a Zacks Industry Rank is in the top 5   It carries a Zacks Rank  1 

Owens Corning   NYSE           This world leader in building materials systems and composite solutions sports a Zacks Rank  1  The Zacks Industry Rank of the stock is in the top 36  

Five9 Inc   NASDAQ          This provider of cloud software for contact centers holds a Zacks Rank  2  The Zacks Industry Rank of the stock is in the top 25  

Axcelis Technologies Inc   NASDAQ         It is a leading producer of ion implantation equipment used in the fabrication of semiconductors  The stock has a Zacks Rank  2 and the Zacks Industry Rank is in the top 10  

	You can get the rest of the stocks on this list by signing up now for your 2 week free trial to the Research Wizard and start using this screen in your own trading  Further  you can also create your own strategies and test them first before taking the investment plunge 

	The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out 

   

About Screen of the Week

	Zacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine  But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use  Each week  Zacks Profit from the Pros free email newsletter shares a new screening strategy  Learn more about it here 

About Zacks 

	Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

 

 

 

 

 

	Follow us on Twitter  

	Join us on Facebook  NASDAQ FB   

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Contact  Jim Giaquinto

	Company  Zacks com

	Phone  312 265 9268

	Email  

	Visit  

	Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   

Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  

	This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visitfor information about the performance numbers displayed in this press release ",2017-07-23,Zacks Investment Research,"https://www.investing.com/analysis/zacks.com-featured-highlights:-vertex-pharmaceuticals,-agco,-owens-corning,-five9-and-axcelis-technologies-200202948",200202948
120803,342318,VRTX,Biotech ETF Industry Outlook For Second Half 2017,opinion,"Biotech stocks have had a strong run so far in 2017 with the NASDAQ Biotechnology Index soaring 19 4  year to date  YTD   This is in sharp contrast to last year s performance when the Index was down 19 1   There were several reasons for the sector s dismal performance last year foremost being the drug pricing controversy  
 
Apart from drug pricing  there were several other factors that impacted the sector    2016 was disappointing from an R D perspective with a fewer number of drugs managing to gain FDA approval  There were some high profile pipeline failures as well  Other factors that weighed on the sector include mixed results  slower than expected new product launches and increasing competition   Read   
 
Recovery on the Cards
 
With the biotech sector performing well this year  it looks like the sector is set for a recovery  New product sales ramp up  R D success and innovation  strong results  a higher number of FDA approvals and continued strong performance from legacy products are some of the factors that could contribute to a sustained recovery in the sector  Tax reforms and cash repatriation would support a recovery as well 
 
Importantly  investors now seem to be more comfortable with the drug pricing scenario and are willing to look at the fundamentals of the sector  Expectations are that steps taken by the Trump administration to drive down drug prices will not be as draconian as previously expected    Read   
 
Deregulation and increased competition seem to be some of the ways that will be used to control drug prices  The FDA is working on a plan to lower healthcare costs by speeding up the development of next generation treatments  especially for rare diseases or targeted cancer therapies 
 
Biosimilars Pose a Threat
 
Although biosimilars are yet to pick pace  they remain a major threat for biotech stocks specially companies that are set to lose patent protection for major blockbuster drugs in the next few years  While a relatively new area  the market for biosimilars is huge and highly lucrative with several blockbuster biologics including Humira and Lantus slated to lose patent protection by 2020  Biosimilars are expected to reduce healthcare costs and provide a large number of patients with access to much needed biologic treatments  Biosimilars are also gaining acceptance across formularies 
 
M As to Pick Pace in 2H17 
 
Expectations are high that the biotech sector will witness an increase in M As as the year progresses    potential tax reform and cash repatriation are expected to lead to a boost in this area  However  not many deals have been announced this year    a key reason could be a  wait and watch  approach regarding the drug pricing situation as well as tax reforms  Another deterrent could be high valuations with companies remaining wary of bidding wars leading to over priced deals 
 
That being said  companies with innovative technologies and pipelines are highly sought after  Niche disease areas like nonalcoholic steatohepatitis  NASH   immuno oncology and multiple sclerosis are in demand  Treatments for orphan diseases are also much sought after with quite a few deals being signed in these areas  Biotech companies like Incyte and Exelixis are often considered attractive takeover targets 
 
Faster Drug Approval Process
 
The FDA is working on streamlining the development process for drugs for rare diseases as well as for targeted cancer therapies  The agency is also working on clearing up a backlog of orphan drug applications 
 
So far in 2017  the FDA has given its nod to 23 new drugs  already surpassing last year s total tally of 22  Among this year s approvals  drugs like Kevzara  adult rheumatoid arthritis  and Dupixent  eczema  have blockbuster potential 
 
According to an IMSQuintiles report  the late phase R D pipeline for the industry indicates that there should be about 40 45 new brand launches every year through 2021 
 
Innovative Pipelines   Catalysts
 
Biotech companies continue to work on bringing innovative new treatments to market  and there could be significant catalysts in the coming quarters in the form of important new product approvals as well as major data read outs especially in key therapeutic areas like immuno oncology  Alzheimer s  hepatitis C virus  HCV   central nervous system disorders  and immunology inflammation 
 
Cancer especially immuno oncology remains a key area of interest  According to IMSQuintiles  68 new cancer drugs were approved for 22 indications from 2011 to 2016 while worldwide costs for cancer therapeutics and supportive care drugs shot up from  91 billion in 2012 to  113 billion in 2016  More than 600 molecules are in late stage development with the majority being targeted therapy 
 
ETFs in Focus
 
Highlighted below are some biotech ETFs    ETFs present a low cost and convenient way to get a diversified exposure to the sector 
 
iShares Nasdaq Biotechnology     
 
IBB  launched in Feb 2001 by BlackRock Investments LLC  tracks the Nasdaq Biotechnology Index  The fund mainly covers biotech stocks  82 5   with pharma accounting for 10 1   life sciences tools   services for 6 9   Health care technology for 0 08   Health care equipment for 0 26  and Health care supplies for 0 04   The top 3 holdings include Celgene Corporation  NASDAQ CELG   8 46    Amgen Inc  NASDAQ AMGN    8 09   and Biogen  NASDAQ BIIB  Inc   8 05    The total assets of the fund as of Jul 13  2017 were  9 69 billion representing 162 holdings  The fund s expense ratio is 0 47  while dividend yield is 0 21   The trading volume is roughly 2 033 019 shares per day 
 
SPDR S P Biotech  MX XBI  ETF   
 
XBI  launched in Jan 2006 by State Street Global Advisors  tracks the S P Biotechnology Select Industry Index  The fund covers health care stocks only  The top 3 holdings include Vertex Pharmaceuticals  NASDAQ VRTX   Inc   3 03    Ionis Pharmaceuticals  Inc   2 75    and Exact Sciences Corp   2 72    The total assets of the fund as of Jul 13  2017 were  3 76 billion representing 92 holdings  The fund s expense ratio is 0 35  while dividend yield is 0 23   The trading volume is roughly 8 983 119 shares per day 
 
First Trust NYSE Arca Biotech ETF   
 
FBT  launched in Jun 2006 by First Trust Advisors  tracks the NYSE Arca Biotechnology Index  The top 3 holdings include Alnylam Pharmaceuticals  Inc   4 78    Myriad Genetics  Inc   4 26    and Regeneron Pharmaceuticals  Inc   4 03    The total assets of the fund as of Jul 12  2017 were  1 billion representing 30 holdings  The fund s expense ratio is 0 56  while dividend yield is nil  The trading volume is roughly 55 387 shares per day 
 
VanEck Vectors Biotech ETF   
 
BBH  launched in Dec 2011 by Van Eck  tracks the Market Vectors US Listed Biotech 25 Index  The fund covers health care stocks  The top 3 holdings include Amgen Inc   12 02    Celgene Corporation  11 09   and Gilead Sciences Inc  NASDAQ GILD    10 12    The total assets of the fund as of Jul 13  2017 were  676 2 million representing 25 holdings  The fund s expense ratio is 0 35  while dividend yield is 0 21   The trading volume is roughly 31 428 shares per day 
 
PowerShares Dynamic Biotech   Genome ETF   
 
PBE  launched in Jun 2005 by Invesco PowerShares  tracks the Dynamic Biotech   Genome Intellidex Index  The top 3 holdings include Alexion Pharmaceuticals Inc  NASDAQ ALXN    5 72    Celgene Corp   5 16    and Ionis Pharmaceuticals  Inc   5 06    The total assets of the fund as of Jul 13  2017 were  244 8 million representing 31 holdings  The fund s expense ratio is 0 50  while dividend yield is 0 91   The trading volume is roughly 15 840 shares per day 
 
Conclusion
 
Although the drug pricing issue will remain in the headlines until the administration comes out with a policy for controlling drug prices  investors seem to be more comfortable with the issue and are focusing on the fundamentals of the sector  Pipeline success in innovative and important therapeutic areas  cost cutting  share buybacks  new products  increased pipeline visibility and appropriate utilization of cash are some of the factors that will help restore investor confidence in biotech stocks 
 
Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2017-07-24,Zacks Investment Research,https://www.investing.com/analysis/biotech-etf-industry-outlook-for-second-half-2017-200203077,200203077
120804,342319,VRTX,Will Radius Health  RDUS  Disappoint This Earnings Season ,opinion,"Radius Health  Inc    NASDAQ RDUS   is scheduled to report second quarter 2017 financial results on Aug 3 Radius Health s shares have outperformed the  in the year so far  The stock has gained 13 7  during this time period against a 6 8  industry s gain Radius Health has a disappointing track record so far  The company has missed estimates in three of the four trailing quarters with a negative average surprise of 3 6  Let s see how things are shaping up for this quarter Factors at PlayRadius Health focuses on the development of therapeutics for the treatment of osteoporosis  oncology and endocrine diseases The company s new drug Tymlos  was approved in the U S  on Apr 28  The drug is instrumental in treating postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture and multiple risk factors for fracture  The drug is also used for patients who have failed or are intolerant to other available osteoporosis therapy  The drug is under review in the EU  The drug is priced at an annualized wholesaler acquisition cost of  19 500 or  1 625 per pen Hence  we expect investors to focus on the impending launch during the upcoming earnings call Although the osteoporosis market in the U S  has great potential as approximately 1 4 million postmenopausal women in the U S  experience osteoporotic fractures each year  Tymlos is expected to face significant competition from Forteo and Prolia Meanwhile  the Committee for Medicinal Products for Human Use  CHMP  issued a second Day 180 List of Outstanding Issues and requested additional data analyses related to the safety and efficacy of abaloparatide SC in the process of their ongoing regulatory review  The company expects the CHMP to issue an opinion regarding the MAA for abaloparatide SC prior to the end of 2017 The company is planning to file a supplemental New Drug Application for Tymlos based on the ACTIVExtend study  In May 2017  results from the ACTIVExtend trial showed statistically significant fracture risk reduction through the 3 5 years of sequential therapy  Tymlos followed by an antiresorptive In Jun 2017  the company announced encouraging results from an ongoing phase I study on pipeline candidate elacestrant  RAD1901  in patients suffering from estrogen receptor positive  ER   breast cancer  The candidate an oral selective estrogen receptor degrader  SERD   is being evaluated for potential use as an oral non steroidal treatment for estrogen receptor positive breast cancer at high doses  During the first quarter earnings call  the company stated that it plans to discuss the next steps for this program with the FDA  We expect the company to throw more light on the same Radius Health  Inc  Price and EPS Surprise   Earnings WhispersOur proven model does not conclusively show that Radius Health is likely to beat estimates this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here  as you will see below Zacks ESP  Earnings ESP for Radius Health is currently pegged at 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of  1 35  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Radius Health has a Zacks Rank  4  Sell   Note that we caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are a few pharma companies that you may consider  as our model shows that they have the right combination of elements to post an earnings beat this quarter Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   is scheduled to release results on Jul 26  The company has an Earnings ESP of  33 3  and a Zacks Rank  1  You can see  
Intercept Pharmaceuticals  Inc    NASDAQ ICPT   has an Earnings ESP of  9 39  and a Zacks Rank  3  The company is expected to release results on Aug 3 Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  3 32  and a Zacks Rank  3  The company is scheduled to release results on Jul 26 More Stock News  Tech Opportunity Worth  386 Billion in 2017
From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential ",2017-07-24,Zacks Investment Research,https://www.investing.com/analysis/will-radius-health-(rdus)-disappoint-this-earnings-season-200203260,200203260
120835,342350,VRTX,Here s Why Vertex Pharmaceuticals  VRTX  Soared Today,opinion,"Shares of Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   soared 24  in morning trading on Wednesday after the company released positive results for its cystic fibrosis treatments 
The pharmaceutical company said yesterday after hours that its cystic fibrosis treatments improved lung function by 9 6  or more in patients with the condition  which surpassed expectations 
The results came from three trials  each consisting of different triple drug combinations in order to determine the best strategy for treating cystic fibrosis  The combinations included VX 440  VX 152  and VX 659 
Because all three trials were successful  Vertex will have a bigger market opportunity  About 75 000 people in the world have the genetic disease cystic fibrosis  which causes an accumulation of mucus in the lungs and other organs  Vertex has now developed medicine that targets 30 000 of these people 
If the company s rally holds  the price stock gain could add about  8 billion to Vertex s market capitalization 
VRTX remains a Zacks Rank  1  Strong Buy   Our consensus estimates show that the company will have extremely strong year over year earnings growth for the current year  Vertex is expected to report its next quarterly earnings on July 26 after market close 
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-07-19,Zacks Investment Research,https://www.investing.com/analysis/here's-why-vertex-pharmaceuticals-(vrtx)-soared-today-200202151,200202151
120836,342351,VRTX,Biotech Stock Roundup  Vertex Boosted By CF Data  FDA Nod For Gilead  Puma Drugs,opinion,"Key highlights this week include impressive data from Vertex s   NASDAQ VRTX   cystic fibrosis  CF  pipeline while companies like Gilead   NASDAQ GILD   and Puma   NASDAQ PBYI   got FDA approval for their hepatitis C virus  HCV  and breast cancer treatments  respectively   Recap of the Week s Most Important StoriesVertex CF Data Impresses  Vertex got a major boost with positive data on three different triple combination regimens in people with cystic fibrosis  CF  who have one F508del mutation and one minimal function mutation  F508del Min   These are the first data to show the potential to treat the underlying cause of CF in these patients  who have a severe and difficult to treat type of the disease  The company is looking to start a pivotal program in the first half of 2018  Vertex s shares were up significantly in pre market trading CRL for Amgen UCB Osteoporosis Drug  Amgen   NASDAQ AMGN   and partner UCB got a Complete Response Letter  CRL  from the FDA for Evenity  romosozumab   their investigational treatment for postmenopausal women with osteoporosis  However  the CRL doesn t come as a surprise considering the emergence of a new safety signal in a late stage study  ARCH   Although Evenity met both the primary endpoints and the key secondary endpoint in the study  the companies said that an imbalance in positively adjudicated cardiovascular serious adverse events was observed The FDA has asked the companies to include data from the ARCH study in the resubmission as well as data from the BRIDGE study in men with osteoporosis  Read more     Amgen is a Zacks Rank  3  Hold  stock    you can see  FDA Nod for Gilead HCV Drug  Gilead has added another drug to its hepatitis C virus  HCV  portfolio with the FDA granting approval to Vosevi  a single tablet regimen for the re treatment of adults with chronic HCV  Vosevi provides physicians with a new therapeutic option for their hardest to treat patients  However  Vosevi comes with a boxed warning regarding the risk of hepatitis B virus  HBV  reactivation in HCV HBV co infected patients    this could limit uptake Gilead s HCV franchise  which was a major revenue generator  is under considerable strain due to new competition and pricing pressure  The company has underperformed the Zacks categorized  industry so far in 2017 with shares gaining 0 1  while the industry is up 8 9  Puma Up on FDA Approval of Nerlynx  Puma gained FDA approval for its breast cancer treatment  Nerlynx  neratinib   which has blockbuster potential  Nerlynx  the first approved drug in Puma s portfolio  is indicated for the extended adjuvant treatment of early stage  HER2  breast cancer  an aggressive type of tumor  This means that Nerlynx can be taken after an initial treatment so that the risk of the cancer coming back can be reduced further  Nerlynx s approval was in line with expectations considering a favorable advisory panel vote earlier this year  Puma s shares were up 8 5  on the news  Year to date  YTD   Puma s shares are up a whopping 204 4  Sarepta BioMarin Settle Patent Dispute  Sarepta   NASDAQ SRPT   and BioMarin settled their patent dispute regarding the use of Sarepta s Exondys 51 and all future exon skipping products for the treatment of Duchenne muscular dystrophy  DMD   The companies signed a licensing agreement providing Sarepta with global exclusive rights to BioMarin s DMD patent estate for Exondys 51 and all future exon skipping products  BioMarin has the option to convert the license to a co exclusive right if it decides to proceed with an exon skipping therapy for DMD  Terms of the deal include a one time  35 million payment from Sarepta as well as certain milestone based payments and royalties  Sarepta s shares were down 3  Performance
Medical   Biomedical and Genetics Industry 5YR   ReturnThe NASDAQ Biotechnology Index was up 1 1  over the last five trading sessions  Among major biotech stocks  Biogen   NASDAQ BIIB   was up almost 4   Over the last six months  Vertex was up 60 2  while Alexion   NASDAQ ALXN   was down 6 7   See the last biotech stock roundup here    
What s Next in the Biotech World Watch out for earnings reports from companies like Biogen and Sarepta Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-07-19,Zacks Investment Research,"https://www.investing.com/analysis/biotech-stock-roundup:-vertex-boosted-by-cf-data,-fda-nod-for-gilead,-puma-drugs-200202086",200202086
120837,342352,VRTX,Company News For July 20  2017,opinion,          Vertex Pharmaceuticals Incorporated s   NASDAQ VRTX   shares surged 20 9  after the drug maker declared positive results from clinical studies of its cystic fibrosis treatments          Shares of Discovery Communications Inc    NASDAQ DISCA   gained 4 3  after the company is in talks to merge with Scripps Networks Interactive Inc  NASDAQ SNI           Shares of United Continental Holdings Inc   NYSE UAL   declined 5 9  after its total operating expenses  excluding special items  grew 8 3  year over year to  8 6 billion          Shares of Crown Castle International Corp    NYSE CCI   increased 2 1  after the company is acquiring Lightower Fiber Networks for about  7 1 billion in cash,2017-07-19,Zacks Investment Research,"https://www.investing.com/analysis/company-news-for-july-20,-2017-200202336",200202336
120838,342353,VRTX,Sarepta  SRPT  Q2 Loss Narrows  Ups Exondys 51 Sales View,opinion,Sarepta Therapeutics  Inc   NASDAQ SRPT   reported narrower than expected loss in the second quarter of 2017  The biotech also increased its 2017 sales outlook for Exondys 51  a treatment for Duchenne muscular dystrophy  DMD  and its only marketed drug  Shares were up almost 15  in after hours trading So far this year  Sarepta s shares are up 24 2   This compares favorably with 10 5  increase registered by the Zacks classified  industry during this period Narrower LossSarepta incurred a loss of 65 cents per share in the second quarter of 2017  narrower than the year ago loss of  1 35 as well as the Zacks Consensus Estimate of a loss of 92 cents Loss per share excludes restructuring costs and gain from asset sale but includes the impact of share based compensation expenses Quarterly DetailsSarepta received a huge boost with the FDA s approval of Exondys 51  its only marketed drug and also the first DMD treatment to gain approval in the U S  The drug is under review in the EU  In the second quarter  Sarepta recorded revenues of  35 million  up 115  sequentially  primarily attributable to sales of Exondys 51  Revenues beat the Zacks Consensus Estimate  In the prior year quarter  Sarepta had recognized no revenues Adjusted research and development  R D  expenses were  34 6 million in the second quarter  down 16 4  year over year  due to lower manufacturing expenses owing to the capitalization of inventory following the approval of Exondys 51 by the FDA  This was partly offset by increased expenses in preclinical studies on PPMO platform and other follow on exons and increased patient enrollment in ongoing clinical studies  However  it excludes a one time payment of  22 million to Summit Therapeutics plc   NASDAQ SMMT   for completing enrolment in a phase II study evaluating utrophin modulator  ezutromid Adjusted selling  general   administrative  SG A  expenses were  25 4 million  up 92 1  year over year  due to increased legal fees and commercial initiatives  compensation and other personnel expenses Both R D and SG A expenses exclude the impact of restructuring costs and share based compensation expenses Subsequent to the quarter in Jul 2017  Sarepta launched a Managed Access Program along with UK based Clinigen to ensure availability of Exondys 51 to DMD patients in certain geographies outside the U S  The company also appointed Douglas S  Ingram as its new President and CEO  Moreover  it also signed a gene therapy research collaboration agreement with Genethon to jointly develop treatments for DMD Earlier this week  the company announced that it hassettled a global patent litigation with BioMarin Pharmaceutical Inc    NASDAQ BMRN   regarding the exclusive license on a patent pertaining to exon skipping technology used in DMD therapies  If Sarepta hadn t settled with BioMarin  the latter could have prevented Sarepta from commercializing Exondys 51 in several jurisdictions OutlookBased on sales trends witnessed in the second quarter  Sarepta updated its guidance for Exondys 51 sales to  125 million to  130 million in 2017  higher than its prior guidance of  95 million  The Zacks Consensus Estimate for 2017 sales is pegged at  103 51 million The biotech company raised its outlook for Exondys 51 for 2017 based on increasing market penetration  start forms from physicians and additional new patients in the second quarter Meanwhile Sarepta is looking to build its own DMD pipeline beyond Exondys 51 by developing other exon skipping treatments  Sarepta has about seven exon skipping candidates in its pipeline that could treat 75  80  of the DMD population  The company expects to present dystrophin data from 4053 101 study by the end of 2017 Sarepta Therapeutics  Inc  Price  Consensus and EPS Surprise   Zacks Rank   Stock to ConsiderSarepta Therapeutics carries a Zacks Rank  3  Hold  A better ranked stock in the health care sector is Vertex Pharmaceuticals Incorporated   NASDAQ VRTX    sporting a Zacks Rank  1  Strong Buy   You can see  Vertex s earnings estimates increased from 43 cents to 50 cents for 2017 and from  1 28 to  1 38 for 2018 over the last 30 days  The company posted positive earnings surprises in three of the four trailing quarters with an average beat of 406 25   The company s shares are up 116 8  so far this year 3 Top Picks to Ride the Hottest Tech TrendZacks just released a Special Report to guide you through a space that has already begun to transform our entire economy   Last year  it was generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for those who make the right trades early ,2017-07-19,Zacks Investment Research,"https://www.investing.com/analysis/sarepta-(srpt)-q2-loss-narrows,-ups-exondys-51-sales-view-200202411",200202411
120839,342354,VRTX,Vertex Pharmaceuticals Stock Shares Jump Up on Positive,opinion,"Vertex Pharmaceuticals  NASDAQ VRTX  
Vertex Pharmaceuticals Incorporated  a global biotechnology company yesterday announced positive results from its Phase 1 and 2 data for their cystic fibrosis treatment 
The studies data showed a 12  point improvement in lung functions of patients with cystic fibrosis who used the triple combination treatment of VX 52  VX 40 AND VX 659 
Vertex Pharmaceuticals Incorporated CMO s Comments

 These safety and efficacy data are clear and compelling  indicating significant potential benefit for people with CF from each of these three different triple combination regimens   said Jeffrey Chodakewitz  M D   Executive Vice President and Chief Medical Officer at Vertex   We will be collecting and evaluating additional data from these and other studies and will make a decision on which regimen s  to take forward into pivotal program s   which we expect to begin in the first half of 2018  


VRTX Technical Analysis


VRTX opened trading yesterday at  129 21 which was exactly the same as the previous day s trading close  VRTX closed trading yesterday at  132 16 and spiked up after market to  165 45  equivalent to a 25  increase from the closing price  Taking a look at the daily chart we can see that we are in unchartered territory as with the spike up VRTX is now trading at all time highs 
Taking a closer look at the daily chart we can see that before the spike up VRTX had already been in an overall upward  dating back to March 28th when it traded at  89 67  VRTX has a  of 247 98 million shares and traded 1 90 times the normal daily trading  on Tuesday 
For trading purposes  I would like to see VRTX open trading on Wednesday above  155 00 and if it does I would be looking to take a long position at the bell  My stop loss would be  2 00 from my entry position fearing anything more than that and the stock would start to fill in the gap up 
Company Profile
Vertex Pharmaceuticals Incorporated discovers  develops  manufactures  and commercializes medicines for serious diseases  The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis  CF  and advancing its research and development programs 
It markets ORKAMBI  lumacaftor in combination with ivacaftor  for the treatment of patients with CF 12 years of age and older who have two copies  homozygous  of the F508del mutation in their cystic fibrosis transmembrane conductance regulator  CFTR  gene  and KALYDECO  ivacaftor  for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene 
The company also develops Tezacaftor  VX 661   a corrector compound that is in a Phase III development program in combination with ivacaftor in multiple CF patients  VX 152 and VX 440 that are CFTR corrector compounds in Phase II clinical trials  as well as VX 659 and VX 445 that are CFTR corrector compounds in Phase I clinical trials  and VX 371  an investigational epithelial sodium channel  which is in a Phase II development program 
In addition  it engages in the research and mid and early stage development programs in the areas of oncology  pain  and neurology  The company sells its products primarily to specialty pharmacy providers and wholesalers in North America  as well as government owned and supported customers internationally 
Vertex Pharmaceuticals Incorporated has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated  Parion Sciences  Inc   Crispr Therapeutics AG  NASDAQ CRSP   Moderna Therapeutics  Inc   BioAxone Biosciences  Inc   Merck  NYSE MRK   and Janssen Pharmaceuticals  Inc  The company was founded in 1989 and is headquartered in Boston  Massachusetts ",2017-07-20,Ticker.tv News,https://www.investing.com/analysis/vertex-pharmaceuticals-inc-$vrtx-stock-shares-jump-up-on-positive-200202227,200202227
120840,342355,VRTX,Stocks Notch Gains Amid Earnings  Upbeat Housing Data,opinion,"U S  equities finished higher  despite uncertainty surrounding looming policy decisions in Europe and Japan  Morgan Stanley  NYSE MS  delivering upbeat results  but gains on the Dow were kept in check after International Business Machines  NYSE IBM  posted its 21st consecutive quarterly decline in revenues  and merger chatter within the media space gave those stocks a boost  Treasuries and the US dollar were nearly flat following a rebound in housing construction activity  while crude oil prices were higher on another bullish government inventory report  and gold was modestly lower 
The Dow Jones Industrial Average  DJIA  rose 66 points  0 3   to 21 641  the S P 500 Index gained 13 points  0 5   to 2 474  and the Nasdaq Composite increased 41 points  0 6   to 6 385  In moderate volume  708 million shares were traded on the NYSE and 1 8 billion shares changed hands on the Nasdaq  WTI crude oil rose  0 73 to  47 32 per barrel and wholesale gasoline was  0 04 higher at  1 62 per gallon  Elsewhere  the Bloomberg gold spot price lost  0 83 to  1 241 64 per ounce  and the Dollar Index a comparison of the U S  dollar to six major world currencies was nearly unchanged at 94 80 
Morgan Stanley  NYSE MS   MS  47  reported Q2 earnings per share  EPS  of  0 87  above the  0 76 FactSet estimate  as revenues rose 6 7  year over year  y y  to  9 5 billion  topping the expected  9 2 billion  The company said its Q2 results demonstrated the resilience of its franchise in a subdued trading environment  aided by solid results from its wealth management and investment banking segments  Separately  MS raised its quarterly dividend by 25 0  to  0 25 per share  and announced a new share repurchase program of up to  5 0 billion  Shares were nicely higher 
Dow member International Business Machines  NYSE IBM   IBM  147  posted Q2 EPS of  2 48  or  2 97 ex items  versus the expected  2 74  as revenues declined 5 0  y y to  19 3 billion  below the forecasted  19 5 billion  IBM reaffirmed its full year profit outlook  This was the 21st consecutive quarterly revenue decline as its cognitive solutions unit missed expectations and growth in its strategic imperatives decelerated  Shares finished lower 
United Continental Holdings Inc  NYSE UAL    UAL  74  announced Q2 earnings of  2 66 per share  or  2 75 ex items  compared to the expected  2 68  as revenues increased 6 4  y y to  10 0 billion  roughly in line with estimates  The airline s passenger revenue per available seat mile  PRASM  a key industry metric rose slightly more than it had projected during the quarter  However  UAL s outlook for PRASM for the current quarter came in below estimates  pointing out weakness in airfares in Asia  Shares were solidly lower 
Vertex Pharmaceuticals Inc   NASDAQ VRTX  160  jumped over 20  after the company announced favorable results from a study of a new triple drug combination to treat cystic fibrosis 
Shares of Scripps Networks Interactive Inc   NASDAQ SNI  77   owner of HGTV and the Food Network  rallied and cable network Discovery Communications Inc   NASDAQ DISCA  27  gained ground amid reports that the two companies have held merger talks  Viacom B Inc  NASDAQ VIAB    VIAB  36  also moved higher as it has been reported to have held discussions to combine with SNI  None of the companies mentioned commented on the reports 
Housing construction activity rebounds Housing starts    for June rose 8 3  month over month  m m  to an annual pace of 1 215 000 units  above the Bloomberg forecast of a 1 160 000 unit rate  May starts were upwardly revised to an annual pace of 1 122 000  Building permits  one of the leading indicators tracked by the Conference Board as it is a gauge of future construction  gained 7 4  m m in June to an annual rate of 1 254 000  after May s unrevised 1 168 000 rate  and north of the expected annual pace of 1 201 000 units  Starts snapped a string a three straight monthly declines and permits rebounded from drops in the prior two months  as activity in single family and multi family structures both grew m m 
The MBA Mortgage Application Index rose 6 3  last week  following the previous week s 7 4  drop  The increase came as a 13 0  jump in the Refinance Index was met with a 1 1  rise for the Purchase Index  The average 30 year mortgage rate remained at 4 22  
Treasuries were little changed  as the yields on the 2 Year and 10 Year notes ticked 1 basis point higher to 1 36  and 2 27   respectively  while the 30 Year bond rate was flat at 2 85  
Bond yields and the U S  dollar have shown some weakness as of late as inflation has remained soft and Fed Chair Janet Yellen offered a dovish semi annual monetary policy testimony last week 
Tomorrow s  will yield weekly initial jobless claims  with economists expecting a slight downtick to a level of 245 000 from the prior week s 247 000  as well as the Philly Fed Manufacturing Index  forecasted to decline to 23 7 for July from the 27 6 posted the month prior  while the Index of Leading Economic indicators  LEI  will round out the day  anticipated to have increased 0 4  for June following the 0 3  rise in May 
Europe higher ahead of monetary policy decision  Asia sees gains 
European equities moved to the upside in late day action  with the euro and British pound losing ground to the U S  dollar  while bond yields in the region finished mixed  The markets eyed tomorrow s monetary policy decision by the European Central Bank along with earnings season on both sides of the pond  which continues to ramp up  Also  U K  Brexit negotiations continued to move forward  and the markets digested heightened U S  political uncertainty after yesterday s healthcare failure 
Stocks in Asia finished higher despite increased U S  political uncertainty  with the markets digesting recent upbeat Chinese economic data and as earnings season ramped up  though monetary policy decisions from the Bank of Japan and European Central Bank are due out tomorrow  Japanese equities ticked higher  with the yen holding onto yesterday s advance  a rally in financials gave stocks in Australia a boost  while mainland Chinese securities and those listed in Hong Kong gained solid ground  South Korean securities rose modestly to extend a record high run  while India s markets advanced  rebounding from yesterday s retreat from all time highs 
In addition to the aforementioned monetary policy decision from the Bank of Japan and the European Central Bank  tomorrow s international economic calendar will be fairly busy and include trade data from Japan  employment figures from Australia  PPI from Germany  and retail sales from the U K ",2017-07-20,Marvin Clark,"https://www.investing.com/analysis/stocks-notch-gains-amid-earnings,-upbeat-housing-data-200202300",200202300
120881,342396,VRTX,Fresh Capital To Be Injected Into Biotech Stocks  5 Must Buys,opinion,The recent rally in tech stocks makes us wonder which other sectors are in a position to lead the charge  One sector that comes to our mind is biotechnology  which is well positioned to move north  Biotech stocks have appeared to come back to life following two years of a lull  A flurry of biotech stocks had topped in the summer of 2015  losing steam soon after Now  however  they are on the verge of a break out cashing on President Trump s tax plan spurring waves of buyouts  innovation reaching exponential levels and drug price outrage easing out  Hence  investing in solid biotech stocks seems to be judicious  Biotech to Break OutInvestors have steered clear of tech behemoths that constitute the bulk of growth stocks on overvaluation concerns  As they believe that they will simply lose too much money here  they repositioned themselves in biotech stocks   Even though this space was caught in the crossfire during the 2016 presidential election on  price gouging  concerns  it has recovered somewhat  Calithera Biosciences Inc   NASDAQ CALA    Esperion Therapeutics Inc   NASDAQ ESPR   and Puma Biotechnology Inc   NASDAQ PBYI   have all added more than 100  this year  a clear indication that when money flows into biotech stocks  they soar The iShares NASDAQ Biotechnology Index  rose about 17  since Trump s win  It  however  has more room to climb as it is still down 23  from its all time intraday high attained in the July of 2015  This makes it an enticing bet for value investors  They look for companies that are fundamentally solid but underpriced and the IBB s components fit the bill M A to Spur Growth  An Island of InnovationTrump has promised to change the tax code so that companies can bring back cash held overseas  This in turn is expected to spur a series of buyouts among innovation starved biotech companies looking for growth  Quantum of deals in this sector has remained low for almost five years  Jay Rao  a medical doctor and money manager at Balyasny Asset Management  says that  M A and consolidation are inevitable  in the biotech sector  Big pharma companies  in the meantime  have already over  500 billion in cash to invest in merger and acquisition activities When it comes to innovation  investors look at Silicon Valley  But  biotech companies aren t lagging much  Rao added that  advances in biology and science are breathtaking  and they are creating tangible benefits for patients   Primary examples of such companies are Regeneron Pharmaceuticals Inc   NASDAQ REGN    Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   and Kite Pharma Inc   NASDAQ KITE   Drug Price Outrage EasedOne fear that has haunted biotech companies is the possibility of a draconian crackdown on drug prices in Washington D C  But  Rao said that Washington will find it difficult to impose any price controls with Tom Price as secretary of Health and Human Services since he has a history of rejecting this sort of policies Moreover  politicians are likely to crack down on products that are visible to consumers like EpiPen  We shouldn t forget that such a product is relatively cheap compared to some of the expensive specialized therapies  Furthermore  the pharma industry did a commendable job by showing politicians that drug costs constitute relatively a small portion of the overall health care expenses  At the same time  they argued that expensive drugs can save money by eliminating chronic diseases and keeping people out of hospitals 5 Top Biotech Stocks to Buy NowTaking such aforesaid bullish trends into consideration  it will be prudent to invest in fundamentally sound biotech firms  We have  thus  selected five biotech stocks that flaunt a Zacks Rank  1  Strong Buy  or 2  Buy  Regeneron Pharmaceuticals is a biopharmaceutical company that discovers  invents  develops  manufactures and commercializes medicines for the treatment of serious medical conditions  The company has a Zacks Rank  1  The company s expected growth rate for the current year is 27 4   more than the  industry s projected gain of 6 3   Regeneron has outperformed the broader industry in the year to date period   35  vs   6 4   Cambrex Corporation   NYSE CBM   provides products and services for the development and commercialization of generic therapeutics  The company has a Zacks Rank  2  The company s expected growth rate for the current year is 8 5   more than the Medical   Biomedical and Genetics industry s projected gain of 6 3   Cambrex has outperformed the broader industry in the year to date period   10 1  vs   6 4   Geron Corporation   NASDAQ GERN   is a biopharmaceutical company  It is engaged in the development of therapeutic products for oncology  The company has a Zacks Rank  2  The company s expected growth rate for the current year is 92 1   more than the Medical   Biomedical and Genetics industry s projected gain of 6 3   Geron has outperformed the broader industry in the year to date period   32 9  vs   6 4    You can see Anavex Life Sciences Corp    NASDAQ AVXL    a clinical stage biopharmaceutical company  engages in the development of drug candidates for the treatment of Alzheimer s disease  other central nervous system diseases  pain  and various cancer  The company has a Zacks Rank  2  The company s expected growth rate for the current year is 11 9   more than the Medical   Biomedical and Genetics industry s projected gain of 6 3   Anavex has outperformed the broader industry in the year to date period   35 9  vs   6 4   Histogenics Corp   NASDAQ HSGX   is a regenerative medicine company  The company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace  The company has a Zacks Rank  2  The company s expected growth rate for the current year is 48 1   more than the Medical   Biomedical and Genetics industry s projected gain of 6 3   Histogenics has outperformed the broader industry in the last three months   2 5  vs   0 5   Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-06-20,Zacks Investment Research,https://www.investing.com/analysis/fresh-capital-to-be-injected-into-biotech-stocks:-5-must-buys-200196639,200196639
120882,342397,VRTX,Here s Why Investors Are Glued To Vertex Pharma  VRTX  Stock,opinion,Vertex Pharmaceuticals  Inc    NASDAQ VRTX    which presently markets two cystic fibrosis  CF  drugs   Kalydeco and Orkambi   also boasts a strong CF pipeline  Its broad portfolio of next generation CF correctors  which could bring in multi billion dollar sales for the company if approved  has been attracting investor attention Vertex s share priceis up 84  so far this year  comparing favorably to an increase of 10 6 for the Zacks classified industry Vertex is developing many new combination regimens of Kalydeco ivacaftor with CFTR modulators  Vertex is evaluating CF corrector tezacaftor  VX 661  in combination with ivacaftor  The ivacaftor  tezacaftor combination is in phase III development  three studies are ongoing   In March  Vertex announced positive data from two phase III studies  EVOLVE and EXPAND  Both studies met their primary endpoints and demonstrated statistically significant improvements in lung function in patients with CF  Based on positive outcome from the studies  the company is planning to submit regulatory applications in the U S  and EU in the third quarter of 2017 Meanwhile  Vertex is also evaluating some next generation CFTR correctors  VX 152  VX 440  VX 659 and VX 445  as part of a triple combination with tezacaftor and ivacaftor  Two separate phase II studies on the triple combination  VX 152  tezacaftor  ivacaftor and VX 440  tezacaftor  ivacaftor  are ongoing in CF patients  Data from both studies are expected in the second half of 2017  Phase I studies on the third and fourth next generation corrector  VX 659 and VX 445  triple combination with tezacaftor and ivacaftor  have been initiated  Data for the VX 659 triple combo study is also expected in the second half of 2017 The multiple triple combo data readouts in CF patients  which are expected in the second half of this year  should keep investors glued to the stock  If the triple combo regimes are successful  Vertex can address a significantly larger CF patient population  In fact  these triple combination CF regimens are considered crucial for long term growth at Vertex Meanwhile  the company is also looking to buy CF candidates  which can be combined with tezacaftor and Kalydeco to create triple combinations  In March  Vertex announced an agreement to buy Concert Pharmaceuticals  Inc  s   NASDAQ CNCE   CF pipeline candidate  CTP 656  Vertex plans to develop CTP 656 for potential use in future once daily regimens in combination with its other pipeline drugs to treat the underlying cause of CF We remind investors that the CF market represents huge commercial potential  It is a rare  life threatening disease estimated to affect about 75 000 people in North America  Europe and Australia  The CF combination regimens  if approved  can strengthen its position further in this market  which can translate into higher revenues Vertex carries a Zacks Rank  3  Hold   Better ranked stocks worth considering in the sector include Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and VIVUS  Inc    NASDAQ VVUS    both sporting a Zacks Rank  1  Strong Buy   You can see VIVUS  loss per share estimates narrowed 22  in 2017 in the last 60 days  The company delivered positive earnings surprises in all four trailing quarters with an average beat of 233 69  Regeneron s earnings estimates have risen almost 10  for 2017 over the last 60 days  Shares of the company have risen 43 3  so far this year Zacks  2017 IPO Watch List    Before looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ,2017-06-22,Zacks Investment Research,https://www.investing.com/analysis/here's-why-investors-are-glued-to-vertex-pharma-(vrtx)-stock-200197137,200197137
120883,342398,VRTX,Zacks com Featured Highlights  Sanderson Farms  American Woodmark  Vertex Pharmaceuticals  Baxter International And A  O  Smith,opinion,"For Immediate Release

	Chicago  IL   July 11  2017   Stocks in this week s article include Sanderson Farms  Inc   NASDAQ         American Woodmark Corp   NASDAQ         Vertex Pharmaceuticals Inc  NASDAQ VRTX    NASDAQ         Baxter International Inc  NYSE BAX   NYSE        and A  O  Smith Corp  NYSE        

Screen of the Week of Zacks Investment Research 

5 Efficient Stocks for a Winning Portfolio

	Efficiency  a company s ability to transform its inputs into outputs  is a potential indicator of a company s financial health  This is because a company with a favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with the company s price performance  But  it is difficult to measure the efficiency level of a company  This is the reason why one must consider popular efficiency ratios while selecting stocks to build a profitable portfolio 

How to Measure Efficiency 

	We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns 

Inventory Turnover

	Inventory level is one of the key indicators of a company s business health  While a high inventory level may indicate that the company is going through a rough phase in terms of sales  a dwindling level may indicate that the company will run out of stock in a favorable sales condition  This is where inventory turnover comes into play  It is the ratio of 12 month cost of goods sold  COGS  to a 4 quarter average inventory  Thus  a high value of the ratio indicates a low level of inventory relative to COGS  while a low ratio signals that the company has excess inventory 

Receivables Turnover

	This ratio is used to measure a company s capability to extend its credit and collect debts on the basis of that credit  Receivables turnover ratio or the  accounts receivable turnover ratio  or the  debtor s turnover ratio  is calculated by dividing 12 month sales by four quarter average receivables  While a high ratio indicates that the company efficiently collects its accounts receivables or has quality customers  a low ratio signals that the company has an inefficient collection procedure or has low quality customers or an inefficient credit policy 

Asset Utilization

	This is a widely used measure of a company s efficiency  Asset utilization indicates a company s potential to utilize its assets  It is a ratio of total sales over the past 12 months to the last 4 quarter average of total assets  So  the higher the ratio  the greater is the chance that the company is utilizing its assets efficiently  On the contrary  a low value of the ratio implies that the company is failing to use its assets effectively 

Operating Margin

	Another popular efficiency ratio is operating margin  Operating profit margin  which is simply operating income over the past 12 months divided by sales over the same period  indicates how well a company is controlling its operating expenses  If a company has a high operating profit margin in relation to its competitors  it is doing a better job at controlling operating expenses 

	All these ratios can be considered as effective measures if one compares different companies within a particular sector or industry  This is the reason why we have considered only those companies that have higher ratios than their respective industry averages 

Screening Parameters

	In addition to the above mentioned ratios  we have added a favorable Zacks Rank   Zacks Rank  1  Strong Buy  or 2  Buy    to the screen with an objective to make this strategy more profitable 

Inventory Turnover  Receivables Turnover  Asset Utilization and Operating Margin greater than industry average 

	 Values of these ratios higher than industry averages may indicate that the efficiency level of the company is higher than its peers  

	The use of these few criteria narrowed down the universe of over 7 906 stocks to only 18 

	Here are five stocks from the 18 that made it through the screen 

Sanderson Farms  Inc   NASDAQ       is engaged in the production  processing  marketing and distribution of fresh and frozen chicken  and also preparation  processing  marketing and distribution of processed and minimally prepared chicken  The compn has a Zacks Rank  1  The company has an average four quarter positive earnings surprise of 8 53  

American Woodmark Corp   NASDAQ       manufactures and distributes kitchen cabinets and vanities for the remodeling and new home construction markets  The company  with a Zacks Rank  2  has an average four quarter positive earnings surprise of 12 94  

Vertex Pharmaceuticals Inc   NASDAQ       is engaged in discovering  developing  manufacturing and commercializing medicines for serious diseases  The company has a Zacks Rank  2  It has an average four quarter positive earnings surprise of 406 25   You can see 

Baxter International Inc  NYSE        through its subsidiaries  provides renal and hospital products  The company has a Zacks Rank  2  The company has an average four quarter positive earnings surprise of 17 14  

A  O  Smith Corp  NYSE       manufactures and markets residential and commercial gas  gas tankless  electric water heaters  and water treatment products in North America  China  Europe  and India  The company has a Zacks Rank  2  The company has an average four quarter positive earnings surprise of 4 88  

	You can get the rest of the stocks on this list by signing up now for your 2 week free trial to the Research Wizard and start using this screen in your own trading  Further  you can also create your own strategies and test them first before taking the investment plunge 

	The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out 

   

Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  

Disclosure  Performance information for Zacks  portfolios and strategies are available at     

Zacks Restaurant Recommendations    In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector  

	Sign up now for your free trial today and start picking better stocks immediately  And with the backtesting feature  you can test your ideas to see how you can improve your trading in both up markets and down markets  Don t wait for the market to get better before you decide to do better  Start learning how to be a better trader today  

Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material 

About Screen of the Week

	Zacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine  But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use  Each week  Zacks Profit from the Pros free email newsletter shares a new screening strategy  Learn more about it here 

About Zacks 

	Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time    

 

 

 

 

 

	Follow us on Twitter  

	Join us on Facebook  NASDAQ FB   

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Contact  Jim Giaquinto

	Company  Zacks com

	Phone  312 265 9268

	Email  

	Visit  

	Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer    

Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-07-10,Zacks Investment Research,"https://www.investing.com/analysis/zacks.com-featured-highlights:-sanderson-farms,-american-woodmark,-vertex-pharmaceuticals,-baxter-international-and-a.-o.-smith-200200324",200200324
120884,342399,VRTX,The Zacks Analyst Blog Highlights  Crescent Point Energy  Vertex Pharmaceuticals  SodaStream International  Commercial Vehicle Group And Melco Crown Entertainment,opinion,"For Immediate Release

	Chicago  IL   July 14  2017   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Crescent Point Energy Corporation  NYSE           Vertex Pharmaceuticals  NASDAQ VRTX  Incorporated  NASDAQ           SodaStream International Ltd   NASDAQ           Commercial Vehicle Group Inc   NASDAQ          and Melco Crown Entertainment Limited  NASDAQ          

	Today  Zacks is promoting its   Buy   stock recommendations     

Here are highlights from Friday s Analyst Blog  

5 Companies That Consistently Beat on Earnings

	As we approach the beginning of earnings season  it is important to remember that earnings estimate revisions and projections are extremely important in determining the Zacks Rank  and quarterly earnings reports have the ability to greatly affect a stocks financial outlook and a company s future potential 

	Zacks customers can utilize our  to search for companies that have consistently surprised and beaten earnings projections in recent quarters  Companies that are constantly able to defeat its earnings projections usually exhibit effective management  stronger upward momentum  and more impressive future outlooks 

	As many earnings reports begin to be released  check out these 5 stocks that are projected to beat earnings estimates once again this quarter 

1  Crescent Point Energy Corporation   NYSE        

	Crescent Point Energy Corporation is engaged in the acquisition  exploration and development of oil and natural gas properties in Western Canada  Notably  Crescent Point has demolished its earnings estimates in each of its past nine operational quarters by a whopping average of 629 97   Not surprisingly  the company features an  A  grade for Growth and a  B  grade for Value on our Style Scoring System  In essence  Crescent Point exhibits ample opportunities for growth  while the company is currently viewed as undervalued 

	Crescent Point pays its shareholders an impressive 3 70  dividend yield  which is intriguing to investors seeking income stocks  Furthermore  Crescent Point holds a projected EPS growth of 94 23  and  3 22 cash flow per share  both of which compare favorably to the industry averages of 82 22  and  0 34  respectively  Additionally  the company possesses a solid price sales ratio of 1 56  which fares well against the industry average  Crescent Point Energy was recently promoted to a Zacks Rank  1  Strong Buy  

2  Vertex Pharmaceuticals Incorporated   NASDAQ        

	Vertex Pharmaceuticals Incorporated discovers  develops  and market small molecule drugs that address major unmet medical needs  The company has defeated its earnings estimates in seven of its past nine operational quarters by an average of 27 39   Additionally  the firm features a current Earnings ESP of 16 67   which means that Vertex Pharmaceuticals is more likely to surprise this earnings season  Also  as of 60 days ago  Vertex has witnessed its full year EPS estimates increase by an impressive 22 50  to  0 49 

	Vertex Pharmaceutical possesses an  A  grade for Growth and  B  grade for Momentum  which means that the company holds excellent growth prospects while its share price has performed well recently  In fact  Vertex s share price has increased by 49 74  over the past year  Vertex also boasts an astronomical projected EPS growth of 492 21  and respectable projected sales growth of 27 33   Vertex Pharmaceuticals currently sits at a Zacks Rank  1  Strong Buy  

3  SodaStream International Ltd    NASDAQ        

	SodaStream International is engaged in the manufacture of home beverage carbonation systems  which enable consumers to transform ordinary tap water into carbonated soft drinks and sparkling water  SodaStream has beaten its earnings projections in each of its past six operational quarters by an average of 103 29   Additionally  SodaStream operates in the discretionary consumer products industry that currently sits in the top 25  of the Zacks Industry Rank 

	The company sports an  A  grade for Growth  which means that the firm is anticipated to continue expanding  SodaStream features a current cash flow growth of 65 86  and net margin of 10 83   which defeat the industry averages of 17 115 and 1 04   respectively  Furthermore  the company boasts an excellent 3 54 current ratio and 31 14 cash price ratio  both of which demolish industry averages  SodaStream International was recently promoted to a Zacks Rank  1  Strong Buy  prior to earnings season 

4  Commercial Vehicle Group Inc    NASDAQ        

	Commercial Vehicle Group Inc  supplies interior systems  vision safety solutions and other cab related products for the global commercial vehicle market  Commercial Vehicle Group has defeated its earnings projections in each of its past four operational quarters by an astounding average of 173 61   Nevertheless  the company sports a beta rating of 0 65  and the firm also belongs to a group of businesses in the top 6  on the Zacks Sector Rank 

	Commercial Vehicle s share price has performed well recently  increasing by a whopping 93 60  over the past year  Additionally  the company holds a projected EPS growth of 41 38  and price book ratio of 3 81  which fare well against the industry averages of 8 54  and 2 59  respectively  Finally  Commercial Vehicle Group supports a solid price sales ratio of 0 39  Commercial Vehicle Group possesses a Zacks Rank  1  Strong Buy  

5  Melco Crown Entertainment Limited   NASDAQ        

	Melco Crown Entertainment Limited is a developer  owner and operator of casino gaming and entertainment casino resort facilities primarily in Asia  Similarly  Melco Crown has been consistent in beating earnings estimates  it has accomplished this feat in each of its past six operational quarters by an average of 106 95   Also  as of 60 days ago  Melco Crown s full year EPS estimates were revised and increased by 5 80  to  0 73 

	Melco Crown pays its shareholders a respectable 1 07  dividend yield  The company boasts a projected sales growth of 12 16  and cash flow per share of  1 61  both of which compare favorably to the industry averages of 1 10  and  1 06  respectively  Melco Crown Entertainment Limited was recently promoted to a Zacks Rank  1  Strong Buy  

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  











	Follow us on Twitter  

	Join us on Facebook  NASDAQ FB   

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-07-13,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-crescent-point-energy,-vertex-pharmaceuticals,-sodastream-international,-commercial-vehicle-group-and-melco-crown-entertainment-200201165",200201165
120928,342443,VRTX,Why Is Vertex Pharma  VRTX  Stock Soaring This Year  ,opinion,"Vertex Pharmaceuticals  Inc  s   NASDAQ VRTX   share price tanked 41 5  in 2016  underperforming a decline of 27 1  for the Zacks classified  industry  Though Vertex s shares declined in 2016  they have picked up well in 2017  This year so far  Vertex s shares have risen 57 8   outperforming the increase of 1 3  for the Zacks classified Large Cap Pharma industry 

 
Vertex s main therapeutic area of focus is cystic fibrosis  CF   Presently  the companymarkets two medicines for the disease   Kalydeco and Orkambi  both of which enjoy blockbuster potential  The CF market represents huge commercial potential  It is a rare  life threatening disease estimated to affect about 75 000 people in North America  Europe and Australia 
In the first quarter of 2017  results reported in April   Vertex beat expectations for both earnings and revenues in Q1 as sales of both its CF drugs rose 
Vertex s efforts to get both Kalydeco and Orkambi approved in additional indications are also encouraging  Label expansion will increase the eligible patient population for these drugs and thus boost their sales 
Vertex s CF pipeline is quite strong with a broad portfolio of next generation CF correctors which could bring in multi billion dollar sales for the company  if approved 
Vertex is evaluating CF corrector tezacaftor  VX 661    in combination with ivacaftor  The ivacaftor  tezacaftor combination is in phase III development  three studies are ongoing   In March  Vertex announced positive data from two phase III studies   EVOLVE and EXPAND  Both studies have met their primary endpoints and demonstrated statistically significant improvements in lung function in patients with CF  Based on positive outcomes from the studies  the company is planning to submit regulatory applications in the U S  and EU in the third quarter of 2017 
Vertex is also evaluating some next generation CFTR correctors  VX 152  VX 440  VX 659 and VX 445  as part of a triple combination with tezacaftor and ivacaftor  Investor focus will now be on these triple combination regimens  which are crucial for long term growth at Vertex  Data from three triple combination regimes in CF patients are expected in the second half of this year 
Meanwhile  the company is also looking to buy CF candidates  which can be combined with its tezacaftor  VX 661  and Kalydeco to create triple combinations 
In March  Vertex announced a definitive deal to buy the worldwide development and commercialization rights of Concert Pharmaceuticals    NASDAQ CNCE   CF pipeline candidate  CTP 656 for an upfront payment of  160 million in cash 
Vertex plans to develop CTP 656 for potential use in future once daily regimens in combination with its other pipeline drugs to treat the underlying cause of CF 
Vertex carries a Zacks Rank  3  Hold   Better ranked stocks in the pharmaceutical sector are Akari Therapeutics  Plc   NASDAQ AKTX   and VIVUS  Inc    NASDAQ VVUS    both with a Zacks Rank  1  Strong Buy   You can see  
Shares of Akari Therapeutics have risen 28 4  this year so far 
Loss estimates for Vivus for 2017 have narrowed by 22  over the past 30 days  The company has delivered an average positive earnings surprise of 233 63  over the past four quarters 
5 Trades Could Profit  Big League  from Trump Policies 
If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course 
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates and spending surges in defense and infrastructure ",2017-05-16,Zacks Investment Research,https://www.investing.com/analysis/why-is-vertex-pharma-(vrtx)-stock-soaring-this-year-200189570,200189570
120929,342444,VRTX,Zacks com Featured Highlights  Covanta Holding  PTC  Etsy  Vertex Pharmaceuticals And Live Nation Entertainment,opinion,"For Immediate Release

	Chicago  IL   May 18  2017   Stocks in this week s article include Covanta Holding Corporation  NYSE         PTC Inc   NASDAQ         Etsy  Inc   NASDAQ         Vertex Pharmaceuticals  NASDAQ VRTX  Incorporated  NASDAQ        and Live Nation Entertainment  Inc   NYSE        

Screen of the Week of Zacks Investment Research 

5 Toxic Stocks to Steer Clear Of or Sell Short

	Investors who can precisely identify overpriced stocks are likely to emerge winners  In practice  the correctly priced stocks and the overblown toxic stocks are mingled in the market place in such a way that it becomes tough to identify them  Investors who can figure out the overpriced stocks and shun them at the right time are the ones who are likely to benefit 
	Generally  toxic stocks are vulnerable to external shocks and burdened with huge debts  In fact  the unreasonably high price of the toxic stocks is short lived as the current price of these stocks is higher than their intrinsic price  So  quite obviously  if you own such toxic stocks for a very long period of time  you are sure to see huge loss in your wealth 
	High price of the toxic stocks can be ascribed to an irrational exuberance associated with them or some serious fundamental lacunae  Presence of such stocks in your portfolio may result in loss of wealth 
	However  if you can precisely spot the toxic stocks  you may gain by resorting to an investing strategy called short selling  This strategy allows you to sell a stock first and then buy it when the price falls 
	While short selling excels in bear markets  it typically loses money in bull markets 
	So  just like owning stocks with growth potential  distinguishing toxic stocks and discarding them at the right time is the key to guard your portfolio from big losses or make profits by short selling them Screening Criteria
	Here is a winning strategy that will help you to identify overpriced toxic stocks Most recent Debt Equity Ratio greater than the median industry average    High debt equity ratio implies high leverage  High leverage indicates a huge level of repayment that the company has to make in connection with the debt amount P E using 12 month forward EPS estimate greater than 50   A very high forward P E implies that a stock is highly overvalued   Change in F  1  and F  2  Estimate  12 Weeks  less than  5    Negative EPS estimate revision for this and the next fiscal year during the past 12 weeks points to analysts  pessimism Zacks Rank more than or equal to  3  Hold    We have not considered Buy rated stocks that generally outperform the market 
	Here are five of the 26 toxic stocks that showed up on the screen Covanta Holding Corporation  NYSE      is a Morristown  NJ based alternative energy company that provides waste and energy services in the U S  and Canada  Over the past 30 days  its second quarter 2017 estimate widened from a loss of 11 cents per share to a loss of 15 cents  The company has a Zacks Rank  3  You can see   PTC Inc    NASDAQ       is a Needham  MA based software company engaged in developing  marketing and supporting software solutions  Over the past one month period  the current quarter estimates declined 26 1  to 17 cents  The stock currently has a Zacks Rank  3 Etsy  Inc   NASDAQ       is a Brooklyn  NY based Internet services company  It operates a marketplace to make  sell and buy goods online and offline worldwide  Over the last 30 days  its current quarter estimate changed from a break even point to a loss of a penny per share  The company has a Zacks Rank  3 
	Boston  MA based  Vertex Pharmaceuticals Incorporated  NASDAQ       is a bio technology company  Over the past one month period  the second quarter 2017 estimate declined 66 7  to 5 cents a share  The stock currently has a Zacks Rank  3 Live Nation Entertainment  Inc   NYSE       is a Beverly Hills  CA based live entertainment company  Over the past seven days  its second quarter 2017 estimate remained unchanged at 17 cents a share 
	Get the rest of the stocks on the list and start putting this and other ideas to the test  It can all be done with the Research Wizard stock picking and backtesting software 
	The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out 

  

Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  

Disclosure  Performance information for Zacks  portfolios and strategies are available at     

Zacks Restaurant Recommendations    In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector  

	Sign up now for your free trial today and start picking better stocks immediately  And with the backtesting feature  you can test your ideas to see how you can improve your trading in both up markets and down markets  Don t wait for the market to get better before you decide to do better  Start learning how to be a better trader today  

Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  



About Screen of the Week

	Zacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine  But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use  Each week  Zacks Profit from the Pros free email newsletter shares a new screening strategy  Learn more about it here 

About Zacks 

	Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time    



 

 

 

 

 

	Follow us on Twitter  

	Join us on Facebook  NASDAQ FB   

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Contact  Jim Giaquinto

	Company  Zacks com

	Phone  312 265 9268

	Email  

	Visit  

	Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer    

Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  

	This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-05-17,Zacks Investment Research,"https://www.investing.com/analysis/zacks.com-featured-highlights:-covanta-holding,-ptc,-etsy,-vertex-pharmaceuticals-and-live-nation-entertainment-200189961",200189961
120930,342445,VRTX,Vertex Ups Kalydeco Sales View As FDA Okays Label Expansion,opinion,Vertex Pharmaceuticals Incorporated s   NASDAQ VRTX   shares gained more than 1  on May 17  after the company announced that the FDA has approved its lead marketed drug  Kalydeco  ivacaftor  for expanded use We note that Kalydeco is already approved in the U S   EU  Australia and Canada for the treatment of certain patients with CF who have specific mutations in their CFTR gene Kalydeco has now been approved for use in CF patients  ages 2 and older  who have one of 23 residual function mutations in the CF transmembrane conductance regulator  CFTR  gene  The label expansion into this indication provides the company access to more than 900 patients in the U S Following the latest approval  the company increased its sales expectations for the drug to a range of  740  770 million in 2017 from the prior expectation of  710  730 million We remind investors that in February last year the FDA had issued a complete response letter  CRL  to the supplemental new drug application  sNDA  seeking approval to expand the use of Kalydeco in this patient population  The company later re submitted the sNDA  With the latest approval  Kalydeco is now approved to treat people who have one of 33 mutations in the CFTR gene with CF  ages 2 and older  Vertex s shares have significantly outperformed the Zacks classified  industry so far this year  Shares of the company have gained 55 2  while the industry registered a decrease of 0 1  Coming back to the latest news  the approval was based on in vitro data and supported by more than five years of real world clinical data that demonstrated strong safety and efficacy profile for Kalydeco in eligible patients The company is holding further talks with the FDA about approval of the candidate for other mutations  including one of five  splice  mutations  If approved  the candidate may be used for the treatment of more than 600 additional patients ages two and older who have such mutations Vertex has two CF drugs   Kalydeco   Orkambi   in its portfolio with blockbuster potential  Meanwhile  Vertex s CF pipeline is quite strong with a broad portfolio of next generation CF correctors  Investor focus will now be on the triple combination CF regimens  which are crucial for long term growth at Vertex   Multiple triple combo data readouts in CF patients are expected in second half of 2017 Vertex Pharmaceuticals Incorporated Price   Zacks Rank   Key PicksVertex currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector include Aeglea BioTherapeutics   NASDAQ AGLE    VIVUS  Inc    NASDAQ VVUS   and MEI Pharma  Inc    NASDAQ MEIP    While Aeglea carries a Zacks Rank  2  Buy   VIVUS and MEI Pharma sport a Zacks Rank  1  Strong Buy   You can see  Aeglea s loss per share estimates narrowed from  3 64 to  2 48 for 2017  over the last 60 days  The company posted positive earnings surprises in three of the four trailing quarters with an average beat of 20 75  VIVUS s loss per share estimates narrowed from 50 cents to 39 cents for 2017  over the last 30 days  The company posted positive earnings surprises in all of the four trailing quarters with an average beat of 233 69  MEI Pharma s posted positive earnings surprises in three of the four trailing quarters with an average beat of 66 56   The company s shares gained 16  so far this year Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-05-17,Zacks Investment Research,https://www.investing.com/analysis/vertex-ups-kalydeco-sales-view-as-fda-okays-label-expansion-200190059,200190059
120931,342446,VRTX,Concert Pharma Falls After Clinical Hold On Hair Loss Drug,opinion,"Concert Pharmaceuticals  Inc    NASDAQ CNCE   shares were down almost 8  on Wednesday after the company announced that the FDA has placed a clinical hold on a mid stage study evaluating its pipeline candidate CTP 543 for the treatment of alopecia areata Shares of Concert Pharma have outperformed the Zacks Classified  industry so far this year  The company has gained 44 4  while the industry rose 4 9  in the period 
The FDA had previously approved the initiation of a phase IIa study on CTP 543  which began earlier this month  However  just before the start of patient dosing  the FDA yesterday informed Concert that the agency needs to review data from one recently completed non clinical toxicology study  There was no safety concern cited by the FDA  However  agency clarified they intend to review this additional non clinical data as support to one year dosage data from the planned phase IIa study With the FDA placing a clinical hold  new patient enrollment in the study has been halted for the time being  The company is actively working with the FDA to resume enrollment in the Phase IIa trial by submitting the requested non clinical study reports as soon as possible  The FDA will notify Concert about the status of clinical hold within 30 days after the company s response We note that Concert is developing CTP 543 for the treatment of alopecia areata  an autoimmune disease resulting in partial or complete loss of hair on the scalp and body  CTP 543 was discovered by applying its deuterium chemistry technology to modify Incyte Corporation s   NASDAQ INCY   oncology drug  Jakafi  Jakafi selectively inhibits Janus kinases 1 and 2  enzymes controlling signal transmission in cells and believed to be involved in this autoimmune disorder  Jakafi has been evaluated in academic settings and reported to promote hair growth in individuals suffering from moderate to severe alopecia areata We remind investors that Concert had inked a definitive deal with Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   in Mar 2017 to sell the worldwide development and commercialization rights of its cystic fibrosis  CF  pipeline candidate  CTP 656 for an upfront payment of  160 million in cash Concert Pharmaceuticals  Inc  Price and Consensus   Zacks Rank   Key PickConcert Pharma currently has a Zacks Rank  4  Sell   A better ranked healthcare stock is VIVUS  Inc    NASDAQ VVUS    Vivus sports a Zacks Rank  1  Strong Buy   You can see  Vivus  loss per share estimates narrowed 22  to 39 cents for 2017 over the last 60 days  The company posted positive surprises in all the four trailing quarters with an average beat of 233 69  Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-05-17,Zacks Investment Research,https://www.investing.com/analysis/concert-pharma-falls-after-clinical-hold-on-hair-loss-drug-200190043,200190043
120932,342447,VRTX,5 Toxic Stocks To Offload Or Play Short For Profit,opinion,"Investing success largely depends on precise identification of overpriced stocks  However  overblown toxic stocks and the correctly priced stocks are intertwined in the market place in such a way that it is indeed tough to spot them  Investors who can figure out the bubble stocks and abandon them at the right time are the ones who are likely to benefit Toxic stocks are generally susceptible to external shocks and burdened with huge debts  In fact  the irrationally high price of the toxic stocks is short lived as the intrinsic value of these stocks lags their current price  So  quite obviously  if you own such toxic stocks for aninordinate period of time  you are likely to witness huge loss in your wealth Steep pricing of the toxic stocks can be ascribed to either an irrational exuberance associated with them or some serious fundamental drawbacks 
However  if you can  correctly pinpoint the toxic stocks  you may gain by resorting to an investing strategy called short selling  This strategy allows you to sell a stock first and then buy it when the price falls While short selling excels in bear markets  it typically loses money in bull markets So  just like identifying stocks with growth potential  spotting toxic stocks and abandoning them at the right time is the key to protect your portfolio from big losses or make profits by short selling them Screening CriteriaHere is a winning strategy that will help you to identify overpriced toxic stocks Most recent Debt Equity Ratio greater than the median industry average  High debt equity ratio implies high leverage  High leverage indicates a huge level of repayment that the company has to make in connection with the debt amount P E using 12 month forward EPS estimate greater than 50  A very high forward P E implies that a stock is highly overvalued   Change in F  1  and F  2  Estimate  12 Weeks  less than  5  Negative EPS estimate revision for this and the next fiscal year during the past 12 weeks points to analysts  pessimism Zacks Rank more than or equal to  3  Hold   We have not considered Buy rated stocks that generally outperform the market Here are five of the 21 toxic stocks that showed up on the screen Salesforce com  inc    NYSE CRM   is a San Francisco  CA based computer software industry firm  Over the past one month period  its second quarter earnings estimate has declined 18 2  to 9 cents a share  Currently  the company carries a Zacks Rank  3  You can see Boston  MA based  Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   is a bio technology company  Over the past one month period  the second quarter estimate has remained unchanged at 5 cents per share  The stock currently has a Zacks Rank  3 Live Nation Entertainment  Inc    NYSE LYV   is a Beverly Hills  CA based live entertainment company  Over the past seven days  its second quarter 2017 estimate remained unchanged at 17 cents a share Covanta Holding Corporation   NYSE CVA   is a Morristown  NJ based alternative energy company that provides waste and energy services in the U S  and Canada  Over the past 30 days  its second quarter estimates narrowed from a loss of 16 cents per share to a loss of 15 cents   The company has a Zacks Rank  3 Etsy  Inc    NASDAQ ETSY   is a Brooklyn  NY based Internet services company  It operates a marketplace to make  sell and buy goods online and offline worldwide  Over the last 30 days  its second quarter estimate changed from a break even point to a loss of a cent per share  The company has a Zacks Rank  3 Get the rest of the stocks on the list and start putting this and other ideas to the test  It can all be done with the Research Wizard stock picking and backtesting software The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at   Zacks Restaurant Recommendations  In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector ",2017-06-01,Zacks Investment Research,https://www.investing.com/analysis/5-toxic-stocks-to-offload-or-play-short-for-profit-200192894,200192894
120933,342448,VRTX,Zacks com Featured Highlights  Salesforce com  Vertex Pharmaceuticals  Live Nation Entertainment  Covanta Holding And Etsy,opinion,"For Immediate Release

	Chicago  IL   June 05  2017   Stocks in this week s article include Salesforce com  inc   NYSE         Vertex Pharmaceuticals  NASDAQ VRTX  Incorporated  NASDAQ         Live Nation Entertainment  Inc   NYSE         Covanta Holding Corporation  NYSE        and Etsy  Inc   NASDAQ        

Screen of the Week of Zacks Investment Research 

5 Toxic Stocks to Offload or Play Short for Profit 

	Investing success largely depends on precise identification of overpriced stocks  However  overblown toxic stocks and the correctly priced stocks are intertwined in the market place in such a way that it is indeed tough to spot them  Investors who can figure out the bubble stocks and abandon them at the right time are the ones who are likely to benefit 
	Toxic stocks are generally susceptible to external shocks and burdened with huge debts  In fact  the irrationally high price of the toxic stocks is short lived as the intrinsic value of these stocks lags their current price  So  quite obviously  if you own such toxic stocks for aninordinate period of time  you are likely to witness huge loss in your wealth 
	Steep pricing of the toxic stocks can be ascribed to either an irrational exuberance associated with them or some serious fundamental drawbacks 

	However  if you can  correctly pinpoint the toxic stocks  you may gain by resorting to an investing strategy called short selling  This strategy allows you to sell a stock first and then buy it when the price falls 
	While short selling excels in bear markets  it typically loses money in bull markets 
	So  just like identifying stocks with growth potential  spotting toxic stocks and abandoning them at the right time is the key to protect your portfolio from big losses or make profits by short selling them Screening Criteria
	Here is a winning strategy that will help you to identify overpriced toxic stocks Most recent Debt Equity Ratio greater than the median industry average    High debt equity ratio implies high leverage  High leverage indicates a huge level of repayment that the company has to make in connection with the debt amount P E using 12 month forward EPS estimate greater than 50   A very high forward P E implies that a stock is highly overvalued   Change in F  1  and F  2  Estimate  12 Weeks  less than  5    Negative EPS estimate revision for this and the next fiscal year during the past 12 weeks points to analysts  pessimism Zacks Rank more than or equal to  3  Hold    We have not considered Buy rated stocks that generally outperform the market 
	Here are five of the 21 toxic stocks that showed up on the screen Salesforce com  inc   NYSE       is a San Francisco  CA based computer software industry firm  Over the past one month period  its second quarter earnings estimate has declined 18 2  to 9 cents a share  Currently  the company carries a Zacks Rank  3  You can see   
	Boston  MA based  Vertex Pharmaceuticals Incorporated  NASDAQ       is a bio technology company  Over the past one month period  the second quarter estimate has remained unchanged at 5 cents per share  The stock currently has a Zacks Rank  3 Live Nation Entertainment  Inc   NYSE       is a Beverly Hills  CA based live entertainment company  Over the past seven days  its second quarter 2017 estimate remained unchanged at 17 cents a share Covanta Holding Corporation  NYSE       is a Morristown  NJ based alternative energy company that provides waste and energy services in the U S  and Canada  Over the past 30 days  its second quarter estimates narrowed from a loss of 16 cents per share to a loss of 15 cents  The company has a Zacks Rank  3 Etsy  Inc   NASDAQ       is a Brooklyn  NY based Internet services company  It operates a marketplace to make  sell and buy goods online and offline worldwide  Over the last 30 days  its second quarter estimate changed from a break even point to a loss of a cent per share  The company has a Zacks Rank  3 
	Get the rest of the stocks on the list and start putting this and other ideas to the test  It can all be done with the Research Wizard stock picking and backtesting software 
	The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out 

  

Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  

Disclosure  Performance information for Zacks  portfolios and strategies are available at     

Zacks Restaurant Recommendations    In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector  

	Sign up now for your free trial today and start picking better stocks immediately  And with the backtesting feature  you can test your ideas to see how you can improve your trading in both up markets and down markets  Don t wait for the market to get better before you decide to do better  Start learning how to be a better trader today  

Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material 

About Screen of the Week

	Zacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine  But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use  Each week  Zacks Profit from the Pros free email newsletter shares a new screening strategy  Learn more about it here 

About Zacks 

	Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time    

 

 

 

 

 

	Follow us on Twitter  

	Join us on Facebook  NASDAQ FB   

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Contact  Jim Giaquinto

	Company  Zacks com

	Phone  312 265 9268

	Email  

	Visit  

	Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer    

Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-06-04,Zacks Investment Research,"https://www.investing.com/analysis/zacks.com-featured-highlights:-salesforce.com,-vertex-pharmaceuticals,-live-nation-entertainment,-covanta-holding-and-etsy-200193179",200193179
120934,342449,VRTX,5 Toxic Stocks To Discard Or Play Short For Profit,opinion,One of the important keys to successful investing is the proper identification of overpriced stocks and correctly priced ones  However  in reality  the overpriced toxic stocks and the fairly priced stocks are intermingled in the market place in such a way that it becomes extremely difficult to distinguish them  Investors who can figure out the toxic stocks and abandon them at the right time are likely to gain Generally  toxic stocks are susceptible to external shocks and are loaded with huge debts  Also  sometimes  the price of the toxic stocks is unjustifiably inflated  The irrationally high price of the toxic stocks is only temporary as the intrinsic value of these stocks is lower than the current bloated price The inflated price of the toxic stocks can be due to either an irrational exuberance associated with them or some serious fundamental drawback  If you own such stocks for a very long period of time  you are sure to see huge erosion in your wealth On the other hand  if you can pinpoint the toxic stocks accurately  you may gain by resorting to an investing strategy called short selling  This strategy allows you to sell a stock first and then buy it when the price falls While short selling excels in bear markets  it typically loses money in bull markets So  identifying toxic stocks and throwing them away at the right time is the key to protect your portfolio from big losses or make profits by short selling them Screening CriteriaHere is a winning strategy that will help you to identify overpriced toxic stocks Most recent Debt Equity Ratio greater than the median industry average  High debt equity ratio implies high leverage  High leverage indicates a huge level of repayment that the company has to make in connection with the debt amount P E using 12 month forward EPS estimate greater than 50  A very high forward P E implies that a stock is highly overvalued   Change in F  1  and F  2  Estimate  12 Weeks  less than  5  Negative EPS estimate revision for this and the next fiscal year during the past 12 weeks points to analysts  pessimism Zacks Rank more than or equal to  3  Hold   We have not considered Buy rated stocks that generally outperform the market Here are five of the 19 toxic stocks that showed up on the screen Etsy  Inc    NASDAQ ETSY   is a Brooklyn  NY based Internet services company  It operates a marketplace to make  sell and buy goods online and offline worldwide  Over the last 30 days  its quarter estimates widened from a loss of a penny per share to a loss of 2 cents  The company has a Zacks Rank  3  You can see  Live Nation Entertainment  Inc    NYSE LYV   is a Beverly Hills  CA based live entertainment company  Over the past 30 days  its second quarter 2017 estimates remained unchanged at 17 cents a share  The stock currently has a Zacks Rank  3 Salesforce com  inc    NYSE CRM   is a San Francisco  CA based computer software industry firm  Over the past one month period  its second quarter earnings estimate has declined 18 2  to 9 cents a share  Currently  the company carries a Zacks Rank  3 Boston  MA based  Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   is a biotechnology company  Over the past one month period  current quarter estimates remained unchanged at 5 cents per share  The stock currently has a Zacks Rank  3 NeoGenomics  Inc    NASDAQ NEO   is a Fort Myers  FL based company belonging to the biomedical and genetics industry  Over the past one month period  current quarter estimates remained unchanged at 2 cents per share  The stock currently has a Zacks Rank  3 Get the rest of the stocks on the list and start putting this and other ideas to the test  It can all be done with the Research Wizard stock picking and backtesting software The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at   Zacks Restaurant Recommendations  In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector ,2017-06-19,Zacks Investment Research,https://www.investing.com/analysis/5-toxic-stocks-to-discard-or-play-short-for-profit-200196038,200196038
120935,342450,VRTX,Zacks com Featured Highlights  Etsy  Live Nation Entertainment  Salesforce com  Vertex Pharmaceuticals And NeoGenomics,opinion,"For Immediate Release

	Chicago  IL   June 20  2017   Stocks in this week s article include Etsy  Inc   NASDAQ         Live Nation Entertainment  Inc   NYSE         Salesforce com  Inc   NYSE         Vertex Pharmaceuticals Inc  NASDAQ VRTX    NASDAQ        and NeoGenomics  Inc   NASDAQ        

Screen of the Week of Zacks Investment Research 

5 Toxic Stocks to Discard or Play Short for Profit 

	One of the important keys to successful investing is the proper identification of overpriced stocks and correctly priced ones  However  in reality  the overpriced toxic stocks and the fairly priced stocks are intermingled in the market place in such a way that it becomes extremely difficult to distinguish them  Investors who can figure out the toxic stocks and abandon them at the right time are likely to gain 

	Generally  toxic stocks are susceptible to external shocks and are loaded with huge debts  Also  sometimes  the price of the toxic stocks is unjustifiably inflated  The irrationally high price of the toxic stocks is only temporary as the intrinsic value of these stocks is lower than the current bloated price 
	The inflated price of the toxic stocks can be due to either an irrational exuberance associated with them or some serious fundamental drawback  If you own such stocks for a very long period of time  you are sure to see huge erosion in your wealth 
	On the other hand  if you can pinpoint the toxic stocks accurately  you may gain by resorting to an investing strategy called short selling  This strategy allows you to sell a stock first and then buy it when the price falls 
	While short selling excels in bear markets  it typically loses money in bull markets 
	So  identifying toxic stocks and throwing them away at the right time is the key to protect your portfolio from big losses or make profits by short selling them Screening Criteria
	Here is a winning strategy that will help you to identify overpriced toxic stocks Most recent Debt Equity Ratio greater than the median industry average    High debt equity ratio implies high leverage  High leverage indicates a huge level of repayment that the company has to make in connection with the debt amount P E using 12 month forward EPS estimate greater than 50   A very high forward P E implies that a stock is highly overvalued   Change in F  1  and F  2  Estimate  12 Weeks  less than  5    Negative EPS estimate revision for this and the next fiscal year during the past 12 weeks points to analysts  pessimism Zacks Rank more than or equal to  3  Hold    We have not considered Buy rated stocks that generally outperform the market 
	Here are five of the 19 toxic stocks that showed up on the screen Etsy  Inc   NASDAQ       is a Brooklyn  NY based Internet services company  It operates a marketplace to make  sell and buy goods online and offline worldwide  Over the last 30 days  its quarter estimates widened from a loss of a penny per share to a loss of 2 cents  The company has a Zacks Rank  3  You can see   Live Nation Entertainment  Inc   NYSE       is a Beverly Hills  CA based live entertainment company  Over the past 30 days  its second quarter 2017 estimates remained unchanged at 17 cents a share  The stock currently has a Zacks Rank  3 Salesforce com  Inc   NYSE       is a San Francisco  CA based computer software industry firm  Over the past one month period  its second quarter earnings estimate has declined 18 2  to 9 cents a share  Currently  the company carries a Zacks Rank  3 
	Boston  MA based  Vertex Pharmaceuticals Inc   NASDAQ        is a biotechnology company  Over the past one month period  current quarter estimates remained unchanged at 5 cents per share  The stock currently has a Zacks Rank  3 NeoGenomics  Inc   NASDAQ       is a Fort Myers  FL based company belonging to the biomedical and genetics industry  Over the past one month period  current quarter estimates remained unchanged at 2 cents per share  The stock currently has a Zacks Rank  3 
	Get the rest of the stocks on the list and start putting this and other ideas to the test  It can all be done with the Research Wizard stock picking and backtesting software 
	The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out 

   

Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  

Disclosure  Performance information for Zacks  portfolios and strategies are available at     

Zacks Restaurant Recommendations    In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector  

	Sign up now for your free trial today and start picking better stocks immediately  And with the backtesting feature  you can test your ideas to see how you can improve your trading in both up markets and down markets  Don t wait for the market to get better before you decide to do better  Start learning how to be a better trader today  

Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material 

About Screen of the Week

	Zacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine  But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use  Each week  Zacks Profit from the Pros free email newsletter shares a new screening strategy  Learn more about it here 

About Zacks 

	Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time    

 

 

 

 

 

	Follow us on Twitter  

	Join us on Facebook  NASDAQ FB   

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Contact  Jim Giaquinto

	Company  Zacks com

	Phone  312 265 9268

	Email  

	Visit  

	Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer    

Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-06-19,Zacks Investment Research,"https://www.investing.com/analysis/zacks.com-featured-highlights:-etsy,-live-nation-entertainment,-salesforce.com,-vertex-pharmaceuticals-and-neogenomics-200196260",200196260
120976,342491,VRTX,The Zacks Analyst Blog Highlights  Esperion Therapeutics  Vertex Pharmaceuticals  Nektar Therapeutics  Argos Therapeutics And Cidara Therapeutics,opinion,"For Immediate Release

	Chicago  IL   April 07  2017   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Esperion Therapeutics  Inc   NASDAQ           Vertex Pharmaceuticals  NASDAQ VRTX  Incorporated  NASDAQ           Nektar Therapeutics  NASDAQ           Argos Therapeutics  Inc   NASDAQ          and Cidara Therapeutics  Inc   NASDAQ          

	Today  Zacks is promoting its   Buy   stock recommendations     

Here are highlights from Thursday s Analyst Blog  

Best and Worst Drug Stocks from Q1

	After a tough and challenging 2016  pharma and biotech stocks have been showing signs of recovery this year  The sector started the year on a strong note with the NASDAQ Biotechnology Index and the NYSE ARCA Pharmaceutical Index gaining 10 7  and 5 7   respectively  in the first quarter of 2017 

	Despite the drug pricing issue remaining a headline risk this year  investors have been gaining confidence in the sector based on strong results  R D success and innovation  FDA approvals  ramp up in new product sales and continued strong performance from legacy products  Expectations are also high that M As will pick up this year 

	There has also been some talk about speeding up the FDA approval process  Last year  the number of new drug approvals slipped to 22  well below the 45 approvals in 2015 and 41 in 2014  President Trump said that the FDA will be streamlined and the drug approval process will be much faster  The recently signed 21st Century Cures Act is a step in this direction  With the passing of this Act  expectations are that there will be more innovation in the sector and  maybe  a surge in new drug approvals  So far in 2017  13 drugs have been approved by the agency 

	While all these factors should work in favor of the sector  challenges remain in the form of additional competition  high profile pipeline setbacks  slowdown in growth of mature products and loss of exclusivity for certain key drugs 

	Here is a look at 3 of the best and worst performing drug stocks in the first quarter of 2017 

3 Best Performing Drug Stocks in Q1

Esperion Therapeutics  Inc    NASDAQ          Ann Arbor  MI based Esperion is a lipid management company focused on developing and commercializing convenient  complementary  cost effective  once daily  oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol  LDL C   The company s lead pipeline candidate  bempedoic acid  is in late stage development with the company looking to file for FDA approval for a LDL C lowering indication by the first half of 2019  Esperion s shares gained a whopping 182  in the first quarter of 2017    a key catalyst was news about the FDA confirming that the company s ongoing LDL C lowering program would be adequate to support approval for this indication  Top line results from these studies should be out by mid 2018  Year to date  YTD   Esperion s shares are up 185 2   outperforming the Zacks categorized  industry  which is up 1 6  

Vertex Pharmaceuticals Incorporated   NASDAQ          Boston  MA based Vertex  which holds a strong position in the cystic fibrosis  CF  market  got a boost with positive data from a couple of late stage studies evaluating a combination of tezacaftor and Kalydeco  ivacaftor   Statistically significant improvements in lung function were observed in people with CF ages 12 and older who have certain mutations in the cystic fibrosis transmembrane conductance regulator  CFTR  gene 

	Vertex plans to seek approval in the U S  and EU in the third quarter of 2017 for the treatment of people with CF ages 12 and older who have two copies of the F508del mutation and in people who have one mutation that results in residual CFTR function and F508del mutation  While the company s shares shot up 48  in the first quarter of the year  shares are up 54 9  YTD  outperforming the Zacks categorized  industry which is up 3 6  so far in 2017 

Nektar Therapeutics   NASDAQ          California based Nektar is a research based biopharma company focused on addressing the unmet medical needs of patients with the company s pipeline including potential treatments for cancer  auto immune disease and chronic pain  The company s shares shot up 91 3  in the first quarter    Nektar received a major boost with positive late stage data on NKTR 181  a first in class opioid analgesic  NKTR 181  which has fast track designation in the U S  for the treatment of moderate to severe chronic pain  is the first full mu opioid agonist designed to provide potent pain relief without the high levels of euphoria that can lead to abuse and addiction with standard opioids  NKTR 181 s efficacy along with significantly lower abuse potential than oxycodone could help it change the way of treating patients with chronic pain conditions  Read more      YTD  Nektar s shares are up 71 8  

	While Nektar and Esperion are Zacks Rank  3  Hold  stocks  Vertex is a Zacks Rank  2  Buy  stock  You can see   

2 Worst Performing Drug Stocks of Q1

Argos Therapeutics  Inc    NASDAQ          Durham  NC based Argos is an immuno oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis technology platform  Argos suffered a huge setback when an interim data analysis showed that the company s pivotal late stage study on its most advanced pipeline candidate  rocapuldencel T  should be discontinued for futility  The company s shares were hit hard by this news and were down 90 8  in the first quarter and 91 8  YTD 

Cidara Therapeutics  Inc    NASDAQ          San Diego  CA based Cidara is a biotech company focused on developing novel anti infectives including immunotherapies  Cidara suffered a setback in February on disappointing mid stage data on CD101 topical which was being evaluated for acute vulvovaginal candidiasis  VVC   The company has decided to stop further development of the topical formulation for VVC and will instead focus its resources towards the development of the IV formulation of CD101  as well as the expansion and acceleration of the Cloudbreak immunotherapy platform  CD101 IV is currently in a mid stage study for candidemia with results expected in the fourth quarter  Cidara s shares declined 25  during Q1 and are down 28 4  YTD 

Now See Our Private Investment Ideas

	While the above ideas are being shared with the public  other trades are hidden from everyone but selected members  Would you like to peek behind the curtain and view them  Starting today  for the next month  you can follow all Zacks  private buys and sells in real time from value to momentum       from stocks under  10 to ETF and option moves       from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors  

	Today  Zacks is promoting its   Buy   stock recommendations    

About Zacks Equity Research

	Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

	Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  











	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-04-06,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-esperion-therapeutics,-vertex-pharmaceuticals,-nektar-therapeutics,-argos-therapeutics-and-cidara-therapeutics-200181803",200181803
120977,342492,VRTX,Biotech Stock Roundup  Geron Gains On Interim Data  OncoMed Slumps On Pipeline Setback,opinion,"Several companies including Geron   NASDAQ GERN   and OncoMed   NASDAQ OMED   provided key pipeline updates this week  While Geron s shares were up this week  OncoMed s shares plunged and hit a 52 week low Recap of the Week s Most Important StoriesGeron Up on Interim Data  Geron s shares were up 19 5  on the completion of the second internal data review of the studies being conducted on the company s telomerase inhibitor imetelstat  The studies  IMerge and IMbark  are being conducted in patients with lower risk myelodysplastic syndromes  MDS  and relapsed or refractory myelofibrosis  MF   respectively  However  development partner Janssen will take a decision regarding the commencement of the phase III stage of the IMerge study later this year and a decision regarding the continued development of imetelstat for the relapsed or refractory MF indication next year  Read more     Geron is a Zacks Rank  2  Buy  stock  You can see  OncoMed Slumps on Study Failure  Clinical stage company  OncoMed  suffered back to back setbacks with a pipeline candidate failing in a mid stage study and a partner pulling out of a collaboration  The company said that demcizumab failed to achieve the primary endpoint in a phase II study conducted in treatment na ve metastatic pancreatic cancer patients  OncoMed has decided to discontinue the study and is conducting additional analyses with its partner  Celgene   NASDAQ CELG   
The second setback for OncoMed came with the news about Bayer  DE BAYGN  Pharma s decision to not exercise its option to license OncoMed s Wnt pathway inhibitors vantictumab and ipafricept for strategic reasons  With these developments  OncoMed s shares hit a 52 week low  Read more    Breakthrough Status for Regeneron Drug  Regeneron   NASDAQ REGN   got Breakthrough Therapy status for evinacumab in the U S  for the treatment of hypercholesterolemia in patients with homozygous familial hypercholesterolemia  HoFH   Breakthrough Therapy status helps the development and review of drugs that target serious or life threatening conditions  An inherited disorder  HoFH is the most severe form of hypercholesterolemia and can lead to premature cardiovascular disease due to very high levels of LDL cholesterol  Regeneron  which reported positive interim mid stage data on evinacumab  is currently planning a phase III study  Read more    Actelion s Uptravi Safety Concerns Cleared by EMA  The European Medicines Agency  EMA   which was conducting a safety review of Actelion s pulmonary arterial hypertension  PAH  drug Uptravi  said that it has completed the review  The review was initiated following 5 patient deaths in France  The EMA said that existing as well as new patients can continue using the drug in accordance with the current prescribing information  No changes were made to the label following the safety review  Uptravi is one of the key drugs in Actelion s PAH portfolio  Actelion is on track to be acquired by Johnson   Johnson  NYSE JNJ  in the second quarter Pediatric Label Expansion for Gilead HCV Drugs  Gilead s   NASDAQ GILD   hepatitis C virus  HCV  drugs  Harvoni and Sovaldi gained FDA approval for use in pediatric patients 12 years and older  With this approval  children in this age group will have access to two direct acting interferon free antiviral regimens that offer high cure rates for HCV genotypes 1 through 6  The approval expands the patient population for these drugs with Gilead estimating that there are about 23 000 46 000 pediatric HCV patients in the U S  with most infected at birth  The label expansion is good news for Gilead which has been struggling to drive sales of its HCV franchise  The franchise  which was once a key revenue generator for Gilead  is expected to record a steep decline in sales this year with changing market dynamics and increasing competition weighing on the segment  Read more    
So far in 2017  Gilead has underperformed the Zacks categorized  industry with shares declining 7 8  compared to the industry gain of 2 7 Performance
Medical   Biomedical and Genetics Industry 5YR   ReturnThe NASDAQ Biotechnology Index declined 1 1  over the last five trading sessions  Among major biotech stocks  Regeneron declined 4 1  while Vertex   NASDAQ VRTX   gained 1 7   Over the last six months  Vertex was up 39 9  while Gilead was down 10 6   See the last biotech stock roundup here    
What s Next in the Biotech World Watch out for the usual pipeline and regulatory updates  Incyte   NASDAQ INCY   could also get a response from the FDA for Olumiant  baricitinib   a once daily oral medication for the treatment of moderate to severe rheumatoid arthritis  RA  Looking for Ideas with Even Greater Upside Most of Zacks  investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ",2017-04-12,Zacks Investment Research,"https://www.investing.com/analysis/biotech-stock-roundup:-geron-gains-on-interim-data,-oncomed-slumps-on-pipeline-setback-200182452",200182452
120978,342493,VRTX,5 Toxic Stocks To Shun Or Play Short Right Now,opinion,Successful investing calls for the appropriate identification of overpriced stocks and correctly priced stocks  However  in practice  the overhyped toxic stocks and the fairly priced stocks are intermixed in the marketplace in such a way that it becomes difficult to distinguish between them  Investors who can correctly spot the overpriced stocks and shun them at the right time are the ones likely to make a profit Usually  toxic stocks are fraught with huge debt loads and susceptible to external shocks  Also  the unjustifiably high price of the toxic stocks is short lived as the intrinsic value of these stocks is less than their current price  Quite naturally  if you own such toxic stocks for a long period of time  you are sure to make huge loss in your wealth Higher price of the toxic stocks can be attributed to either an irrational exuberance associated with them or some serious fundamental lacuna associated with them  If you own such stocks for long  you are likely to see a big loss in your wealth On the other hand  if you can accurately pinpoint the toxic stocks  you are likely to gain by resorting to an investing strategy called short selling  This strategy allows you to sell a stock first and then buy it when the price falls While short selling excels in bear markets  it typically loses money in bull markets So  just like picking up stocks with strong growth potential  pinpointing toxic stocks and abandoning them at the right time is the key to protect your portfolio from big losses or make profits by short selling them Screening CriteriaHere is a winning strategy that will help you to identify overpriced toxic stocks Most recent Debt Equity Ratio greater than the median industry average  High debt equity ratio implies high leverage  High leverage indicates a huge level of repayment that the company has to make in connection with the debt amount P E using 12 month forward EPS estimate greater than 50  A very high forward P E implies that a stock is highly overvalued   Change in F  1  and F  2  Estimate  12 Weeks  less than  5  Negative EPS estimate revision for this and the next fiscal year during the past 12 weeks points to analysts  pessimism Zacks Rank more than or equal to  3  Hold   We have not considered Buy rated stocks that generally outperform the market Here are five of the 25 toxic stocks that showed up on the screen PTC Inc    NASDAQ PTC   is a Needham  MA based software company engaged in developing  marketing and supporting software solutions  Over the past one month period  first quarter 2017 estimate remained unchanged at 16 cents  The stock currently has a Zacks Rank  3  You can see  Covanta Holding Corporation   NYSE CVA   is a Morristown  NJ based alternative energy company that provides waste and energy services in the U S  and Canada  Over the past 30 days  its first quarter 2017 estimate remained unchanged at a loss of 20 cents per share  The company has a Zacks Rank  3 Live Nation Entertainment  Inc    NYSE LYV   is a Beverly Hills  CA based live entertainment company  Over the past 30 days  its first quarter 2017 estimate widened from a loss of 32 cents a share to a loss of 33 cents Wilmington  DE based Incyte Corporation   NASDAQ INCY   is a drug discovery company  Over the last 30 days  its first quarter estimate widened from a loss of 80 cents a share to a loss of 87 cents  Incyte carries a Zacks Rank  4  Sell  Boston  MA based  Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   is a bio technology company  Over the past one month period  the first quarter 2017 estimate remained unchanged at 4 cents a share  The stock currently has a Zacks Rank  3 Get the rest of the stocks on the list and start putting this and other ideas to the test  It can all be done with the Research Wizard stock picking and backtesting software The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at   Zacks Restaurant Recommendations  In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector ,2017-04-16,Zacks Investment Research,https://www.investing.com/analysis/5-toxic-stocks-to-shun-or-play-short-right-now-200183165,200183165
120979,342494,VRTX,Zacks com Featured Highlights  PTC  Covanta Holding  Live Nation Entertainment  Incyte And Vertex Pharmaceuticals,opinion,"For Immediate Release

	Chicago  IL   April 18  2017   Stocks in this week s article include PTC Inc   NASDAQ         Covanta Holding Corporation  NYSE         Live Nation Entertainment  Inc   NYSE         Incyte Corporation  NASDAQ        and Vertex Pharmaceuticals Inc  NASDAQ VRTX    NASDAQ        

Screen of the Week of Zacks Investment Research 

5 Toxic Stocks to Shun or Play Short Right Now

	Successful investing calls for the appropriate identification of overpriced stocks and correctly priced stocks  However  in practice  the overhyped toxic stocks and the fairly priced stocks are intermixed in the marketplace in such a way that it becomes difficult to distinguish between them  Investors who can correctly spot the overpriced stocks and shun them at the right time are the ones likely to make a profit 

	Usually  toxic stocks are fraught with huge debt loads and susceptible to external shocks  Also  the unjustifiably high price of the toxic stocks is short lived as the intrinsic value of these stocks is less than their current price  Quite naturally  if you own such toxic stocks for a long period of time  you are sure to make huge loss in your wealth 
	Higher price of the toxic stocks can be attributed to either an irrational exuberance associated with them or some serious fundamental lacuna associated with them  If you own such stocks for long  you are likely to see a big loss in your wealth 
	On the other hand  if you can accurately pinpoint the toxic stocks  you are likely to gain by resorting to an investing strategy called short selling  This strategy allows you to sell a stock first and then buy it when the price falls 
	While short selling excels in bear markets  it typically loses money in bull markets 
	So  just like picking up stocks with strong growth potential  pinpointing toxic stocks and abandoning them at the right time is the key to protect your portfolio from big losses or make profits by short selling them Screening Criteria
	Here is a winning strategy that will help you to identify overpriced toxic stocks Most recent Debt Equity Ratio greater than the median industry average    High debt equity ratio implies high leverage  High leverage indicates a huge level of repayment that the company has to make in connection with the debt amount P E using 12 month forward EPS estimate greater than 50   A very high forward P E implies that a stock is highly overvalued   Change in F  1  and F  2  Estimate  12 Weeks  less than  5    Negative EPS estimate revision for this and the next fiscal year during the past 12 weeks points to analysts  pessimism Zacks Rank more than or equal to  3  Hold    We have not considered Buy rated stocks that generally outperform the market 
	Here are five of the 25 toxic stocks that showed up on the screen PTC Inc   NASDAQ       is a Needham  MA based software company engaged in developing  marketing and supporting software solutions  Over the past one month period  first quarter 2017 estimate remained unchanged at 16 cents  The stock currently has a Zacks Rank  3  You can see   Covanta Holding Corporation  NYSE       is a Morristown  NJ based alternative energy company that provides waste and energy services in the U S  and Canada  Over the past 30 days  its first quarter 2017 estimate remained unchanged at a loss of 20 cents per share  The company has a Zacks Rank  3 Live Nation Entertainment  Inc   NYSE       is a Beverly Hills  CA based live entertainment company  Over the past 30 days  its first quarter 2017 estimate widened from a loss of 32 cents a share to a loss of 33 cents 
	Wilmington  DE based Incyte Corporation  NASDAQ        is a drug discovery company  Over the last 30 days  its first quarter estimate widened from a loss of 80 cents a share to a loss of 87 cents  Incyte carries a Zacks Rank  4  Sell  
	Boston  MA based  Vertex Pharmaceuticals Inc   NASDAQ        is a bio technology company  Over the past one month period  the first quarter 2017 estimate remained unchanged at 4 cents a share  The stock currently has a Zacks Rank  3 
	Get the rest of the stocks on the list and start putting this and other ideas to the test  It can all be done with the Research Wizard stock picking and backtesting software 
	The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out 

  

Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  

Disclosure  Performance information for Zacks  portfolios and strategies are available at     

Zacks Restaurant Recommendations    In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector  

	Sign up now for your free trial today and start picking better stocks immediately  And with the backtesting feature  you can test your ideas to see how you can improve your trading in both up markets and down markets  Don t wait for the market to get better before you decide to do better  Start learning how to be a better trader today  

Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material 

About Screen of the Week

	Zacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine  But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use  Each week  Zacks Profit from the Pros free email newsletter shares a new screening strategy  Learn more about it here 

About Zacks 

	Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time    

 

 

 

 

 

	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Contact  Jim Giaquinto

	Company  Zacks com

	Phone  312 265 9268

	Email  

	Visit  

	Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer    

Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  

	This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-04-17,Zacks Investment Research,"https://www.investing.com/analysis/zacks.com-featured-highlights:-ptc,-covanta-holding,-live-nation-entertainment,-incyte-and-vertex-pharmaceuticals-200183428",200183428
120980,342495,VRTX,What s In Store For Nivalis  NVLS  This Earnings Season ,opinion,Nivalis Therapeutics  Inc    NASDAQ NVLS   is expected to report first quarter 2017 results early next month  Last quarter  the company had a positive surprise of 9 09  Year to date  Nivalis  shares lost 4   while the Zacks classified  industry recorded an increase of 2 3  Nivalis  earnings history is a mixed bag  Over the four trailing quarters  the company missed expectations on two occasions and beat the same in the other two with an average positive earnings surprise to 1 51  Nivalis Therapeutics  Inc  Price and EPS Surprise    Let s see how things are shaping up for this announcement Factors at PlayNivalis  a development stage pharmaceutical company  is focused on the discovery  development and commercialization of treatments for cystic fibrosis  CF   With no approved product in its portfolio  Nivalis does not generate any revenue yet  As a result  we expect investor focus to be on the company s progress with its pipeline In Apr 2017  Nivalis entered into a definitive merger agreement with privately held biotechnology company  Alpine Immune Sciences  The merger will lead to the development of a combined novel immunotherapy platform focused on both inflammation and immuno oncology The company s lead product candidate   Cavosonstat  N91115    is being evaluated for the treatment of patients with CF  We note that in Nov 2016  the company announced discouraging results from a phase II study on Cavosonstat  The study failed to achieve its primary endpoint of lung function improvement and a key secondary endpoint of sweat chloride reduction  Subsequently  the company decided to discontinue any further development of the drug Note that the company implemented a workforce reduction in by approximately 84  in Jan 2017  This strategy was adopted to better align resources with the company s operational needs  Also  the move should result in substantial cost savings The company is also evaluating the efficacy and safety of Cavosonstat in combination with Vertex Pharmaceuticals Incorpor s   NASDAQ VRTX   Kalydeco  ivacaftor  in a separate phase II trial of 19 adult CF patients  In Feb 2017  the company announced disappointing top line results from the study  which also missed its primary end points Earnings WhispersOur proven model does not conclusively show that Nivalis is likely to beat estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  for this to happen  However  this is not the case here as you will see below Zacks ESP  Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at a loss of 48 cents You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Though Nivalis  Zacks Rank  2 increases the predictive power of the ESP  its 0 00  Earnings ESP makes surprise prediction difficult Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks That Warrant a LookHere are some health care stocks that you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter Proteostasis Therapeutics  Inc    NASDAQ PTI    which is expected to release results on May 12  has an Earnings ESP of  5 17  and a Zacks Rank  1  You can see  Ultragenyx Pharmaceutical Inc    NASDAQ RARE   is expected to release results on May 8  The company has an Earnings ESP of  0 59  and a Zacks Rank  3 Looking for Ideas with Even Greater Upside Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ,2017-04-25,Zacks Investment Research,https://www.investing.com/analysis/what's-in-store-for-nivalis-(nvls)-this-earnings-season-200185318,200185318
120981,342496,VRTX,Vertex  VRTX  Q1 Earnings Top  CF Products Sales Strong,opinion,Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   reported first quarter 2017 earnings per share of 13 cents  including the impact of stock based compensation expense   which beat the Zacks Consensus Estimate of 4 cents  Notably  the company had posted a loss of 13 cents in the year ago quarter  Strong product revenues and cost control led to higher profits in the quarter Excluding stock based compensation expense  first quarter adjusted earnings were 41 cents per share compared with the year ago figure of 9 cents Including upfront revenues of  230 million received from German phama company  Merck  NYSE MRK  KGaA for the out licensing of four oncology programs  restructuring costs and other adjustments  reported earnings were 99 cents per share Vertex reported revenues of  714 7 million in the first quarter  up 79 5  year over year gaining from the upfront payment from Merck KGaA  Excluding the upfront revenues  adjusted total revenue was  482 3 million  which surpassed the Zacks Consensus Estimate of  459 1 million by 5 3  This year so far  Vertex s shares have risen 61 5   outperforming an increase of 4 8  for the Zacks classified industry CF Franchise Sales Rise Vertex s first quarter revenues consisted of sales from cystic fibrosis  CF  products Kalydeco and Orkambi  collaborative   232 6 million  and royalty revenues   1 5 million   CF product revenues were  481 million in the first quarter  up 22  year over year The company reported a 9  increase in Kalydeco sales to  186 million  Kalydeco sales gained from one time adjustments mainly related to European reimbursement agreements Orkambi  lumacaftor ivacaftor  delivered sales of  295 0 million  up 32  year over year  On a sequential basis  Orkambi sales rose around 7  in the first quarter supported by rapid uptake in the pediatric indication for which approval was received in Sep 2016 Cost DiscussionAdjusted  including stock based compensation expenses  research and development expenses increased 5 9  to  271 4 million in the first quarter due to higher costs related to progress on the CF pipeline  Adjusted  including stock based compensation expenses  selling  general and administrative  SG A  expenses increased 5 5  to  110 5 million due to increased investment to support the global launch of Orkambi Maintains 2017 GuidanceVertex maintained its 2017 guidance for Orkambi revenues  which was provided in early Jan 2017  while raising the same for Kalydeco  Orkambi revenues are expected in the range of  1 1  1 3 billion while Kalydeco revenues are estimated in the range of  710 to  730 million  higher than  690  710 million guided previously  Management said the uptick in guidance was the result of a one time gain received this quarter as well as strong demand trends for the product Management continues to believe that Orkambi sales growth will be dependent on reimbursement discussions in Europe in 2017  Vertex has faced many challenges with respect to commercialization of Orkambi in ex U S  markets due to re imbursement hurdles  discontinuations by patients who had previously initiated treatment with Orkambi and a slower than anticipated launch in Germany Combined adjusted research and development  R D  and selling  general and administrative  SG A  expenses in 2017 are anticipated in the range of  1 25  1 30 billion  Costs are expected to be higher than 2016 levels due to increased costs related to CF pipeline development and increased commercial investment to support Orkambi and Kalydeco Our TakeVertex s first quarter results were strong with the company beating expectations for both earnings and revenues as sales of its CF drugs rose Meanwhile  Vertex s CF pipeline is quite strong with a broad portfolio of next generation CF correctors  Investor focus will now be on the triple combination CF regimens  which are crucial for long term growth at Vertex  Data from three triple combination regimes in CF patients are expected in the second half of this year  We remind investors that last month  Vertex announced positive data from two phase III studies evaluating Kalydeco in combination with VX 661  tezacaftor  in patients suffering from CF aged 12 years and above with two copies of the F508del mutation  Both studies   EVOLVE and EXPAND   met their primary endpoints and demonstrated statistically significant improvements in lung function in patients with CF Based on positive outcome from the studies  the company is planning to submit regulatory applications in the U S  and EU in the third quarter of 2017 Meanwhile  the company is also looking to buy CF candidates  which can be combined with its tezacaftor  VX 661  and Kalydeco to create triple combinations Just last month  Vertex announced a definitive deal to buy the worldwide development and commercialization rights of Concert Pharmaceuticals    NASDAQ CNCE   CF pipeline candidate  CTP 656 for an upfront payment of  160 million in cash Vertex plans to develop CTP 656 for potential use in future once daily regimens in combination with its other pipeline drugs to treat the underlying cause of CF Vertex Pharmaceuticals Incorporated Price  Consensus and EPS Surprise    Undoubtedly  the CF market has been attracting the interest of several companies like AbbVie  Pfizer  Inc    NYSE PFE   and Sanofi   NYSE SNY    These companies are pursuing the development of CFTR potentiators  CFTR correctors and candidates with other mechanisms of action that can address the underlying cause of CF Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-04-27,Zacks Investment Research,"https://www.investing.com/analysis/vertex-(vrtx)-q1-earnings-top,-cf-products-sales-strong-200186010",200186010
120982,342497,VRTX,Drug Stocks Q1 Earnings Slated For May 2  MRK  PFE   GILD,opinion,The Q1 earnings season is in full swing with financial results from 288 S P 500 members or 63 8  of the index already out as of Apr 28  2017  according to the latest report Total earnings for these index members jumped 13 7  from the year ago quarter driven by 8 2  improvement in revenues  The beat ratio was 76 4  for earnings and 68 1  for revenues Johnson   Johnson   NYSE JNJ   began the earnings season for the pharma sector with a lower than expected performance in the first quarter  This left the investment community worrying about the performance of the other pharma companies in the quarter  However  quite a few large pharma companies released their earnings last week and the picture is not as bad as anticipated Among the pharma bigwigs that reported last week  Bristol Myers Squibb Company   NYSE BMY    Vertex Pharmaceuticals Incorporated  NASDAQ VRTX   AbbVie   NYSE ABBV   and Biogen  Inc    NASDAQ BIIB   reported better than expected Q1 results  However  it was a mixed quarter for Amgen  Inc    NASDAQ AMGN    Celgene Corporation   NASDAQ CELG   and Eli Lilly and Company   NYSE LLY   as all three beat earnings expectations but missed sales estimates Three pharma biotech giants are scheduled to release their earnings result on May 2  Let s see how things are shaping up for these three pharma biotech companies that are set to report Q1 results on May 2 Merck   Co   Inc    NYSE MRK  Merck   Company  Inc  Price and EPS Surprise    Merck is scheduled to release Q1 earnings before market opens  The company posted a positive surprise of 1 14  in the last quarter  Moreover  the company s performance has been encouraging in the recent past with its earnings surpassing expectations in all of the trailing four quarters with an average positive surprise of 4 03  However  our proven model does not conclusively show thatMerck is likely to beat on earnings this quarter  Though the company s favorable Zacks Rank  3  Hold  increases the predictive power of the ESP  its  of 0 00  makes surprise prediction difficult  You can uncover the best stocks to buy or sell before they re reported with our   TheWe expect investors to remain focused on the company s performance as well as the sales ramp up of newly launched Zinplava alongside pipeline updates at the Q1 earnings call   Read More    Pfizer Inc    NYSE PFE  Pfizer  Inc  Price and EPS Surprise    Pfizer  which is scheduled to release earnings before the market opens  posted a negative surprise of 6  in the last quarter  The company s performance has been mixed with earnings beating expectations in two of the last four quarters and missing the same in the other two  It had an average positive surprise of 4 36  Our proven show thatPfizer is likely to beat on earnings this quarter  This is because Pfizer has a favorable Zacks Rank  3  Hold  and an Earnings ESPof  1 49   The Zacks Consensus Estimate for Q1 is pegged at 67 cents per share Our previous article did not show that Pfizer was likely to beat on earnings this quarter  However  estimates changed thereafter and we are now reasonably certain of an earnings beat this season  We expect investors to remain focused on the performance company s new products like Xalkori  lung cancer   Xeljanz  rheumatoid arthritis  and Ibrance  breast cancer  as well as older product like Lyrica  neuropathic pain   which are expected to contribute to the top line meaningfully in Q1   Read More  Pfizer   Gilead Sciences Inc    NASDAQ GILD  Gilead Sciences  Inc  Price and EPS Surprise    Gilead is scheduled to announce results after the closing bell  The company searnings history is mixed  Its earnings surpassed expectations in two of the last four quarters and missing the same in the other two  It hadan average positive surprise to 2 88  Last quarter  Gilead posted a positive surprise of 14 29   The Zacks Consensus Estimate for Q1 is pegged at  2 17 The company has an Earnings ESP of  2 77  and a Zacks Rank  3  Hold   which makes us reasonably confident of an earnings beat  You can see  We expect investors to remain focused on the company s newly launched TAF based products   Genvoya  Odefsey and Descovy   which are performing well in both the U S  and EU   Read More    Sell These Stocks  Now Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These are sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 ,2017-04-30,Zacks Investment Research,"https://www.investing.com/analysis/drug-stocks-q1-earnings-slated-for-may-2:-mrk,-pfe---gild-200186297",200186297
121024,342539,VRTX,Nivalis Therapeutics Stock Shares Fall On Announcement,opinion,"Nivalis Therapeutics Inc  NASDAQ NVLS 
Nivalis Therapeutics  Inc   NVLS   a clinical stage pharmaceutical company yesterday announced their results for their phase 2 cystic fibrosis drug has failed  The study showed that the drug failed to reach its primary endpoints in the clinical trial 
Nivalis Therapeutics  Inc  CEO s Comments
 While we are disappointed in the outcome of this trial  we plan to continue to investigate the therapeutic potential of cavosonstat and our S nitrosoglutathione reductase  GSNOR  inhibitor portfolio to determine next steps   said Jon Congleton  president and chief executive officer of Nivalis  
NVLS Technical Analysis

NVLS opened trading yesterday at  6 32 which was up from the previous day s trading close of  6 28  NVLS closed trading yesterday at  6 25 and crashed down after market to  2 95  equivalent to a 53  decrease from the closing price  Taking a look at the daily chart we can see that we are in unchartered territory as NVLS is now trading at all time lows Taking a closer look at the daily chart we can see that before the spike down NVLS had already been in an overall downward trend dating back to September 20th when it traded at  34 60  NVLS has a float of 6 93 million shares and traded below the normal daily trading volume on Monday  For trading purposes  I would like to see NVLS open trading on Tuesday below  4 and if it does I would be looking to take a short position at the bell  My stop loss would be  0 40 from my entry position fearing anything more than that and the stock would start to fill in the gap down  My friend Ross over at Warrior Trading is applying his  to these types of stocks 
Company Profile
Nivalis Therapeutics  Inc   incorporated on March 30  2007  is a clinical stage pharmaceutical company  The Company discovers  develops and commercializes product candidates for patients with cystic fibrosis  CF   The Company focuses on utilizing its S nitrosoglutathione reductase  GSNOR  inhibitor portfolio to develop therapeutics for other diseases  The Company operates through discovering and development of potential drugs segment  The Company s operations are focused on discovery and development of its portfolio of GSNOR inhibitors  including N91115  GSNOR inhibitor portfolio includes other compounds with differing chemical structures and properties suitable for oral  inhaled  injectable and topical administration  Its drug candidate portfolio consists of multiple compounds  which are designed for oral  intravenous  IV  or inhaled administration  The Company s product candidate  N91115  is a small molecule compound that addresses a defect in the cystic fibrosis transmembrane conductance regulator  CFTR  resulting from mutations in the CFTR gene  the underlying cause of CF  It has completed a Phase Ib clinical trial to evaluate the safety of N91115 in adult CF patients homozygous for F508del  The Company is conducting a Phase II clinical trial designed to demonstrate the safety of a triple therapy of N91115 along with lumacaftor ivacaftor in over 130 adult CF patients homozygous for F508del  The N91115 development program is focused on demonstrating the clinical benefit of a triple CFTR modulator therapy for CF patients homozygous for F508del  The Company competes with Vertex Pharmaceuticals  NASDAQ VRTX   Inc   PTC Therapeutics  Novartis AG  NYSE NVS   Pfizer  NYSE PFE   Galapagos  ProQR Therapeutics  Flatley Discovery Labs  Parion Sciences  Concert  Proteostasis  Calista  Shire  Gilead Sciences  NASDAQ GILD   AbbVie Inc  NYSE ABBV   AmpliPhi Biosciences and F  Hoffmann LaRoche ",2016-11-30,Warrior Trading,"https://www.investing.com/analysis/nivalis-therapeutics,-inc.-$nvls-stock-shares-fall-on-announcement-200167562",200167562
121025,342540,VRTX,Economic Calendar And Watch List  March 29  2017,opinion,"Economic Calendar and Watch List
Morning Notes
U S  Futures are little changed this morning along with European stocks which are also mostly flat  Continued strength in crude is lifting energy producing stocks after news out of Libya that their production would be dropping due to the country s largest pipeline going offline  Asian stocks closed mostly mixed 
Technicals

The SPY  NYSE SPY  held the 50 day SMA after reclaiming it on Monday  recouping more than half the move that occurred on Tuesday of last week  Support will lie at the 50 day SMA at  233 20  followed by low of yesterday s range at  233 14  then  231 61   230 62   229 56   229 39   228 31   228 10 and the 100 day SMA at  227 31  Resistance will lie at the 20 day EMA at  235 32  followed by the high of yesterday s range at  235 81  then  237 61   237 97   238 10   239 20   239 44   239 57  and record highs at  240 32 
Small Cap Watch List
 Please refer to the momentum scanners displayed live in the chat room for potential plays at the market open  
  Others On Watch  
Vertex Pharmaceuticals Inc  NASDAQ VRTX RH  NYSE RH 
Economic Calendar
9 20 Chicago Fed President Charles Evans
10 00 February pending home sales expected  2 5 
10 30 EIA Weekly Petroleum Status Report
11 30 Boston Fed President Eric Rosengren speaks
Notable Earnings Before Open NONE
Notable Earnings After Closelululemon athletica inc  NASDAQ LULU    EPS Est   1 01",2017-03-29,Warrior Trading,https://www.investing.com/analysis/economic-calendar---watch-list-3-29-2017-200180578,200180578
121026,342541,VRTX,Stocks Diverge As Financials Lag,opinion,"U S  stocks finished the regular trading session mixed as crude oil extended a rebound and as the U K  formally began the process to exit the European Union  Financial shares lagged with Treasury yields remaining under pressure despite some hawkish Fed commentary  In equity news  Vertex Pharmaceuticals announced positive results from two studies of its experimental treatment for cystic fibrosis  Gold and the U S  dollar ticked higher 
The Dow Jones Industrial Average  DJIA  declined 42 points  0 2   to 20 659  the S P 500 Index increased 3 points  0 1   to 2 361  and the NASDAQ Composite was 22 points  0 4   higher at 5 898  In moderate volume  728 million shares were traded on the NYSE and 1 7 billion shares changed hands on the NASDAQ  WTI crude oil gained  1 14 higher to  49 51 per barrel and wholesale Gasoline gained  0 03 to  1 67 per gallon  Elsewhere  the Bloomberg gold spot price ticked  0 63 higher to  1 252 45 per ounce  and the dollar index  a comparison of the U S  dollar to six major world currencies  advanced 0 2  to 99 93 
RH  NYSE RH  44   also known as Restoration Hardware  was solidly higher after issuing 1Q and full year 2017 revenue guidance that topped the Street s expectations  while its full year earnings per share  EPS  outlook also had a midpoint that exceeded estimates  The company noted that while it expects revenue growth to accelerate  operating margins to expand  and to generate significant free cash flow in fiscal 2017 

We are taking a cautiously optimistic approach to our outlook given the uncertain macro environment in addition to the many initiatives and investments we are undertaking 

The upbeat guidance accompanied its 4Q earnings report that it pre announced last month 
Vertex Pharmaceuticals Inc   NASDAQ VRTX  108  is charging higher after the company announced positive results from two final stage studies of its experimental treatment for cystic fibrosis  The company said it will apply for U S  regulatory approval in the third quarter 
Dave   Buster s Entertainment  NASDAQ PLAY   60  saw solid pressure after the company reported a 3 2  year over year  y y  gain in 4Q same store sales  missing the FactSet estimate of a 3 7  increase  The Company did top the Street s EPS expectations and matched revenue forecasts 
Mortgage applications dip
The MBA Mortgage Application Index declined 0 8  last week  following the previous week s 2 7  drop  The decrease came as a 2 9  fall in the Refinance Index more than offset a 1 2  gain for the Purchase Index  The average 30 year mortgage rate fell 13 basis points  bps  to 4 33  
Pending home sales jumped 5 5  month over month  m m  in February  versus the Bloomberg projection of a 2 5  gain  and following the unrevised 2 8  drop registered in January  Compared to last year  sales were 2 4  lower  Pending home sales reflect contract signings and are used as a gauge of the pipeline of existing home sales  which fell more than expected in February from the fastest pace since 2007 
Treasuries were higher  with the yield on the 2 year note declining 3 bps to 1 27  and the yields on the 10 year note and the 30 year bond decreasing 4 bps to 2 38  and 2 99   respectively 
Treasury yields continued to pullback  though the U S  dollar recovered slightly from its recent slide  The markets are grappling with calmed concerns about a faster than expected pace of Fed rate hikes this year and flared up political uncertainty in the wake of last week s failed U S  healthcare reform bill  which has contributed to the pullback in the stock markets 
Tomorrow  the U S  economic calendar will deliver the third and final read for 4Q GDP  with economists expecting the headline figure to be revised higher to a 2 0  quarter over quarter annualized rate of expansion from the 1 9  posted in the second report  but down from the 3Q final read of 3 5   Also  weekly initial jobless claims will be reported and are expected to have decreased by 14 000 to a level of 247 000 
Europe shows some resiliency  Asia mixed 
European equities finished mostly higher  with oil   gas issues leading the way as crude oil prices added to yesterday s recovery  bolstered by some bullish U S   oil inventory data  Most markets shrugged off the expected triggering of article 50 by the U K  to begin formal negotiations to leave the European Union  EU   known as Brexit  The British pound saw some pressure to help U K  stocks  but was well off the worst levels of the day 
The beginning of the Brexit clock  which could take multiple years to complete the exit process  comes as a key French Presidential election looms and the Scottish First Minister Sturgeon is proposing a new independence referendum that has been rejected by the British government  The euro lost ground on the U S  dollar and bond yields in the region finished lower 
Stocks in Asia finished mixed  with global political uncertainty continuing to hamstring conviction  though sentiment found some support after yesterday s rebound in U S  stocks that snapped a string of losses  The advance in the U S  came courtesy of an unexpected jump in Consumer Confidence and comments out of Washington that suggested last week s failed healthcare reform efforts will likely not derail President Donald Trump s plans for tax reform and infrastructure spending 
Japanese equities ticked higher  with the yen retreating after a recent rally but gains were likely limited by a softer than expected read on the nation s retail sales for last month 
Crude oil s rebound that led a recovery in the commodity sector helped lift Australian securities  Stocks trading in South Korea  India and Hong Kong rose  while mainland Chinese shares declined with the property sector seeing some pressure as some local governments rolled out more measures to cool the real estate sector  per Bloomberg  Markets in Asia also continued to grapple with the March Fed rate hike and outlook for future increases this year 
Tomorrow s international economic docket will be relatively light  offering new home sales from Australia  CPI from Germany and consumer confidence from the Eurozone ",2017-03-30,Marvin Clark,https://www.investing.com/analysis/stocks-diverge-as-financials-lag-200180684,200180684
121064,342579,VRTX,What Makes Vertex Pharmaceuticals  VRTX  A Strong Sell ,opinion,Similar to wise buying decisions  exiting certain underperformers at the right time helps maximize portfolio returns  Selling off losers can be difficult  but if both the share price and estimates are falling  it could be time to get rid of the security before more losses hit your portfolio One such stock that you may want to consider dropping is Vertex Pharmaceuticals Incorporated   NASDAQ VRTX    which has witnessed a significant price decline in the past four weeks  and it has seen negative earnings estimate revisions for the current quarter and the current year  A Zacks Rank  5  Strong Sell  further confirms weakness in VRTX A key reason for this move has been the negative trend in earnings estimate revisions  For the full year  we have seen 4 estimates moving down in the past 30 days  compared with no upward revisions  This trend has caused the consensus estimate to trend lower  going from 3 cents a share a month ago to its current level of a loss of 10 cents Also  for the current quarter  Vertex Pharmaceuticals has seen 4 downward estimate revisions versus no revisions in the opposite direction  dragging the consensus estimate down to a loss of 4 cents a share from 2 cents over the past 30 days   The stock also has seen some pretty dismal trading lately  as the share price has dropped 14 3  in the past month VERTEX PHARM Price and Consensus   So it may not be a good decision to keep this stock in your portfolio anymore  at least if you don t have a long time horizon to wait If you are still interested in the Medical Biomedical Genetics industry  you may instead consider a better ranked stock   BioMarin Pharmaceutical Inc    NASDAQ BMRN    The stock currently holds a Zacks Rank  1  Strong Buy  and may be a better selection at this time  You can see  Confidential from Zacks Beyond this Tale of the Tape  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-12,Zacks Investment Research,https://www.investing.com/analysis/what-makes-vertex-pharmaceuticals-(vrtx)-a-strong-sell-200158572,200158572
121065,342580,VRTX,Biotech Stock Roundup  ARIAD Down On Drug Pricing Tweet  Regeneron Study On Clinical Hold,opinion,"Once again  a single tweet on drug pricing resulted in weakness in the biotech sector with ARIAD   NASDAQ ARIA   losing ground on a tweet regarding the company s price hikes for cancer drug  Iclusig  Meanwhile  Regeneron   NASDAQ REGN   suffered a pipeline setback with the FDA putting a clinical hold on one of its studies Recap of the Week s Most Important StoriesARIAD Shares Fall on Sanders Tweet  Shares of ARIAD declined 14 8  after Senator Bernie Sanders tweeted on the company s price hike of leukemia drug Iclusig  The tweet  Drug corporations  greed is unbelievable  Ariad has raised the price of a leukemia drug to almost  199 000 a year  was in response to an article according to which ARIAD had raised the price of Iclusig the fourth time this year with the treatment now costing  16 561 per month  or almost  199 000 per year  excluding discounts or rebates  Drug pricing issues are not something new but with the Presidential election round the corner  concerns regarding the implementation of new drug pricing policies are picking up Regeneron Teva Study on Clinical Hold  Regeneron and partner Teva were hit by a clinical hold on their experimental pain treatment  fasinumab  The FDA placed a phase IIb study in patients with chronic low back pain on clinical hold and asked for the study protocol to be amended following the discovery of adjudicated arthropathy in a patient receiving high dose fasinumab   the patient had advanced osteoarthritis at study entry Fasinumab is an investigational nerve growth factor  NGF  antibody  Dosing in the study has been stopped and Teva and Regeneron are now planning a pivotal phase III study for chronic low back pain excluding patients with advanced osteoarthritis Meanwhile  the companies plan to study only lower doses in the phase III osteoarthritis pain program as the incidence of adjudicated arthropathies was found to be potentially dose dependent  with a higher rate in the higher dose groups  Shares of both Regeneron and Teva were down on the fasinumab update  Read more     Regeneron is a Zacks Rank  3  Hold  stock  You can see  Ocular Gains on Regeneron Collaboration  Ocular Therapeutix s   NASDAQ OCUL   shares jumped on the company s collaboration agreement with Regeneron for the development of a sustained release formulation of the latter s blockbuster eye drug  Eylea  aflibercept  for the treatment of wet age related macular degeneration  wet AMD  and other serious retinal diseases  In addition to receiving milestone payments  Ocular will be entitled to royalties on potential future sales  Read more    PTC Plunges on Translarna Update  PTC Therapeutics    NASDAQ PTCT   shares declined almost 40  with the FDA s Office of Drug Evaluation I  ODE I  denying the company s first appeal of the refuse to file letter for its Duchenne muscular dystrophy treatment  Translarna  earlier this year  The company said that it intends to appeal to the next supervisory level of the FDA and believes that multiple cycles of appeals to progressively higher levels of the FDA may be required The Medicines Co  Gains on PCSK9 Data  The Medicines Company s   NASDAQ MDCO   shares were up on positive top line results from a Day 90 interim analysis of an ongoing phase II study  ORION 1  being conducted on PCSK9si  an investigational PCSK9 inhibitor  The company said that the safety and efficacy data support a triannual  and potentially biannual  low volume subcutaneous dose regimen  for treating patients with hypercholesterolemia  Currently approved PCSK9 inhibitors include Sanofi  PA SASY  and Regeneron s Praluent and Amgen s Repatha  Repatha gained FDA approval for a new  monthly single dose administration option in July this year 
Performance
Medical   Biomedical and Genetics Industry Price IndexThe NASDAQ Biotechnology Index declined 2 8  over the last five trading days  Almost all major biotech stocks recorded a decline with Regeneron losing 3 8  while Vertex   NASDAQ VRTX   was up 1 6   Over the last six months  Biogen   NASDAQ BIIB   was up 8 1  while Gilead lost 26   See the last biotech stock roundup here    
What s Next in the Biotech World Watch out for earnings reports from companies like Biogen and Vertex in the coming days Looking for Ideas with Even Greater Upside Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ",2016-10-18,Zacks Investment Research,"https://www.investing.com/analysis/biotech-stock-roundup:-ariad-down-on-drug-pricing-tweet,-regeneron-study-on-clinical-hold-200159536",200159536
121066,342581,VRTX,5 Toxic Stocks To Cast Aside Or Play Short,opinion,The proper identification of rightly priced stocks and overpriced stocks makes investing an easy task  However  in a complicated marketplace  the correctly priced stocks and their steeply priced counterparts are intertwined in such a way that making a distinction is tough  Nevertheless  figuring out the bloated toxic stocks on a regular basis and getting rid of them at the right time is one of the secrets to a winning investment strategy Generally  toxic companies are characterized by huge debt burdens and are susceptible to external shocks  Unjustifiably high price of the toxic stocks is short lived as their current price is higher than their intrinsic value and these are bound to result into loss for investors over time Overpricing of the toxic stocks can be attributed to either an irrational exuberance associated with them or some serious fundamental lacunae  If you own such overblown stocks for a long period of time  you are bound to see considerable erosion of wealth However  if you can accurately identify such toxic stocks  you may gain by resorting to an investing strategy called short selling  This strategy allows you to sell a stock first and then buy it when the price falls While short selling excels in bear markets  it typically loses money in bull markets So  just like spotting stocks with growth potential  figuring out toxic stocks and abandoning them at the right time is the key to shield your portfolio from big losses or make profits by short selling them Screening CriteriaHere is a winning strategy that will help you identify the overhyped toxic stocks Most recent Debt Equity Ratio greater than the median industry average  High debt equity ratio implies high leverage  High leverage indicates a huge level of repayment that the company has to make in connection with the debt amount P E using 12 month forward EPS estimate greater than 50  A very high forward P E implies that a stock is highly overvalued   Change in F  1  and F  2  Estimate  12 Weeks  less than  2  Negative EPS estimate revision for this and the next fiscal year during the past 12 weeks points to analysts  pessimism Zacks Rank more than or equal to  3  Hold   We have not considered Buy rated stocks that generally outperform the market Here are five of the 10 toxic stocks that showed up on the screen Houston  TX based Cabot Oil   Gas Corporation   NYSE COG   is an oil and gas company engaged in the exploration  development  acquisition and exploitation of oil and gas properties in the U S  Over the past one month period  its quarterly estimate has declined 40  to 3 cents  The stock currently has a Zacks Rank  3 Boulder  CO based Zayo Group Holdings  Inc    NYSE ZAYO   is a provider of bandwidth infrastructure solutions to the communications industry in the U S   Canada  and Europe  Over the last 30 days  quarterly estimates remained stable at 5 cents a share  The company has a Zacks Rank  3  You can see  Etsy  Inc    NASDAQ ETSY   is a Brooklyn  NY based Internet services company  which operates a marketplace to make  sell  and buy goods online and offline worldwide  Over the last 30 days  quarterly estimates remained stable at 1 cent a share  The company has a Zacks Rank  3 Live Nation Entertainment  Inc    NYSE LYV   is a Beverly Hills  CA based live entertainment company  Over the past one month period  the quarterly estimate has declined 2  to 48 cents  The stock currently has a Zacks Rank  3 Boston  MA based  Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   is a bio technology company  Over the past one month period  the current quarter estimate has moved down from 9 cents a share to a no loss  no gain situation  The stock currently has a Zacks Rank  4  Sell  Get the rest of the stocks on the list and start putting this and other ideas to the test  It can all be done with the Research Wizard stock picking and backtesting software The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at   Zacks Restaurant Recommendations  In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector ,2016-11-03,Zacks Investment Research,https://www.investing.com/analysis/5-toxic-stocks-to-cast-aside-or-play-short-200162935,200162935
121067,342582,VRTX,The Zacks Analyst Blog Highlights  Cabot Oil   Gas  Zayo Group Holdings  Etsy  Live Nation Entertainment And Vertex Pharmaceuticals,opinion,"For Immediate Release

	Chicago  IL   November 07  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Cabot Oil   Gas Corporation  NYSE COG   NYSE     Zayo Group Holdings  Inc   NYSE     Etsy  Inc   NASDAQ     Live Nation Entertainment  Inc   NYSE     and Vertex Pharmaceuticals  NASDAQ VRTX  Incorporated  NASDAQ      

	Today  Zacks is promoting its   Buy   stock recommendations    

Here are highlights from Friday s Analyst Blog  

5 Toxic Stocks to Cast Aside or Play Short

	The proper identification of rightly priced stocks and overpriced stocks makes investing an easy task  However  in a complicated marketplace  the correctly priced stocks and their steeply priced counterparts are intertwined in such a way that making a distinction is tough  Nevertheless  figuring out the bloated toxic stocks on a regular basis and getting rid of them at the right time is one of the secrets to a winning investment strategy 


	Generally  toxic companies are characterized by huge debt burdens and are susceptible to external shocks  Unjustifiably high price of the toxic stocks is short lived as their current price is higher than their intrinsic value and these are bound to result into loss for investors over time 
	Overpricing of the toxic stocks can be attributed to either an irrational exuberance associated with them or some serious fundamental lacunae  If you own such overblown stocks for a long period of time  you are bound to see considerable erosion of wealth 
	However  if you can accurately identify such toxic stocks  you may gain by resorting to an investing strategy called short selling  This strategy allows you to sell a stock first and then buy it when the price falls 
	While short selling excels in bear markets  it typically loses money in bull markets 
	So  just like spotting stocks with growth potential  figuring out toxic stocks and abandoning them at the right time is the key to shield your portfolio from big losses or make profits by short selling them Screening Criteria
	Here is a winning strategy that will help you identify the overhyped toxic stocks Most recent Debt Equity Ratio greater than the median industry average  High debt equity ratio implies high leverage  High leverage indicates a huge level of repayment that the company has to make in connection with the debt amount P E using 12 month forward EPS estimate greater than 50  A very high forward P E implies that a stock is highly overvalued 

  Change in F  1  and F  2  Estimate  12 Weeks  less than  2  Negative EPS estimate revision for this and the next fiscal year during the past 12 weeks points to analysts  pessimism Zacks Rank more than or equal to  3  Hold   We have not considered Buy rated stocks that generally outperform the market 
	Here are five of the 10 toxic stocks that showed up on the screen 
	Houston  TX based Cabot Oil   Gas Corporation  NYSE      is an oil and gas company engaged in the exploration  development  acquisition and exploitation of oil and gas properties in the U S  Over the past one month period  its quarterly estimate has declined 40  to 3 cents  The stock currently has a Zacks Rank  3 
	Boulder  CO based Zayo Group Holdings  Inc   NYSE      is a provider of bandwidth infrastructure solutions to the communications industry in the U S   Canada  and Europe  Over the last 30 days  quarterly estimates remained stable at 5 cents a share  The company has a Zacks Rank  3  You can see   Etsy  Inc   NASDAQ      is a Brooklyn  NY based Internet services company  which operates a marketplace to make  sell  and buy goods online and offline worldwide  Over the last 30 days  quarterly estimates remained stable at 1 cent a share  The company has a Zacks Rank  3 Live Nation Entertainment  Inc     NYSE      is a Beverly Hills  CA based live entertainment company  Over the past one month period  the quarterly estimate has declined 2  to 48 cents  The stock currently has a Zacks Rank  3 
	Boston  MA based Vertex Pharmaceuticals Incorporated  NASDAQ      is a bio technology company  Over the past one month period  the current quarter estimate has moved down from 9 cents a share to a no loss  no gain situation  The stock currently has a Zacks Rank  4  Sell  
	Get the rest of the stocks on the list and start putting this and other ideas to the test  It can all be done with the Research Wizard stock picking and backtesting software 
	The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out   
	Disclosure   Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  
	Disclosure  Performance information for Zacks  portfolios and strategies are available at   

	Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

	Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

	Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  











	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact
	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  

	This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-11-06,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-cabot-oil---gas,-zayo-group-holdings,-etsy,-live-nation-entertainment-and-vertex-pharmaceuticals-200163136",200163136
121068,342583,VRTX,Nivalis  NVLS  Cystic Fibrosis Study Misses Primary Endpoint,opinion,Nivalis Therapeutics  Inc  s   NASDAQ NVLS   shares plunged almost 53  in after hours trading on Nov 28 after the company announced disappointing top line data from a phase II study on its lead candidate  cavosonstat  for the treatment of cystic fibrosis  CF  The double blinded  randomized  placebo controlled  parallel group study was conducted to evaluate the efficacy and safety of two doses of cavosonstat  200 mg and 400 mg  administered twice daily  in adults with CF who had two copies of the F508del CFTR mutation and were being treated with Vertex Pharmaceuticals Inc  s   NASDAQ VRTX   Orkambi Data showed that the study failed to meet the primary endpoint of demonstrating a benefit in the absolute change in percent predicted FEV1  lung function  or in sweat chloride reduction at 12 weeks  in comparison to placebo  However  there was no dose limiting toxicity and cavosonstat was found to be well tolerated across all the doses in the study NIVALIS THERAPT Price    Nivalis intends to continue evaluating the potential of cavosonstat with these data and its S nitrosoglutathione reductase inhibitor portfolio  which it will develop for the treatment of other diseases  to decide on the next step forward  The company plans to remain focused on the completion of the CF research program We note that earlier this month  Nivalis announced the completion of enrollment in a second phase II study on cavosonstat  The study will evaluate the efficacy and safety of cavosonstat  400 mg twice daily  as add on therapy to Vertex s Kalydeco in adults who have one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein  Top line data is anticipated in the first quarter of 2017 Cavosonstat was granted Orphan Drug and Fast Track status for the treatment of CF by the FDA earlier this year However  considering that cavosonstat is the lead candidate in the company s pipeline  the latest phase II study results are far from encouraging Zacks Rank   Key PicksNivalis currently carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the health care sector are Sucampo Pharmaceuticals  Inc    NASDAQ SCMP   and Vanda Pharmaceuticals  Inc    NASDAQ VNDA    Both the stocks sport a Zacks Rank  1  Strong Buy   You can see  Sucampo s earnings estimates increased from  1 03 to  1 22 for 2016 and from  1 30 to  1 58 for 2017 over the last 60 days  The company posted a positive surprise in all of the four trailing quarters with an average beat of 35 55  Vanda s loss estimates narrowed from 68 cents to 56 cents for 2016  while its earnings estimates increased from 16 cents to 17 cents for 2017 over the last 60 days  The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 56 65   Its share price has surged approximately 84  year to date The Best Place to Start Your Stock SearchToday  you are invited to download the full list of 220 Zacks Rank  1  Strong Buy  stocks   absolutely free of charge  Since 1988  Zacks Rank  1 stocks have nearly tripled the market  with average gains of  26  per year  Plus  you can access the list of portfolio killing Zacks Rank  5  Strong Sells  and other private research ,2016-11-28,Zacks Investment Research,https://www.investing.com/analysis/nivalis-(nvls)-cystic-fibrosis-study-misses-primary-endpoint-200167154,200167154
121105,342620,VRTX,Biotech Stock Roundup  Vertex Slips On Study Halt  Aurinia Plunges On Lupus Data ,opinion,"With second quarter earnings season drawing to a close  focus is back on pipeline and regulatory updates  Companies like Vertex   NASDAQ VRTX    OncoGenex   NASDAQ OGXI   and Aurinia   NASDAQ AUPH   were in focus this week with the companies losing ground on pipeline updates Recap of the Week s Most Important Stories1  Vertex s shares slipped on news that the company will be stopping a late stage study evaluating a VX 661   ivacaftor  trade name  Kalydeco  combination for cystic fibrosis  While the news came as a disappointment  it was not very surprising as expectations were low from this study  Read more    2  Aurinia s shares plunged 55 7  on data from a 24 week analysis of a mid stage study on the company s experimental lupus treatment  voclosporin  Although voclosporin met the primary endpoint  a high number of deaths in the study left investors jittery  The next step is for the company to meet the FDA in the fourth quarter to discuss the next stage of clinical development  Read more    3  OncoGenex s shares plunged 41  on news that the company s experimental cancer treatment  custirsen  failed to meet the primary endpoint in a late stage study in men with metastatic castrate resistant prostate cancer  OncoGenex is now looking to enter discussions with the FDA to evaluate options related to an early analysis of the phase III ENSPIRIT study investigating custirsen in combination with docetaxel as second line chemotherapy in patients with non small cell lung cancer  NSCLC  4  Cancer focused AVEO   NASDAQ AVEO   has started an early stage study that will evaluate its lead pipeline candidate  tivozanib  an oral  once daily  vascular endothelial growth factor  VEGF  tyrosine kinase inhibitor  TKI   in combination with Bristol Myers  anti PD 1 therapy  Opdivo  in advanced renal cell carcinoma  RCC   The goal is to combine VEGF inhibitors with immune checkpoint inhibitors to improve outcomes with tolerable safety profiles We note that AVEO s efforts to develop tivozanib have not exactly been successful with the company receiving a complete response letter  CRL  from the FDA in Jun 2013 for the first line treatment of advanced RCC  The company is currently conducting a new phase III study on tivozanib for the third line treatment of patients with refractory RCC to address the concerns raised by the agency in its CRL  Meanwhile  tivozanib is currently under regulatory review in the EU for front line RCC 5  Results from a study on the cost effectiveness of PCSK9 inhibitors and their potential effect on U S  health care spending were published in The Journal of the American Medical Association  JAMA   PCSK9 inhibitors include Amgen s   NASDAQ AMGN   Repatha and Sanofi Regeneron s Praluent According to the study findings  the use of PCSK9 inhibitors as indicated could substantially reduce myocardial infarctions  MIs   strokes  and cardiovascular deaths  However  even if they prove highly effective in preventing atherosclerotic cardiovascular disease  ASCVD   they are not cost effective at 2015 prices  In fact  in order to achieve commonly accepted cost effectiveness thresholds  price would have to be reduced by more than two thirds PerformanceMEDICAL BIOMED GENETICS Industry Price Index The NASDAQ Biotechnology Index declined 1 3  over the last five trading days  Among major biotech stocks  Amgen was up slightly while Vertex declined 2 8  reflecting the impact of the discontinuation of the phase III study on VX 661 and ivacaftor 
Over the last six months  Biogen   NASDAQ BIIB   was up 22 2  while Gilead   NASDAQ GILD   lost 13 1   See the last biotech stock roundup here    
What s Next in the Biotech World Watch out for the usual pipeline and regulatory updates from biotech companies Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-08-17,Zacks Investment Research,"https://www.investing.com/analysis/biotech-stock-roundup:-vertex-slips-on-study-halt,-aurinia-plunges-on-lupus-data-200148550",200148550
121106,342621,VRTX,Stock Market News For August 25  2016,opinion,"Benchmarks ended in the red on Wednesday following decline in Mylan s shares  which had a negative impact on the biotech stocks and eventually on the broader healthcare sector  Strong political pressure on Mylan  NASDAQ MYL  for over pricing its life saving drug  EpiPens  led the shares of the company to fall  Moreover  bigger than expected rise in crude inventories also weighed on investor sentiment  Both the Dow and S P 500 reached their lowest settlements since early Aug and the Nasdaq witnessed its biggest one day percentage fall in last three weeks and settled at its lowest level since Aug 8 

	For a look at the issues currently facing the markets  make sure to read today s  article 

	The Dow Jones Industrial Average  DJI  decreased 0 4   to close at 18 481 48  The S P 500 fell 0 5  to close at 2 175 44  The tech laden Nasdaq Composite Index closed at 5 217 70 losing 0 8   The fear gauge CBOE Volatility Index  VIX  increased 8 6  to settle at 13 45  A total of around 6 09 billion shares were traded on Wednesday  lower than the last 20 session average of 6 26 billion  Decliners significantly outpaced advancing stocks on the NYSE  For 68  stocks that declined  29  advanced 

What Dragged the Benchmarks 

	Shares of Mylan N V     slumped 5 5  after U S  senators raised questions over inflated prices of its epinephrine auto injector  EpiPen  which is approved for the treatment of severe allergic reactions  read more    

	Declines in Mylan led the iShares Nasdaq Biotechnology  IBB  to decrease 3 4   Key holdings from the sector including  Gilead Sciences Inc  NASDAQ GILD        Illumina Inc  NASDAQ ILMN       Vertex Pharmaceuticals  NASDAQ VRTX  Incorporated    and Endo International plc     decreased 1 2   1 9   4 2  and 6 6   respectively  The Health Care Select Sector SPDR ETF  NYSE XLV  fell by 1 6   posting its worst percentage fall since June 24  and was the biggest loser among the S P 500 companies 

	Additionally  the U S  Energy Information Administration  EIA  reported that the U S  commercial crude oil inventories rose 2 5 million barrels to 523 6 million for the week ended August 19  higher than analysts  projections of an increase of 200 000 barrels 

	WTI crude fell 2 8  to  46 77 per barrel  Brent crude also declined 1 9  to  49 05 a barrel  Decrease in oil prices led the Energy Select Sector SPDR  XLE  NYSE XLE   to fall 0 4   Further  the Materials Select Sector SPDR  XLB  decreased 1 2  and was second worst performer among S P 500 sectors 

	Also  investors remained cautious ahead of Fed Chairwoman Janet Yellen s speech at Jackson Hole  Wyoming tomorrow 

	Moreover  sales of existing homes declined 3 2  in July from June to a seasonally adjusted rate of 5 39 million  according to the National Association of Realtors  This was lower than the consensus estimate of 5 57 million and June s figure of 5 52 million 

Stocks that Made Headlines



	Chinese offshore giant  China National Offshore Oil Corp  or CNOOC     reported net loss for the first half of 2016  The downside primarily stemmed from a substantial decline in realized oil prices     



	HP Inc     reported better than expected results for the third quarter of fiscal 2016  wherein both its top line and bottom line surpassed the respective Zacks Consensus Estimate     



	PVH Corporation    delivered another strong quarter with second quarter fiscal 2016 earnings per share surpassing estimates for the ninth consecutive quarter     



	Offshore contract driller  SeaDrill Limited     reported strong second quarter 2016 earnings owing to a decrease in operating expenses  However  it registered poor quarterly revenues due to underperformances by Jack up Rigs and Floaters     



	Fitbit Inc     has received a favorable ruling in the latest round of the Jawbone trade secret case    ",2016-08-24,Zacks Investment Research,"https://www.investing.com/analysis/stock-market-news-for-august-25,-2016-200150009",200150009
121107,342622,VRTX,Biotech ETF Industry Outlook,opinion,"The biotech sector has had a rough start to the year with the NASDAQ Biotechnology Index declining approximately 16  year to date  Sector specific issues like increasing political and media focus on high price tags for new drugs and the changing competitive scenario have been weighing on biotech stocks over the last few quarters 
 
However  the sector s fundamentals remain strong and mergers and acquisitions  M As   product approvals and positive data flow should act as catalysts   Read   
 
Drug Pricing to Remain in Focus 
 
With Presidential candidates  policymakers  the media and the general public focusing on the high price tags for drugs  drug companies may find it a bit difficult to justify their high prices by citing the years and funds that go into bringing new treatments to market and the need to invest in R D to bring additional treatments to market 
 
According to the Oct 2015 Kaiser Health Tracking poll  affordability of prescription drugs remains at the top of the public s priority list for the President and Congress   focus should be on ensuring the affordability of high cost drugs to people who need them and taking steps to lower prescription drug prices 
 
In this scenario  the drug pricing issue is not likely to die down easily    at least not until elections are over  Proposed health care plans include suggestions on how to rein in the prices of new drugs  Read   
 
Biosimilars Gaining Importance 
 
With the FDA approval of the first biosimilar in the U S   Sandoz s Zarxio   a biosimilar of Amgen s Neupogen  last year  this area is fast gaining importance with a lot of companies working on bringing biosimilars of blockbuster biologic treatments to market 
 
Pfizer  NYSE PFE  and Celltrion s biosimilar version of Johnson   Johnson s blockbuster drug Remicade gained FDA approval earlier this year while the agency is expected to decide on the approval status of Amgen s biosimilar version of AbbVie s Humira in Sep 2016 
 
Deals to Continue
 
Licensing agreements and deals including those with opt in arrangements should continue being signed with immuno oncology remaining a favorite area  Moreover  with valuations approaching reasonable levels  we could see several merger and acquisition agreements being announced as the year progresses  Quite a few of the major biotech companies are rumored to be on the look out for suitable deals  Meanwhile  small bolt on acquisitions will continue 
 
New Products Should Gain Traction in 2H16
 
Highly awaited new products that gained approval last year should contribute significantly to revenues  Some of the important new product approvals include cystic fibrosis treatment  Orkambi  heart failure treatment  Corlanor  PCSK9 inhibitors   Repatha and Praluent  and Genvoya  HIV  
 
Meanwhile  so far in 2016  the FDA has approved 16 new drugs including Epclusa  HCV  Ocaliva  rare  chronic liver disease   Zinbryta  multiple sclerosis   and Venclexta  chronic lymphocytic leukemia in patients with a specific chromosomal abnormality  among others  The FDA also expanded the label of cancer drugs like Kyprolis and Imbruvica 
 
ETFs in Focus
 
Highlighted below are some biotech ETFs   ETFs present a low cost and convenient way to get a diversified exposure to the sector 
 
iShares Nasdaq Biotechnology     
 
IBB  launched in Feb 2001 by BlackRock Investments LLC  tracks the Nasdaq Biotechnology Index  The fund mainly covers biotech stocks  79 6   with pharma accounting for 12 6   life sciences tools   services for 7 7  and Health care supplies for 0 12   The top 3 holdings include Amgen Inc  NASDAQ AMGN    8 37    Biogen  NASDAQ BIIB  Inc   8 22   and Celgene Corporation  NASDAQ CELG   8 09    The total assets of the fund as of Aug 18  2016 were  7 73 billion representing 187 holdings  The fund s expense ratio is 0 47  while dividend yield is 0 12   The trading volume is roughly 625 662 shares per day 
 
SPDR S P Biotech ETF   
 
XBI  launched in Jan 2006 by State Street Global Advisors  tracks the S P Biotechnology Select Industry Index  The fund primarily covers biotech stocks  99 9    The top 3 holdings include Ionis Pharmaceuticals  Inc   3 48    Biogen Inc   2 81    and Sarepta Therapeutics  Inc   2 77    The total assets of the fund as of Aug 17  2016 were  2 2 billion representing 89 holdings  The fund s expense ratio is 0 35  while dividend yield is 0 48   The trading volume is roughly 3 469 172 shares per day 
 
First Trust NYSE Arca Biotech ETF   
 
FBT  launched in Jun 2006 by First Trust Advisors  tracks the NYSE Arca Biotechnology Index  The top 3 holdings include Ionis Pharmaceuticals  Inc   3 99    Qiagen NV  3 97    and Biogen Inc   3 80    The total assets of the fund as of Aug 17  2016 were  867 million representing 30 holdings  The fund s expense ratio is 0 55  while dividend yield is 0 02   The trading volume is roughly 61 979 shares per day 
 
VanEck Vectors Biotech ETF   
 
BBH  launched in Dec 2011 by Van Eck  tracks the Market Vectors US Listed Biotech 25 Index  The fund covers health care stocks  The fund s expense ratio is 0 35  while dividend yield is 0 29   The trading volume is roughly 30 490 shares per day 
 
PowerShares Dynamic Biotech   Genome ETF   
 
PBE  launched in Jun 2005 by Invesco PowerShares  tracks the Dynamic Biotech   Genome Intellidex Index  The top 3 holdings include Amgen Inc   5 32    Biogen Inc   5 29    and Vertex Pharmaceuticals  NASDAQ VRTX  Incorporated  5 23    The total assets of the fund as of Aug 18  2016 were  266 4 million representing 31 holdings  The fund s expense ratio is 0 57  while dividend yield is 1 06   The trading volume is roughly 11 131 shares per day 
 
Conclusion 
 
 High risk and high returns  is a term often associated with the biotech sector  Biotech drugs  which are developed through a biological process system or by using living organisms  require a lot of investment  The drugs are complex in nature and take several years to develop  Companies which hit the bull s eye become overnight success stories with shares even doubling or tripling on positive news  However  negative outcomes have an equally strong effect on the shares and failure may very well spell doom for these companies 
 
Strong pipelines  innovative treatments  impressive results  growing demand for drugs especially for rare to treat diseases  an aging population and increased health care spending should support growth in this sector 
 
On the flip side  the high cost of treatments  pricing controversies and the threat of biosimilars remain dampeners for this high risk high return sector 
 
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2016-08-31,Zacks Investment Research,https://www.investing.com/analysis/biotech-etf-industry-outlook-200151169,200151169
121108,342623,VRTX,Drug Stocks Remain In Focus As Pricing Debate Continues,opinion,"The drug pricing controversy continues to make news with lawmakers now questioning Medicaid rebates for Mylan N V  s   NASDAQ MYL   EpiPen and Democratic Presidential candidate Hillary Clinton announcing a health care plan that will address the excessive price hikes of treatments that have been available for years But First a Look at the EpiPen Medicaid Issue Mylan is currently in the midst of a drug pricing controversy due to a huge hike in the price of EpiPen    according to lawmakers  as of May 2016  Mylan hiked the price of this life saving combination product by more than 480  in the U S    from  103 50 for a set of two in 2009 to  608 61  While Mylan took steps to lower the impact of this issue by increasing the maximum value of its savings cards to  300  from  100   expanding eligibility of its patient assistance program and announcing the upcoming launch of a generic EpiPen at a 50   discount to the branded product  the company remains in troubled waters with lawmakers now questioning Medicaid rebates for the product U S  Senator Amy Klobuchar said that the Centers for Medicare   Medicaid Services  CMS  found that Mylan had misclassified EpiPen as a  Non Innovator Multiple Source Drug   or a generic drug  This led to millions of dollars in overpayment for the drug by states and the federal government through the Medicaid Drug Rebate Program  Klobuchar said that the Minnesota Department of Human Services has estimated that this misclassification will cost the state more than  4 million dollars in overpayment this year alone  And this is just one state  one drug and one year  Klobuchar said that an immediate and thorough nationwide investigation into the overpayments by all states should be conducted  Mylan s shares are down 24  so far in 2016 
MYLAN NV Price   Clinton Unveils New PlanMeanwhile  Hillary Clinton  who had tweeted about the EpiPen pricing controversy  announced a new plan to curb drug prices  In her statement  she mentioned that during the 2008 2015 timeframe  prices of almost 400 generic drugs were hiked by more than 1 000   Most of these drug companies did not even manufacture the drugs themselves    they acquired the drugs and raised the prices    Clinton s plan includes the setting up of a group that will check whether a longstanding treatment has been priced exorbitantly   once this is established  steps will be taken like increasing competition and making alternate treatments available  emergency importation of treatments from developed countries with strong safety standards and holding drug makers accountable for unjustified price increases with new penalties Clinton reaffirmed her earlier broader plan as well which was announced last year in September with the aim to lower drug prices for all Americans Impact on Drug StocksOver the past one year  drug companies have been under immense pressure due to the pricing controversy  While the high price of drugs has always been a matter of concern  political and media focus on this issue has increased significantly since last September following Hillary Clinton s  price gouging  tweet Both pharma and biotech stocks with high priced drugs have seen their share prices falling reflecting investor concerns regarding their profitability if drug prices are cut  While the NASDAQ Biotechnology Index is down 20 3  over the past one year  the NYSE ARCA Pharmaceutical Index lost 6  during this period 
MEDICAL BIOMED GENETICS Industry Price IndexValeant Pharmaceuticals International  Inc    NYSE VRX   was one of the companies hit hard by the pricing controversy due to its strategy of acquiring companies and selling their drugs at higher prices with shares declining 87 7  over the last one year  Other companies that were affected by the increasing focus on drug prices last year include Gilead Sciences Inc    NASDAQ GILD   and Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   among others    Meanwhile  earlier this year  lawmakers asked the Department of Health and Human Services and the National Institutes of Health  NIH  to hold a public meeting related to the pricing of Medivation  Inc    NASDAQ MDVN   and Astellas Pharma  Inc  s   OTC ALPMY   prostate cancer drug  Xtandi With drug costs remaining a major concern and lawmakers focusing on the need to control drug prices and make prescription drugs affordable  drug companies may find it a bit difficult to justify their high prices by citing the years and funds that go into bringing new treatments to market and the need to invest in R D to bring additional treatments to market According to the Aug 2016 Kaiser Health Tracking poll  two thirds of voters believe the future of Medicare and access and affordability of health care are top priorities for the candidates to be discussing during the 2016 presidential campaign 
Irrespective of who wins the presidential race  drug pricing will remain a topic of discussion among policymakers  the media and the general public  We expect to see more volatility in this sector as the drug pricing debate continues Confidential  Zacks  Best Investment Ideas  Would you like to see a hand picked  all star  selection of investment ideas from the man who heads up Zacks  trading and investing services  Steve Reitmeister knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-05,Zacks Investment Research,https://www.investing.com/analysis/drug-stocks-remain-in-focus-as-pricing-debate-continues-200151817,200151817
121109,342624,VRTX,3 Drug Stocks That Could Benefit From Key FDA Events In Sep 2016 ,opinion,"The drug development process is often lengthy and time consuming and requires the utilization of a lot of funds and resources  It may well take a drug anything between 10 12 years to be successfully developed and reach the market  In such a scenario  key pipeline events including data readouts and regulatory updates are of paramount importance   companies which hit the bull s eye become overnight success stories with shares even doubling or tripling on positive news while negative outcomes have an equally strong effect on the shares and failure may very well spell doom for these companies Here is a look at three stocks that have important regulatory events scheduled for this month Spectrum Pharmaceuticals  Inc  s   NASDAQ SPPI   new drug application for Qapzola  apaziquone  will be reviewed by an FDA advisory panel later this week  The FDA s Oncologic Drugs Advisory Committee is meeting on Sep 14 to review the NDA   the proposed indication for the product is for the immediate intravesical instillation post transurethral resection of bladder tumors in patients with non muscle invasive bladder cancer Advisory panels provide the FDA with independent opinions and recommendations from outside experts on new drugs as well as FDA policies  While the agency is not required to do so  it usually follows the advisory committee s recommendation  Therefore  FDA advisory panel meetings are closely followed by investors as they give an insight into the FDA s final decision regarding the approval status of the candidate  A positive panel recommendation would be a major boost for Spectrum  a Zacks Rank  3  Hold  stock 
Price and Consensus   Next on the list is biotech major  Amgen Inc    NASDAQ AMGN    which has an important regulatory event coming up later this month with the FDA expected to decide on the approval status of the company s Biologics License Application  BLA  for ABP 501 ABP 501 is a biosimilar candidate to AbbVie Inc  s   NYSE ABBV   Humira  an anti tumor necrosis factor alpha  TNF    monoclonal antibody  which is approved in many regions for the treatment of several inflammatory diseases  With an FDA advisory panel voting in favor of ABP 501 earlier this year  expectations are high that the FDA will give its nod to ABP 501 on the target action date of Sep 25  2016 Why is this approval important for Amgen  Well  Amgen is pretty committed to the biosimilars effort and if approved  ABP 501 would be the first biosimilar from Amgen s pipeline to gain approval  The Zacks Rank  3 stock has quite a few biosimilars in development including biosimilar versions of cancer drugs  Avastin and Herceptin  Amgen has even tied up with Japanese company  Daiichi Sankyo  to commercialize nine biosimilars in Japan Last year  on an analyst call  Amgen had said that it expects to launch five new biosimilars between 2017 and 2019  The biosimilars opportunity represents annual revenues of more than  3 billion for Amgen  Humira brought in 2015 sales of  8 4 billion in the U S  alone where the composition of matter patent is expected to expire in Dec 2016 But even if it gains FDA approval  Amgen will have to take a decision regarding its launch plans for ABP 501 considering AbbVie has initiated a patent infringement lawsuit against the company 
Price and Consensus   Third on the list is Vertex Pharmaceuticals  Inc    NASDAQ VRTX    a company focused on cystic fibrosis  CF  treatments  which is currently looking to expand the label of its CF treatment  Orkambi  Orkambi  approved in Jul 2015  for the treatment of the underlying cause of CF in people  ages 12 and above  with two copies of the F508del mutation  is currently under FDA review for use in the 6 11 years age group  Approval for this age group would expand the patient population by about 2 400 in the U S  A response from the agency is expected on Sep 30 and approval would be a positive catalyst for this Zacks Rank  3 stock  You can see  
Price and Consensus   
Now See Our Private Investment IdeasWhile the above ideas are being shared with the public  other trades are hidden from everyone but selected members  Would you like to peek behind the curtain and view them  Starting today  for the next month  you can follow all Zacks  private buys and sells in real time from value to momentum        from stocks under  10 to ETF and option moves       from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2016-09-11,Zacks Investment Research,https://www.investing.com/analysis/3-drug-stocks-that-could-benefit-from-key-fda-events-in-sep-2016-200153056,200153056
121110,342625,VRTX,The Zacks Analyst Blog Highlights  Spectrum Pharmaceuticals  Amgen  AbbVie And Vertex Pharmaceuticals,opinion,"For Immediate Release 

Chicago  IL   September 13  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Spectrum Pharmaceuticals  Inc      Amgen Inc  NASDAQ AMGN       AbbVie Inc     and Vertex Pharmaceuticals  NASDAQ VRTX   Inc      

Today  Zacks is promoting its   Buy   stock recommendations   

Here are highlights from Monday s Analyst Blog  

3 Drug Stocks that Could Benefit from Key FDA Events This Month

The drug development process is often lengthy and time consuming and requires the utilization of a lot of funds and resources  It may well take a drug anything between 10 12 years to be successfully developed and reach the market  In such a scenario  key pipeline events including data readouts and regulatory updates are of paramount importance   companies which hit the bull s eye become overnight success stories with shares even doubling or tripling on positive news while negative outcomes have an equally strong effect on the shares and failure may very well spell doom for these companies 

Here is a look at three stocks that have important regulatory events scheduled for this month Spectrum Pharmaceuticals  Inc  s     new drug application for Qapzola  apaziquone  will be reviewed by an FDA advisory panel later this week  The FDA s Oncologic Drugs Advisory Committee is meeting on Sep 14 to review the NDA   the proposed indication for the product is for the immediate intravesical instillation post transurethral resection of bladder tumors in patients with non muscle invasive bladder cancer 
	Advisory panels provide the FDA with independent opinions and recommendations from outside experts on new drugs as well as FDA policies  While the agency is not required to do so  it usually follows the advisory committee s recommendation  Therefore  FDA advisory panel meetings are closely followed by investors as they give an insight into the FDA s final decision regarding the approval status of the candidate  A positive panel recommendation would be a major boost for Spectrum  a Zacks Rank  3  Hold  stock 

   

Next on the list is biotech major  Amgen Inc      which has an important regulatory event coming up later this month with the FDA expected to decide on the approval status of the company s Biologics License Application  BLA  for ABP 501 
	ABP 501 is a biosimilar candidate to AbbVie Inc  NYSE ABBV   s    Humira  an anti tumor necrosis factor alpha  TNF    monoclonal antibody  which is approved in many regions for the treatment of several inflammatory diseases  With an FDA advisory panel voting in favor of ABP 501 earlier this year  expectations are high that the FDA will give its nod to ABP 501 on the target action date of Sep 25  2016 
	Why is this approval important for Amgen  Well  Amgen is pretty committed to the biosimilars effort and if approved  ABP 501 would be the first biosimilar from Amgen s pipeline to gain approval  The Zacks Rank  3 stock has quite a few biosimilars in development including biosimilar versions of cancer drugs  Avastin and Herceptin  Amgen has even tied up with Japanese company  Daiichi Sankyo  to commercialize nine biosimilars in Japan 
	Last year  on an analyst call  Amgen had said that it expects to launch five new biosimilars between 2017 and 2019  The biosimilars opportunity represents annual revenues of more than  3 billion for Amgen  Humira brought in 2015 sales of  8 4 billion in the U S  alone where the composition of matter patent is expected to expire in Dec 2016 
	But even if it gains FDA approval  Amgen will have to take a decision regarding its launch plans for ABP 501 considering AbbVie has initiated a patent infringement lawsuit against the company 

   

Third on the list is Vertex Pharmaceuticals  Inc      a company focused on cystic fibrosis  CF  treatments  which is currently looking to expand the label of its CF treatment  Orkambi  Orkambi  approved in Jul 2015  for the treatment of the underlying cause of CF in people  ages 12 and above  with two copies of the F508del mutation  is currently under FDA review for use in the 6 11 years age group  Approval for this age group would expand the patient population by about 2 400 in the U S  A response from the agency is expected on Sep 30 and approval would be a positive catalyst for this Zacks Rank  3 stock  You can see   

Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research   

About Zacks 

Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

Follow us on Twitter  

Join us on Facebook  

Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

Media Contact
	Zacks Investment Research

800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-09-12,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-spectrum-pharmaceuticals,-amgen,-abbvie-and-vertex-pharmaceuticals-200153244",200153244
121111,342626,VRTX,Vertex Orkambi s Label Expanded In U S   Outlook Revised,opinion,"Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   announced that its cystic fibrosis  CF  drug  Orkambi  was approved in the U S  for the treatment of CF in patients aged 6 11 years who have two copies of the F508del mutation  The company said that the drug will be available to the eligible population shortly Vertex also plans to file a Marketing Authorization Application  MAA  variation in the EU for the same indication in the first half of 2017 Note that Orkambi is a combination of lumacaftor and Kalydeco  ivacaftor   a marketed CF drug in the company s portfolio  Orkambi was approved in the U S  and the EU in Jul 2015 and Nov 2015  respectively  for the treatment of CF in patients aged 12 years and older  who have two copies of the F508del mutation in their CF transmembrane conductance regulator  CFTR  gene  In the first six months of 2016  Orkambi raked in sales of  468 7 million VERTEX PHARM Price
    Meanwhile  Vertex has lowered its 2016 guidance for Orkambi sales to the range of  950  990 million from the previously expected  1 0  1 1 billion  The revision was primarily due to slower than anticipated launch of Orkambi in Germany and less than expected refills in the months of July and August  Sales of the drug are expected in the range of  230  235 million in the third quarter of 2016 CF  a rare  life threatening disease  is estimated to affect approximately 75 000 people in the U S   Europe and Australia  The company expects the latest label expansion of Orkambi to cover approximately 11 000 patients in the U S Although Vertex is the first company to successfully develop drugs for the treatment of the underlying cause of CF  several other players in the pharma and biotech space are involved in the development of drugs for this indication  Nivalis Therapeutics  Inc    NASDAQ NVLS   is currently evaluating its own CF candidate  N91115  in a phase II study  Top line results of the study are expected by the end of 2016 Earlier this year  Galapagos NV   NASDAQ GLPG   and AbbVie Inc    NYSE ABBV   expanded their collaboration agreement for CF and aimed to develop a triple CFTR combination therapy We expect investor focus to remain on further news related to the CF market Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-29,Zacks Investment Research,"https://www.investing.com/analysis/vertex-orkambi's-label-expanded-in-u.s.,-outlook-revised-200156476",200156476
121112,342627,VRTX,Biotech Stock Roundup  Summit Soars On Sarepta Deal  Regeneron Presents Data ,opinion,"It was an eventful week for the biotech sector with companies like Regeneron   NASDAQ REGN   and Intra Cellular Therapies   NASDAQ ITCI   presenting data while Summit   NASDAQ SMMT   shot up on a collaboration agreement with Sarepta   NASDAQ SRPT   Recap of the Week s Most Important StoriesSummit Shoots Up on Sarepta Collaboration  Summit s shares shot up 65 9  on the company s deal with Sarepta granting rights to its utrophin modulator pipeline in Europe  Turkey and the Commonwealth of Independent States for the treatment of Duchenne muscular dystrophy  DMD   The companies will collaborate for the development of novel treatments for DMD  In addition to receiving an upfront payment of  40 million  Summit is entitled to receive up to  522 million on the achievement of ezutromid related milestones plus escalating royalties  The companies will share R D costs  Ezutromid is the lead candidate in Summit s pipeline  Summit s utrophin modulation technology has the potential to lead to the development of disease modifying treatments for all DMD patients  regardless of their underlying dystrophin gene mutation Summit is a Zacks Rank  2  Buy  stock  You can see  Regeneron Continues to Present Promising Data on Blockbuster Hopeful Eczema Drug  Regeneron and partner Sanofi  PA SASY  continue to add to the data supporting their blockbuster hopeful eczema treatment  Dupixent  dupilumab   Detailed data from a couple of phase III studies showed that the primary as well as key secondary endpoints like itch reduction  one of the most burdensome symptoms for eczema patients  and improvement in patient reported anxiety and depression symptoms were met  These data should support the use of Dupixent as a new treatment option for patients struggling to manage their disease  Dupixent is currently under priority review in the U S  for the treatment of patients with moderate to severe atopic dermatitis with a response expected on Mar 29  2017  Dupixent is also being evaluated for other atopic or allergic diseases including asthma  eosinophilic esophagitis and nasal polyposis Meanwhile  Regeneron s blockbuster eye treatment  Eylea  came up short in a mid stage study evaluating Eylea in combination with rinucumab  an anti PDGFR beta antibody  for wet age related macular degeneration  The combination was compared to Eylea monotherapy  The results are a setback for the company s life cycle management plans for Eylea  Eylea has already clocked  1 6 billion in sales in the U S  where sales are expected to grow 20 25  in 2016  With the rinucumab combination study failing  focus will now shift to the Eylea nesvacumab  an anti angiopoietin 2 antibody  combination studies  Read more    Vertex Cuts Orkambi Outlook  Vertex   NASDAQ VRTX    which gained FDA approval for the use of its CF drug in children  ages 6 through 11  with two copies of the F508del mutation  cut its 2016 outlook for the treatment  Orkambi was earlier approved for use in people ages 12 and older with two copies of the F508del mutation  With the label expansion  about 11 000 CF patients in the U S  including approximately 2 400 children in the U S  are eligible for treatment with Orkambi However  despite the label expansion  Vertex lowered its 2016 outlook for Orkambi and said it now expects sales of  950 million    990 million instead of  1 0 billion    1 1 billion  Factors like a slower than expected launch in Germany  slower than anticipated refills in July and August and near peak penetration in the U S  led to the lowered outlook  Read more    Intra Cellular Schizophrenia Data Disappoints  Intra Cellular Therapies  shares plunged on top line data from a late stage study on its lead pipeline candidate  ITI 007  which failed to meet the primary endpoint in the study conducted for the treatment of schizophrenia  The company  however  plans to meet with the FDA s Division of Psychiatry Products to discuss the regulatory path for the candidate  Read more     Boxed Warning for Gilead  AbbVie HCV Drugs  The FDA has issued a warning about the risk of hepatitis B virus  HBV  becoming an active infection again in any patient who has or had HBV and is being treated with certain direct acting antiviral  DAA  medicines for hepatitis C virus  HCV   With some of the HBV reactivation cases leading to serious liver problems or death  the FDA is requiring the addition of a Boxed Warning to the labels of 9 DAA medicines including Gilead s   NASDAQ GILD   Epclusa  Harvoni and Sovaldi and AbbVie s Viekira Pak  Viekira Pak XR and Technivie Performance
Medical   Biomedical and Genetics Industry Price IndexThe NASDAQ Biotechnology Index declined 3 2  over the last five trading days  All major biotech stocks recorded a decline with Regeneron declining 5 8  and Vertex 3   Over the last six months  Biogen   NASDAQ BIIB   was up 17 9  while Gilead  GILD  lost 18   See the last biotech stock roundup here    
What s Next in the Biotech World Watch out for the usual pipeline and regulatory updates from biotech companies Looking for Ideas with Even Greater Upside Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ",2016-10-04,Zacks Investment Research,"https://www.investing.com/analysis/biotech-stock-roundup:-summit-soars-on-sarepta-deal,-regeneron-presents-data-200157248",200157248
121147,342662,VRTX,Stock Market News For June 08  2016,opinion,"Benchmarks closed mostly in the green on Tuesday following gains in energy stocks  Continued rally in oil prices boosted the energy sector  which in turn helped the S P 500 to reach its highest settlement since July 22  While rise in oil prices also pushed the Dow to finish in positive territory  the Nasdaq ended in the red following losses in biotech stocks For a look at the issues currently facing the markets  make sure to read today s  article

The Dow Jones Industrial Average  DJI  increased 0 1   to close at 17 938 28  The S P 500 also rose 0 1  to close at 2 112 13  However  the tech laden Nasdaq Composite Index closed at 4 961 75  losing 0 1   However  the fear gauge CBOE Volatility Index  VIX  increased 2 9  to settle at 14 05  A total of around 6 4 billion shares were traded on Tuesday  lower than the last 20 session average of 6 9 billion shares  Advancers outpaced declining stocks on the NYSE  For 61  stocks that advanced  36  declined 

Oil prices increased yesterday following continued global production disruptions and weaker dollar  Militant attacks on oil pipeline in Nigeria resulted in a decline in its crude output  Also  the Energy Information Administration said that the U S  crude output slumped by 250 000 barrels a day last month  positing its biggest one month fall in several years 

Further  the U S  dollar weakened following uncertainty over when the Fed might raise rate  The U S  dollar index was down 0 4  with the euro came nearly at  1 136 and the yen was about 107 3 yen against the U S  dollar  WTI crude increased 1 3  to  50 36 a barrel  crossing the  50 per barrel mark for the first time since July 21  Brent crude rose 1 7  to  51 44 per barrel  reaching its highest settlement since Oct 9 

Increase in oil prices led the Energy Select Sector SPDR  XLE  NYSE XLE   to increase 2 3  and become the biggest gainer among the S P 500 sectors  Key energy stocks including  EOG Resources  NYSE EOG   Inc      ConocoPhillips  NYSE COP      Pioneer Natural Resources Co      Halliburton Company  NYSE HAL     and Occidental Petroleum Corporation  NYSE OXY     advanced 5 1   4 4   2 9   2 7  and 1 9   respectively  Dow components Exxon Mobil Corporation  NYSE XOM     and Chevron Corporation  NYSE CVX     increased 1 5  and 2 1   respectively 

Meanwhile  the Fed Chairwoman Janet Yellen s comments on Monday continued to have a positive impact on key indexes even yesterday  Yellen said that most of the U S  economic data had been encouraging  She also said that although last month s employment growth was  disappointing   overall domestic labor market data was favorable  Yellen indicated that Fed will increase rate this year  but refrained from giving the exact timing for rate hikes 

In company news  shares of Biogen  NASDAQ BIIB  Inc     plunged 12 8  after the company s Phase 2 study of its treatment for relapsing multiple sclerosis failed to meet its primary and secondary endpoints  Also  Alexion Pharmaceuticals  NASDAQ ALXN   Inc s    shares slumped 10 9  after the company announced disappointing top line data  As per the data its drug eculizumab failed to meet the primary efficacy endpoint in a phase III study  REGAIN  in patients suffering from refractory generalized myasthenia gravis  gMG  

Losses in Biogen and Alexion Pharmaceuticals led the NASDAQ Biotechnology Index  NBI  to slump 2 5   registering its worst percentage fall since May 11  Also  the iShares Nasdaq Biotechnology  IBB  fell 2 6  

Key stocks from the bio tech sector including Vertex Pharmaceuticals  NASDAQ VRTX  Incorporated     Illumina Inc  NASDAQ ILMN       Amgen Inc  NASDAQ AMGN       Regeneron Pharmaceuticals  Inc     and Juno Therapeutics Inc     fell 1 4   1 8   0 8   2 3  and 0 5   respectively  Decline in biotech sector led the Health Care Select Sector SPDR  XLV  to decline by 0 6  and become the biggest loser among the S P 500 sectors 

In economic news  as per the Bureau of Labor Statistics  non farm business sector labor productivity fell 0 6  in the first quarter of 2016  but was narrower than 1  decline expected earlier 

Additionally  the Board of Governors of the Federal Reserve System reported that consumer credit increased by  13 4 billion in April  following March s  28 4 billion increase  Consumer credit increased at a seasonally adjusted annual rate of 4 5  in April  However  it came short of March s 9 6  increase ",2016-06-07,Zacks Investment Research,"https://www.investing.com/analysis/stock-market-news-for-june-08,-2016-200134754",200134754
121148,342663,VRTX,5 Toxic Stocks To Discard From Your Portfolio Right Now,opinion,Stocks trading above their true potential are bound to lose value over time  as their current price is not at all supported by their fundamentals  Identifying such toxic stocks on a regular basis and removing them from one s portfolio is a secret to investing success Overpricing of these stocks can be attributed to associated irrational exuberance or some serious inherent drawbacks  And if investors own such stocks for an inordinate period  they could see massive erosion of wealth On the contrary  if these toxic stocks are identified  investors may gain in a bear market by resorting to an investing strategy  known as short selling  By using this strategy  one can sell a stock first and then purchase it when its price falls Naturally  short selling excels in bear markets  while it typically loses money in bull markets So  just like picking good stocks  identifying toxic stocks and getting rid of them at the right time is vital to safeguarding one s portfolio from massive losses or making profits via short selling Screening CriteriaHere is a winning strategy that will help you identify the over hyped toxic stocks      Most recent Debt Equity Ratio greater than the median industry average  High debt equity ratio implies high leverage  And high leverage indicates a huge level of repayment that the company has to make in connection with the debt amount      P E using 12 month forward EPS estimate greater than 50  A very high forward P E implies that a stock is highly overvalued        Change in F  1  and F  2  Estimate  12 Weeks  less than  5  Negative EPS estimate revision for this fiscal year and the next during the past 12 weeks point to analysts  pessimism      Zacks Rank more than or equal to  3  We have not considered the Buy rated stocks that generally outperform the market   Here are five of the 11 stocks that made it through the screen Lions Gate Entertainment Corp    NYSE LGF   is a Santa Monica  CA based entertainment company that has seen its current quarter estimate being revised from earnings of 35 cents per share to a loss of 18 cents over the past 30 days  Lions Gate Entertainment holds a Zacks Rank  4  Sell  Pleasanton  CA based ZELTIQ Aesthetics  Inc    NASDAQ ZLTQ   is a medical technology company  Over the past 30 days  its current quarter estimate has widened from a loss of 1 cent to a loss of 7 cents per share  Presently  the company has a Zacks Rank  3  Hold  salesforce com  inc    NYSE CRM   is a San Francisco  CA based computer software industry firm  Over the past one month period  its current quarter earnings estimate has been revised down from 9 cents per share to 6 cents  Currently  the company carries a Zacks Rank  3 Boston  MA based  Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   is a bio technology company  Over the past one month period  its current quarter earnings estimate has remained unchanged at 5 cents per share  However  over the past two months  the estimate has been revised down from earnings of 25 cents to 5 cents per share  The stock currently has a Zacks Rank  5  Strong Sell  The Ultimate Software Group  Inc    NASDAQ ULTI   is a Weston  FL based Internet software and services firm  Over the past one month period  the current quarter earnings estimate has remained unchanged at 22 cents per share  But over the past two months  it has been revised down from 27 cents to 22 cents  The stock currently has a Zacks Rank  3 Get the rest of the stocks on the list and start putting this and other ideas to the test  It can all be done with the Research Wizard stock picking and backtesting software The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at   Zacks Restaurant Recommendations  In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector ,2016-06-09,Zacks Investment Research,https://www.investing.com/analysis/5-toxic-stocks-to-discard-from-your-portfolio-right-now-200135040,200135040
121149,342664,VRTX,Dump These 5 Toxic Stocks To Avoid Portfolio Bleeding,opinion,Investing in a stock whose current valuation exceeds its true inherent potential  is bound to result in loss over time  Spotting such toxic stocks accurately on a regular basis and dumping them at the right time is one of the keys to a winning investing strategy Overpricing of these toxic stocks can be ascribed to irrational exuberance associated with them  And if you own such stocks for an unreasonable period  they could end up significantly eroding your wealth However  if you can detect toxic stocks  you may gain in a bear market by resorting to an investing strategy called short selling  This strategy allows one to sell a stock first and then purchase it when its price falls Naturally  short selling excels in bear markets  while it typically loses money in bull markets So  just like picking up promising stocks  identifying toxic stocks and dumping them at the right time is crucial to guarding one s portfolio from massive losses or making profits by short selling them Screening CriteriaHere is a winning strategy that will help you identify the over hyped toxic stocks      Most recent Debt Equity Ratio greater than the median industry average  High debt equity ratio implies high leverage  And high leverage indicates a huge level of repayment that the company has to make in connection with the debt amount      P E using 12 month forward EPS estimate greater than 50  A very high forward P E implies that a stock is highly overvalued        Change in F  1  and F  2  Estimate  12 Weeks  less than  5  Negative EPS estimate revision for this fiscal year and next fiscal year during the past 12 weeks point to analysts  pessimism      Zacks Rank more than or equal to  3  We have not considered the Buy rated stocks that generally outperform the market  Here are five of the 12 stocks that made it through the screen Antero Resources Corporation   NYSE AR   is a Denver  CO based company engaged in the exploration  development and acquisition of natural gas and oil properties in the U S  Its current quarter estimate has remained unchanged at a loss of 3 cents per share over the past 30 days  But over the past two months  the estimate has been revised down from earnings of a penny per share to a loss of 3 cents  Antero Resources carries a Zacks Rank  3  Hold  Pleasanton  CA based ZELTIQ Aesthetics  Inc    NASDAQ ZLTQ   is a medical technology company  Over the past 30 days  its current quarter estimate has remained unchanged at a loss of 7 cents per share but over a 60 day period  the estimate has widened from a loss of 1 cent to a loss of 7 cents per share  Presently  the company has a Zacks Rank  3 Boston  MA based  Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   is a bio technology company  Over the past one month period  the current quarter earnings estimate has remained unchanged at 5 cents per share  but over the past two months  it has been revised down around 79  to 5 cents  The stock currently has a Zacks Rank  5  Strong Sell  ViaSat Inc    NASDAQ VSAT   is a Carlsbad  CA based wireless equipment company  Over the past two months  the current quarter earnings estimate has remained unchanged at 15 cents per share  The stock currently has a Zacks Rank  4  Sell  Lumos Networks Corp    NASDAQ LMOS   is a Waynesboro  VA based diversified communication services firm  Over the past one month period  the current quarter earnings estimate has remained unchanged at 33 cents per share  but over the past two months  it has been revised up 50  to 3 cents  The stock currently has a Zacks Rank  3 Get the rest of the stocks on the list and start putting this and other ideas to the test  It can all be done with the Research Wizard stock picking and backtesting software The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at   Zacks Restaurant Recommendations  In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector ,2016-06-26,Zacks Investment Research,https://www.investing.com/analysis/dump-these-5-toxic-stocks-to-avoid-portfolio-bleeding-200138445,200138445
121150,342665,VRTX,How Does Brexit Impact Healthcare Stocks ,opinion,Now that the UK has decided to leave the EU  the global market is in turmoil leaving everyone jittery about the impact of this decision  Some of the immediately pressing concerns are a possible recession in the UK  unemployment woes  a plunging pound  and uncertainty regarding M A deals in the UK among others A big question is how will Brexit impact drug companies The first thing that comes to mind is the impact of Brexit on the drug approval process in the UK and EU  Currently  the European Medicines Agency  EMA  looks into the approval process under a centralized authorization procedure which allows drug companies to submit a single marketing authorization application to the EMA  Under this process  the companies are able to market their medicines throughout the EU on the basis of a single marketing authorization thereby saving cost and time But with Brexit  a lot now depends on whether the UK will remain within the ambit of the EMA the way countries like Norway are or whether the UK will set up its own regulatory authority for drug approval  If the first scenario prevails  the approval process will continue as it is  However  if the UK sets up its own regulatory agency  the approval process could end up being lengthier as well as more expensive for companies seeking UK and EU approval for their drugs Meanwhile  the EMA  which is based in London  will now have to look for new headquarters Another factor that could be impacted by Brexit is the flow of research funds into the UK from the EU  With Britain exiting the EU  more of these funds could be diverted to other countries or research hubs On the other hand  the falling pound should prove to be a tailwind for companies like GlaxoSmithKline plc   NYSE GSK    Moreover  most of the drug companies generate a major part of their revenues from the U S  though companies like Alexion Pharmaceuticals  Inc    NASDAQ ALXN    Vertex Pharmaceuticals Incorporated   NASDAQ VRTX    Celgene Corporation   NASDAQ CELG   and BioMarin Pharmaceutical Inc    NASDAQ BMRN   among others do generate quite a bit of revenues from Europe  Nevertheless  that should not be a cause for concern in the long term as factors like an aging population  growing medical needs  and easier access to medical products will continue driving demand for healthcare products While Brexit does create economic uncertainty and there could be some near term volatility in the sector  the general verdict is that Brexit s impact on drug stocks will be limited  What could end up being more concerning is the exit of additional countries from the EU Medical Sector Price IndexGlaxo  Celgene and BioMarin are all Zacks Rank  3  Hold  stocks  while Alexion is a Zacks Rank  4  Sell  stock and Vertex a Zacks Rank  5  Strong Sell  stock Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-06-26,Zacks Investment Research,https://www.investing.com/analysis/how-does-brexit-impact-healthcare-stocks-200138430,200138430
121151,342666,VRTX,Zacks com Featured Highlights  Antero Resources  ZELTIQ Aesthetics  Vertex Pharmaceuticals  ViaSat And Lumos Networks,opinion,"For Immediate Release

	Chicago  IL   June 28  2016   Stocks in this week s article include  Antero Resources Corporation     ZELTIQ Aesthetics  Inc      Vertex Pharmaceuticals  NASDAQ VRTX  Incorporated     ViaSat Inc     and Lumos Networks Corp      

Screen of the Week of Zacks Investment Research Dump These 5 Toxic Stocks to Avoid Portfolio Bleeding 

	Investing in a stock whose current valuation exceeds its true inherent potential  is bound to result in loss over time  Spotting such toxic stocks accurately on a regular basis and dumping them at the right time is one of the keys to a winning investing strategy 


	Overpricing of these toxic stocks can be ascribed to irrational exuberance associated with them  And if you own such stocks for an unreasonable period  they could end up significantly eroding your wealth 
	However  if you can detect toxic stocks  you may gain in a bear market by resorting to an investing strategy called short selling  This strategy allows one to sell a stock first and then purchase it when its price falls 
	Naturally  short selling excels in bear markets  while it typically loses money in bull markets 
	So  just like picking up promising stocks  identifying toxic stocks and dumping them at the right time is crucial to guarding one s portfolio from massive losses or making profits by short selling them Screening Criteria
	Here is a winning strategy that will help you identify the over hyped toxic stocks 
	  Most recent Debt Equity Ratio greater than the median industry average  High debt equity ratio implies high leverage  And high leverage indicates a huge level of repayment that the company has to make in connection with the debt amount 
	   P E using 12 month forward EPS estimate greater than 50  A very high forward P E implies that a stock is highly overvalued 
	    Change in F  1  and F  2  Estimate  12 Weeks  less than  5  Negative EPS estimate revision for this fiscal year and next fiscal year during the past 12 weeks point to analysts  pessimism 

	   Zacks Rank more than or equal to  3  We have not considered the Buy rated stocks that generally outperform the market 
	Here are five of the 12 stocks that made it through the screen Antero Resources Corporation    is a Denver  CO based company engaged in the exploration  development and acquisition of natural gas and oil properties in the U S  Its current quarter estimate has remained unchanged at a loss of 3 cents per share over the past 30 days  But over the past two months  the estimate has been revised down from earnings of a penny per share to a loss of 3 cents  Antero Resources carries a Zacks Rank  3  Hold  
	Pleasanton  CA based ZELTIQ Aesthetics  Inc     is a medical technology company  Over the past 30 days  its current quarter estimate has remained unchanged at a loss of 7 cents per share but over a 60 day period  the estimate has widened from a loss of 1 cent to a loss of 7 cents per share  Presently  the company has a Zacks Rank  3 
	Boston  MA based  Vertex Pharmaceuticals Incorporated    is a bio technology company  Over the past one month period  the current quarter earnings estimate has remained unchanged at 5 cents per share  but over the past two months  it has been revised down around 79  to 5 cents  The stock currently has a Zacks Rank  5  Strong Sell  ViaSat Inc     is a Carlsbad  CA based wireless equipment company  Over the past two months  the current quarter earnings estimate has remained unchanged at 15 cents per share  The stock currently has a Zacks Rank  4  Sell  Lumos Networks Corp     is a Waynesboro  VA based diversified communication services firm  Over the past one month period  the current quarter earnings estimate has remained unchanged at 33 cents per share  but over the past two months  it has been revised up 50  to 3 cents  The stock currently has a Zacks Rank  3 
	Get the rest of the stocks on the list and start putting this and other ideas to the test  It can all be done with the Research Wizard stock picking and backtesting software 
	The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out   Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  Disclosure  Performance information for Zacks  portfolios and strategies are available at    Zacks Restaurant Recommendations   In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector  

	Sign up now for your free trial today and start picking better stocks immediately  And with the backtesting feature  you can test your ideas to see how you can improve your trading in both up markets and down markets  Don t wait for the market to get better before you decide to do better  Start learning how to be a better trader today  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  

About Screen of the Week 

	Zacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine  But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use  Each week  Zacks Profit from the Pros free email newsletter shares a new screening strategy  Learn more about it here 

About Zacks 

	Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Contact  Jim Giaquinto
	Company  Zacks com
	Phone  312 265 9268
	Email  
	Visit  

	Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer    

Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  

	This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ",2016-06-27,Zacks Investment Research,"https://www.investing.com/analysis/zacks.com-featured-highlights:-antero-resources,-zeltiq-aesthetics,-vertex-pharmaceuticals,-viasat-and-lumos-networks-200138695",200138695
121152,342667,VRTX,Stock Market News For July 07  2016,opinion,"Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged  Moreover  better than expected service data and gains in biotech stocks also pushed key U S  indexes northward  Additionally  rally in oil prices boosted investor sentiment For a look at the issues currently facing the markets  make sure to read today s  article 

	The Dow Jones Industrial Average  DJI  increased 0 4   to close at 17 918 62  The S P 500 rose 0 5  to close at 2 099 73  The tech laden Nasdaq Composite Index closed at 4 859 16  gaining 0 8   The fear gauge CBOE Volatility Index  VIX  decreased 4  to settle at 14 96  A total of around 7 4 billion shares were traded on Wednesday  lower than the last 20 session average of 7 72 billion shares  Advancers outpaced declining stocks on the NYSE  For 62  stocks that advanced  34  declined 

	Investors shed  Brexit  fears yesterday after the FOMC minutes of June 14 15 s policy meeting indicated that most of the Fed policymakers decided to keep the rate unchanged  Per the minutes   almost all participants judged that the surprisingly weak May employment report  raised uncertainty over the labor market outlook 

	Moreover  the minutes highlighted that another reason for not hiking rates was policymakers  decision to wait for the British referendum s results  This was mainly because most of them anticipated that the outcome of the referendum  could generate financial market turbulence  that may weigh on  domestic economic performance  

	Additionally  the Institute for Supply Management reported that ISM Services Index advanced from 52 9  in May to 56 5  in June  its best rise in last seven months  Also  the reading was more than the consensus estimate of 53 3   As per Markit  the final services PMI increased from 51 3 in May to 51 4 in June 

	In company news  shares of Medivation  Inc     increased 0 9  after its board of directors said that Medivation has signed confidentiality agreements with several companies including Celgene Corporation  NASDAQ CELG       who are interested in acquiring the company 

	Following the news  shares of Celgene rose 4 3   becoming the biggest gainer among the healthcare sector  Gains in Celgene led the iShares Nasdaq Biotechnology ETF  IBB  to increase 2 4   Key biotech stocks including  Biogen  NASDAQ BIIB  Inc      Gilead Sciences Inc  NASDAQ GILD       Regeneron Pharmaceuticals  Inc       Vertex Pharmaceuticals  NASDAQ VRTX  Incorporated    and Alexion Pharmaceuticals  NASDAQ ALXN   Inc     rose 2 3   2 2   3 3   3 6  and 3   respectively 

	Gains in biotech stocks helped the Health Care Select Sector SPDR ETF  NYSE XLV  to increase 1 1   emerging as the best performer among the S P 500 sectors  Dow components Merck  NYSE MRK    Co  Inc     and UnitedHealth Group Incorporated  NYSE UNH      advanced 2  and 0 6   respectively 

	Further  oil prices rose after API reported a wider than expected decline in crude inventories  According to the report  crude inventories decreased by 6 7 million barrels to 520 9 million for the week ended July 1  wider than analysts  projections of a 2 3 million barrels decinel  Weakening dollar also boosted oil prices yesterday  Both WTI and Brent crude progressed 1 8  and 1 7  to  47 43 a barrel and  48 80 per barrel  respectively 

	Increase in oil prices led the Energy Select Sector SPDR  XLE  NYSE XLE   to rise 0 4   Dow components Exxon Mobil Corporation  NYSE XOM      and Chevron Corporation  NYSE CVX     surged 1 2  and 1   respectively 

	Meanwhile  the U S  Census Bureau reported that trade deficit increased in May to  41 1 billion from April s deficit of  37 38 billion  wider than the consensus estimate of a decrease to  40 billion  Moreover  it was the highest trade deficit in last three months ",2016-07-06,Zacks Investment Research,"https://www.investing.com/analysis/stock-market-news-for-july-07,-2016-200140521",200140521
121153,342668,VRTX,Biotech Stock Roundup  Biogen Q2 Results Impress  Gilead HCV Franchise Under Pressure,opinion,"Earnings season for the biotech sector has kicked off with two big biotech names  Biogen   NASDAQ BIIB   and Gilead   NASDAQ GILD   reporting second quarter results  Meanwhile  companies like AbbVie   NYSE ABBV   and Amgen   NASDAQ AMGN   provided updates on their pipeline efforts Recap of the Week s Most Important Stories1  Two major biotech companies reported second quarter results over the last few days   Biogen and Gilead  First a look at Biogen s results   Biogen s second quarter results were pretty good with the company surpassing earnings expectations by a huge margin and beating on revenues as well 
The company also raised its outlook for the year  However  Biogen s CEO announced that he will be stepping down once a successor is identified  Read more    Meanwhile  Gilead s results were mixed with the company beating on earnings by a penny and revenues falling short of expectations  Moreover  Gilead cut its product sales outlook for the year  Read more    with its hepatitis C virus  HCV  segment under pressure 2  AbbVie  which will be reporting second quarter results later this week  came out with quite a few updates on the pipeline and regulatory front  The company s extended release once daily version of HCV treatment  Viekira Pak  gained FDA approval  Viekira XR is approved for the treatment of patients with chronic genotype 1  GT1  HCV  including those with compensated cirrhosis  Child Pugh A  Additionally  AbbVie is a step closer to gaining EU approval for a 12 week regimen of Viekirax with ribavirin for genotype 4  GT4  chronic HCV infected adult patients with or without compensated cirrhosis  with the CHMP issuing a positive opinion AbbVie also entered into a clinical trial collaboration with Bristol Myers under which the safety  tolerability and efficacy of AbbVie s investigational biomarker specific antibody drug conjugate rova T  rovalpituzumab tesirine  will be evaluated in combination with Bristol Myers  Opdivo and Opdivo   Yervoy regimen for the treatment of relapsed extensive stage small cell lung cancer  SCLC   Rova T became a part of AbbVie s pipeline following the recent Stemcentrx acquisition 3  Celgene   NASDAQ CELG   has decided it will not seek marketing approval for the expansion of the label of its blockbuster drug  Revlimid  as maintenance treatment in a certain type of diffuse large B cell lymphoma  DLBCL  patients  The decision is based on data from a phase III study   while patients on Revlimid showed an improvement in progression free survival  an interim analysis revealed that no benefit was seen in the Revlimid arm where overall survival is concerned 4  Amgen also provided some updates on the pipeline front  Firstly  the company and its partner  UCB  have filed for FDA approval of their experimental osteoporosis treatment  romosozumab  The other update came from the biosimilar front   Amgen and partner Allergan  NYSE AGN pa  said that their biosimilar version of cancer treatment  Herceptin  trastuzumab  fared well in a late stage study  We note that Amgen has nine biosimilars in its pipeline and recently got a favorable FDA advisory panel recommendation for its Humira biosimilar 
PerformanceMEDICAL BIOMED GENETICS Industry Price IndexThe NASDAQ Biotechnology Index was up 3 8  over the last five trading days  The biggest gainer among major biotech stocks was Biogen  which was up 10 5  on strong second quarter results  Gilead declined 5 1  during this period reflecting disappointment regarding the company s second quarter results and outlook  Over the last six months  Biogen was up 10 5  while Alexion   NASDAQ ALXN   lost 17 0   See the last biotech stock roundup here    
What s Next in the Biotech World Quite a few major biotech companies will be reporting second quarter results over the next few days including Vertex   NASDAQ VRTX    Celgene  AbbVie and Amgen Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-07-27,Zacks Investment Research,"https://www.investing.com/analysis/biotech-stock-roundup:-biogen-q2-results-impress,-gilead-hcv-franchise-under-pressure-200144467",200144467
121154,342669,VRTX,Nivalis  NVLS   Can The Stock Surprise This Earnings Season ,opinion,"Nivalis Therapeutics  Inc    NASDAQ NVLS   is expected to report second quarter 2016 results on Aug 1  Last quarter  the company had posted a negative surprise of 15 91   Let s see how things are shaping up for this announcement 
Factors at Play
Nivalis  a development stage pharmaceutical company  is focused on the discovery  development and commercialization of treatments for cystic fibrosis  CF   With no approved products in its portfolio at the moment  Nivalis does not generate revenues yet  In this scenario  investor focus will be on the company s progress with regard to its lead candidate  cavosonstat  N91115  
Recently  the company announced the completion of enrollment in the phase II study evaluating cavosonstat for the treatment of patients with CF  who have two copies of the F508del mutation  when added to Vertex Pharmaceuticals Inc  s   NASDAQ VRTX   Orkambi  Top line data should be out by the end of this year 
During the quarter  Nivalis dosed the first patient in a second phase II study on cavosonstat  This proof of concept study is being conducted to evaluate the effect of cavosonstat as add on therapy to Vertex s Kalydeco in adults who have one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein  Data from the study is expected in the first half of 2017 
Meanwhile  Nivalis is expected to see a sequential rise in operating expenses due to continued investment in the development of cavosonstat among other things 
Surprise History
Nivalis  performance has been disappointing over the last four reported quarters  While the company has missed expectations on three occasions  it posted in line results in one  Overall  the company has delivered an average negative miss of 71 27  NIVALIS THERAPT Price and EPS Surprise
   What Our Model Indicates
Our proven model does not conclusively show that Nivalis is likely to beat estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  for this to happen  However  that is not the case here  as you will see below 
Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at a loss of 52 cents per share 
Zacks Rank  Though Nivalis  Zacks Rank  2 increases the predictive power of the ESP  an ESP of 0 00  makes a surprise prediction difficult 
Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Stocks to Consider
Here are a couple of health care stocks you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter 
United Therapeutics Corp    NASDAQ UTHR   has an Earnings ESP of  3 37  and a Zacks Rank  2  It is scheduled to report second quarter results on Jul 28 
Bristol Myers Squibb Co    NYSE BMY   has an Earnings ESP of  1 49  and a Zacks Rank  1  It is also scheduled to report second quarter results on Jul 28 ",2016-07-27,Zacks Investment Research,https://www.investing.com/analysis/nivalis-(nvls):-can-the-stock-surprise-this-earnings-season-200144486,200144486
121155,342670,VRTX,Vertex  VRTX  Posts Narrower Q2 Loss  Revenues Fall Short,opinion,Vertex Pharmaceuticals Inc    NASDAQ VRTX   posted a second quarter 2016 loss of 1 cent per share  including the impact of stock based compensation expense   narrower than the year ago loss of 81 cents per share and the Zacks Consensus Estimate of a loss of 2 cents per share Excluding stock based compensation expense  the company reported second quarter earnings of 24 cents per share  compared to the year ago loss of 54 cents Vertex reported revenues of  431 6 million in the second quarter of 2016  slightly below the Zacks Consensus Estimate of  432 6 million but up 159 9  from the year ago period CF Franchise Sales Grow SequentiallyVertex s second quarter revenues consisted of sales from cystic fibrosis  CF  products Kalydeco   180 2 million   Orkambi   245 5 million   collaborative   0 07 million  and royalty revenues   5 3 million  The company reported a 16  increase in Kalydeco sales in the second quarter of 2016 from the year ago period Orkambi  lumacaftor ivacaftor   approved for the treatment of CF in people aged 12 and older with two copies of the F508del mutation  delivered sales of  245 5 million  U S    229 million  ex U S    16 million   up 10  sequentially  As of Jun 30  2016  the company estimates that about 6 000 patients in the U S  have started treatment with Orkambi However  uptake in Germany continues to be slower than that observed in the U S  As of Jun 30  about 380 of the 2 500 eligible patients in Germany had initiated treatment  Uptake in France was rapid and strong Vertex is currently looking to get Orkambi approved for use in children  6   11 years old     with the FDA granting priority review  a response should be out by Sep 30  2016  About 2 400 children with CF in the U S  fall in this category  A six month phase III efficacy study in this patient population is currently ongoing to support EU approval where a regulatory application is slated to be submitted in the first half of 2017  About 3 400 children fall in this category in the EU  Orkambi is also in a late stage study in children belonging to the 2 5 years age group Adjusted  including stock based compensation expense  research and development  R D  expenses increased 15 6  to  258 3 million  Second quarter 2016 adjusted  including stock based compensation expense  selling  general and administrative  SG A  expenses increased 17 4  to  109 9 million Maintains Kalydeco and Orkambi GuidanceVertex maintained its guidance for Kalydeco and Orkambi revenues  While Kalydeco revenues are expected in the range of  685    705 million  Orkambi revenues are expected in the range of  1 billion    1 1 billion  The company estimates that about 70    80  of Orkambi patients will remain on treatment  Meanwhile  the overall compliance rate  reflects the number of pills actually taken by a patient in a given month   is expected to be 70    80  Orkambi guidance includes sales that may result from the potential label expansion of the drug in the U S  for the 6 to 11 years age group  expected in the fourth quarter of 2016 and sales of Orkambi outside the U S   primarily in Germany Given the slower than expected launch in Germany and the close to peak penetration for the approved indication in the U S   Vertex expects further revenue growth for Orkambi to occur mainly in the fourth quarter provided its label is expanded Vertex continues to expect operating expenses to shoot up from approximately  1 06 billion in 2015 to  1 18    1 23 billion in 2016  In addition to working on expanding Kalydeco s and Orkambi s labels  Vertex is developing VX 661  VX 371 and its next generation correctors   VX 152 and VX 440 Vertex is a Zacks Rank  3  Hold  stock  Some better ranked stocks in the health care sector include Innoviva  Inc    NASDAQ INVA    ANI Pharmaceuticals  Inc   NASDAQ ANIP   and Biogen Inc    NASDAQ BIIB    While ANI and Innoviva are Zacks Rank  1  Strong Buy  stocks  Biogen is a Zacks Rank  2  Buy  stock VERTEX PHARM Price  ,2016-07-28,Zacks Investment Research,"https://www.investing.com/analysis/vertex-(vrtx)-posts-narrower-q2-loss,-revenues-fall-short-200144610",200144610
121191,342706,VRTX,Headline Risk Is Poison For Pharma And Biotech,opinion,"With yesterday s 300 point collapse  the Dow Jones 30 is now down 7 3 percent since January 1st  Other indexes have cratered as well  The smaller company Russell 2000 has shed over 11 percent  In the midst of this carnage  investors are understandably searching for  safe haven  stocks that generate dividends  are inexpensive  and offer less volatility than the overall market  Unfortunately  these ports in the storm are few and far between at the moment  People are looking for any excuse to sell stocks right now  which means anyone looking to buy has to be particularly sensitive to headline risk 
Today no sector faces greater headline risk than the biotechnology and pharmaceutical space  especially companies that have engaged in price gouging  In this toxic environment  names like Valeant Pharmaceuticals International Inc  N VRX   Shire PLC  O SHPG   Vertex Pharmaceuticals Inc  O VRTX   Biomarin Pharmaceutical Inc  O BMRN   and others are the financial equivalent of the Zika virus 
On Thursday  the House Committee on Oversight and Government Reform will hold hearings to investigate exorbitant drug price increases  The committee s ranking Democrat  Maryland Congressman Elijah Cummings  and other committee members will grill Valeant s interim CEO Howard Schiller  The management of Turing Pharma which first made headlines last fall for astronomically jacking up prices on an obscure but important medicine will also be questioned  News outlets will broadcast the hearings far and wide  and company stocks could very well drop  some precipitously  as negative sound bytes make their way through the media 
Politicians will take every opportunity to exacerbate this negative publicity  The presidential campaign is just starting to heat up and nothing gets attention like exposing corporate greed  At a recent town hall Hillary Clinton read a note about a Valeant migraine medication that cost 356 percent more than it did a year earlier  Hillary did not mince words   This is predatory pricing  it is unjustified  it is wrong   she said  adding   I m going after them  we are going to stop this  
Guess what  Hillary is right  I ve made no secret about my disgust for Valeant s now publicized  buy and burn  strategy of acquiring smaller drug companies and axing research and development spending while ripping prices higher  Since Clinton first raised the issue of drug prices back in September  Valeant has garnered more bad press for its secret use of specialty pharmacies  The company s sales force instructed doctors to get patients to buy Valeant drugs from those pharmacies so that the ultimate payer either a for profit insurer or Medicaid and Medicare would be coerced to pay for high priced Valeant drugs even when less expensive and equally efficacious alternatives existed 
What has disgusted me even more than Valeant s business practices is the investment community s defense of the company  Numerous high profile firms hold large stakes in Valeant  Bill Ackman s Pershing Square  N SQ   Jeff Ubbin s Valueact  Steve Mandel s Lone Pine Capital and Glenn Greenberg s Brave Warrior Advisors all own millions of shares  When news of these transgressions came to light  I assumed these wealthy managers would denounce the company and exit their positions  I was wrong  One after another  they defended Valeant  None  to my knowledge  unloaded their holdings  Unbelievably  Ackman increased his stake in the company and  in his annual letter  blamed  attacks by short sellers and the termination of a distribution agreement  for its stock s decline  Wow 
Valeant deserves all of the negative press it receives  It massively overcharges taxpayers for drugs  Hopefully  Congress instructs Medicare and Medicaid  whenever possible  to help patients buy anything but Valeant drugs  And hopefully state and municipal pensions redeem all of their money from firms funds that continue to own stocks in predatory drug companies  These are businesses that prey on the sick and the ill informed  And fund managers who own their stocks are doing the same ",2016-02-04,Scott Fearon,https://www.investing.com/analysis/headline-risk-is-poison-for-pharma-and-biotech-383184,383184
121192,342707,VRTX,Vertex  VRTX  to Report Q1 Earnings  Is a Surprise in Store ,opinion,"Biotech company Vertex Pharmaceuticals   NASDAQ VRTX   will be reporting first quarter 2016 results on Apr 27  after the market closes Vertex s track record is mixed with the company delivering positive surprises in two of the last four quarters and missing expectations in the remaining two quarters  The average earnings surprise over the last four quarters is  25 57  
Let s see how things are shaping up for this quarter Factors at PlayVertex  known for its strong presence in the cystic fibrosis  CF  market  has two key CF products in its portfolio   Kalydeco and Orkambi While Kalydeco revenues should continue growing  the growth rate in patients on Kalydeco will be tempered by enrollment in the VX 661 program First quarter sales will also be impacted by inventory stocking of about  6 million in the fourth quarter Meanwhile  patient starts for recently launched Orkambi  lumacaftor ivacaftor   approved for the treatment of CF in people ages 12 and older with two copies of the F508del mutation  are expected to decline sequentially  in line with the company s prior statements regarding expectations for the rate of uptake for Orkambi  Vertex expects this trend to continue through the end of 2016  by which time the vast majority of the 8 500 eligible patients in the U S  should have initiated treatment with Orkambi Orkambi sales in 2016 will comprise primarily of revenues generated in the U S  and Germany Operating expenses will also shoot up as Vertex develops its pipeline and works on expanding Kalydeco s and Orkambi s labels and continues to invest in the Orkambi launch What Our Model IndicatesOur proven model does not conclusively show that Vertex is likely to beat estimates this quarter  That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to be able to beat earnings  That is not the case here as you will see below Zacks ESP  The   which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is 0 00  since both the Most Accurate and the Zacks Consensus Estimate are 5 cents per share Zacks Rank  Vertex carries a Zacks Rank  3  Vertex s Zacks Rank  3 when combined with an ESP of 0 00  makes surprise prediction difficult We caution against stocks with a Zacks Rank  4 and  5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks That Warrant a LookHere are some health care stocks that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter BioMarin Pharmaceutical Inc    NASDAQ BMRN   has an Earnings ESP of  22 35  and carries a Zacks Rank  3  It will be reporting results on Apr 28 Amgen Inc    NASDAQ AMGN   has an Earnings ESP of  3 52  and carries a Zacks Rank  3  It will be reporting results on Apr 28 The Earnings ESP for Sanofi   NYSE SNY   is  4 17  and it carries a Zacks Rank  2  The company is scheduled to release results on Apr 29 Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-04-22,Zacks Investment Research,https://www.investing.com/analysis/vertex-(vrtx)-to-report-q1-earnings:-is-a-surprise-in-store-200126205,200126205
121193,342708,VRTX,Nivalis Starts Dosing In Second Phase II Cystic Fibrosis Study,opinion,"Nivalis Therapeutics  Inc    NASDAQ NVLS   announced that it has dosed the first patient in a second phase II study on its lead candidate  N91115  being evaluated for the treatment of cystic fibrosis  CF  
The 12 week  double blind  randomized  placebo controlled  parallel group  proof of concept study is being conducted to evaluate the effect of N91115  400 mg  as add on therapy to Vertex Pharmaceuticals Incorporated s  VRTX  Kalydeco in adults with CF  who have one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein  Data from the study is expected in the first half of 2017 proof of conceptstudy is being conducted to evaluate the effect of N91115  400 mg  as add on therapy to Vertex Pharmaceuticals Incorporated s   NASDAQ VRTX   Kalydeco in adults with CF  who have one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein  Data from the study is expected in the first half of 2017Early last month  Nivalis announced achieving a 50  enrollment milestone in a phase II study on N91115  The study is in progress to evaluate the efficacy and safety of two doses of N91115  200 mg and 400 mg  in adults with CF who have two copies of the F508del CFTR mutation and are being treated with Vertex s Orkambi  The company expects to report data from this study in the fourth quarter of 2016 
We are encouraged by the company s progress with N91115  According to the Cystic Fibrosis Foundation  CF affects an estimated 70 000 people across the world  mainly in the U S  and Europe 
We note that the FDA granted Fast Track and orphan drug status to N91115 earlier this year for the treatment of patients with CF 
Nivalis carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the health care sector are Retrophin  Inc    NASDAQ RTRX   and ANI Pharmaceuticals  Inc    NASDAQ ANIP    each sporting a Zacks Rank  1  Strong Buy  ",2016-05-16,Zacks Investment Research,https://www.investing.com/analysis/nivalis-starts-dosing-in-second-phase-ii-cystic-fibrosis-study-200130474,200130474
121194,342709,VRTX,Biotech Stock Roundup  Pfizer To Buy Anacor For  5 2B  Pipeline Setbacks For Aduro  Trevena,opinion,"Acquisitions and deals continue to make news in the biotech sector  Pfizer  NYSE PFE   which is rumored to be interested in acquiring Medivation   NASDAQ MDVN    announced that it will be acquiring Anacor   NASDAQ ANAC   for about  5 2 billion  Meanwhile  Sanofi  PA SASY  remains committed to acquiring Medivation Apart from this  companies like Aduro   NASDAQ ADRO   and Trevena   NASDAQ TRVN   came out with disappointing data from mid stage studies Recap of the Week s Most Important Stories1  Anacor s shares shot up more than 57  with the company agreeing to be acquired by Pfizer for approximately  5 2 billion  The acquisition is slated to close in the third quarter   Anacor has a late stage eczema treatment currently under FDA review with a response from the agency expected by Jan 7  2017  Read more    2  Aduro suffered a setback with the company failing to hit the primary endpoint in a mid stage study being conducted on its experimental pancreatic cancer immunotherapy regimen of CRS 207 and GVAX Pancreas  Read more    3  Trevena also came out with disappointing news on the development front with the company saying that TRV027 failed to meet the primary as well as secondary endpoints in a mid stage study for acute heart failure  AHF   The company has decided to shift focus to its lead pipeline candidate  oliceridine  which is currently in late stage development for pain management and earlier stage programs  Read more    4  Tetraphase s   NASDAQ TTPH   shares were down following an update regarding the regulatory path for its lead candidate  eravacycline  an antibiotic  The company said that the FDA has asked it to provide data from an additional phase III study  The company will be conducting two late stage studies  Top line data from the pivotal complicated intra abdominal infections  cIAI  study are expected in the fourth quarter of 2017 assuming the study commences in the fourth quarter of 2016 The other study will be conducted in patients with complicated urinary tract infections  cUTI  to support label expansion   5  French drugmaker  Sanofi  remains committed to acquiring Medivation  Last week  the company filed for premerger notification regarding its intention to acquire Medivation   Sanofi intends to acquire Medivation for  52 50 per share  approximately  9 3 billion   However  Medivation has rejected Sanofi s proposal while companies like Amgen   NASDAQ AMGN   and Pfizer are rumored to be interested in acquiring Medivation   PerformanceVertex   NASDAQ VRTX   recorded a decline of 2 30  last week while Regeneron gained 4 95  during this period  Meanwhile  Vertex lost 38 68  over the last six months 

 
The NASDAQ Biotechnology Index was up 2 56  over the last five trading days  See the last biotech stock roundup here    What s Next in the Biotech World Medivation will remain in the news as acquisition chatter continues  Meanwhile  investor focus will remain on the usual pipeline and regulatory updates Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-05-19,Zacks Investment Research,"https://www.investing.com/analysis/biotech-stock-roundup:-pfizer-to-buy-anacor-for-$5.2b,-pipeline-setbacks-for-aduro,-trevena-200131044",200131044
121195,342710,VRTX,How Is Fidelity Select Biotechnology Portfolio Fund  FBIOX  Performing ,opinion,"Fidelity Select Biotechnology Portfolio     a Zacks Ranked  2  Buy  was incepted in December 1985 and managed by the Fidelity Group  the objective of this fund is to seek capital appreciation  FBIOX normally invests at least 80  of assets in common stocks of companies principally engaged in the research  development  manufacture  and distribution of various biotechnological products  services  and processes and companies that benefit significantly from scientific and technological advances in biotechnology 

	This Sector Health product  as of the last filing  allocates their fund in one major group  Small Growth  Further  as of the last filing  Alexion Pharmaceuticals  NASDAQ ALXN   Inc   Regeneron Pharmaceuticals  Inc  and Vertex Pharmaceuticals  NASDAQ VRTX  Incorporated were the top holdings for FBIOX 

	Fidelity Select Biotechnology Portfolio  managed by   carries an expense ratio of 0 72   Moreover  FBIOX requires a minimal initial investment of  2 500 

	FBIOX has a history of positive total returns for over 10 years  Specifically  the fund s returns over the 3  5 year benchmarks  3 year 14 52  and 5 year 21 18   To see how this fund performed compared in its category   

	FBIOX s performance  as of the last filing  when compared to funds in its category was in the top 87  in 1 year  top 53  over the past 3 years  and in the 2  over the past 5 years 

Zacks Premium

	To see the Zacks Mutual Fund Rank for the funds you re interested in  plus  gain access to the Zacks Rank for your stocks and ETFs  Premium Screens  Equity Research Reports  Focus List portfolio of 50 longer term stocks and more   ",2016-05-19,Zacks Investment Research,https://www.investing.com/analysis/how-is-fidelity-select-biotechnology-portfolio-fund-(fbiox)-performing-200131018,200131018
121227,342742,VRTX,Top Trade Ideas For This Week,opinion,"Copa Holdings SA  NYSE CPA  


Copa Holdings  had been in a falling trend  making lower lows since the end of July  The market low in October may have set a bottom for it though as this week it made its first higher high  On top of that the RSI has moved into the bullish zone and the MACD is rising  both supporting more upside 

Intercontinental Exchange Group Inc  NYSE ICE 

Intercontinental Exchange  has made a long rounded bottom throughout 2014  The rise has been apparent since early September with only a moderate pullback when the market went lower  Both the RSI and MACD remain as bullish support 

Kansas City Southern  NYSE KSU 

Kansas City Southern  is approaching year long resistance at 123 25  As it arrives from a higher low the RSI and MACD are both giving bullish signals  Look for a break above to enter 

Royal Bank Of Canada  NYSE RY 

Royal Bank of Canada  had a long run higher in early 2014  September ended that with a pullback that climaxed with the market bottom in mid October and a strong bounce  shown by the long red candle followed by a Piercing Line  Now at consolidation it has support for more upside from a rising RSI crossing the mid line and a rising MACD 

Vertex Pharmaceuticals Inc  NASDAQ VRTX 

Vertex Pharmaceuticals  is approaching prior resistance at 115 from a higher low  As it arrives the RSI is in the bullish zone and turning back higher with a MACD that crossed up last week and is rising  Both support further upside 

Up Next  Bonus Idea

After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Friday which  as the calendar turns to November  sees the equity markets are looking higher  Elsewhere look for Gold to continue lower while Crude Oil consolidates  watching for a reversal  The US Dollar Index looks to continue higher to new multi year highs while US Treasuries are biased lower in consolidation  The Shanghai Composite and Emerging Markets are biased to the upside with China looking very strong  Volatility looks to remain subdued after the pullback keeping the bias higher for the equity index ETF s SPY  IWM and QQQ  Their charts show great strength ion the weekly timeframe with some potential exhaustion signals in the short run  Use this information as you prepare for the coming week and trad em well 
Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2014-11-03,Gregory W. Harmon,https://www.investing.com/analysis/top-trade-ideas-for-this-week-231076,231076
121228,342743,VRTX,Individual Stock Performance Into Year End,opinion,Yesterday we dove into which sectors performed the best into the end of the year   If you missed this the article can be viewed    Today we will dig deeper to see which stocks in the S P 500 perform the best and worst into the end of the year   In order to find the best seasonally performing stocks we will look at performance since 2000 with a minimum ten year price history  Since 2000  the best performing stock in the Month of November based on average returns is Akamai Technologies Inc  NASDAQ AKAM  with an average 16 41  return   American Tower Corporation REIT  NYSE AMT   Sealed Air Corporation  NYSE SEE   and Corning Incorporated  NYSE GLW  followed with returns above 10  each   Based on win rates  Machinery Erection Construction JSC  HN VMC and McDonald s Corporation  NYSE MCD  have never been lower in November   A number of other stocks have win rates of 92 86   The worst performing stock since 2000 in the month of November is Vertex Pharmaceuticals Inc  NASDAQ VRTX  with an average return of  9 23  and a 28 57  win rate   Genworth Financial Inc  NYSE GNW   Chesapeake Energy Corporation  NYSE CHK   and Citigroup Inc  NYSE C  have all lost greater than 4  on average in the month of November   Based on win rates  EWT  T  KSS  Chesapeake Energy Corporation  NYSE CHK   and VRTX are all tied with a 28 57  win rate  Since 2000  GNW has been the best performing stock based on average returns in December   GNW has averaged a 14 60  return and an 80  win rate   Owens Illinois Inc  NYSE OI  was a close contender with an average return of 14 19    Based on win rates Aetna Inc  NYSE AET   Stryker Corporation  NYSE SYK   Northeast Utilities  NYSE NU   PEPCO Holdings Inc  NYSE POM  and Dominion Resources Inc  NYSE D  have all closed higher 92 86  of the time in December  Moving on to the stocks that have performed the worst in December  Celgene Corporation  NASDAQ CELG  has topped the list with a negative return of  4 82  on average   Furthermore F5 Networks Inc  NASDAQ FFIV  Dollar Tree Inc  NASDAQ DLTR   and GameStop Corp  NYSE GME  have all fallen more than 3  on average   Based on win rates  Kroger Company  NYSE KR  has closed higher in December 28 57  of the time and has an average return of  2 45   In conclusion  seasonality plays a strong role in year end market performance   This list should provide investors a number of names to keep on the radar as we close out the year that have historically outperformed the overall market ,2014-11-04,Chad Gassaway,https://www.investing.com/analysis/individual-stock-performance-into-year-end-231349,231349
121229,342744,VRTX,The Significance of Round Numbers ,opinion,"The round number theory is a strategy we like to employ here at ChartSmarter  Very simply stocks seem to stall and find support at the round figures  There are some that are more important than others to me like 20  50 and 100  but you will frequently find stocks exhibit certain behaviors around all of them  VMW for one bounced precisely off the round 80 figure on 10 22 after falling 7 1  after its last earnings report and has since traded up 6 1 2 handles  There are many examples and lets look at 3 that were recently highlighted in our Game Plans 
In our Wednesday 10 15 Game Plan we looked at Vertex Pharmaceuticals Inc  NASDAQ VRTX   VRTX is a pharma play now up 57  YTD and 91  over the last one year period  Notice how the stock grappled with resistance at the round par level in early July before smashing through on 9 19 jumping 6 6  on huge trade  We recommended a buy at the round 100 number on 10 15 and to stress the importance of CLOSING prices notice how it traded as low as 96 43 before recovering almost 5 handles to finish above 100  VRTX is now 16 handles HIGHER from the highlighted entry 
Stocks that can be bought at the round numbers are VRTX  VRTX we last profiled in our Thursday 9 18 Game Plan with a 96 50 cup with handle trigger that was taken out on that session and for good measure it rose an additional 6 6  the following day on enormous trade  taking out the round par figure for the first time ever  It went on to gain almost 10  the following week  The stock has gained 40  YTD and 47  over the last one year period  VRTX is off a quick 11  from its all time high and with the volatility recently in the group  look at GILD today  this name could trade back to par in a heart beat and lets take advantage their with a long position Trigger VRTX 100   Stop 95 30 In our Tuesday 11 4 Game Plan we looked at EA  EA is a best of breed gaming play up a very smart 80  in 2014  On 10 28 the stock gapped up 3 8  after a well received earnings report and pierced the round 40 handle for the first time in 6 years but was unable to CLOSE above it  The following session it closed just beneath it before finally finishing above 40 on Halloween  EA has held that number ever since and it looks like firm support now  Further the weekly chart displays very tight  bullish action the last 2 1 2 weeks  We recommended a buy at 40 25 and it is now UP more than 2  above that pivot and a move above 41 50 can be added to 
Stocks that can be bought at the round numbers are Electronic Arts Inc  NASDAQ EA   EA is a consumer play that is higher by 79  YTD and by 60  over the last one year period  Last week EA reported earnings on Wednesday and it rose 3 8   taking out a 38 40 double bottom trigger in the process  In fact it lost ground just once in 2014 after releasing numbers on 7 23 down 6 2   Other than that it jumped 21 and 1 6  on 5 7 and 1 29  Notice the precise support at the 200 day SMA on 10 15 and the nice finish that session at highs for the day  The stock recently took out the round 40 handle for the first time since the fall of 2008 on Friday  Lets look to enter on a slight pullback toward that figure at 40 25 Trigger EA 40 25   Stop 38 90 
In our Thursday 10 30 Game Plan we looked at Carbo Ceramics Inc  NYSE CRR   CRR is an idea that is still in play on the short side  The stock has made pit stops at 50 point intervals since having issues with the round 150 number in June and July  The 100 level was support in August and September  and now the 50 figure is holding as tenuous support  A drop below the 50 number could be hazardous for this name that is more than 67  off its recent 52 week high made just 4 1 2 months ago 
Stocks to be considered shorting opportunities are CRR  CRR is a member of the energy equipment group and it has been decimated more than actual group  which is hard to do  It is 66   2 3rds of its value not a typo  off its recent 52 week highs  Notice how the round numbers come into play with CRR as the 150 handle was resistance in July  100 was support between the beginning of August through mid September  and now 50 is support for the last couple weeks  This stock REPORTS tomorrow and if it opens higher and then reverses below the round 50 number take a short  do not play it if it gaps below that round number  In that scenario you can try a short if it reverses higher into the 50 handle  Those round numbers are something  huh Trigger CRR 49 75   Buy stop 53 ",2014-11-12,Douglas Busch,https://www.investing.com/analysis/the-significance-of-round-numbers-232283,232283
121230,342745,VRTX,5 Biotechs To Watch In Q1 2015,opinion,"2014 has been an eventful year on Wall Street  Now that it is coming to an end  what stocks should investors be on the lookout for in the first quarter of the new year  To answer the question  William Blair analyst  named 5 Biotechnology stocks to watch in the first quarter of 2015 Medivation  NASDAQ MDVN  Medivation is best known for developing therapies to treat serious diseases  Earlier this year  the biopharmaceutical company received FDA approval to expand the use of Xtandi  a prescription medicine used to treat men with prostate cancer  Since the expansion of the drug was approved  Medivation s stock has increased about 60  and they raked in  200 million in revenue in their most recent quarter  In the first quarter of 2015  Medivation is poised to report data collected from the TERRAIN study  which evaluated Xtandi in comparison to Casodex  a direct competitor of the treatment  in metastatic prostate cancer 
Xu gave Medivation an Outperform rating and a  116 price target  reasoning that data from the TERRAIN study  could push Xtandi to eventually replace Casodex  becoming the biggest prostate cancer drug   The analyst believes  Positive TERRAIN data will further push urology adoption   which is the  key for Xtandi s next leg of growth  Xu has rated Medivation twice since February 2011  earning an overwhelming  143 5  average return per recommendation Dynavax Technologies Corporation  NASDAQ DVAX  Dynavax is known for developing products to prevent and treat infectious and inflammatory diseases and cancer  Three total interim data safety monitoring board reviews have been scheduled for Dynavax s HBV 23 treatment  the company s adult hepatitis B vaccine candidate  with the first review recently completed in October of this year  The second review is set to happen in February 2015 Xu gave Dynavax an Outperform rating with a  40 price target  noting  the focus of HBV 23 is on the safety side  therefore  each positive DSMB review should further de risk the study  Xu has rated Dynavax 6 times since May 2010  earning a 67  success rate recommending the stock Tokai Pharmaceuticals  NASDAQ TKAI  Tokai Pharmaceuticals focuses on developing proprietary therapies for prostate cancer and other hormonally driven diseases  Tokai has plans to begin enrollment in its Phase III ARMOR3 SV study in the first half of 2015  The company s Phase III study is meant to target men with prostate cancer who have shown resistance to Johnson   Johnson s  NYSE  JNJ  Zytiga and Medivation s Xtandi Xu gave Takai an Outperform rating and a  44 price target  Xu acknowledged that  the development of a companion diagnostic to identify AR V7 expression for the study enrollment  as well as FDA approval for this diagnostic  is a prerequisite to beginning this Phase III trial   Thus   finalizing and validating the assay is the next major milestone to be achieved in the development program   in her opinion  This is the first time Xu has given a recommendation for Tokai Vertex Pharmaceuticals  NASDAQ VRTX  Vertex develops new medicines for people with serious diseases  The final readout of Vertex s 12 week Phase II study data of its cystic fibrosis treatment  Kalydeco  with VX 661  a placebo  in homozygous patients is expected during the first quarter of 2015  The data will be benchmarked with two different studies titled TRAFFIC and TRANSPORT  The company is getting ready to start a Phase III trial in early 2015 in patients 12 years and older with cystic fibrosis Xu gave Vertex an Outperform rating with a  115 price target with the expectation that the data from the company s Phase II study of Kalydeco with VX 661  to be better than that observed with TRAFFIC and TRANSPORT  Xu last rated Vertex in January 2010  earning a  13 8  return Chimerix  NASDAQ CMRX  Chimerix develops oral antiviral treatments in areas of high unmet medical need  The company plans to initiate a Phase III study of CMV and BKV  which will  determine the effectiveness of brincidofonier in the prevention of cytomegalovirus  CMV  and BK Virus  BKV  infection in kidney and kidney pancreas transplant recipients   according to Xu s research note Xu gave Chimerix an Outperform rating and a  46 price target  noting  The study initiation in the renal transplant setting will be followed by top line data releases from two earlier Phase III programs during 2015  SUPRESS study data in the third quarter 2 15 and AdVise study data around the end of 2015  Xu last rated Chimerix in October of this year  earning a  15 4  return on the stock ",2014-12-23,Uri Gruenbaum,https://www.investing.com/analysis/5-biotechs-to-watch-in-q1-2015-236692,236692
121231,342746,VRTX,Top Trade Ideas For This Week ,opinion,"Top trade ideas for this week of January 5  2015
Intercontinental Exchange   NYSE ICE 

Intercontinental Exchange  ICE  has gone through a long pullback and reversal  creating a Cup  in 2014  The last 2 months may be the Handle to go along with it  This is a bullish pattern on a break of the Handle higher  but offers a downside trade as well on a new low under 215  The The RSI is holding in the bullish zone for now  but the MACD is running to the downside 
Marathon Oil   NYSE MRO 

Marathon Oil  MRO  was hit hard  like all Crude Oil names  before finding a bottom in mid December  It is holding under resistance now with the 20 day SMA above and a gap to fill above that  The RSI is pushing against the mid line and the MACD is rising 
ON Semiconductors   NASDAQ ONNN 

ON Semiconductors  ONNN  is trading at 3 and a half year highs as it consolidates  A break higher could look to the 2011 highs and beyond  The RSI is strong and bullish while the MACD is leveling as the price churns  Watch the Golden Cross form as a possible catalyst 
Och Ziff Capital   NYSE OZM 

Och Ziff Capital  OZM  bounced off of the October low and ran up to its 200 day SMA  It took a small pullback from there before reversing higher  The Measured Move targets 13 25 and has support from a rising and bullish RSI and a MACD crossing up 
Vertex Pharmaceuticals   NASDAQ VRTX 

Vertex Pharmaceuticals  VRTX  had been moving higher since August until it started to consolidate in a range in November  It is now peeking above the top of that range  A continuation has no resistance higher  The RSI is bullish and rising and the MACD is crossed up   a buy signal  and running higher as well 
Up Next  Bonus Idea
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed last Friday which  heading into the first full week of 2015 week  sees the equity index ETF s looking as though they may continue to the downside 
Elsewhere look for gold to continue in its tight range while oil continues lower  The dollar looks strong and should continue higher while US Treasuries are biased higher  and on the edge of a breakout  The Shanghai Composite continues to look strong but very overbought while Emerging Markets are weak and biased to the downside  Volatility looks to remain subdued keeping the bias higher for the equity index ETF s  SPY  IWM  and QQQ  despite the moves lower this week 
Their charts show a downside bias with the QQQ leading the way and the IWM the strongest  possibly confirming a rotation from one to the other  The possible reversal candles seen Friday could always kick in and the indexes might move higher though 
Disclaimer The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer ",2015-01-05,Gregory W. Harmon,https://www.investing.com/analysis/top-trade-ideas-for-this-week-237325,237325
121232,342747,VRTX,J P  Morgan Chimes In With Ratings On BioTech Stocks,opinion,J P  Morgan analyst Cory Kasimov rated a slew of bio technology stocks on January 5th  including Vertex Pharmaceuticals  NASDAQ VRTX   Regeneron  NASDAQ REGN   Gilead Sciences  NASDAQ GILD   Celgene Corporation  NASDAQ CELG   Biogen Idec  NASDAQ BIIB   and Acorda Therapeutics  NASDAQ ACOR   Kasimov s ratings are mostly Bullish  however he has a few reservations about some stocks Vertex Pharmaceuticals Vertex  NASDAQ VRTX  develops new medicines for people with serious diseases  The final readout of Vertex s 12 week Phase II study data of its cystic fibrosis treatment  Kalydeco  in homozygous patients is expected during the first quarter of 2015 Kasimov s firm reiterated an Overweight rating on Vertex with a  130 price target  expecting an eventful 2015 for the company  The analyst anticipates  continued geographic label expansion for Kalydeco plus the likely US EU approval of the VX 809 Kalydeco combo to drive significant top line growth   In addition   There s also the potential for significantly more LT growth driven by VX  661 Kalydeco  which will generate data imminently and is poised to enter an extensive pivotal program in 1H15 evaluating several CF populations  including the difficult to treat heterozygous F508del  Regeneron Regeneron  develops and manufactures treatments for serious medical conditions  The company s key product is Eylea  which is used to treat age related macular degeneration  In the third quarter of 2014  U S sales of Eylea increased 23   marking over 60  of the company s total revenue  In addition  Regeneron currently has 16 different treatments in clinical development Kasimov reiterated a Neutral rating on Regeneron with a  402 price target  citing potential for significant longer term value creation  The analyst noted   It s hard to argue with REGN s recent success  and we believe the pipeline offers the potential for even more long term optionality  That said  we are maintaining a Neutral rating  as we suspect nearer term drivers are largely already appreciated by investors  Gilead Sciences Gilead Sciences shares dropped a couple weeks ago when Express Scripts made a deal with Gilead s competitor  AbbVie  NYSE ABBV   to exclusively distribute their Hepatitis C treatment to their customers  However  Gilead made a comeback by striking a deal with CVS Health Corp  NYSE CVS  on January 5th in which the pharmacy will now exclusively offer Gilead s hepatitis C drug  Harvoni Kasimov maintained an Overweight rating on the company following the announcement of Gilead s deal with CVS  The analyst explained  This is clearly a positive  albeit unsurprising  development for GILD following the exclusion of its drugs from ESRX s formularies as announced in late Dec   Kasimov thinks   this news should go a long way toward easing fears around GILD s longer term market share  Celgene Corporation Celgene Corporation is best known for developing cancer and inflammatory fighting drugs  The company s best selling drug is Revlimid  a therapy used for multiple myeloma  The drug originally came on the market in 2006  Since then  sales of Revlimid have continued to steadily increase  reaching  1 3 billion in the third quarter of 2014 However  Kasomiv reiterated a Neutral rating on Celgene with a  120 price target  noting a lack of  incremental drivers of near term upside that aren t already appreciated by investors   Although the analyst is  impressed by the continued growth of the Revlimid franchise  strong launches of Pomalyst and Abraxane  and compelling pipeline assets  GED 0301 and earlier partnered programs    He has a neutral rating  as  he  await s  additional drivers that are incremental to current expectations  Biogen Idec Biogen Idec specializes in developing therapies for the treatment of neurodegenerative  hematologic and autoimmune diseases  In the beginning of December  Biogen announced positive interim results from an early stage study of their Alzheimer s disease treatment called BIIB037 that attacks amyloid plaques in the brain  The company is now planning to move  aggressively  into Phase III  the most advanced stage of studies  This is generally the last step before seeking regulatory approval Kasimov reiterated an Overweight rating on Biogen with a  407 price target  revealing updated thoughts on the company  The analyst noted   In our view  BIIB s pipeline is one of the most compelling in large cap biotech  with highly innovative programs like LINGO in MS and various Alzheimer s assets that  while early stage  have the potential to produce high profile data in 2015   Beyond this   strength in MS  Tecfidera specifically  and hemophilia should drive top and bottom line growth   Kasmov concluded   All in  we anticipate this combination of meaningful earnings growth plus significant pipeline optionality to generate investor interest in 2015  Acorda Therapeutics Acorda Therapeutics  NASDAQ ACOR  is best known for developing drugs that improve neurological function in people with multiple sclerosis  spinal cord injuries  and other disorders of the central nervous system  Around mid Decemember  Acorda Therapeutics acquired Civitas Therapeutics after Civitas officially cancelled its plans for an initial public offering  Acorda Therapeutics acquired Civitas for  525 million Kasimov set a Neutral rating on Acorda Therapeitics  believing the company has a lack of meaningful catalysts coming into 2015  Although the analyst is  particularly intrigued by the recent acquisition of Civitas  a potentially transformative deal at a purchase price of only  1x management s conservative peak sales estimate  ACOR shares were up 40  in 2014  not leaving much to look forward to in 2015 Cory Kasimov has successfully made 15 general ratings out of 30 total over the past year  earning a 50  success rate recommending stocks and a  16 6  average return per recommendation ,2015-01-06,Uri Gruenbaum,https://www.investing.com/analysis/j.p.-morgan-chimes-in-with-ratings-on-biotech-stocks-237555,237555
121233,342748,VRTX,Massive Froth  Negative Divergence  Leading Sector Breakdowns,opinion,Where to start  We can first take notice of how froth has been consistently out of control for roughly sixty consecutive weeks save two of them  Only two of them have had bull bear spreads of under 30   That was last October when we were correcting  Most of the time we have been above the dangerous level of 35   We have also spent  I believe  at least ten weeks over 40   We are at 42 5  coming in to this week  That s completely out of control  You can pretend to deny it  or even ignore it  but it s not going away just because you re bullish and wish it weren t so Due to the actions of our leader  Fed Yellen  the market has found a way to hold up under this tremendous froth longer than anyone could have thought humanly possible  I  for sure  never thought it possible  The most we have corrected from this type of froth is 9 9  on the S P 500 last year and that loss was taken back very quickly once things calmed down just a bit  The desire to be involved in the market overwhelmed every attempt by the bears  We still don t know  even at 42 5  on the spread  if the froth is actually kicking in for real  Maybe this is nothing more than a simple pullback before trying higher again  It doesn t seem that way to me  but  hey  what do I know  The marker reacted in a way today consistent with froth finally starting to make some noise  I ll discuss more of that below  Today was not a good day for the bulls for many reasons  but  to me  froth was the biggest catalyst to the move lower So what happened today that is really bad for the bulls  We turn our attention to the charts of the transport  biotech  semiconductor  and bank sector charts  All of them with gap downs  and all of them losing  in unison  their 50 day exponential moving averages on those key daily charts  The 20 s on the bios  The first time in a very long time that we have seen that type of behavior  A total change of trend not seen in quite some time  and whenever you have a change of trend of this magnitude  you better take notice Each one of those sector charts have been strong  If one gets sold the market turned its attention to the other sectors to make up the difference  The market found a way to rotate the cash around and keep market prices higher  Today we did not see rotation  and that  too  is a massive change of trend  This is the first time the bulls could not find a way to get a key  leading sector to rise when they needed it to  They lost their hold on the process of rotation  A first  A portent of things to come  Not sure  but definitely worth noticing  If those sectors don t immediately come back  and take those lost 50 s back  things could get ugly very quickly  Four of the key  leading sectors and none of them could stop the bleeding today  Respect it for the potential message that reality may be sending Lessons taught  The market is famous for doing this over and over  Wash  rinse  and repeat this process for what seems like forever  New traders come in and enjoy the fruits of getting involved to some degree with the froth  Over time the stocks run higher and higher and those traders can t take it any longer  The need to get fully involved is overwhelming  Emotion kicks in and they run in to these stocks with everything they have  In this case  those biotechnology stocks  the bubble of this bull market and the allure of what was possible  is just too much fun to not get involved  And as usual  you can t make the following reality up  Biogen Idec Inc   NASDAQ BIIB   the biggest froth of them all  had its largest volume up day ever on Friday  The stock was up tremendously prior  and the emotion was just too high for traders to ignore The same day  the index ETF iShares Nasdaq Biotechnology  NASDAQ IBB  had its largest volume of the year and it  too  has been slaughtered ever since  I can name many more in that sector but the list is too long  Vertex Pharmaceuticals Incorporated  NASDAQ VRTX   Kite Pharma  NASDAQ KITE   Bluebird Bio  NASDAQ BLUE   Esperion Therapeutics  NASDAQ ESPR  and many others also culprits of froth  The full list is over thirty long  The carnage too intense to take for most  Some even showing distribution volume off the top  Vertex Pharmaceuticals  NASDAQ VRTX  for example  These stocks will recover some and have great rallies but the technical damage is in  They should struggle for some time to come in between those quick  strong rallies  The market  in the biggest bubble of this bull  takes out the masses once again  Wash  rinse  and repeat The monthly charts have negative divergences  They also have very elevated oscillators  That combination  over time  usually plays out to the down side  but  of course  timing that is never easy when you have such a protective Fed Governor  Her actions regarding rates are keeping folks involved when one would think it s impossible  The daily chart on the Nasdaq has joined the party regarding negative divergence  Again  there s no way to know if  and when  it ll kick in  but it s there  and needs to be respected  If it plays out  things could get somewhat ugly for a while  The point  of course  being that nothing is easy for the market here when you add up the potential negatives Ms Yellen keeps trying  Maybe she ll get away with it a while longer  but there are enough problems to keep me thinking cash is great  If you want some scratch after today s poor action that s up to you  To me  extreme caution is warranted  That said  and this is very critical for the bears  Stop with the excuses  You have everything on your side  You couldn t ask for more positives  The market needs to stop the rally moves higher every time we have a decent down day  The bears need a thrust lower  No more excuses  Keep the markets oversold the way the bulls keep them overbought  Can t rally hard every time any key  time frame charts hits 30 RSI  The bears have their chance  Time to seize the opportunity and thrust this market lower  We shall see what they can do ,2015-03-26,Jack Steiman,https://www.investing.com/analysis/massive-froth...negative-divergences....leading-sector-breakdowns....les-246281,246281
121234,342749,VRTX,Will Gilead Sciences Buy Vertex ,opinion,"Gilead Sciences  NASDAQ GILD  has been rolling in the money since the release of its hepatitis C drug duo  Sovaldi and Harvoni  Now investors are wondering how Gilead will put its pile of cash to work 
In its Q4 earnings report Gilead announced that its cash position had increased from  2 6 billion to  11 7 billion in one year  On top of quadrupling its bank account  Gilead repurchased  5 3 billion worth of stock throughout 2014 
On April 21 Bernstein analyst Geoffrey Porges put out a note suggesting that Gilead make a bid for Vertex Pharmaceuticals  NASDAQ VRTX   Vertex has a cystic fibrosis drug which appears promising and could fetch huge returns  With Vertex s market cap at  30 billion  Porges  estimate of  45 billion seems reasonable 
Gilead s biggest problem right now is a good one to have  The company is making so money that it needs to find efficient ways to spend its cash  Thus far  management has been a steward of capital  avoiding high risk maneuvers  Gilead s largest expense in the past year was its share repurchase program 
Aside from  5 3 billion in buybacks Gilead s next largest expenditure was the acquisition of Phenex Pharmaceuticals reported back in January which could cost up to  470 million  With the acquisition of Phenex  Gilead wrapped its arms around several potential treatments for nonalcoholic steatohepatitis  a common liver disease 

Harvoni was FDA approved in October 2014 and drove a huge earnings beat for Gilead last quarter  This quarter Estimize contributors expect more of the same  The consensus estimate from 140 contributing analysts is that Gilead will report earnings of  2 48 per share on top of  7 04 billion in revenue  Compare that to the estimate from Wall Street   2 16 in EPS and  6 76 billion in sales 
Since the release of Sovaldi in FQ1 2014 Gilead has trampled the Wall Street earnings consensus 3 times and reported in line just once  When biotech companies release new drugs  the first 2 quarters after the release often show a great deal of uncertainty  The Estimize community is setting the bar high in a show of faith that Gilead will report a strong quarter 
The expectation from Estimize is that Harvoni will drive a 68  year over year increase to earnings and a 41  improvement in revenues  Apart from roaring financial results  investors will look to see if Gilead has figured out a way to spend its mountain of cash  potentially on a blockbuster acquisition ",2015-04-29,Estimize,https://www.investing.com/analysis/will-gilead-sciences-buy-vertex-250101,250101
121235,342750,VRTX,Shares of Vertex Increased Nearly 8  In Pre Market Trading,opinion,"On May 12  the FDA advisory committee recommended that the FDA approve Vertex Pharmaceuticals   NASDAQ VRTX  Orkambi therapy to treat cystic fibrosis  Shares of Vertex increased nearly 8  in pre market trading following the announcement The FDA advisory committee provides the FDA with independent sources verifying the safety and efficacy of the new therapies  The FDA has agency over making the final approval decision but often follows the advice of the advisory committee  The FDA is expected to announce Orkambi s final approval or rejection by early July 
Orkambi is an oral medication taken in tablet form  It is intended for use in people with cystic fibrosis over the age of 12 who have two copies of the F508del mutation  which is the leading cause of cystic fibrosis  According to Vertex  there are approximately 8 500 people in the United States who fit this criteria  representing the largest group of people with cystic fibrosis  If approved  Orkambi will be the first medication to treat this population of cystic fibrosis patients 
If Orkambi is approved  analysts estimate it could bring in  1 6 billion in revenue over the next year and more than  4 billion by 2020  However  health care experts are already concerned about the potential high cost of Orkambi and the burden it will pose on insurance companies and pharmacies 
According to    of J P  Morgan reiterated an Overweight rating on VRTX with a  138 price target on May 12 following Orkambi approval from the FDA advisory committee  Kasimov noted he was not surprised that the FDA advisory committee approved Orkambi due to  the high unmet need of CF patients and the lack of current treatments   Although  things got dicey for a moment or two  while the advisory committee discussed the drug  the committee ultimately  voted almost unanimously  in favor of its approval  Looking forward  Kasimov remains confident that Orkambi will be approved by July 
Cory Kasimov has rated Vertex Pharmaceuticals 5 times since July 2014  earning a 100  success rate recommending the stock with a  10  average return per VRTX rating  Overall  Kasimov has a 61  success rate recommending stocks with a  10 4  average return per recommendation 
Separately on May 12   of Canaccord Genuity reiterated a Buy on Vertex Pharmaceuticals with a  150 price target 
Walsh expected the FDA advisory committee to vote in favor of Orkambi and is confident that the FDA will fully approve it by July  He added that pricing of the drug may be impacted by a  modest treatment effect observed in P3 trials   However  Walsh s KOL consultants predict Orkambi will penetrate more than 90  of the target population  so  the total Orkambi market opportunity will be primarily determined by price   Walsh continues   However  we remind investors that our reimbursement specialist KOL  who advises pharmaceutical and biotechnology companies on pricing strategies  argues that pricing on par with Kalydeco is more likely   Kalydeco is an already approved cystic fibrosis drug developed by Vertex but aimed at a smaller population of CF patients 
Adam Walsh has rated Vertex twice before in the past two months  earning a loss of  1 4  between both ratings  Overall  Walsh has a 76  success rate recommending stocks with a  28 3  average return per rating On average  the top analyst consensus for Vertex Pharmaceuticals on  is Moderate Buy ",2015-05-13,Sarah Roden,https://www.investing.com/analysis/j.p.morgan-and-canaccord-genuity-are-confident-that-vertex-pharmaceutica-251623,251623
121277,342792,VRTX,Vertex Pharmaceuticals  Street s CF Sales Up Significantly ,opinion,Investment summary  VX 661 and then someVertex s  VRTX  remarkable c  7 2bn  62   increase in market capitalisation last week  on the back of VX 661 Phase IIa top line data in cystic fibrosis  CF  patients with two copies of F580del mutations  poses a difficult question for investors  While the valuation reflects the market s confidence in the strength of its potential franchise in CF   possibly worth up to  10bn in peak sales   it also assumes a high probability of success  Vertex is now the undisputed leader in CF with one approved  Kalydeco  ivacaftor  drug and three clinical candidates  VX 809   661 and  983  in the pipeline  but Edison cautions that the risk is now asymmetric to the downside VX 661 data clear cutIn the Phase II study  128 patients with homozygous F580del mutations were treated with placebo  VX 661 alone  or VX 661 in combination with ivacaftor for 28 days  At the two highest doses  100mg and 150mg once daily  qd   VX 661 with ivacaftor resulted in a statistically significant increase of FEV1  relative and absolute  from baseline vs placebo  While VX 661 monotherapy failed to improve patients  FEV1  it did not worsen FEV1 from the baseline  Worsening of FEV1 from baseline by VX 809 monotherapy in a Phase II trial had caused confusion and concern in the investment community VX 661 solidifies Vertex s leading position in CFVX 661 s positive combination results  and its read through to the VX 809 ivacaftor combo pivotal programme  suggest that Vertex now has drugs regimens that can treat up to 50  of a total of 70 000 CF patients globally  Vertex intends to reach the rest of CF patients through developing second generation correctors  VX 661 and VX 983  or triple combinations for which clinical data is lacking at this point Catching up  Street s CF sales up significantlyStreet estimates for sales in F580del homozygous patients now range from  4bn to  6bn with total CF franchise sales as high as  10bn  Besides bullish sales estimates  the strong earnings power of the CF franchise  premium pricing  targeted patients and high commercialisation margin  also supports Vertex s impressive valuation Valuation  Impressive EV of  16 6bnVertex s EV of  16 6bn  market cap minus net cash of  0 9bn at end 2012  reflects bullish CF sales and high probability of clinical success post VX 661 data To Read the Entire Report Please Click on the pdf File Below ,2013-04-24,Edison,https://www.investing.com/analysis/vertex-pharmaceuticals:-streets-cf-sales-up-significantly-164769,164769
121278,342793,VRTX,Biotech Has A Hiccup,opinion,The S P 500 Biotechnology stock price index  Alexion Pharmaceuticals Inc  NASDAQ ALXN   Amgen Inc  NASDAQ AMGN   Biogen Idec Inc  NASDAQ BIIB   Celgene Corporation  NASDAQ CELG   Gilead Sciences Inc  NASDAQ GILD   Regeneron Pharmaceuticals Inc  NASDAQ REGN   Vertex Pharmaceuticals Inc  NASDAQ VRTX   peaked at a record high on February 24  It is down 10 5  since then through yesterday s close  It is still up 208  from its 2011 trough  when the forward P E fell to 10  This valuation multiple is now 22 0    Driving valuations higher in the industry since mid 2011 has been an amazing increase in industry analysts  expectations for short term and long term earnings growth  The former has tripled to over 30   while the latter has doubled to almost 25   The recent correction in Biotechs was triggered by concerns that the government will pressure the industry to reduce the prices of some of its higher priced products    Today s Morning Briefing  Internal Correction   1  S P 500 remains at record high despite everything   2  FSMI rebounding   3  Priciest industries a bit less so   4  A good excuse for taking some profits out of Biotech   5  Internet Retailing is full of hot air   6  Internet Software is cheaper  but not cheap   7  Is there a shortage of growth stocks   8  Growth stocks tend to attract attention and well financed competitive startups   9  Internal corrections broaden the bull market   10  Financials may be too cheap now that they are so regulated   11  The parable of Alibaba and Tencent ,2014-03-26,Ed Yardeni,https://www.investing.com/analysis/biotech-has-a-hiccup-207347,207347
121279,342794,VRTX,Oversold Biotech Stocks Haven t Bottomed Yet ,opinion,"One of the hottest stock sectors in 2013 were the biotechnology stocks  Leading biotech stocks such as Celgene Corporation  NASDAQ CELG   Gilead Sciences Inc   NASDAQ GILD   Vertex Pharmaceuticals Incorporated  NASDAQ VRTX   and Amgen Inc  NASDAQ AMGN  were some of the biggest winners last year  So far in 2014  this high growth industry group has been in correction mode  Many of the leading biotech stocks are now trading lower by 20 0 percent or more since the start of the new year  While it is safe to say that the biotech sector is severely oversold  this important industry group has not yet bottomed out 
Traders and investors can expect minor bounces in the biotech stocks from current levels  but it is not a true bottom in the industry group just yet  Remember  nothing in the stock market goes down or up in a straight line  One of the ways that traders and investors can play the entire biotech sector is to use and follow the iShares NASDAQ Biotechnology Index ETF  NASDAQ IBB   At this time  the IBB is signaling downside to the  202 00 level  This is an area where the institutional money will likely come back in and support the biotech stocks  Until then  the bounces in the sector are likely to be just small rallies from an oversold condition ",2014-04-08,Nicholas Santiago,https://www.investing.com/analysis/oversold-biotech-stocks-havent-bottomed-yet-208902,208902
121280,342795,VRTX,ProQR Therapeutics IPO  Neutral To Slightly Positive Outlook,opinion,"ProQR Therapeutics B V   NASDAQ PRQR     Scheduled IPO  September 18 2014
Overview
PRQR is an innovative biopharmaceutical company engaged in the discovery and development of RNA based therapeutics for the treatment of severe genetic disorders  including a disease modifying therapy for the treatment of cystic fibrosis   PRQR has had positive preclinical results and plans  to file in Q4 2014an IND  investigational new drug  with the FDA 
During August 2014  PRQR entered into an agreement with Cystic Fibrosis Foundation Therapeutics to provide PRQR  with up to  3 million to support the clinical development of QR 010  the lead product  Based in Boston  MA ProQR Therapeutics B V   PRQR  scheduled a  76 million IPO on NASDAQ with a market capitalization of  294 million at a price range midpoint of  12 for Thursday  September 18  2014 
  Manager  Co managers   Leerink Partners  Deutsche Bank Securities
Joint managers   JMP Securities  H C  Wainwright   Co   LLC

Conclusion
The rating on PRQR is neutral to slightly positive  PRQR has had positive preclinical results for cystic fibrosis  Plans  to file in Q4 2014 an IND  investigational new drug  with the FDA  Certain insiders have indicated an interest in purchasing up to  20mm on the IPO  
To put the conclusions and observations in context  the following is reorganized  edited and summarized from the full S 1 referenced above  
Valuation  Valuation Ratios
Mrkt Cap   mm    294
Price  Sls  n a
Price  Erngs   16 3
Price  BkVlue   2 6
Price  TanBV   2 2
  offered in IPO   26 
 Business
PRQR is an innovative biopharmaceutical company engaged in the discovery and development of RNA based therapeutics for the treatment of severe genetic disorders  Utilizing unique  proprietary RNA repair technologies  PRQR believes it will be able to treat genetic disorders in which a single protein is defective due to certain types of genetic mutations  
PRQR designs its therapeutic candidates to specifically target and repair the defective messenger RNA  or mRNA  that is a product of a mutated gene in order to restore the expression and function of normal  or wild type  protein  PRQR s primary focus is on the development of a disease modifying therapy for the treatment of cystic fibrosis  or CF  a genetic disease that affects an estimated 70 000 to 100 000 patients worldwide and causes early morbidity and mortality  CF is a genetic disease that currently has no cure  The median age of death for CF patients is 27  and more than 90  of CF patients die from respiratory failure  
To date  all but one of the therapies approved to treat CF patients are designed to treat the symptoms of the disease rather than address the underlying cause  CF results from mutations in the gene that encodes a protein called cystic fibrosis transmembrane conductance regulator  or CFTR  Although there are more than 1 900 different genetic mutations that cause CF  the DF508 mutation that PRQR is targeting is the most prevalent and is present in approximately 70  of all CF patients 
PRQR is also developing a treatment for Leber s Congenital Amaurosis  or LCA  the leading genetic cause of blindness in childhood  Further  based its own research and initial selection criteria  PRQR believes that its RNA repair technologies can potentially be used to treat a broad range of other severe genetic diseases that are currently untreatable or have limited effective treatment options and have to date identified more than 50 potential target indications  
Lead product candidate PRQR s lead product candidate  QR 010  has generated compelling data in pre clinical studies  which PRQR believes supports its potential as a disease modifying therapy for CF patients  PRQR intends to advance QR 010 into clinical trials in CF patients with the DF508 mutation  which affects approximately 70  of all CF patients  In the fourth quarter of 2014  PRQR plans to file an IND  investigational new drug  with the FDA  file a  CTA with the EMA and initiate the first clinical trial directly in CF patients 
PRQR is also studying applications of RNA repair technologies for mutations other than DF508 that could potentially be used to treat an additional 10  of CF patients  including those with the G551D mutation 
Cystic Fibrosis Foundation Therapeutics  Inc  agreementIn August 2014  PRQR entered into an agreement with Cystic Fibrosis Foundation Therapeutics  Inc   or CFFT  a subsidiary of the Cystic Fibrosis Foundation  pursuant to which CFFT agreed to provide PRQR  with up to  3 million to support the clinical development of QR 010  The Cystic Fibrosis Foundation is a professional patient advocacy organization that supports select CF drug development programs by providing financial support and access to its Therapeutic Development Network  a network of CF key opinion leaders  as well as to an extensive clinical trial network infrastructure 
Pursuant to the terms of the agreement  PRQR is obligated to make a one time milestone payment to CFFT of up to approximately  80 million  payable in three equal annual installments following the first commercial sale of QR 010  the first of which is due within 90 days following the first commercial sale  PRQR is also obligated to make a one time milestone payment to CFFT of up to  3 million if net sales of QR 010 exceed  500 million in a calendar year  Lastly  PRQR is obligated to make a payment to CFFT of up to approximately  6 million if PRQR transfers  sells or licenses QR 010 other than for certain clinical or development purposes  or if PRQR enters into a change of control transaction  
FinancingTo date  PRQR has financed operations primarily through private placements of equity securities  and to a lesser extent from funding from governmental bodies and patient organizations  including Cystic Fibrosis Foundation Therapeutics  Inc   or CFFT  a subsidiary of the Cystic Fibrosis Foundation  From inception on February 21  2012 through June 30  2014  PRQR raised gross proceeds of approximately  45 6 million from private placements of equity securities  including  2 500 000 from the conversion of a convertible loan   2 588 000 in loans from a governmental body and approximately  143 000 in grants from patient organizations 
As of June 30  2014  PRQR had cash and cash equivalents of  38 193 000  To date  we have not generated any revenues from royalties or product sales  Based on our current plans  we do not expect to generate royalty or product revenues for the foreseeable future  
Intellectual propertyPatent Rights Relating to PRQR s Cystic Fibrosis Program  With regard to the lead product candidate  QR 010  PRQR owns an international patent application filed under the Patent Cooperation Treaty  or PCT  relating to certain aspects of PRQR s RNA repair technology platform  including method of use claims relating to the use of certain single stranded oligonucleotides  particularly modified RNA oligonucleotides  for making a change in the sequence of a target RNA molecule in a living cell  as well as composition of matter claims relating to PRQR s QR 010 product candidate 
The term of any patents resulting from this application  if issued  would be expected to extend to July 2033   In addition  in May 2012  PRQR entered into an exclusive license agreement with Massachusetts General Hospital  or MGH  to obtain rights to a patent family with claims directed to an alternative RNA repair platform that uses an RNA oligonucleotide complex rather than a single stranded oligonucleotide  
This patent family includes an issued U S  patent with a composition of matter claim directed to an RNA oligonucleotide complex containing two specific oligonucleotide sequences for modulating the expression or activity of a CFTR gene product  and an allowed U S  patent application with method of use claims relating to the treatment of a symptom of cystic fibrosis in a subject by administering to the subject an RNA oligonucleotide complex comprising two oligonucleotides  as well as a composition of matter claim directed to a specific RNA complex for modulating the activity of a CFTR gene product  The issued and allowed claims  however  cover elements of PRQR s RNA repair technologies  but may not cover the QR 010 product or its use  The term of the issued U S  patent is expected to extend to October 2027  and the allowed U S  application  when and if issued  would be expected to extend to March 2025  
In addition  PRQR has rights in a pending U S  patent application in which it will pursue composition of matter claims relating to QR 010  The term of any patent resulting from this application  if issued  would be expected to extend to March 2025 
Patent Rights Relating to PRQR s LCA Program  With regard to the LCA Program  in April 2014  PRQR entered into an exclusive license agreement with the Radboud University Medical Center  Nijmegen  the Netherlands  to obtain rights in a patent family with composition of matters claims directed to certain antisense oligonucleotides for treating LCA and method of use claims relating to modulation of the splicing of the CEP290 gene product  
Patent applications currently are pending in the U S  as well as Brazil  Canada  Australia  Europe  and Eurasia  The term of any patents resulting from these applications  if issued  would be expected to extend to 2032 
CompetitionPRQR believes that a significant number of products are currently under development  and may become commercially available in the future  for the treatment of conditions for which PRQR may try to develop product candidates  PRQR ise aware of multiple companies that are working in the field of CF therapeutics  including major pharmaceutical companies such as Vertex Pharmaceuticals Inc  NASDAQ VRTX   F  Hoffmann LaRoche Ltd   Novartis  NYSE NVS   Gilead Sciences Inc  NASDAQ GILD   Abbott Laboratories  NYSE ABT   Targeted Genetics  Pfizer Inc  NYSE PFE   and Bayer AG NA  XETRA BAYGN  
If PRQR s lead product candidate  QR 010  is approved for the indications currently being pursued  it will compete with a range of therapeutic treatments that are either in development or currently marketed  For example  Vertex s Kalydeco is approved for use by the FDA and works to improve the function of the defective CFTR protein in CF patients with the G551D mutation and certain other gating mutations  Vertex is currently seeking marketing approval for additional mutations  which would increase Kalydeco s target population to up to 10  of the total CF patient population  Vertex is also developing lumacaftor  VX 809   which is intended for a  much broader CF patient population  including patients who are homozygous for the DF508 mutation  In June 2014  Vertex announced that its two Phase 3 clinical trials of lumacaftor  when used in combination with Kalydeco in CF patients homozygous for the DF508 mutation  showed statistically significant improvement in the study s primary endpoint of improved lung function  compared to placebo  Clinical trial results are considered statistically significant when the probability of the results occurring by chance  rather than from the efficacy of the drug candidate  is sufficiently low 
When that probability is less than 5   or pOther signs of clinical improvement were either limited or not statistically different from placebo  PRQR believes these studies validate that DF508 CFTR is a treatable target and indicate there is need for more efficacious therapies  There are also a number of products that are marketed or in clinical development for the treatment of symptoms manifested in CF patients  These treatments include inhaled antibiotics  mucus thinners  pancreatic enzymes and anti inflammatory drugs  
5  shareholders pre IPO
Sofinnova Capital VII FCPR  17 5 
Entities affiliated with Fidelity Select Portfolios  Biotechnology Portfolio  11 5 
Appel B V   8 25 
Vogelgezang B V   7 
Jennison Global Healthcare Master Fund  Ltd   6 5 
Progress Therapeutics B V   7 
J H J  Voskamp Participaties B V   5 4 
Cooperatieve Gilde Healthcare III Sub Holding 2 U A   5 4 

Use of proceedsPRQR expects to net  67 5mm from its IPO   Proceeds are allocated as follows   
 33 3 million   25 2 million  to fund development costs associated with our planned Phase 1b clinical trial and POC trial for QR 010 
 32 2 million   24 4 million  to fund development costs associated with our planned Phase 2a clinical trials for QR 010 
 12 0 million   9 1 million  to fund development costs associated with pre clinical studies and related activities for QR 110  and
the remainder for discovery and other pipeline projects  as well as for working capital and other general corporate purposes and potentially for acquisitions or investments in other businesses  technologies or product candidates 
A full IPO calendar is available at",2014-09-18,Francis Gaskins,https://www.investing.com/analysis/proqr-therapeutics-ipo:-neutral-to-slightly-positive-outlook-226225,226225
121325,342840,VRTX,Vertex Pharma  Depressed Vol In Gapping Stock ,opinion,Vertex Pharmaceuticals Incorporated  VRTX  is in the business of discovering  developing  manufacturing and commercializing small molecule drugs for the treatment of serious diseases    But this is a company with   9 billion market cap and revenue nearing  2b   yr  This isn t a baby bio tech  Having said that  it s still a bio tech and this is a vol note    depressed vol in particular  I found VRTX using a real time custom scan that hunts for depressed vols   Custom Scan Details Stock Price GTE  5  IV30  GTE 20 IV30  Percentile LTE 10 Average Option Volume GTE 1 200  The goal with this scan is to identify short term implied vol  IV30   that is depressed to its own annual history  at most in the 10th percentile   I m also looking for a reasonable amount of liquidity in the options  thus the minimum average option volume   and I want a minimum vol level so I don t pick up any boring ETF s  or whatever   The stock price requirement helps me identify names that have enough strike prices to trade or spread   The VRTX one year Charts Tab is included  below   The top portion is the stock price the bottom is the vol  IV30    red vs HV20    blue vs HV180    pink  On the stock side we can a radical gap up on 5 7 2012  when the stock rose from  37 41 to  64 16 in two days  We can also see the steady decline after that move up until the last few trading days  where VRTX has made a nice turn up  On 12 7 2012 the stock closed at  38 88 and is now trading at  42 32  so a healthy pop over the last five calendar days  The 52 wk range in VRTX is   28 49    66 10  On the vol side we can see how the implied has been dipping  I ve included the IV30  one year vol chart in isolation  below While there have been some rather impressive peaks  as of this writing we can see that the implied is sitting just above an annual low  The 52 wk range in IV30  is  36 99   76 45    putting the current level in the 2nd percentile  annual   It s this vol level that caught my eye  Note that the HV180  is 69 78   or in English  the long term historical realized vol of this sock is well above the short term implied Finally  let s look to the Options Tab  below   Across the top we can see the monthly vols are priced to 37 16   38 43  and 45 01  for Dec  Jan and Apr  respectively  The next earnings release should be in Feb    so outside of the front two expiries and inside Apr  In any case  given the industry  overall systematic risk of the market and the low vol level relative to its own past    I thought this was an interesting one to look at  Disclosure  This is trade analysis  not a recommendation Images provided by Livevol ,2012-12-13,Ophir Gottlieb,https://www.investing.com/analysis/vertex-pharma:-depressed-vol-in-gapping-stock-147431,147431
121363,342878,VRTX,Vertex Pharmaceuticals  Cystic Fibrosis Focus  Hepatitis Lead ,opinion,Investment summary  CF focus  HCV dataDespite Vertex  VRTX  having the leading position in the hepatitis C virus  HCV  space  competitive threats from potential new all oral  interferon  IFN  free combinations means Incivek s  telaprevir  blockbuster status is likely to be short lived  Hence  investors have moved on to its cystic fibrosis  CF  therapies  particularly Kalydeco  ivacaftor   as it is the primary investment thesis and value driver  Nevertheless  Vertex reaffirmed its 2012 sales guidance for Incivek   1 1 1 25bn  and entered collaborations with GSK and J J to test drug combos with VX 135  putting it back in the game for developing a second generation all oral anti HCV regimen CF is the main driver for nowResults from four ongoing  three pivotal  trials of Kalydeco monotherapy in four subgroups  R117H mutation  non G551D gating mutation  children aged 2 5 years and pts with residual CTFR function  could expand use from 4   G551D  currently to 14  of CF pts  The Kalydeco VX 809 combo in del508 homozygous pts  could  if positive  add a further 50   The second generation corrector  VX 661 and others  plus Kalydeco and or VX 809  aimed for del508 heterozygous pts  may reach another 25   We believe Vertex can deliver multi billion dollar sales from its CF franchise if these trials are positive  The CF business is highly profitable because of easy to target patients and small commercialisation infrastructure required HCV  New collaborations tested with VX 135VX 135  a nucleotide polymerase inhibitor  is the anchor drug in Vertex s all oral  IFN free effort  Four 135 combo studies  one each with telaprevir  ribavirin  GSK 2336805  a NS5A inhibitor  and J J s simeprivir  a protease inhibitor   could yield Phase II data by the end of 2013  The best combo s  will enter pivotal trials in 2014 Valuation  Fairly valued for the momentVertex saw a 10  share price fall after reporting below consensus sales for Incivek and Kalydeco in Q3  but the valuation seems reasonable for now   the EV is  9 1bn including convertible shares and stock options  Data on VX 661 Phase II trial  H113   all oral anti HCV combo  year end 2013  and VX 809 Kalydeco combo  2014  are the catalysts for any significant re rating To Read the Entire Report Please Click on the pdf File Below ,2012-11-07,Edison,"https://www.investing.com/analysis/vertex-pharmaceuticals:-cystic-fibrosis-focus,-hepatitis-lead-142601",142601
